<SEC-DOCUMENT>0001628280-17-001603.txt : 20170223
<SEC-HEADER>0001628280-17-001603.hdr.sgml : 20170223
<ACCEPTANCE-DATETIME>20170223085849
ACCESSION NUMBER:		0001628280-17-001603
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170223
DATE AS OF CHANGE:		20170223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OBALON THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001427570
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37897
		FILM NUMBER:		17630884

	BUSINESS ADDRESS:	
		STREET 1:		5421 AVENIDA ENCINAS
		STREET 2:		SUITE F
		CITY:			San Diego
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		858-480-2400

	MAIL ADDRESS:	
		STREET 1:		5421 AVENIDA ENCINAS
		STREET 2:		SUITE F
		CITY:			San Diego
		STATE:			CA
		ZIP:			92008
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>obln-123116x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6AA504DDF7B99B9226017564EE439ADB"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#9746;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the fiscal year ended December 31, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">or</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#9744;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:33px;text-indent:-34px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">For the transition period from   to   .</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 001-37897</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">OBALON THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26-1828101</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5421 Avenida Encinas, Suite F</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carlsbad, California</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92008</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(760) 795-6558</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:3%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock, $0.001 par value per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">The Nasdaq Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act: None</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;Yes&#160;&#9746;&#160;&#160;No&#160;&#9744;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;Yes&#160;&#9746;&#160;&#160;No&#160;&#9744;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#9746;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:4%;"></td><td style="width:44%;"></td><td style="width:25%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes&#160;&#9744;&#160;&#160;No&#160;&#9746;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant was not a public company as of the last business day of its most recently completed second fiscal quarter and therefore, cannot calculate the aggregate market value of its voting and non-voting common equity held by non-affiliates as of such date. The registrant&#8217;s common stock began trading on The NASDAQ Global Market on October 6, 2016</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total shares of common stock outstanding as of the close of business on February 17, 2017 was 16,773,205 shares.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information required to be disclosed in Part&#160;III of this report is incorporated by reference from the registrant&#8217;s definitive Proxy Statement for the 2017 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120&#160;days after the end of the fiscal year covered by this report.</font></div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sCD6F6CEAA0EE3A418B4C7564EE99B7E5"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:14%;"></td><td style="width:71%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">PART&#160;I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s34E16CD377835107E6627564EF196156"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s34E16CD377835107E6627564EF196156">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1292B8F812D9DC0763607564EF43F3B9"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1292B8F812D9DC0763607564EF43F3B9">24</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1B.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BBBF539DC65DDC210577564EF9509ED"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BBBF539DC65DDC210577564EF9509ED">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s745373114C02603BCFBD7564EFA7B047"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s745373114C02603BCFBD7564EFA7B047">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF37785F73D8D2E4B3A197564EFC0BCCC"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF37785F73D8D2E4B3A197564EFC0BCCC">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s882D08B8418B91ED5F427564EFE1A308"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s882D08B8418B91ED5F427564EFE1A308">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">PART&#160;II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s224CA085C022E5DB8A517564F0362FF6"><font style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s224CA085C022E5DB8A517564F0362FF6">55</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD61852106BBFDEBFEC637564EC87FF2B"><font style="font-family:inherit;font-size:10pt;">Selected Consolidated Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD61852106BBFDEBFEC637564EC87FF2B">56</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 7.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5AF7DAA1FF72A9FD411F7564F0885DF8"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5AF7DAA1FF72A9FD411F7564F0885DF8">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 7A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2AD2F7548ECE721490CF7564F22D8A3D"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2AD2F7548ECE721490CF7564F22D8A3D">67</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 8.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA0A583A3E37378F9E4FB7564F25B025E"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA0A583A3E37378F9E4FB7564F25B025E">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s34D12B1266A9BEE3479D7564F280688D"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s34D12B1266A9BEE3479D7564F280688D">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF5F71EE3544B1D81C7DD7564F2AE655B"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF5F71EE3544B1D81C7DD7564F2AE655B">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9B.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB54B236920F8231B67667564F2D2E2E0"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB54B236920F8231B67667564F2D2E2E0">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">PART&#160;III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 10.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BB6DD9AAA244E0F2DBA7564F324E399"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BB6DD9AAA244E0F2DBA7564F324E399">69</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 11.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE537D631E17C1EEEC80D7564F356039E"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE537D631E17C1EEEC80D7564F356039E">69</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 12.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7A7F3AC859FF8AD00AAC7564F37627F0"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7A7F3AC859FF8AD00AAC7564F37627F0">69</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 13.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E7F44D8EA0C0FFD8D0A7564F3A8CDB0"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E7F44D8EA0C0FFD8D0A7564F3A8CDB0">69</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 14.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2094357DB51C98A351B87564F3C9F9AC"><font style="font-family:inherit;font-size:10pt;">Principal Accountant Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2094357DB51C98A351B87564F3C9F9AC">69</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">PART&#160;IV</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 15.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s129CAC5AEF91611BD8987564F41E209D"><font style="font-family:inherit;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s129CAC5AEF91611BD8987564F41E209D">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 16. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s218b17b940854fe588cf93427f8681fe"><font style="font-family:inherit;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s218b17b940854fe588cf93427f8681fe">97</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s364A7BD75E56BD320C237564F7BDD0A1"><font style="font-family:inherit;font-size:10pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s364A7BD75E56BD320C237564F7BDD0A1">97</a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:14px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sFAC7BAD0CC4BFAE59FB57564EEC60739"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div><a name="sD6E261D01A051AFE5B617564EEEA69D8"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Annual Report on Form 10-K, or this Annual Report, including the sections entitled &#8220;Business,&#8221; &#8220;Risk factors,&#8221; and &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; contains forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk factors&#8221; and elsewhere in this Annual Report. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot assure you that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these statements to actual results or to changes in our expectations, except as required by law. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the SEC with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </font></div><div><a name="s34E16CD377835107E6627564EF196156"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OVERVIEW </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a vertically integrated medical device company focused on developing and commercializing innovative medical devices to treat obese and overweight people by facilitating weight loss. Our initial product offering is the Obalon balloon system, the first and only U.S. Food and Drug Administration, or FDA, approved swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients.  We designed the Obalon balloon system to address many of the limitations of prior devices intended to treat weight loss, including traditional saline-filled intragastric balloons. We believe the Obalon balloon system offers patients and physicians benefits over prior weight loss devices including but not limited to: a favorable safety profile, improved patient tolerability and comfort, progressive weight loss with durable results, simple and convenient placement, and attractive economics for patients and physicians.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, we received premarket approval, or PMA, from the FDA, and commenced U.S. commercialization in January 2017. The Obalon balloon system is FDA approved for temporary use to facilitate weight loss in obese adults with a body mass index, or BMI, of 30 to 40, who have failed to lose weight through diet and exercise. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system has the potential to provide patients and physicians with a cost-effective, reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. As of December 31, 2016, we had sold over 26,000 of our earlier generation Obalon balloon systems for commercial use outside the United States.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received PMA approval for our Obalon balloon system based on the results of our U.S. pivotal clinical trial, referred to as the SMART trial. The SMART trial was a prospective, double-blinded, multi-center, randomized (1:1), parallel-group, active sham-controlled trial involving 387 patients, which demonstrated that patients in the Obalon treatment group lost, on average, approximately twice as much body weight as patients in the sham-control group, while at the same time maintaining a low rate of serious adverse device events, or SADEs. In the SMART trial, the Obalon balloon system also demonstrated a strong safety profile, showed statistically significant differences in metabolic profiles and demonstrated that patients were able to maintain most of their weight loss for at least six months following the removal of the balloons. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE OBESITY EPIDEMIC </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obesity has been identified by the U.S. Surgeon General as an epidemic and a significant threat to the quality of life in the United States. Based on results from the 2013-2014 National Health and Nutrition Examination Survey, it is estimated that more than 86&#160;million adults in the United States were obese, defined as a BMI&#160;of 30 or greater (calculated as weight in kilograms divided by height in meters squared), of which approximately 17.6&#160;million were considered extremely obese with a BMI of 40 or greater, and an additional 75&#160;million adults in the United States were overweight, defined as a BMI between 25 and 29. Research sponsored by the Centers for Disease Control and Prevention, or CDC, suggests that if current obesity rates persist, more than half of the U.S. population will be obese by 2030. Similarly, obesity is also a significant health problem outside of the United States. The number of obese adults worldwide has more than doubled since 1980, and the World Health Organization estimates that more than 600&#160;million adults were obese and more than 1.9 billion were overweight in 2014. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The CDC has identified obesity as a leading cause of preventable death in the United States. Obesity-related disorders, known as comorbidities, include Type 2 diabetes, hypertension, stroke and certain cancers as well as psychological disorders such as anxiety, depression and insomnia. The national medical care costs of obesity-related illness in adults, including out-of-pocket expenses, third-party payer expenses and Medicaid, were estimated to be approximately $210 billion in 2008. Furthermore, the annual global economic impact of obesity is estimated to be $2 trillion. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect the obesity epidemic among adults to continue to grow worldwide given the excess caloric intake of highly-processed, fatty foods, increasingly sedentary lifestyles and a growing prevalence of obesity among children and adolescents. Despite the growing public interest in the obesity epidemic and the significant medical and economic repercussions associated with the disease, there remains a significant unmet need for more effective treatments. </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT TREATMENTS AND LIMITATIONS </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current treatment alternatives for obese and overweight patients begin with lifestyle modification, such as diet and exercise. If this alternative fails to produce the desired results, physicians may prescribe pharmaceutical therapies, and in patients with more severe obesity, physicians may pursue aggressive surgical treatments, such as gastric bypass and gastric banding. These approaches are associated with safety concerns, lifestyle impact and ease of use, cost and compliance issues that have limited their adoption. Additionally, some patients may seek to address the symptoms of weight-gain through the use of aesthetic products, certain of which have been approved for individuals with a BMI of 30 or less. We believe such products only treat the symptoms and not the underlying disease. They are also not indicated for obese patients. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lifestyle modification </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lifestyle modification, which includes diet, exercise and behavior modification, is usually prescribed as an initial treatment for an obese or overweight patient and is typically prescribed in all obesity management approaches. However, lifestyle modification alone has generally been ineffective in producing sustainable weight loss in obese patients due to inability to comply with the modifications over an extended period. Many studies have shown that a significant majority of dieters will regain lost weight and many will gain more than they originally lost. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical therapy </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Several pharmaceutical products have been approved by the FDA for obesity in the United States. Pharmaceutical therapy often represents a first option in the treatment of obese patients that have failed to achieve weight loss goals through lifestyle modifications alone. Pharmaceutical therapy can have limited effectiveness due to patient non-compliance. Additionally, pharmaceutical therapy may carry significant safety risks and negative side effects, such as adverse gastrointestinal, cardiovascular and central nervous system issues, some of which are serious or life threatening. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bariatric surgery </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bariatric surgery is a treatment option generally reserved for cases of severe obesity, or patients with a BMI in excess of 40. The two most common forms of bariatric surgery, gastric bypass and gastric banding, promote weight loss by surgically restricting the stomach&#8217;s capacity and outlet size. Gastric bypass also affects weight loss by restricting the body&#8217;s ability to absorb nutrients. While largely effective, these procedures are generally invasive, expensive for the patient and irreversible. Bariatric surgery patients are generally required to make significant postoperative lifestyle changes, including strict dietary changes, vitamin supplementation and long-term medical follow-up programs. Side effects of bariatric surgery include a high rate of re-operation, nausea, vomiting, dumping syndrome, dehydration, dental problems and other issues. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently developed treatment alternatives </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the shortcomings and limitations of the existing treatment alternatives, new medical procedures have been recently introduced in an attempt to address the gap in care between pharmaceutical treatment and invasive surgical procedures. These new procedures include: neuroblocking therapy, aspiration therapy and traditional saline-filled intragastric balloons. Neuroblocking therapy involves a surgical procedure in which a neuromodulation device is implanted in the body and used to block electrical signals from the stomach to the brain. By blocking those signals, the device attempts to control the patient&#8217;s feelings of hunger. Aspiration therapy involves a surgical procedure in which a feeding tube is implanted in the abdomen in order to remove food from the stomach before calories are absorbed into the body. We believe high costs, procedural complications and the risk of SADEs may limit their adoption. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intragastric balloons are a type of space-occupying device placed in the stomach in order to cause a sensation of fullness. Currently marketed traditional balloons are large, saline-filled silicone devices that are placed in the stomach endoscopically, under anesthesia, for a treatment period of up to six months. Following treatment, the balloons are removed in a second endoscopic procedure. Other approved traditional saline-filled intragastric balloons in the United States are the ReShape Duo Balloon and the ORBERA Balloon. While generally effective in delivering weight loss, these traditional saline-filled intragastric balloons have been accompanied by a number of limitations that have impeded their adoption, including: high rate of SADEs, lack of comfort and tolerability, limited ability to provide progressive and sustained weight loss, and inconvenient placement procedure.</font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OUR SOLUTION </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed our Obalon balloon system to overcome the limitations of prior devices intended to treat weight loss, including traditional saline-filled intragastric balloons. Based on our clinical data and commercial experiences, we believe the Obalon balloon system provides the following benefits to our patients and their physicians: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Favorable safety profile.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In our pivotal SMART trial, only one of 336 (0.3%) patients that received our Obalon balloon experienced a SADE. As of December 2016, we had sold over 26,000 units of our earlier generation Obalon balloon systems in international markets with a minimal number of SADEs reported to us, none of which were required to be reported to the applicable foreign regulatory authorities. Our investigations determined that all of the international SADEs occurred in patients where the device was not used in accordance with approved labeling. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Improved patient tolerability and comfort.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The Obalon balloon is inflated with a proprietary mix of gas. This creates a light, buoyant balloon that floats at the top of the stomach instead of sinking to the bottom of the stomach like a traditional saline-filled intragastric balloon. Further, the Obalon balloon system consists of three separate 250cc balloons placed individually over a three-month period to progressively add volume. We believe these design elements have the potential to improve patient comfort and tolerability of our Obalon balloon. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Progressive weight loss with durable results.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In our pivotal SMART trial, patients in the Obalon treatment group lost, on average, approximately twice as much body weight as patients in the sham-control group. In addition, patients in the Obalon treatment group showed, on average, progressive weight loss over the balloon treatment period, which we believe is attributable to the individual placement of three separate Obalon balloons over the treatment period. Subsequent data analysis at 12&#160;months also showed that, on average, 89.5% of the weight loss was maintained six months after balloon removal. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Simple and convenient placement.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The Obalon balloon is placed without anesthesia or an endoscopy through a swallowable capsule that dissolves in the stomach and releases the balloon. These unique features allow patients the flexibility to receive the Obalon balloon discreetly in an outpatient setting. Placement typically occurs in less than ten&#160;minutes and can be scheduled in the morning before work, during a lunch break or in the evening. Treated patients can return promptly to their normal daily activities. The balloons are removed endoscopically under light, conscious sedation six months after the first balloon placement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Attractive economics for patients and physicians.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;By eliminating the need for an endoscopic delivery procedure, anesthesia and use of a special endoscopy suite, we believe our Obalon balloon system has the potential to reduce physician costs and allow more time to perform additional procedures. Furthermore, the Obalon balloon&#8217;s tolerability profile may reduce the need for ongoing patient management. We believe patients will benefit from lower treatment costs, no post-placement recovery period and a quick return to daily activities. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OUR STRATEGY </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective is to be the leading provider of medical devices for the non-surgical treatment of obese and overweight individuals. The key elements of our strategy are to: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Drive product adoption by working with key thought leaders in bariatrics, gastroenterology and plastic surgery.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; We are initially focused on direct sales to the leading bariatric surgeons, gastroenterologists, and plastic surgeons in the United States. We estimate that there are approximately 3,500 bariatric surgery centers in the United States, and we believe the leading 700 centers provide an opportunity to effectively access obese patients using an efficiently-sized sales force. In addition, there are over 15,000 gastroenterologists, many of which are expanding their practices to include weight loss treatments, and 1,900 aesthetically focused plastic surgeons. We believe adoption of our technology by these thought leaders will accelerate broader adoption of the Obalon balloon system in each physician specialty area. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Partner with physicians to create consumer awareness and drive patients into the channel.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Our initial strategy is to establish marketing and support programs with physicians to create patient awareness and demand for the Obalon balloon system. We support these physicians with best practices and tools to treat qualified patients already in the channel and through local outreach to attract new patients to the practice. We also provide physicians with the clinical training to utilize our Obalon balloon system, as well as the practice development support to manage their practices as self-pay centers. In addition, we believe we can address an even larger patient population by creating a recognizable brand name through a direct-to-patient campaign designed to differentiate the Obalon balloon system using targeted, cost effective digital and social media platforms, and media outreach through public relations efforts. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Continue to develop innovative products to facilitate market penetration.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;We plan to leverage our proprietary product technology and research and development expertise to develop products for weight loss that improve clinical outcomes, increase ease of use and reduce cost. For example, we plan to seek supplemental approval for improvements to our Obalon balloon system, including a new, automated, easier-to-use inflation system. Other products currently in our development pipeline include a navigation system that would reduce the need for imaging at every placement, a balloon with a treatment period of longer than six months and a self-deflating and self-passing balloon that could eliminate the need for endoscopic balloon removal. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Optimize manufacturing to drive operating leverage.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;We have built a highly leverageable manufacturing facility at our headquarters in Carlsbad, California, where we design, develop and manufacture our products in-house using some components and sub-assemblies provided by third-party suppliers. We believe that controlling the manufacturing and assembly of our products allows us to innovate more quickly and cost-efficiently and produce higher quality products than if we outsourced manufacturing. We believe we have the ability to increase our manufacturing scale within our current facility in a cost-effective manner. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Protect and expand our strong intellectual property portfolio.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;We have developed a strong portfolio of issued patents and pending applications that protect our products and technology. We believe we have also developed know-how critical to creating current and future products that we hold and protect as trade secrets. We have an inventive culture and expect to continue innovating to create a proprietary pathway for future product development. We intend to aggressively protect and enforce our intellectual property, both for existing and new products. </font></div></td></tr></table><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OUR PRODUCTS AND TECHNOLOGY </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Obalon balloon system was designed to overcome the historical limitations of traditional saline-filled intragastric balloons and nonsurgical treatments for weight loss. We have developed the individual components of the Obalon balloon system to collectively improve clinical outcomes, increase ease of use and reduce cost. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Obalon balloon system </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The main components of the Obalon balloon system are: a swallowable capsule that contains the balloon attached to a microcatheter, a hand-held inflation system and a pre-filled can of our proprietary mix of gas. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;"><img src="obln10kproformaimage1.jpg" alt="obln10kproformaimage1.jpg" style="height:228px;width:608px;"></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Capsule, balloon and microcatheter technology </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dissolvable capsule </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We designed the capsule to be large enough to accommodate the folded balloon, yet small enough to be swallowed. The capsule is titrated to optimize dissolution timing. If the capsule dissolves too quickly, the balloon could be prematurely released before entering the stomach, and if too slowly, the patient and physician are inconvenienced by having to wait longer to inflate the balloon. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Balloon film </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our film is a coextruded, multilayer polymer consisting primarily of nylon and polyethylene. We designed the film to be thin enough to fit into a swallowable capsule, yet stable enough to withstand the chemical and mechanical forces in the stomach. Our film is biocompatible, cost-effective to manufacture, puncture and abrasion resistant, smooth and atraumatic to the stomach&#8217;s lining and able to appropriately retain gas. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Balloon valve </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our balloon valve is an innovative combination of materials, including silicone and titanium, designed to be highly reliable. The valve is small enough to fit into a swallowable capsule and radiopaqued for visibility under digital imaging. A key feature of our valve is the ability to effectively reseal after the inflation catheter is removed to prevent leaks. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Microcatheter </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our microcatheter is designed to quickly and reliably inflate the Obalon balloon. It is small, flexible and smooth in order to minimize any potential discomfort to the patient during balloon placement. The catheter utilizes a hydrophilic coating to reduce friction during swallowing. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inflation system </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our hand-held inflation system, the EzFill inflation system, is a reusable device that delivers our proprietary mixture of gas to consistently inflate the Obalon balloon to the standardized volume and pressure. The inflation system is equipped with pre-pulse, a confirmation system that provides pressure feedback measurements to confirm that the Obalon balloon is both properly placed and able to be correctly inflated in the stomach. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Proprietary gas </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Obalon balloon is inflated with our proprietary mix of gas, which, in combination with the permeability of the balloon film and the stomach gases, enables the balloon to remain inflated for the full six-month treatment period. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Obalon balloon treatment </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Placement of the Obalon balloon typically occurs in less than ten minutes and can be accomplished in an outpatient setting. To place the Obalon balloon, the patient swallows the capsule, which has the Obalon balloon folded inside, with a glass of water. No sedation or anesthesia is required. Once swallowed, placement of the capsule is confirmed in the stomach with digital imaging. The microcatheter, which is attached to the Obalon balloon, is then connected to our EzFill inflation system. The EzFill inflation system provides real-time pressure measurements to confirm that the Obalon balloon is both properly placed and able to be correctly inflated in the stomach. A pre-filled can of gas is inserted into the EzFill inflation system and then the gas is discharged to fill the balloon to a volume of 250cc. Once the inflation of the Obalon balloon is confirmed, the microcatheter is detached from the balloon via hydrostatic pressure and is removed through the patient&#8217;s mouth. The patient returns two&#160;more times over the following eight to 12 weeks to receive a second and third Obalon balloon, expanding total balloon volume within the stomach to 750cc. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the balloons are removed in a single procedure six months after the placement of the initial balloon. Removal of the Obalon balloon typically requires approximately 15 minutes. The balloons are removed endoscopically under light conscious sedation, using standard commercially-available endoscopy tools. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following pictures depict the treatment steps of the Obalon balloon system: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;"><img src="obln10kproformaimage2.jpg" alt="obln10kproformaimage2.jpg" style="height:277px;width:566px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;"><img src="obln10kproformaimage3.jpg" alt="obln10kproformaimage3.jpg" style="height:254px;width:373px;"></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product pipeline </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a robust pipeline of new products and product improvements for weight loss intended to improve clinical outcomes, increase ease of use and reduce cost. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Next generation balloon capsule </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed a next generation HydroxyPropylMethylCellulose, or HPMC, Obalon balloon capsule that is fully vegetable-derived and is intended to eliminate potential cultural or religious concerns with animal-derived gelatin capsules. We submitted a PMA supplement for the HPMC Obalon balloon capsule in the United States in November 2016. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Next generation inflation system </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our next generation inflation system, the Obalon Touch inflation system (formerly known as the EzPz inflation system), is designed to be automated, simpler to operate and to provide more reliable Obalon balloon placements. Due to the enhancements, we are currently updating our Certificat de Conformit&#233;, or CE, mark registrations as well as applying for a modification to the existing EzPz approval in Brazil and select Middle East markets.  In the United States, we believe the Obalon Touch inflation system will require a PMA Supplement for approval.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Navigation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing a balloon and navigation system for balloon placements that would reduce the need for digital imaging at each placement. We believe this navigation system has the potential to reduce the cost and logistics related to confirmatory digital imaging during the Obalon balloon placement, which could enable physician practices to treat higher volumes of patients and increase the number of physicians and sites offering the Obalon balloon system. The navigation system consists of hardware, software and a display to be used in conjunction with the current Obalon balloon. We have completed two feasibility studies for proof-of-concept and intend to conduct further clinical studies with this navigation system. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Longer-term duration balloon system </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing a balloon intended for a longer duration of treatment, potentially up to one year. In our SMART trial, patients in the Obalon treatment group continued, on average, to lose weight throughout the six months of balloon treatment. We have completed the initial engineering testing on the proprietary materials and systems, which we believe would permit reliable balloon performance over a longer period of up to twelve months. We intend to complete more rigorous engineering testing and submit for approval to conduct human trials to understand if longer balloon treatment may address higher BMI patients or those desiring a longer weight loss treatment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deflateable-passable balloon system </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a balloon system in development that is intended to self-deflate at the end of a specified treatment period and then pass naturally through the digestive system to be excreted as waste, thereby potentially eliminating the need for endoscopy and creating a procedureless balloon treatment. However, it is of paramount importance to patient safety that such a balloon would pass with an extremely high level of reliability and not create a blockage of the intestines, which could require surgery and cause significant patient injury or death. We have conducted initial engineering and animal testing successfully on self-deflating and self-passing balloons, and we believe we have developed novel technology with a strong intellectual property portfolio. We intend to continue development and testing, and, if the results of our studies warrant, move toward human clinical trials in support of regulatory approvals. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and development </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, we had 11 employees focused on research and development. In addition to our internal team, we retain third-party contractors from time to time to provide us with assistance on specialized projects. We also work closely with experts in the medical community to supplement our internal research and development resources. Research and development expenses for the years ended December&#160;31, 2016, 2015 and 2014 were </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CLINICAL TRIALS AND DATA </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SMART trial </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on our clinical data, we believe our Obalon balloon has the potential to offer a compelling combination of efficacy and safety.&#160;We have evaluated various versions of our Obalon balloon system in numerous clinical trials, which included a total of 655 patients as of December 31, 2016. Based on the results of our U.S. pivotal trial, the SMART trial, we received FDA approval for our current Obalon balloon system in September 2016. The SMART trial met its primary weight loss endpoints, demonstrated a strong safety profile, showed statistically significant differences in metabolic profiles and demonstrated that patients were able to maintain most of the weight loss for at least six months following the removal of the Obalon balloons. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SMART trial was a prospective, double-blinded, multi-center, randomized (1:1), parallel-group, active sham-controlled trial of 387 patients. The Obalon treatment group received three balloons placed individually at approximately week zero, week three and week 12. Alternatively, the sham-control group received placebo capsules with microcatheters and were led to believe in a mock placement that a balloon was placed and inflated in their stomachs at week zero, week three and week 12. The patients ranged in age from 22 to 64 years and had a BMI range of 30 to 40. The patients enrolled were required to have previously attempted to lose weight unsuccessfully through a change in diet and could not use weight loss medications or undergo gastric surgery for the duration of the trial. Patients were given minimal diet counseling of 25 minutes every three weeks in order to isolate the impact of the Obalon balloon on weight reduction. The trial was conducted by both bariatric surgeons and gastroenterologists at 15 U.S. centers. The trial evaluated a co-primary endpoint comprised of (i)&#160;a minimum difference in mean percent total body loss, or TBL, between the Obalon treatment group and sham-control group of at least 2.1% and (ii)&#160;achievement by at least 35% of the Obalon treatment group patients of at least 5% TBL at the end of six-months of treatment. Additional observational measures included metabolic metrics and weight loss maintenance after removal of balloons. The median time for each balloon placement was nine minutes, while the median balloon removal time for three balloons was 14 minutes. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results from the SMART trial met both the co-primary endpoints. The per protocol analysis included 366 patients (185 in the Obalon treatment group and 181 in the sham-control group) and showed patients in the Obalon treatment group achieved mean TBL of 6.86%, or 15.06&#160;lbs, vs 3.59%, or 7.77&#160;lbs, in the sham-control group, showing a difference of 3.28%, or 7.28&#160;lbs. The following table summarizes average percentage of TBL, percentage of excess weight loss, or EWL, and weight loss (in pounds) for the Obalon treatment group and the sham-control group in the SMART trial. All weight loss metrics below were statistically significant. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:44%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weight Loss Metric</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Per Protocol Cohort</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Obalon <br>Treatment <br>Group</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(N = 185)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sham-Control</font></div><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Group</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(N&#160;=&#160;181)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Difference</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">p-value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent&#160;TBL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-6.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-3.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-3.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent&#160;EWL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-25.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-12.95</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-12.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&lt;&#160;0.0001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weight&#160;Loss&#160;(lbs.)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-15.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-7.77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-7.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&lt;&#160;0.0001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, 64.9% of the Obalon treatment group patients met or exceeded the 5% TBL endpoint whereas only 32.0% of the sham-control group met or exceeded 5% TBL. The following table summarizes the 5% TBL responder rates for the Obalon treatment group and the sham-control group in the SMART trial. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:56%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Main Analysis of -5% TBL Responder Rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obalon&#160;Treatment&#160;Group&#8212;Per&#160;Protocol&#160;Cohort*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120&#160;/&#160;185&#160;(64.9%)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sham-Control Group</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58&#160;/&#160;181 (32.0%)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Difference (Treatment less Control)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.8%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:57px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:41px;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">p-value &lt;0.0001 </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the various responder rate thresholds for the Obalon treatment group and the sham-control group in the SMART trial. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Responder&#160;Rate&#160;Threshold</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(-%TBL)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Obalon Treatment <br>Group</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sham-Control <br>Group</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98&#160;/&#160;185&#160;(53.0%)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47&#160;/&#160;181&#160;(26.0%)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81&#160;/&#160;185 (43.8%)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38&#160;/&#160;181 (21.0%)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68&#160;/&#160;185 (36.8%)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35&#160;/&#160;181&#160;(19.3%)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55&#160;/&#160;185 (29.7%)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29&#160;/&#160;181&#160;(16.0%)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49&#160;/&#160;185 (26.5%)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23&#160;/&#160;181&#160;(12.7%)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notably, the Obalon treatment group demonstrated a progressive weight loss profile for the duration of the six month therapy period. The following chart shows percent TBL by week for the Obalon treatment group and sham-control group. The arrows represent the average week of each balloon placement. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;"><img src="obln10kproformaimage4.jpg" alt="obln10kproformaimage4.jpg" style="height:284px;width:577px;"></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, nearly all patients in the Obalon treatment group, including patients in the bottom 25% of the group, achieved TBL, EWL and weight loss and a reduction in BMI. The table below summarizes the mean, the average of the top 25% of the results, the average of the bottom 25% of the results and the single best changes in TBL, EWL, weight loss and BMI achieved by patients in the Obalon treatment group. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weight Loss Metric</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Mean</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Top&#160;25%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Worst&#160;25%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Single</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Best</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent TBL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-6.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-10.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-3.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-19.3%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent EWL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-25.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-36.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-12.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-80.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weight Loss (lbs.)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-15.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-21.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-49.7</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMI Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-2.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-3.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-1.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-7.1</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In an observational analysis at six months, the Obalon treatment group also demonstrated statistically significant improvements in systolic blood pressure, fasting glucose, total cholesterol and triglycerides compared to both their own baseline measures and to the sham-control group. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the conclusion of the six-month treatment period, the Obalon treatment group patients continued with the standardized behavior modification program for six additional months after the Obalon balloon removal. An additional observational data analysis of the subjects who lost weight in the first six months of the study and were evaluated for up to an additional six months, suggests that, on average, 89.5% of the weight loss was maintained six months after balloon removal. The following graph depicts the weight loss maintained for the one-year period in the Obalon treatment group. We did not continue to collect data from patients in the sham-control group who received the Obalon balloons subsequent to balloon removal. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;"><img src="obln10kproformaimage5.jpg" alt="obln10kproformaimage5.jpg" style="height:338px;width:493px;"></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Safety</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the SMART trial, we actively solicited patients to provide details of any adverse events, or AEs, by contacting all patients 24 hours after each Obalon balloon placement and balloon removal as well as at every office visit. All AEs were first assigned a device-relatedness and a pre-defined severity rating.&#160;Mild events did not require intervention, required homeopathic remedies (including chamomile tea, peppermint oil tea and Altoids) or required over the counter remedies to treat and resolve the events.&#160;Moderate severity events required a prescription medication to treat and resolve the event. Severe events required medical intervention beyond a prescription medication.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our SMART trial, only one out of 336 patients (0.3%) receiving Obalon balloons in both phases experienced a SADE.&#160;The event was described as peptic ulcer disease, or bleeding. The patient was hospitalized, and after stabilization, the patient was discharged from the hospital without sequelae.&#160;During the Obalon balloon therapy period the subject underwent an outpatient total knee replacement surgery.&#160;During the surgery and as part of post-operative recovery, the subject was prescribed both a high dose of nonsteroidal anti-inflammatory drugs, or NSAIDs, and aspirin, both of which are contraindicated for use with each other as well as for use in conjunction with the Obalon balloon system.&#160;The SADE event was determined to be &#8220;possibly,&#8221; but not &#8220;probably,&#8221; device-related by the investigator since concomitant high dose NSAID and aspirin use is also known to cause peptic ulcer disease.&#160;The investigator felt that the NSAID and aspirin use was the primary cause of the event but could not rule out the balloons completely. The patient previously had no ulcers per the upper gastrointestinal screen performed at time of enrollment and was not taking medications prior to surgery. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our SMART trial, there were no surgical removals or other hospitalizations due to a SADE other than the SADE described above.&#160;The most common other adverse device events during balloon placement were abdominal pain (72.6% of patients), nausea (56.0% of patients) and vomiting (17.3% of patients), all of which were classified as mild or moderate.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercial safety experience </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 2016, we had sold over 26,000 units of our earlier generation Obalon balloon systems in international markets. In our commercial experience, nine serious adverse events have been reported to us, of which six related to balloon deflations resulting in migration and three related to an esophageal laceration or rupture. We investigated each of these events and determined that all nine of these events occurred in patients where the device was not used in accordance with approved labeling. None of these events were required to be reported to the applicable foreign regulatory authorities. We have never had a case of pancreatitis or spontaneous hyperinflation reported in almost five years of international commercialization.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SMARTCAR trial </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, we received an Investigational Device Exemption, or IDE, approval from the FDA to conduct a single arm clinical study, which we named SMARTCAR,&#160;to evaluate the safety and efficacy profile of our new HPMC vegetable-derived capsule and the EzPz inflation system (currently Obalon Touch inflation system). We enrolled an initial 25 patients for the trial at three clinical sites in the United States. Twenty-one patients met the SMART Pivotal Trial Per Protocol requirement of having at least two balloons placed for 18 weeks or more and demonstrated weight loss of 11.3% TBL and 23.2 pounds.  There were no serious adverse events reported.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Post-approval study </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To help assure the continued safety and effectiveness of the Obalon balloon system, the FDA has required a post-approval study as a condition of approval under 21 CFR 814.82(a)(2). As part of our PMA approval, we agreed with the FDA to conduct a post-approval study that will evaluate 200 patients who will be enrolled at a maximum of 15 sites in the United States. The study is a prospective, open-label, single-arm, 12-month follow-up study in which patients will be treated during the first six months with placement of up to three Obalon balloons in conjunction with a moderate intensity weight loss and behavioral modification program standardized throughout the sites, followed by observational evaluation for an additional six months after device removal. The primary endpoint is to evaluate the safety of the Obalon balloon system by assessing the rate of device- or procedure-related serious adverse events. We are required to submit an Interim Post-Approval Study Status Report every six months after the date of PMA approval for the first two years of the study and annually thereafter until 200 patients have completed the study. We are currently working with FDA to finalize the data collection requirements for the study.</font></div><div style="line-height:174%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercial-Use Patient Registry</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to most closely monitor the safety, efficacy and quality of the Obalon balloon system real time in actual commercial use, we have created an online clinical performance database, or registry.  All physicians and sites using the Obalon balloon system have access to the registry to enter their patient data and to compare their performance to national or regional data. The data collected in the registry includes, gender, initial height and weight, weights at each subsequent balloon placement, weight at removal, adverse events occurring during the treatment, and product quality and performance. Obalon may use knowledge gained from analyzing the data from the registry for scientific publications, for improving clinical practices, for developing new and improved products, for commercial purposes or to provide information to regulatory bodies.  </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SALES AND MARKETING </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary sales efforts are expected to be conducted in the United States, with some sales generated through distributors in select international markets. We sell in the United States through a direct sales organization consisting of regional sales directors, executive account managers and product specialists. Our sales team encompasses three key disciplines that we believe are necessary to create and grow the market for our Obalon balloon system in the United States: sales conversion, practice development and clinical training and application. In select international markets, we plan to utilize distributors. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have an agreement to sell to Bader Sultan&#160;&amp; Bros. Co. W.L.L., or Bader,  as the sole distributor of our Obalon balloon system in the Middle East. Our agreement with Bader restricts Bader&#8217;s ability to sell competing products and requires Bader to purchase a certain number of products from us monthly based on annual forecasts that we provide to Bader. If Bader does not resell the minimum purchase quantity specified in the contract by the applicable date, then we have the right, in our sole discretion, to sell to other distributors in the Middle East or terminate our agreement with Bader. The agreement can be terminated by us immediately upon certain breaches by Bader, or by either Bader or us for uncured material breach of the agreement. We have discontinued sales of our prior generation product in the Middle East and do not plan to begin selling in the Middle East again until our next generation inflation system is approved. We are currently working closely with Bader to determine the best timing and strategy for launch of the current generation Obalon balloon system with the next generation inflation system in the Middle East. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our initial U.S. marketing efforts are focused on differentiating the benefits of our technology, leveraging the strong clinical outcome from our SMART trial, working with key thought leaders in bariatrics, gastroenterology, and plastic surgery, and partnering with physicians to create consumer awareness and drive patients into the channel. We also intend to provide physicians with the clinical training to utilize our Obalon balloon system, as well as the practice development support to manage their practices as self-pay centers. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In an effort to evaluate the potential U.S. market opportunity for our Obalon balloon system, we commissioned a survey of 3,000 individuals. Each participant was asked to complete a survey containing a series of questions relating to income level, weight and interest in various weight loss alternatives. We took the results of that survey and applied them generally to the U.S. population figures for 2015 to estimate that there are approximately 11.0 million individuals in the United States with a household income greater than $30,000 and a BMI between 30 and 40 that would be interested in receiving treatment using the Obalon balloon system. We also used this information to estimate that the percentage of potentially interested individuals that are men or women is approximately the same. We cannot assure you that the individuals selected for the survey are representative of the characteristics and interests of the broader U.S. population, or that the responses of these individuals to our survey or our estimates are reliable or accurate. To the extent our assumptions regarding these individuals and data are inaccurate, our estimated market opportunity could be significantly different. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have very limited experience as a company in the sales and marketing of our products, and no experience with sales and marketing in the United States. Identifying and recruiting qualified sales personnel and training them in the use of our Obalon balloon system to achieve the level of clinical competency expected by physicians, and compliance with applicable federal and state laws and regulations and our internal policies and procedures, requires significant time, expense and attention. It can take several months before our sales representatives are fully trained and productive. </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPETITION </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The medical device industry is highly competitive, subject to rapid change and significantly affected by new product introductions, results of clinical research, corporate combinations, actions by regulatory bodies, changes by public and private payers and other factors relating to our industry. Because of the market opportunity and the high growth potential of the non-surgical device market for weight loss and obesity, competitors and potential competitors have historically dedicated, and will continue to dedicate, significant resources to aggressively develop and commercialize their products. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, our product competes with a variety of pharmaceuticals, surgical procedures and devices for the treatment of obese and overweight people. There are several competitors in the pharmaceutical segment including those recently approved by the FDA, including Vivus, Inc., Arena Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., and those with older brands or generics including Takeda Pharmaceutical Company Ltd, AstraZeneca plc, and Actavis plc. Large competitors in the surgical segment for weight loss and obesity include Ethicon Inc. (subsidiary of Johnson&#160;&amp; Johnson), Medtronic plc (formerly Covidien Ltd.) and Apollo EndoSurgery, Inc., which acquired the Lap-Band from Allergan plc and currently sells that device worldwide. After approximately a decade, four new devices were approved by the FDA in 2015 and 2016. Enteromedics Inc. received FDA approval for the Maestro, which is intended to create weight loss by vagal nerve stimulation. ReShape Medical Inc. and Apollo EndoSurgery, Inc. received FDA approval for the ReShape Duo Balloon and the ORBERA Balloon, respectively, each a traditional intragastric balloon filled with saline. Aspire Bariatrics received FDA approval for the Aspire Assist, a device that allow you to aspirate food after a meal. Allurion Technologies, Inc. has also developed a swallowable, passable saline-filled intragastric balloon that has been approved for sale in Europe and Middle East. Additionally, there are many more companies around the world working to develop less invasive and less costly alternatives for the treatment of obesity, which could compete with us in the future. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time, these or other competitors may introduce new or alternative products that compete directly or indirectly with our products and services. They may also develop and patent products and processes earlier than we can or obtain regulatory clearance or approvals faster than us, which could impair our ability to develop and commercialize similar products or services. If clinical outcomes of procedures performed with our competitors&#8217; products are, or are perceived to be, superior to treatments performed with our products, sales of our products could be negatively affected and our business, results of operations and financial condition could suffer. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our competitors have significantly greater financial and other resources than we do, as well as: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">well-established reputations and name recognition with key opinion leaders and physician networks; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an established base of long-time customers with strong brand loyalty; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">products supported by long-term data; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">longer operating histories; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significantly larger installed bases of equipment; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater existing market share in the obesity and weight management market; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">broader product offerings and established distribution channels; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater ability to cross-sell products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or incentives; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">more experience in conducting research and development, manufacturing, performing clinical trials and obtaining regulatory approvals or clearances. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competition with these companies could result in significant price-cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations. In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or products that could effectively compete with our existing and future products, which may cause our revenues to decline and harm our business. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to compete effectively, we plan to continue to develop new product offerings and enhancements to our existing Obalon balloon system, price our product competitively with traditional saline-filled intragastric balloons and maintain adequate research and development and sales and marketing personnel and resources to meet the demands of the market. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INTELLECTUAL PROPERTY </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to remain competitive, we must develop and maintain protection of the proprietary aspects of our technologies. We rely on a combination of patents, trademarks, trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our policy to require our employees, consultants, contractors, outside scientific collaborators and other advisors to execute non-disclosure and assignment of invention agreements on commencement of their employment or engagement. Agreements with our employees also forbid them from using the proprietary rights of third parties in their work for us. We also require third parties that receive our confidential data or material to enter into confidentiality or material transfer agreements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, we held 14 issued U.S. patents and had 19 pending U.S. patent applications, as well as 17 international patents issued in Europe, Mexico, Australia, Canada, Asia, China and Israel and 34 pending international patent applications in Australia, Canada, Europe, Asia, the Middle East and South America. Our issued patents expire between the years 2023 and 2032, and are directed to various features and combinations of features of the Obalon balloon system technology, including the apparatus for connecting the balloon to an inflation catheter, the structure and composition of the balloon wall, and the composition of the initial fill gas. As we continue to research and develop our Obalon balloon system technology, we intend to file additional U.S. and foreign patent applications related to the design, manufacture and therapeutic uses of our balloon and navigation devices. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology. Any patents issued to us may be challenged by third parties as being invalid or unenforceable, or third parties may independently develop similar or competing technology that does not infringe our patents. The laws of certain foreign countries do not protect our intellectual property rights to the same extent as do the laws of the United States. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, we held one registered U.S. trademark and 13 registered marks in Europe, Asia and Mexico. We have three pending U.S. trademark applications and 8 pending marks outside the United States, including in Europe, the Middle East, Asia and Mexico. </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MANUFACTURING </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our products are manufactured or assembled in-house using components and sub-assemblies at our facilities in Carlsbad, California. We rely on single suppliers for the extruded film, swallowable capsule, molded silicone valve used to manufacture our Obalon balloons and the hydrophilic coating for our catheters. Our suppliers have no contractual obligations to supply us with, and we are not contractually obligated to purchase any of our supplies from them. Order quantities and lead times for components purchased from our suppliers are based on our forecasts derived from historical demand and anticipated future demand. Lead times for components may vary significantly depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components and subassemblies. To date, we have not experienced significant delays in obtaining any of our components or subassemblies. However, these components are critical to our products and there are relatively few alternative sources of supply. We do not carry a significant inventory of these components, and identifying and qualifying additional or replacement suppliers for any of the components or sub-assemblies used in our products could involve significant time and cost, and may delay our commercialization efforts. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have registered with the FDA as a medical device manufacturer and have obtained a manufacturing license from the Center for Devices and Radiological Health. We and our component suppliers are required to manufacture our products in compliance with the FDA&#8217;s Quality System Regulation, or QSR, in 21 CFR part&#160;820 of the Federal Food, Drug and Cosmetic Act. The QSR regulates extensively the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. The FDA enforces the QSR through periodic unannounced inspections that may include the manufacturing facilities of our subcontractors. Since we began manufacturing onsite, our quality system has undergone 15 external audits, the last of which occurred in November 2016 and resulted in no non conformances.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we expect our third-party suppliers to supply us with components that meet our specifications and comply with regulatory and quality requirements, we do not control our suppliers outside of our agreements, as they operate and oversee their own businesses. There is a risk that our suppliers will not always act consistent with our best interests, and may not always supply components that meet our needs. Any significant delay or interruption in the supply of components or sub-assemblies, or our inability to obtain substitute components, sub-assemblies or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and harm our business. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we will need to increase our manufacturing capabilities in order to satisfy expected demand for our Obalon balloon system, and we have no experience manufacturing our Obalon balloon system in such quantities. If we are unable to keep up with demand for our Obalon balloon system, our revenue could be impaired, market acceptance for our Obalon balloon system could be harmed and our customers might instead purchase our competitors&#8217; products. </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GOVERNMENT REGULATION </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products and operations are subject to extensive and rigorous regulation by the FDA and other federal, state and local authorities, as well as foreign regulatory authorities. The FDA regulates, among other things, the research, development, testing, design, manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion and marketing, distribution, post approval monitoring and reporting and import and export of medical devices (such as the Obalon balloon system) in the United States to assure the safety and effectiveness of medical products for their intended use. The Federal Trade Commission also regulates the advertising of our products in the United States. Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training and other practices to government scrutiny. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulatory system for medical devices in the United States </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the United States will require either a premarket notification to the FDA requesting permission for commercial distribution under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act, or FFDCA, also referred to as a 510(k) clearance, or approval from the FDA of a PMA application. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees, unless an exemption is available. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Device classification </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the FFDCA, medical devices are classified into one of three classes&#8212;Class&#160;I, Class&#160;II or Class&#160;III&#8212;depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Class&#160;I devices are those for which safety and effectiveness can be reasonably assured by adherence to a set of regulations, referred to as General Controls, which require compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class&#160;I devices, also called Class&#160;I reserved devices, also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class&#160;I products are exempt from the premarket notification requirements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Class&#160;II devices are those that are subject to the General Controls, as well as Special Controls, which can include performance standards, guidelines and post-market surveillance. Most Class&#160;II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class&#160;II devices is accomplished through the 510(k) premarket notification process. Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent,&#8221; as defined in the statute, to either: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a device that was legally marketed prior to May&#160;28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">another commercially available, similar device that was cleared through the 510(k) process. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After a 510(k) notice is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90&#160;days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. If the FDA requires a new 510(k) clearance or approval of a PMA application for any modifications to a previously cleared product, the applicant may be required to cease marketing or recall the modified device until clearance or approval is received. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite PMA application(s). In addition, the FDA is currently evaluating the 510(k) process and may make substantial changes to industry requirements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class&#160;III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:inherit;font-size:10pt;">&#32;process. Pursuant to amendments to the statute in 2012, a manufacturer can also submit a petition for direct </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:inherit;font-size:10pt;">&#32;review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Class&#160;III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class&#160;III devices cannot be reasonably assured solely by the General Controls and Special Controls described above. Therefore, these devices are subject to the PMA application process, which is generally more costly and time consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The investigational device process </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an IDE application. Some types of studies deemed to present &#8220;non-significant risk&#8221; are deemed to have an approved IDE once certain requirements are addressed and IRB approval is obtained. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of subjects. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review boards at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and efficacy, even if the trial meets its intended success criteria. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA&#8217;s regulations for institutional review board approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable, or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product. The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but not limited to, the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients do not enroll in clinical trials at the rate expected; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients do not comply with trial protocols; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patient follow-up is not at the rate expected; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients experience adverse events; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients die during a clinical trial, even though their death may not be related to the products that are part of the trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">device malfunctions occur with unexpected frequency or potential adverse consequences; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">side effects or device malfunctions of similar products already in the market that change the FDA&#8217;s view toward approval of new or similar PMAs or result in the imposition of new requirements or testing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">institutional review boards and third-party clinical investigators may delay or reject the trial protocol; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other FDA or IRB requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party investigators are disqualified by the FDA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records, and reports of sponsors of clinical investigations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results unreliable, or the company or investigators fail to disclose such interests; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in government regulations or administrative actions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA concludes that our trial design is unreliable or inadequate to demonstrate safety and efficacy. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The PMA approval process </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA, by statute and by regulation, has 180&#160;days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an applicant fails to respond to an FDA request for information (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:10pt;">, major deficiency letter) within a total of 360&#160;days. Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. Prior to approval of a PMA, the FDA may conduct a bioresearch monitoring inspection of the clinical trial data and clinical trial sites, and a QSR inspection of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years, but may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the device may not be shown safe or effective to the FDA&#8217;s satisfaction; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the manufacturing process or facilities may not meet applicable requirements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in FDA approval policies or adoption of new regulations may require additional data. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also require post-market surveillance for certain devices cleared under a 510(k) notification, such as implants or life-supporting or life-sustaining devices used outside a device user facility. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use. Intragastric balloons, including the Obalon balloon system, are considered Class III medical devices. In order to support a PMA application, the FDA required us to conduct a large, rigorous and expensive, double-blinded, randomized, sham-controlled trial. We will be required to file new PMA applications or PMA supplement applications for modifications to our PMA-approved Obalon balloon system or any of its components, including modifications to our manufacturing processes, device labeling and device design. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pervasive and continuing FDA regulation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the FDA permits a device to enter commercial distribution, numerous regulatory requirements continue to apply. These include: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA&#8217;s QSR, which requires manufacturers, including third party manufacturers, to follow stringent design, testing, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">labeling regulations, unique device identification requirements and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advertising and promotion requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on sale, distribution or use of a device; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PMA annual reporting requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PMA approval of product modifications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">medical device reporting, or MDR, regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">medical device correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recall requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health consequences or death; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an order of repair, replacement or refund; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">device tracking requirements; and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The MDR regulations require that we report to the FDA any incident in which our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury.   In February 2017, the FDA issued a letter to Healthcare Practitioners citing they had received multiple reports for two different types of adverse events associated with traditional, saline-filled intragastric balloons.  Although the letter specifically states that these adverse events have not been reported for the Obalon balloon system, this action may indicate closer scrutiny of the intragastric balloon category which could have detrimental effects on our efforts to commercialize our products or get new products approved. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have registered with the FDA as a medical device manufacturer and have obtained a manufacturing license from the California Department of Health Services, or CDHS. The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of CDHS to determine our compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of our suppliers. BSI, our European Notified Body, most recently inspected our facility in 2016 and found zero non-conformances. Our current facility has been inspected by the FDA in 2014 and 2016, and four observations were noted in the first inspection and zero observations were noted in the second inspection. Responses to the observations in the 2014 FDA audit were accepted by the FDA and no response was required by us in the 2016 inspection. We believe that we are in substantial compliance with the QSR. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning letters, fines, injunctions, consent decrees and civil penalties; </font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated expenditures, repair, replacement, refunds, recall or seizure of our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions, partial suspension or total shutdown of production; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA&#8217;s refusal of our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawing 510(k) clearance or premarket approvals that have already been granted; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">criminal prosecution. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulatory system for medical devices in Europe </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The European Union consists of 25 member states and has a coordinated system for the authorization of medical devices. The European Union Medical Devices Directive, or MDD, sets out the basic regulatory framework for medical devices in the European Union. This directive has been separately enacted in more detail in the national legislation of the individual member states of the European Union. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The system of regulating medical devices operates by way of a certification for each medical device. Each certificated device is marked with CE mark which shows that the device has a Certificat de Conformit&#233;. There are national bodies known as Competent Authorities in each member state which oversee the implementation of the MDD within their jurisdiction. The means for achieving the requirements for CE mark varies according to the nature of the device. Devices are classified in accordance with their perceived risks, similarly to the U.S. system. The class of a product determines the requirements to be fulfilled before CE mark can be placed on a product, known as a conformity assessment. Conformity assessments for our products are carried out as required by the MDD. Each member state can appoint Notified Bodies within its jurisdiction. If a Notified Body of one member state has issued a Certificat de Conformit&#233;, the device can be sold throughout the European Union without further conformance tests being required in other member states. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to the MDD, the Obalon balloon system, when delivered with a porcine capsule, is considered a Class III product. The Obalon balloon system when delivered with a cellulose-based capsule is considered a Class IIb product. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulatory frameworks for medical devices in certain countries in the Middle East </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlike Europe, while the Gulf Cooperation Council, or GCC, jurisdictions often work together to purchase certain medical products in a coordinated fashion for government hospitals, there is not a coordinated system for the authorization of medical devices. Most GCC jurisdictions require that the official registered distributor of a product be wholly owned by nationals of that particular GCC jurisdiction. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Kingdom of Saudi Arabia, or KSA </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most pertinent regulation is the Interim Regulation for Medical Devices, issued by the Saudi Food&#160;&amp; Drug Authority, or SFDA, Board of Directors&#8217; Decree number 1-8-1429 dated approximately December&#160;27, 2008 and the implementing regulations of the same. The SFDA is an independent regulatory body that is responsible for the authorization of medical devices, and current guidelines are generally based on pre-existing approval in one of the five founding member nations of the Global Harmonization Task Force, or GHTF, which are Australia, Canada, United States, European Union and Japan. There are no overt requirements for the provision of safety and effectiveness data in the form of clinical trials or other studies but these would likely come as a part of the approvals described above that are used as a basis to support approval within the KSA. The SFDA reserves its rights to require its own independent clinical trials as it deems necessary or appropriate. Regulatory authorization is required for all medical devices, regardless of device class. A potential exception to this requirement is for medical devices that were designed and constructed by local health care facility and staff for internal use. Similar to the United States, the SFDA requires post market surveillance to ensure safety and quality. This program is meant to be conducted by the Authorized Representative. With respect to the use of medical devices, it is the responsibility of the health care institution to inform the manufacturer and the SFDA of any adverse events associated with this use. We have appointed Al Sultan Saudi Medical Company as our responsible Authorized Representative for the KSA. Our Medical Device Marketing Authorisation was renewed on July 26,&#160;2016 and expires on May 14,&#160;2020. In KSA it is possible for a foreign party to establish a Technical&#160;&amp; Scientific Office and register the medical device, while working with a locally licensed Authorized Representative to conduct sales of such approved medical devices. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Kuwait </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical devices in Kuwait are regulated by the Medicines and Medical Supplies, Pharmaceuticals and Herbal Medicines Registration and Control Administration Department in the Ministry of Health. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order for any company/manufacturer to sell a medical device in Kuwait, the specific medical device must be approved for use and registered in Kuwait with the Ministry of Health. The manufacturer of the device, through its agent/distributor should submit an application to the Ministry of Health for the approval and registration of the device. The documents required to register a medical device with the Ministry of Health in summary include: (i)&#160;the original Manufacturing License and Good Manufacturing Practice certificates; (ii)&#160;the original Free Sale Certificate which should mention the trade name, scientific name, indications, and detailed composition for active and inactive ingredients and which should be issued by the health authority in the country of origin of the device; (iii)&#160;the status of registration of the product in the country of origin; (iv)&#160;the original letter of appointment of an exclusive agent/distributor for the device; (v)&#160;a list of countries where the product is registered with registration dates and numbers; (vi)&#160;a sample of the product with information about the product on the outer and inner packaging in English or Arabic (the information on the packaging should include: the name of the product, its content/composition, uses, batch number, manufacturing date, expiry date, storage conditions, and instructions on use); (vii)&#160;a certificate of analysis of the finished product; (viii)&#160;safety and efficacy studies from an approved international authority (and/or clinical studies if applicable); and (ix)&#160;any other information the Ministry of Health may require. Once all documents are in order and the Ministry of Health does not require any further information, it will register the device under the names of the manufacturer and the relevant agent/distributor. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The promotion, distribution and sale of medical devices in Kuwait can only be done by a Kuwaiti entity that is appointed by the manufacturer of the device as its exclusive agent/distributor for Kuwait. Such agent/distributor must be authorized by and registered with the Medicines and Medical Supplies, Pharmaceuticals and Herbal Medicines Registration and Control Administration Department in the Ministry of Health and the Ministry of Commerce and Industry to do so.&#160;The device may be sold in licensed pharmacies and other places approved by the Ministry of Health. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have appointed Bader as our exclusive agent/distributor in Kuwait. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">United Arab Emirates, or UAE </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most pertinent regulation is UAE Federal Law No.&#160;4 of 1983 for the Pharmaceutical Profession and Institutions and to Medical Device Regulations. There are many similarities between the SFDA and the Registration and Drug Control Department that is run out of the Ministry of Health&#160;&amp; Prevention of the UAE. Applications for registration of medical devices in the UAE are done with the UAE Ministry of Health Registration&#160;&amp; Drug Control Department and must include data on effectiveness in addition to safety (a nod to the requirements of the FDA). The UAE body has its own device classification system that is most closely related to that used by the European Union, defined as class 1, low risk; class 2, medium risk but nonimplantable; class 3, medium risk but implantable; and class 4, high risk. The Obalon balloon system is considered a Class 4 (high risk) device when delivered with a porcine-based gelatin capsule. We have appointed Sohail Faris Medical Equipment Trading as the responsible Authorized Representative for the UAE. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Privacy and security laws </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, directed the Secretary of the U.S. Department of Health and Human Services, or HHS, to promulgate regulations establishing protections for the privacy and security of individually identifiable health information, known as &#8220;protected health information&#8221; and prescribing standard requirements for electronic health care transactions. HIPAA generally requires certain entities, referred to as &#8220;covered entities&#8221; (including most healthcare providers, healthcare clearing houses and health plans), to comply with established standards, including standards regarding the privacy and security of protected health information, or PHI. HIPAA further requires that covered entities enter into agreements meeting certain regulatory requirements with their &#8220;business associates,&#8221; as such term is defined by HIPAA, which, among other things, obligate the business associates to safeguard the covered entity&#8217;s PHI against improper use and disclosure. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The American Recovery and Economic Reinvestment Act of 2009, or ARRA, signed into law by President Obama on February&#160;17, 2009, contained significant changes to the privacy and security provisions of HIPAA, including major changes to the enforcement provisions. Among other things, ARRA significantly increased the amount of civil monetary penalties that can be imposed for HIPAA violations. ARRA also authorized state attorneys general to bring civil enforcement actions under HIPAA. These enhanced penalties and enforcement provisions went into effect immediately upon enactment of ARRA. ARRA also required that HHS promulgate regulations requiring that certain notifications be made to individuals, to HHS and potentially to the media in the event of certain types of breaches of the privacy of protected health information. These breach notification regulations went into effect on September&#160;23, 2009, and HHS began to enforce violations on February&#160;22, 2010. Violations of the breach notification provisions of HIPAA can trigger the increased civil monetary penalties described above. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Health Information Technology for Economic and Clinical Health Act, or HITECH, was also enacted in conjunction with ARRA. On January&#160;25, 2013, HHS issued final modifications to the HIPAA Privacy, Security, and Enforcement Rules mandated by HITECH, which had been previously issued as a proposed rule on July&#160;14, 2010. Among other things, these modifications make business associates of covered entities directly liable for compliance with certain HIPAA requirements, strengthen the limitations on the use and disclosure of protected health information without individual authorizations, and adopt the additional HITECH enhancements, including enforcement of noncompliance with HIPAA due to willful neglect. The changes to HIPAA enacted as part of ARRA reflect a Congressional intent that HIPAA&#8217;s privacy and security provisions be more strictly enforced. It is likely that these changes will stimulate increased enforcement activity and enhance the potential that health care providers will be subject to financial penalties for violations of HIPAA. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the federal laws and regulations, there are a number of state laws regarding the privacy and security of health information and personal data. The compliance requirements of these laws, including additional breach reporting requirements, and the penalties for violation, vary widely, and new privacy and security laws in this area are evolving. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe we are not a covered entity for purposes of HIPAA, and we believe that we generally do not conduct our business in a manner that would cause us to be a business associate under HIPAA. Although we do not believe the business is subject to HIPAA, we nevertheless are committed to maintaining the security and privacy of patients&#8217; health information. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anti-kickback statutes</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Anti-Kickback Statute prohibits persons from (among other things) knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce the referral of an individual, or the recommending, furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Courts have interpreted the Anti-Kickback Statute quite broadly, holding that the statute will be violated if even one purpose of a payment &#8211; though not its sole or primary purpose &#8211; is to induce an act prohibited by the statute with a willful intent to act improperly. The statute prohibits many arrangements and practices that are otherwise lawful in businesses outside of the healthcare industry. Prosecutors may infer intent from the surrounding circumstances and, because courts have interpreted the statute to be violated if even one purpose of a payment is to induce the purchase of items or services paid for by federal healthcare programs, prosecutors have broad discretion in choosing arrangements to prosecute under the statute. There are statutory exceptions and regulatory &#8220;safe harbors&#8221; available to protect certain appropriately structured arrangements that otherwise would implicate the Anti-Kickback Statute. Those who structure their business arrangements to satisfy all of the criteria of a safe harbor are protected from liability under the statute. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Penalties for violation of the Anti-Kickback Statute are severe and may include, in addition to the fines and jail time described above, penalties imposed under the Civil Monetary Penalties Law, or the CMP Law, including exclusion from participation in Federal healthcare programs, civil monetary penalties of up to $50,000 for each improper act, and damages of up to three times the amount of remuneration at issue (regardless of whether some of the remuneration was for a lawful purpose). Because we do not anticipate that the Obalon balloon system will be reimbursed by any federal healthcare program, we do not believe that we will be subject to the federal Anti-Kickback Statute. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many states have adopted laws similar to the Anti-Kickback Statute, however, and some of these state prohibitions apply to arrangements involving healthcare items or services reimbursed by any source, and not only by Medicare, Medicaid or another federal healthcare program. These state laws do not always have the same exceptions or safe harbors of the federal Anti-Kickback Statute. The business may be subject to some of these laws. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government officials have focused recent enforcement efforts on the marketing of healthcare services and products, among other activities, and have brought cases against companies, and certain individual sales, marketing and executive personnel, for allegedly offering unlawful inducements to potential or existing customers in an attempt to procure their business. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">False claims laws </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal False Claims Act imposes liability on any individual or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;">&#32;or &#8220;whistleblower&#8221; provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has violated the False Claims Act and to share in any monetary recovery. In recent years, the number of lawsuits brought against healthcare industry participants by private individuals has increased dramatically. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties of between $5,500 and $11,000 for each separate instance of false claim. As part of any settlement, the government may ask the entity to enter into a corporate integrity agreement, which imposes certain compliance, certification and reporting obligations. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The federal government has used the False Claims Act to assert liability on the basis of inadequate care, kickbacks and other improper referrals, and the provision of inaccurate reimbursement coding advice, in addition to the more predictable allegations as to misrepresentations with respect to the services rendered. In addition, companies have been sued under the False Claims Act in connection with the off-label promotion of products. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various states have also enacted false claims laws that are analogous to the federal False Claims Act. Many of these state laws apply to claims submitted to any third-party payor and are not limited to claims submitted to a federal healthcare program. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we do not expect the Obalon balloon system to be reimbursed by federal healthcare programs or any other third-party payor, we do not believe that the business generally will be subject to many of these laws. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transparency laws</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Physician Payment Sunshine Act, or the Sunshine Act, which was enacted as part of the Patient Protection and Affordable Care Act, or the PPACA, generally requires certain manufacturers of a drug, device, biologic or other medical supply that is covered by Medicare, Medicaid or the Children&#8217;s Health Insurance Program and applicable group purchasing organizations to report on an annual basis: (i)&#160;certain payments and other transfers of value given to physicians and teaching hospitals and (ii)&#160;any ownership or investment interest that physicians, or their immediate family members, have in their company. The payments required to be reported include the cost of meals provided to a physician, travel reimbursements and other transfers of value, including those provided as part of contracted services such as speaker programs, advisory boards, consultation services and clinical trial services. Under the statute, the federal government makes reported information available to the public. Failure to comply with the reporting requirements can result in significant civil monetary penalties ranging from $1,000 to $10,000 for each payment or other transfer of value that is not reported (up to a maximum per annual report of $150,000) and from $10,000 to $100,000 for each knowing failure to report (up to a maximum per annual report of $1&#160;million). Additionally, there are criminal penalties if an entity intentionally makes false statements in the reports. Because we do not expect the Obalon balloon system to be covered or reimbursed by any federal healthcare program, we do not believe that our business will be subject to the federal Sunshine Act. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been a recent trend of separate state regulation of payments and transfers of value by manufacturers of medical devices to healthcare professionals and entities, however, and some state transparency laws apply more broadly than does the federal Sunshine Act. Our business may be subject to some of these state laws. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Corrupt Practices Act</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Foreign Corrupt Practices Act, or FCPA, prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records, which in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the corporation, including international subsidiaries, if any, and to devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">International laws</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Europe, and throughout the world, other countries have enacted anti-bribery laws and/or regulations similar to the FCPA. Violations of any of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are also international privacy laws that impose restrictions on the access, use, and disclosure of health information. All of these laws may impact our business. Our failure to comply with these privacy laws or significant changes in the laws restricting our ability to obtain required patient information could significantly impact our business and our future business plans. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. healthcare reform </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of the Obalon balloon system. By way of example, PPACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the medical device industry. PPACA, among other things, imposed a 2.3% excise tax on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions. Although the excise tax has been suspended for 2016 and 2017, absent further legislative action, the tax will be reinstated starting January&#160;1, 2018. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There will continue to be proposals by legislators at both the federal and state levels, regulators and third party payors to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge and/or patients&#8217; willingness to pay for the Obalon balloon system. While in general it is too early to predict what effect, if any, PPACA and its implementation, or any future healthcare reform legislation or policies will have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition. </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EMPLOYEES </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, we had 91 employees, including 24 in manufacturing and operations, 32 in sales and marketing, 11 in research and development, 14 in clinical affairs, regulatory affairs and quality assurance and 10 in finance, general administrative and executive administration. All 91&#160;employees are full time employees. None of our employees are represented by a labor union or are parties to a collective bargaining agreement, and we believe that our employee relations are good. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL INFORMATION </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our operations and allocate resources as a single reporting segment. Financial information regarding our operations, assets and liabilities, including our net loss for the years ended December&#160;31, 2016, 2015 and 2014 and our total assets as of December&#160;31, 2016 and 2015, is included in our Consolidated Financial Statements in Item&#160;8 of this Annual Report. </font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CORPORATE INFORMATION </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were incorporated under the laws of the State of Delaware in January 2008. Our principal executive offices are located at 5421 Avenida Encinas, Suite F, Carlsbad, California 92008, and our telephone number is (760)&#160;795-6558. Our website address is www.obalon.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AVAILABLE INFORMATION </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other information with the Securities and Exchange Commission, or SEC. Our filings with the SEC are available free of charge on the SEC&#8217;s website at </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">&#32;and on the &#8220;Investor Information&#8221; section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. You may also read and copy, at SEC prescribed rates, any document we file with the SEC at the SEC&#8217;s Public Reference Room located at 100 F Street, N.E., Washington D.C. 20549. You can call the SEC at 1-800-SEC-0330 to obtain information on the operation of the Public Reference Room. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><a name="s1292B8F812D9DC0763607564EF43F3B9"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1A.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related nothighes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. The market price of our common stock would likely decline, and you could lose all or part of your investment.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATED TO OUR BUSINESS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have limited operating experience and a history of net losses, and we may not be able to achieve or sustain profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a limited operating history and have focused primarily on research and development, clinical trials, product engineering and building our manufacturing capabilities. We have also conducted a commercial launch of a previous generation of the Obalon balloon system in certain international markets, but our commercial sales experience in these international markets has been limited and our total revenue to date is approximately </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;">. We have incurred significant losses in each period since our inception in 2008, with net losses of </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;">, $15.6&#160;million and $9.9&#160;million for the years ended December&#160;31, 2016, 2015 and 2014, respectively. As of December 31, 2016, we had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$76.6 million</font><font style="font-family:inherit;font-size:10pt;">. These losses and our accumulated deficit reflect the substantial investments we have made to develop, seek and obtain regulatory approval for our Obalon balloon system and sell our Obalon balloon system internationally.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our costs and expenses to increase in the future as we continue U.S. commercialization of our product, including the cost of a direct sales force and the expansion of our manufacturing facilities, and as we continue to expend substantial amounts on research and development, including conducting clinical trials of our products in development. As a result, we expect our losses to continue for the foreseeable future. In addition, as a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. Accordingly, we cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will sustain profitability. Our failure to achieve and sustain profitability would negatively impact the market price of our common stock.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are currently a single product company with limited commercial sales experience, which makes it difficult to evaluate our current business, predict our future prospects and forecast our financial performance and growth.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were incorporated in 2008, and to date our business activities have been focused primarily on the development and regulatory approval of our Obalon balloon system. All of our revenue to date is, and we expect for the foreseeable future will be, attributable to sales of our Obalon balloon system and its component parts. Our commercial sales experience to date has been limited to sales to distributors in a limited number of countries outside the United States. We recently obtained premarket approval, or PMA, from the U.S. Food and Drug Administration, or FDA, to market the current generation of our balloon system in the United States, and we expect that sales in the United States will account for a majority of our revenue for the foreseeable future. Our limited operating experience and lack of commercialization experience in what we expect will be our primary market make it difficult to evaluate our current business and predict our future prospects. A number of factors that are outside our control may contribute to fluctuations in our financial results, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patient and physician demand for our Obalon balloon system, including the rate at which physicians recommend our Obalon balloon system to their patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">positive or negative media coverage, or public, patient and/or physician perception, of our Obalon balloon system, the procedures or products of our competitors, or our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any safety or efficacy concerns that arise through patient experience with our Obalon balloon system;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any safety or efficacy concerns for the category of intragastric balloons including traditional saline-filled balloon such as those safety issues stated in the February 2017 FDA Health Care Provider letter warning about pancreatitis and hyperinflation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated delays in product development or product launches;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to maintain our current or obtain further regulatory clearances or approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in, or failure of, product and component deliveries by our third-party suppliers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">introduction of new procedures or products for treating obese or overweight patients that compete with our product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse changes in the economy that reduce patient demand for elective procedures; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance of our international distributors.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is therefore difficult to predict our future financial performance and growth, and such forecasts are inherently limited and subject to a number of uncertainties. If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we devote substantially all of our resources to our Obalon balloon system and rely on our Obalon balloon system as our sole source of revenue, any factors that negatively impact our product, or result in decreasing product sales, would materially and adversely affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Physicians and patients may be slow to adopt and use intragastric balloons, and adverse events or other negative developments involving other companies&#8217; intragastric balloons or other obesity treatments may further slow physician and patient adoption. If any of these events were to occur, our business and prospects would be negatively affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intragastric balloons are a new treatment option for obese and overweight patients. Currently, we are aware of only two other intragastric balloons available for sale in the United States, neither of which was available prior to 2015. As a result, physician and patient awareness of intragastric balloons as a treatment option for obesity and weight management, and experience with intragastric balloons, is minimal. Our success depends in large part on our ability to educate physicians and patients, and successfully demonstrate the safety, tolerability, ease of use, efficacy, cost effectiveness and other merits of our Obalon balloon system. Since we received PMA approval for the Obalon balloon system in September 2016, we began engaging in an active marketing campaign to raise awareness of our Obalon balloon system and its benefits among physicians, but we cannot assure you that these efforts will be successful or that they will not prove to be cost-prohibitive.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Physicians play a significant role in determining the course of a patient&#8217;s weight management or obesity treatments and as a result, the type of treatment that will be recommended or provided to a patient. We intend to target our sales efforts at bariatric surgeons, gastroenterologists, and plastic surgeons, because they are either the physicians treating obese and overweight patients and/or have experience with endoscopic procedures. However, the initial point of contact for many obese and overweight patients may be general practitioners, bariatricians, endocrinologists, obstetricians and gynecologists, each of whom commonly manage and regularly see patients that are obese or overweight. If these physicians are not made aware of our Obalon balloon system, they may not refer patients to bariatric surgeons, gastroenterologists or plastic surgeons for treatment using our product, and those patients may instead not seek treatment at all or be treated with pharmaceuticals or an alternative device or surgical procedure.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, because the market for intragastric balloons is new and developing and contains a limited number of market participants, our products could be negatively impacted by unfavorable market reactions to these other devices. If the use of these or future intragastric balloons results in serious adverse device events, or SADEs, or such products are subject to malfunctions or misuse, patients and physicians may attribute such negative events to intragastric balloons generally, which may adversely affect market adoption of our Obalon balloon system. In February 2017, the FDA issued a letter to Healthcare Practitioners citing they had received multiple reports for two different types of adverse events associated with Reshape and Apollo saline-filled intragastric balloons.  Although the letter specifically states that these events have not been reported for the Obalon balloon system, this action could create negative perceptions of the entire category and slow down the acceptance of the Obalon Balloon.  Additionally, if patients undergoing treatment with our Obalon balloon perceive the weight loss inadequate or adverse events too numerous or severe as compared with the retreatment rates of alternative balloons or procedures, it will be difficult to demonstrate the value of our Obalon balloon system to patients and physicians. As a result, demand for our Obalon balloon system may decline or may not increase at the pace or to the levels we expect.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to convince physicians to adopt our Obalon balloon system and recommend it to their patients, we may be unable to sell our products, grow our business or achieve profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to sell our Obalon balloon system depends heavily on the willingness of physicians to adopt our system and recommend it to their patients. Physicians may not adopt our Obalon balloon system unless they are able to determine, based on experience, long-term clinical data, recommendations from other physicians and published peer-reviewed journal articles, that it provides a safe and effective treatment alternative for obesity. Even if we are able to raise awareness among physicians, physicians tend to be slow in changing their medical treatment practices and may be hesitant to select our Obalon balloon system for recommendation to patients for a variety of reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">long-standing relationships with competitors and distributors that sell other products and their competitive response and negative selling efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of experience with our products and concerns that we are relatively new to the obesity market, or concerns that our competitors offer greater support or have larger amounts of resources than our company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perceived liability risk generally associated with the use of new products and procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack or perceived lack of sufficient clinical evidence supporting clinical benefits;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reluctance to change to or use new products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perceptions that our products are unproven or experimental; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">time and skill commitment that may be required to gain familiarity with a new system.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also aware of certain characteristics and features of our Obalon balloon system that may prevent widespread market adoption. For example, our Obalon balloon system is approved as an adjunct to a moderate intensity diet and behavior modification program. As a result, physicians will need to develop the appropriate practice management programs, which include treatment protocols, nutritional counseling and patient management, to treat patients in a manner consistent with our treatment protocol. If physicians are unable or unwilling to implement the appropriate practice management programs to successfully treat patients with the Obalon balloon, they may not adopt our balloon system. Our current EzFill inflation system requires certain pre-programming that is dependent upon the altitude of the physician&#8217;s practice, which may hinder or make it more difficult for us to market and commercialize our products.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The effectiveness and safety of our Obalon balloon system depends critically on our ability to educate physicians on its safe and proper use. If we are unable to do so, we may not achieve our expected growth and may be subject to risks and liabilities.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to educating physicians on the clinical benefits of our Obalon balloon system, we must also train physicians on its safe and appropriate use. In particular, our FDA approved labeling requires physicians to complete an Obalon training program before they can place the device and for us to provide clinical support as needed. If we are unable to provide an adequate training program, product misuse may occur that could lead to SADEs. Many physicians may be unfamiliar with such treatments or find it more complex than competitive products or alternative treatments. As such, there is a learning process involved for physicians to become proficient in the use of our products and it may take several procedures for a physician to be able to use our Obalon balloon system comfortably. In addition, it is also critical for physicians to be educated and trained on best practices in order to achieve optimal results, including patient selection and eligibility criteria as well as complementary methods of use such as diet or behavioral modification programs. Convincing physicians to dedicate the time and energy necessary for adequate training is challenging, and we cannot assure you that we will be successful in these efforts. This training process may also take longer than we expect. In the event that physicians are not properly trained in the use of our Obalon balloon system, they may misuse or ineffectively use our products for the treatment of patients. As a result, patients may experience adverse events or not be able to enjoy the benefits of our system or achieve the weight loss outcomes they expect, leading to dissatisfaction and market rejection of our products. In addition, misuse of our products in any stage of the treatment may result in, among other things, patient injury, adverse side effects, negative publicity or lawsuits against us. Any of these events could have an adverse effect on our business and reputation.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If patients are unable to successfully swallow the capsule, our device malfunctions during delivery or physicians cannot deploy the Obalon balloon, physicians may be unwilling to continue to recommend our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients may be unable to successfully swallow the capsule that contains the Obalon balloon, potentially creating an economic disincentive for physicians in adopting our technology. In our SMART trial, 7.6% of the combined treatment and control group patients failed to swallow a capsule with the microcatheter attached despite success swallowing a placebo that did not have a catheter attached. There were also instances where balloon deployment was negatively impacted due to a leak in the microcatheter, which was caused by the patient biting the catheter during placement. There may be other reasons for unsuccessful placements that we are not yet aware. If the balloon is not successfully placed for any reason, the patient may attempt to seek a refund or monetary damages for the treatment. Alternatively, physicians that have paid us for a balloon, but have not been paid by their patient because of a treatment </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure, may seek a refund or monetary damages from us. Either scenario could cause a negative financial impact for us and could also create ill will with patients and physicians.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patients may experience SADEs as the result of the misuse or malfunction of, or design flaws in, our products, which could expose us to expensive litigation, divert management&#8217;s attention and harm our reputation and business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business is subject to significant risks associated with manufacture, distribution and use of medical devices that are placed inside the human body, including the risk that patients may be severely injured by or even die from the misuse or malfunction of our products caused by design flaws or manufacturing defects. In addition, our business may suffer adverse consequences even in circumstances where a patient injury is caused by the actions of others, such as where a patient is injured due to the improper or negligent use of our products by a physician.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For instance, if the Obalon capsule does not reach a patient&#8217;s stomach and is inflated in another portion of the body, such as the esophagus, the patient could experience a serious injury. A patient who experiences an esophageal inflation of the balloon would most likely require surgical intervention, and could die as a result of an esophageal inflation or as a result of complications from the subsequent intervention. Serious injury could also occur if one or more of the balloons deflates and migrates into the lower intestine causing an obstruction. This can also lead to surgical removal of the device and associated complications including death. Esophageal perforation leading to sepsis and death associated with the sepsis has been reported with use of our product. Balloon deflation and migration into the lower intestine requiring surgical removal has also been reported with use of our product. While we have designed our products, and established instructions and protocols for physicians, to attempt to mitigate such risks, we cannot guarantee that adverse events will not occur again in the future. For example, physicians have in the past have failed, and may again in the future fail, to follow our instructions and protocols, and the safety systems we design into our products may not prevent all possible adverse events and injuries and/or our products may fail to function properly.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our quality assurance testing programs may not be adequate to detect all defects, which may result in patient adverse events, interfere with customer satisfaction, reduce sales opportunities, harm our marketplace reputation, increase warranty repairs or reduce gross margins. Our inability to remedy a product defect could result in the financial failure of products, a product recall, temporary or permanent withdrawal of a product from a market, product liability suits, damage to our reputation or our brand, inventory costs or product reengineering expenses, any of which could have a material impact on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we fail to grow our sales and marketing capabilities and develop widespread brand awareness cost effectively, our growth will be impeded and our business may suffer.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have very limited experience as a company in the sales and marketing of our products. The majority of our product sales to date have been through a single international distributor in the Middle East, with a lesser percentage sold through distributors or directly to physicians in Europe and Mexico. We recently obtained FDA approval to market our Obalon balloon system in the United States, and commercialized in select U.S. states in January 2017 through a direct sales force.  Training our U.S. sales force in use of our Obalon balloon system to achieve the level of clinical competency expected by physicians, and to comply with applicable federal and state laws and regulations and our internal policies and procedures requires significant time, expense and attention. It can take several months before our sales representatives are fully trained and productive. Our business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in revenues. In particular, there is significant competition for qualified and experienced sales personnel. If we are unable to hire, develop and retain talented sales personnel or if new sales personnel are unable to achieve desired productivity levels in a reasonable period of time, we may not be able to realize the expected benefits of this investment or increase our revenues.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, factors that may inhibit our efforts to commercialize our Obalon balloon system and any other products that may receive FDA approval include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability of our sales and marketing personnel to perform their duties and conduct business in a manner that is compliant with our internal policies and procedures and FDA law and regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to recommend any current and future products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">efforts by our competitors to commercialize products at or about the time when our product would be coming to market.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to increase our customer base and achieve broader market acceptance of our Obalon balloon system will depend to a significant extent on our ability to expand our marketing programs. We plan to dedicate significant financial and other resources to our marketing programs. Our business will be harmed if our marketing efforts and expenditures do not generate an increase in revenue.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we believe that developing and maintaining widespread awareness of our brand in a cost-effective manner is critical to achieving widespread acceptance of our product and attracting new customers. Brand promotion activities may not generate customer awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the customers necessary to realize a sufficient return on our brand-building efforts, or to achieve the widespread brand awareness that is critical for broad customer adoption of our Obalon balloon system.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We actively employ social media as part of our marketing strategy, which could give rise to regulatory violations, liability, breaches of data security or reputational damage.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Despite our efforts to monitor evolving&#160;social media&#160;communication guidelines and comply with applicable rules, there is&#160;risk&#160;that the use of&#160;social media&#160;by us, our employees or our customers to communicate about our products or business may cause us to be found in violation of applicable requirements, including requirements of regulatory bodies such as the FDA and Federal Trade Commission. For example, adverse events, product complaints, off-label usage by physicians, unapproved marketing or other unintended messages could require an active response from us, which may not be completed in a timely manner and could result in regulatory action by a governing body. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image and goodwill. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We do not expect that physicians or patients will receive third-party reimbursement for treatment with our products. As a result, we expect that our success will depend on the ability and willingness of physicians to adopt self-pay practice management infrastructure and of patients to pay out-of-pocket for treatment with our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain elective treatments, such as an intragastric balloon, are typically not covered by insurance. Accordingly, we do not expect that any third-party payors will cover or reimburse physicians or patients for the Obalon balloon system. As a result, we expect that our success will depend on the ability and willingness of physicians that may not have historically operated a self-pay practice to adopt the policies and procedures needed to successfully operate such a practice. Our initial sales and marketing efforts in the United States are targeted at bariatric surgeons, gastroenterologists and plastic surgeons. Bariatric surgeons and gastroenterologists are accustomed to providing services that are reimbursed by third-party payors. As a result, these physicians may need to augment their administrative staff and billing procedures to address the logistics of a self-pay practice. If physicians are unable or unwilling to make such changes, adoption of our products may be slower than anticipated.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will also depend on the ability and willingness of patients to pay out-of-pocket for treatment with our products. Adverse changes in the economy may cause consumers to reassess their spending choices and reduce the demand for elective treatments and could have an adverse effect on consumer spending. This shift could have an adverse effect on our net sales. Furthermore, consumer preferences and trends may shift due to a variety of factors, including changes in demographic and social trends, public health initiatives and product innovations, which may reduce consumer demand for our products. The decision by a patient to elect to undergo treatment with the Obalon balloon system may be influenced by a number of additional factors, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of any sales and marketing programs, including direct-to-consumer marketing efforts, that we, or any third parties we engage, undertake, and as to which we have limited experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which physicians offer the Obalon balloon system to their patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which the Obalon balloon system satisfies patient expectations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost, safety, comfort, tolerability, ease of use, and effectiveness of the Obalon balloon system as compared to other treatments; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general consumer confidence, which may be impacted by economic and political conditions.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial performance will be materially harmed if we cannot generate significant physician or patient demand for the Obalon balloon system.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have limited experience manufacturing our Obalon balloon system in commercial quantities.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our product sales through December 31, 2016 have occurred internationally using an earlier generation of the Obalon balloon system. We transitioned to production of the current generation of the Obalon balloon system in November 2016. As a result, we have limited experience in manufacturing the current Obalon balloon system in commercial quantities, and we will need to increase our manufacturing capabilities in order to satisfy expected demand for our Obalon balloon system. We may encounter production delays or shortfalls caused by many factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and process needed to assimilate the changes necessary to enable our production processes to accommodate anticipated demand;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shortages that we may experience in any of the key components or sub-assemblies that we obtain from third-party suppliers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays that we may experience in completing validation and verification testing for new controlled-environment rooms at our manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays that we may experience in seeking FDA review and approval of PMA supplements required for certain changes in manufacturing facilities, methods or quality control procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our limited experience in complying with the FDA&#8217;s Quality System Regulation, or the QSR, which sets forth good manufacturing practice requirements for medical devices and applies to the manufacture of the components of our Obalon balloon system; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to attract and retain qualified employees, who are in short supply, in order to increase our manufacturing output.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to keep up with demand for our Obalon balloon system, our revenue could be impaired, market acceptance for our product could be harmed and our customers might instead purchase our competitors&#8217; products. Our inability to successfully manufacture components of our Obalon balloon system in quantities sufficient to meet expected demand would materially harm our business.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We depend on third-party suppliers, including single source suppliers, to manufacture some of our components and sub-assemblies, which could make us vulnerable to supply shortages, interruptions in production and price fluctuations that could harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently manufacture our Obalon balloon system and some of its components and sub-assemblies at our Carlsbad facility and we rely on third-party suppliers for other components and sub-assemblies used in production. In some cases, these suppliers are single source suppliers. For example, we rely on single suppliers for the extruded film, swallowable capsule, molded silicone valve used to manufacture our Obalon balloons and the hydrophilic coating for our catheters. These components are critical to our products and there are relatively few alternative sources of supply. We do not carry a significant inventory of these components. Identifying and qualifying additional or replacement suppliers for any of the components or sub-assemblies used in our products could involve significant time and cost and could delay production and adversely affect our ability to fill product orders. For example, given that we have received PMA approval for our Obalon balloon system, any replacement supplier will have to be assessed by us through audits and other verification and assessment tools and found capable of producing quality components that meet our approved specifications, and we may be required to notify or obtain approval from the FDA for a change in a supplier prior to our ability to use the components it provides. If we were unable to find a replacement supplier, it could result in significant delays as we would be unable to produce additional product until such replacement supplier had been identified and qualified. If an existing or replacement supplier proposes to change any component specifications or quality requirements, the change may require FDA approval of a PMA supplement. If a supplier changes a component without notifying us, that change could result in an undetected change being incorporated into the finished product.&#160;Once detected and investigated, if the change is found to potentially affect the safety or effectiveness of the product, we would have to take corrective and preventive action, including possibly recalling the product, which could be time-consuming and expensive, and could impair our ability to meet the demand of our customers and harm our business and reputation.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our reliance on third-party suppliers subjects us to a number of risks that could impact our ability to manufacture our products and harm our business, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">interruption of supply resulting from modifications to, or discontinuation of, a supplier&#8217;s operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in product shipments resulting from uncorrected defects, reliability issues or a supplier&#8217;s failure to consistently produce quality components that meet our specifications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to obtain adequate supply in a timely manner or on commercially reasonable terms;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty identifying and qualifying alternative suppliers for components in a timely manner;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability of suppliers to comply with applicable provisions of the QSR or other applicable laws or regulations enforced by the FDA and state regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to ensure the quality of products manufactured by third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">production delays related to the evaluation and testing of products from alternative suppliers and corresponding regulatory qualifications; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in delivery by our suppliers due to changes in demand from us or their other customers.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we require our third-party suppliers to supply us with components that meet our specifications and comply with applicable provisions of the QSR and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to assure the components meet our requirements, there is a risk that our suppliers will not always act consistent with our best interests, and may not always supply components that meet our requirements. Any significant delay or interruption in the supply of components or sub-assemblies, or our inability to obtain substitute components, sub-assemblies or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and harm our business.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not be able to secure additional financing on favorable terms, or at all, to meet our future capital needs and our failure to obtain additional financing when needed could force us to delay, reduce or eliminate our commercialization efforts and product development programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operations have consumed substantial amounts of cash since inception. We believe that the net proceeds from our initial public offering, or IPO, together with our existing cash and cash equivalents and short-term investments and expected revenue, will be sufficient to meet our capital requirements and fund our operations through the next two years.  Since we commenced U.S. commercialization of our Obalon balloon system in January 2017, we expect our costs and expenses to increase in the future, including the development of a direct sales force, increased marketing programs, the expansion of our manufacturing facilities, and as we continue to expend substantial amounts on research and development, including for conducting clinical trials, of our products in development. We also may need additional funds to complete the development and commercialization of advancements to our existing Obalon balloon system as well as our additional products under development. Additionally, we will continue to incur costs as a result of operating as a public company. Our future capital requirements will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs and expenses of our U.S. sales and marketing infrastructure and our manufacturing operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the degree of success we experience in commercializing our Obalon balloon system;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the revenue generated by sales of our Obalon balloon system and any other products that may be approved in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs, timing and outcomes of clinical trials and regulatory reviews associated with our products under development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs and timing of developing enhancements of our Obalon balloon system and obtaining FDA clearance or approval of such enhancements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the emergence of competing or complementary technological developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which our Obalon balloon system is adopted by the physician community and patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number and types of future products we develop and commercialize;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of operating as a public company and compliance with existing and future regulations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent and scope of our general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional financing may not be available on a timely basis on terms acceptable to us, or at all. We may raise funds in equity or debt financings or enter into additional credit facilities in order to access funds for our capital needs. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution in their percentage ownership of our company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. Any debt financing obtained by us in the future would cause us to incur additional debt service expenses and could include restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and pursue business opportunities. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products. If this were to occur, our ability to continue to grow and support our business and to respond to business challenges could be significantly limited.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A majority of our historical revenue in 2016 and 2015, prior to our U.S. Launch in January 2017 was derived from a single distributor that is also one of our principal stockholders</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bader Sultan&#160;&amp; Bros. Co. W.L.L., or Bader, is currently the sole distributor of our Obalon balloon system in the Middle East. Revenue received from Bader&#8217;s distribution of our Obalon balloon system in the Middle East represented 100% of our total revenue for the year ended December&#160;31, 2016 and a majority of our total revenue for the year ended December 31, 2015. We have discontinued sales of our prior generation product in the Middle East and do not plan to begin selling in the Middle East again until our next generation inflation system is approved. We are currently working closely with Bader to determine the best timing and strategy for launch of the current generation Obalon balloon system with the next generation inflation system in the Middle East. We have limited control over Bader&#8217;s sales and marketing efforts for our product. If Bader fails to effectively market and sell our products in full compliance with applicable laws, or if we are unable to maintain our existing relationship with Bader, we may not be able to find a distributor with the scale and resources of Bader, maintain existing levels of international revenue or realize expected long-term international revenue growth. In addition, since the Obalon balloon system is our sole source of revenue, a delay or failure by Bader to successfully market our Obalon balloon system or the loss of Bader as a distributor could have a significant impact on our revenues and financial health.  </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We do not currently intend to devote significant additional resources in the near-term to market our Obalon balloon system internationally, which will limit our potential revenue from our product.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing our Obalon balloon system outside of the United States would require substantial additional sales and marketing, regulatory and personnel expenses. As part of our product development and regulatory strategy, we plan to expand into other select international markets, but we do not currently intend to devote significant additional resources to market our Obalon balloon system internationally. Our decision to market our product primarily in the United States in the near-term will limit our ability to reach all of our potential markets and will limit our potential sources of revenue. In addition, our competitors will have an opportunity to further penetrate and achieve market share outside of the United States until such time, if ever, that we devote significant additional resources to market our product internationally.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The medical device industry, and the market for weight loss and obesity in particular, is highly competitive. If our competitors are able to develop and market products that are safer, more effective, easier to use or more readily adopted by patients and physicians, our commercial opportunities will be reduced or eliminated.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The medical device industry is highly competitive, subject to rapid change and significantly affected by new product introductions, results of clinical research, corporate combinations, actions by regulatory bodies, changes by public and private payers and other factors relating to our industry. Because of the market opportunity and the high growth potential of the non-surgical device market for weight loss and obesity, competitors and potential competitors have historically dedicated, and will continue to dedicate, significant resources to aggressively develop and commercialize their products.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, our product competes with a variety of pharmaceuticals, surgical procedures and devices for the treatment of obese and overweight people. There are several competitors in the pharmaceutical segment including those recently approved by the FDA, including Vivus, Inc., Arena Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., and those with older brands or generics including Takeda Pharmaceutical Company Ltd, AstraZeneca plc, and Actavis plc. Large competitors in the surgical segment for weight loss and obesity include Ethicon Inc. (subsidiary of Johnson&#160;&amp; Johnson), Medtronic plc (formerly Covidien Ltd.) and Apollo EndoSurgery, Inc., which acquired the Lap-Band from Allergan plc and currently sells that device worldwide. After approximately a decade, four new devices were approved by the FDA in 2015 and 2016. Enteromedics Inc. received FDA approval for the Maestro, which is intended to create weight loss by vagal nerve stimulation. ReShape Medical Inc. and Apollo EndoSurgery, Inc. received FDA approval for the ReShape Duo Balloon and the ORBERA Balloon, respectively, each a traditional saline-filled intragastric balloon. Aspire Bariatrics received FDA approval for the Aspire Assist, a device that allows a patient to aspirate food after a meal. Allurion Technologies, Inc. has also developed a swallowable, passable saline-filled intragastric balloon that has been approved for sale in Europe and the Middle East. Additionally, there are many more companies around the world working to develop less invasive and less costly alternatives for the treatment of obesity, which could compete with us in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time, these or other competitors may introduce new or alternative products that compete directly or indirectly with our products and services. They may also develop and patent products and processes earlier than we can or obtain regulatory clearance or approvals faster than us, which could impair our ability to develop and commercialize similar products or services. If clinical outcomes of procedures performed with our competitors&#8217; products are, or are perceived to be, superior to treatments performed with our products, sales of our products could be negatively affected and our business, results of operations and financial condition could suffer.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our competitors have significantly greater financial and other resources than we do, as well as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">well-established reputations and name recognition with key opinion leaders and physician networks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an established base of long-time customers with strong brand loyalty;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">products supported by long-term data;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">longer operating histories;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significantly larger installed bases of equipment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater existing market share in the obesity and weight management market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">broader product offerings and established distribution channels;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater ability to cross-sell products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or incentives; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">more experience in conducting research and development, manufacturing, performing clinical trials and obtaining regulatory approvals or clearances.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competition with these companies could result in significant price-cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations. In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or products that could effectively compete with our existing and future products, which may cause our revenues to decline and harm our business.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If our manufacturing facility becomes damaged or inoperable, or we are required to vacate the facility, our ability to manufacture and sell our Obalon balloon system and to pursue our research and development efforts may be jeopardized.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently manufacture and assemble our Obalon balloon system in our single manufacturing facility in Carlsbad, California. Our products consist of components sourced from a variety of contract manufacturers, with final assembly completed at our facility. Our facility and equipment, or those of our suppliers, could be harmed or rendered inoperable by natural or man-made disasters, including fire, earthquake, terrorism, flooding and power outages. Any of these may render it difficult or impossible for us to manufacture products for an extended period of time. If our facility is inoperable for even a short period of time, the inability to manufacture our current products, and the interruption in research and development of any future products, may result in harm to our reputation, increased costs, lower revenues and the loss of customers. Furthermore, it could be costly and time-consuming to repair or replace our facilities and the equipment we use to perform our research and development work and manufacture our products, particularly as the use of a new facility or new manufacturing, quality control, or environmental control equipment or systems would require FDA review and approval of a PMA supplement.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success largely depends upon the continued services of our executive management team and key employees and the loss of one or more of our executive officers or key employees could harm us and directly impact our financial results. Although we have entered into employment agreements with some of our executive officers and key employees, each of them may terminate their employment with us at any time. Changes in our executive management team resulting from the hiring or departure of executives could disrupt our business. In particular, our President and Chief Executive Officer, Andrew Rasdal, who has been with us since inception, has been instrumental in building operational capabilities, raising capital and guiding product development and regulatory strategy. We do not currently maintain key personnel life insurance policies on any of our employees, including Mr. Rasdal.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To execute our growth plan, we must attract and retain highly qualified personnel. Competition for skilled personnel is intense, especially for engineers with high levels of experience in designing and developing medical devices and for sales executives. We have, from time to time, experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize medical devices.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the companies with which we compete for experienced personnel have greater resources than we have. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees, particularly in the San Diego area, often consider the value of the stock awards they receive in connection with their employment. If the perceived value of our stock awards declines, either because we are a public company or otherwise, it may harm our ability to recruit and retain highly skilled employees. In addition, we invest significant time and expense in training our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employees, which increases their value to competitors who may seek to recruit them. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to manage the anticipated growth of our business, our future revenues and results of operations may be harmed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been growing rapidly in recent periods and have a relatively short operating history as a commercial company, with no history as a commercial company in the United States. We intend to continue to grow our business and may experience periods of rapid growth and expansion. Future growth will impose significant additional responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth will place a strain on our administrative personnel, information technology systems and other operational infrastructure. We must successfully expand our sales force to achieve broad market penetration and geographical coverage within the United States. We must also successfully increase manufacturing output to meet expected customer demand, and may experience difficulties with yields, quality control, component supply and shortages of qualified personnel, among others. Any failure to manage our expected growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals, which in turn could adversely impact our business and results of operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in coverage and reimbursement for obesity treatments and procedures could affect the adoption of our Obalon balloon system and our future revenues.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, intragastric balloon products are not reimbursed by third-party payors. We do not plan on submitting any requests to any third-party payor for coverage or billing codes specific to our products. However, payors may change their coverage and reimbursement policies for intragastric balloon products as a category and/or for other obesity treatments and procedures, and these changes could negatively impact our business. For example, healthcare reform legislation or regulation that may be proposed or enacted in the future that results in a favorable change in coverage and reimbursement for competitive products and procedures in weight loss and obesity could also negatively impact adoption of our products and our future revenues, and our business could be harmed as we would be at an economic disadvantage when competing for customers.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">From time to time, we engage outside parties to perform services related to certain of our clinical studies and trials, and any failure of those parties to fulfill their obligations could increase costs and cause delays.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we engage consultants to help design, monitor and analyze the results of certain of our clinical studies and trials. The consultants we engage interact with clinical investigators to enroll patients in our clinical trials. We depend on these consultants and clinical investigators to help facilitate the clinical studies and trials and monitor and analyze data from these studies and trials under the investigational plan and protocol for the study or trial and to comply with applicable regulations and standards, commonly referred to as good clinical practices, or GCP, requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product properly and on time. While we will have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. We may face delays in our regulatory approval process if these parties do not perform their obligations in a timely, compliant or competent manner. If these third parties do not successfully carry out their duties or meet expected deadlines, or if the quality, completeness or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical trial protocols or for other reasons, our clinical studies or trials may be extended, delayed or terminated or may otherwise prove to be unsuccessful to support product approval of a commercially viable product, or at all, and we may have to conduct additional studies, which would significantly increase our costs, in order to obtain the regulatory clearances or approvals that we need to commercialize our products and delay commercialization.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Obalon balloon system may in the future be subject to product recalls that could harm our reputation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture. A government-mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design or labeling defects. Recalls of our Obalon balloon system would divert managerial attention, be expensive, harm our reputation with customers and harm our financial condition and results of operations. A recall announcement would negatively affect our stock price.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may face product liability claims that could result in costly litigation and significant liabilities.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business exposes us to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of medical devices, including those which may arise from the misuse or malfunction of, or design flaws in, our products. Claims may be made by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients, healthcare providers or others selling our products. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, we rely on physicians in connection with the placement of our Obalon balloon into patients. If these physicians are not properly trained or are negligent, the capabilities of our products may be diminished or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and raw materials. This risk exists even if a device or product is cleared or approved for commercial sale by the FDA or other foreign regulators and manufactured in facilities registered with and regulated by the FDA or an applicable foreign regulatory authority.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we have, and intend to maintain, product liability and clinical trial liability insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, or at all, and, if available, the coverages may not be adequate to protect us against any future product liability claims. In addition, we may seek additional insurance coverage; however, if we are unable to obtain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may harm our business. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant costs and significant harm to our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For instance, patients could be harmed by the Obalon balloon if it is improperly inflated or inflated in the body other than in the stomach or if it deflates while in the body. Additionally, we do not sell our product sterilized, and it may be contaminated with forms of microorganisms prior to use. Any failure to follow the physician&#8217;s directions for use or the patient information guide, or any other defects, misuse or abuse associated with our product, could result in patient injury or death. The medical device industry has historically been subject to extensive litigation over product liability claims, and we cannot assure you that we will not face product liability suits.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, regardless of merit or eventual outcome, product liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairment of our brand and business reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costly litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">distraction of management&#8217;s attention from our primary business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability to commercialize our product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product recall or withdrawal from the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients or other claimants.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We cannot assure you that we will be successful in initiating appropriate recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Any such recalls and market withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our products, either of which could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If patients using our products experience adverse events or other undesirable side effects, regulatory authorities could withdraw or modify our commercial approvals, which would adversely affect our reputation and commercial prospects and/or result in other significant negative consequences.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undesirable side effects caused by our Obalon balloon system could cause us, the FDA or other regulatory authorities to interrupt, delay or halt clinical trials, and could result in more restrictive labeling than originally required, cause the FDA or other regulatory authorities to subsequently withdraw or modify our PMA or other commercial approvals, or result in the delay or denial of regulatory approval by other notified bodies. For example, in the 1980s and early 1990s, the FDA required post-market safety and efficacy data be collected on an earlier version of an intragastric balloon after patients suffered severe side effects and complications with the device, which ultimately resulted in the withdrawal of the PMA approval.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to demonstrate that any adverse events are not related to our product, the FDA or other regulatory authorities could order us to cease further development of, require more restrictive indications for use and/or additional warnings, precautions and/or contraindications in the labeling than originally required, or delay or deny approval of any of our future products. Even if we are able to do so, such event could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our products, the commercial prospects of such product may be harmed and our ability to generate product revenues from our product may be delayed or eliminated. Any of these occurrences may harm our ability to develop other products, and may harm our business, financial condition and prospects significantly.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we or others may later identify undesirable side effects caused by the product (or any other similar product), resulting in potentially significant consequences, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or European notified bodies may withdraw or limit their approval of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or European notified bodies may require the addition of labeling statements, such as a contraindication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to correct or remove the products from the marketplace or decide to conduct a voluntary recall;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may decide to alert physicians through customer notifications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA may use publicity such as a press release to alert our customers and the public of the issue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">physicians and patients may be dissatisfied, seek refunds and refuse to use our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we could be sued and held liable for injury caused to individuals using our product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of our Obalon balloon system and could substantially increase the costs of commercializing our product and significantly impact our ability to successfully commercialize our product and generate product sales.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our international operations subject us to regulatory and legal risks and certain operating risks, which could adversely impact our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sale of our Obalon balloon system across international borders and our international operations subject us to U.S. and foreign governmental trade, import and export and customs regulations and laws. Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act, as well as export control laws and economic sanctions laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant costs and disruption of business associated with an internal and/or government investigation, criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our international operations expose us and our distributors to risks inherent in operating in foreign jurisdictions. These risks include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign currency exchange rate fluctuations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a shortage of high-quality sales people and distributors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pricing pressure that we may experience internationally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competitive disadvantage to competitors who have more established business and customer relationships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced or varied intellectual property rights available in some countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">economic instability of certain countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the imposition of additional U.S. and foreign governmental controls, regulations and laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in duties and tariffs, license obligations and other non-tariff barriers to trade;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">scrutiny of foreign tax authorities which could result in significant fines, penalties and additional taxes being imposed on us; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">laws and business practices favoring local companies.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we experience any of these events, our business, results of operations and financial condition may be harmed.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016 and December 2016, we amended our loan and security agreement with Pacific Western Bank (as successor in interest to Square 1 Bank), pursuant to which an additional $5.0 million was made available to us, which has not been drawn down. As of December 31, 2016, we had $10.0&#160;million in principal and interest outstanding under our loan and security agreement. We are required to make interest-only monthly payments on the outstanding debt through June 2018, followed by 30 equal monthly installments of principal and interest, which diverts a portion of our resources from other activities. Our debt with Pacific Western Bank is collateralized by substantially all of our assets and contains customary financial and operating covenants limiting our ability to, among other things, incur additional indebtedness, change the name, location, office or executive management of our business, change our business, merge with or acquire other entities, pay dividends or make other distributions to holders of our capital stock, make certain investments, engage in transactions with our affiliates, create liens, sell assets, pay any subordinated debt and store certain inventory and equipment with third parties. These covenants may make it difficult to operate our business. We are also subject to standard event of default provisions under the credit agreement that, if triggered, would allow the debt to be accelerated, which could significantly deplete our cash resources, cause us to raise additional capital at unfavorable terms, require us to sell portions of our business or result in us becoming insolvent. The existing collateral pledged under the credit agreement, and the covenants to which we are bound may prevent us from being able to secure additional debt or equity financing on favorable terms, or at all, or to pursue business opportunities, including potential acquisitions, heighten our vulnerability to downturns in our business or our industry or the general economy, limit our ability to adjust to changing market conditions and place us at a competitive disadvantage compared to our competitors who have greater capital resources.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If there are significant disruptions in our information technology systems, our business, financial condition and operating results could be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The efficient operation of our business depends on our information technology systems. We rely on our information technology systems to effectively manage sales and marketing data, accounting and financial functions, inventory, product development tasks, clinical data, and customer service and technical support functions. Our information technology systems are vulnerable to damage or interruption from earthquakes, fires, floods and other natural disasters, terrorist attacks, computer viruses or hackers, power losses, and computer system or data network failures. In addition, a variety of our software systems are cloud-based data management applications hosted by third-party service providers whose security and information technology systems are subject to similar risks.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The failure of our or our service providers&#8217; information technology could disrupt our entire operation or result in decreased sales, increased overhead costs and product shortages. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could also incur liability and the further development of our product could be delayed. Any of these events could have a material adverse effect on our reputation, business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our costs could substantially increase if we experience a significant number of warranty claims.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide limited product warranties against manufacturing defects of our products. Our product warranty requires us to repair defects arising from product design and production processes, and, if necessary, replace defective components. The future costs associated with our warranty claims are uncertain due to our limited commercialization experience. Thus far, we have not accrued a significant liability contingency for potential warranty claims.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have instituted a swallow guarantee which may provide replacement of product for physicians when patients are unable to swallow a capsule. To qualify for a replacement of product, the physician must adhere by our policies and procedures. The swallow guarantee is limited to a certain number of swallow attempts per balloon placement, as well as other procedural and technical requirements.  As a result of this program, our financial results or gross margin may be adversely impacted.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we experience warranty claims, including manufacturing defects as well as our swallow guarantee, in excess of our expectations, or if our repair and replacement costs associated with warranty claims increase significantly, we will incur liabilities for potential warranty claims that may be greater than we expect. An increase in the frequency of warranty claims or amount of warranty costs may harm our reputation and could have a material adverse effect on our business, results of operations and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If our clinical trials are unsuccessful or significantly delayed, or if we do not complete our clinical trials, our business may be harmed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical development of Class III medical device systems and accessories such as the Obalon balloon system is a rigorous, lengthy, expensive and uncertain process. It is also subject to delays and the risk that products may ultimately prove unsafe or ineffective in treating the indications for which they are designed. Completion of clinical trials may take several years or more. We cannot provide any assurance that we will successfully, or in a timely manner, enroll our clinical trials, that our clinical data will be found reliable by the FDA, that our clinical trials will meet their primary endpoints or that such trials or their results will be accepted by the FDA or foreign regulatory authorities and support product approval. Successful results of pre-clinical studies are not necessarily indicative of future clinical trial results, and predecessor clinical trial results may not be replicated in subsequent clinical trials. Additionally, the FDA or foreign regulatory authorities may disagree with our analyses and interpretation of the data from our clinical trial, or may find the clinical trial design, conduct, monitoring, or results unreliable or inadequate to prove safety or efficacy, and may require us to pursue additional pre-clinical studies or clinical trials, which could further delay the clearance or approval of our products. The data we collect from our clinical trials may not be sufficient to support FDA clearance or approval, and if we are unable to demonstrate the safety and efficacy of our future products in our clinical trials, we will be unable to obtain regulatory clearance or approval to market our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we may estimate and publicly announce the anticipated timing of the accomplishment of various clinical, regulatory and other product development goals, which are often referred to as milestones. These milestones could include the obtainment of the right to affix the Certificat de Conformit&#233;, or CE, mark in the European Union, the submission to the FDA of an IDE application, PMA application, or PMA supplement, the enrollment of patients in clinical trials, the release of data from clinical trials; and other clinical and regulatory events. The actual timing of these milestones could vary dramatically compared to our estimates, in some cases for reasons beyond our control. We cannot assure you that we will meet our projected milestones and if we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and, as a result, our stock price may decline.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials are necessary to support PMA applications for our device and may be necessary to support PMA supplements for modified versions of our marketed device products or to support comparative safety, effectiveness or performance claims. This could require the enrollment of large numbers of suitable subjects, which may be difficult to identify, recruit and maintain as participants in the clinical trial.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may experience numerous unforeseen events during, or because of, the clinical trial process that could delay or prevent us from receiving regulatory clearance or approval for new products or modifications of existing products, for new or expanded indications for use for existing products, or for comparative safety, effectiveness, or performance claims for existing products, including new indications for existing products, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enrollment in our clinical trials may be slower than we anticipate, or we may experience high screen failure rates in our clinical trials, resulting in significant delays;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or preclinical testing which may be expensive and time consuming;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">trial results may not meet the level of statistical significance required by the FDA or other regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or similar foreign regulatory authorities may find the product is not sufficiently safe for investigational use in humans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or similar foreign regulatory authorities may interpret data from preclinical testing and clinical trials in different ways than we do;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">there may be delays or failure in obtaining approval of our clinical trial protocols from the FDA or other regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">there may be delays in obtaining institutional review board approvals or government approvals to conduct clinical trials at prospective sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or similar foreign regulatory authorities may find our or our suppliers&#8217; manufacturing processes or facilities unsatisfactory;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or similar foreign regulatory authorities may change their review policies or adopt new regulations that may negatively affect or delay our ability to bring a product to market or receive approvals or clearances to treat new indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may have trouble in managing multiple clinical sites or adding a sufficient number of clinical trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may have trouble addressing any patient safety concerns that arise during the course of a clinical trial;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may experience delays in agreeing on acceptable terms with prospective clinical research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or regulators, may suspend or terminate our clinical trials because the participating patients are being exposed to unacceptable health risks.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient enrollment in clinical trials and completion of patient follow-up depend on many factors, including the size of the trial patient population, the nature of the trial protocol, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, patient compliance, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product being studied in relation to other available therapies, including any new treatments that may be approved for the indications we are investigating. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and efficacy of a product, or they may be persuaded to participate in contemporaneous clinical trials of a competitor&#8217;s product. In addition, patients participating in our clinical trials may drop out before completion of the trial or suffer adverse medical events unrelated to our products. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may delay commencement or completion of the clinical trial, cause an increase in the costs of the clinical trial and delay, or result in the failure of the clinical trial.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We could also encounter delays if the FDA or foreign regulatory authority concluded that our financial relationships with our principal investigators resulted in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself. Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash compensation and/or stock options in connection with such services. If these relationships and any related compensation to or ownership interest by the clinical investigator carrying out the study result in perceived or actual conflicts of interest, or the FDA or foreign regulatory authority concludes that the financial relationship may have affected interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of our application by the FDA. Any such delay or rejection could prevent us from commercializing any of our products currently in development.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decrease.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our annual report for the year ending December&#160;31, 2017, provide a management report on our internal control over financial reporting, However, while we remain an emerging growth company we will not be required to include the attestation report issued by our independent registered public accounting firm.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are in the process of designing and implementing our internal control over financial reporting, which will be time consuming, costly and complicated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section&#160;404 in a timely manner, if we are unable to assert that our internal control over financial reporting is effective or, once required, if our independent registered public accounting firm is unable to attest that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decrease. We could also become subject to stockholder or other third-party litigation as well as investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions or other remedies.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may acquire other companies or technologies, which could divert our management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our results of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our Obalon balloon system, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the growth in our business has been organic, and we have no experience in acquiring other businesses. In any acquisition, we may not be able to realize the benefits of acquiring such businesses if we are unable to successfully integrate the acquired business </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">with our existing operations, technologies and company culture. We cannot assure you that following any such acquisition we would achieve the expected synergies to justify the transaction.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our ability to utilize our net operating loss carryovers may be limited.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016, we had federal and state net operating loss carryforwards, or NOLs, of approximately $58.7&#160;million and $14.4&#160;million, respectively. Each of the federal and state NOLs will begin expiring in 2028, unless previously utilized. We also had federal and California research and development tax credit carryforwards totaling $1.8&#160;million and $1.6&#160;million, respectively. The federal research and development tax credit carryforward will begin to expire in 2028 unless previously utilized. The California research tax credits do not expire.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or IRC, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOLs and certain other tax assets to offset future taxable income, and an ownership change is generally defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. We have not completed a formal study to determine if any ownership changes within the meaning of IRC Section&#160;382 have occurred.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If ownership changes within the meaning of IRC Section&#160;382 have occurred, it could restrict our ability to use NOL carryforwards and research and development tax credits generated since inception. Limitations on our ability to use NOL carryforwards and research and development tax credits to offset future taxable income could require us to pay U.S. federal income taxes earlier than would be required if such limitations were not in effect. Similar rules and limitations may apply for state income tax purposes.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATED TO REGULATORY APPROVAL</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our success depends on our ability to obtain FDA approval or other regulatory approvals for our future products and product improvements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The successful commercialization of the Obalon balloon system is dependent on the successful development and commercialization of future devices intended to improve the safety, efficacy, ease-of-use or cost of the Obalon balloon system. We have filed a PMA-Supplement for approval of our vegetable-based HydroxyPropylMethylCellulose, or HPMC, capsule, which is expected to replace the current animal-based gelatin capsule. It is not anticipated that human clinical data will be required for approval of this PMA-Supplement and the primary information used to support the approval will be in vitro testing. However, it is possible that the FDA may require this information, which could delay potential approval or we may fail to receive regulatory clearance at all.  To support a potential request for human data, we evaluated the HPMC capsule in our SMARTCAR study.  In the future, we intend to file a PMA-Supplement for approval of the Obalon Touch Inflation System, our next generation inflation system that is expected to replace the EzFill inflation system used to inflate the balloon with gas.  The Obalon Touch is a refinement of the EzPz Dispenser project based on the learning from actual usage. It is not anticipated that human clinical data will be required for approval and we expect the PMA-Supplement to based primarily on in vitro testing including, but not limited to, software validation and human factors assessment. However, it is possible that the FDA may require this information, which could delay potential approval. While we expect to successfully complete the in vitro testing required to submit a PMA supplement for the Obalon Touch inflation system, there can be no guarantee that these product enhancements will be completed or that we will receive regulatory approval for the sale and marketing of the Obalon Touch inflation system in the United States or in other regulatory jurisdictions outside the United States. A number of companies in the medical device field have suffered significant setbacks during evaluation due to lack of efficacy or unacceptable safety issues, notwithstanding promising preliminary results. Because we are depending on Obalon Touch inflation system, HPMC capsule and other new products to achieve our revenue goals in future years, failure to receive FDA approval or regulatory approval in jurisdictions outside the United States, in a timely manner or at all, will harm our financial results and ability to become profitable. Even if we obtain such regulatory approval, our ability to successfully market the Obalon balloon system may be limited. If we cannot sell our Obalon balloon system with Obalon Touch inflation system, the HPMC capsule and other new products as planned, our financial results could be harmed.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The FDA and other regulatory agencies actively enforce the laws and regulations governing the development, approval and commercialization of medical devices. If we are found to have failed to comply with these laws and regulations, we may become subject to significant liability.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Obalon balloon system is classified by the FDA as a Class III medical device. As a result, we are subject to extensive government regulation in the United States by the FDA and state regulatory authorities. We are also subject to foreign regulatory authorities in the countries in which we currently and intend to conduct business. These regulations relate to, among other things, research and development, design, pre-clinical testing, clinical trials, manufacturing, packaging, storage, premarket approval, environmental controls, safety and efficacy, labeling, advertising, promotion, pricing, recordkeeping, reporting, import and export, post-approval studies and the sale and distribution of the Obalon balloon system.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, before we can market a new medical device, or label and market a previously cleared or approved device for a new intended use or new indication for use, or make a significant modification to a previously cleared or approved device, we must first receive either FDA clearance under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act or approval of a PMA application from the FDA, unless an exemption applies. The process of obtaining PMA approval, which was required for the Obalon balloon system, is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, in order to clear the proposed device for marketing. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices for which the 510(k) process cannot be used and that are deemed to pose the greatest risk.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modifications to products that are approved through a PMA application generally need FDA approval of a PMA supplement. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k). The FDA&#8217;s 510(k) clearance process usually takes from three to 12&#160;months, but may last longer. The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory approvals would have a material adverse effect on our business, financial condition and prospects.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are safe or effective for their intended uses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the disagreement of the FDA or the applicable foreign regulatory body with the design, conduct or implementation of our clinical trials or the analyses or interpretation of data from pre-clinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">serious and unexpected adverse device effects experienced by participants in our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the applicable regulatory authority may identify deficiencies in the chemistry, manufacturing and control sections of our application, our manufacturing processes, facilities or analytical methods or those of our third party contract manufacturers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or foreign regulatory authorities may audit our clinical trial data and conclude that the data is not sufficiently reliable to support a PMA application.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, the FDA and European regulatory authorities strictly regulate the indications for use and associated promotional safety and effectiveness claims, including comparative and superiority claims vis a vis competitors&#8217; products, that may be made about products, such as the Obalon balloon system. In particular, a medical device may not be promoted for uses or indications that are not approved by the FDA or other regulatory agencies as reflected in the product&#8217;s approved labeling. For example, we will not be able to promote or make claims for the Obalon balloon system for the treatment of patients outside of the BMI ranges specifically approved by the FDA or other regulatory authorities. In the United States, we received FDA approval of the Obalon balloon system for temporary use to facilitate weight loss in adults with obesity (BMI of 30 to 40) who have failed to lose weight through diet and exercise. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. Our pivotal trial inclusion and exclusion criteria included patients with a BMI of 30 to 40; thus, our approved labeling is limited to the same BMI range. We also will not be able to make comparative or superiority claims for the Obalon balloon system versus other products without scientific data supporting or establishing those claims, including possibly data from head-to-head clinical trials if appropriate. Our CE mark label includes patients with a BMI of 27 or greater. As a part of our PMA approval, we agreed with the FDA to conduct a post-approval study at 10 to 15 sites in the United States to evaluate the safety and efficacy of our Obalon balloon system in 200 subjects over a twelve-month period, consisting of six months of treatment with the Obalon balloon system followed by six months of observation after balloon removal. We will be required to update </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our product labeling in a PMA supplement as results, including any adverse event data, from the post-approval study become available.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Physicians may choose to prescribe such products to their patients in a manner that is inconsistent with the approved label, as the FDA does not restrict or regulate a physician&#8217;s choice of treatment within the practice of medicine. However, if the FDA determines that our promotional materials or physician training, including our paid consultants&#8217; educational materials, constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to enforcement action, including warning letters, untitled letters, fines, penalties, or seizures. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines and/or other penalties against companies for alleged improper promotion and has investigated, prosecuted, and/or enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed, curtailed or prohibited. If we cannot successfully manage the promotion of and training for our Obalon balloon system, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material modifications to our Obalon balloon system may require new premarket approvals and may require us to recall or cease marketing our Obalon balloon system until approvals are obtained.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once a medical device is approved, a manufacturer must notify the FDA of any modifications to the device. Any modification to a device that has received FDA clearance or approval that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires premarket clearance or approval from the FDA pursuant to a new 510(k) clearance or approval of a PMA supplement. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement, notice in an annual report or clearance; however, the FDA can review a manufacturer&#8217;s decision. Any modification to an FDA-cleared device that would significantly affect its safety or efficacy or that would constitute a major change in its intended use would require a new 510(k) clearance or possibly a premarket approval. Any modification to a PMA approved device requires a PMA supplement, notification to the FDA in a PMA annual report, or possibly a new PMA. We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or obtain approval of PMA supplements or new PMAs for modifications to, or additional indications for, our Obalon balloon system in a timely fashion, or at all. Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. If we make additional modifications in the future that we believe do not or will not require additional clearances or approvals and the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop selling or marketing our Obalon balloon system as modified, which could harm our operating results and require us to redesign our Obalon balloon system. In these circumstances, we may be subject to significant enforcement actions.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Even though we have received FDA approval of our PMA application to commercially market the Obalon balloon system in the United States, we will continue to be subject to extensive FDA regulatory oversight.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Obalon balloon system is a medical device that is subject to extensive regulation by the FDA in the United States and by regulatory agencies in other countries where we do business. We will be required to timely file various reports with the FDA, including reports required by the medical device reporting regulations, or MDRs, that require that we report to the regulatory authorities if our devices may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If these reports are not filed timely, regulators may impose sanctions and sales of our products may suffer, and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, as a condition of approving a PMA application, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device. As a part of our PMA approval, we agreed with the FDA to conduct a post-approval study at 10 to 15 sites in the United States to evaluate the safety and efficacy of our Obalon balloon system in 200 subjects over a twelve-month period, consisting of six months of treatment with the Obalon balloon system followed by six months of observation after balloon removal. The product labeling must be updated and submitted in a PMA supplement as results, including any adverse event data, from the post-approval study become available. Failure to conduct the post-approval study in compliance with applicable regulations or to timely complete required post-approval studies or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we initiate a correction or removal for one of our devices, issue a safety alert, or undertake a field action or recall to reduce a risk to health posed by the device, we would be required to submit a publically available Correction and Removal report to the FDA and in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall, which could </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our devices and to negative publicity, including FDA alerts, press releases, or administrative or judicial enforcement actions. Furthermore, the submission of these reports has been and could be used by competitors against us in competitive situations and cause customers to delay purchase decisions or cancel orders and would harm our reputation.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and the Federal Trade Commission, or FTC, also regulate the advertising and promotion of our products to ensure that the claims we make are consistent with our regulatory clearances, that there are adequate and reasonable data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our advertising or promotional claims are false, misleading, not substantiated or not permissible, we may be subject to enforcement actions, including Warning Letters, and we may be required to revise our promotional claims and make other corrections or restitutions.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the medical device industry&#8217;s relationship with physicians is under increasing scrutiny by the Health and Human Services Office of Inspector General, or OIG, the Department of Justice, or DOJ, state attorneys general, and other foreign and domestic government agencies. Our failure to comply with laws, rules and regulations governing our relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general and other government agencies, could significantly harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions, partial suspension or total shutdown of production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">customer notifications or repair, replacement or refunds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusing our requests for 510(k) clearance or PMA approvals or foreign regulatory approvals of new products, new intended uses or modifications to existing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawals of current 510(k) clearances or PMAs or foreign regulatory approvals, resulting in prohibitions on sales of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">criminal prosecution.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we fail to obtain and maintain regulatory approval in foreign jurisdictions, our market opportunities will be limited.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market our products in the European Union, the Middle East or other foreign jurisdictions, we must obtain and maintain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies from country to country and can involve additional testing. The time required to obtain approval abroad may be longer than the time required to obtain FDA clearance or approval. Foreign regulatory approval processes include many of the risks associated with obtaining FDA clearance or approval and we may not obtain foreign regulatory approvals on a timely basis, if at all. FDA clearance or approval does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries. However, the failure to obtain clearance or approval in one jurisdiction may have a negative impact on our ability to obtain clearance or approval elsewhere. If we do not obtain or maintain necessary approvals to commercialize our products in markets outside the United States, it would negatively affect our overall market penetration.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we or our suppliers fail to comply with the FDA and International quality system requirements, our manufacturing operations could be delayed or shut down and sales of our Obalon balloon system could suffer.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our manufacturing processes and those of our third-party suppliers are required to comply with the FDA&#8217;s QSR, which covers the procedures and documentation of the design, testing, production, control, quality assurance, inspection, complaint handling, recordkeeping, management review, labeling, packaging, sterilization, storage and shipping of our Obalon balloon system. We are also subject to similar state requirements and licenses. In addition, we must engage in extensive recordkeeping and reporting and must make available our manufacturing facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities and comparable agencies in other countries. If we are found to not be in compliance at the conclusion of an </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA QSR inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take adequate corrective action in response to an adverse QSR inspection could result in, among other things, issuance of a Warning Letter, a shut-down of our manufacturing operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would cause our business to suffer. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our product and cause our revenues to decline.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have registered with the FDA as a medical device manufacturer and have obtained a manufacturing license from the California Department of Public Health, or CDPH. The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of CDPH to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of our suppliers. Our current facility has been inspected by the FDA in 2014 and 2016, with four and zero inspectional observations, respectively, noted during those inspections. Although we believe our manufacturing facilities and those of our critical component suppliers are in compliance with the QSR requirements, we can provide no assurance that we will continue to remain in compliance with the QSR. If our manufacturing facilities or those of any of our component suppliers are found to be in violation of applicable laws and regulations, or we or our suppliers have significant noncompliance issues or fail to timely and adequately respond to any adverse inspectional observations or product safety issues, or if any corrective action plan that we or our suppliers propose in response to observed deficiencies is not sufficient, the FDA could take enforcement action, including any of the following sanctions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">untitled letters or warning letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines, injunctions, consent decrees and civil penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions or partial suspension or total shutdown of production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusing or delaying our requests for clearance or approval of new products or modified products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawing clearances or approvals that have already been granted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to grant export approval for our products; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">criminal prosecution.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a shutdown or delay at our manufacturing facility we may be unable to produce our Obalon balloon system, which would harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outside the United States, our products and operations are also often required to comply with standards set by industrial standards bodies, such as the International Organization for Standardization. Foreign regulatory bodies may evaluate our products or the testing that our products undergo against these standards. The specific standards, types of evaluation and scope of review differ among foreign regulatory bodies. If we fail to adequately comply with any of these standards, a foreign regulatory body may take adverse actions similar to those within the power of the FDA. Any such action may harm our reputation and could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have an ISO 13485:2003 Quality System Certificate through British Standards Institution, or BSI, that is required to support our CE mark. We have been audited at least annually and are subject to unannounced audits by BSI which could result in major nonconformances. Major nonconformances could result in the suspension or revocation of our ISO Certificate, which would disrupt distribution in the European Union and other countries that require certificated Quality Systems.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Healthcare providers, physicians and others will play a primary role in the recommendation and ordering of, and treatment using, our Obalon balloon system. Although intragastric balloon products similar to our Obalon balloon system are not currently reimbursed by United States federal healthcare programs (such as Medicare or Medicaid) or other third-party payors, any future reimbursement by third-party payors could expose our business to broadly applicable fraud and abuse and other healthcare laws and regulations that would regulate the business, including laws that would regulate financial arrangements and relationships through which we market, sell and distribute the Obalon balloon system. Additionally, as a device manufacturer, we are still subject to certain healthcare fraud and abuse regulation, including those laws that apply to self-pay products, and enforcement by the federal government and the states in which we conduct our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Applicable and potentially applicable United States federal and state healthcare laws and regulations include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-Kickback Laws.</font><font style="font-family:inherit;font-size:10pt;">&#32;The federal healthcare program Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as Medicare and Medicaid, unless the arrangement fits within one of several statutory exceptions or regulatory &#8220;safe harbors.&#8221; Courts have interpreted the term &#8220;remuneration&#8221; broadly under the Anti-Kickback Statute to include anything of value, such as, for example, gifts, discounts, payments of cash and waivers of payments. Violations can result in significant penalties, imprisonment and exclusion from Medicare, Medicaid and other federal healthcare programs. Exclusion of a manufacturer would preclude any federal healthcare program from paying for the manufacturer&#8217;s products. A person does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, kickback arrangements can provide the basis for an action under the False Claims Act, which is discussed in more detail below.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government officials have recently increased enforcement efforts with respect to sales and marketing activities of pharmaceutical, medical device, and other healthcare companies, and they have brought cases against individuals and entities that allegedly offered unlawful inducements to potential or existing customers in an attempt to procure business. Settlements of these government cases have involved significant fines and penalties and, in some instances, criminal pleas.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the federal Anti-Kickback Statute, many states have their own anti-kickback laws. Often, these laws closely follow the language of the federal law, although they do not always have the same exceptions or safe harbors. In some states, the restrictions imposed by anti-kickback laws are not limited to items and services paid for by government programs but, instead, apply with respect to all payors for healthcare items and services, including commercial health insurance companies.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">False Claims Laws.</font><font style="font-family:inherit;font-size:10pt;">&#32;The federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. A manufacturer can be held liable under false claims laws, even if it does not submit claims to the government, if it is found to have caused submission of false claims. For example, these laws may apply to a manufacturer that provides information regarding coverage, coding or reimbursement of its products to persons who bill third-party payers. In addition, under the Patient Protection and Affordable Care Act, as amended, or PPACA, a violation of the federal Anti-Kickback Statute is deemed to be a violation of the federal False Claims Act.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal False Claims Act also includes whistleblower provisions that allow private citizens to bring suit against an entity or individual on behalf of the United States and to recover a portion of any monetary recovery. Many of the recent, highly publicized settlements in the healthcare industry relating to sales and marketing practices have related to cases brought under the federal False Claims Act.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of states also have adopted statutes or regulations similar to the federal laws, which apply to items and services reimbursed under Medicaid and other state programs. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer&#8217;s products from reimbursement under government programs, criminal fines and imprisonment.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Privacy and Security Laws.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and accompanying regulations, which we collectively refer to as HIPAA, require certain entities, referred to as &#8220;covered entities&#8221; (including most healthcare providers and health plans), to comply with established standards, including standards regarding the privacy and security of protected health information, or PHI. HIPAA further requires that covered entities enter into agreements meeting certain regulatory requirements with their &#8220;Business Associates,&#8221; as such term is defined by HIPAA, which, among other things, obligate the Business Associates to safeguard the covered entity&#8217;s PHI against improper use and disclosure. In addition, a Business Associate may face significant statutory and contractual liability if the Business Associate breaches the agreement or causes the covered entity to fail to comply with HIPAA. We believe that we generally do not conduct our business in a manner that would cause us to be a Business Associate under HIPAA, but we are nevertheless committed to maintaining the security and privacy of patients&#8217; health information. Although we believe the business is not currently subject to HIPAA, there is no guarantee that government enforcement agencies will agree. Violation of HIPAA could result in the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, many state laws regulate the use and disclosure of health information and require notification in the event the confidentiality of such information is breached. Those state laws that are more protective of individually identifiable health information are not preempted by HIPAA. Violation of applicable state privacy laws also may result in significant fines and other penalties.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transparency Laws.</font><font style="font-family:inherit;font-size:10pt;">&#32;There has been a recent trend of increased federal and state regulation of payments and transfers of value provided to healthcare professionals and entities. For example, the Physician Payment Sunshine Act, which was enacted as part of PPACA, imposes annual reporting requirements on certain manufacturers of drugs, medical devices, biologics and medical </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:33px;padding-top:8px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">supplies with respect to payments and other transfers of value provided by them, directly or indirectly, to physicians and teaching hospitals, as well as with respect to certain ownership and investment interests held by physicians and their family members. A manufacturer&#8217;s failure to submit timely, accurately and completely the required information regarding all payments, transfers of value or ownership or investment interests may result in civil monetary penalties. Certain states also mandate implementation of commercial compliance programs, impose restrictions on medical device manufacturers&#8217; marketing practices, and require the tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities under certain circumstances.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. In addition, the dynamic healthcare regulatory compliance environment and the need to build and maintain robust systems to comply with different reporting and other legal requirements in multiple jurisdictions, increase the possibility that a healthcare company may fail to comply fully with one or more of these laws or regulations. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. If our operations are found to be in violation of any of the healthcare regulatory laws to which the business is subject, or any other laws that apply to the business, we may be subject to penalties, including potentially significant criminal and civil and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the clearance or approval and commercialization of any of our products outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Compliance with environmental laws and regulations could be expensive. Failure to comply with environmental laws and regulations could subject us to significant liability.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development and manufacturing operations involve the use of hazardous substances and a greenhouse gas, and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances as well as the control and reduction of greenhouse gas emissions. In addition, our research and development and manufacturing operations produce biological waste materials, such as human and animal tissue, and waste solvents, such as isopropyl alcohol. These operations are permitted by regulatory authorities, and the resultant waste materials are disposed of in material compliance with environmental laws and regulations. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive and non-compliance could result in substantial liabilities, fines and penalties, personal injury and third part property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to adequately protect our proprietary technology or maintain issued patents that are sufficient to protect our Obalon balloon system or our other products, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success will depend in part on our ability to protect our proprietary rights to the technologies and inventions used in, or embodied by, our products. We rely on a combination of patents, trademarks, trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights. If we do not adequately protect our intellectual property rights and proprietary technology, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our business and ability to achieve profitability.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, we held 14 issued U.S. patents and had 19 pending U.S. patent applications, as well as 17 international patents issued in Europe, Mexico, Australia, Canada, Asia, China and Israel and 34 pending international patent applications in Australia, Canada, Europe, Asia, the Middle East and South America. Our issued patents expire between the years 2023 and 2032.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability, and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect the Obalon balloon system or any other products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any of our pending patent applications will issue as patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we will be able to successfully commercialize our Obalon balloon system before our relevant patents expire;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we were the first to make the inventions covered by each of our patents and pending patent applications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we were the first to file patent applications for these inventions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others will not develop similar or alternative technologies that do not infringe our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any of our patents will be found to ultimately be valid and enforceable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we will develop additional proprietary technologies or products that are separately patentable; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">that our commercial activities or products will not infringe upon the patents of others.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to patent protection, we also rely on other proprietary rights, including protection of unpatented trade secrets, unpatented know-how and confidential and proprietary information, which we seek to protect, in part, by confidentiality agreements with our employees and our collaborators and consultants. We also have agreements with our employees and selected consultants that obligate them to assign their inventions to us and have non-compete agreements with some, but not all, of our consultants. It is possible that technology relevant to our business will become known or be independently developed by a person that is not a party to such an agreement, including our competitors. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors, former employees and current employees. If the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. For example, each of our patents and patent applications names one or more inventors having past or present affiliations with other institutions, and any of these institutions may assert an ownership claim. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may infringe or be alleged to infringe the intellectual property rights of others, which may result in costly and time-consuming litigation, delay our product development efforts or prevent us from commercializing the Obalon balloon system.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. The medical device industry is characterized by rapid technological change and extensive litigation regarding patent and other intellectual property rights. Our competitors and other industry participants, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained, or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. In addition, numerous third-party patents exist in the fields relating to our products. We cannot assure you that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, third parties, including our competitors as well as other industry participants and/or non-practicing entities, may allege that the Obalon balloon system or the use of our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. For example, we have received and may from time to time in the ordinary course of business continue to receive, letters from third parties advising us of third-party patents that may </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relate to our business. The letters do not explicitly seek any particular action or relief from us. Although these letters do not threaten legal action, these letters may be deemed to put us on notice that continued operation of our business might infringe the patent rights of such third parties. If we decide not to seek a license or do not otherwise obtain a license to such third-party patents, there can be no assurance that we will not become subject to infringement claims or will not be forced to initiate legal proceedings in order to dispose of such actual or potential infringement claims or to seek to invalidate the claims of such third-party patents.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and can have an uncertain outcome. Any claim relating to intellectual property infringement that is successfully asserted against us may require us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing another party&#8217;s patents, for past use of the asserted intellectual property and royalties and other consideration going forward if we determine it necessary or are required to take a license. In addition, if any such claim were successfully asserted against us and we could not obtain such a license, an injunction may force us to stop or delay developing, manufacturing, selling or otherwise commercializing the Obalon balloon system or our other products.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property claims or litigation, regardless of merit, may be expensive and time-consuming to resolve, result in negative publicity, and divert our management&#8217;s attention from our core business. In addition, if we are subject to intellectual property claims or litigation, we may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be subject to a protected period of uncertainty while the claims or litigation remain unresolved, which could adversely affect our ability to raise additional capital and otherwise adversely affect our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property rights against others; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be required to redesign those products that contain the allegedly infringing intellectual property, which could be costly, disruptive and/or infeasible.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, we also rely on our trademarks as one means to distinguish our products from the products of our competitors, and have registered or applied to register many of these trademarks. However, our trademark applications may not be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of the risks described above come to fruition, our business, results of operations, financial condition and prospects could be harmed.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. Patent and Trademark Office, or U.S. PTO, and various international, foreign governmental and foreign regional patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the U.S. PTO and foreign patent agencies over the lifetime of the patent. There are situations in which noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be involved in legal proceedings to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competitors may infringe our patents, trademarks or other intellectual property rights. Our ability to enforce our intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components of their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To counter infringement of our intellectual property rights, we have in the past been, and may in the future be, required to file infringement claims, which can be expensive and time-consuming. Even if successful, litigation to enforce our intellectual property rights could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. Moreover, we may not have sufficient resources to bring these actions to a successful conclusion. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in an infringement proceeding, a court may decide that a patent of ours is not infringed and may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interference proceedings instituted by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to obtain a license under such rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or offer us a license at all. Our defense of interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issued patents covering our products could be found invalid or unenforceable if challenged in court or before administrative bodies.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we initiated legal proceedings against a third party to enforce one of our patents, the defendant could counterclaim that the patent is invalid and/or unenforceable. Even if legal proceedings were not initiated, if we threatened a third party with a patent infringement lawsuit, the third party may preemptively sue us in a declaratory judgment action and seek to have our patent declared invalid or not infringed. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, e.g., opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our products or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products. Such a loss of patent protection would have a material adverse impact on our business. An adverse result in any legal proceeding could put one or more of our patents at risk of being invalidated, found unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We do not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filing, prosecuting and defending intellectual property rights related to our products in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If these problems were to occur, they could have a material adverse effect on our sales. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to medical devices, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may not adequately protect our rights or permit us to gain or keep any competitive advantage.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United&#160;States has recently enacted and is currently implementing the America Invents Act of 2011, a wide-ranging patent reform legislation. Further, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents or future patents.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees, consultants or third parties we engage to manufacture our products have wrongfully used, or disclosed, alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our employees were previously employed at pharmaceutical companies and other medical device companies, including our potential competitors, in some cases until recently. We may be subject to claims that we, our employees, consultants or third parties have inadvertently or otherwise used or disclosed alleged trade secrets or proprietary information of these former employers or competitors. In addition, we may be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction for our management. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with third parties. A loss of key personnel or their work product could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our stock price may be volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The public trading price for our common stock is affected by a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a slowdown in the medical device industry, the aesthetics industry or the general economy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">quarterly variations in our or our competitors&#8217; results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated or serious safety concerns related to the use of any of our products or competitive traditional saline-filled intragastric balloon products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse regulatory decisions, including failure to receive regulatory approval for any of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory or legal developments in the United States and other countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in analysts&#8217; estimates, investors&#8217; perceptions, recommendations by securities analysts or our failure to achieve analysts&#8217; estimates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in operating performance and stock market valuations of other technology companies generally, or those in the medical device industry in particular;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance of third parties on whom we rely, including for the manufacture of the components for our product, including their ability to comply with regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to obtain adequate supply of the components for any of our products, or inability to do so at acceptable prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the loss of key personnel, including changes in our board of directors and management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">legislation or regulation of our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our commencement of, or involvement in, litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the announcement of new products or product enhancements by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition from existing technologies and products or new technologies and products that may emerge;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments, announcements or disputes related to patents or other proprietary rights issued to us or our competitors and to litigation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments in our industry.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In recent years, the stock markets generally and the stock prices of many companies in the medical device industry have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may not be able to sell your common stock at or above the price at which you purchased it, and you may lose some or all of your investment.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our share price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our shares or change their opinion of our shares, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Future sales and issuances of our common stock or other securities may result in significant dilution and could cause the price of our common stock to decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the stockholders who held shares of our capital stock prior to our IPO are subject to a market standoff and/or lock-up agreement with the underwriters of our IPO that restrict such stockholders&#8217; ability to transfer shares of our common stock. Subject to certain limitations, approximately 11 million shares will become eligible for sale beginning on April 4, 2017. In addition, shares issued or issuable upon exercise of options vested as of the expiration of the lock-up period will be eligible for sale at that time. Sales of stock by these stockholders could have a material adverse effect on the trading price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain holders of shares of our common stock are also entitled to rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders. We also intend to register shares of common stock that we may issue under our equity incentive plans. Once we register these shares, they can be sold freely in the public market upon issuance, subject to volume limitations applicable to affiliates and the 180-day lock-up period under the lock-up agreements described above.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options, or the perception that such sales may occur, could adversely affect the market price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are an emerging growth company, and intend to take advantage of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which we have total annual gross revenue of $1 billion or more; (ii)&#160;the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (iii)&#160;the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced disclosure obligations regarding executive compensation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may choose to take advantage of some, but not all, of the available exemptions described above. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We will continue to incur increased costs as a result of operating as a public company and our management will be required to devote substantial time to compliance initiatives.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company, and particularly after we are no longer an emerging growth company, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and NASDAQ, have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also expect that being a public company and compliance with applicable rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantially higher costs to obtain and maintain the same or similar coverage. These factors could also make it more difficult for us to attract and retain qualified executive officers and members of our board of directors.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our executive officers, directors, principal stockholders and their affiliates have significant influence over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned a majority of our outstanding capital stock. As a result, this group of stockholders will have the ability to control us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We could be subject to securities class action litigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and harm our business, results of operations, financial condition, reputation and cash flows. These factors may materially and adversely affect the market price of our common stock.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provisions in our restated certificate of incorporation and our restated bylaws discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish a classified board of directors so that not all members of our board are elected at one time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">permit only the board of directors to establish the number of directors and fill vacancies on the board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan, also known as a &#8220;poison pill&#8221;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">eliminate the ability of our stockholders to call special meetings of stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prohibit cumulative voting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common stock. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our restated certificate of incorporation or our restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our restated certificate of incorporation. This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid any cash dividends on our common stock and do not currently intend to do so for the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business. In addition, our loan and security agreement with Pacific Western Bank prohibits us from, among other things, paying any dividends or making any other distribution or payment on account of our common stock. Any return to stockholders will be limited to the appreciation of stock. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in the value of the stock. We cannot guarantee you that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.</font></div><div><a name="s2BBBF539DC65DDC210577564EF9509ED"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1B.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unresolved Staff Comments</font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s745373114C02603BCFBD7564EFA7B047"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2.&#160;&#160;&#160;&#160; Properties</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive offices are located in a 17,500 square foot facility in Carlsbad, California. The term of the lease for our facility extends through March 2019. Our facility houses our research and development, sales, marketing, manufacturing, finance and administrative activities. We believe that our current facilities are adequate for our current needs.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF37785F73D8D2E4B3A197564EFC0BCCC"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we are involved in legal proceedings in the ordinary course of business. We are currently not a party to any legal proceedings that we believe would have a material adverse effect on our business, financial condition or results of operations.</font></div><div><a name="s882D08B8418B91ED5F427564EFE1A308"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4.&#160;&#160;&#160;&#160; Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><a name="sFD5A88359CA707F7181E7564F014BD0F"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:14px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div><a name="s224CA085C022E5DB8A517564F0362FF6"></a></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;5.&#160;&#160;&#160;&#160;Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock began trading on The NASDAQ Global Market on October 6, 2016 and trades under the symbol &#8220;OBLN.&#8221; Prior to October 6, 2016, there was no public market for our common stock. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth for the indicated periods the high and low sales price of our common stock on The NASDAQ Global Market.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December&#160;31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth quarter (from October 6, 2016)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 17, 2017, the last reported sale price of our common stock was $9.31.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Performance Graph</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Obalon Therapeutics, Inc. under the Securities Act or the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following graph shows a comparison from October 6, 2016 (the date our common stock commenced trading on The NASDAQ Global Market) through December&#160;31, 2016 of the cumulative total return for our common stock and NASDAQ Biotechnology Index and NASDAQ Composite. The graph assumes that $100 was invested at the close of market on October 6, 2016 in the common stock of Obalon Therapeutics, Inc., NASDAQ Biotechnology Index and NASDAQ Composite. The stock price performance of the following graph is not necessarily indicative of future stock price performance.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:32px;"><img src="performancecharta01.jpg" alt="performancecharta01.jpg" style="height:286px;width:720px;"></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cumulative Total Return Comparison </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">October 16, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obalon Therapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ Biotechnology </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ Composite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Holders of Record</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">As of February 17, 2017, there were approximately 60 stockholders of record of our common stock. Certain shares are held in &#8220;street&#8221; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Securities Authorized for Issuance under Equity Compensation Plans</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information called for by this item is incorporated by reference to our definitive proxy statement for the 2017 Annual Meeting of Stockholders. See Part III, Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From January 1, 2016 to December 31, 2016, we granted to our directors and employees options to purchase 740,782 shares of common stock under our 2008 Stock Plan with a weighted-average per share exercise price of $1.85. In the same period, we issued and sold 808,885 shares of common stock upon exercise of stock options issued under the 2008 Stock Plan to our directors, officers, employees, consultants and other service providers for cash consideration at prices ranging from $0.76 to $2.61 for an aggregate purchase price of $1.1 million. These transactions were exempt from the registration requirements of the Securities Act in reliance upon Rule 701 promulgated under the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April&#160;29, 2016 and May&#160;4, 2016, we issued in two closings an aggregate of 1,916,425 shares of Series E convertible preferred stock at a purchase price of $8.2932 per share for an aggregate purchase price of $15.8 million to 12 purchasers that represented to the Registrant that they were each an accredited investor. These transactions were exempt from the registration requirements of the Securities Act in reliance upon Section&#160;4(a)(2) of the Securities Act or Regulation&#160;D promulgated under the Securities Act.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Proceeds</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 5, 2016, our Registration Statement on Form S-1 (File No. 333-213551) relating to the IPO of our common stock was declared effective by the SEC. Pursuant to the IPO, we sold an aggregate of 5,000,000 shares of our common stock at a price of $15.00 per share. UBS Securities LLC, Canaccord Genuity Inc. and Stifel, Nicolaus &amp; Company, Incorporated acted as joint book-running managers of the offering and as representatives of the underwriters. BTIG LLC acted as co-manager for the offering. The offering did not terminate before all of the securities registered in the Registration Statement were sold. On October 12, 2016, we closed the sale of such shares, resulting in net proceeds to us of $67.2 million, after deducting underwriting discounts and commissions of approximately $5.2 million, and offering costs of approximately $2.6 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been no material change in the expected use of the net proceeds from our IPO, as described in our final Prospectus filed with the SEC on October 6, 2016 pursuant to Rule 424(b).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="sD61852106BBFDEBFEC637564EC87FF2B"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.  Selected Consolidated Financial Data</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have derived the following selected consolidated statement of operations data for the years ended December&#160;31, 2016, 2015 and 2014 and the selected consolidated balance sheet data as of December&#160;31, 2016 and 2015 from our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. The selected consolidated balance sheet data as of December&#160;31, 2014 is derived from our audited consolidated financial statements which are not included in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of the results that may be expected in the future. Please read the following selected financial data in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Consolidated Financial Statements and related notes included elsewhere in this Annual Report on Form&#160;10-K.</font></div><div><br></div><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated statements of operations data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, related party   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,809</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,503</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,467</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,840</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) gain from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(466</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (expense) income, net   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,890</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and comprehensive loss   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,468</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,552</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted(1)   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding, basic and  <br>diluted(1)   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,221,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">See Note 4 to our audited financial statements appearing elsewhere in this Annual Report for an explanation of the method used to calculate the   basic and diluted net loss per common share and the number of shares used in the computation of the per share amounts.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated balance sheet data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and short-term investments   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,244</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,778</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,221</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,609</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56,142</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,585</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity (deficit) </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="s5AF7DAA1FF72A9FD411F7564F0885DF8"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7.  Management's Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks, uncertainties and assumptions. You should read the &#8220;Special note regarding forward-looking statements&#8221; and "Risk Factors" section of this Annual Report on Form 10-K  for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </font></div><div><a name="s6EFB1EA3FDFED2521E3D7564F0BA6827"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;OVERVIEW </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a vertically integrated medical device company focused on developing and commercializing innovative medical devices to treat obese and overweight people. Our initial product offering is the Obalon balloon system, the first and only U.S. Food and Drug Administration, or FDA approved swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. In September 2016, we received premarket approval from the FDA to market our balloon system for temporary use to facilitate weight loss in obese adults with a body mass index, or BMI, of 30 to 40, who have failed to lose weight through diet and exercise. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. The Obalon balloon system has the potential to provide patients and physicians with a cost-effective, reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. We commenced the U.S. commercial launch of our Obalon balloon system with both initial shipments to physicians and first commercial patient placements by physicians in January 2017. As of December 31, 2016, we had sold over 26,000 of our earlier generation Obalon balloon systems for commercial use outside the United States.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We began selling an earlier version of our Obalon balloon system in international markets in the third quarter of 2012. In 2015, we discontinued sales in certain international markets to conserve financial resources.  We continued distribution of our earlier generation product in the Middle East through December 2016 while we focused on developing our current Obalon balloon system for the United States market. We have discontinued sales of our prior generation product in the Middle East and do not plan to begin selling in the Middle East again until our next generation inflation system is approved. We are currently working closely with Bader Sultan&#160;&amp; Bros. Co W.L.L., or Bader, to determine the best timing and strategy for launch of the current generation Obalon balloon system with the next generation inflation system in the Middle East. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2013, we entered into a distribution agreement with Bader, a healthcare products distributor based in Sufat, Kuwait, which subsequently became one of our significant stockholders. Pursuant to the distribution agreement, in November 2013, we began selling our earlier generation Obalon balloon system to Bader, our sole distributor in the Middle East. Sales to Bader for the years ended December 31, 2016, 2015 and 2014 totaled </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, $3.8 million and $1.9 million, which represented 100%, 94.7% and 52.4% of total revenue, respectively.  For the year ended December 31, 2016, all of our total revenue consisted of sales of our earlier generation Obalon balloon system to Bader. We expect Bader to account for a significantly lower percentage of our total revenue in the future as we commenced commercial sales in the United States in January 2017.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to focus our sales and marketing efforts primarily on selling our product in the United States through a direct sales force, as well as selling our products through Bader in the Middle East and other distributors in select international markets. We have built a direct sales organization consisting of regional sales directors, executive account managers and product specialists. We are selling the Obalon balloon system on a self-pay basis into existing physician specialty areas with weight loss practices, such as bariatric surgeons and gastroenterologists. In addition, we are selling to plastic surgeons, due to their client base and experience managing self-pay and cash pay practices. Given the initial focus of our sales and marketing efforts, we are targeting the U.S. market with a sales organization of approximately 25 individuals.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generated total revenue, including revenue recognized from related parties, of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, $4.0 million and $3.5 million for the years ended December 31, 2016, 2015 and 2014, respectively. For the years ended December&#160;31, 2016, 2015 and 2014, our net loss was </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;">, $15.6 million and $9.9 million, respectively. We have not been profitable since inception, and as of December 31, 2016, our accumulated deficit was </font><font style="font-family:inherit;font-size:10pt;">$76.6 million</font><font style="font-family:inherit;font-size:10pt;">. From inception through December 31, 2016, we financed our operations primarily through private placements of our preferred securities, the sale of common stock in our initial public offering, or IPO in October 2016, and, to a lesser extent, debt financing arrangements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 5, 2016, our Registration Statement on Form S-1 relating to the IPO of our common stock was declared effective by the SEC. Pursuant to such Registration Statement, we sold an aggregate of 5,000,000 shares of our common stock at a price of $15.00 per share for aggregate cash proceeds of approximately $67.2 million, net of underwriting discounts, commissions, and offering costs. The IPO closed on October 12, 2016.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to incur net losses for the foreseeable future as we commercialize our product in the United States, including supporting our sales and marketing efforts in the United States, continuing research and development efforts, and seeking regulatory approval for new products and product enhancements. We may need additional funding to pay expenses relating to our operating activities, including selling, general and administrative expenses and research and development expenses. Adequate funding, if needed, may not be available to us on acceptable terms, or at all. Our failure to obtain sufficient funds on acceptable terms could have a material adverse effect on our business, results of operations or financial condition.</font></div><div><a name="s9F36985AE42BC4B2EF417564F0E0C3D5"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPONENTS OF OUR RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue consists of international sales of an earlier generation of our Obalon balloon system. Revenue consists of sales of our Obalon balloon system to distributors or directly to physicians in international markets outside of the Middle East, and revenue, related party reflects sales of our Obalon balloon system to Bader in the Middle East. During the third quarter of 2015, we discontinued sales in international markets other than the Middle East, and for the year ended December 31, 2016, total revenue consisted of sales of our Obalon balloon system to Bader in the Middle East.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017 we shifted our focus to selling our Obalon balloon system in the United States, which we anticipate will be our primary market. We expect that, as a result, total revenue will increase as we implement our U.S. sales strategy and our revenue from international sales will constitute a smaller percentage of total revenue. However, the degree to which our revenue increases depends on many factors, including acceptance of our Obalon balloon system by doctors and patients, the emergence of competing products and general economic trends.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost of revenue and gross margin</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue consists primarily of costs related to the direct materials and direct labor that are used to manufacture our products and the manufacturing overhead that directly supports manufacturing. Currently, a significant portion of our cost of revenue consists of manufacturing overhead, which is mostly fixed in nature. These overhead costs include the costs of compensation for operations supervision and management, material procurement, inventory control, allocated quality assurance costs associated with manufacturing our product, facilities and depreciation on production equipment. We expect cost of revenue to increase in absolute dollars to the extent our total revenue grows but decrease as a percentage total of revenue over time as the fixed portion of our overhead costs is allocated over a greater number of units.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We calculate gross margin as gross profit divided by total revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily production volumes, manufacturing costs, product yields, headcount and cost-reduction strategies. We expect our gross margin to increase over the long term as our production volume increases and as we allocate the fixed portion of our manufacturing overhead costs over a larger number of units produced, thereby reducing our per unit manufacturing costs. We intend to use our design, engineering and manufacturing capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and increase our gross margin. While we expect gross margin to increase over the long term, it will likely fluctuate from quarter to quarter as we continue to introduce new products, obsolete old products and adopt new manufacturing processes and technologies.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, we began offering a swallow guarantee program in the United States where we may replace some balloons that cannot be swallowed by patients, subject to certain requirements and restrictions.  As a result of this program our financial results or gross margin may be adversely impacted.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and development expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development, or R&amp;D, expenses consist of the cost of engineering, clinical affairs, regulatory affairs and quality assurance associated with developing our Obalon balloon system. R&amp;D expenses consist primarily of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employee-related expenses, including salaries, benefits, travel expense and stock-based compensation expense;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost of outside consultants who assist with technology development, regulatory affairs, clinical affairs and quality assurance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost of clinical trial activities performed by third party medical partners; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost of facilities, depreciation on R&amp;D equipment and supplies used for internal research and development and clinical activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expense R&amp;D costs as incurred. In the future, we expect R&amp;D expenses to increase in absolute dollars as we continue to develop new products and enhance existing products and technologies. However, we expect R&amp;D expenses as a percentage of total revenue to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial and other related activities.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selling, general and administrative expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative, or SG&amp;A, expenses consist of employee-related expenses, including salaries, benefits, travel expense and stock-based compensation expense. Other SG&amp;A expenses include promotional activities, marketing, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses and allocated facilities-related expenses. We have grown our sales and marketing headcount and programs significantly in the recent quarter in preparation for the commercial launch of our Obalon balloon system in the United States which occurred in January 2017. As a result, SG&amp;A expenses have grown significantly in the recent quarter, and are expected to continue to increase in absolute dollars and as a percentage of total revenue for the foreseeable future as we continue to expand our sales and marketing infrastructure to drive and support anticipated growth in revenue and due to the additional legal, accounting, insurance and other expenses associated with being a public company.</font></div><div><a name="s3B1BD85B5C21A88EB7C77564F10D61D2"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES AND ESTIMATES </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to sales of components of the Obalon balloon system, which includes the balloon and accessory kit, EzFill inflation system, pre-filled can of gas and placebo capsule. For the year ended December 31, 2016, the product was sold to one customer, Bader, a related party and healthcare product distributor based in Sufat, Kuwait. We recognize revenue when the following criteria are met: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Persuasive evidence of an arrangement exists.</font><font style="font-family:inherit;font-size:10pt;">&#32;We consider this criterion satisfied when we have an agreement or contract in place with the customer. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Delivery has occurred.</font><font style="font-family:inherit;font-size:10pt;">&#32;Our standard terms specify that title and risk of loss transfers upon shipment to customer. We use third-party shipping documents to verify that title has transferred. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The selling price is fixed or determinable.</font><font style="font-family:inherit;font-size:10pt;">&#32;We assess whether the sales price is fixed or determinable at the time of the transaction. Sales prices are documented in the executed sales contract or purchase order received prior to shipment. Our standard terms do not allow for trial or evaluation periods, rights of return or refund, payments contingent upon the customer obtaining financing or other terms that could impact the customer&#8217;s obligation. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collectability is reasonably assured.</font><font style="font-family:inherit;font-size:10pt;">&#32;We assess whether collection is reasonably assured based on a number of factors, including the customer&#8217;s past transaction history and credit worthiness. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based compensation expense </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain an equity incentive plan to provide long-term incentive for employees, members of our board of directors and consultants. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to non-employee directors and consultants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards, including employee stock options. We recognize this expense over the requisite service period. In addition, we recognize stock-based compensation expense in the statements of operations and comprehensive loss based on awards expected to vest and, therefore, the amount of expense has been reduced for estimated forfeitures. We use the straight-line method for expense attribution. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The valuation model we used for calculating the fair value of awards for stock-based compensation expense is the Black-Scholes option-pricing model, or the Black-Scholes model. The Black-Scholes model requires us to make assumptions and judgments about the variables used in the calculation, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expected term.</font><font style="font-family:inherit;font-size:10pt;">&#32;We do not believe we are able to rely on our historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term for use in determining the fair value-based measurement of our options. Therefore, we have opted to use the &#8220;simplified method&#8221; for estimating the expected term of options, which is the average of the weighted-average vesting period and contractual term of the option. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expected volatility.</font><font style="font-family:inherit;font-size:10pt;">&#32;Since there has been no public market for our common stock and lack of company specific historical volatility, we have determined the share price volatility for options granted based on an analysis of the volatility of a peer group of publicly traded companies. In evaluating similarity, we consider factors such as stage of development, risk profile, enterprise value and position within the industry. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risk-free interest rate.</font><font style="font-family:inherit;font-size:10pt;">&#32;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for zero-coupon U.S. Treasury notes with remaining terms similar to the expected term of the options. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividend rate.</font><font style="font-family:inherit;font-size:10pt;">&#32;We assumed the expected dividend to be zero as we have never paid dividends and have no current plans to do so. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expected forfeiture rate.</font><font style="font-family:inherit;font-size:10pt;">&#32;We are required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, we record the difference as a cumulative adjustment in the period that the estimates are revised. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Service period.</font><font style="font-family:inherit;font-size:10pt;">&#32;We amortize all stock-based compensation over the requisite service period of the awards, which is generally the same as the vesting period of the awards. We amortize the stock-based compensation cost on a straight-line basis over the expected service periods. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of common stock.</font><font style="font-family:inherit;font-size:10pt;">&#32;Prior to the completion of our initial public offering, the fair value of the common stock underlying our stock options has historically been determined by our board of directors after considering, among other things, contemporaneous valuations of our common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</font><font style="font-family:inherit;font-size:10pt;">. Given the absence of a public trading market for our common stock, our board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including our stage of development; the rights, preferences and privileges of our convertible preferred stock relative to those of our common stock; our results of operations and financial condition, including our levels of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions and the lack of marketability of our common stock; and valuations obtained from sales of our preferred stock to unrelated parties. For stock awards after the completion of our initial public offering, our board of directors determines the fair value of each share of underlying common stock based on the closing price of our common stock as reported on The NASDAQ Global Market on the date of grant. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If factors change and we employ different assumptions, stock-based compensation expense may differ significantly from what we have recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. To the extent that our assumptions are incorrect, the amount of stock-based compensation recorded will change. We have not recognized, and we do not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance on our deferred tax assets including deferred tax assets related to our net operating loss carryforwards.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and development expenses </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the process of preparing our financial statements, we are required to estimate our accrued R&amp;D expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued R&amp;D expenses include the costs incurred for services performed by our vendors in connection with R&amp;D activities for which we have not yet been invoiced. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We base our expenses related to R&amp;D activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct R&amp;D on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the R&amp;D expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Advance payments for goods and services that will be used in future R&amp;D activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there has been no material differences between our estimates of such expenses and the amounts actually incurred. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the uncertainty surrounding possible Internal Revenue Code of 1986, as amended, or IRC, section&#160;382 and 383 limitations on the use of our U.S. federal and state tax net operating loss carryforwards and tax credits, such tax loss carryforwards and tax credits have been removed from the deferred tax assets as of December&#160;31, 2016 and December&#160;31, 2015. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, under Sections 382 and 383 of the IRC, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses, or NOLs, and certain other tax assets to offset future taxable income, and an ownership change is generally defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three year period. We have not completed a formal study to determine if any ownership changes within the meaning of IRC Section&#160;382 and 383 have occurred. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If ownership changes within the meaning of IRC Section&#160;382 and 383 have occurred, it could restrict our ability to use NOL carryforwards and research and development tax credits generated since inception. Limitations on our ability to use NOL carryforwards and research and development tax credits to offset future taxable income could require us to pay U.S. federal income taxes earlier than would be required if such limitations were not in effect. Similar rules and limitations may apply for state income tax purposes. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="sF21F4AD2F34533A671717564EC18F982"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESULTS OF OPERATIONS</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated statements of operations data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, related party   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,809</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,503</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,467</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,840</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) gain from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(466</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (expense) income, net   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,890</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and comprehensive loss   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,468</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,552</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of years ended December 31, 2016 and 2015</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total revenue.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Total revenue decreased </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2016, compared to $4.0&#160;million during the year ended December 31, 2015. This decrease was primarily attributable to a decrease in the volume sold as we discontinued sales of our previous generation product in international markets outside the Middle East beginning in the third quarter of 2015.  In 2016, we also reduced the volume sold in the Middle East in preparation for transition to our current generation product in 2017, which was partially offset by an increase in the price per unit sold.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of revenue.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Cost of revenue increased </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2016, compared to $2.5&#160;million during the year ended December 31, 2015. This increase was primarily attributable to increased payroll costs and changes in the allocation of production cost between R&amp;D expense and cost of revenue. Cost of revenue was also impacted by increased expenses associated with FDA approval including employee related expenses and write-down of obsolete materials.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;R&amp;D expenses decreased </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2016, compared to $13.0 million during the year ended December 31, 2015. This decrease was primarily due to a decrease of $4.6 million in clinical trials expenses as we concluded the SMART trial, partially offset by an increase of $1.1 million in headcount related expenses and an increase of $0.4 million to supplies and outside consultant expenses.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selling, general and administrative expenses.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;SG&amp;A expenses increased </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2016, compared to $3.5&#160;million during the year ended December 31, 2015. This increase was primarily attributable to a $3.0 million increase in headcount related expenses in preparation for U.S. commercialization, a $1.3 million increase in outside consultant expenses for sales and marketing activities in preparation for U.S. commercialization, and a $1.2 million increase in legal fees associated with increased intellectual property development and protection.  The remaining year over year increase was primarily related to higher expenses due to becoming a public company.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest expense, net.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Interest expense, net remained consistent at </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2016 and 2015.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of years ended December&#160;31, 2015 and 2014 </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total revenue.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Total revenue increased by $0.5&#160;million to $4.0&#160;million during the year ended December&#160;31, 2015, compared to $3.5&#160;million during the year ended December&#160;31, 2014. This increase was attributable to a $2.0 million increase in revenue, related party due to the increased volume sold in the Middle Eastern market during the year ended December&#160;31, 2015 as a result of our distributor selling to new territories, offset by a $1.5 million decrease in revenue, as we discontinued sales in Europe and Mexico beginning in the third quarter of 2015 and the volume sold in those regions decreased substantially. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of revenue.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Cost of revenue decreased by $0.4&#160;million to $2.5&#160;million during the year ended December&#160;31, 2015, compared to $2.9&#160;million during the year ended December&#160;31, 2014. This decrease was primarily attributable to lower payroll and outside consulting expense associated with manufacturing our products. During the year ended December&#160;31, 2015, we operated with a lower engineering and supervisory headcount in our manufacturing department compared to the year ended December&#160;31, 2014. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;R&amp;D expenses increased $7.2&#160;million to $13.0&#160;million during the year ended December&#160;31, 2015, compared to $5.8&#160;million during the year ended December&#160;31, 2014. This increase was primarily attributable to the initiation of our SMART trial in April 2015. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selling, general and administrative expenses.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;SG&amp;A expenses decreased $1.2&#160;million to $3.5&#160;million during the year ended December&#160;31, 2015, compared to $4.7&#160;million during the year ended December&#160;31, 2014. This decrease was primarily attributable to decreases in selling and marketing expenses due to the discontinuation of sales in Mexico and Europe beginning in the third quarter of 2015. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest expense, net.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Interest expense, net increased $0.3 million to $0.5 million during the year ended December&#160;31, 2015, compared to an expense of $0.2 million during the year ended December&#160;31, 2014. The increase in interest expense was attributable to an increase in outstanding debt to support our operations during the year ended December&#160;31, 2015 as compared to the year ended December&#160;31, 2014. </font></div><div><a name="sA77D732018AD01D0C7197564F161C7A5"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;LIQUIDITY AND CAPITAL RESOURCES</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, we had cash and cash equivalents and short-term investments of </font><font style="font-family:inherit;font-size:10pt;">$75.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$76.6 million</font><font style="font-family:inherit;font-size:10pt;">. Our primary sources of capital have been the sale of common stock in our IPO, private placements of preferred stock and the incurrence of debt. On October 5, 2016, our Registration Statement on Form S-1 relating to the IPO of our common stock was declared effective by the SEC. Pursuant to such Registration Statement, we sold an aggregate of 5,000,000 shares of our common stock at a price of $15.00 per share for aggregate cash proceeds of approximately $67.2 million, net of underwriting discounts, commissions, and offering costs. The IPO closed on October&#160;12, 2016. In addition, we have raised an aggregate of $70.5 million in proceeds from convertible preferred stock financings. Furthermore, we have $10.0 million in debt with Pacific Western Bank (as successor in interest to Square 1 Bank) that was amended in September and December 2016 and allows us to borrow an additional $5.0 million through December 2017. As of December 31, 2016, our aggregate outstanding indebtedness under the loan and security agreement was $10.0 million.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to incur substantial additional expenditures in the next 12 months to support the commercial launch of our product in the United States. We believe that our existing cash and cash equivalents and short-term investments and expected revenue, will be sufficient to meet our capital requirements and fund our operations through the next two years. We expect our costs and expenses to increase in the future as we continue U.S. commercialization of our Obalon balloon system, including support of a direct sales force and the expansion of our manufacturing facilities, and as we continue to make substantial expenditures on research and development, including for conducting clinical trials of our products in development. Additionally, we expect to incur additional costs as a result of operating as a public company. Our future capital requirements will depend on many factors, including:</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs and expenses of maintaining and growing our U.S. sales and marketing infrastructure and our manufacturing operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the degree of success we experience in commercializing our Obalon balloon system;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the revenue generated by sales of our Obalon balloon system and other products that may be approved in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs, timing and outcomes of clinical trials and regulatory reviews associated with our products under development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs and timing of developing variations of our Obalon balloon system, and, if necessary, obtaining FDA approval of such variations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the emergence of competing or complementary technological developments;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which our Obalon balloon system is adopted by the physician community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number and types of future products we develop and commercialize;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent and scope of our general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional financing, if necessary, may not be available on a timely basis on terms acceptable to us, or at all. We may raise funds in equity or debt financings or enter into additional credit facilities in order to access funds for our capital needs. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution in their percentage ownership of our company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. Any debt financing obtained by us in the future would cause us to incur additional debt service expenses and could include restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and pursue business opportunities. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment or expansion of sales and marketing capabilities or other activities necessary to commercialize our products.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loan and security agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2013, we entered into a $3.0&#160;million loan and security agreement with Square&#160;1 Bank (predecessor in interest to Pacific Western Bank), which we subsequently amended in October 2014, September 2016 and December 2016.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, we could borrow up to $15.0 million in two tranches as follows: a first tranche consisting of $10.0 million which was carried over from our previous agreement in September 2016, and a second tranche of $5.0 million which may be drawn by us any time prior to December 21, 2017. As of December 31, 2016, we have not drawn down on this second tranche, and had $10.0 million outstanding under this loan and security agreement. The outstanding debt has a variable annual interest rate equal to the greater of the prime rate plus 1.50% or 5.0%, and matures in December 2020. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loan and security agreement provides for an interest-only period through June 21, 2018, followed by a 30-month principal and interest period. Pursuant to the loan and security agreement, we provided a first priority security interest in all existing and after-acquired assets, excluding intellectual property, owned by us.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loan and security agreement provides for restrictions on, among other things, our ability to incur additional indebtedness, change the name or location of our business, change our business, merge with or acquire other entities, pay dividends or make other distributions to holders of our capital stock, make certain investments, engage in transactions with our affiliates, create liens, sell assets, pay any subordinated debt, and store certain inventory and equipment with third parties. In addition, the loan and security agreement also requires that the Company's accounts maintained with the bank contain an aggregate balance in an amount equal to or greater than the total amount of outstanding debt under the loan and security agreement. </font></div><div><a name="s2DB98DBD9D759E7264397564EC8BCECB"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;CASH FLOWS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of the net cash flow activity for each of the periods set forth below (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,368</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,392</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,907</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,062</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exchange rate effect   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,619</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash used in operating activities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2016, net cash used in operating activities was </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;">, consisting primarily of a net loss of </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a decrease in net operating assets of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">.  These items were partially offset by non-cash charges of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">, consisting primarily of changes in the fair value of warrant liability, stock-based compensation expense, depreciation and non-cash interest expense related to amortization of investment premium and debt discount.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December&#160;31, 2015, net cash used in operating activities was $11.4&#160;million, consisting primarily of a net loss of $15.6&#160;million, offset by a decrease in net operating assets of $3.4&#160;million and non-cash charges of $0.8 million. The decrease in net operating assets primarily consisted of increased accrued expenses for our SMART trial and a customer deposit received from Bader. The non-cash charges consisted primarily of depreciation, stock-based compensation, and non-cash interest expense related to amortization of investment premium and debt discount.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December&#160;31, 2014, net cash used in operating activities was $9.9&#160;million, consisting primarily of a net loss of $9.9&#160;million and an increase in net operating assets of $0.3 million, partially offset by non-cash charges of $0.3&#160;million. The increase in net operating assets was primarily attributable to increases in inventory and other current assets and decreases in accrued clinical expenses. The non-cash charges primarily consisted of depreciation, stock-based compensation expense and non-cash interest expense related to amortization of investment premium and debt discount. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by (used in) investing activities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2016, net cash provided by investing activities was </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">, consisting primarily of maturities of short-term investments, partially offset by purchases of short term investments.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December&#160;31, 2015, net cash provided by investing activities was $2.8&#160;million, consisting primarily of maturities of short-term investments, partially offset by purchases of short term investments.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December&#160;31, 2014, net cash used in investing activities was $7.9&#160;million, consisting primarily of purchases of short-term investments, partially offset by maturities of short-term investments. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by financing activities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2016, net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$82.8 million</font><font style="font-family:inherit;font-size:10pt;">, consisting of net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$67.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from our IPO, net proceeds of $14.5 million from the issuance of Series E convertible preferred stock and proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from sale of common stock upon exercise of stock options.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December&#160;31, 2015, net cash provided by financing activities was $5.1&#160;million, consisting primarily of proceeds of $5.0&#160;million from borrowings under our loan and security agreement with Pacific Western Bank. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December&#160;31, 2014, net cash provided by financing activities was $22.2&#160;million, consisting primarily of net proceeds of $20.2&#160;million from the issuance of Series&#160;D convertible preferred stock and a $2.0 million increase in borrowings under our loan and security agreement with Pacific Western Bank. </font></div><div><a name="sF255D8485B4FA223220A7564F1B499B4"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OFF-BALANCE SHEET ARRANGEMENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have no off-balance sheet arrangements, such as structured finance, special purpose entities or variable interest entities.</font></div><div><a name="s971487F5960771EB34B47564EC020744"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTRACTUAL OBLIGATIONS </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal obligations consist of the operating lease for our facility and our loan and security agreement with Pacific Western Bank. The following table sets out, as of December&#160;31, 2016, our contractual obligations due by period:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments due by period</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;than <br>1 Year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1-3 <br>Years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3-5 <br>Years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">More <br>than&#160;5 <br>Years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease obligations(1).   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Consists of obligations under a multi-year, non-cancelable building lease for our facility in Carlsbad, California. An amendment to the lease was executed in February 2017 and is reflected herein. The lease will expire on March&#160;31, 2019. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturing organizations and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above. As of December 31, 2016, we had completed our lead clinical trial and all material expenses were accrued. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="sC557E217D91490AC08BE7564F207FBC4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:115%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EFFECTS OF INFLATION</font></div><div style="line-height:115%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.</font></div><div style="line-height:174%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See &#8220;Notes to Financial Statements-Note 2-Recent Accounting Pronouncements&#8221; of our annual financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2AD2F7548ECE721490CF7564F22D8A3D"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;7A.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="line-height:115%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INTEREST RATE RISK</font></div><div style="line-height:115%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk associated with fluctuating interest rates is primarily limited to our cash equivalents, short-term investments, and long term debt.  All of our cash equivalents and short-term investments are carried at quoted market prices.  All of our short-term investments are U.S. treasury notes with maturities of less than one year. Due to the short-term maturities and low risk profile of our cash equivalents and short-term investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our cash equivalents. We do not currently use or plan to use financial derivatives in our investment portfolio.</font></div><div style="line-height:115%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have outstanding debt under our loan and security agreement with Pacific Western Bank that bears interest. As of December 31, 2016, our aggregate outstanding indebtedness was $10.0 million, which bears interest at the rate equal to the greater of the prime rate plus 1.50% or 5.0%. We do not believe an immediate 10% increase in interest rates would have a material effect on interest expense for the loan with Pacific Western Bank, and therefore we do not expect our operating results or cash flows to be materially affected to any degree by a sudden change in market interest rates.</font></div><div style="line-height:115%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CREDIT RISK</font></div><div style="line-height:115%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016 and 2015, our cash and cash equivalents were maintained with one financial institution in the United States, and our current deposits are likely in excess of insured limits. We have reviewed the financial statements of this institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.</font></div><div style="line-height:115%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="sA0A583A3E37378F9E4FB7564F25B025E"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;8.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements and supplemental data required by this item are set forth at the pages indicated in Part&#160;IV, Item&#160;15(a)(1) of this Annual Report on Form 10-K.</font></div><div><a name="s34D12B1266A9BEE3479D7564F280688D"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;9.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="sF5F71EE3544B1D81C7DD7564F2AE655B"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;9A.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form&#160;10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2016, our disclosure controls and procedures were effective at the reasonable assurance level. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting due to a transition period established by the rules of the SEC, which requires such assessment to be included beginning with a registrant's second Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </font></div><div><a name="sB54B236920F8231B67667564F2D2E2E0"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;9B.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Information</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><br></div><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><a name="sA8997F7101E2F55449207564F30191E8"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:14px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div><a name="s2BB6DD9AAA244E0F2DBA7564F324E399"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;10.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors, Executive Officers and Corporate Governance </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</font></div><div><a name="sE537D631E17C1EEEC80D7564F356039E"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;11.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</font></div><div><a name="s7A7F3AC859FF8AD00AAC7564F37627F0"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;12.&#160;&#160;&#160;&#160; Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</font></div><div><a name="s5E7F44D8EA0C0FFD8D0A7564F3A8CDB0"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;13.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K. </font></div><div><a name="s2094357DB51C98A351B87564F3C9F9AC"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;14.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Accountant Fees and Services</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><a name="sEA581FA654641B6252967564F3FB760E"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s129CAC5AEF91611BD8987564F41E209D"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.  Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have filed the following documents as part of this Annual Report:</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page(s)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8248CF5F3A600E4656677564F450D9A1"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8248CF5F3A600E4656677564F450D9A1">71</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s034317303E80B0AFEBCB7564F47167AD"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of December 31, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s034317303E80B0AFEBCB7564F47167AD">72</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s80810C5929B1F7C5662A7564F4A31DC5"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2016, 2015 and 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s80810C5929B1F7C5662A7564F4A31DC5">74</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4A586C35CF8600A28C277564F4CCDCCA"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Years Ended December 31, 2016, 2015 and 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4A586C35CF8600A28C277564F4CCDCCA">75</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCBC8042C8F3B22D8F3367564F574B6BA"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2016, 2015 and 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCBC8042C8F3B22D8F3367564F574B6BA">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A4DF6F2D48B4F3F2F507564F5A7AEEB"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A4DF6F2D48B4F3F2F507564F5A7AEEB">78</a></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><a name="s8248CF5F3A600E4656677564F450D9A1"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Stockholders</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obalon Therapeutics, Inc.: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Obalon Therapeutics, Inc. and&#160;subsidiaries as of December&#160;31, 2016 and 2015, and the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the three-year period ended December&#160;31, 2016. These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Obalon Therapeutics, Inc. and&#160;subsidiaries as of December&#160;31, 2016 and 2015, and the results of their operations and their cash flows for each of the years in the three-year period ended December&#160;31, 2016, in conformity with U.S.&#160;generally accepted accounting principles. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">San Diego, California </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;23, 2017 </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><a name="s034317303E80B0AFEBCB7564F47167AD"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:113%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OBALON THERAPEUTICS, INC.</font></div><div style="line-height:113%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:113%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except shares and par value data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, related party   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">827</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,803</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and equipment, net</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,399</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer deposit from related party   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term loan   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,567</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term loan, excluding current portion</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,094</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and contingencies (See Note 10)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible preferred stock</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A convertible preferred stock, $0.001 par value; 2,333,332 shares authorized; none and 804,595 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively; liquidation preference of $0 and $7,000 at December 31, 2016 and December 31, 2015, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,773</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B convertible preferred stock, $0.001 par value; 4,333,332 shares authorized; none and 1,494,248 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively; liquidation preference of $0 and $6,500 at December 31, 2016 and December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C convertible preferred stock, $0.001 par value; none and 7,809,939 shares authorized at December 31, 2016 and December 31, 2015, respectively; none and 2,668,533 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively; liquidation preference of $0 and $16,523 at December 31, 2016 and December 31, 2015, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C-1 convertible preferred stock, $0.001 par value; none and 2,783,334 and shares authorized at December 31, 2016 and December 31, 2015, respectively; none and 480,286 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively; liquidation preference of $0 and $5,000 at December 31, 2016 and December 31, 2015, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D convertible preferred stock, $0.001 par value; none and 11,546,013 shares authorized at December 31, 2016 and December 31, 2015, respectively; none and 2,732,552 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively; liquidation preference of $0 and $41,180 at December 31, 2016 and December 31, 2015, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,095</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series E convertible preferred stock, $0.001 par value; 0 shares authorized at December 31, 2016 and 2015, respectively; 0 shares issued and outstanding at December 31, 2016 and 2015, respectively; liquidation preference of $0 at December 31, 2016 and 2015, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; equity (deficit):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value; 300,000,000 and 35,000,000 shares authorized at December 31, 2016 and December 31, 2015, respectively; 16,773,205 and 575,126 shares issued and outstanding at  December 31, 2016 and December 31, 2015, respectively   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,609</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total stockholders&#8217; equity (deficit)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><a name="s80810C5929B1F7C5662A7564F4A31DC5"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OBALON THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except shares and per share data)</font></div><div style="line-height:120%;padding-bottom:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, related party   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,809</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,503</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,872</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,467</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(477</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(549</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) gain from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (expense) income, net   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and comprehensive loss   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,468</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,552</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding, basic and diluted   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,221,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><a name="s4A586C35CF8600A28C277564F4CCDCCA"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OBALON THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except shares and per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"></td></tr><tr><td style="width:7%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series A <br>convertible <br>preferred stock</font><font style="font-family:inherit;font-size:6pt;">&#160;&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series B <br>convertible <br>preferred stock</font><font style="font-family:inherit;font-size:6pt;">&#160;&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series C <br>convertible <br>preferred stock</font><font style="font-family:inherit;font-size:6pt;">&#160;&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series C-1 <br>convertible <br>preferred stock</font><font style="font-family:inherit;font-size:6pt;">&#160;&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series D <br>convertible <br>preferred stock</font><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series E <br>convertible <br>preferred stock</font><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common stock</font><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional <br>paid-in <br>capital</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated <br>other <br>comprehensive <br>(loss) income</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated <br>deficit</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total <br>stockholders&#8217; <br>deficit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Balance at December&#160;31, 2013   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">804,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,494,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">6,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">2,668,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">16,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">480,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">529,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(30,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(30,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock for cash   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4,285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of preferred stock at $7.5351 per share, net of issuance costs of $368   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">2,732,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">20,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Stock-based compensation   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Foreign currency translation adjustment and other comprehensive loss   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net loss   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(9,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(9,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Balance at December&#160;31, 2014   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">804,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,494,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">6,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">2,668,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">16,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">480,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">2,732,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">20,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">533,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(40,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(39,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock for cash   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">41,642</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of warrants in connection with preferred stock financing   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Stock-based compensation   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Foreign currency translation adjustment and other comprehensive loss   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net loss   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(15,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(15,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Balance at December&#160;31, 2015   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">804,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,494,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">6,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">2,668,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">16,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">480,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">2,732,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">20,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">575,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(56,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(55,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock for cash upon exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">808,885</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">820</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of preferred stock at $8.2932 per share, net of issuance costs of $94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,916,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">15,799</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"></td></tr><tr><td style="width:7%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Stock-based compensation   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">563</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">563</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Conversion of preferred stock to common stock in connection with initial public offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(804,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1,494,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(6,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(2,668,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(16,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(480,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(4,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(2,732,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(20,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(1,916,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(15,799</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">10,360,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">70,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">70,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">5,000,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">67,228</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">67,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net exercise of common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">28,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Reclassification of warrant liability as equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Foreign currency translation adjustment and other comprehensive loss   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net loss   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(20,467</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(20,467</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Balance at December&#160;31, 2016   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">16,773,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">140,898</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(76,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">64,305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><a name="sCBC8042C8F3B22D8F3367564F574B6BA"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OBALON THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,890</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Depreciation and amortization   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss on disposal of fixed assets   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortization of investment premium, net   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">260</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortization of debt discount   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable, net   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable from related party   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(481</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Inventory   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other current assets   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(985</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(109</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable and accrued expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued compensation   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,247</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued clinical expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other current liabilities   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">517</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer deposit from related party   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:112px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash used in operating activities   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,368</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,392</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,907</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Purchases of short-term investments   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,590</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,400</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Maturities of short-term investments   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales of short-term investments   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Purchase of property and equipment   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from disposal of property and equipment   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:112px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash provided by (used in) investing activities   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of preferred stock for cash, net of offering costs   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of preferred stock to related party for cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from initial public offering, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from long-term loan, net of issuance costs   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,958</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fees paid in connection with loan amendment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Repayments of long-term loans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sale of common stock upon exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,066</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:112px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash provided by financing activities   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effect of exchange rate changes on cash and cash equivalents   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:112px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net increase (decrease) in cash and cash equivalents   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,619</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,546</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents at beginning of period   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents at end of period   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Supplemental cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest paid   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">527</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income taxes paid   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Conversion of convertible preferred stock to common stock</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net exercises of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Conversion of customer deposit from related party to preferred stock   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment in accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><a name="s5A4DF6F2D48B4F3F2F507564F5A7AEEB"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OBALON THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s734E2702CBFD4271E7287564F5C0C018"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Organization and Basis of Presentation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obalon Therapeutics, Inc., or the&#160;Company, was incorporated in the state of Delaware on January&#160;2, 2008. The Company is a vertically-integrated medical device company focused on developing and commercializing innovative medical devices to treat obese and overweight people. Using its patented technology, the Company has developed the Obalon balloon system, the first and only FDA approved swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Obalon Therapeutics, Inc., and its wholly owned subsidiaries, Obalon Italy SRL and Obalon Therapeutics, LLC. Obalon Therapeutics, LLC is a shell Company, which owns </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;">&#32;of Obalon Mexico DE RL CV.  Obalon Italy SRL was dissolved during 2015 and Obalon Mexico DE RL CV was dissolved during 2016.   All intercompany balances and transactions have been eliminated in consolidation.  </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles, or GAAP. The Company&#8217;s principal operations are located in Carlsbad, California and it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;business segment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016, the Company has devoted a substantial portion of its efforts to product development, raising capital, and building infrastructure. The Company has incurred operating losses and has experienced negative cash flows from operations since its inception. In July&#160;2012, the Company realized initial revenue from its planned principal operations. The Company recognized revenue, including revenue from related parties, of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended December&#160;31, 2016, 2015 and 2014, respectively. However, the Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and has funded its activities to date almost exclusively from debt and equity financings. On September&#160;8, 2016, the Company received premarket approval from the U.S. Food and Drug Administration, or FDA, to market the Obalon balloon system for temporary use to facilitate weight loss in obese adults with a body mass index, or BMI of 30 to 40 who have failed to lose weight through diet and exercise. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. For all periods presented, all sales are to customers outside of the United States.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 5, 2016, the Company&#8217;s Registration Statement on Form S-1 (File No. 333-213551) relating to the initial public offering, or IPO, of its common stock was declared effective by the Securities and Exchange Commission, or SEC. Pursuant to such Registration Statement, the Company sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for aggregate cash proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$67.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts, commissions, and offering costs. The IPO closed on October 12, 2016. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2016, immediately prior to the closing of the IPO, the following events occurred:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate of </font><font style="font-family:inherit;font-size:10pt;">10,360,419</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, excluding any warrant conversions, were issued to the holders of the Company&#8217;s Series A, Series B, Series C, Series C-1, Series D and Series E convertible preferred stockholders upon the automatic conversion of all shares of convertible preferred stock to common stock. As a result, no Series A, Series B, Series C, Series C-1, Series D or Series E convertible preferred stock remain outstanding at December 31, 2016.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiated on October 11, 2016, Series C-1 and D warrants for </font><font style="font-family:inherit;font-size:10pt;">36,562</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's preferred stock were exercised by Pacific Western Bank (as successor in interest to Square 1 Bank) via cashless exercise resulting in the subsequent issuance of </font><font style="font-family:inherit;font-size:10pt;">16,558</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock on October 12, 2016.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D warrants for </font><font style="font-family:inherit;font-size:10pt;">24,550</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s preferred stock were automatically net exercised resulting in the issuance of </font><font style="font-family:inherit;font-size:10pt;">12,217</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The remaining outstanding Series C preferred stock warrants exercisable for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">24,224</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of convertible preferred stock automatically converted into warrants exercisable for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">24,224</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Plan, and the 2016 ESPP, as described in Note 7, were adopted.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate of </font><font style="font-family:inherit;font-size:10pt;">223,371</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock reserved but not issued under the 2008 Plan became available for grant under the 2016 Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company filed its amended and restated certificate of incorporation on October 12, 2016, authorizing </font><font style="font-family:inherit;font-size:10pt;">300,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">10,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of preferred stock.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">February 2014 Reverse Stock Split </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the board of directors of the Company approved a 3-for-1 reverse stock split of the Company&#8217;s common and preferred stock. All share and per share information included in the accompanying consolidated financial statements and notes to consolidated financial statements give retroactive effect to this reverse stock split for the Company&#8217;s common and preferred stock. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September 2016 Reverse Stock Split</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, the Company&#8217;s board of directors approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock and convertible preferred stock at a 2.9-to-1 ratio, which was effected on September&#160;23, 2016. All share and per share information included in the accompanying consolidated financial statements and notes to the consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for the Company&#8217;s common and preferred stock for all periods presented.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As reflected in the accompanying consolidated financial statements, the Company has a limited operating history and the sales and income potential of the Company&#8217;s business are unproven. The Company has not been profitable since inception, and as of December 31, 2016, its accumulated deficit was </font><font style="font-family:inherit;font-size:10pt;">$76.6 million</font><font style="font-family:inherit;font-size:10pt;">. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its IPO and, to a lesser extent, debt financing arrangements. The Company expects to continue to incur net losses for the foreseeable future as it builds its sales and marketing organization, supports commercialization of its product in the United States and continues research and development efforts. The Company may need additional funding to pay expenses relating to its operating activities, including selling, general and administrative expenses and research and development expenses. Adequate funding, if needed, may not be available to the Company on acceptable terms, or at all. The failure to obtain sufficient funds on acceptable terms could have a material adverse effect on the Company&#8217;s business, results of operations or financial condition. The Company believes that its existing cash and cash equivalents and short-term investments and expected revenue will be sufficient to meet its capital requirements and fund its operations through the next two years. </font></div><div><a name="s58F6ABC5E38A063845B17564F5EF82BF"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses, if any, reported as a component of other comprehensive loss within the consolidated statements of operations and comprehensive loss. All of the Company&#8217;s short-term investments are U.S.&#160;Treasury notes with maturities of less than one&#160;year. For the years ended December&#160;31, 2016, 2015 and 2014, unrealized losses were immaterial amounts, respectively. Realized gains and losses would be calculated on the specific-identification method and recorded as interest income. There have been no material realized gains and losses for the years ended December&#160;31, 2016, 2015 and 2014. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable from related party, accounts payable, and accrued expenses approximate their fair values due to the short maturity of these instruments. The carrying value of the term loan approximates its fair value as the interest rate and other terms are that which is currently available to the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels in accordance with authoritative accounting guidance: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2 inputs: Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables are unsecured and are carried at net realizable value including an allowance for estimated uncollectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest, although a finance charge may be applied to such receivables that are more than 30&#160;days past due. The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical expense, credit quality, the age of the account receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. The Company&#8217;s allowance for doubtful accounts was </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">&#32;at both December 31, 2016 and 2015, respectively. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company&#8217;s customers consist of distributors. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div><div style="line-height:100%;padding-top:1px;text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes certain financial data for the customers who accounted for 10.0% or more of sales and accounts receivable. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:56%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Single largest customer:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, related party   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, related party   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second largest customer:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or net realizable value, computed on a standard cost basis. Inventory that is obsolete or is in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The useful lives of the property and equipment are as follows: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter&#160;of&#160;3&#160;years&#160;or&#160;length&#160;of&#160;software license</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of the assets to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the difference between the carrying amount and the fair value of the impaired asset. The Company did not recognize any material impairment losses for the respective years ended December&#160;31, 2016, 2015 and 2014. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All research and development costs are charged to expense as incurred. Research and development expenses primarily include (i)&#160;payroll and related costs associated with research and development performed, (ii)&#160;costs related to clinical and preclinical testing of our technologies under development and (iii)&#160;other research and development expenses. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into contracts with third party hospitals and doctors to perform clinical trial activities. The Company accrues expenses for clinical trial activities performed by third parties based on estimates of work performed by each third party as of the balance sheet date. The Company&#8217;s clinical trial expense is primarily driven by patient visits to the third party hospitals and doctors. As such, the Company uses the estimated patient visits based on third-party reporting and the contractually agreed upon cost for each visit to calculate its clinical accrual. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based awards issued to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). Because non-cash stock compensation expense is based on awards ultimately expected to vest, it is reduced by an estimate for future forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for interest and penalties related to income tax matters, if any, as a component of income tax expense or benefit. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to sales of components of the Obalon balloon system, which includes the balloon and accessory kit, EzFill inflation system, pre-filled can of gas and placebo capsule. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when (i)&#160;persuasive evidence of an arrangement exists, (ii)&#160;delivery has occurred, (iii)&#160;the selling price is fixed or determinable and (iv)&#160;collectability is reasonably assured. Determination of criteria (iii)&#160;and (iv)&#160;are based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company does not provide for rights of return to customers on product sales, with the exception of products that fail to conform to the Company&#8217;s specifications. As these non-conforming returns have historically been immaterial, the Company does not record a provision for returns. The Company does not have any post shipment obligations or acceptance provisions within its customer contracts. The Company occasionally offers discounts off its standard prices to non-distributor customers, which are agreed upon and known at the time of sale. In these cases, revenue is recognized net of these discounts. Shipping charges billed to customers are included in product revenue and the related shipping costs are included in cost of revenue. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Warranty </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company warranties its products to be of good quality and free from defects in design, materials, or workmanship for approximately one&#160;year from the date of purchase. The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based on historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is possible that the Company&#8217;s underlying assumptions will not reflect the actual experience and in that case, future adjustments will be made to the recorded warranty obligation. The warranty expense as of December&#160;31, 2016, 2015 and 2014 was immaterial for each year. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Costs </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs are expensed as incurred and included in selling, general and administrative expense. Advertising costs for the years ended December&#160;31, 2016, 2015 and 2014 were approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for 2016, 2015 and 2014, respectively. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock Warrants </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of preferred stock warrants issued in conjunction with debt issuances was initially recorded as a warrant liability and debt discount. The debt discount associated with the initial warrant fair value is being amortized to interest expense using the effective-interest method in the Company&#8217;s consolidated statements of operations and comprehensive loss over the term of the debt. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of preferred stock warrants issued in conjunction with preferred stock issuances was initially recorded as a warrant liability and reduction of the proceeds received. The fair value of the warrants was estimated using the Black-Scholes option pricing model based on the estimated fair value of the preferred stock at the valuation date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying preferred stock. Prior to the automatic conversion of the warrants in conjunction with the IPO on October 12, 2016, the warrant liability was remeasured each reporting period with changes in fair value being recognized in the consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As noted above in Note 1, in connection with the completion of the Company&#8217;s IPO, all the remaining outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As such, the Company reclassified the remaining warrant liability to stockholders&#8217; equity as the converted warrants met the definition of an equity instrument under derivative accounting guidance. The Company performed the final remeasurement of the warrant liability as of the IPO closing date. See Note 3 for the amounts associated with the fair value remeasurements and Note 8 for further description of the remaining warrants.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per common share, since the effects of potentially dilutive securities are anti-dilutive. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive common stock equivalents are comprised of convertible preferred stock, warrants and unexercised stock options outstanding under the Company&#8217;s equity plan. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.</font><font style="font-family:inherit;font-size:10pt;">&#32;ASU 2014-15 requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable that when, considered in the aggregate, raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued, for both annual and interim periods. ASU 2014-15 also requires certain disclosures around management&#8217;s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that will alleviate the substantial doubt. ASU 2014-15 is effective for annual reporting periods, and interim periods within those periods, beginning after December&#160;15, 2016. The adoption of ASU 2014-15 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July&#160;2015, FASB&#160;issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. This update applies to companies that measure inventory on a first in, first out, or FIFO, or average cost basis. Under this update, companies are to measure their inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion. The amendments in this update are effective for annual reporting periods, and interim periods within those periods, beginning after December&#160;15, 2016 with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. Under this new guidance, at the commencement date, lessees will be required to recognize (i)&#160;a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii)&#160;a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09, which was issued in March 2014 and has been codified with the Accounting Standards Codification as Topic 606, is now effective for public companies for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. ASC 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">industry-specific guidance. In addition, ASC 606 provides guidance on accounting for certain revenue-related costs including, but not limited to, when to capitalize costs associated with obtaining and fulfilling a contract. ASC 606 provides companies with two implementation methods: (a) full retrospective adoption, meaning the standard is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance.&#160;Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within ASC 606 to clarify various elements of the guidance. While the Company is continuing to assess all potential impacts of the standard, they do not believe that their current revenue streams will be materially affected. As the Company begins commercialization in the U.S. during 2017 and enters into sales agreements with customers as part of this commercialization, the Company will continue to assess the potential impacts of the standard, including the impact to the pattern with which they recognize revenue based on the terms entered into and finalizing the determination of transition approach.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which involves several aspects of the accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This new guidance will require all income&#160;tax effects of awards to be recognized as income tax expense or benefit in the income statement when the awards vest or are settled, as opposed to additional paid-in-capital where it is currently recorded. It&#160;also will allow an employer to repurchase more of an employee&#8217;s shares than it can today for tax withholding purposes without triggering liability accounting. All tax-related cash flows resulting from stock-based payments are to be reported as operating activities on&#160;the statement of cash flows. The guidance also allows a Company to make a policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. This new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2016, with early adoption permitted. The Company does not recognize any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance on its deferred tax assets. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, which addresses the following eight specific cash flow issues: Debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies); distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2017, with early adoption permitted.&#160;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The Company does not anticipate that the adoption of ASU 2016-15 will have a material impact on its consolidated financial statements.</font></div><div><a name="sD586E9CE9768D074F3E77564EC06F2E7"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Fair Value Measurements </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Instruments Recorded at Fair Value on a Recurring Basis </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2016 and 2015 are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices<br>in&#160;active<br>markets&#160;for<br>identical&#160;assets<br>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br>other<br>observable<br>inputs<br>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br>unobservable<br>inputs<br>(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury bonds(2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;active <br>markets for <br>identical&#160;assets <br>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br>other <br>observable <br>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br>unobservable <br>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds(1)   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury bonds(2)   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Classified as cash and cash equivalents on the consolidated balance sheets. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Classified as short-term investments on the consolidated balance sheets. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s investments in Level 1 assets are valued based on publicly available quoted market prices for identical securities as of December&#160;31, 2016 and 2015. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 2 above, </font><font style="font-family:inherit;font-size:10pt;">61,112</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants were exercised to common stock and all of the remaining outstanding </font><font style="font-family:inherit;font-size:10pt;">24,224</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock in connection with the IPO and are equity classified at December 31, 2016. Prior to the exercise and the conversion, the Company estimated the fair value of convertible preferred stock warrants at the time of issuance and subsequent remeasurements using the Black-Scholes option-pricing model at each reporting date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following assumptions were used in the Black-Scholes option-pricing model to determine the fair value of the convertible preferred stock warrants at the exercise and conversion date, and December 31, 2015:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:63%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">October 12,</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed risk-free interest rate   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.90% - 1.64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.28%&#160;-&#160;2.06%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed volatility   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.42% - 62.36%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.76%&#160;-&#160;70.66%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.40 yrs - 7.96 yrs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.15&#160;-&#160;8.75 yrs</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock fair value:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.41</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C-1   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.72</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions were determined as follows: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed risk-free interest rate &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on the average yield of U.S. Treasury bills as of the valuation date for the expected term of the award. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed volatility &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on the historical volatility of a number of publicly traded companies comparable in size, business model, industry and business description. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected life &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on the remaining contractual term of warrant as of the valuation date. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected dividend yield &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based upon the Company&#8217;s historic dividends and dividend expectations for the foreseeable future. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred stock fair value &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;On October 12, 2016, the conversion date, the Company used the closing price of its common stock. Given the absence of a public trading market on December 31, 2015, the Company considered numerous objective and subjective factors to determine the fair value of preferred stock at each valuation date. These factors included, but were not limited to, (i)&#160;contemporaneous valuations of preferred stock performed by unrelated third-party specialists; (ii)&#160;the prices for preferred stock sold </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to outside investors; (iii)&#160;the rights, preferences and privileges of preferred stock relative to common stock; (iv)&#160;developments in the business; and (v)&#160;the likelihood of achieving a liquidity event, such as an IPO or a merger or acquisition of the Company, given prevailing market conditions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2015, reasonable changes in the unobservable inputs would not be expected to have a significant impact on the consolidated financial statements. The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no significant transfers into or out of Level&#160;1, 2, or 3 for the years ended December&#160;31, 2016 and 2015. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides reconciliation for all liabilities measured at fair value using significant unobservable inputs (Level&#160;3) for the years ended December&#160;31, 2016 and 2015 (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value <br>measurements <br>at reporting <br>date using <br>significant <br>unobservable <br>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2014  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of warrants for the purchase of convertible preferred stock   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants exercised</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of warrants to stockholders' equity (deficit) </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2016   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Instruments Not Recorded at Fair Value on a Recurring Basis </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of long-term loan is determined by Level&#160;2 inputs and is based primarily on quoted market prices for the same or similar issues. The recorded value of long-term loan approximates the current fair value due to the proximity of when the long-term loan was negotiated.</font><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><a name="s1A1ECA7A6458AE8B2DD97564EC4DDDB9"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Net Loss per Share </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except shares and per share data): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,890</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,221,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the outstanding potentially dilutive securities determined using the treasury stock and if-converted methods that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:56%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:13px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock, on an as-converted basis   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,443,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,654,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,443,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,714,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><a name="sD19393342ACC32E2265C7564F66429D7"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Balance Sheet Details </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity <br>(in&#160;years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br>cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br>unrealized <br>gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br>unrealized <br>losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated <br>fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury   </font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;year&#160;or&#160;</font></div><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,501</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity <br>(in&#160;years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br>cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br>unrealized <br>gains</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br>unrealized <br>losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated <br>fair value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2015:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;year&#160;or&#160;</font></div><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid assets   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest receivable   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress, or CIP   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,312</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense for the years ended December&#160;31, 2016, 2015 and 2014 was $</font><font style="font-family:inherit;font-size:10pt;">0.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million for all periods, respectively. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,399</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s9BA09B5EAD90242444957564EC8189E8"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Term Loan </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2013, the Company entered into a loan and security agreement, or 2013 Loan Agreement, with Pacific Western Bank (as successor in interest to Square&#160;1 Bank) allowing for borrowings up to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">. In addition to the interest payments, Pacific Western Bank received warrants for the purchase of up to </font><font style="font-family:inherit;font-size:10pt;">8,693</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s Series&#160;C-1 convertible preferred stock. On October 11, 2016, all the warrants were net exercised into </font><font style="font-family:inherit;font-size:10pt;">2,689</font><font style="font-family:inherit;font-size:10pt;">&#32;shares which were subsequently issued as common stock on October 12, 2016 in conjunction with the IPO closing. In October&#160;2014, the Company amended the 2013 Loan Agreement and executed a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;credit facility with Pacific Western Bank, or 2014 Loan Agreement. The 2014 Loan Agreement was separated into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;tranches, Term Loan A and Term Loan B. Term Loan A was </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">, which included the existing </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of outstanding debt and the additional </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that was funded upon closing of the 2014 Loan Agreement. Term Loan B was </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and was available upon receipt of at least </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in proceeds from the issuance and sale of the Company&#8217;s equity securities to investors. Term Loan B was funded after the close of the Company&#8217;s Series&#160;D financing in January&#160;2015. As part of the 2014 Loan Agreement, the Company issued Pacific Western&#160;Bank additional warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">27,869</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of its Series&#160;D convertible preferred stock at </font><font style="font-family:inherit;font-size:10pt;">$7.5351</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. On October 11, 2016, all the warrants were net exercised into </font><font style="font-family:inherit;font-size:10pt;">13,869</font><font style="font-family:inherit;font-size:10pt;">&#32;shares which were subsequently issued as common stock on October 12, 2016 in conjunction with the IPO closing. As of December 31, 2016, Pacific Western Bank held </font><font style="font-family:inherit;font-size:10pt;">16,558</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock associated with its warrant exercises and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants outstanding.  </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The present value of the future cash flows under the 2014 Loan Agreement terms did not exceed the present value of the future cash flows under the 2013 Loan Agreement terms by more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">. As such, the Company treated this amendment as a modification and recorded the associated immaterial facility fee and the associated immaterial fair value of the warrants as a discount to the 2014 Loan Agreement. This discount and the remaining balance of debt issuance costs and debt discount of the 2013 Loan Agreement were amortized to interest expense over the remaining term of the 2014 Loan Agreement using the effective-interest method.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September&#160;7, 2016, the Company entered into the September 2016 Loan Agreement, with Pacific Western Bank, which amended the existing outstanding debt agreement described above. The September 2016 Loan Agreement allows for total borrowings up to </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;tranches as follows: a first tranche consisting of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;funded on September&#160;7, 2016, of which the full </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;must be used to settle the existing debt with Pacific Western Bank on a net settlement basis (pursuant to its original terms); and a second tranche consisting of an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which may be drawn at any time prior to March&#160;7, 2017. The first tranche and the second tranche are collectively referred to as the &#8220;Term Loans.&#8221; The Term Loans bear interest at the greater of prime rate plus </font><font style="font-family:inherit;font-size:10pt;">1.50%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum, or </font><font style="font-family:inherit;font-size:10pt;">5.00%</font><font style="font-family:inherit;font-size:10pt;">. The Term Loans mature on September&#160;7, 2020 and have an interest-only period through March 2018 followed by </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;equal monthly installments of principal and interest. The Term Loans may be prepaid in full at any time with no additional cost.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the September 2016 Loan Agreement, the Company issued to Pacific Western Bank a warrant to purchase a number of the Company&#8217;s Series&#160;E Preferred Stock, at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total amount of up to </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of debt drawn over </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;divided by the purchase price, which automatically converted into a warrant to purchase the same number of shares of common stock immediately prior to the closing of the Company&#8217;s IPO, and will only be exercisable in the event that the Company borrows all or part of the second tranche. As the Company had not drawn down on the second tranche, </font><font style="font-family:inherit;font-size:10pt;">none</font><font style="font-family:inherit;font-size:10pt;">&#32;of these warrants were exercisable.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 21, 2016, the Company entered into the December 2016 Loan Agreement with Pacific Western Bank, which further amended the existing outstanding debt agreements described above. The December 2016 Loan Agreement kept total borrowings consistent of up to </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;tranches as follows: a first tranche consisting of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;funded on December 21, 2016, of which the full </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;must be used to settle the existing debt with Pacific Western Bank on a net settlement basis (pursuant to its original terms); and a second tranche consisting of an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which may be drawn at any time prior to December 21, 2017. The Term Loans bear interest at the greater of prime rate plus </font><font style="font-family:inherit;font-size:10pt;">1.50%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum, or </font><font style="font-family:inherit;font-size:10pt;">5.00%</font><font style="font-family:inherit;font-size:10pt;">. The Term Loans mature   on December 21, 2020 and have an interest-only period through June 21, 2018 followed by </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;equal monthly installments of principal </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and interest. The Term Loans may be prepaid in full at any time with no additional cost. The Series E warrant issued with the 2016 Loan Agreement was canceled without exercise in conjunction with the amendment.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The present value of the future cash flows under the 2016 Loan Agreement and the December 2016 Loan Amendment did not exceed the present value of the future cash flows under the predecessor terms by more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">. As such, the Company treated the amendments as modifications and recorded the associated immaterial facility fees as a discount to the amended debt. This discount and the remaining balance of debt issuance costs and debt discount are amortized to interest expense over the remaining term of the December 2016 Loan Agreement using the effective-interest method.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2016 Loan Agreement also requires that the Company's accounts maintained with the bank contain an aggregate balance in an amount equal to or greater than the total amount of outstanding debt under the December 2016 Loan Agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan and unamortized debt discount balances are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Face value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion of long-term loan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan, excluding current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016, future principal payments due under the December 2016 Loan Agreement are as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future principal payments due under the December 2016</font></div><div style="padding-top:1px;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Loan Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s66014AB17C5AA0A9A6427564EC1D8976"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Stock-Based Compensation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted an Equity Incentive Plan, or the&#160;2008 Plan, in 2008, under which </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;further shares of common stock are reserved for issuance to employees, nonemployee directors, and consultants of the Company. The Plan provides for the grant of incentive stock options, nonstatutory stock options, rights to purchase restricted stock, stock appreciation rights, dividend equivalents, stock payments, and restricted stock units to eligible recipients. On October 4, 2016, the 2016 Equity Incentive Plan, or the&#160;2016 Plan, became effective. The 2016 Plan serves as a successor to the 2008 Plan. The 2016 Plan permits the award of stock options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards, cash awards and stock bonuses. The Company reserved </font><font style="font-family:inherit;font-size:10pt;">2,200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock for issuance under the 2016 Plan, plus the </font><font style="font-family:inherit;font-size:10pt;">223,371</font><font style="font-family:inherit;font-size:10pt;">&#32;reserved and unissued shares under the 2008 plan on the effective date of the 2016 Plan. The number of shares reserved for issuance under the 2016 Plan will increase automatically on January 1 of each calendar year continuing through the tenth calendar year during the term of the 2016 Plan by the number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total outstanding shares of the Company's common stock and common stock equivalents as of the immediately preceding December&#160;31.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recipients of incentive stock options shall be eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Plan is ten&#160;years. The options generally vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">. At December&#160;31, 2016, </font><font style="font-family:inherit;font-size:10pt;">1,386,549</font><font style="font-family:inherit;font-size:10pt;">&#32;options remained available for future grant under the 2016 Plan. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed risk-free interest rate &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on the average yield of U.S. Treasury bills as of the valuation date for the expected term of the award. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed volatility &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Due to limited historical data, the expected volatility is estimated based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group consisted of other publicly-traded companies in the same industry and in a similar stage of development. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected life &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based based on the simplified method, which is an average of the contractual term of the options and its ordinary vesting period.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected dividend yield &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based upon the Company&#8217;s historic dividends and dividend expectations for the foreseeable future. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common stock fair value &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;Upon the effective date of the IPO, the Company began using the closing price of its common stock for the price of new stock option awards. Prior to the effectiveness of the Company&#8217;s IPO, given the absence of a public trading market, the Board of Directors considered numerous objective and subjective factors to determine the fair value of common stock at each grant date. These factors included, but were not limited to, (i)&#160;contemporaneous valuations of common stock performed by unrelated third-party specialists; (ii)&#160;the prices for preferred stock sold to outside investors; (iii)&#160;the rights, preferences and privileges of preferred stock relative to common stock; (iv)&#160;the lack of marketability of common stock; (v)&#160;developments in the business; and (vi) the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of the Company, given prevailing market conditions. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed risk-free interest rate   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">1.40% -1.53%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.57%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.82%&#160;-&#160;2.09%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed volatility   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">52.91% - 53.49%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.53%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71.09%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected option life   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized stock-based compensation straight-line over the vesting term of the options. The Company recorded non-cash compensation, including non-cash compensation to employees and nonemployees in the consolidated statements of operations and comprehensive loss as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized compensation expense at December&#160;31, 2016 was approximately </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average term of&#160;</font><font style="font-family:inherit;font-size:10pt;">3.4</font><font style="font-family:inherit;font-size:10pt;">&#32;years. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity instruments issued to nonemployees are initially recorded at their grant-date fair value and are periodically revalued using the Black-Scholes option pricing model as the equity instruments vest and are recognized as expense over the related service period. Stock-based compensation expense to nonemployees was immaterial for the years ended December&#160;31, 2016, 2015 and 2014. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option transactions for the Plan for the years ended December&#160;31, 2016, 2015 and 2014 (in thousands, except shares and per share data): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of <br>shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br>average <br>exercise <br>price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br>average <br>remaining <br>contractual <br>life</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate <br>intrinsic value <br>(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,787,517</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(808,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,816</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,225,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,929,465</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,792</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and exercisable at December&#160;31, 2016   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average fair value of options granted during the years ended December&#160;31, 2016 was </font><font style="font-family:inherit;font-size:10pt;">$2.99</font><font style="font-family:inherit;font-size:10pt;">. The intrinsic value of options exercised for the years ended December&#160;31, 2016 was </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and immaterial for the years ended December 31, 2015 and 2014. </font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All options outstanding under the 2008 Plan are exercisable under the early exercise provisions of the Plan. Options granted under the Plan that are exercised prior to vesting are subject to repurchase by the Company at the original issue price and will vest according to the respective option agreement. For the year ended December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">252,453</font><font style="font-family:inherit;font-size:10pt;">&#32;options were early exercised and </font><font style="font-family:inherit;font-size:10pt;">238,638</font><font style="font-family:inherit;font-size:10pt;">&#32;remain unvested with a related liability of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded under other current liabilities on the Company&#8217;s consolidated balance sheet as of December 31, 2016. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;options were early exercised for the years ended December 31, 2015 and 2014.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 5, 2016, the 2016 Employee Stock Purchase Plan, or ESPP, became effective.&#160;The 2016 ESPP was adopted in order to enable eligible employees to purchase shares of the Company&#8217;s common stock at a discount. Purchases will be accomplished through participation in discrete offering periods.&#160;&#160;The Company initially reserved </font><font style="font-family:inherit;font-size:10pt;">180,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock for issuance under the 2016 ESPP. The number of shares reserved for issuance under the 2016 ESPP will increase automatically on January 1 of each calendar year beginning after the first offering date and continuing through the first ten calendar years by the number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total outstanding shares of our common stock and common stock equivalents as of the immediately preceding December&#160;31. Stock compensation expense related to the ESPP was immaterial for the year ended December 31, 2016 and is included in total stock compensation expense disclosed above.</font></div><div><a name="sCC3855ACC4405ED721437564EC52C002"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Convertible Preferred Stock and Stockholders&#8217; Deficit </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Preferred Stock </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock prior to automatic conversion of all shares to common stock immediately prior to the closing of the IPO consisted of the following (in thousands, except for shares):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares&#160;issued</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">carrying</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">liquidation</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">preference</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,333,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">804,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,333,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494,248</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,809,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,668,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,418,042</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,286</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,984</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,076,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,732,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series E</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,490,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916,425</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,893</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,460,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,096,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series E Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2016, the Company completed its Series E financing.&#160;The Company sold </font><font style="font-family:inherit;font-size:10pt;">1,916,425</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series E stock at </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for proceeds of </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;">, net of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in issuance costs, which includes a non-cash amount of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;issued to a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">related party as further described in Note 11.&#160;The holders of Series E stock are entitled to receive dividends, if declared, at a rate of </font><font style="font-family:inherit;font-size:10pt;">$0.6635</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum.&#160;In the event of liquidation, the holders of Series E shares are entitled to receive liquidation preferences at the rate of </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;Each share of Series E stock is convertible to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of common stock immediately upon (i)&#160;the Company&#8217;s sale of its common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, in which per share price is at least </font><font style="font-family:inherit;font-size:10pt;">$12.44</font><font style="font-family:inherit;font-size:10pt;">&#32;(as adjusted)&#160;or (ii)&#160;the affirmative vote of more than </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the holders of the then-outstanding preferred stock voting together as a single class.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2015, the convertible preferred stock was classified as temporary equity in the accompanying balance sheet as the shares included provisions that allowed the holder to cause redemption of the shares upon certain changes in control events that are outside of the Company&#8217;s control. An aggregate of </font><font style="font-family:inherit;font-size:10pt;">10,360,419</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, excluding any warrant conversions, were issued to the holders of the Company&#8217;s Series A, Series B, Series C, Series C-1, Series D and Series E convertible preferred stockholders upon the automatic conversion of all shares of convertible preferred stock to common stock immediately prior to the closing of the IPO. As a result, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;Series A, Series B, Series C, Series C-1, Series D or Series E convertible preferred stock remain outstanding at December 31, 2016.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Warrants </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following warrants were outstanding as of December 31, 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:33%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br>average <br>exercise <br>price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issuance date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration date</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feb&#160;24, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feb&#160;24, 2019</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Prior to conversion upon IPO, the remaining warrants were for the purchase of Series C preferred stock.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter 2016, warrants for </font><font style="font-family:inherit;font-size:10pt;">61,112</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of </font><font style="font-family:inherit;font-size:10pt;">28,775</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Reserved for Future Issuance </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock reserved for future issuance consists of the following at December&#160;31, 2016: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:86%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,225,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized for future option grants   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,386,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,636,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><a name="sF3D5391129B5844318A97564EC218FC0"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax provision (benefit) consists of the following (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign   </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current provision   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred provision   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax provision (benefit)   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The difference between income tax benefits and income taxes computed using the U.S. federal income tax rate as of December&#160;31, 2016, 2015 and 2014 are as follows (in thousands): </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal provision (benefit)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At statutory rates   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,959</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes, net of federal   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,961</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,291</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,364</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign operations   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax provision (benefit)   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Internal Revenue Code, or IRC, Sections&#160;382 and 383, annual use of the Company&#8217;s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an IRC Section&#160;382 and 383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Until this analysis has been completed, the Company has removed deferred tax assets for Federal and California net operating losses of approximately $</font><font style="font-family:inherit;font-size:10pt;">20.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and research and experimental credits of approximately $</font><font style="font-family:inherit;font-size:10pt;">2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#160;generated through 2016 from its deferred tax schedule, and has recorded a corresponding decrease to its valuation allowance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets as are shown below: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign net operating losses   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total gross deferred tax assets   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less valuation allowance   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A valuation allowance of $</font><font style="font-family:inherit;font-size:10pt;">5.5 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and $</font><font style="font-family:inherit;font-size:10pt;">7.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December&#160;31, 2016 and 2015, respectively, has been established to offset the deferred tax assets as realization of such assets are uncertain. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016, the Company had federal and state net operating loss carryforwards of approximately $</font><font style="font-family:inherit;font-size:10pt;">58.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">14.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Each of the federal and state tax loss carryforwards will begin expiring in 2028, unless previously utilized. The Company also has federal and California research and development tax credit carryforwards totaling $</font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">1.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The federal research and development tax credit carryforward will begin to expire in 2028 unless previously utilized. The California research tax credits do not expire. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commencing with the 2013&#160;year, the Company computed its California net operating losses, or California NOLs, under the Multistate Tax Compact apportionment rules as provided for in the California Court of Appeal&#8217;s decision in Gillette v. FTB. That decision was overturned by the California Supreme Court on December&#160;31, 2015. As such, it is the Company&#8217;s intent to compute its California apportionment factor, and resulting California NOLs, under California&#8217;s Single Sales Factor Market rules. In 2015, the Company adjusted its California NOLs and deferred tax assets to the Single Sales Factor state rate. The impact to the California NOLs was approximately $</font><font style="font-family:inherit;font-size:10pt;">(13.5) million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not provided U.S.&#160;income taxes and foreign withholding taxes on the undistributed earnings of foreign subsidiaries as of December&#160;31, 2015 and 2014, because it intends to permanently reinvest such earnings outside the United States. If these foreign earnings on these were to be repatriated in the future, the related U.S.&#160;tax liability may be reduced by any foreign income taxes previously paid on these earnings. Due to historical losses, as of December 31, 2015 and 2014, the foreign subsidiaries do not have cumulative earnings. As of December&#160;31, 2016, all of these entities have been dissolved. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon an audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. As of December&#160;31, 2016, 2015 and 2014, the Company continued to have no unrecognized tax benefits. There are no unrecognized tax benefits included on the consolidated balance sheet sheets that would, if recognized, impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><a name="s6035D9927119FCD40B937564F74E8622"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Commitments and Contingencies </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases facilities under a noncancelable operating lease that expires on March&#160;31, 2019. Under the terms of the facilities lease, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturing organizations and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table below. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Future noncancelable minimum payment obligations under the operating lease were as follows as of December 31, 2016 (in thousands):</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future payments due under building lease   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense totaled </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December&#160;31, 2016 and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended December 31, 2015 and 2014. </font></div><div><a name="s4C3E6BBBF8D09AB5E8977564F7663C89"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;Related Party Transactions </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2013, the Company and Bader Sultan&#160;&amp; Bros. Co W.L.L., or Bader, a healthcare products distributor based in Sufat, Kuwait, entered into a distribution agreement, whereby the Company appointed Bader as a distributor of its products. Sales to Bader began in November&#160;2013. The Company&#8217;s agreement with Bader restricts Bader&#8217;s ability to sell competing products and requires Bader to purchase a certain number of products from the Company monthly based on annual forecasts that the Company provides to Bader. If Bader does not resell the minimum purchase quantity specified in the contract by the applicable date, then the Company has the right, in its sole discretion, to sell to other distributors in the Middle East or terminate its agreement with Bader. The initial term of the agreement expires in December 2019. The agreement can be terminated by the Company immediately upon certain breaches by Bader, or by either Bader or the Company for uncured material breach of the agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the 2014 Series&#160;D convertible preferred stock financing, Bader purchased </font><font style="font-family:inherit;font-size:10pt;">875,903</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s Series&#160;D convertible preferred stock. All terms of the purchase of preferred stock were the same for Bader as the other investors. Sales to Bader for the years ended December&#160;31, 2016, 2015 and 2014 totaled </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which represents </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">94.7%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">52.4%</font><font style="font-family:inherit;font-size:10pt;">&#32;of total revenue for the respective years. As of December&#160;31, 2016, the Company had accounts receivable from Bader of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January&#160;2015, the Company and Bader amended the distribution agreement. In accordance with the amendment, Bader provided the Company with a deposit of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, and committed to minimum product purchases for calendar year 2015. Under the terms of the amendment, the Company reserved the right to keep the deposit as liquidated damages if Bader did not meet the minimum product purchases. The Company classified the deposit as a current liability at December&#160;31, 2015 on the consolidated balance sheets as the minimum product purchase levels were met. In April&#160;2016, the Company and Bader entered into a Payment Direction Letter, resulting in the exchange of the distribution agreement deposit for </font><font style="font-family:inherit;font-size:10pt;">154,585</font><font style="font-family:inherit;font-size:10pt;">&#32;shares Series&#160;E convertible preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. All of Bader's outstanding convertible preferred stock converted to common stock in connection with the Company's IPO.</font></div><div><a name="s652C2CFD00E67AE8E1D77564F7933682"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Selected Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the quarterly results of the Company for the years ended December&#160;31, 2016 and 2015&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(unaudited, in thousands, except for per share data)</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div><br></div><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue         </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,131</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,495</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="16" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue         </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,093</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,020</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,370</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,674</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><a name="s9395d29926654a51bac3dd92ca0619ae"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Subsequent Events</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Extension</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 15, 2017, the Company extended its facility lease agreement under a noncancelable operating lease that expires on March&#160;31, 2019. All commitment tables previously presented reflect incorporation of the amendment. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Grants</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to December 31, 2016, stock options for </font><font style="font-family:inherit;font-size:10pt;">0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s common stock were granted to new Company employees, including the Company's new Board of Director member.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s218b17b940854fe588cf93427f8681fe"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16. Form 10-K Summary</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div><a name="s364A7BD75E56BD320C237564F7BDD0A1"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:4%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OBALON THERAPEUTICS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February 23, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">by:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Andrew Rasdal</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February 23, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">by:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William Plovanic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Andrew Rasdal and William Plovanic as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.</font></div><div><br></div><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Andrew Rasdal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director (Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Andrew Rasdal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ William Plovanic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer (Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">William Plovanic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Nooshin Hussainy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President of Finance (Principal Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nooshin Hussainy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Kim Kamdar</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairperson of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Kim Kamdar</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Ray Dittamore</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ray Dittamore</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Douglas Fisher</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Douglas Fisher</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Les Howe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Les Howe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Jonah Shacknai</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Jonah Shacknai</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Sharon Stevenson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 23, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sharon Stevenson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><a name="sEEE150DAAD4498426E367564F7E37CA0"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO EXHIBITS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:9%;"></td><td style="width:33%;"></td><td style="width:10%;"></td><td style="width:16%;"></td><td style="width:10%;"></td><td style="width:9%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description of Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Filing&#160;Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed/Furnished Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restated Certificate of Incorporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restated Bylaws</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Common Stock Certificate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Amended and Restated Investors&#8217; Rights Agreement dated April 29, 2016 among the Registrant and certain of its stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Series C Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Warrant to Purchase Stock issued to Square 1 Bank to purchase shares of Series C-1 Preferred Stock, issued June&#160;14, 2013, as amended October&#160;1, 2014.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Warrant to Purchase Stock issued to Square 1 Bank to purchase shares of Series&#160;D Preferred Stock, dated October 1, 2014. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Indemnity Agreement by and between the Registrant and its directors and officers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2008 Stock Plan and form of award agreements thereunder.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 Equity Incentive Plan and form of award agreements thereunder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 Employee Stock Purchase Plan and form of enrollment agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obalon Therapeutics, Inc. Bonus Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of CEO Retention Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37897</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/10/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Executive Retention Agreement (Non-CEO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37897</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/10/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Non-Employee Director Option Agreement.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offer Letter dated June 9, 2008 between the Registrant and Andrew Rasdal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offer Letter dated June 16, 2008 between the Registrant and Mark Brister</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offer Letter dated November 24, 2008 between the Registrant and Amy VandenBerg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/26/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leases dated October 3, 2011 and November 23, 2015 between the Registrant and Pleta &amp; San Gal Trusts dba: Ocean Point Tech Centre, and related amendments.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment to Lease, dated January 30, 2017, by and between Pleta &amp; San Gal Trusts dba: Ocean Point and Registrant.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution Agreement dated June 26, 2013 between the Registrant and Bader Sultan &amp; Bros. Co. W.L.L., as amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loan and Security Agreement dated June 14, 2013 between the Registrant and Pacific Western Bank (as successor in interest to Square 1 Bank), as amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Amendment to Loan and Security Agreement, dated December 21, 2016, between the Registrant and Pacific Western Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:9%;"></td><td style="width:33%;"></td><td style="width:10%;"></td><td style="width:16%;"></td><td style="width:10%;"></td><td style="width:9%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsidiaries of the Registrant.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-213551</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/9/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Power of Attorney. Reference is made to the signature page hereto.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certifications Pursuant to U.S.C. Section&#160;1350, As Adopted Pursuant to Section&#160;906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Labels Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to confidential treatment request under Rule 406 promulgated under the Securities Act.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8225;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management contract or compensatory plan or arrangement.</font></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>directoroptionagreement3.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s480A6DD0BEEA04F83ED367EE51015A6C"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 10.8</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTICE OF STOCK OPTION GRANT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OBALON THERAPEUTICS INC. 2016 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Unless otherwise defined herein, the terms defined in the Obalon Therapeutics Inc. (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;) 2016 Equity Incentive Plan (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:inherit;font-size:11pt;">&#8221;) shall have the same meanings in this Notice of Stock Option Grant (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Notice of Grant</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and the attached Stock Option Agreement, including any special terms and conditions for your country set forth in the appendix attached thereto (collectively, the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;). You have been granted an Option to purchase shares of Common Stock of the Company under the Plan subject to the terms and conditions of the Plan, this Notice of Grant and the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;                            </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Date of Grant</font><font style="font-family:inherit;font-size:11pt;">:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting Commencement Date</font><font style="font-family:inherit;font-size:11pt;">:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;                                   </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exercise Price per Share</font><font style="font-family:inherit;font-size:11pt;">:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;                                   </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Total Number of Shares</font><font style="font-family:inherit;font-size:11pt;">:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;                                   </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Type of Option</font><font style="font-family:inherit;font-size:11pt;">:&#160;&#160;&#160;&#160;_____ Non-Qualified Stock Option</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:216px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">_____ Incentive Stock Option</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Expiration Date</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td><td style="vertical-align:top;padding-left:168px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-168px;"><font style="font-family:inherit;font-size:11pt;">_____________; this Option expires earlier if your Service terminates earlier, as described in the Option Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting Schedule; Acceleration</font><font style="font-family:inherit;font-size:11pt;">:   </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Option becomes exercisable with respect to the first 1/36</font><font style="font-family:inherit;font-size:8.5pt;">th </font><font style="font-family:inherit;font-size:11pt;">of the Shares subject to this Option when you complete one (1) month of Service from the Vesting Commencement Date. Thereafter, this Option becomes exercisable with respect to an additional 1/36</font><font style="font-family:inherit;font-size:8.5pt;">th </font><font style="font-family:inherit;font-size:11pt;">of the Shares subject to this Option when you complete each month of Service.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the event of a Corporate Transaction (as defined in the Plan), this Option will become vested and exercisable in full as of immediately prior to the consummation of the Corporate Transaction.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You understand that your employment or consulting relationship with the Company or a Parent, Subsidiary or Affiliate is for an unspecified duration, can be terminated at any time, and that nothing in this Notice of Grant, the Option Agreement or the Plan changes the nature of that relationship.  By accepting this Option, you and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan, this Notice of Grant and the Option Agreement.  By accepting this Option, you consent to the electronic delivery and acceptance as further set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OBALON THERAPEUTICS INC.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:12pt;">&#32;_______________________________</font></div><div style="line-height:120%;text-align:left;padding-left:90px;text-indent:-91px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andrew Rasdal</font></div><div style="line-height:120%;text-align:left;padding-left:90px;text-indent:-91px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President and CEO </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s28726656799EE7D5CD3367EE512F0E7A"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:240%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">STOCK OPTION AGREEMENT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OBALON THERAPEUTICS INC. 2016 </font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You have been granted an Option by Obalon Therapeutics Inc. (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;) under the 2016 Equity Incentive Plan (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to purchase Shares (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:inherit;font-size:11pt;">&#8221;), subject to the terms, restrictions and conditions of the Plan, the Notice of Stock Option Grant (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Notice of Grant</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and this Stock Option Agreement, including any special terms and conditions for your country set forth in the appendix attached hereto (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Appendix</font><font style="font-family:inherit;font-size:11pt;">&#8221;) (collectively, the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Grant of Option</font><font style="font-family:inherit;font-size:11pt;">.  You have been granted the Option for the number of Shares set forth in the Notice of Grant at the Exercise Price per Share set forth in the Notice of Grant.  In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Agreement, the terms and conditions of the Plan shall prevail.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If designated in the Notice of Grant as an Incentive Stock Option (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ISO</font><font style="font-family:inherit;font-size:11pt;">&#8221;), this Option is intended to qualify as an Incentive Stock Option under Section&#160;422 of the Code.  However, if this Option is intended to be an ISO, to the extent that it exceeds the $100,000 limit under Code Section 422(d), it shall be treated as a Nonqualified Stock Option (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">NSO</font><font style="font-family:inherit;font-size:11pt;">&#8221;). </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Termination</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">General Rule</font><font style="font-family:inherit;font-size:11pt;">.  If your Service terminates for any reason except death or Disability, and other than for Cause, then this Option will expire at the close of business at Company headquarters on the date three months after your termination of Service (subject to the expiration detailed in Section 6).  If your Service is terminated for Cause, this Option will expire upon the date of such termination.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge and agree that the vesting schedule set forth in the Notice of Grant may change prospectively in the event that your service status changes between full and part-time status in accordance with Company policies relating to work schedules and vesting of awards.  You acknowledge that the vesting of the Shares pursuant to this Agreement is earned only by continuing Service.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Death; Disability</font><font style="font-family:inherit;font-size:11pt;">.  If you die before your Service terminates (or you die within three months of your termination of Service other than for Cause), then this Option will expire at the close of business at Company headquarters on the date 12 months after the date of death (subject to the expiration detailed in Section 6).  If your Service terminates because of your Disability, then this Option will expire at the close of business at Company headquarters on the date 12 months after your termination date (subject to the expiration detailed in Section 6).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination Date</font><font style="font-family:inherit;font-size:11pt;">.  For purposes of this Option, your Service will be considered terminated as of the date you are no longer actively providing services to </font><font style="font-family:inherit;font-size:11pt;">the Company or a Parent, Subsidiary or Affiliate </font><font style="font-family:inherit;font-size:11pt;">(regardless of the reason for such termination and whether or not later found to be invalid or in breach of labor laws in the jurisdiction where you are employed or engaged or the terms of your employment or consulting agreement, if any), and your period of Service will not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under labor laws in the jurisdiction where you are employed or engaged or the terms of your employment or consulting agreement, if any.  The Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of this Option (including whether you may still be considered to be providing services while on a leave of absence).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Notice</font><font style="font-family:inherit;font-size:11pt;">.  You are responsible for keeping track of these exercise periods following your termination of Service for any reason.  The Company will not provide further notice of such periods.  In no event shall this Option be exercised later than the Expiration Date set forth in the Notice of Grant.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exercise of Option</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Right to Exercise</font><font style="font-family:inherit;font-size:11pt;">.  This Option is exercisable during its term in accordance with the vesting schedule set forth in the Notice of Grant and the applicable provisions of the Plan and this Agreement.  In the event of your death, Disability, or other cessation of Service, the exercisability of the Option is governed by the applicable provisions of the Plan, the Notice of Grant and this Agreement.  This Option may not be exercised for a fraction of a Share.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Method of Exercise</font><font style="font-family:inherit;font-size:11pt;">.  This Option is exercisable by delivery of an exercise notice in a form specified by the Company (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Exercise Notice</font><font style="font-family:inherit;font-size:11pt;">&#8221;), which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Exercised Shares</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan.  The Exercise Notice shall be delivered in person, by mail, via electronic mail or facsimile or by other authorized method to the Secretary of the Company or other person designated by the Company.  The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares.  This Option shall be deemed to be exercised upon receipt by the Company of a fully executed Exercise Notice accompanied by the aggregate Exercise Price and any applicable withholding of Tax-Related Items as detailed in Section 8 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exercise by Another</font><font style="font-family:inherit;font-size:11pt;">.  If another person wants to exercise this Option after it has been transferred to him or her in compliance with this Agreement, that person must prove to the Company&#8217;s satisfaction that he or she is entitled to exercise this Option.  That person must also complete the proper Exercise Notice form (as described above) and pay the Exercise Price (as described below) and any applicable withholding of Tax-Related Items as described below.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Method of Payment</font><font style="font-family:inherit;font-size:11pt;">.  Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at your election:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">your personal check, wire transfer, or a cashier&#8217;s check; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">for U.S. taxpayers only: certificates for shares of Company stock that you own, along with any forms needed to effect a transfer of those shares to the Company; the value of the shares, determined as of the effective date of the Option exercise, will be applied to the Exercise Price.  Instead of surrendering shares of Company stock, you may attest to the ownership of those shares on a form provided by the Company and have the same number of shares subtracted from the Exercised Shares issued to you.  However, you may not surrender, or attest to the ownership of, shares of Company stock in payment of the Exercise Price of your Option if your action would cause the Company to recognize compensation expense (or additional compensation expense) with respect to this Option for financial reporting purposes;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">cashless exercise through irrevocable directions to a securities broker approved by the Company to sell all or part of the Exercised Shares and to deliver to the Company from the sale proceeds an amount sufficient to pay the Exercise Price and any withholding of Tax-Related Items.  The balance of the sale proceeds, if any, will be delivered to you.  The directions must be given by signing a special notice of exercise form provided by the Company; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">other method authorized by the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Transferability of Option</font><font style="font-family:inherit;font-size:11pt;">.  In general, except as provided below, only you may exercise this Option prior to your death.  You may not transfer or assign this Option, except as provided below.  For instance, you may not sell this Option or use it as security for a loan.  If you attempt to do any of these things, this Option will immediately become invalid.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">However, if you are a U.S. taxpayer, you may dispose of this Option in your will or in a beneficiary designation.  If you are a U.S. taxpayer and this Option is designated as a NSO in the Notice of Grant, then </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the Committee may, in its sole discretion, allow you to transfer this Option as a gift to one or more family members.  For purposes of this Agreement, &#8220;family member&#8221; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in- law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law (including adoptive relationships), any individual sharing your household (other than a tenant or employee), a trust in which one or more of these individuals have more than 50% of the beneficial interest, a foundation in which you or one or more of these persons control the management of assets, and any entity in which you or one or more of these persons own more than 50% of the voting interest.  In addition, if you are a U.S. taxpayer and this Option is designated as a NSO in the Notice of Grant, then the Committee may, in its sole discretion, allow you to transfer this Option to your spouse or former spouse pursuant to a domestic relations order in settlement of marital property rights.  The Committee will allow you to transfer this Option only if both you and the transferee(s) execute the forms prescribed by the Committee, which include the consent of the transferee(s) to be bound by this Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Option may not be transferred in any manner other than by will or by the laws of descent or distribution or court order and may be exercised during the lifetime of you only by you, your guardian, or legal representative, as permitted in the Plan and applicable local laws.  The terms of the Plan and this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of you.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Term of Option</font><font style="font-family:inherit;font-size:11pt;">.  This Option shall in any event expire on the expiration date set forth in the Notice of Grant, which date is ten years after the grant date (five years after the grant date if this Option is designated as an ISO in the Notice of Grant and Section 5.3 of the Plan applies). </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Tax Consequences</font><font style="font-family:inherit;font-size:11pt;">.  You should consult a tax adviser for tax consequences relating to this Option in the jurisdiction in which you are subject to tax.  YOU SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exercising the Option</font><font style="font-family:inherit;font-size:11pt;">.  You will not be allowed to exercise this Option unless you make arrangements acceptable to the Company to pay any withholding of Tax-Related Items.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notice of Disqualifying Disposition of ISO Shares</font><font style="font-family:inherit;font-size:11pt;">.  If you sell or otherwise dispose of any of the Shares acquired pursuant to an ISO on or before the later of (i)&#160;two years after the grant date, or (ii)&#160;one year after the exercise date, you shall immediately notify the Company in writing of such disposition.  You agree that you may be subject to income tax withholding by the Company on the compensation income recognized from such early disposition of ISO Shares by payment in cash or out of the current compensation paid to you.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Responsibility for Taxes</font><font style="font-family:inherit;font-size:11pt;">.  Regardless of any action the Company or, if different, your actual employer (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employer</font><font style="font-family:inherit;font-size:11pt;">&#8221;) takes with respect to any or all income tax, social insurance contributions, payroll tax, fringe benefits tax, payment on account or other tax-related withholding (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Tax-Related Items</font><font style="font-family:inherit;font-size:11pt;">&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (1)&#160;make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Option, including the grant, vesting or exercise of this Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends; and (2)&#160;do not commit to structure the terms of the grant or any aspect of this Option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result.  You acknowledge that if you are subject to Tax-Related Items in more than one jurisdiction, the Company and/or the Employer may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Prior to exercise of the Option, you shall pay or make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all Tax-Related Item withholding and payment on account obligations of the Company and/or the Employer.  In this regard, you authorize the Company and/or the Employer, and their respective agents, at their discretion, to withhold all applicable Tax-Related Items legally </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">payable by you from your wages or other cash compensation paid to you by the Company and/or the Employer.  With the Company&#8217;s consent, these arrangements may also include, if permissible under local law, (a) withholding Shares that otherwise would be issued to you when you exercise this Option, provided that the Company only withholds the amount of Shares necessary to satisfy the minimum statutory withholding amount, (b) having the Company withhold taxes from the proceeds of the sale of the Shares, either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf and pursuant to this authorization), (c) your payment of a cash amount, or (d) any other arrangement approved by the Company; all under such rules as may be established by the Committee and in compliance with the Company&#8217;s Insider Trading Policy and 10b5-1 Trading Plan Policy, if applicable; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Committee (as constituted in accordance with Rule 16b-3 under the Exchange Act) shall establish the method of withholding from alternatives (a)-(d) above, and the Committee shall establish the method prior to the taxable or withholding event.  The Fair Market Value of these Shares, determined as of the effective date of the Option exercise, will be applied as a credit against the Tax-Related Items. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the Shares equivalent.  If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, you are deemed to have been issued the full number of Shares subject to the vested RSUs, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Finally, you agree to pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold as a result of your participation in the Plan or your purchase of Shares that cannot be satisfied by the means previously described.  You acknowledge that the Company has no obligation to deliver Shares to you until you have satisfied the obligations in connection with the Tax-Related Items as described in this Section.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Nature of Grant</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:11pt;">In accepting this Option, you acknowledge, understand and agree that:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, suspended or terminated by the Company at any time, to the extent permitted by the Plan;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the grant of this Option is voluntary and occasional and does not create any contractual or other right to receive future grants of stock options, or benefits in lieu of stock options, even if stock options have been granted in the past; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">all decisions with respect to future stock options or other grants, if any, will be at the sole discretion of the Company; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">you are voluntarily participating in the Plan; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">this Option and any Shares acquired under the Plan, and the income and value of same, are not intended to replace any pension rights or compensation;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">this Option and any Shares acquired under the Plan, and the income and value of same, are not part of normal or expected compensation for purpose of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement benefits or payments or welfare benefits or similar payments; </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">unless otherwise agreed with the Company, this Option and any Shares acquired under the Plan, and the income and value of same, are not granted as consideration for, or in connection with, any Service you may provide as a director of any Parent, Subsidiary or Affiliate;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the future value of the Shares underlying this Option is unknown, indeterminable, and cannot be predicted with certainty; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">if the underlying Shares do not increase in value, this Option will have no value; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">if you exercise this Option and acquire Shares, the value of such Shares may increase or decrease in value, even below the Exercise Price;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">no claim or entitlement to compensation or damages shall arise from forfeiture of this Option resulting from the termination of your Service (for any reason whatsoever, whether or not later found to be invalid or in breach of labor laws in the jurisdiction where you are employed or engaged or the terms of your employment or service agreement, if any), and in consideration of the grant of this Option to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, the Employer or any Parent, Subsidiary or Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer or any Parent, Subsidiary or Affiliate from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#010000;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">if you are providing Service outside the United States, neither the Employer, the Company nor any Parent, Subsidiary or Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of this Option or of any amounts due to you pursuant to the exercise of this Option or the subsequent sale of any Shares acquired upon exercise. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Data Privacy</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">.  You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Option grant materials by and among, as applicable, the Employer, the Company and any Parent, Subsidiary or Affiliate for the exclusive purpose of implementing, administering and managing your participation in the Plan. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">You understand that the Company and the Employer may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all stock options or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Data</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8221;), for the exclusive purpose of implementing, administering and managing the Plan. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">You understand that Data will be transferred to third parties in connection with the implementation, administration and management of the Plan.  You understand that the recipients of Data may be located in the United States or elsewhere, and that the recipient&#8217;s country (</font><font style="font-family:inherit;font-size:11pt;">e.g.</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">, the United States) may have different data privacy laws and protections than your country.  You understand that if you reside outside the United States, he or she may request a list with the names and addresses of any potential recipients of Data by contacting your local human resources representative.  You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purposes of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understands that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your Service status and career with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that Company would not be able to grant you stock options or other equity awards or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Acknowledgement</font><font style="font-family:inherit;font-size:11pt;">.  The Company and you agree that this Option is granted under and governed by the Notice of Grant, this Agreement and the provisions of the Plan (incorporated herein by reference).  You: (i) acknowledge receipt of a copy of the Plan prospectus, (ii) represent that you have carefully read and are familiar with the provisions in the grant documents, and (iii) hereby accept this Option subject to all of the terms and conditions set forth in this Agreement and those set forth in the Plan and the Notice of Grant.  You hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice of Grant and this Agreement. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Consent to Electronic Delivery and Acceptance of All Plan Documents and Disclosures</font><font style="font-family:inherit;font-size:11pt;">.  By your acceptance of this Option, you consent to the electronic delivery of the Notice of Grant, this Agreement, account statements, Plan prospectuses required by the SEC, U.S. financial reports of the Company, and all other documents that the Company is required to deliver to its stockholders (including, without limitation, annual reports and proxy statements) or other communications or information related to this Option.  Electronic delivery may include the delivery of a link to a Company intranet or the internet site of a third party involved in administering the Plan, the delivery of the document via e-mail or such other delivery determined at the Company&#8217;s discretion.  You acknowledge that you may receive from the Company a paper copy of any documents delivered electronically at no cost if you contact the Company by telephone, through a postal service or electronic mail </font><font style="font-family:inherit;font-size:11pt;">at investor@obalon.com.  You further acknowledge that you will be provided with a paper copy of any documents delivered electronically if electronic delivery fails; similarly, you understand that you must provide on request to the Company or any designated third party a paper copy of any documents delivered electronically if electronic delivery fails. You agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.  Also, you understand that your consent may be revoked or changed, including any change in the electronic mail address to which documents are delivered (if you have provided an electronic mail address), at any time by notifying the Company of such revised or revoked consent by telephone, postal service or electronic mail at investor@obalon.com </font><font style="font-family:inherit;font-size:11pt;">Finally, you understand that you are not required to consent to electronic delivery.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Compliance with Laws and Regulations</font><font style="font-family:inherit;font-size:11pt;">.  The exercise of this Option will be subject to and conditioned upon compliance by the Company and you with all applicable state, federal and foreign laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#8217;s Common Stock may be listed or quoted at the time of such issuance or transfer, which compliance the Company shall, in its absolute discretion, deem necessary or advisable.  You understand that the Company is under no obligation to register or qualify the Common Stock with any state, federal or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares.  Further, you agree that the Company shall have unilateral authority to amend the Plan and this Agreement without your consent to the extent necessary to comply with securities or other laws applicable to issuance of Shares.  Finally, the Shares issued pursuant to this Agreement shall be endorsed with appropriate legends, if any, determined by the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">No Advice Regarding Grant</font><font style="font-family:inherit;font-size:11pt;">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares.  You are hereby advised to consult with your own personal tax, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Governing Law; Venue</font><font style="font-family:inherit;font-size:11pt;">.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;">This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law.  For purposes of litigating any dispute that may arise directly or indirectly from the Plan, the Notice of Grant and this Agreement, the parties hereby submit and consent to litigation in the exclusive jurisdiction of the State of California and agree that any such litigation shall be conducted only in the courts of California in San Diego County, California or the federal courts of the United States for the Southern District of California and no other courts.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:11pt;">.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">No Rights as Employee, Director or Consultant</font><font style="font-family:inherit;font-size:11pt;">.  Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent, Subsidiary or Affiliate of the Company, to terminate your Service, for any reason, with or without Cause.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Adjustment</font><font style="font-family:inherit;font-size:11pt;">.  In the event of a stock split, a stock dividend or a similar change in Company stock, the number of Shares covered by this Option and the Exercise Price per Share may be adjusted pursuant to the Plan. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Lock-Up Agreement</font><font style="font-family:inherit;font-size:11pt;">.  In connection with the initial public offering of the Company&#8217;s securities and upon request of the Company or the underwriters managing any underwritten offering of the Company&#8217;s securities, you hereby agree not to sell, make any short sale of, loan, grant any Option for the purchase of, or otherwise dispose of any securities of the Company however and whenever acquired (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days) from the effective date of such registration as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the public offering; provided however that, if during the last seventeen (17) days of the restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or prior to the expiration of the restricted period the Company announces that it will release earnings results during the sixteen (16)-day period beginning on the last day of the restricted period, then, upon the request of the managing underwriter, to the extent required by any FINRA rules, the restrictions imposed by this Section shall continue to apply until the end of the third trading day following the expiration of the fifteen (15)-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.  In no event will the restricted period extend beyond two hundred sixteen (216) days after the effective date of the registration statement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Award Subject to Company Clawback or Recoupment</font><font style="font-family:inherit;font-size:11pt;">.  To the extent permitted by applicable law, the Option shall be subject to clawback or recoupment pursuant to any clawback or recoupment policy adopted by the Board or required by law during the term of your employment or other Service that is applicable to you.  In addition to any other remedies available under such policy, applicable law may require the cancellation of your Option (whether vested or unvested) and the recoupment of any gains realized with respect to your Option.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">21.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Entire Agreement; Enforcement of Rights.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;This Agreement, the Plan and the Notice of Grant constitute the entire agreement and understanding of the parties relating to the subject matter herein </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning this Option are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">22.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Insider Trading Restrictions/Market Abuse Laws</font><font style="font-family:inherit;font-size:11pt;">.  You acknowledge that you may be subject to insider trading restrictions and/or market abuse laws, which may affect your ability to acquire or sell the Shares or rights to Shares under the Plan during such times as you are considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in your country).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions, and you are advised to speak to your personal advisor on this matter.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">23.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Language</font><font style="font-family:inherit;font-size:11pt;">.  If you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">24.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Appendix</font><font style="font-family:inherit;font-size:11pt;">. Notwithstanding any provisions in this Agreement, this Option shall be subject to any special terms and conditions set forth in any Appendix hereto for your country.  Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of this Agreement. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">25.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Imposition of Other Requirements</font><font style="font-family:inherit;font-size:11pt;">.  The Company reserves the right to impose other requirements on your participation in the Plan, on this Option and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;color:#010000;font-weight:bold;padding-right:48px;">26.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:11pt;">.  You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BY ACCEPTING THIS OPTION, YOU AGREE TO ALL OF THE TERMS AND CONDITIONS DESCRIBED ABOVE AND IN THE PLAN. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><a name="s8906D2BA1F6AA85FD8D367EE5150D0E6"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">APPENDIX TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STOCK</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;OPTION AGREEMENT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OBALON THERAPEUTICS INC. 2016 </font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Capitalized terms, unless explicitly defined in this Appendix, shall have the meanings given to them in the Stock Option Agreement, the Notice of Grant or in the Plan.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Terms and Conditions </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Appendix includes special terms and conditions that govern this Option if you reside and/or work in one of the countries listed below.  If you are a citizen or resident (or are considered as such for local law purposes) of a country other than the country in which you are currently residing and/or working, or if you transfer to another country after receiving this Option, the Company shall, in its discretion, determine to what extent the special terms and conditions contained herein shall be applicable to you.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Notifications</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Appendix also includes information regarding securities, exchange control, tax and certain other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the securities, exchange control, tax and other laws in effect in the respective countries as of September 2016.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the information contained herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time you exercise this Option or at the time you sell any Shares acquired under the Plan.  In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Therefore, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your individual situation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If you are a citizen or resident (or are considered as such for local tax purposes) of a country other than the country in which you are currently residing and/or working, or if you transfer to another country after the grant of this Option, the information contained herein may not be applicable to you in the same manner.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">There are no country-specific provisions.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>revisedobalondraftamendmen.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB74EEA1880632E8EA7A167F3D06A617B"></a></div><div><div style="line-height:120%;text-align:right;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;font-weight:bold;">Exhibit 10.13</font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;font-weight:bold;">AMENDMENT TO LEASE DATED JANUARY 30, 2017 BY AND BETWEEN PLETA &amp; SAN GAL TRUSTS, DBA: OCEAN POINT, HEREINAFTER REFERRED TO AS &#8220;LESSOR&#8221; AND OBALON THERAPEUTICS INC., A DELAWARE CORPORATION, HEREINAFTER REFERRED TO AS &#8220;LESSEE&#8221;.</font></div><div style="line-height:120%;"><hr></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The undersigned parties do hereby for the first time amend, affirm and ratify that certain Lease between the undersigned originally dated November 23, 2015, for premises located at 5421 Avenida Encinas, Suite J, Carlsbad, California 92008 and for the third time amend, affirm and ratify that certain Lease between the undersigned originally dated on or about October 3, 2011, as amended by the Amendment Renewal dated August 5, 2013, regarding the Lease of 5421 Avenida Encinas, Suites A through G, Carlsbad, California 92008 and generally described as the &#8220;Premises&#8221; (collectively the &#8220;Lease&#8221;).  The terms used in this Amendment shall have the same definitions as those set forth in the Lease.  This Amendment document shall be identified and referred to as the Third Amendment to the collective Lease.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree that, subject to the full execution and delivery of this Amendment, the parties&#8217; respective rights and obligations under the Lease are hereby modified and amended as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">PREMISES:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;The Premises size shall be 17,500 total square feet by consolidating the Lease for Suites A-G and the Lease for Suite J in this amendment.  Previous square footage for suites A-G contained 13,650 and previous Lease for suite J contained 3,850 square feet. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">TERM (Paragraph 1.3)</font><font style="font-family:Arial;font-size:10pt;">:&#160; The Expiration Date shall hereby be changed to March 31, 2019.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">RENTAL SCHEDULE (Paragraph 50)</font><font style="font-family:Arial;font-size:10pt;">:  For this extended Term of the Lease, the following schedule for Base Rent and Common Area Operating Expenses (also referred to within the Lease as &#8220;CAM&#8221; or &#8220;CAM Charges&#8221;) shall be in effect:</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-left:54px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.45299145299145%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:31%;"></td><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:23%;"></td><td style="width:4%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">TERM</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">MONTHLY</font></div><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">BASE RENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">MONTHLY</font></div><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">ESTIMATED CAM</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">MONTHLY</font></div><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">RENT</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">04/01/17 through 03/31/18</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$29,750.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$2,625.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">=</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$32,375.00</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">04/01/18 through 03/31/19</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$30,643.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$2,625.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">=</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$33,268.00</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">RENTAL ABATEMENT</font><font style="font-family:Arial;font-size:10pt;">:  Provided that Lessee is not in Default or Breach of this Lease, Base Rent shall be abated for months two (2) through four (4).  In the event Lessee does not fulfill its obligations per the Lease, said Rental Abatement shall be recaptured per Paragraph 13.3 of the Lease.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">CAM CHARGES</font><font style="font-family:Arial;font-size:10pt;">:  CAM Charges shall continue to be estimated for this extended Term of the Lease.  CAM Charges as of the date of this Amendment are estimated to be $2,625.00 per month and shall be reconciled quarterly.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">RIGHT OF FIRST REFUSAL:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Lessee and Lessor agree that effective immediately, Lessee hereby forfeits the Right of First Refusal granted in the original Lease and will no longer hold the Right for the entire Project or any space within the Project.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">RESTORATION OF PREMISES:</font><font style="font-family:Arial;font-size:10pt;">&#32;Upon termination of the Lease, Lessee, at Lessees sole cost and expense, shall be obligated to remove Improvements as described on Exhibit A attached to this Amendment.  In addition to the improvement restoration, Lessee is obligated at Lessee sole cost and expense, to ensure all electrical, HVAC and plumbing services are not comingled between meters.  All excess communications and computer wires, cables and related devices in excess of one (1) set of the same, will be removed.    </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">GH&#160;&#160;&#160;&#160;_</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">AR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Initials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initials</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;font-weight:bold;">AMENDMENT TO LEASE DATED JANUARY 30, 2017 BY AND BETWEEN PLETA &amp; SAN GAL TRUSTS, DBA: OCEAN POINT, HEREINAFTER REFERRED TO AS &#8220;LESSOR&#8221; AND OBALON THERAPEUTICS INC., A DELAWARE CORPORATION, HEREINAFTER REFERRED TO AS &#8220;LESSEE&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">REPRESENTATION</font><font style="font-family:Arial;font-size:10pt;">:&#160; Sandra Watson of Gildred Development Company represents Lessor exclusively and Scot Ginsburg of Hughes Marino represents the Lessee in this transaction (please see Exhibit A to this Amendment, attached hereto and incorporated by this reference).&#160; Lessee and Lessor each represent and warrant to the other that no person, firm, broker or finder is entitled to any commission or finder&#8217;s fee in connection herewith, except for Hughes Marino, which will receive a 3% commission paid on Base Rent collected for the extended term.&#160; Each of the Parties represents, acknowledges and agrees that it has been represented by such independent counsel and/or brokers, and has consulted with such consultants and other professionals, as each such Party has deemed necessary or appropriate and as it has voluntarily chosen throughout all negotiations which preceded the execution of this Amendment; and that this Amendment has been executed on the advice of such independent counsel, broker(s), consultant(s) and other professional(s). The Parties further agree that each has cooperated and participated in the drafting of this Amendment and, therefore, any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not apply in the interpretation of this Amendment.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-7px;"><font style="font-family:Arial;font-size:10pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">CONFIDENTIALITY</font><font style="font-family:Arial;font-size:10pt;">:  Lessee agrees that the terms of this Lease will be kept strictly confidential and not disclosed to any other person without written consent from Lessor.  Disclosure to persons or tenants other than the Lessee will constitute a material uncurable Breach of this Lease.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.  &#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">GENERAL PROVISIONS:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lessee and Lessor further covenants and agrees that:  (i) Lessor/Lessee has fully performed or satisfied all obligations of Lessor/Lessee under or in connection with, and Lessor/Lessee is not in breach of any term or condition of the Lease;  (ii)  any and all required work or contributions of Lessor to or on account of any tenant improvements respecting the Premises have been fully satisfied or received; and (iii) there are no defenses, offsets, counterclaims, or deductions against rents or other sums due to Lessor respecting the Premises, or which Lessee has against Lessor&#8217;s enforcement of the Lease.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Except as otherwise provided herein, the provisions of this Amendment shall be deemed to obligate, extend to, and inure to the benefit of the successors, assigns, agents, principals, transferees, grantees, trustors, representatives, beneficiaries, insurers and indemnitees of each of the parties.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that any provision of this Amendment is in conflict with any provision of the Lease, the conflicting provision of this Amendment shall take precedence and govern.  Except as otherwise specified herein, the Lease remains in full force and effect.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If either Party hereto is a corporation, trust, limited liability company, partnership, or similar entity, each individual executing this Amendment on behalf of such entity represents and warrants that he or she is duly authorized to execute and deliver this Amendment on its behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Article, Section and other headings of this Amendment are for convenience of reference only and shall not be construed to affect the meaning of any provision contained herein.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LESSOR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LESSEE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PLETA &amp; SAN GAL TRUSTS,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OBALON THERAPEUTICS, INC.,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DBA: OCEAN POINT &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A DELAWARE CORPORATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Gregg Haggart&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;By:</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Andrew Rasdal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Gregg Haggart, Special Trustee   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;         Andrew Rasdal, Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date:</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2/15/2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Date:</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;2/9/2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">GH&#160;&#160;&#160;&#160;_</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">AR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Initials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initials</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;font-weight:bold;">AMENDMENT TO LEASE DATED JANUARY 30, 2017 BY AND BETWEEN PLETA &amp; SAN GAL TRUSTS, DBA: OCEAN POINT, HEREINAFTER REFERRED TO AS &#8220;LESSOR&#8221; AND OBALON THERAPEUTICS INC., A DELAWARE CORPORATION, HEREINAFTER REFERRED TO AS &#8220;LESSEE&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;color:#221d1d;font-weight:bold;">EXHIBIT B</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;color:#221d1d;font-weight:bold;">DISCLOSURE REGARDING</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">REAL ESTATE AGENCY RELATIONSHIP</font></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(As required by the Civil Code)</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:122%;padding-top:2px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">When you enter into a discussion with a real estate agent regarding a real estate transaction</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">you should from the outset understand what type of agency relationship or representation you wish to have with the agent in the transaction</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">SELLER&#8217;S AGENT (&#8220;Seller&#8221; includes both a vendor and a lessor)</font></div><div style="line-height:125%;padding-top:1px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">A Seller&#8217;s agent under a listing agreement with the Seller acts as the agent for the Seller only</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">A Seller&#8217;s agent or a subagent of that agent has the following affirmative obligations:</font></div><div style="line-height:122%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">To the Seller: A Fiduciary duty of utmost care</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">integrity</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">honesty and loyalty in dealings with the Seller. To the Buyer and the Seller: &#160;&#160;&#160;&#160;(a) Diligent exercise of reasonable skill and care in performance of the agent&#8217;s duties</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:justify;text-indent:48px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">(b) A duty of honest and fair dealing and good faith</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">(c)  A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">or within the diligent attention and observation of</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the parties</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">An agent is not obligated to reveal to either party any confidential information obtained from the other party that does not involve the affirmative duties set forth above</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">BUYER&#8217;S AGENT (&#8220;Buyer&#8221; includes both a purchaser and a lessee).</font></div><div style="line-height:124%;padding-top:1px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">A selling agent can</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">with a Buyer&#8217;s consent, agree to act as agent for the Buyer only</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">In these situations</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the agent is not the Seller&#8217;s agent, even if by agreement the agent may receive compensation for services rendered</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">either in full or in part from the Seller</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">An agent acting only for a Buyer has the following affirmative obligations:</font></div><div style="line-height:122%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">To the Buyer: A fiduciary duty of utmost care</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">integrity</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">honesty and loyalty in dealings with the Buyer. To the Buyer and the Seller: &#160;&#160;&#160;&#160;(a) Diligent exercise of reasonable skill and care in performance of the agent&#8217;s duties</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">(b)  A duty of honest and fair dealing and good faith</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:124%;text-align:justify;text-indent:48px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">(c)  A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">or within the diligent attention and observation of, the parties</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:100%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">An agent is not obligated to reveal to either party any confidential information obtained from the other party that does not involve the affirmative</font></div><div style="line-height:100%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Duties set forth above</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">AGENT REPRESENTING BOTH SELLER AND BUYER</font></div><div style="line-height:124%;padding-top:1px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">A real estate agent, either acting directly or through one or more associate licensees</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">can legally be the agent of both the Seller and the Buyer in a transaction</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">but only with the knowledge and consent of both the Seller and the Buyer</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:100%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">In a dual agency situation</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the agent has the following affirmative obligations to both the Seller and the Buyer:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">(a)  A fiduciary duty of utmost care</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">integrity</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">honesty and loyalty in the dealings with either the Seller or the Buyer</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">(b) Other duties to the Seller and the Buyer as stated above in their respective sections</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:124%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">In representing both Seller and Buyer</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the agent may not, without the express permission of the respective party</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">disclose to the other party that the Seller will accept a price less than the listing price or that the Buyer will pay a price greater than the price offered</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The above duties of the agent in a real estate transaction do not relieve a Seller or Buyer from the responsibility to protect his or her own</font><font style="font-family:Arial;font-size:8pt;">&#32;</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">interests. You should carefully read all agreements to assure that they adequately express your understanding of the transaction</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">A real estate agent is a person qualified to advice about real estate</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">If legal or tax advice is desired</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">consult a competent professional</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:100%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Throughout your real property transaction, you may receive more than one disclosure form, depending upon the number of agents assisting in</font><font style="font-family:Arial;font-size:8pt;">&#32;</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the transaction</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The law requires each agent with whom you have more than a casual relationship to present you with this disclosure form. You should read its contents each time it is presented to you</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">considering the relationship between you and the real estate agent in your specific transaction. </font></div><div style="line-height:100%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">This disclosure form includes the provisions of Sections 2079</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;font-weight:bold;">.</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">13 to 2079</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;font-weight:bold;">.</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">24</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;font-weight:bold;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">inclusive</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;font-weight:bold;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">of the Civil Code set forth on page</font></div><div style="line-height:122%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;font-weight:bold;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">Read it carefully. I/WE ACKNOWLEDGE RECEIPT OF A COPY OF THIS DISCLOSURE AND THE PORTIONS OF THE CIVIL CODE PRINTED ON THE BACK (OR A SEPARATE PAGE)</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">GH&#160;&#160;&#160;&#160;_</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">AR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Initials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initials</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;font-weight:bold;">AMENDMENT TO LEASE DATED JANUARY 30, 2017 BY AND BETWEEN PLETA &amp; SAN GAL TRUSTS, DBA: OCEAN POINT, HEREINAFTER REFERRED TO AS &#8220;LESSOR&#8221; AND OBALON THERAPEUTICS INC., A DELAWARE CORPORATION, HEREINAFTER REFERRED TO AS &#8220;LESSEE&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:122%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:122%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LESSEE REPRESENTED BY HUGHES MARINO &#8211; SCOT GINSBERG ACKNOWLEDGED BY LESSEE:</font></div><div style="line-height:122%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:122%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">By:</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Andrew Rasdal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;Date:</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;2/9/2017&#160;&#160;&#160;&#160;</font></div><div style="line-height:122%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Andrew Rasdal, Chief Executive Officer</font></div><div style="line-height:122%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SANDRA WATSON OF GILDRED DEVELOPMENT REPRESENTS LESSOR EXCLUSIVELY:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ACKNOWLEDGED BY LESSOR:</font></div><div style="line-height:122%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:122%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">By:</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Gregg Haggart&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;Date:</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;2/15/2017&#160;&#160;&#160;&#160;</font></div><div style="line-height:122%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Gregg Haggart, Special Trustee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Agent:</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#32;&#32;Gildred Development Company /Gregg Haggart&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BRE Lic. #</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#32;&#32;&#32;01071252 / 00941329&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Real Estate Broker (Firm)</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;">By: </font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;text-decoration:underline;">&#32;&#32;Sandra Watson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;">BRE Lic. # </font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;text-decoration:underline;">&#32;&#32;01031752&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;">&#32;Date:</font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;text-decoration:underline;">&#32;&#32;11/30/2015&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  </font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;(Salesperson or Broker-Associate)</font></div><div style="line-height:122%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#221d1d;">THIS FORM HAS BEEN PREPARED BY THE AIR COMMERCIAL REAL ESTATE ASSOCIATION. NO REPRESENTATION IS MADE AS TO THE LEGAL VALIDITY OR ADEQUACY OF THIS FORM FOR ANY SPECIFIC TRANSACTION</font><font style="font-family:inherit;font-size:9pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:9pt;color:#221d1d;">PLEASE SEEK LEGAL COUNSEL AS TO THE APPROPRIATENESS OF THIS FORM</font><font style="font-family:inherit;font-size:9pt;color:#221d1d;">.</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#221d1d;font-weight:bold;">DISCLOSURE REGARDING REAL ESTATE AGENCY RELATIONSHIP</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#221d1d;font-weight:bold;">CIVIL CODE SECTIONS 2079</font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;">.</font><font style="font-family:Arial;font-size:10pt;color:#221d1d;font-weight:bold;">13 THROUGH 2079</font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;">.</font><font style="font-family:Arial;font-size:10pt;color:#221d1d;font-weight:bold;">24 (2079</font><font style="font-family:inherit;font-size:10pt;color:#221d1d;font-weight:bold;">.</font><font style="font-family:Arial;font-size:10pt;color:#221d1d;font-weight:bold;">16 APPEARS ON THE FRONT)</font></div><div style="line-height:100%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.13 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">As used in Sections 2079</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">14 to 2079</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">24</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">inclusive</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the following terms have the following meanings:</font></div><div style="line-height:121%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(a) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Agent&#8221; means a person acting under provisions of Title 9 (commencing with Section 2295) in a real property transaction, and includes a person who is licensed as a real estate broker under Chapter 3 (commencing with Section 10130) of Part 1 of Division 4 of the Business and Professions Code, and under whose license a listing is executed or an offer to purchase is obtained.  </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(b) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Associate licensee&#8221; means a person who is licensed as a real estate broker or salesperson under Chapter 3 (commencing with Section 10130) of Part 1 of Division 4 of the Business and Professions Code and who is either licensed under a broker or has entered into a written contract with a broker to act as the broker&#8217;s agent in connection with acts requiring a real estate license and to function under the broker&#8217;s supervision in the capacity of an associate licensee. The agent in the real property transaction bears responsibility for his or her associate licensees who perform as agents of the agent. When an associate licensee owes a duty to any principal, or to any buyer or seller who is not a principal, in a real property transaction, that duty is equivalent to the duty owed to that party by the broker for whom the associate licensee functions. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(c) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Buyer&#8221; means a transferee in a real property transaction, and includes a person who executes an offer to purchase real property from a seller through an agent, or who seeks the services of an agent in more than a casual, transitory, or preliminary manner, with the object of entering into a real property transaction. &#8220;Buyer&#8221; includes vendee or lessee. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(d) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Commercial real property&#8221; means all real property in the state, except single-family residential real property, dwelling units made subject to Chapter 2 (commencing with Section 1940) of Title 5, mobile homes, as defined in Section 798.3, or recreational vehicles, as defined in Section 799.29. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(e) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Dual agent&#8221; means an agent acting, either directly or through an associate licensee, as agent for both the seller and the buyer in a real property transaction. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(f) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Listing agreement&#8221; means a contract between an owner of real property and an agent, by which the agent has been authorized to sell the real property or to find or obtain a buyer. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(g) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Listing agent&#8221; means a person who has obtained a listing of real property to act as an agent for compensation. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(h) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Listing price&#8221; is the amount expressed in dollars specified in the listing for which the seller is willing to sell the real property through the listing agent. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(i) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Offering price&#8221; is the amount expressed in dollars specified in an offer to purchase for which the buyer is willing to buy the real property. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(j) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Offer to purchase&#8221; means a written contract executed by a buyer acting through a selling agent that becomes the contract for the sale of the real property upon acceptance by the seller. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(k) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Real property&#8221; means any estate specified by subdivision (1) or (2) of Section 761 in property that constitutes or is improved with one to four dwelling units, any commercial real property, any leasehold in these types of property exceeding one year&#8217;s duration, and mobile homes, when offered for sale or sold through an agent pursuant to the authority contained in Section 10131.6 of the Business and Professions Code. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(l) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Real property transaction&#8221; means a transaction for the sale of real </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">GH&#160;&#160;&#160;&#160;_</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">AR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Initials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initials</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;font-weight:bold;">AMENDMENT TO LEASE DATED JANUARY 30, 2017 BY AND BETWEEN PLETA &amp; SAN GAL TRUSTS, DBA: OCEAN POINT, HEREINAFTER REFERRED TO AS &#8220;LESSOR&#8221; AND OBALON THERAPEUTICS INC., A DELAWARE CORPORATION, HEREINAFTER REFERRED TO AS &#8220;LESSEE&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:121%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">property in which an agent is employed by one or more of the principals to act in that transaction, and includes a listing or an offer to purchase.</font></div><div style="line-height:123%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(m) &#8220;</font><font style="font-family:Arial;font-size:8pt;">Sell,&#8221; &#8220;sale,&#8221; or &#8220;sold&#8221; refers to a transaction for the transfer of real property from the seller to the buyer, and includes exchanges of real property between the seller and buyer, transactions for the creation of a real property sales contract within the meaning of Section 2985, and transactions for the creation of a lease hold exceeding one year&#8217;s duration. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(n) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Seller&#8221; means the transferor in a real property transaction, and includes an owner who lists real property with an agent, whether or not a transfer results, or who receives an offer to purchase real property of which he or she is the owner from an agent on behalf of another. &#8220;Seller&#8221; includes both a vendor and a lessor. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(o) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Selling agent&#8221; means a listing agent who acts alone, or an agent who acts in cooperation with a listing agent, and who sells or finds and obtains a buyer for the real property, or an agent who locates property for a buyer or who finds a buyer for a property for which no listing exists and presents an offer to purchase to the seller. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(p) </font><font style="font-family:Arial;font-size:8pt;">&#8220;Subagent&#8221; means a person to whom an agent delegates agency powers as provided in Article 5 (commencing with Section 2349) of Chapter 1 of Title 9. However, &#8220;subagent&#8221; does not include an associate licensee who is acting under the supervision of an agent in a real property transaction.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:125%;padding-top:2px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.14 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Listing agents and selling agents shall provide the seller and buyer in a real property transaction with a copy of the disclosure form specified in Section 2079</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">16, and, except as provided in subdivision (c), shall obtain a signed acknowledgement of receipt from that seller or buyer</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">except as provided in this section or Section 2079</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">15</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">as follows: </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(a) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The listing agent</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">if any</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">shall provide the disclosure form to the seller prior to entering into the listing agreement</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(b) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The selling agent shall provide the disclosure form to the seller as soon as practicable prior to presenting the seller with an offer to purchase, unless the selling agent previously provided the seller with a copy of the disclosure form pursuant to subdivision (a)</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:123%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(c) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Where the selling agent does not deal on a face-to</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">-</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">face basis with the seller</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the disclosure form prepared by the selling agent may be furnished to the seller (and acknowledgement of receipt obtained for the selling agent from the seller) by the listing agent</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">or the selling agent may deliver the disclosure form by certified mail addressed to the seller at his or her last known address, in which case no signed acknowledgement of receipt is required</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(d) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The selling agent shall provide the disclosure form to the buyer as soon as practicable prior to execution of the buyer&#8217;s offer to purchase</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">except that if the offer to purchase is not prepared by the selling agent</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the selling agent shall present the disclosure form to the buyer not later than the next business day after the selling agent receives the offer to purchase from the buyer</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:122%;padding-top:2px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:122%;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:122%;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.15 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">In any circumstance in which the seller or buyer refuses to sign an acknowledgement of receipt pursuant to Section 2079</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">14, the agent</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">or an associate licensee acting for an agent</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">shall set forth, sign</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">and date a written declaration of the facts of the refusal.</font></div><div style="line-height:120%;padding-top:5px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2079.16 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Reproduced on Page 1 of this form</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:123%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.17 (a) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">As soon as practicable</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the selling agent shall disclose to the buyer and seller whether the selling agent is acting in the real property transaction exclusively as the buyer&#8217;s agent</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">exclusively as the seller&#8217;s agent</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">or as a dual agent representing both the buyer and the seller</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">This relationship shall be confirmed in the contract to purchase and sell real property or in a separate writing executed or acknowledged by the seller, the buyer, and the selling agent prior to or coincident with execution of that contract by the buyer and the seller</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">respectively</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(b) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">As soon as practicable</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">, </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">the listing agent shall disclose to the seller whether the listing agent is acting in the real property transaction exclusively as the seller&#8217;s agent, or as a dual agent representing both the buyer and seller</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">. </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">This relationship shall be confirmed in the contract to purchase and sell real property or in a separate writing executed or acknowledged by the seller and the listing agent prior to or coincident with the execution of that contract by the seller</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:100%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(c) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The confirmation required by subdivisions (a) and (b) shall be in the following form</font><font style="font-family:inherit;font-size:8pt;color:#221d1d;">.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">(d) </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The disclosures and confirmation required by this section shall be in addition to the disclosure required by Section 2079.14.</font></div><div style="line-height:122%;padding-top:1px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.18 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">No selling agent in a real property transaction may act as an agent for the buyer only, when the selling agent is also acting as the listing agent in the transaction.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.19 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">The payment of compensation or the obligation to pay compensation to an agent by the seller or buyer is not necessarily determinative of a particular agency relationship between an agent and the seller or buyer. A listing agent and a selling agent may agree to share any compensation or commission paid, or any right to any compensation or commission for which an obligation arises as the result of a real estate transaction, and the terms of any such agreement shall not necessarily be determinative of a particular relationship.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.20 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Nothing in this article prevents an agent from selecting, as a condition of the agent&#8217;s employment, a specific form of agency relationship not specifically prohibited by this article if the requirements of Section 2079.14 and Section 2079.17 are complied with.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.21 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">A dual agent shall not disclose to the buyer that the seller is willing to sell the property at a price less than the listing price, without the express written consent of the seller. A dual agent shall not disclose to the seller that the buyer is willing to pay a price greater than the offering price, without the express written consent of the buyer. This section does not alter in any way the duty or responsibility of a dual agent to any principal with respect to confidential information other than price.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.22 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Nothing in this article precludes a listing agent from also being a selling agent, and the combination of these functions in one agent does not, of itself, make that agent a dual agent.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">GH&#160;&#160;&#160;&#160;_</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">AR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Initials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initials</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;font-weight:bold;">AMENDMENT TO LEASE DATED JANUARY 30, 2017 BY AND BETWEEN PLETA &amp; SAN GAL TRUSTS, DBA: OCEAN POINT, HEREINAFTER REFERRED TO AS &#8220;LESSOR&#8221; AND OBALON THERAPEUTICS INC., A DELAWARE CORPORATION, HEREINAFTER REFERRED TO AS &#8220;LESSEE&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.23 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">A contract between the principal and agent may be modified or altered to change the agency relationship at any time before the performance of the act which is the object of the agency with the written consent of the parties to the agency relationship.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#221d1d;font-weight:bold;">2079.24 </font><font style="font-family:Arial;font-size:8pt;color:#221d1d;">Nothing in this article shall be construed to either diminish the duty of disclosure owed buyers and sellers by agents and their associate licensees, subagents, and employees or to relieve agents and their associate licensees, subagents, and employees from liability for their conduct in connection with acts governed by this article or for any breach of a fiduciary duty or a duty of disclosure.</font></div><div style="line-height:100%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:126%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">NOTICE:  These forms are often modified to meet changing requirements of law and industry needs.  Always write or call to make sure you are utilizing the most current form:  AIR Commercial Real Estate Association, 500 N Brand Blvd, </font></div><div style="line-height:126%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Suite 900, Glendale, CA 91203. Telephone No. (213) 687-8777.  Fax No.: (213) 687-8616.</font></div><div style="line-height:126%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:126%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:126%;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;"><br></font></div><div style="line-height:126%;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;"><br></font></div><div style="line-height:126%;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;"><br></font></div><div style="line-height:126%;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</font></div><div style="line-height:126%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">GH&#160;&#160;&#160;&#160;_</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">AR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Initials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initials</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>obalon-3rdamendmenttolsaxe.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA90D99097323B8B47F7467F072779898"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 10.16</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIRD AMENDMENT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TO</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LOAN AND SECURITY AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Third Amendment to Loan and Security Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;), is made and entered into as of December 21, 2016, by and among PACIFIC WESTERN BANK, a California state chartered bank (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Bank</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and OBALON THERAPEUTICS, INC. and  OBALON THERAPEUTICS, LLC (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;, and collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Borrowers</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrowers and Bank are parties to that certain Loan and Security Agreement dated as of June 14, 2013 (as amended from time to time, with related documents, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  The parties desire to amend the Agreement in accordance with the terms of this Amendment.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, the parties agree as follows:</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bank and Borrowers hereby agree that that certain Third Warrant to Purchase Stock issued by Obalon Therapeutics, Inc. to Bank on September 7, 2016 is hereby cancelled without exercise.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.1(b) of the Agreement is hereby amended and restated, as follows:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Term Loans</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;text-indent:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Term Loan A</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;">Subject to and upon the terms and conditions of this Agreement, on December 21, 2016 or as soon thereafter as all conditions precedent to the making thereof have been met, Bank shall make a term loan to Borrowers in the principal amount of $10,000,000 (the &#8220;Term Loan A&#8221;).  The proceeds of the Term Loan A shall be used to refinance the aggregate principal amount of all indebtedness owing from Borrowers to Bank as of December 21, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;text-indent:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term Loans B</font><font style="font-family:inherit;font-size:12pt;">.  Subject to and upon the terms and conditions of this Agreement, Bank agrees to make one (1) or more term loans to Borrowers in an aggregate principal amount not to exceed $5,000,000 (each a &#8220;Term Loan B&#8221; and collectively the &#8220;Term Loans B&#8221;, and together with the Term Loan A, each a &#8220;Term Loan&#8221; and collectively, the &#8220;Term Loans&#8221;).  Borrowers may request Term Loans B at any time on or before the Availability End Date.  The proceeds of the Term Loans B shall be used for general working capital purposes and for capital expenditures.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;text-indent:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;Interest shall accrue from the date of each Term Loan at the rate specified in Section 2.3(a), and prior to the Interest-Only End Date shall be payable monthly beginning on the first day of the month next following such Term Loan, and continuing on the same day of each month thereafter.  Any Term Loans outstanding on the Interest-Only End Date shall be payable in equal monthly installments of principal, plus all accrued interest, beginning on the date that is one month immediately following the Interest-Only End Date, and continuing </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">on the same day of each month thereafter through the Term Loan Maturity Date, at which time all amounts due in connection with the Term Loans and any other amounts due under this Agreement shall be immediately due and payable.  Term Loans, once repaid, may not be reborrowed.  Borrowers may prepay any Term Loan without penalty or premium. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;text-indent:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">When Borrowers desire to obtain a Term Loan B, Borrowers shall notify Bank (which notice shall be irrevocable) by facsimile transmission to be received no later than 3:30 p.m. Eastern time on the day on which the Term Loan B is to be made.  Such notice shall be substantially in the form of Exhibit C.  The notice shall be signed by an Authorized Officer.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.1(c) of the Agreement is hereby deleted.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.6 of the Agreement is hereby amended and restated, as follows:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.6&#160;&#160;&#160;&#160;Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Borrowers shall at all times maintain Cash in accounts at Bank in an aggregate amount equal to or greater than the aggregate amount of all Indebtedness of Borrowers to Bank then outstanding.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.7 of the Agreement is hereby amended and restated, as follows:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.7&#160;&#160;&#160;&#160;[Reserved]</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The following defined terms in Exhibit A to the Agreement are hereby amended and restated, as follows:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Availability End Date&#8221; means December 21, 2017. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Interest-Only End Date&#8221; means June 21, 2018.</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Term Loan Maturity Date&#8221; means December 21, 2020.</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement.  The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects.  Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof.  Each Borrower ratifies and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Borrower represents and warrants that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">this Amendment, duly executed by each Borrower;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">payment of a $15,000 facility fee, which may be debited from any Borrower&#8217;s accounts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">payment of all Bank Expenses, including Bank&#8217;s expenses for the documentation of this amendment and any related documents, and any UCC, good standing or intellectual property search or filing fees, which may be debited from any Borrower&#8217;s accounts; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">such other documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">[Signature Page Follows]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFB85A996D666EBAD101667F072A715F5"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OBALON THERAPEUTICS, INC.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;   /s/ Andrew Rasdal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;   Andrew Rasdal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;            </font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;  Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OBALON THERAPEUTICS, LLC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;   /s/ Andrew Rasdal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;   Andrew Rasdal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;            </font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;  Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PACIFIC WESTERN BANK&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Sean Noonan&#160;&#160;&#160;&#160;               &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Sean Noonan&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Vice President&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit23.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB03B5C58F2ED269CA65D68945A3DFE95"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;padding-top:16px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Board of Directors <br>Obalon Therapeutics, Inc.:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We consent to the incorporation by reference in the registration statement (No. 333-213988) on Form S-8 of Obalon Therapeutics, Inc. of our report dated February 23, 2017, with respect to the consolidated balance sheets of Obalon Therapeutics, Inc. and subsidiaries as of December&#160;31, 2016 and 2015, and the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the three-year period ended December&#160;31, 2016, which report appears in the December&#160;31, 2016 annual report on Form 10-K of Obalon Therapeutics, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ KPMG LLP</font></div><div style="line-height:120%;padding-bottom:40px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">San Diego, California <br>February 23, 2017</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;</font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>obln123116ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBDC378A4FAABCF31F7F463387EBE3DAC"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Andrew Rasdal, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;I have reviewed this Annual Report on Form 10-K of Obalon Therapeutics, Inc.;</font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or person performing the equivalent functions):</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February 23, 2017</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Andrew Rasdal</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew Rasdal</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>obln123116ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0998D775FCA1F9F5D334633942FAEE26"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, William Plovanic, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;I have reviewed this Annual Report on Form 10-K of Obalon Therapeutics, Inc.;</font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or person performing the equivalent functions):</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February 23, 2017</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William Plovanic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Plovanic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>obln123116ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF0812FEDBCC02109D77B6339B89E46EA"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report on Form 10-K of Obalon Therapeutics, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Andrew Rasdal, the President and Chief Executive Officer, and William Plovanic, the Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: February 23, 2017</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Andrew Rasdal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William Plovanic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew Rasdal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Plovanic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>obln-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:1da6359d8ca14e3c8169148d749d05c8,x:69ef30afb25d4d9990a60678f70cab93-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:obln="http://www.obalon.com/20161231" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="obln-20161231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb17">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct5_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-05</xbrli:startDate>
			<xbrli:endDate>2016-10-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct12_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-12</xbrli:startDate>
			<xbrli:endDate>2016-10-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct12_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-12</xbrli:startDate>
			<xbrli:endDate>2016-10-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct5_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct5_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-05</xbrli:startDate>
			<xbrli:endDate>2016-10-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_PlanNameAxis_obln_TwoThousandAndEightPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:TwoThousandAndEightPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct11_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-11</xbrli:startDate>
			<xbrli:endDate>2016-10-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_dei_LegalEntityAxis_obln_ObalonMexicoDERLCVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">obln:ObalonMexicoDERLCVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb1-28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2014-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sept1-30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">obln:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">obln:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">obln:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">obln:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">obln:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-12</xbrli:startDate>
			<xbrli:endDate>2016-10-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_obln_SeriesCOnePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOnePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOnePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOnePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-12</xbrli:startDate>
			<xbrli:endDate>2016-10-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-12</xbrli:startDate>
			<xbrli:endDate>2016-10-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">obln:AvailableForSaleSecuritiesMaturityInOneYearOrLessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">obln:AvailableForSaleSecuritiesMaturityInOneYearOrLessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_obln_ScientificEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">obln:ScientificEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_obln_ScientificEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">obln:ScientificEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:DecemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:DecemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_FirstTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:DecemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">obln:FirstTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_SecondTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">obln:SecondTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">obln:TermLoanBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_DebtInstrumentAxis_obln_TwoThousandThirteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandThirteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_DebtInstrumentAxis_obln_TwoThousandThirteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandThirteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_DebtInstrumentAxis_obln_TwoThousandThirteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandThirteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_FirstTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">obln:FirstTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">obln:TermLoanAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Oct1-31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">obln:TermLoanAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:SeptemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:TwoThousandFourteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:DecemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-21</xbrli:startDate>
			<xbrli:endDate>2016-12-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_SecondTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">obln:DecemberTwoThousandSixteenLoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">obln:PacificWesternBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">obln:SecondTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_obln_StockOptionsIssuedAndOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">obln:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-04</xbrli:startDate>
			<xbrli:endDate>2016-10-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PlanNameAxis_obln_EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-04</xbrli:startDate>
			<xbrli:endDate>2016-10-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct4_us-gaap_PlanNameAxis_obln_EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">obln:EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">obln:FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May4_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-04</xbrli:startDate>
			<xbrli:endDate>2016-05-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">obln:BaderSultanAndBrosCoWLLMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_StatementGeographicalAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">obln:BaderSultanAndBrosCoWLLMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">obln:BaderSultanAndBrosCoWLLMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">obln:BaderSultanAndBrosCoWLLMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2Apr30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_obln_DistributionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">obln:BaderSultanAndBrosCoWLLMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">obln:DistributionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">obln:BaderSultanAndBrosCoWLLMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">obln:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">obln:BaderSultanAndBrosCoWLLMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb24_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-02-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>obln:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="tranche">
		<xbrli:measure>obln:tranche</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="installment">
		<xbrli:measure>obln:installment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2016Q4YTD" id="Fact-70F5E6BE27C6C4A506698F8A42F3C129">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q4YTD" id="Fact-7B56301762B0271B26F98F8ABA54DE94">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q4YTD" id="Fact-69B29A04BF45F1D531328F8A6F8C0585">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q4YTD" id="Fact-0E7F87F5A8F78B6963628F8A60A474B1">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q4YTD" id="Fact-D25DCF464B87AB1422548F8A52430A46">2016-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q4YTD" id="Fact-DF8F06C366B534A01A0F8F8A35FCD774">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q4YTD" id="Fact-5A02E697E8330E79EEF98F8A9C775150">0001427570 </dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q1Feb17" decimals="INF" id="Fact-ECB6C103E871D97BB7738F8AD987C490" unitRef="shares">16773205</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2016Q4YTD" id="Fact-00A020ACDF56BEEC88FDBD955E81C43E">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2016Q4YTD" id="Fact-6F758EBEADE04053F3028F8AC86FD22C">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2016Q2" decimals="-6" id="Fact-B745EBFEC17A3E2121724E64466E7585" unitRef="usd">0</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2016Q4YTD" id="Fact-FE2300DE766981C47D788F8A8C764A56">OBALON THERAPEUTICS INC</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2016Q4YTD" id="Fact-F4F7D44304781A0CF5DBBD94E606C539">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2016Q4YTD" id="Fact-733C33E30302043EB7E9BD94A8985247">No</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="FD2016Q4YTD" id="Fact-8D2431056C8177C6C7B38F8A7D6B15D9">OBLN</dei:TradingSymbol>
	<obln:AccruedClinicalExpensesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-95C50A1032104B61EBF98F94D54D1F01" unitRef="usd">913000</obln:AccruedClinicalExpensesCurrent>
	<obln:AccruedClinicalExpensesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AF5E9E9155DD2AB777C18F94D557ED92" unitRef="usd">101000</obln:AccruedClinicalExpensesCurrent>
	<obln:AccruedLegalCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-34E2CB4A13247C2DF6348FF133431BC6" unitRef="usd">162000</obln:AccruedLegalCurrent>
	<obln:AccruedLegalCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-2CB288A0CB648614863C8FF1333C4435" unitRef="usd">53000</obln:AccruedLegalCurrent>
	<obln:ClassOfWarrantOrRightExercised contextRef="D2016Q4Oct11_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-75821F348834AB79D3E54E23241B7780" unitRef="shares">36562</obln:ClassOfWarrantOrRightExercised>
	<obln:ClassOfWarrantOrRightExercised contextRef="D2016Q4Oct12" decimals="INF" id="Fact-C749F9D06290F34C01E36267745A8BAE" unitRef="shares">61112</obln:ClassOfWarrantOrRightExercised>
	<obln:ClassOfWarrantOrRightExercised contextRef="D2016Q4Oct12_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-ABCA71C0B44D2CE3F9EB4E2262BF5781" unitRef="shares">24550</obln:ClassOfWarrantOrRightExercised>
	<obln:ClassOfWarrantOrRightExercised contextRef="FD2016Q4QTD" decimals="INF" id="Fact-E861EC40159FF23A9FA5F58B9B8C6922" unitRef="shares">61112</obln:ClassOfWarrantOrRightExercised>
	<obln:ClassOfWarrantsOrRightsIssuedForPurchaseOfStock contextRef="FI2013Q2_us-gaap_DebtInstrumentAxis_obln_TwoThousandThirteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-765AA6A4D5A48615D555CD780FBF27B4" unitRef="shares">8693</obln:ClassOfWarrantsOrRightsIssuedForPurchaseOfStock>
	<obln:ClassOfWarrantsOrRightsIssuedForPurchaseOfStock contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-39C72306AA2E52123DBBCD80E951153B" unitRef="shares">27869</obln:ClassOfWarrantsOrRightsIssuedForPurchaseOfStock>
	<obln:ConversionOfCustomerDepositFromRelatedPartyToPreferredStock contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C28A3E99A86CE7CCD2C738E900EF2BED" unitRef="usd">0</obln:ConversionOfCustomerDepositFromRelatedPartyToPreferredStock>
	<obln:ConversionOfCustomerDepositFromRelatedPartyToPreferredStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6FB7D33C71F487ECBFE98FBE50553D31" unitRef="usd">0</obln:ConversionOfCustomerDepositFromRelatedPartyToPreferredStock>
	<obln:ConversionOfCustomerDepositFromRelatedPartyToPreferredStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1F0A0568CE708235A0278FBE504861CA" unitRef="usd">1283000</obln:ConversionOfCustomerDepositFromRelatedPartyToPreferredStock>
	<obln:ConversionOfTemporaryEquityToCommonStockPercentage contextRef="D2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-F92BBA0AFD407746E4EAD1E9EB8379CF" unitRef="number">1</obln:ConversionOfTemporaryEquityToCommonStockPercentage>
	<obln:IncreaseDecreaseInAccruedClinicalExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-196D8BE163E7F46DF0DE38E8F03AD778" unitRef="usd">-129000</obln:IncreaseDecreaseInAccruedClinicalExpenses>
	<obln:IncreaseDecreaseInAccruedClinicalExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E7607DAC972E63EBF2C38FB9D0E011C7" unitRef="usd">898000</obln:IncreaseDecreaseInAccruedClinicalExpenses>
	<obln:IncreaseDecreaseInAccruedClinicalExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2755B5DEFC57D03986008FB9D0D9DA22" unitRef="usd">-812000</obln:IncreaseDecreaseInAccruedClinicalExpenses>
	<obln:LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments contextRef="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-7C98DD1A8FF110244A61CDCB7AB89031" unitRef="installment">30</obln:LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments>
	<obln:LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments contextRef="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-7BDD09104FF0A115E93E6A0CF386BE89" unitRef="installment">30</obln:LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments>
	<obln:MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock contextRef="I2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-F046C337E77C287B6C4BD1CCE3CC45C8" unitRef="number">0.67</obln:MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock>
	<obln:MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanBMember" decimals="INF" id="Fact-15EECE964F15DF6AFF08CD801E980A09" unitRef="usd">20000000.0</obln:MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility>
	<obln:NonvestedStockOptionsEarlyExercised contextRef="FI2014Q4" decimals="INF" id="Fact-743176DD26E1B6F25726D1857851682F" unitRef="shares">0</obln:NonvestedStockOptionsEarlyExercised>
	<obln:NonvestedStockOptionsEarlyExercised contextRef="FI2015Q4" decimals="INF" id="Fact-4C46FB9AA44F723AD6DED18627D9D2E9" unitRef="shares">0</obln:NonvestedStockOptionsEarlyExercised>
	<obln:NonvestedStockOptionsEarlyExercised contextRef="FI2016Q4" decimals="INF" id="Fact-F553F4D7DD4CDC56E820D1ED56998352" unitRef="shares">238638</obln:NonvestedStockOptionsEarlyExercised>
	<obln:NumberOfTranches contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-7B531DC151B270B2C5DACD7A40039DED" unitRef="tranche">2</obln:NumberOfTranches>
	<obln:NumberOfTranches contextRef="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-7083CABACC4EF294CC46CD8BB02CEE63" unitRef="tranche">2</obln:NumberOfTranches>
	<obln:NumberOfTranches contextRef="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-45D307F116CAF8D316346A0C395261CB" unitRef="tranche">2</obln:NumberOfTranches>
	<obln:NumberOfWarrantsExercise contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-45E7973EC48549BD5114F5AF4AF1D50B" unitRef="shares">0</obln:NumberOfWarrantsExercise>
	<obln:NumberOfWarrantsExercise contextRef="I2016Q4Oct11_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-48A3E66B50BFB23F919D4DBDB147CF75" unitRef="shares">13869</obln:NumberOfWarrantsExercise>
	<obln:NumberOfWarrantsExercise contextRef="I2016Q4Oct11_us-gaap_DebtInstrumentAxis_obln_TwoThousandThirteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-D723361E3F745A5A4E874DBEBB086EBD" unitRef="shares">2689</obln:NumberOfWarrantsExercise>
	<obln:OwnershipPercentageHeldByShellCompany contextRef="FI2016Q4_dei_LegalEntityAxis_obln_ObalonMexicoDERLCVMember" decimals="2" id="Fact-611A1F12D79DB1697B83BE2B413BDD5D" unitRef="number">0.99</obln:OwnershipPercentageHeldByShellCompany>
	<obln:PercentageChangeInPresentValueOfFutureCashFlows contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember" decimals="INF" id="Fact-E9D17C0CD1A29F075E154DC32F72A00E" unitRef="number">0.1</obln:PercentageChangeInPresentValueOfFutureCashFlows>
	<obln:PercentageChangeInPresentValueOfFutureCashFlows contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember" decimals="INF" id="Fact-A6E979A383F6350F1750CD848ADD5267" unitRef="number">0.1</obln:PercentageChangeInPresentValueOfFutureCashFlows>
	<obln:PercentageOfBorrowingsForIssuanceOfWarrant contextRef="D2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-69082918B521EA72F174F5AE79A1C80D" unitRef="number">0.03</obln:PercentageOfBorrowingsForIssuanceOfWarrant>
	<obln:ProceedsfromIssuanceofPreferredStocktoRelatedParty contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DFFF19F1C33663C40B8038F33F61E055" unitRef="usd">6600000</obln:ProceedsfromIssuanceofPreferredStocktoRelatedParty>
	<obln:ProceedsfromIssuanceofPreferredStocktoRelatedParty contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1044AC196262FC91845638F33F5799A8" unitRef="usd">0</obln:ProceedsfromIssuanceofPreferredStocktoRelatedParty>
	<obln:ProceedsfromIssuanceofPreferredStocktoRelatedParty contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E3DB1912B349985471C438F33F575E03" unitRef="usd">0</obln:ProceedsfromIssuanceofPreferredStocktoRelatedParty>
	<obln:PurchasePricePerShare contextRef="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-197F124620A95C30C8C9F5AE3FD6C50B" unitRef="usdPerShare">8.2932</obln:PurchasePricePerShare>
	<obln:ReclassificationsofWarrantLiabilitytoPermanentEquity contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1AC4CCAD95DB7027687FF5763B75ECFD" unitRef="usd">591000</obln:ReclassificationsofWarrantLiabilitytoPermanentEquity>
	<obln:ReclassificationsofWarrantLiabilitytoPermanentEquity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-363793B6FA38F4AA85E8F5763B7386BB" unitRef="usd">591000</obln:ReclassificationsofWarrantLiabilitytoPermanentEquity>
	<obln:ReclassificationsofWarrantLiabilitytoPermanentEquityShares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-867231478D6FC676599B4E5AFF75B354" unitRef="shares">28775</obln:ReclassificationsofWarrantLiabilitytoPermanentEquityShares>
	<obln:RevenueFromRelatedPartiesAsPercentageOfNetRevenue contextRef="FD2014Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="3" id="Fact-B7AC735ABCF3252E0A7E947E31B3CF39" unitRef="number">0.524</obln:RevenueFromRelatedPartiesAsPercentageOfNetRevenue>
	<obln:RevenueFromRelatedPartiesAsPercentageOfNetRevenue contextRef="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="3" id="Fact-30445C6DE5BB045FFD71947E31C6CB76" unitRef="number">0.947</obln:RevenueFromRelatedPartiesAsPercentageOfNetRevenue>
	<obln:RevenueFromRelatedPartiesAsPercentageOfNetRevenue contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="2" id="Fact-4053AB6FAF0987EC677D947E31BF903D" unitRef="number">1.00</obln:RevenueFromRelatedPartiesAsPercentageOfNetRevenue>
	<obln:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents contextRef="D2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-C200E11D8170741D5C36D1820E2ED1AE" unitRef="number">0.01</obln:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents>
	<obln:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents contextRef="D2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember" decimals="INF" id="Fact-14E3A4B2D50DAFFB1EC3D18133C3457B" unitRef="number">0.04</obln:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents>
	<obln:SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants contextRef="D2016Q4Oct12_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-1D3DAFDBE2A02CC291E74E2F3B05C05C" unitRef="shares">16558</obln:SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants>
	<obln:SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants contextRef="D2016Q4Oct12_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-36AFEF3F3B5B77F736914E21AC07650E" unitRef="shares">12217</obln:SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants>
	<obln:SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants contextRef="FD2016Q4QTD" decimals="INF" id="Fact-09274B25655DEA4E708CF58C0ABF402C" unitRef="shares">28775</obln:SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants>
	<obln:StockOptionsEarlyExercised contextRef="FD2016Q4YTD" decimals="0" id="Fact-E280BB5001E1F5BF423466D51B9A8024" unitRef="shares">252453</obln:StockOptionsEarlyExercised>
	<obln:StockOptionsEarlyExercisedLiability contextRef="FI2016Q4" decimals="-5" id="Fact-6910E1C8A55094092174D1EECC9EEB3B" unitRef="usd">200000</obln:StockOptionsEarlyExercisedLiability>
	<obln:TemporaryEquityDividendRatePerShareAmount contextRef="D2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="4" id="Fact-F2A50A87E4B806FB9952D1CB033E99A3" unitRef="usdPerShare">0.6635</obln:TemporaryEquityDividendRatePerShareAmount>
	<obln:WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock contextRef="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-76EBFDA304FA5F9443DB4E2CECF5C48E" unitRef="shares">24224</obln:WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-47FB65D0499CCBA15A9A8F94ABEE5BAB" unitRef="usd">549000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-83A7E097DC3ABED0EFFB8F94ABF85861" unitRef="usd">595000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember" decimals="-5" id="Fact-768C64E760C9793CC970D2CB07EC788A" unitRef="usd">500000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F43CDEA40A48CB2B664938E8EA7A5F6C" unitRef="usd">-64000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9302CC64AB8700B1A99C8FB812ECB722" unitRef="usd">-260000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CF9E32D905BE40B0946C8FB812EECCE4" unitRef="usd">-125000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C88BA2165F81D7ABC11C8FF12156D710" unitRef="usd">195000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-90284BDC55EC22FC2E0A8FF121638059" unitRef="usd">560000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-210D14B9C1E4850182718FECEE817230" unitRef="usd">894000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-A2EDF0586BCCBFA1D3C48FECEE808F15" unitRef="usd">1084000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-3" id="Fact-D5086AF70678854C00308F96AC76243B" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-153FBD99C1CBC0A049C68F96AC76AEDC" unitRef="usd">-1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q4" decimals="-3" id="Fact-4797E73CE4A5EBEE0A3A8F969B82060E" unitRef="usd">1002000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q4" decimals="-3" id="Fact-063DE0FE4C4672DBEE0E8F969B827ED1" unitRef="usd">140898000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D5BD2A47C4B7520A809994F234A1BEDA" unitRef="usd">185000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E5D6F88B8E9F1CE0EBB794F234785E0C" unitRef="usd">185000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5BDB1B73E36874748A8A94F1EA55C493" unitRef="usd">207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DCEF4D0A8A0E198CF76094F1EA57EB60" unitRef="usd">207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A5D46E47A5BD65EF6C1894F25C62931D" unitRef="usd">563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-244B3FD8427847FE957594F25C513892" unitRef="usd">563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2014Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-6D9D64F1D5CFD84EF4C39537D9546B47" unitRef="usd">368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-29B0F815AD82318FC40F624F60EE9D30" unitRef="usd">94000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1A7529B2BC0CA9EB0BAAD297417C4EA9" unitRef="usd">207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-15461058DB41C7CC33A5D2974179FADB" unitRef="usd">207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdvertisingExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-52DB25E5367DBFA2096C38F804DB5944" unitRef="usd">300000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FD7746918938DB217B0EBE4F66D28B15" unitRef="usd">300000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-CB42C4B99A8BD994F4BAD222DC5DA0CF" unitRef="usd">900000</us-gaap:AdvertisingExpense>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2015Q4" decimals="-5" id="Fact-17670BC6E9584C8C182A38F68BCF59DF" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2016Q4" decimals="-5" id="Fact-0365D3E2EDFB243F8F01CD9B6FDAA0DC" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F31AD6D05C68380E673138E8EB2A4B65" unitRef="usd">41000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2015Q4YTD" decimals="-3" id="Fact-648451F14D4A3B5F237F8FB826C885F2" unitRef="usd">79000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3E4CAE35DDEA5B0C2E5F8FB826C7D618" unitRef="usd">70000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q4YTD" decimals="INF" id="Fact-E4A976C81667077D52D8D2F681579FB5" unitRef="shares">6714172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="INF" id="Fact-B755EE795F3028E2144DD2F681596245" unitRef="shares">6654734</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-FFE72723B0D80C2C9A4DD2F68154E6E5" unitRef="shares">59438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD" decimals="INF" id="Fact-0D494210AA40AA5614FED2F68150BDA8" unitRef="shares">8443994</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="INF" id="Fact-A62D6ECDA831C5185DC8D2F681560B40" unitRef="shares">8443994</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-6A0CA63AE6385E3D3F51D2F681582ACE" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD" decimals="INF" id="Fact-F11C1038C981FE10814DD2F6814F7777" unitRef="shares">830145</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="INF" id="Fact-DA893B304B0C2E9E284CD2F68152F97C" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-AE889B536522219204D4D2F6814D95A4" unitRef="shares">830145</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-60BB50665097C9B1D56B8F9489C289EA" unitRef="usd">14221000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-EDD1608B8A7F8BFBD42C8F9489C26668" unitRef="usd">78778000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-2871682336761E6317EB8F946161959F" unitRef="usd">13803000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6D6F3358FD80348B1CE38F9461615937" unitRef="usd">78061000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4" decimals="-3" id="Fact-EFC52AE68F4635CF872B9446B0E643E2" unitRef="usd">12768000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-F0D671A7620AAB6A3AF89446B0194B3D" unitRef="usd">3593000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-68C255B48C466FF3A8509446B12C27B0" unitRef="usd">3593000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-684BFE2B14C031AAC1679446B0A38935" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-5B0105E6AD2432ED3C529446AF88E82B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-18BFB3257E23C132A4E19446B04FF2A4" unitRef="usd">9175000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-70C12E265FCCC7C6835B9446B079806F" unitRef="usd">9175000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-C88E6224E8B4986254429446B028B001" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-1F6367EB8C9C3BCD9E0E9446AFA1D173" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-578E7CA9AD30B74C68969446AFC36811" unitRef="usd">12768000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-FF5575061BD2F39AE51B9446AFCAA6EB" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-E74A181DA1219AD1DC1F9446AFD6B454" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4" decimals="-3" id="Fact-3C287C6FFCA3A4474F399442CCDAB08E" unitRef="usd">2500000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-A1B69A29A57249B713B99442CCD7F9CC" unitRef="usd">2500000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-9F4EE5B78B67200FC2A39442CCE9B16D" unitRef="usd">2500000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-2459FC8653A2DBFF4CB99442CCD51142" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-43A21938BF59625593599442CCED2088" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-D47AD1830FD73A424D569442CCD163F0" unitRef="usd">2500000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-26A0FD445669ABA44E839442CCE5164A" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-D8BCB0292F70C75B75819442CCD8D01D" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-2416B5F8EEDDECC5D42C94298261D8D4" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-F433F6B2702D50D645B394294B4EE74D" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-A5C9FFF4685F45DE822594298E4E60BE" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-8EF7D5602DA4BE62FC07942956A02954" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-ED85F6FE001B66093042942976421F0B" unitRef="usd">9178000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-0E401CA697F32CC2EC9294293E409F1F" unitRef="usd">2501000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2015Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-9F0F74F181B92A7A6EC794299D9BD472" unitRef="usd">9175000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4_us-gaap_InformationByCategoryOfDebtSecurityAxis_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-919AEE29073BE69804BF942964027A04" unitRef="usd">2500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C2DC2CE36D6B99D140734E51782C6965" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AE23C7DE2E5A75C3BBC1F55BE5D15C2D" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-62C001F2F57C1EA33346F55BE57FEB42" unitRef="usd">140000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-44B650E296094E14BA0638E8FDE9878C" unitRef="usd">2527000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-54650BCE01E63FD3B7178FBDAFA83593" unitRef="usd">6902000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-1A27EE35C0D48B38235D8F93F0265B6C" unitRef="usd">3356000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-5D56B178027C25D9A0428F93F026D8BB" unitRef="usd">72975000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1383C5B89930EE2B75FA38E8FD3DFC06" unitRef="usd">4375000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-66CEAABE11C6AA2CBDA18FBF00428342" unitRef="usd">-3546000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F8D0464BA0F197E267588FBF003F1EAD" unitRef="usd">69619000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="4" id="Fact-C48A865064994EB9B6E893E14D82B312" unitRef="usdPerShare">6.1918</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="4" id="Fact-7917276B09275DC3489FCD829D0953F0" unitRef="usdPerShare">7.5351</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-949ADAC2E3468287864962667495FC0B" unitRef="shares">24224</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q4Oct12_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6E13022FF9D4059995B94E2B8B117B95" unitRef="shares">24224</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-A21CE535F11BDEBCE88DD1DE35AD2BD5" unitRef="shares">24224</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-7474662458B41700BF554DBB1F0A796C" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-C655A82D31DE78EA0C7C8F959318C14F" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-265F75863722BBA1273C8F959318D686" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2016Q4" decimals="INF" id="Fact-5C98AA6D8FF76168A42C93E4320E1334" unitRef="shares">3636457</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2016Q4_us-gaap_AwardTypeAxis_obln_StockOptionsIssuedAndOutstandingMember" decimals="INF" id="Fact-632D4689B8D40FEFF330D2CC46B78CE8" unitRef="shares">2225684</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2016Q4_us-gaap_PlanNameAxis_obln_EquityIncentivePlanMember" decimals="INF" id="Fact-0C5DAFE3EA1D4087DB8DF5935F01C5DB" unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2016Q4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember" decimals="INF" id="Fact-D03734F1A89FFA85FBF8D2D0A9BC4A36" unitRef="shares">1386549</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-B28A6E7F7B3603AE94D8D2FCD4DB47FC" unitRef="shares">24224</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2016Q4Oct12_us-gaap_PlanNameAxis_obln_TwoThousandAndEightPlanMember" decimals="INF" id="Fact-0A7B1550EDF36F6B69134E272935E918" unitRef="shares">223371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2016Q4Oct4_us-gaap_PlanNameAxis_obln_EquityIncentivePlanMember" decimals="INF" id="Fact-F27CCC88135586887CCCD18420F7F06C" unitRef="shares">223371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-42BCF8E144AB2917600DD18230ECDAA8" unitRef="shares">180000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember" decimals="INF" id="Fact-8DB468E7828C3A72BF9CD16C3BFC2D7E" unitRef="shares">2200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-330D2F5CAB61CE000B58BDF01D80527F" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-183E542E13415E87A6B5BDF01D967F05" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-FB2139C8A63180B67BC0BDF0306F93BB" unitRef="shares">35000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-31EC77E46A886B96724DBDF0306B3D47" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2016Q4Oct12" decimals="INF" id="Fact-C69806628D487D1604984E290C662818" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-12CCF01423879DE3BE81BDF04075423B" unitRef="shares">575126</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-C7BF304ED0A7A8F36255BDF04066844D" unitRef="shares">16773205</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-D347885349716C42D5049525B0E6FC7A" unitRef="shares">804595</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-B4DB35926DB7795AE8279525B0E0CFB5" unitRef="shares">1494248</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-05E88B35939EEBE1A2489525B0E3E635" unitRef="shares">2668533</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-C23E32324DB27C59F0909525B0E4087A" unitRef="shares">480286</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-DC40F120900BDC1ADE0A9525B0E745ED" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-F36132ABD7457EB2ED2FD27ACAC1F1D5" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6B0C20E1E293F811278B94ED42F546E8" unitRef="shares">529199</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-C45EA907D55D3A8120F89525F85943EC" unitRef="shares">804595</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-001B71FFDD08880E040F9525F8563D78" unitRef="shares">1494248</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-19C303BAD43AF90339D89525F857344F" unitRef="shares">2668533</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-9C4479C465A725A2BCBC9525F8547C3B" unitRef="shares">480286</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-7944FE051744C9786D799525F85BE62C" unitRef="shares">2732552</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-40592B77F2E7DE587FA0D27AE7007F13" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6B7C34FC5C4B4A13809B94EE61E5CFA6" unitRef="shares">533484</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-6A13913B7CB5AF0FFC60BDF05B4F43FD" unitRef="shares">575126</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-61059F32B2E82E90D87195261E024F4F" unitRef="shares">804595</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-84C16381A17038CF499295261E0640FD" unitRef="shares">1494248</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-68485BCEE784DDA683E095261DFE1E12" unitRef="shares">2668533</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-5CF22A3D03E2F5B13C0295261E041DAD" unitRef="shares">480286</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-0301CAB82C9E90DBD67E95261E00BAC0" unitRef="shares">2732552</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-8A9BA2BF323A0AD77B4BD27B0D689215" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9868A04A1B42A8CD878394EF0C812482" unitRef="shares">575126</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-4853F440A3BBB71DE7EEBDF05B53582D" unitRef="shares">16773205</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-99A85F6AB0C05CA05D45952652D097DC" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-B7EC359368C47AC7140B952652C92930" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-53AC98E2DAE5C516C2A8952652CB7853" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-07B3FFD6F040B351B006952652CCABDB" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-86EA5BBA28E16826EE77952652CE1126" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-0DFF8E25A2E6D667E8D5D27B3D46F9C9" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-76D0C531A54BBBFF79B794EF5A897893" unitRef="shares">16773205</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-59993474CF9207E63B738F96887AB93C" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-13F7F2527F12BA0A24D48F96888E0236" unitRef="usd">17000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DDB5D39F963F578361448FB2E5409B75" unitRef="usd">-9881000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6102D2A53F0E6BA06F968FB2E533B0B4" unitRef="usd">-15552000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EE6B8DBE16647EFFD9278FB2E5491DB6" unitRef="usd">-20468000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember" decimals="3" id="Fact-DF26278C5F4D30D846C4D25B619B45FF" unitRef="number">0.610</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerTwoMember" decimals="3" id="Fact-EA35E5C7869DEC424275D25B61E65DC8" unitRef="number">0.026</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember" decimals="3" id="Fact-55E149C2FC7E980805D2D25B611D74F9" unitRef="number">0.524</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerTwoMember" decimals="3" id="Fact-5672899A31807F95076DD25B617F4640" unitRef="number">0.100</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember" decimals="3" id="Fact-6E61C16329AC6B5F69EED25B61898543" unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember" decimals="3" id="Fact-2E5E9F6B37C74033886FD25B61437D99" unitRef="number">0.947</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember" decimals="3" id="Fact-206C479796D0715780E7D25B61B12A06" unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_obln_CustomerOneMember" decimals="3" id="Fact-35278A003F7EBE61690CD25B615C2578" unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-EF0AC2332119FAE89A764E58BFBE5F0C" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0FCB9029AB5E57168A644E58BFC86562" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3D90DA16CC9FFA3816514E58BFC8323F" unitRef="usd">70498000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2016Q4Oct12" decimals="INF" id="Fact-F32E92BF988D2165F8124E191DA16F96" unitRef="shares">10360419</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CostOfRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E9C3081541FA09813B7F8FAFFADD9B3B" unitRef="usd">2912000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ECE9AAF923A2C0827B9C8FAFFAD8B681" unitRef="usd">2503000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B2B99A25AEC71D4BEDE88FAFFADBD55E" unitRef="usd">2809000</us-gaap:CostOfRevenue>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-50D0196AC9110A725128949452BAA401" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2733CE5F15FF4D134A609494529C3214" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7DFC1E6B0CF37E6271F3949452E2B32B" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2E5E58FCA6AEEE9344AC9494FD5D168E" unitRef="usd">14000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9508AFEE91FFEBDD958D9494FD53839B" unitRef="usd">-15000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-34711A37C1333CFECC77949564CC67C2" unitRef="usd">16000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C4852708C6B96171D1CA949564A4464E" unitRef="usd">-13000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4B1A4051E6C5A8BC1D659495649AAF0F" unitRef="usd">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-70709A270B577E31FE539494A45DA682" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A362989F10F3076B298B9494A45D8209" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A31CF8CE18621A81DCAF4D462A964245" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-068CA7BDAAF22AEA6D6DCD91353909B9" unitRef="number">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-643979BB85F0F3DF38646A0CD1BDDB2A" unitRef="number">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q4" decimals="-3" id="Fact-436DC1339EFD38854E21D2F2FD29A25E" unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-930F84D84D9CFCE2A59ACD9164C067E5" unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-22DD7092088C98D156BE6A0C1C60464F" unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F914C360EFE4A66A61CA94979F780976" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FD79EB4103C32D1E33CE94979F6EE92B" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6BA39EAB1BA6A8B1221594979F789A6F" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2016Q4" decimals="-3" id="Fact-C44274CE96E92CB7C281D2F2FD317964" unitRef="usd">119000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C27049CCA66DCC8B121C949853177C1E" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-45F292A35DA1E9BC9459949852DB1BE2" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EA0AD5F427C53D1776D0949852EFA18A" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8E175E0FF3FA6F8686B894990B6F54DF" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C2C6B451031B7287842494990B6FB040" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DEAA68D737E77E2849F094990B6F5CBA" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D202F08A914DC4E23A3A9497FA623B64" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F5629B05833D38DB7C4B9497FA4E7D48" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5F045A87E50C459289239497FA942EAC" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2015Q4" decimals="-3" id="Fact-3C068B6107109110D96D94B27688A75A" unitRef="usd">7919000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-3359DD27754BAFF9778694B2767C4C60" unitRef="usd">5538000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2015Q4" decimals="-3" id="Fact-D5CD51D9C538F17590B894B14E9326F3" unitRef="usd">7420000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2016Q4" decimals="-3" id="Fact-B673D1EA793613CA537C4D46361D13FC" unitRef="usd">5279000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2015Q4" decimals="-3" id="Fact-A0CD43BCC1BAB6ED3B5694B3343F53B8" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-8E12E29F9E483F73851494B334412B74" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="FI2015Q4" decimals="-3" id="Fact-2F38C75449CB4B44DE1494B08912A8DE" unitRef="usd">388000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="FI2016Q4" decimals="-3" id="Fact-541137BA5E5137175EA94D4636316A93" unitRef="usd">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2015Q4" decimals="-3" id="Fact-B723FF6300806B577C6194B1B8F1C10B" unitRef="usd">111000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2016Q4" decimals="-3" id="Fact-5E2256132DA31855F19D4D46362A1E8E" unitRef="usd">259000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-5" id="Fact-00C9D08B1574896002864DE13525AC5A" unitRef="usd">7900000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-4D72AEB72F3A76796A5194B2D52801CA" unitRef="usd">7919000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-5" id="Fact-BEEFE26D300D86B0BEA74DE215FE87DC" unitRef="usd">5500000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-A0A464A61CC197F5C5224D4636242411" unitRef="usd">5538000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DepreciationAndAmortization contextRef="FD2014Q4YTD" decimals="-5" id="Fact-309A846142273999CE918FEF92264341" unitRef="usd">200000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2014Q4YTD" decimals="-3" id="Fact-03ECA747FF92AC07319A38E8E7E207B4" unitRef="usd">166000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B29A14D95685454A4A7C8FB7C190DA97" unitRef="usd">167000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0E778EC620E8CD4D259CF587DB08F0E5" unitRef="usd">200000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8C049515E60700DB318B8FEE6BD4B880" unitRef="usd">200000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2016Q4YTD" decimals="-3" id="Fact-14B03F36228EFE75B46F8FB7C192FF9B" unitRef="usd">192000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-9B238190B9B3757A2C7A8F952B39AEC7" unitRef="usd">332000</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6F09CCCD74CDEE859D138F952B39169D" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DueFromJointVentures contextRef="I2016Q2May4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-5" id="Fact-C47AB2F2BFD8DE654BA14E010A22DB79" unitRef="usd">1300000</us-gaap:DueFromJointVentures>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-2A76508056F23CAE92FA8F9427FAA4B6" unitRef="usd">636000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-D7CCB71F96A9374221768F9427FA92E1" unitRef="usd">515000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-6645B9556484342AFEDC8FB2F81FFDDF" unitRef="usdPerShare">-18.61</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q1QTD" decimals="2" id="Fact-00981534AC32CE99E9ADF5899C97C133" unitRef="usdPerShare">-3.74</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q2QTD" decimals="2" id="Fact-6265F2597E31172A52A5F5899C58B91D" unitRef="usdPerShare">-8.75</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q3QTD" decimals="2" id="Fact-7EBBEB473ABD6EE07123F5899CF5154F" unitRef="usdPerShare">-6.21</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4QTD" decimals="2" id="Fact-53407AD7A42B3D77CE04F5899C0B6251" unitRef="usdPerShare">-8.42</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-60FAB743A9DD5545984A8FB2F822454B" unitRef="usdPerShare">-27.14</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-939C0EBF922EEF8255B6F5899C4901B2" unitRef="usdPerShare">-6.22</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-2E99E152E30B40D0381AF5899C40C55F" unitRef="usdPerShare">-7.15</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-0B949AA81A5EA55C882AF5899C77B1FC" unitRef="usdPerShare">-5.46</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-AD2000CC8C30B01BE50CF5899C413D0E" unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-217C5834AEDAA68F75AF8FB2F821E5CE" unitRef="usdPerShare">-4.85</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2A1364BC415D2FCD386938E8FC928502" unitRef="usd">12000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="-3" id="Fact-080A9AABAE4FDD6F6C1A8FBF1B7A66C9" unitRef="usd">7000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q4YTD" decimals="-3" id="Fact-186CE3E9F795FDC7131D8FBF1B82E9B2" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-0E12CE8E823CF30019888F94BD338AF5" unitRef="usd">1250000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-44BD03202E94C5670BF08F94BD33385F" unitRef="usd">2497000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q4" decimals="-5" id="Fact-D76F498C09DCA53E72FCD2CFF832A891" unitRef="usd">5100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2016Q4YTD" id="Fact-6E7A37C29B3F0AD0F5E0D2D02CBBB092">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0CCCE7EB94EB9E49FFB98FB291F1EB08" unitRef="usd">-167000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4B2939AFA981FE7C1B328FB291F53D7D" unitRef="usd">34000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-70CA77772031922DB6898FB291F398F7" unitRef="usd">466000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2016Q4Oct12" decimals="INF" id="Fact-C3EBC9DA2E821D599CCED2DDCB07AB4F" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-D89C386056FFF265DE5194368C9AB005" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2016Q4Oct12" id="Fact-F6B24B032BF221B2D675943D79DE333E">P2Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-B2E13EFFBE55DBEC10AC699D9C45A960">P7Y11M16D</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-695A0C690D4F686A2376943D79E315C3">P8Y9M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-1A9E16B445A98A1888C5943D79F5D1AF">P3Y1M24D</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-5931ABD66B0ADBFE8F7938FC9AD50B9F" unitRef="number">0.6236</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-C6830869D80C75C9B3E438FC99D5218A" unitRef="number">0.5342</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-8151DEDA31912E4D13D2943D6461547C" unitRef="number">0.7066</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-6406E7F31DA3615E69FD943D644A5521" unitRef="number">0.6676</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-79F3DF904484BF869A3E38FDD0314224" unitRef="number">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-AA2715D9A23C38E4EB9038FDCF4381AD" unitRef="number">0.0090</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-9E5A92662DB32FA50724943D4384F329" unitRef="number">0.0206</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-749E443B80CC72207F8C943D4363AA71" unitRef="number">0.0128</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EC5F73DB02FC039A4470D2DDD2004E03" unitRef="usd">207000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1A55F5F2E43991784F56D2DDD1FE2613" unitRef="usd">34000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q4YTD" decimals="-3" id="Fact-16EF605219875EC2825DD2DDD2034069" unitRef="usd">466000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9328DB253B1EAF27A2CCD2DDD207805F" unitRef="usd">242000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C0FE94656DBF4D79DC544E1F3A3D30E5" unitRef="usd">591000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2014Q4" decimals="-3" id="Fact-02190D8B03D3EFE345FDD2DDD205881D" unitRef="usd">56000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2015Q4" decimals="-3" id="Fact-713015520D7B98A8A1BAD2DDD206D14F" unitRef="usd">332000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4" decimals="-3" id="Fact-7B8D701AFDE1F0FB6D7ED2DDD2021DC6" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GainLossOnDispositionOfAssets1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-686F1766A75182F07FF438E8E932979E" unitRef="usd">-5000</us-gaap:GainLossOnDispositionOfAssets1>
	<us-gaap:GainLossOnDispositionOfAssets1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5CD08B0D4846684A86E78FB7E910C591" unitRef="usd">-19000</us-gaap:GainLossOnDispositionOfAssets1>
	<us-gaap:GainLossOnDispositionOfAssets1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2DFD7960404A163A37548FB7E90F8AEB" unitRef="usd">-13000</us-gaap:GainLossOnDispositionOfAssets1>
	<us-gaap:GrossProfit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-ED4BD026D8D471A582B58FB0151DBE74" unitRef="usd">627000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q1QTD" decimals="-3" id="Fact-A5C40689CD493D37D590F5899C33A6E8" unitRef="usd">331000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q2QTD" decimals="-3" id="Fact-4AE0D8E42D1449A935FFF5899C0BB320" unitRef="usd">427000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q3QTD" decimals="-3" id="Fact-D044176E94AFE8935C17F5899CD55119" unitRef="usd">449000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q4QTD" decimals="-3" id="Fact-227D82E58FFB3386D059F5899CB65F1A" unitRef="usd">329000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E1BEF987041A51D04A6D8FB01508FC44" unitRef="usd">1536000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q1QTD" decimals="-3" id="Fact-87A16B6D115346310D95F5899CF50CEB" unitRef="usd">447000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q2QTD" decimals="-3" id="Fact-3CCEE1ABBA3D3C2EBAD7F5899C58283B" unitRef="usd">107000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q3QTD" decimals="-3" id="Fact-10C461D521DBAFFBF6A3F5899C877D84" unitRef="usd">129000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q4QTD" decimals="-3" id="Fact-CA9BAED8A126DD42A26DF5899CA69639" unitRef="usd">-99000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4F28FD83AF3C7C90D1048FB01515C039" unitRef="usd">584000</us-gaap:GrossProfit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6F63DF3A950F9F0709A8949A514CD488" unitRef="usd">16000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8B520D6E670F83D5BA71949A51560045" unitRef="usd">-13000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E7368F725DDC01A8F1DF4D462A8EB31A" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2014Q4YTD" decimals="-3" id="Fact-71CE9B4A7F446906726594A87A350D34" unitRef="usd">3364000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B019682453ED99E3448794A87A394D9C" unitRef="usd">5291000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6C095341DC1EF79B7FD64D46305BD2E4" unitRef="usd">6961000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6C67ABFE60FF05EC0A6394A92871559F" unitRef="usd">14000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7DF567A5444E281E77C194A9286C7249" unitRef="usd">-15000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F6AB9EE94510390C7F264D463063F881" unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A59A8E67302179B874E394A64E17B4F0" unitRef="usd">-3363000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-67333F24D6CF08FB16E794A64E03EDAB" unitRef="usd">-5290000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8933FC1887FDF55690004D463054B78B" unitRef="usd">-6959000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q4YTD" decimals="-3" id="Fact-AAE89DC522EFA0388FF294A7F02E66AC" unitRef="usd">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2DD6457F3363BC52C11994A7F03C1811" unitRef="usd">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="-3" id="Fact-14CBF6653D7D040B65BB4D463061B83B" unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxesPaid contextRef="FD2014Q4YTD" decimals="-3" id="Fact-AD8CC368AF9D3A7B483B38E9004C6121" unitRef="usd">1000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F3B5DE64F7CC656A45948FC39BDE925E" unitRef="usd">2000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BD7CBAB898CAB0DDCA2F8FC39BE1EAC7" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6B30718C67C35412DED638E8EEEBF0ED" unitRef="usd">-33000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DC446055335D24179FB78FB9F302FC5C" unitRef="usd">370000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5AEE4A1EB7AAF81A3C808FB9F301A66A" unitRef="usd">46000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1C02C92D3CB0EA9FA64E38E8EC569B34" unitRef="usd">-83000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0E2680C410ED0D92B10C8FBA4411F8DC" unitRef="usd">-96000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-476F59EBE3BA24F3D15A8FBA440FF768" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C9E941010AB431C16DA338E8ECF1F712" unitRef="usd">-4000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C1DC49829382B24AF5728FBA347A19A7" unitRef="usd">481000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2016Q4YTD" decimals="-3" id="Fact-069EE8FE378AC088A9FF8FBA347848A5" unitRef="usd">-121000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A858A0205C306CB6C3D138E8F1806727" unitRef="usd">0</us-gaap:IncreaseDecreaseInDueToRelatedParties>
	<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="FD2015Q4YTD" decimals="-3" id="Fact-52EB6556CCA7D82564F68FB9AC83664E" unitRef="usd">1283000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
	<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="FD2016Q4YTD" decimals="-3" id="Fact-18FCB5888D34771697008FB9AC8572C6" unitRef="usd">0</us-gaap:IncreaseDecreaseInDueToRelatedParties>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6A9409A03FB21431C4BC38E8EF91158E" unitRef="usd">33000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F5B0B78D5F8CE3A6162A8FB9E234F6B0" unitRef="usd">1018000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DA0D827172820652822D8FB9E237EAAD" unitRef="usd">1247000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9F7F73019288C479EF9538E8ED9DF43F" unitRef="usd">166000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F5C04C679B286E2E82608FBA18F69768" unitRef="usd">-77000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q4YTD" decimals="-3" id="Fact-ED53CE7ADA563EDD16548FBA18EE8E51" unitRef="usd">464000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-01DE523C576E1552472538E8EE4B1A64" unitRef="usd">109000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-49A9080C5687BD61E5D78FBA07B9C3D7" unitRef="usd">-27000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3A4BDBDDB050961563F98FBA07B16324" unitRef="usd">985000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B7344F79BC941EEC6A9238E8F0D9EA29" unitRef="usd">6000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C4D6D75EA480CEA2FB788FB9BD5DDF82" unitRef="usd">111000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-24354A6142A79CB2F2908FB9BD64937D" unitRef="usd">517000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F0F33087E2380890EACF8FB27C764450" unitRef="usd">-220000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7B70D768935F70576F578FB27C737F96" unitRef="usd">-549000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7C4F7F1FAF913B5B52628FB27C78AEBF" unitRef="usd">-477000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestPaid contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DCEA75609D6E416A845D38E8FFA96736" unitRef="usd">164000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-88CB46B4412AEF6CF55F8FBE187B1042" unitRef="usd">475000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3F5787B7612D2A209B408FBE18793CE7" unitRef="usd">527000</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-26A01164A70AC1B6D64C8FF10B5AAF57" unitRef="usd">44000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9746EEA68152A999B56B8FF10B619F23" unitRef="usd">44000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestReceivableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-1C6FF010AECA901132308FEBF8B81680" unitRef="usd">25000</us-gaap:InterestReceivableCurrent>
	<us-gaap:InterestReceivableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F7A4122A292958224D3C8FEBF8BADFB1" unitRef="usd">5000</us-gaap:InterestReceivableCurrent>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2015Q4" decimals="-3" id="Fact-09971D1EC7AEB8D37DB98FEACB0DB91A" unitRef="usd">7000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q4" decimals="-3" id="Fact-11B0F840B5A94C987ABB8FEACB0B2624" unitRef="usd">209000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2015Q4" decimals="-3" id="Fact-D4C69501608462A150078F9439FBC5EC" unitRef="usd">363000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-3" id="Fact-CA3219DD70428DC690B18F943A0573F7" unitRef="usd">827000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2015Q4" decimals="-3" id="Fact-5B6FF576E95C7B7D02108FEA8DF6849A" unitRef="usd">235000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q4" decimals="-3" id="Fact-B4B583412A6A33430D828FEA9E542967" unitRef="usd">379000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2015Q4" decimals="-3" id="Fact-1469675516A5BF6C423D8FEAB8D466B6" unitRef="usd">121000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q4" decimals="-3" id="Fact-7109649328B94D426B618FEAB8D2E48A" unitRef="usd">239000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2016Q4_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-57D86120AE6FABC493844DC182F947F8" unitRef="shares">16558</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-C0A56689CB436ABB97FB8F95694F3D9F" unitRef="usd">14661000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-50EC4EF26AC79B6EEC638F9569457C63" unitRef="usd">14473000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-9BC39D612CBB547DA4AD8F96E54311D1" unitRef="usd">14221000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-60E59DF7468CB542E2D48F96E543B6E7" unitRef="usd">78778000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-35F6F5DFF04A011975248F953EA1864E" unitRef="usd">5567000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-DD30B9FAE303863C2BCB8F953EA1FAE7" unitRef="usd">4592000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4" decimals="-3" id="Fact-5B4CD47A60BB25FBFFB69446DA63952A" unitRef="usd">332000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-55FFD81F2DA6E69D003D9446DA568527" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember" decimals="-3" id="Fact-A5470D48CA364FB5EC8C9446DA4C9485" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-7FA21AD1FB865AA1B7999446DA5B8D3D" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember" decimals="-3" id="Fact-9004CDF9AB6257383F619446DA5E4A2F" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-460B3F56B2AA527FACAF9446DA47CBD9" unitRef="usd">332000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember" decimals="-3" id="Fact-F5F40D7BB22C06722B859446DA51E3C9" unitRef="usd">332000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_obln_WarrantLiabilityMember" decimals="-3" id="Fact-BAE6C3ADD505328116509446DA4E5CA4" unitRef="usd">332000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LineOfCredit contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanAMember" decimals="-5" id="Fact-F1E0A5DAE57025B2735FCD7D9753D48D" unitRef="usd">3000000</us-gaap:LineOfCredit>
	<us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet contextRef="D2014Q4Oct1-31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanAMember" decimals="-5" id="Fact-02C07EAD45C03C04225ECD7DCCB880ED" unitRef="usd">2000000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2013Q2_us-gaap_DebtInstrumentAxis_obln_TwoThousandThirteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="-5" id="Fact-D1A788370CF21D53A859CD768ACFADFB" unitRef="usd">3000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="-5" id="Fact-A4F85C9D18ECCD872D56CD78B254526A" unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanAMember" decimals="-5" id="Fact-7DE0CDE6C00572EFEF74CD7B9CE12AF3" unitRef="usd">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2014Q4Oct31_us-gaap_DebtInstrumentAxis_obln_TwoThousandFourteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_TermLoanBMember" decimals="-5" id="Fact-373370B34A040640486CCD7F6A82BD60" unitRef="usd">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-293C122CE775B46C8A6DCD8BC31CB90C" unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_FirstTrancheMember" decimals="INF" id="Fact-80992FF9C6C2B368332ACD90B4D2512C" unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember" decimals="INF" id="Fact-D7EB6639D4240EA03E8B6A0BCCC5899E" unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_FirstTrancheMember" decimals="INF" id="Fact-F3085BF4ACA0DDBE407F6A0BE747AEDE" unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="I2016Q3Sept7_us-gaap_DebtInstrumentAxis_obln_SeptemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_SecondTrancheMember" decimals="-5" id="Fact-B5DF32678E450171D51DCD910F11910D" unitRef="usd">5000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="I2016Q4Dec21_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember_us-gaap_LineOfCreditFacilityAxis_obln_PacificWesternBankMember_us-gaap_LongtermDebtTypeAxis_obln_SecondTrancheMember" decimals="-5" id="Fact-E7064E68172E7B6F55756A0C0100F86F" unitRef="usd">5000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2016Q4" decimals="-3" id="Fact-D78F502D2528AB96E5B6D2F2FD2C61D4" unitRef="usd">9881000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember" decimals="-3" id="Fact-EF9DC9504A824AF9887BD2F2F8945AC3" unitRef="usd">10000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-69513EC6727E20F639C48F951905ED19" unitRef="usd">747000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-75773868D75FEB9756428F951905D811" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember" decimals="-3" id="Fact-428D62AA55DE67BEE206F5A48C24D455" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember" decimals="-3" id="Fact-1FEC8EBDD72786A982C2D2F2F88347EF" unitRef="usd">4000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember" decimals="-3" id="Fact-F070BABCA2FAD09D0311D2F2F896260F" unitRef="usd">4000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember" decimals="-3" id="Fact-B953282322082059E84AD2F2F89212A1" unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_obln_DecemberTwoThousandSixteenLoanAgreementMember" decimals="-3" id="Fact-ABFDDCCD4F0AC66D4800D2F2F8957A7D" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-FF84A1BDA6F60CF4B3918F954EB84563" unitRef="usd">9094000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BEFD6B992BEFB3F7D7B48F954EB8BBEE" unitRef="usd">9881000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-158A0A0C907C7F0A900538E8FBF11C06" unitRef="usd">22188000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-88C2A9A2A507F240539E8FBFA576DD99" unitRef="usd">5062000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-33481AF2B560BCB163FD8FBFA588F4FA" unitRef="usd">82786000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D302AF47985DF404333A38E8F68425E5" unitRef="usd">-7918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DF90097B1C99323834078FBC7DFE4446" unitRef="usd">2777000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BB8E1BE373D2EA3E99A58FBC7E008922" unitRef="usd">6201000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D217E352CBDD0184D59F38E8F22EE406" unitRef="usd">-9907000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8947B8A91B76FE9962078FB97CD916A8" unitRef="usd">-11392000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-ED35B8EF9A7C5C5C5D928FB97CD794DB" unitRef="usd">-19368000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F10DAE2594EC873E7EBB8FB2B7EADDEE" unitRef="usd">-9890000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-56E26F210B84C3C6ABA5BDF9304E6556" unitRef="usd">-9890000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1QTD" decimals="-3" id="Fact-19EE761DF68EC989746EF5899CF5D0E1" unitRef="usd">-2133000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-717ACD125911E3A5AEF5F5899C77D824" unitRef="usd">-5024000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-574C0D8C63A42C133AA9F5899C49246A" unitRef="usd">-3562000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4QTD" decimals="-3" id="Fact-255087E8D819AD407B55F5899BEC8E48" unitRef="usd">-4838000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FBDE88E924A9C97C22348FB2B7E8C477" unitRef="usd">-15557000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-F804645153C2687F6E9E94EFECB7874B" unitRef="usd">-15557000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-767C748AE29911913A3FF5899C3992FF" unitRef="usd">-3581000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-D4C85EBDB725F2C5AFABF5899D1464A1" unitRef="usd">-4131000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-D63D47E0AE0FAF5AFF86F5899CE5172F" unitRef="usd">-5260000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-55C774FDDF1C579212C5F5899D058D80" unitRef="usd">-7495000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-13DB907AA84DBBBBEB388FB2B7E56BFD" unitRef="usd">-20467000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-57FB3A7C71F8140EB4A795009DA68F50" unitRef="usd">-20467000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2016Q4YTD" decimals="INF" id="Fact-D1337CD7A9AA6B58B3E1BE2F5619B2C8" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-66FF1B7DC0B45535941B8FB0538511B8" unitRef="usd">10467000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7428F54FC575213EB1948FB05384680B" unitRef="usd">16469000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BC74947AE99C1000AFFC8FB053888397" unitRef="usd">20089000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-FA700BD4B2FF0B8A34588FB2679F3A5F" unitRef="usd">-9840000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q1QTD" decimals="-3" id="Fact-A68F6CA2B8B053BDD4DBF5899D050753" unitRef="usd">-2020000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-FEC86EA7967A82618598F5899C6849D0" unitRef="usd">-4869000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-D30472087E017E64826AF5899CA61BDC" unitRef="usd">-3370000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4QTD" decimals="-3" id="Fact-031CF510120EE1A7A85CF5899CD580CB" unitRef="usd">-4674000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1581C7C1EA4CC7ACC2298FB267BC869F" unitRef="usd">-14933000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-AAD50945643F3B21D22EF5899CB6E755" unitRef="usd">-3444000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-98415B7BF6C84A7D456EF5899D14C2F1" unitRef="usd">-4075000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-2DE5074BC07FF97B2739F5899C975862" unitRef="usd">-4452000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-B4479AA56943AB5D8C2CF5899CF5A7DA" unitRef="usd">-7534000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CA25CF1BEE900D163BC38FB267B48310" unitRef="usd">-19505000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2016Q4" decimals="-3" id="Fact-CE8D8E7B4AC3EEE38BFA8FF4373FEE85" unitRef="usd">745000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2016Q4" decimals="-3" id="Fact-0D7351E292D2C2D1A4DE4D5F13E91A21" unitRef="usd">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2016Q4" decimals="-3" id="Fact-8E19DE04CF87C8F7AAAAD20853D45AD9" unitRef="usd">397000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2016Q4" decimals="-3" id="Fact-6DD88DF47486B2D4A6B6D20853D94243" unitRef="usd">248000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0E81CB6AF0B86BE20072F5B5DA288CBA" unitRef="usd">200000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2B07C1E576CD4CA243E062469D3C002A" unitRef="usd">200000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C395C763C99C8738CBABD208C023FB5F" unitRef="usd">300000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-0E0EB8BCEDE7774708C64DE2963F443E" unitRef="usd">58700000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="1" id="Fact-8A7DA4EA3F4996275F464DE32347927C" unitRef="usd">14400000.0</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="FI2016Q4" decimals="-5" id="Fact-94987F5DB7B25AB241534DED995A405A" unitRef="usd">20800000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-27586F8D8590A47E3A6D8FF0F36B1982" unitRef="usd">92000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-01F54E0E7D115E37BFBC8FF0F36A5D6B" unitRef="usd">742000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-AE191E8CCBEC557B68CE8F944BFC09EB" unitRef="usd">273000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4A26B6047191DEC934CE8F944BFC3779" unitRef="usd">1244000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsMiscellaneousCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-B503675B63E5503221358FEC0972A2A8" unitRef="usd">14000</us-gaap:OtherAssetsMiscellaneousCurrent>
	<us-gaap:OtherAssetsMiscellaneousCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-41B6D177BEDBE29F63E08FEC0973595E" unitRef="usd">277000</us-gaap:OtherAssetsMiscellaneousCurrent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CC0BA8C40DDAFF328DFB8FB2CE36A771" unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-055CDAEB08F507C40F1295028F1F6D05" unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D9311CBB84C1777AED188FB2CE343341" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-33A7A859D592D878ED4595028F1D2C26" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B8899A88C41B0B1548CC8FB2CE3107D8" unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-D2C58F39B9EEF2621E2295028F1C1242" unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-993FF9E3AC0509A655268F94E7D7669E" unitRef="usd">493000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-033F38C13CC8A0ABAAC58F94E7D7899B" unitRef="usd">1399000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A9E1DFACCC9D091398BF8FB2A70DF12C" unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-855C88A1593B8DF61CA08FB2A722542D" unitRef="usd">-41000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-650CE5CF69C44686BACA8FB2A715631C" unitRef="usd">-19000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsOfDebtRestructuringCosts contextRef="FD2014Q4YTD" decimals="-3" id="Fact-ED6DE0DD085B91C4402438E8FA19731E" unitRef="usd">0</us-gaap:PaymentsOfDebtRestructuringCosts>
	<us-gaap:PaymentsOfDebtRestructuringCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-100B7FA1C293F05C0356BE165ED61EC9" unitRef="usd">0</us-gaap:PaymentsOfDebtRestructuringCosts>
	<us-gaap:PaymentsOfDebtRestructuringCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3348EE3BFBB992F5B4DDBE165ED4D59D" unitRef="usd">30000</us-gaap:PaymentsOfDebtRestructuringCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-5" id="Fact-9335E741398B483A41C9D1CAF5178656" unitRef="usd">100000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A4E31E027D2E763EC8B238E8F5363F78" unitRef="usd">268000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D1AFDD919C13B4E8B6E28FBC6C196B5A" unitRef="usd">139000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-055DED0009C7431125848FBC6C20B2CC" unitRef="usd">352000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-035CF8B70DE14C9C199738E8F3428CBF" unitRef="usd">12400000</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-23A5B0542052AD6C05578FBC32768D19" unitRef="usd">18590000</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CB9474220F501DE9BB258FBC3278C4E2" unitRef="usd">18897000</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2016Q4Oct12" decimals="INF" id="Fact-4AC7BA18B7599FABF3354E29CF4F0C76" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-57DE19B749B826126EA08FEBE63A21D9" unitRef="usd">234000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6E75CEBF4A14175F9FA38FEBE63B0A55" unitRef="usd">962000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2016Q4Oct5_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-C51B247565FB1C50E08BBE4702858C0C" unitRef="usd">67200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2014Q4YTD" decimals="-3" id="Fact-23E9CB4251FA5564A92338E8F8D280E2" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C1C9EC9C34C90FB84F4EBE19BACD69BF" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B051ED1658CB93F76DFABE19BACB3F31" unitRef="usd">67233000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-EE3274F7FF22ECF8C41E38E8F98DC6D8" unitRef="usd">4958000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6DA0DE0C0E61DA05951C8FC090E13551" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3F3D6C0D396E441756018FC090E3E641" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2014Q4YTD" decimals="-3" id="Fact-08DE8C0DFC96E31C3AE238E8F7AF00B9" unitRef="usd">13622000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-490A3C04B370CBF91DB58FC0538065F6" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A0BDD650598A6C211DC98FC0538DCD0E" unitRef="usd">14517000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-5" id="Fact-9C07AE412B3CCC17358FD1CAE19032B8" unitRef="usd">15800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2014Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-5" id="Fact-12FCB1ADF497C6578D0B9480E3B05159" unitRef="usd">1900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-5" id="Fact-04699B9218B1C97F8B779480FCA4BDEA" unitRef="usd">3800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2016Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-5" id="Fact-7A09B70CFFDCE3ACA7436362D9B0EAE4" unitRef="usd">3400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-713C54C87AE3FDA45F8238E8F3FAA620" unitRef="usd">4250000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7A4EC59C74EB34830FFD8FBC43155E1A" unitRef="usd">21500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-89E406EC5EBB602233A68FBC43212065" unitRef="usd">25450000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-237F7D4CD5051675C12538E8F5E4BAA7" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A876DA95D2C784896109BE0F3FB594FA" unitRef="usd">6000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2206D6115625E10E3FE0BE0F3FB26666" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CE285A73918E8BA6856638E8F48F05D2" unitRef="usd">500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
	<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-556B1AA26191466F330DBE0CEBDEC4E0" unitRef="usd">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
	<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-059E0DF2B918151DD5F9BE0CEBE02D5D" unitRef="usd">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-FD4B115C4D75BFAD36A338E8FB47BB53" unitRef="usd">8000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E9F698F47BA4E9695F558FC0C24FD419" unitRef="usd">62000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AB28698F3F0A00F39FBB8FC0C25BD1E3" unitRef="usd">1066000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-CEAE27975CE71E7F2FDD8FECDA9A0A04" unitRef="usd">1312000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_obln_ScientificEquipmentMember" decimals="-3" id="Fact-8B430759F7C5DBA7892C8FECDC37C89C" unitRef="usd">770000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-CF1531159FAF955160928FECDE099720" unitRef="usd">255000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-A374F59CFBDC89F1FF168FECD9A9DEAC" unitRef="usd">24000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-461D6CACF9E6E9ECC60B8FECDA0E62BE" unitRef="usd">82000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-F24EEA536E477A021B8F8FECDE28BE10" unitRef="usd">181000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-26C1D12CEB058C4F7DE58FECD916FCBE" unitRef="usd">1801000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_obln_ScientificEquipmentMember" decimals="-3" id="Fact-8CD2D1DEB18727CA685E8FECD9605CA0" unitRef="usd">854000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-9494FB2EB2A6528FC2968FECD92D8CE3" unitRef="usd">334000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-3613BAB29645C8F144688FECDB52AA90" unitRef="usd">302000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-936665BA8FF2F220E5288FECDC57C6CB" unitRef="usd">118000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-74F32C2B5F0F6889BABF8FECD90A030F" unitRef="usd">193000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-2DCECF4D8521FCF3F66B8F947584A2DA" unitRef="usd">418000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-98120F5B18627F6B55CB8F947584F693" unitRef="usd">717000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-0187CF6C0AB2A70088ECD2694E19C94D">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-2C120C545DD64CD6AD85D2694E2274A5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-034513C581E17BC9F202D2694E142DF6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" id="Fact-08C9F286777C5789B9FDD2694E1E4AE3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RelatedPartyDepositLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-B8F3F51EA897F20D21578F95006B90C4" unitRef="usd">1283000</us-gaap:RelatedPartyDepositLiabilities>
	<us-gaap:RelatedPartyDepositLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-170D48F1EDF487F991698F95006191CD" unitRef="usd">0</us-gaap:RelatedPartyDepositLiabilities>
	<us-gaap:RelatedPartyDepositLiabilities contextRef="I2015Q1Jan31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember" decimals="-5" id="Fact-EDA23D450CB06788098C9452FF29268D" unitRef="usd">1300000</us-gaap:RelatedPartyDepositLiabilities>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E86AA852E08DBFC92B3538EBBFE16390" unitRef="usd">3000000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-64BFF715A95CDB2E126638EBBFEB8C81" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6A9071B6B8B42093497338EBBFE1E1DA" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BB6EAD30FE7BA51CFA3C8FB02B295C38" unitRef="usd">5767000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4678778D795134381A9A8FB02B3EE8B3" unitRef="usd">12978000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3FB2E678E1BA9BFF69688FB02B365219" unitRef="usd">9872000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-3" id="Fact-2C5F07EE4553F9F372B38F96C3DBC76B" unitRef="usd">-56142000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-A2D9298E784D6A812E178F96C3D1CCBE" unitRef="usd">-76609000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-5" id="Fact-3D57CECC966F5AFA4E4663623196943A" unitRef="usd">-76600000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2014Q4YTD" decimals="-3" id="Fact-11A297C7DF49B304D4D68FAFA4683AD7" unitRef="usd">1856000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2015Q4YTD" decimals="-3" id="Fact-61DF7070327A7D597A918FAFA4709107" unitRef="usd">3823000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2B350ECEB34DDBDAEF3B8FAFA46C8106" unitRef="usd">3393000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:Revenues contextRef="FD2014Q4YTD" decimals="-5" id="Fact-BB3000992DCAB4DCF3BABE2AB86D2840" unitRef="usd">3500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BD049998CB1856E5EF788FAFB5844A7B" unitRef="usd">3539000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q1QTD" decimals="-3" id="Fact-4923688D3C59C462F448F5899CE5E5D3" unitRef="usd">911000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q2QTD" decimals="-3" id="Fact-AECEC11306AD46ADB1FCF5899C2CEE07" unitRef="usd">1052000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-3" id="Fact-A10C681519E8BF9A5F95F5899CD5ECD2" unitRef="usd">1093000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4QTD" decimals="-3" id="Fact-4E4567B7F1CF8662E56AF5899C49CD9B" unitRef="usd">983000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-28A1C7A162AA4D3A41018FAFB586AA8E" unitRef="usd">4039000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2C329E10DDEE4686DB33BE2AB86A4F9A" unitRef="usd">4000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD" decimals="-3" id="Fact-529DB06C0B66AFB4DA5FF5899C77BA46" unitRef="usd">1069000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-3" id="Fact-91A0F48CA9C18EAF8097F5899C0B5F13" unitRef="usd">779000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-3" id="Fact-3D140EEDBED03F45C304F5899C870772" unitRef="usd">773000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4QTD" decimals="-3" id="Fact-EBB3F79B416AE1B750D9F5899C1B4785" unitRef="usd">772000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0BE2E2F0424841F6340A671D8551D211" unitRef="usd">3400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9ACDF90CA9FEFC91D1A08FAFB58227D8" unitRef="usd">3393000</us-gaap:Revenues>
	<us-gaap:SaleOfStockPricePerShare contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="4" id="Fact-2F8DB7C39EA534F4E299953B85F59DEC" unitRef="usdPerShare">7.5351</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="4" id="Fact-FF30953626A10554FBA9624F5F0C5699" unitRef="usdPerShare">8.2932</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SalesRevenueServicesNet contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D83DB59EF5552B5EAF748FAF917EEB61" unitRef="usd">1683000</us-gaap:SalesRevenueServicesNet>
	<us-gaap:SalesRevenueServicesNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8046512ADE971EE0DBB18FAF91905400" unitRef="usd">216000</us-gaap:SalesRevenueServicesNet>
	<us-gaap:SalesRevenueServicesNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3958DE6E17B21453B60F8FAF9198E004" unitRef="usd">0</us-gaap:SalesRevenueServicesNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-3C8E6D1F12F8F3A054E28FB0414B8E00" unitRef="usd">4700000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D27B7DD20A4B7C3CBE358FB04148AA7D" unitRef="usd">3491000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7ED5990536C9715CDB248FB0414E17A6" unitRef="usd">10217000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-84A74101FCA9AB2674F738E8E8846D6B" unitRef="usd">185000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-873C873535916FF5227093FE04208F6E" unitRef="usd">30000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3661D66BA1BF06BD4DB193FE045BDF55" unitRef="usd">45000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-F5FA19754F562F6A105093FE044080EE" unitRef="usd">110000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-58BED12D3E29F0B6CC398FB7D345803B" unitRef="usd">207000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-2D0CE68BB999EA0780BF93FE03583C4B" unitRef="usd">31000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-D020A9DC4302B7577E4D93FE034E6DA2" unitRef="usd">47000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-66758A22987248B1789093FE0362A929" unitRef="usd">129000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F793B17AC3AEC438B9E18FB7D3471945" unitRef="usd">563000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-C618B5A04B13D6E242D5D2CC3704E7DF" unitRef="usd">46000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-BD663EE5031433773602D2CC3712946A" unitRef="usd">115000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-7D7E1E334846CCFAFDE6D2CC3713F9DF" unitRef="usd">402000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember" id="Fact-761E0E74B7E7A00D7101D171429CB7A7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-ABDE6DC1E03A852279CB93EE11E8B7FD" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-B550F60181BC1E50E75193EE05D410C0" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-28D83701705315656F44D2CC3C14DDCF" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD" decimals="4" id="Fact-AE6AABBA134780D3EE2B93EDE1848289" unitRef="number">0.7109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD" decimals="4" id="Fact-6C1037BDB6AB8EA500C093EDD3F72937" unitRef="number">0.6153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-14E3AD590520CCF1F067F59DA41433F4" unitRef="number">0.5349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-D8A8EBC299CCFA169D54F59DA32A6936" unitRef="number">0.5291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-CB0DCCFFBDB287095E1193FA66113722" unitRef="number">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-48FADA65E8C67BFC683393FA64C685AF" unitRef="number">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD" decimals="4" id="Fact-B3950F3B2A9DD0DB6F83D48C4D7DC31F" unitRef="number">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-7F54C3C5BEB2E35B0592F59EAC3F3D1E" unitRef="number">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-FA1E34257DBC2746C5CCF59E8A838FD6" unitRef="number">0.0140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9602BF4694A17DDAB4C5D2CE5B47676E" unitRef="usd">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD" decimals="INF" id="Fact-7A917EDB1A49049A00FAD2CC46AE5537" unitRef="shares">51816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2017Q1Feb24_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-E1AD4F45FC716FE270DF4DB55956AD49" unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD" decimals="INF" id="Fact-5BD05CBF1627ADE391FFD2CC46BA654F" unitRef="shares">1787517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-8916F722D7E6D070B99BD2CE91471AB4" unitRef="usdPerShare">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-3DEAA010EF9CBEC61665D2CC46ADE325" unitRef="usd">8560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-1250C2D797665D523C384E604CEE8E56" unitRef="shares">1298868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-D9823AE9136EFC16FE3E94066569FE7C" unitRef="usdPerShare">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-DE2B8E16D0D1F37A1A2AD2CC46B1ABF0" unitRef="usdPerShare">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-66A0686A7E9DC4499A3ED2CC46BB8E2B" unitRef="usd">3368000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="FI2016Q4" decimals="INF" id="Fact-C18A278BD2A2307B2B49D2CC46C09B9C" unitRef="shares">485770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-4B1D9421AC66B9828FB8D2CC46B3CE78" unitRef="usdPerShare">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-1CCBD1E939DC9FAAAB43D2CC46B5F0B3" unitRef="usd">7792000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-7292E7380641F57FC968D2CC46AA0E66" unitRef="shares">1929465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-F9B51B8DAC26ECFFA296D2CC46C1985F" unitRef="usdPerShare">4.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-ED45243B3488793B1082D2CC46C33A57" unitRef="usdPerShare">1.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-C17E15AEB7E376603838D2CC46B241F0" unitRef="usdPerShare">3.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-18E3E187C02DA698970CD2CC46B61C0F" unitRef="usdPerShare">5.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOnePreferredStockMember" decimals="2" id="Fact-9935E5001B26522943B294362CAF13D6" unitRef="usdPerShare">2.24</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="2" id="Fact-FCC489646972FD990FBD94362C85B2F1" unitRef="usdPerShare">1.72</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="2" id="Fact-5478D6B8A218E1F95D2694362CC3C2FE" unitRef="usdPerShare">8.41</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q2May4_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-EA14702AC3105A8F14BBD1CCFC86502B" unitRef="usdPerShare">12.44</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_obln_SeriesCOnePreferredStockMember" decimals="2" id="Fact-72276F597D4E5BD6A56994362CA1755D" unitRef="usdPerShare">13.92</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="2" id="Fact-3C2661B64354C3EB426B94362C73F9B9" unitRef="usdPerShare">13.92</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q4Oct12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="2" id="Fact-624CFFFA93862029B64A94362C993044" unitRef="usdPerShare">13.92</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q4Oct5_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="2" id="Fact-CC6935E715737E4E3900BE457BAA35DE" unitRef="usdPerShare">15.00</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="D2016Q4Oct4_us-gaap_PlanNameAxis_obln_TwoThousandSixteenEquityIncentivePlanMember" decimals="2" id="Fact-EF5535CEB6DFE4F77415D17024DB751A" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q4YTD" id="Fact-36AC82C37F337ADC965493F01011AD7F">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD" id="Fact-46E506334D09DDAA841493F0101B397B">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD" id="Fact-5E380D355DE961B13A29D2CC3C1624C8">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-D4862C581BC69492AB25D2CC46BF1A09">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD" id="Fact-8F7CE5011A8ACA007989D2CC46BD8970">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD" id="Fact-0BC7FDDBE9E448B93901D2CC46A83DF3">P8Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="4" id="Fact-46AD4ACAA708F1ED35A9D1CA59394F0A" unitRef="usdPerShare">8.2932</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:ShortTermInvestments contextRef="FI2015Q4" decimals="-3" id="Fact-38D61616686A7135CBA68F940C0AAFBD" unitRef="usd">9175000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-ADBC3DCD4F0D26ED62748F940C00D194" unitRef="usd">2500000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssued1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-177ED3BA47500AB9C0634E573B32E521" unitRef="usd">0</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-981BC9A1D61591F3DF044E573AFE2D9C" unitRef="usd">0</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A5C942E35A2446F0F1464E573B2677CB" unitRef="usd">591000</us-gaap:StockIssued1>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-F8849387A11365BE334CD2AF3285C70C" unitRef="shares">-804595</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-F7E4D7843BB03237DD2BD2AF328E1FF4" unitRef="shares">-1494248</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-84C644C1621F5F0297F5D2AF32A21ED8" unitRef="shares">-2668533</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-72477F0D0A70D1DFE92AD2AF328A58F1" unitRef="shares">-480286</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-AE15FE30F0E70A7025F4D2AF32805E2F" unitRef="shares">-2732552</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-B83F69433D7292B40403D2AF32836DF0" unitRef="shares">-1916425</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-114C98EA61980A0542B3D291EB2EAF7D" unitRef="shares">10360419</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q4Oct5_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-1FC77E3EC3E51D8E44F6BE4601BBB6DB" unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-DC6055BAC63EF669CE6A9524938C6B06" unitRef="shares">2732552</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-BBEF370C58B2DB6B20239450DBA46443" unitRef="shares">875903</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-FE31A0D6644AA106411CD28E8F507161" unitRef="shares">1916425</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-CB90F8B0BB1C3C53E4A0D2A7060228C4" unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C158909827AE30E8844494F3B7BF54F0" unitRef="shares">4285</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5FA08603CCDB131EDB0E94F4A803BA6D" unitRef="shares">41642</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD" decimals="INF" id="Fact-2193288512098C31735AD2CC46B9BD21" unitRef="shares">808885</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-DE492B85E9145BFB202894F4D3D99542" unitRef="shares">808885</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-45D0F2DAC9A0F866F30AD2AB17C0B2BC" unitRef="usd">70498000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-6DAF67F909982B741955D2AD6FC824D3" unitRef="usd">-6773000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-824556A40E0BB85F08C1D2AD6FCB401B" unitRef="usd">-6454000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-B4ECB5EE8C592DDCCD0ED2AD6FC401E0" unitRef="usd">-16393000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-CB7D763D2426A0099E84D2AD6FC57E80" unitRef="usd">-4984000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-C835E6C429FAF45A95FED2AD70CB3804" unitRef="usd">-20095000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-CADECD2705118080D06BD2AD6FC1EACD" unitRef="usd">-15799000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2BD781C2846A38811B51D2AB17B2DB27" unitRef="usd">70488000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A41F88CD3487DF6CF217D2AB17D4A39B" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DED893E42FBE96C218B0D2A66FEE0DC4" unitRef="usd">67233000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-42862B9EFE1A7AA6480DD2A66FD82006" unitRef="usd">67228000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A06946D3F2E42D1B4CFAD2A66FEB059F" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CD93FC822DAC3D9AA49494F35287D30A" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-34B9EB50A8D660D6649194F352892252" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-40D1E71572FBC5486FA694F493F77C50" unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-65B3C0B87AD8822CF5D594F493CF0BD4" unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-58B8FF9CED8678688DE394F4E69F1818" unitRef="usd">820000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B06A9375B8F2CB8EE8DC94F4E69DADEA" unitRef="usd">819000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6CC67C53F014EBA75937D2860EB41248" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-60AB7D2E0844F8865B3A8F96D42D3678" unitRef="usd">-55139000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-4E2C2D1DDD1468DB3B018F96D42D7B28" unitRef="usd">64305000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4" decimals="-3" id="Fact-07221B045295BA006C1894EBC34C97A2" unitRef="usd">-30168000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-EBCD1C0195EEB426F3EE94EBC33E9984" unitRef="usd">-14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9740925F6EB9B0A9CDAB94EBC308D4F9" unitRef="usd">540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9F3B46D59D389873573394EBC32FAD8B" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-BD0C5DCE002B0F8C5F5B94EBC31C9B90" unitRef="usd">-30695000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-3" id="Fact-8A190CA653F2C7D9BEF294EEEB16946B" unitRef="usd">-39856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-FDA84E8BFD309831AE4394EEEB133B57" unitRef="usd">-5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-ED93156B02320920772994EEE7E03240" unitRef="usd">733000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8439B48BB7F8906F94B694EEE7E5807C" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-80B72D49DB913E718DBD94EEE7E3CA89" unitRef="usd">-40585000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-3" id="Fact-CEEC8464BA51F6EA464994EF326AF698" unitRef="usd">-55139000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-4F17201507D5C2A087A194EF326F569E" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A1C57A28A84FE3E8063D94EF326E43F3" unitRef="usd">1002000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C5E9FA329995260C233894EF327117AC" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-ECF0E0663A6AD74985DD94EF326C14DA" unitRef="usd">-56142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-3" id="Fact-34CAB9B5E2ED4421386894EF65625B8A" unitRef="usd">64305000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-3E66B3FB34A47C07955E94EF656ABC28" unitRef="usd">-1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-44F9FE518A156AEE2C8394EF6567E180" unitRef="usd">140898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E373F1868550252C40FF94EF65649BE2" unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-98CD2E94EC21F2A4866894EF656DCE4A" unitRef="usd">-76609000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2016Q1Feb1-28" decimals="INF" id="Fact-47388E225148BCCCD236BE286AC76C90" unitRef="number">0.333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2016Q3Sept1-30" decimals="INF" id="Fact-1212314B20945627F5F9BE286AAE779E" unitRef="number">0.3448</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-3D470BB31CAB1E34EF504DDCBD56BE52" unitRef="usd">1800000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_StatementGeographicalAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-FF56221A99F92B464CB84DDB91F822FB" unitRef="usd">1600000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardValuationAllowance contextRef="FI2016Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-91D6E1D5DBF812889A464DED85DA4A08" unitRef="usd">2800000</us-gaap:TaxCreditCarryforwardValuationAllowance>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4" decimals="-3" id="Fact-9BAC26A98F0ADCBC247B8F970C987BF0" unitRef="usd">54699000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-35DAC214C84881A76C988F973E158DF4" unitRef="usd">6773000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-D82BB373C22518BDE9EB8F973D1B0B99" unitRef="usd">6454000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-9394CF1E29BA37E20EA78F973EBFFA18" unitRef="usd">16393000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-6B4E502DCB8D5BADB4838F973D252849" unitRef="usd">4984000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-C046E08CFF7FBB9666338F973EF1117C" unitRef="usd">20095000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-D32145B1C64C941FB2D8F56EFF3AE46E" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4" decimals="-3" id="Fact-5ABD872CA011D3E913528F970C848849" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-986F1173E362D856A7EE8F973F557BD5" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-211B1B6CA321E443C9B28F973D2F4E13" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-822ACFFF502583BBB9408F973F5F4F32" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-1465D4266E857F65030F8F973D93F6CD" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-4E53FB6058A78EE3263C8F973F7D0E31" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-ECB7A12F2C8AF795F6CCF56EFCC0A3C1" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2016Q4Oct11" decimals="-3" id="Fact-7B512E60954CBF4EC6AB8FFD3680B424" unitRef="usd">70498000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-B40826FCDF9282D918CB8FFD34BCD735" unitRef="usd">6773000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-44FDF78CDC6AC0ED42CF8FFD34B26D4D" unitRef="usd">6454000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-38180024E74DBCAAC7488FFD34E4D241" unitRef="usd">16393000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-B26ADC1B7B68315C9E098FFD35667508" unitRef="usd">4984000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-E7435E554CD18885C12E8FFD3516F1CE" unitRef="usd">20095000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-701BF7A1ABF758F54BFD8FFD35E8FC46" unitRef="usd">15799000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-05C78FC71B9515AE9CFB9505E245FD87" unitRef="usd">6773000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-E05417E0874633A33C8A9505E23EB79C" unitRef="usd">6454000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-506747685CAE5E6382D39505E23C4F72" unitRef="usd">16393000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-7E92113B4F8DC8FE933C9505E24BC523" unitRef="usd">4984000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-DFB71094B01BB5EDDFF09505E24121BD" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2013Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-D0D8A839490E33FAEE92D27ACCC5B7E7" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-992BB25C0A58A4106B37950663BB4E33" unitRef="usd">6773000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-B259D760E0A26E273C0F950663B9C31A" unitRef="usd">6454000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-AFDF0630F21686079B4D950663C7FB76" unitRef="usd">16393000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-5E6618B4EBEF1F0DABC1950663BD714D" unitRef="usd">4984000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-D8A2F2FF4553491E62A0950663C1F3E9" unitRef="usd">20222000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-B14BAC0747DEC40684D4D27AE84AB465" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-40A8B47CC00EEBFEDDF595069825B3A2" unitRef="usd">6773000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-D74D45E85D406D3501E49506974B49E0" unitRef="usd">6454000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-ECC149DFCACDC12696C6950697736B5B" unitRef="usd">16393000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-051A56B49E94327FBE079506973F0B7B" unitRef="usd">4984000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-5BEB62523A47A518DF9D950697BB3238" unitRef="usd">20095000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-48E2143EA2C248390855D27B0EBB3380" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-AE97D902C2F42114E11B9506CBA3805A" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-BF09A4A99D64B023B86F9506CBAF3426" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-97C4A08FAE235DE4BD4C9506CBD69C2C" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-F5BA9A3DAB49AC0CB0AF9506CC1A0FB5" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-B6545C3102EADE30B2309506CC88274F" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-ED65833EBD76CD7538B4D27B3EE48ADF" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-0296A989FA3DF5FA80ACBDDD5E0038A7" unitRef="usd">7000000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-D71225C247E380677488BDDD5DE5DD89" unitRef="usd">6500000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-9F666A6B869B60211619BDDDF11EDABF" unitRef="usd">16523000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-B38FB2F628E06F533E07BDDDDAF71FDA" unitRef="usd">5000000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-50CB72E3B7284A7F5319BDDDD9D405ED" unitRef="usd">41180000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-455691BD0F00B4517092F572148B55A0" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-130026862AC3D6FD86ECBDDD5DE9AC5D" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-9D559DFA8B5AE762CCC2BDDD5DE2BA87" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-F9C160420084CDFCA4BEBDDDF10DA83F" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-0E47A1B8606C2F259FC9BDDDDA628FFE" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-1FF1A5BDF7B53E9804EEBDDDD962B96B" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-5546ABACBAB1A07E05A9F572129600AD" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="I2016Q4Oct11" decimals="-3" id="Fact-31BA0E931CE4FEB7A9B98FFD64049AC2" unitRef="usd">71506000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="-3" id="Fact-0CC00583EA6086D557D38FFD640E252F" unitRef="usd">7000000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact-852B19776EA74DB72B038FFD642C75EC" unitRef="usd">6500000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="-3" id="Fact-B61AC356B1FEEB662B258FFD640ECE3B" unitRef="usd">16523000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="-3" id="Fact-768435481C564A891B308FFD64189B15" unitRef="usd">5000000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-CC59A9E31F9AD5F1C1228FFD6404A34C" unitRef="usd">20590000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-88368BD397D3E224CB0C8FFD642296FC" unitRef="usd">15893000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="I2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="4" id="Fact-A296146A6D03FC0A6287D1CB8F2929FA" unitRef="usdPerShare">8.2932</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-85C55DE765DE58D5ED28BDDC4D025E89" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-6D3A72A61B4782B1ECC7BDDC65C944D7" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-3986ACB2DE41DE3AC976BDDC65FD8DB8" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-2C88FF8D133C145276CDBDDC866B986E" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-7BC0668ED2F0FF3D8C77BDDC869484AD" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-C6B575301248E5FA6EFBF5720797B225" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-552C2304DEF04D944BB3BDDC4CFFEF5A" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-0DE30B051914647323EBBDDC65B55586" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-0E106ADA6F57A73E52C7BDDC65DD1C27" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-7410519CE876EA8A821BBDDC86B35A98" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-61C9EED86B7208EC464CBDDC86D2EC6A" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-00CF320CB7C47FC32475F57204D39E1F" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="I2016Q2Apr30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_obln_DistributionAgreementMember" decimals="4" id="Fact-F445702322C9190AFE5B94525EAF987C" unitRef="usdPerShare">8.2932</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-F96358380955A08769B3BDDCE7A498BA" unitRef="shares">2333332</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-C06CB82E81BA2960C9ECBDDD25105E67" unitRef="shares">4333332</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-37B3BC8D1BFED7C7C374BDDCC8BA600C" unitRef="shares">7809939</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-A406A4AD46416C8D033FBDDCC895D0D0" unitRef="shares">2783334</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-D2300668FD25D47699D3BDDCC8504800" unitRef="shares">11546013</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-36757331A6DBC1E385A7F5720AC8EF16" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-09C7A608BD1295FE3701BDDCE70BBD09" unitRef="shares">2333332</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-4C8D753061CA1B6125EFBDDD2471F6FC" unitRef="shares">4333332</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-E4E12327A384591B672EBDDCC85D5398" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-7F4A3CBA53C943A8F26BBDDCC871B832" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-569F055A5DB6C59FB1FBBDDCC8C1BDCF" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-38789C6C3E350F5B96D7F57208E519FF" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="I2016Q4Oct11" decimals="INF" id="Fact-0806205F88F60B89B3C68FFD07F0F919" unitRef="shares">34460759</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-6E3BCE4A1C304CF75E5B8FFD080472BD" unitRef="shares">2333332</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-079FE3E4904DA818BA8B8FFD07FA2E7D" unitRef="shares">4333332</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-D94578F3BB0BA84325A78FFD07E62750" unitRef="shares">7809006</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-891463C7D737B315EE988FFD07E67EF2" unitRef="shares">1418042</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-9E6F18FDF9D973AC6A2C8FFD07E60D72" unitRef="shares">8076436</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-37424B607D01A510F4BE8FFD07F0FACB" unitRef="shares">10490611</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-1971838E3830B1B70965BDDCF8D61508" unitRef="shares">804595</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-72468787DCBC0FCE72A0BDDD15FDED4F" unitRef="shares">1494248</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-800BFC45B1DF8266823DBDDE4D2EA6CF" unitRef="shares">2668533</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-4EFB8BD4D219E0C3323ABDDE7005BCCB" unitRef="shares">480286</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-8F57F739D7A7FEEB3FE4BDDE6EB93799" unitRef="shares">2732552</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-5F81AEB589EA534E7855F5720E073D30" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-5B8B9F25912BE96EF402BDDCF8C8E4ED" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-F74087DED1264621A692BDDD15F8E4AE" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-8A710BB75150BE8B69C0BDDE4D25692B" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-D2204A2B022A9DE3E144BDDE6EECBA02" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-D66F0BB9524B51C438A6BDDE6F7A539C" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-1A071F6C63C2C8F49EADF5720C13727A" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q2Apr30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_obln_BaderSultanAndBrosCoWLLMember_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_obln_DistributionAgreementMember" decimals="INF" id="Fact-6EAB3467BE32874FB6D79452507BF6E7" unitRef="shares">154585</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q2May4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-8F8CF8DB8E70B1BBF7F0D1BEDD6A3931" unitRef="shares">1916425</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q4Oct11" decimals="INF" id="Fact-11FC03B8EE1FAEC84BD88FFD1FC5D290" unitRef="shares">10096639</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-0716E99EC13510AD3D648FFD1F89F439" unitRef="shares">804595</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-01D450E1E3261E99317F8FFD208466A9" unitRef="shares">1494248</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-AF0A5A56B6637B3FB3998FFD1F6B68C1" unitRef="shares">2668533</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-C10BE02FCDBD536194B68FFD2124C659" unitRef="shares">480286</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-936A0172AC52BE2D45318FFD1F617327" unitRef="shares">2732552</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-A756F2BF4868384577F68FFD2016F7DB" unitRef="shares">1916425</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-7975B623435D1B86E3F1BDDDA7241AB1" unitRef="shares">804595</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-79645834BC85B5575465BDDDA721B96E" unitRef="shares">1494248</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-E9D6151A8334BE102D17BDDE37C527B4" unitRef="shares">2668533</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-AA241727B34176708E23BDDE1DDB4D10" unitRef="shares">480286</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-97D0D54F3E12DDE07DDABDDE0604F647" unitRef="shares">2732552</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-49B5DD0374E314C15566F572114E74E2" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-90B2A06BFF84A0F8A4A24E0888DE34D4" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-593F2EC19A8C66E76E33BDDDA7286C31" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-0CEA238F607280119CA6BDDDA72DF0E3" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-AAD388DAB992EC2E97D6BDDE37778B11" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-2DEF66F474BCDE4D3133BDDE1D4A5B4E" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-8F6F4BDCE57BCC14C6A6BDDE0610CCD9" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-6BA0F58F4B77182871FDF5720F5A7066" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2016Q4Oct11" decimals="INF" id="Fact-945A692949752D55343090016C427C0C" unitRef="shares">10096639</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesAConvertiblePreferredStockMember" decimals="INF" id="Fact-9C0B554E3131475E7B5690016C74515B" unitRef="shares">804595</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact-C0135368E5D6C58E386A90016C6A9AE9" unitRef="shares">1494248</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCConvertiblePreferredStockMember" decimals="INF" id="Fact-79A47A6B4312B89A2E2590016C2ED4E3" unitRef="shares">2668533</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesCOneConvertiblePreferredStockMember" decimals="INF" id="Fact-5A96C55FED964896293690016C382CD1" unitRef="shares">480286</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="INF" id="Fact-211D767031A0FFB010F090016C4C6D66" unitRef="shares">2732552</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2016Q4Oct11_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="INF" id="Fact-41583C8A7C060231DAC490016C5624D6" unitRef="shares">1916425</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-06AC5169E2AF843C2BA694FF693F9E35" unitRef="usd">20222000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-80B982AB94B73702A5F294FF69510C66" unitRef="usd">127000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesDConvertiblePreferredStockMember" decimals="-3" id="Fact-CD334E9A1D3BC5F52F7D94FF6979108A" unitRef="usd">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_obln_SeriesEConvertiblePreferredStockMember" decimals="-3" id="Fact-73E6C44A79D986A1E25DD28E8FA8EC1B" unitRef="usd">15799000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-CD2FA09994B4429A30DE4DE86F59DEB1" unitRef="usd">13500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q4YTD" decimals="0" id="Fact-1779C57BC2446625600F8FB30DD5DA93" unitRef="shares">531430</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q4YTD" decimals="0" id="Fact-4AE3291C0FF5DF97F74B8FB30DD3F42E" unitRef="shares">573181</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-78FEBC16BD2D0E9211128FB30DD1A6DF" unitRef="shares">4221893</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<obln:ClinicalTrialExpensesPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-C38AEB87B772798BDF8AD22B76899C3B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Clinical Trial Expenses &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into contracts with third party hospitals and doctors to perform clinical trial activities. The Company accrues expenses for clinical trial activities performed by third parties based on estimates of work performed by each third party as of the balance sheet date. The Company&amp;#8217;s clinical trial expense is primarily driven by patient visits to the third party hospitals and doctors. As such, the Company uses the estimated patient visits based on third-party reporting and the contractually agreed upon cost for each visit to calculate its clinical accrual. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</obln:ClinicalTrialExpensesPolicyPolicyTextBlock>
	<obln:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="FD2016Q4YTD" id="Fact-806DC2CEC1DAB6D566AD8FFC1CAAD484">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock reserved for future issuance consists of the following at December&amp;#160;31, 2016: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options issued and outstanding   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,225,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Authorized for future option grants   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,386,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants outstanding   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,636,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</obln:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
	<us-gaap:AdvertisingCostsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-0DC1F860E9E09BAB4CDE8FD0A30BBB06">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising Costs &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Advertising costs are expensed as incurred and included in selling, general and administrative expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-DD319E2AEC6C0198A6DF8FC97F42656B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all highly liquid investments with original maturities of three&amp;#160;months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-32F4E85CA10561721DDD8FF2E7EFD91E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;Commitments and Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company leases facilities under a noncancelable operating lease that expires on March&amp;#160;31, 2019. Under the terms of the facilities lease, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturing organizations and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table below. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future noncancelable minimum payment obligations under the operating lease were as follows as of December 31, 2016 (in thousands):&lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future payments due under building lease   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rent expense totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December&amp;#160;31, 2016 and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended December 31, 2015 and 2014.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2016Q4YTD" id="Fact-00C88134149E25BB96D98FCD34F6C203">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company&amp;#8217;s customers consist of distributors. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-F8363A0C7D8B2DA7D13794140943F53F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;Term Loan &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June&amp;#160;2013, the Company entered into a loan and security agreement, or 2013 Loan Agreement, with Pacific Western Bank (as successor in interest to Square&amp;#160;1 Bank) allowing for borrowings up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition to the interest payments, Pacific Western Bank received warrants for the purchase of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,693&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of the Company&amp;#8217;s Series&amp;#160;C-1 convertible preferred stock. On October 11, 2016, all the warrants were net exercised into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,689&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares which were subsequently issued as common stock on October 12, 2016 in conjunction with the IPO closing. In October&amp;#160;2014, the Company amended the 2013 Loan Agreement and executed a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; credit facility with Pacific Western Bank, or 2014 Loan Agreement. The 2014 Loan Agreement was separated into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tranches, Term Loan A and Term Loan B. Term Loan A was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which included the existing &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of outstanding debt and the additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that was funded upon closing of the 2014 Loan Agreement. Term Loan B was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and was available upon receipt of at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in proceeds from the issuance and sale of the Company&amp;#8217;s equity securities to investors. Term Loan B was funded after the close of the Company&amp;#8217;s Series&amp;#160;D financing in January&amp;#160;2015. As part of the 2014 Loan Agreement, the Company issued Pacific Western&amp;#160;Bank additional warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,869&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of its Series&amp;#160;D convertible preferred stock at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.5351&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. On October 11, 2016, all the warrants were net exercised into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,869&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares which were subsequently issued as common stock on October 12, 2016 in conjunction with the IPO closing. As of December 31, 2016, Pacific Western Bank held &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,558&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock associated with its warrant exercises and had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants outstanding.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The present value of the future cash flows under the 2014 Loan Agreement terms did not exceed the present value of the future cash flows under the 2013 Loan Agreement terms by more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As such, the Company treated this amendment as a modification and recorded the associated immaterial facility fee and the associated immaterial fair value of the warrants as a discount to the 2014 Loan Agreement. This discount and the remaining balance of debt issuance costs and debt discount of the 2013 Loan Agreement were amortized to interest expense over the remaining term of the 2014 Loan Agreement using the effective-interest method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September&amp;#160;7, 2016, the Company entered into the September 2016 Loan Agreement, with Pacific Western Bank, which amended the existing outstanding debt agreement described above. The September 2016 Loan Agreement allows for total borrowings up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tranches as follows: a first tranche consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; funded on September&amp;#160;7, 2016, of which the full &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; must be used to settle the existing debt with Pacific Western Bank on a net settlement basis (pursuant to its original terms); and a second tranche consisting of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which may be drawn at any time prior to March&amp;#160;7, 2017. The first tranche and the second tranche are collectively referred to as the &amp;#8220;Term Loans.&amp;#8221; The Term Loans bear interest at the greater of prime rate plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Term Loans mature on September&amp;#160;7, 2020 and have an interest-only period through March 2018 followed by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equal monthly installments of principal and interest. The Term Loans may be prepaid in full at any time with no additional cost.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the September 2016 Loan Agreement, the Company issued to Pacific Western Bank a warrant to purchase a number of the Company&amp;#8217;s Series&amp;#160;E Preferred Stock, at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.2932&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total amount of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of debt drawn over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; divided by the purchase price, which automatically converted into a warrant to purchase the same number of shares of common stock immediately prior to the closing of the Company&amp;#8217;s IPO, and will only be exercisable in the event that the Company borrows all or part of the second tranche. As the Company had not drawn down on the second tranche, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;none&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of these warrants were exercisable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 21, 2016, the Company entered into the December 2016 Loan Agreement with Pacific Western Bank, which further amended the existing outstanding debt agreements described above. The December 2016 Loan Agreement kept total borrowings consistent of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tranches as follows: a first tranche consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; funded on December 21, 2016, of which the full &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; must be used to settle the existing debt with Pacific Western Bank on a net settlement basis (pursuant to its original terms); and a second tranche consisting of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which may be drawn at any time prior to December 21, 2017. The Term Loans bear interest at the greater of prime rate plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Term Loans mature   on December 21, 2020 and have an interest-only period through June 21, 2018 followed by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equal monthly installments of principal and interest. The Term Loans may be prepaid in full at any time with no additional cost. The Series E warrant issued with the 2016 Loan Agreement was canceled without exercise in conjunction with the amendment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The present value of the future cash flows under the 2016 Loan Agreement and the December 2016 Loan Amendment did not exceed the present value of the future cash flows under the predecessor terms by more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As such, the Company treated the amendments as modifications and recorded the associated immaterial facility fees as a discount to the amended debt. This discount and the remaining balance of debt issuance costs and debt discount are amortized to interest expense over the remaining term of the December 2016 Loan Agreement using the effective-interest method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The December 2016 Loan Agreement also requires that the Company's accounts maintained with the bank contain an aggregate balance in an amount equal to or greater than the total amount of outstanding debt under the December 2016 Loan Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term loan and unamortized debt discount balances are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Face value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term loan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: current portion of long-term loan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term loan, excluding current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December&amp;#160;31, 2016, future principal payments due under the December 2016 Loan Agreement are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;padding-left:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future principal payments due under the December 2016&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;padding-left:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Loan Agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q4YTD" id="Fact-3D99A80064D2DE14A3F393EBEE320718">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted an Equity Incentive Plan, or the&amp;#160;2008 Plan, in 2008, under which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; further shares of common stock are reserved for issuance to employees, nonemployee directors, and consultants of the Company. The Plan provides for the grant of incentive stock options, nonstatutory stock options, rights to purchase restricted stock, stock appreciation rights, dividend equivalents, stock payments, and restricted stock units to eligible recipients. On October 4, 2016, the 2016 Equity Incentive Plan, or the&amp;#160;2016 Plan, became effective. The 2016 Plan serves as a successor to the 2008 Plan. The 2016 Plan permits the award of stock options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards, cash awards and stock bonuses. The Company reserved &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for issuance under the 2016 Plan, plus the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,371&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reserved and unissued shares under the 2008 plan on the effective date of the 2016 Plan. The number of shares reserved for issuance under the 2016 Plan will increase automatically on January 1 of each calendar year continuing through the tenth calendar year during the term of the 2016 Plan by the number of shares equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total outstanding shares of the Company's common stock and common stock equivalents as of the immediately preceding December&amp;#160;31.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Recipients of incentive stock options shall be eligible to purchase shares of the Company&amp;#8217;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Plan is ten&amp;#160;years. The options generally vest &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. At December&amp;#160;31, 2016, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,386,549&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options remained available for future grant under the 2016 Plan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Assumed risk-free interest rate &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Based on the average yield of U.S. Treasury bills as of the valuation date for the expected term of the award. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Assumed volatility &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Due to limited historical data, the expected volatility is estimated based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group consisted of other publicly-traded companies in the same industry and in a similar stage of development. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected life &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Based based on the simplified method, which is an average of the contractual term of the options and its ordinary vesting period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected dividend yield &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Based upon the Company&amp;#8217;s historic dividends and dividend expectations for the foreseeable future. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common stock fair value &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Upon the effective date of the IPO, the Company began using the closing price of its common stock for the price of new stock option awards. Prior to the effectiveness of the Company&amp;#8217;s IPO, given the absence of a public trading market, the Board of Directors considered numerous objective and subjective factors to determine the fair value of common stock at each grant date. These factors included, but were not limited to, (i)&amp;#160;contemporaneous valuations of common stock performed by unrelated third-party specialists; (ii)&amp;#160;the prices for preferred stock sold to outside investors; (iii)&amp;#160;the rights, preferences and privileges of preferred stock relative to common stock; (iv)&amp;#160;the lack of marketability of common stock; (v)&amp;#160;developments in the business; and (vi) the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of the Company, given prevailing market conditions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed risk-free interest rate   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.40% -1.53%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.57%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.82%&amp;#160;-&amp;#160;2.09%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed volatility   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;52.91% - 53.49%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61.53%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71.09%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected option life   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized stock-based compensation straight-line over the vesting term of the options. The Company recorded non-cash compensation, including non-cash compensation to employees and nonemployees in the consolidated statements of operations and comprehensive loss as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:8px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of revenue   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;563&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized compensation expense at December&amp;#160;31, 2016 was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average term of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity instruments issued to nonemployees are initially recorded at their grant-date fair value and are periodically revalued using the Black-Scholes option pricing model as the equity instruments vest and are recognized as expense over the related service period. Stock-based compensation expense to nonemployees was immaterial for the years ended December&amp;#160;31, 2016, 2015 and 2014. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option transactions for the Plan for the years ended December&amp;#160;31, 2016, 2015 and 2014 (in thousands, except shares and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of &lt;br clear="none"/&gt;shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;average &lt;br clear="none"/&gt;exercise &lt;br clear="none"/&gt;price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;average &lt;br clear="none"/&gt;remaining &lt;br clear="none"/&gt;contractual &lt;br clear="none"/&gt;life&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate &lt;br clear="none"/&gt;intrinsic value &lt;br clear="none"/&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2015   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,298,868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,787,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(808,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(51,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,225,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,929,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and exercisable at December&amp;#160;31, 2016   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;485,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted-average fair value of options granted during the years ended December&amp;#160;31, 2016 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.99&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The intrinsic value of options exercised for the years ended December&amp;#160;31, 2016 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and immaterial for the years ended December 31, 2015 and 2014. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All options outstanding under the 2008 Plan are exercisable under the early exercise provisions of the Plan. Options granted under the Plan that are exercised prior to vesting are subject to repurchase by the Company at the original issue price and will vest according to the respective option agreement. For the year ended December 31, 2016, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;252,453&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options were early exercised and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238,638&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; remain unvested with a related liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded under other current liabilities on the Company&amp;#8217;s consolidated balance sheet as of December 31, 2016. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options were early exercised for the years ended December 31, 2015 and 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 5, 2016, the 2016 Employee Stock Purchase Plan, or ESPP, became effective.&amp;#160;The 2016 ESPP was adopted in order to enable eligible employees to purchase shares of the Company&amp;#8217;s common stock at a discount. Purchases will be accomplished through participation in discrete offering periods.&amp;#160;&amp;#160;The Company initially reserved &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;180,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for issuance under the 2016 ESPP. The number of shares reserved for issuance under the 2016 ESPP will increase automatically on January 1 of each calendar year beginning after the first offering date and continuing through the first ten calendar years by the number of shares equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total outstanding shares of our common stock and common stock equivalents as of the immediately preceding December&amp;#160;31. Stock compensation expense related to the ESPP was immaterial for the year ended December 31, 2016 and is included in total stock compensation expense disclosed above.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-904A0B089D4836C9E70E8FC73362BC4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Share &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per common share, since the effects of potentially dilutive securities are anti-dilutive. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive common stock equivalents are comprised of convertible preferred stock, warrants and unexercised stock options outstanding under the Company&amp;#8217;s equity plan. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2016Q4YTD" id="Fact-68F17487E3E24729E4F48FE1BC347D70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss per Share &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except shares and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares used in computing net loss per share   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,221,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;573,181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;531,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the outstanding potentially dilutive securities determined using the treasury stock and if-converted methods that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:13px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock, on an as-converted basis   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,443,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,654,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;830,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;830,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,443,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,714,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2016Q4YTD" id="Fact-537E256E0DF481EBE6128FDFD766D7C7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Instruments Recorded at Fair Value on a Recurring Basis &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities measured at fair value on a recurring basis at December&amp;#160;31, 2016 and 2015 are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;value&amp;#160;measurements&amp;#160;at&amp;#160;reporting&amp;#160;date&amp;#160;using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;prices&lt;br clear="none"/&gt;in&amp;#160;active&lt;br clear="none"/&gt;markets&amp;#160;for&lt;br clear="none"/&gt;identical&amp;#160;assets&lt;br clear="none"/&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br clear="none"/&gt;other&lt;br clear="none"/&gt;observable&lt;br clear="none"/&gt;inputs&lt;br clear="none"/&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br clear="none"/&gt;unobservable&lt;br clear="none"/&gt;inputs&lt;br clear="none"/&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury bonds(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;value&amp;#160;measurements&amp;#160;at&amp;#160;reporting&amp;#160;date&amp;#160;using&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;prices&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;active &lt;br clear="none"/&gt;markets for &lt;br clear="none"/&gt;identical&amp;#160;assets &lt;br clear="none"/&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant &lt;br clear="none"/&gt;other &lt;br clear="none"/&gt;observable &lt;br clear="none"/&gt;inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant &lt;br clear="none"/&gt;unobservable &lt;br clear="none"/&gt;inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds(1)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury bonds(2)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant liability   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Classified as cash and cash equivalents on the consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Classified as short-term investments on the consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s investments in Level 1 assets are valued based on publicly available quoted market prices for identical securities as of December&amp;#160;31, 2016 and 2015. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As discussed in Note 2 above, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,112&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants were exercised to common stock and all of the remaining outstanding &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,224&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock in connection with the IPO and are equity classified at December 31, 2016. Prior to the exercise and the conversion, the Company estimated the fair value of convertible preferred stock warrants at the time of issuance and subsequent remeasurements using the Black-Scholes option-pricing model at each reporting date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following assumptions were used in the Black-Scholes option-pricing model to determine the fair value of the convertible preferred stock warrants at the exercise and conversion date, and December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;October 12,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed risk-free interest rate   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.90% - 1.64%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.28%&amp;#160;-&amp;#160;2.06%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed volatility   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.42% - 62.36%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66.76%&amp;#160;-&amp;#160;70.66%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.40 yrs - 7.96 yrs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.15&amp;#160;-&amp;#160;8.75 yrs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred stock fair value:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series D   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C-1   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The assumptions were determined as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Assumed risk-free interest rate &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Based on the average yield of U.S. Treasury bills as of the valuation date for the expected term of the award. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Assumed volatility &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Based on the historical volatility of a number of publicly traded companies comparable in size, business model, industry and business description. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected life &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Based on the remaining contractual term of warrant as of the valuation date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected dividend yield &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Based upon the Company&amp;#8217;s historic dividends and dividend expectations for the foreseeable future. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred stock fair value &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; On October 12, 2016, the conversion date, the Company used the closing price of its common stock. Given the absence of a public trading market on December 31, 2015, the Company considered numerous objective and subjective factors to determine the fair value of preferred stock at each valuation date. These factors included, but were not limited to, (i)&amp;#160;contemporaneous valuations of preferred stock performed by unrelated third-party specialists; (ii)&amp;#160;the prices for preferred stock sold to outside investors; (iii)&amp;#160;the rights, preferences and privileges of preferred stock relative to common stock; (iv)&amp;#160;developments in the business; and (v)&amp;#160;the likelihood of achieving a liquidity event, such as an IPO or a merger or acquisition of the Company, given prevailing market conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December&amp;#160;31, 2015, reasonable changes in the unobservable inputs would not be expected to have a significant impact on the consolidated financial statements. The Company&amp;#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no significant transfers into or out of Level&amp;#160;1, 2, or 3 for the years ended December&amp;#160;31, 2016 and 2015. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides reconciliation for all liabilities measured at fair value using significant unobservable inputs (Level&amp;#160;3) for the years ended December&amp;#160;31, 2016 and 2015 (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair value &lt;br clear="none"/&gt;measurements &lt;br clear="none"/&gt;at reporting &lt;br clear="none"/&gt;date using &lt;br clear="none"/&gt;significant &lt;br clear="none"/&gt;unobservable &lt;br clear="none"/&gt;inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2014  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuance of warrants for the purchase of convertible preferred stock   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from change in fair value of warrant liability   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2015   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from change in fair value of warrant liability   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reclassification of warrants to stockholders' equity (deficit) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2016   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Instruments Not Recorded at Fair Value on a Recurring Basis &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of long-term loan is determined by Level&amp;#160;2 inputs and is based primarily on quoted market prices for the same or similar issues. The recorded value of long-term loan approximates the current fair value due to the proximity of when the long-term loan was negotiated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-665DD272FD7B6D8F6AF58FE0F2028E95">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;October 12,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed risk-free interest rate   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.90% - 1.64%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.28%&amp;#160;-&amp;#160;2.06%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed volatility   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.42% - 62.36%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66.76%&amp;#160;-&amp;#160;70.66%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.40 yrs - 7.96 yrs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.15&amp;#160;-&amp;#160;8.75 yrs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred stock fair value:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series D   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C-1   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2016Q4YTD" id="Fact-AFF6184EE924515D51369430137B8778">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides reconciliation for all liabilities measured at fair value using significant unobservable inputs (Level&amp;#160;3) for the years ended December&amp;#160;31, 2016 and 2015 (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair value &lt;br clear="none"/&gt;measurements &lt;br clear="none"/&gt;at reporting &lt;br clear="none"/&gt;date using &lt;br clear="none"/&gt;significant &lt;br clear="none"/&gt;unobservable &lt;br clear="none"/&gt;inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2014  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuance of warrants for the purchase of convertible preferred stock   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from change in fair value of warrant liability   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2015   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from change in fair value of warrant liability   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reclassification of warrants to stockholders' equity (deficit) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2016   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-EE73EB27D5AAA512C9DF8FC802C8F510">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying values of the Company&amp;#8217;s financial instruments, including cash and cash equivalents, accounts receivable from related party, accounts payable, and accrued expenses approximate their fair values due to the short maturity of these instruments. The carrying value of the term loan approximates its fair value as the interest rate and other terms are that which is currently available to the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels in accordance with authoritative accounting guidance: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:16px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:16px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2 inputs: Other than quoted prices included in Level&amp;#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:16px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-0F4E3A5E750A5C3B2989D2251DCA8F14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of the assets to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the difference between the carrying amount and the fair value of the impaired asset. The Company did not recognize any material impairment losses for the respective years ended December&amp;#160;31, 2016, 2015 and 2014. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-6C260CE52D4832114E6C8FF90C69199B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The income tax provision (benefit) consists of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total current provision   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred provision   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax provision (benefit)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The difference between income tax benefits and income taxes computed using the U.S. federal income tax rate as of December&amp;#160;31, 2016, 2015 and 2014 are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At statutory rates   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes, net of federal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,291&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign operations   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax provision (benefit)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to Internal Revenue Code, or IRC, Sections&amp;#160;382 and 383, annual use of the Company&amp;#8217;s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an IRC Section&amp;#160;382 and 383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Until this analysis has been completed, the Company has removed deferred tax assets for Federal and California net operating losses of approximately $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and research and experimental credits of approximately $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;generated through 2016 from its deferred tax schedule, and has recorded a corresponding decrease to its valuation allowance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets as are shown below: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign net operating losses   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research and development   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total gross deferred tax assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less valuation allowance   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A valuation allowance of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December&amp;#160;31, 2016 and 2015, respectively, has been established to offset the deferred tax assets as realization of such assets are uncertain. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, 2016, the Company had federal and state net operating loss carryforwards of approximately $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Each of the federal and state tax loss carryforwards will begin expiring in 2028, unless previously utilized. The Company also has federal and California research and development tax credit carryforwards totaling $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The federal research and development tax credit carryforward will begin to expire in 2028 unless previously utilized. The California research tax credits do not expire. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commencing with the 2013&amp;#160;year, the Company computed its California net operating losses, or California NOLs, under the Multistate Tax Compact apportionment rules as provided for in the California Court of Appeal&amp;#8217;s decision in Gillette v. FTB. That decision was overturned by the California Supreme Court on December&amp;#160;31, 2015. As such, it is the Company&amp;#8217;s intent to compute its California apportionment factor, and resulting California NOLs, under California&amp;#8217;s Single Sales Factor Market rules. In 2015, the Company adjusted its California NOLs and deferred tax assets to the Single Sales Factor state rate. The impact to the California NOLs was approximately $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13.5) million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has not provided U.S.&amp;#160;income taxes and foreign withholding taxes on the undistributed earnings of foreign subsidiaries as of December&amp;#160;31, 2015 and 2014, because it intends to permanently reinvest such earnings outside the United States. If these foreign earnings on these were to be repatriated in the future, the related U.S.&amp;#160;tax liability may be reduced by any foreign income taxes previously paid on these earnings. Due to historical losses, as of December 31, 2015 and 2014, the foreign subsidiaries do not have cumulative earnings. As of December&amp;#160;31, 2016, all of these entities have been dissolved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon an audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. As of December&amp;#160;31, 2016, 2015 and 2014, the Company continued to have no unrecognized tax benefits. There are no unrecognized tax benefits included on the consolidated balance sheet sheets that would, if recognized, impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-BA94C093F62E32C9EA8E8FD45D0301B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for interest and penalties related to income tax matters, if any, as a component of income tax expense or benefit. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-90ECDA3C81D01684FE198FCE175BD99E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or net realizable value, computed on a standard cost basis. Inventory that is obsolete or is in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-A35616B8DE5D5B286D418FC8447DF25D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term Investments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses, if any, reported as a component of other comprehensive loss within the consolidated statements of operations and comprehensive loss. All of the Company&amp;#8217;s short-term investments are U.S.&amp;#160;Treasury notes with maturities of less than one&amp;#160;year. For the years ended December&amp;#160;31, 2016, 2015 and 2014, unrealized losses were immaterial amounts, respectively. Realized gains and losses would be calculated on the specific-identification method and recorded as interest income. There have been no material realized gains and losses for the years ended December&amp;#160;31, 2016, 2015 and 2014. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-1A787A332CA9C4D89A788FC6F922855C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ASU 2014-15 requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable that when, considered in the aggregate, raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued, for both annual and interim periods. ASU 2014-15 also requires certain disclosures around management&amp;#8217;s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that will alleviate the substantial doubt. ASU 2014-15 is effective for annual reporting periods, and interim periods within those periods, beginning after December&amp;#160;15, 2016. The adoption of ASU 2014-15 did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July&amp;#160;2015, FASB&amp;#160;issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This update applies to companies that measure inventory on a first in, first out, or FIFO, or average cost basis. Under this update, companies are to measure their inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion. The amendments in this update are effective for annual reporting periods, and interim periods within those periods, beginning after December&amp;#160;15, 2016 with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Under this new guidance, at the commencement date, lessees will be required to recognize (i)&amp;#160;a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii)&amp;#160;a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted.&amp;#160;The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2015, the FASB issued ASU 2015-14, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09, which was issued in March 2014 and has been codified with the Accounting Standards Codification as Topic 606, is now effective for public companies for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. ASC 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In addition, ASC 606 provides guidance on accounting for certain revenue-related costs including, but not limited to, when to capitalize costs associated with obtaining and fulfilling a contract. ASC 606 provides companies with two implementation methods: (a) full retrospective adoption, meaning the standard is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance.&amp;#160;Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within ASC 606 to clarify various elements of the guidance. While the Company is continuing to assess all potential impacts of the standard, they do not believe that their current revenue streams will be materially affected. As the Company begins commercialization in the U.S. during 2017 and enters into sales agreements with customers as part of this commercialization, the Company will continue to assess the potential impacts of the standard, including the impact to the pattern with which they recognize revenue based on the terms entered into and finalizing the determination of transition approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which involves several aspects of the accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This new guidance will require all income&amp;#160;tax effects of awards to be recognized as income tax expense or benefit in the income statement when the awards vest or are settled, as opposed to additional paid-in-capital where it is currently recorded. It&amp;#160;also will allow an employer to repurchase more of an employee&amp;#8217;s shares than it can today for tax withholding purposes without triggering liability accounting. All tax-related cash flows resulting from stock-based payments are to be reported as operating activities on&amp;#160;the statement of cash flows. The guidance also allows a Company to make a policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. This new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2016, with early adoption permitted. The Company does not recognize any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance on its deferred tax assets. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;, which addresses the following eight specific cash flow issues: Debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies); distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2017, with early adoption permitted.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;The Company does not anticipate that the adoption of ASU 2016-15 will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-193ED8A0808020319CCE8FC53D62FCA1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Organization and Basis of Presentation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Obalon Therapeutics, Inc., or the&amp;#160;Company, was incorporated in the state of Delaware on January&amp;#160;2, 2008. The Company is a vertically-integrated medical device company focused on developing and commercializing innovative medical devices to treat obese and overweight people. Using its patented technology, the Company has developed the Obalon balloon system, the first and only FDA approved swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the accounts of Obalon Therapeutics, Inc., and its wholly owned subsidiaries, Obalon Italy SRL and Obalon Therapeutics, LLC. Obalon Therapeutics, LLC is a shell Company, which owns &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of Obalon Mexico DE RL CV.  Obalon Italy SRL was dissolved during 2015 and Obalon Mexico DE RL CV was dissolved during 2016.   All intercompany balances and transactions have been eliminated in consolidation.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S.&amp;#160;generally accepted accounting principles, or GAAP. The Company&amp;#8217;s principal operations are located in Carlsbad, California and it operates in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; business segment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December&amp;#160;31, 2016, the Company has devoted a substantial portion of its efforts to product development, raising capital, and building infrastructure. The Company has incurred operating losses and has experienced negative cash flows from operations since its inception. In July&amp;#160;2012, the Company realized initial revenue from its planned principal operations. The Company recognized revenue, including revenue from related parties, of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended December&amp;#160;31, 2016, 2015 and 2014, respectively. However, the Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and has funded its activities to date almost exclusively from debt and equity financings. On September&amp;#160;8, 2016, the Company received premarket approval from the U.S. Food and Drug Administration, or FDA, to market the Obalon balloon system for temporary use to facilitate weight loss in obese adults with a body mass index, or BMI of 30 to 40 who have failed to lose weight through diet and exercise. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. For all periods presented, all sales are to customers outside of the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Initial Public Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 5, 2016, the Company&amp;#8217;s Registration Statement on Form S-1 (File No. 333-213551) relating to the initial public offering, or IPO, of its common stock was declared effective by the Securities and Exchange Commission, or SEC. Pursuant to such Registration Statement, the Company sold an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for aggregate cash proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$67.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of underwriting discounts, commissions, and offering costs. The IPO closed on October 12, 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 12, 2016, immediately prior to the closing of the IPO, the following events occurred:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:26px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;An aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,360,419&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, excluding any warrant conversions, were issued to the holders of the Company&amp;#8217;s Series A, Series B, Series C, Series C-1, Series D and Series E convertible preferred stockholders upon the automatic conversion of all shares of convertible preferred stock to common stock. As a result, no Series A, Series B, Series C, Series C-1, Series D or Series E convertible preferred stock remain outstanding at December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:26px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Initiated on October 11, 2016, Series C-1 and D warrants for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,562&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's preferred stock were exercised by Pacific Western Bank (as successor in interest to Square 1 Bank) via cashless exercise resulting in the subsequent issuance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,558&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock on October 12, 2016.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:26px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series D warrants for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,550&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s preferred stock were automatically net exercised resulting in the issuance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,217&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:26px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The remaining outstanding Series C preferred stock warrants exercisable for an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,224&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of convertible preferred stock automatically converted into warrants exercisable for an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,224&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:26px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Plan, and the 2016 ESPP, as described in Note 7, were adopted.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:26px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;An aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,371&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock reserved but not issued under the 2008 Plan became available for grant under the 2016 Plan.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:26px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company filed its amended and restated certificate of incorporation on October 12, 2016, authorizing &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;300,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;February 2014 Reverse Stock Split &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2014, the board of directors of the Company approved a 3-for-1 reverse stock split of the Company&amp;#8217;s common and preferred stock. All share and per share information included in the accompanying consolidated financial statements and notes to consolidated financial statements give retroactive effect to this reverse stock split for the Company&amp;#8217;s common and preferred stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;September 2016 Reverse Stock Split&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2016, the Company&amp;#8217;s board of directors approved an amendment to the Company&amp;#8217;s amended and restated certificate of incorporation to effect a reverse stock split of the Company&amp;#8217;s issued and outstanding common stock and convertible preferred stock at a 2.9-to-1 ratio, which was effected on September&amp;#160;23, 2016. All share and per share information included in the accompanying consolidated financial statements and notes to the consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for the Company&amp;#8217;s common and preferred stock for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As reflected in the accompanying consolidated financial statements, the Company has a limited operating history and the sales and income potential of the Company&amp;#8217;s business are unproven. The Company has not been profitable since inception, and as of December 31, 2016, its accumulated deficit was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$76.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its IPO and, to a lesser extent, debt financing arrangements. The Company expects to continue to incur net losses for the foreseeable future as it builds its sales and marketing organization, supports commercialization of its product in the United States and continues research and development efforts. The Company may need additional funding to pay expenses relating to its operating activities, including selling, general and administrative expenses and research and development expenses. Adequate funding, if needed, may not be available to the Company on acceptable terms, or at all. The failure to obtain sufficient funds on acceptable terms could have a material adverse effect on the Company&amp;#8217;s business, results of operations or financial condition. The Company believes that its existing cash and cash equivalents and short-term investments and expected revenue will be sufficient to meet its capital requirements and fund its operations through the next two years.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-ED851FDF13D786722C338FE6FD53B8DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current liabilities consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,399&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-C3E5A7AE68F23EB1DB288FCF2494D27F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The useful lives of the property and equipment are as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer software   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter&amp;#160;of&amp;#160;3&amp;#160;years&amp;#160;or&amp;#160;length&amp;#160;of&amp;#160;software license&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2016Q4YTD" id="Fact-641DE95B395DFA7AFEABD2149A6DD6B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The useful lives of the property and equipment are as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer software   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter&amp;#160;of&amp;#160;3&amp;#160;years&amp;#160;or&amp;#160;length&amp;#160;of&amp;#160;software license&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress, or CIP   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2016Q4YTD" id="Fact-B00C2C40FA42DC4B6CB49467544B6B24">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Selected Quarterly Financial Data (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the quarterly results of the Company for the years ended December&amp;#160;31, 2016 and 2015&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(unaudited, in thousands, except for per share data)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue         &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross profit   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Per common share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue         &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross profit   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Per common share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-3B12B862B1938CED0F378FF2A739DC23">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June&amp;#160;2013, the Company and Bader Sultan&amp;#160;&amp;amp; Bros. Co W.L.L., or Bader, a healthcare products distributor based in Sufat, Kuwait, entered into a distribution agreement, whereby the Company appointed Bader as a distributor of its products. Sales to Bader began in November&amp;#160;2013. The Company&amp;#8217;s agreement with Bader restricts Bader&amp;#8217;s ability to sell competing products and requires Bader to purchase a certain number of products from the Company monthly based on annual forecasts that the Company provides to Bader. If Bader does not resell the minimum purchase quantity specified in the contract by the applicable date, then the Company has the right, in its sole discretion, to sell to other distributors in the Middle East or terminate its agreement with Bader. The initial term of the agreement expires in December 2019. The agreement can be terminated by the Company immediately upon certain breaches by Bader, or by either Bader or the Company for uncured material breach of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the 2014 Series&amp;#160;D convertible preferred stock financing, Bader purchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;875,903&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of the Company&amp;#8217;s Series&amp;#160;D convertible preferred stock. All terms of the purchase of preferred stock were the same for Bader as the other investors. Sales to Bader for the years ended December&amp;#160;31, 2016, 2015 and 2014 totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, which represents &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94.7%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52.4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of total revenue for the respective years. As of December&amp;#160;31, 2016, the Company had accounts receivable from Bader of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January&amp;#160;2015, the Company and Bader amended the distribution agreement. In accordance with the amendment, Bader provided the Company with a deposit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and committed to minimum product purchases for calendar year 2015. Under the terms of the amendment, the Company reserved the right to keep the deposit as liquidated damages if Bader did not meet the minimum product purchases. The Company classified the deposit as a current liability at December&amp;#160;31, 2015 on the consolidated balance sheets as the minimum product purchase levels were met. In April&amp;#160;2016, the Company and Bader entered into a Payment Direction Letter, resulting in the exchange of the distribution agreement deposit for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;154,585&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares Series&amp;#160;E convertible preferred stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.2932&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. All of Bader's outstanding convertible preferred stock converted to common stock in connection with the Company's IPO.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2016Q4YTD" id="Fact-F38B46A7ED443275BDA5D226712BA175">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All research and development costs are charged to expense as incurred. Research and development expenses primarily include (i)&amp;#160;payroll and related costs associated with research and development performed, (ii)&amp;#160;costs related to clinical and preclinical testing of our technologies under development and (iii)&amp;#160;other research and development expenses. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-3E1E726D246A17EA0AAF8FD2D661453B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue relates to sales of components of the Obalon balloon system, which includes the balloon and accessory kit, EzFill inflation system, pre-filled can of gas and placebo capsule. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when (i)&amp;#160;persuasive evidence of an arrangement exists, (ii)&amp;#160;delivery has occurred, (iii)&amp;#160;the selling price is fixed or determinable and (iv)&amp;#160;collectability is reasonably assured. Determination of criteria (iii)&amp;#160;and (iv)&amp;#160;are based on management&amp;#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company does not provide for rights of return to customers on product sales, with the exception of products that fail to conform to the Company&amp;#8217;s specifications. As these non-conforming returns have historically been immaterial, the Company does not record a provision for returns. The Company does not have any post shipment obligations or acceptance provisions within its customer contracts. The Company occasionally offers discounts off its standard prices to non-distributor customers, which are agreed upon and known at the time of sale. In these cases, revenue is recognized net of these discounts. Shipping charges billed to customers are included in product revenue and the related shipping costs are included in cost of revenue. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2016Q4YTD" id="Fact-337694B114D176B12CE28FE231781A71">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the outstanding potentially dilutive securities determined using the treasury stock and if-converted methods that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:13px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock, on an as-converted basis   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,443,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,654,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;830,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;830,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,443,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,714,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-83118A2AA835B498DB538FE610088652">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity &lt;br clear="none"/&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized &lt;br clear="none"/&gt;cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated &lt;br clear="none"/&gt;fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&amp;#160;year&amp;#160;or&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity &lt;br clear="none"/&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized &lt;br clear="none"/&gt;cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated &lt;br clear="none"/&gt;fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&amp;#160;year&amp;#160;or&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2016Q4YTD" id="Fact-79BAF4D30AFB9ECC2D1194868042211C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The income tax provision (benefit) consists of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total current provision   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred provision   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax provision (benefit)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2016Q4YTD" id="Fact-9DAF2E8C335533C3B13E94146ABC5173">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term loan and unamortized debt discount balances are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Face value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term loan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: current portion of long-term loan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term loan, excluding current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-AE644B74ACC0E0079AF994888DBF86DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets as are shown below: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign net operating losses   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research and development   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total gross deferred tax assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less valuation allowance   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2016Q4YTD" id="Fact-1B41FB9D2C35B583A6C78FE1FC411205">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except shares and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares used in computing net loss per share   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,221,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;573,181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;531,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-04C28B19F1F25ED13EBE9488033F9122">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The difference between income tax benefits and income taxes computed using the U.S. federal income tax rate as of December&amp;#160;31, 2016, 2015 and 2014 are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At statutory rates   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes, net of federal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,291&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign operations   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax provision (benefit)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q4YTD" id="Fact-327D0E428C0EC1739D7C93EC9B657519">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recorded non-cash compensation, including non-cash compensation to employees and nonemployees in the consolidated statements of operations and comprehensive loss as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:8px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of revenue   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;563&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2016Q4YTD" id="Fact-FE22C921F459009A078E8FE041D9C49C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities measured at fair value on a recurring basis at December&amp;#160;31, 2016 and 2015 are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;value&amp;#160;measurements&amp;#160;at&amp;#160;reporting&amp;#160;date&amp;#160;using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;prices&lt;br clear="none"/&gt;in&amp;#160;active&lt;br clear="none"/&gt;markets&amp;#160;for&lt;br clear="none"/&gt;identical&amp;#160;assets&lt;br clear="none"/&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br clear="none"/&gt;other&lt;br clear="none"/&gt;observable&lt;br clear="none"/&gt;inputs&lt;br clear="none"/&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br clear="none"/&gt;unobservable&lt;br clear="none"/&gt;inputs&lt;br clear="none"/&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury bonds(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;value&amp;#160;measurements&amp;#160;at&amp;#160;reporting&amp;#160;date&amp;#160;using&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;prices&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;active &lt;br clear="none"/&gt;markets for &lt;br clear="none"/&gt;identical&amp;#160;assets &lt;br clear="none"/&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant &lt;br clear="none"/&gt;other &lt;br clear="none"/&gt;observable &lt;br clear="none"/&gt;inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant &lt;br clear="none"/&gt;unobservable &lt;br clear="none"/&gt;inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds(1)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury bonds(2)   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant liability   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Classified as cash and cash equivalents on the consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Classified as short-term investments on the consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-AFB01BEC146C812A2E0C8FF34190556F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future noncancelable minimum payment obligations under the operating lease were as follows as of December 31, 2016 (in thousands):&lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future payments due under building lease   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2016Q4YTD" id="Fact-04080AE9ABC5538116168FE647F9EAE4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work in process   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;209&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2016Q4YTD" id="Fact-6D480F56ABF58E1B667A9414438DA6EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December&amp;#160;31, 2016, future principal payments due under the December 2016 Loan Agreement are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;padding-left:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future principal payments due under the December 2016&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;padding-left:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Loan Agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-80AFFAE30FA91AA9A1328FE68B82C3A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current assets consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;234&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest receivable   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-12B0CAF113DE177B87D0946943EE2E45">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the quarterly results of the Company for the years ended December&amp;#160;31, 2016 and 2015&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(unaudited, in thousands, except for per share data)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue         &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross profit   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Per common share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue         &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross profit   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Per common share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-229858BAD41B7128E0F093EC3DB4664D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option transactions for the Plan for the years ended December&amp;#160;31, 2016, 2015 and 2014 (in thousands, except shares and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of &lt;br clear="none"/&gt;shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;average &lt;br clear="none"/&gt;exercise &lt;br clear="none"/&gt;price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;average &lt;br clear="none"/&gt;remaining &lt;br clear="none"/&gt;contractual &lt;br clear="none"/&gt;life&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate &lt;br clear="none"/&gt;intrinsic value &lt;br clear="none"/&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2015   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,298,868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,787,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(808,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(51,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,225,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,929,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and exercisable at December&amp;#160;31, 2016   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;485,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-B3D48F123B319A1F42C293ECD9422A2D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed risk-free interest rate   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.40% -1.53%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.57%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.82%&amp;#160;-&amp;#160;2.09%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assumed volatility   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;52.91% - 53.49%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61.53%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71.09%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected option life   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2016Q4YTD" id="Fact-A9402BF8A5EAD5341F3C8FFBE3704152">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following warrants were outstanding as of December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;average &lt;br clear="none"/&gt;exercise &lt;br clear="none"/&gt;price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issuance date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Feb&amp;#160;24, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Feb&amp;#160;24, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2016Q4YTD" id="Fact-283C287B550AA92DBE94D20CC326FA3F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes certain financial data for the customers who accounted for 10.0% or more of sales and accounts receivable. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Single largest customer:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue, related party   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable, related party   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Second largest customer:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2016Q4YTD" id="Fact-87B265ED59A020A06A9A8FD6E7AE70C9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based awards issued to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the employee&amp;#8217;s or director&amp;#8217;s requisite service period (generally the vesting period). Because non-cash stock compensation expense is based on awards ultimately expected to vest, it is reduced by an estimate for future forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2016Q4YTD" id="Fact-09AECF6D698455FC075A8FC6865444AF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all highly liquid investments with original maturities of three&amp;#160;months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term Investments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses, if any, reported as a component of other comprehensive loss within the consolidated statements of operations and comprehensive loss. All of the Company&amp;#8217;s short-term investments are U.S.&amp;#160;Treasury notes with maturities of less than one&amp;#160;year. For the years ended December&amp;#160;31, 2016, 2015 and 2014, unrealized losses were immaterial amounts, respectively. Realized gains and losses would be calculated on the specific-identification method and recorded as interest income. There have been no material realized gains and losses for the years ended December&amp;#160;31, 2016, 2015 and 2014. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying values of the Company&amp;#8217;s financial instruments, including cash and cash equivalents, accounts receivable from related party, accounts payable, and accrued expenses approximate their fair values due to the short maturity of these instruments. The carrying value of the term loan approximates its fair value as the interest rate and other terms are that which is currently available to the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels in accordance with authoritative accounting guidance: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:16px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:16px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2 inputs: Other than quoted prices included in Level&amp;#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:16px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Receivables are unsecured and are carried at net realizable value including an allowance for estimated uncollectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest, although a finance charge may be applied to such receivables that are more than 30&amp;#160;days past due. The allowance for doubtful accounts is based on the Company&amp;#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical expense, credit quality, the age of the account receivable balances, and current economic conditions that may affect a customer&amp;#8217;s ability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. The Company&amp;#8217;s allowance for doubtful accounts was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at both December 31, 2016 and 2015, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company&amp;#8217;s customers consist of distributors. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:100%;padding-top:1px;text-align:center;font-size:4pt;"&gt;&lt;font style="font-family:inherit;font-size:4pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes certain financial data for the customers who accounted for 10.0% or more of sales and accounts receivable. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Single largest customer:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue, related party   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable, related party   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Second largest customer:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or net realizable value, computed on a standard cost basis. Inventory that is obsolete or is in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The useful lives of the property and equipment are as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer software   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter&amp;#160;of&amp;#160;3&amp;#160;years&amp;#160;or&amp;#160;length&amp;#160;of&amp;#160;software license&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of the assets to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the difference between the carrying amount and the fair value of the impaired asset. The Company did not recognize any material impairment losses for the respective years ended December&amp;#160;31, 2016, 2015 and 2014. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All research and development costs are charged to expense as incurred. Research and development expenses primarily include (i)&amp;#160;payroll and related costs associated with research and development performed, (ii)&amp;#160;costs related to clinical and preclinical testing of our technologies under development and (iii)&amp;#160;other research and development expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Clinical Trial Expenses &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into contracts with third party hospitals and doctors to perform clinical trial activities. The Company accrues expenses for clinical trial activities performed by third parties based on estimates of work performed by each third party as of the balance sheet date. The Company&amp;#8217;s clinical trial expense is primarily driven by patient visits to the third party hospitals and doctors. As such, the Company uses the estimated patient visits based on third-party reporting and the contractually agreed upon cost for each visit to calculate its clinical accrual. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based awards issued to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the employee&amp;#8217;s or director&amp;#8217;s requisite service period (generally the vesting period). Because non-cash stock compensation expense is based on awards ultimately expected to vest, it is reduced by an estimate for future forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for interest and penalties related to income tax matters, if any, as a component of income tax expense or benefit. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue relates to sales of components of the Obalon balloon system, which includes the balloon and accessory kit, EzFill inflation system, pre-filled can of gas and placebo capsule. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when (i)&amp;#160;persuasive evidence of an arrangement exists, (ii)&amp;#160;delivery has occurred, (iii)&amp;#160;the selling price is fixed or determinable and (iv)&amp;#160;collectability is reasonably assured. Determination of criteria (iii)&amp;#160;and (iv)&amp;#160;are based on management&amp;#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company does not provide for rights of return to customers on product sales, with the exception of products that fail to conform to the Company&amp;#8217;s specifications. As these non-conforming returns have historically been immaterial, the Company does not record a provision for returns. The Company does not have any post shipment obligations or acceptance provisions within its customer contracts. The Company occasionally offers discounts off its standard prices to non-distributor customers, which are agreed upon and known at the time of sale. In these cases, revenue is recognized net of these discounts. Shipping charges billed to customers are included in product revenue and the related shipping costs are included in cost of revenue. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Product Warranty &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company warranties its products to be of good quality and free from defects in design, materials, or workmanship for approximately one&amp;#160;year from the date of purchase. The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based on historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;It is possible that the Company&amp;#8217;s underlying assumptions will not reflect the actual experience and in that case, future adjustments will be made to the recorded warranty obligation. The warranty expense as of December&amp;#160;31, 2016, 2015 and 2014 was immaterial for each year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising Costs &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Advertising costs are expensed as incurred and included in selling, general and administrative expense. Advertising costs for the years ended December&amp;#160;31, 2016, 2015 and 2014 were approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for 2016, 2015 and 2014, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Preferred Stock Warrants &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of preferred stock warrants issued in conjunction with debt issuances was initially recorded as a warrant liability and debt discount. The debt discount associated with the initial warrant fair value is being amortized to interest expense using the effective-interest method in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss over the term of the debt. The fair value of preferred stock warrants issued in conjunction with preferred stock issuances was initially recorded as a warrant liability and reduction of the proceeds received. The fair value of the warrants was estimated using the Black-Scholes option pricing model based on the estimated fair value of the preferred stock at the valuation date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying preferred stock. Prior to the automatic conversion of the warrants in conjunction with the IPO on October 12, 2016, the warrant liability was remeasured each reporting period with changes in fair value being recognized in the consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As noted above in Note 1, in connection with the completion of the Company&amp;#8217;s IPO, all the remaining outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As such, the Company reclassified the remaining warrant liability to stockholders&amp;#8217; equity as the converted warrants met the definition of an equity instrument under derivative accounting guidance. The Company performed the final remeasurement of the warrant liability as of the IPO closing date. See Note 3 for the amounts associated with the fair value remeasurements and Note 8 for further description of the remaining warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Share &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per common share, since the effects of potentially dilutive securities are anti-dilutive. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive common stock equivalents are comprised of convertible preferred stock, warrants and unexercised stock options outstanding under the Company&amp;#8217;s equity plan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ASU 2014-15 requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable that when, considered in the aggregate, raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued, for both annual and interim periods. ASU 2014-15 also requires certain disclosures around management&amp;#8217;s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that will alleviate the substantial doubt. ASU 2014-15 is effective for annual reporting periods, and interim periods within those periods, beginning after December&amp;#160;15, 2016. The adoption of ASU 2014-15 did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July&amp;#160;2015, FASB&amp;#160;issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This update applies to companies that measure inventory on a first in, first out, or FIFO, or average cost basis. Under this update, companies are to measure their inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion. The amendments in this update are effective for annual reporting periods, and interim periods within those periods, beginning after December&amp;#160;15, 2016 with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Under this new guidance, at the commencement date, lessees will be required to recognize (i)&amp;#160;a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii)&amp;#160;a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted.&amp;#160;The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2015, the FASB issued ASU 2015-14, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09, which was issued in March 2014 and has been codified with the Accounting Standards Codification as Topic 606, is now effective for public companies for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. ASC 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In addition, ASC 606 provides guidance on accounting for certain revenue-related costs including, but not limited to, when to capitalize costs associated with obtaining and fulfilling a contract. ASC 606 provides companies with two implementation methods: (a) full retrospective adoption, meaning the standard is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance.&amp;#160;Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within ASC 606 to clarify various elements of the guidance. While the Company is continuing to assess all potential impacts of the standard, they do not believe that their current revenue streams will be materially affected. As the Company begins commercialization in the U.S. during 2017 and enters into sales agreements with customers as part of this commercialization, the Company will continue to assess the potential impacts of the standard, including the impact to the pattern with which they recognize revenue based on the terms entered into and finalizing the determination of transition approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which involves several aspects of the accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This new guidance will require all income&amp;#160;tax effects of awards to be recognized as income tax expense or benefit in the income statement when the awards vest or are settled, as opposed to additional paid-in-capital where it is currently recorded. It&amp;#160;also will allow an employer to repurchase more of an employee&amp;#8217;s shares than it can today for tax withholding purposes without triggering liability accounting. All tax-related cash flows resulting from stock-based payments are to be reported as operating activities on&amp;#160;the statement of cash flows. The guidance also allows a Company to make a policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. This new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2016, with early adoption permitted. The Company does not recognize any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance on its deferred tax assets. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;, which addresses the following eight specific cash flow issues: Debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies); distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2017, with early adoption permitted.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;The Company does not anticipate that the adoption of ASU 2016-15 will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StandardProductWarrantyPolicy contextRef="FD2016Q4YTD" id="Fact-5457B0EA3B069D25A31A8FD171158940">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Product Warranty &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company warranties its products to be of good quality and free from defects in design, materials, or workmanship for approximately one&amp;#160;year from the date of purchase. The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based on historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;It is possible that the Company&amp;#8217;s underlying assumptions will not reflect the actual experience and in that case, future adjustments will be made to the recorded warranty obligation. The warranty expense as of December&amp;#160;31, 2016, 2015 and 2014 was immaterial for each year. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StandardProductWarrantyPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-6D6467F5BA82E6EC0F488FFAE45E33A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Convertible Preferred Stock and Stockholders&amp;#8217; Deficit &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Convertible Preferred Stock &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock prior to automatic conversion of all shares to common stock immediately prior to the closing of the IPO consisted of the following (in thousands, except for shares):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&amp;#160;issued&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;and&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;liquidation&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;preference&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,333,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;804,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,333,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,494,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,809,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,668,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C-1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,418,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;480,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,076,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,732,552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series E&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,490,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,916,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,799&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,460,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,096,639&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Series E Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 4, 2016, the Company completed its Series E financing.&amp;#160;The Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,916,425&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series E stock at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.2932&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in issuance costs, which includes a non-cash amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; issued to a related party as further described in Note 11.&amp;#160;The holders of Series E stock are entitled to receive dividends, if declared, at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6635&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum.&amp;#160;In the event of liquidation, the holders of Series E shares are entitled to receive liquidation preferences at the rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.2932&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160;Each share of Series E stock is convertible to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of common stock immediately upon (i)&amp;#160;the Company&amp;#8217;s sale of its common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, in which per share price is at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.44&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (as adjusted)&amp;#160;or (ii)&amp;#160;the affirmative vote of more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the holders of the then-outstanding preferred stock voting together as a single class.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2015, the convertible preferred stock was classified as temporary equity in the accompanying balance sheet as the shares included provisions that allowed the holder to cause redemption of the shares upon certain changes in control events that are outside of the Company&amp;#8217;s control. An aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,360,419&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, excluding any warrant conversions, were issued to the holders of the Company&amp;#8217;s Series A, Series B, Series C, Series C-1, Series D and Series E convertible preferred stockholders upon the automatic conversion of all shares of convertible preferred stock to common stock immediately prior to the closing of the IPO. As a result, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series A, Series B, Series C, Series C-1, Series D or Series E convertible preferred stock remain outstanding at December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Outstanding Warrants &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following warrants were outstanding as of December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;average &lt;br clear="none"/&gt;exercise &lt;br clear="none"/&gt;price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issuance date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Feb&amp;#160;24, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Feb&amp;#160;24, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1) Prior to conversion upon IPO, the remaining warrants were for the purchase of Series C preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the fourth quarter 2016, warrants for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,112&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,775&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Reserved for Future Issuance &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock reserved for future issuance consists of the following at December&amp;#160;31, 2016: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options issued and outstanding   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,225,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Authorized for future option grants   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,386,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants outstanding   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,636,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="FD2016Q4YTD" id="Fact-12F0BD507287CF584B448FDD6CD0FDA8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Preferred Stock Warrants &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of preferred stock warrants issued in conjunction with debt issuances was initially recorded as a warrant liability and debt discount. The debt discount associated with the initial warrant fair value is being amortized to interest expense using the effective-interest method in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss over the term of the debt. The fair value of preferred stock warrants issued in conjunction with preferred stock issuances was initially recorded as a warrant liability and reduction of the proceeds received. The fair value of the warrants was estimated using the Black-Scholes option pricing model based on the estimated fair value of the preferred stock at the valuation date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying preferred stock. Prior to the automatic conversion of the warrants in conjunction with the IPO on October 12, 2016, the warrant liability was remeasured each reporting period with changes in fair value being recognized in the consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As noted above in Note 1, in connection with the completion of the Company&amp;#8217;s IPO, all the remaining outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As such, the Company reclassified the remaining warrant liability to stockholders&amp;#8217; equity as the converted warrants met the definition of an equity instrument under derivative accounting guidance. The Company performed the final remeasurement of the warrant liability as of the IPO closing date. See Note 3 for the amounts associated with the fair value remeasurements and Note 8 for further description of the remaining warrants.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2016Q4YTD" id="Fact-706EA3D5E7E394B9EDFA4D43F71CF514">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Lease Extension&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 15, 2017, the Company extended its facility lease agreement under a noncancelable operating lease that expires on March&amp;#160;31, 2019. All commitment tables previously presented reflect incorporation of the amendment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Option Grants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subsequent to December 31, 2016, stock options for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of the Company&amp;#8217;s common stock were granted to new Company employees, including the Company's new Board of Director member.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2016Q4YTD" id="Fact-5ECEC5E3EF9702D05F5A8FE5D581EDAB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;Balance Sheet Details &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity &lt;br clear="none"/&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized &lt;br clear="none"/&gt;cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated &lt;br clear="none"/&gt;fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&amp;#160;year&amp;#160;or&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity &lt;br clear="none"/&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized &lt;br clear="none"/&gt;cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross &lt;br clear="none"/&gt;unrealized &lt;br clear="none"/&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated &lt;br clear="none"/&gt;fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&amp;#160;year&amp;#160;or&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work in process   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;209&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current assets consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;234&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest receivable   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other assets   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress, or CIP   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization expense for the years ended December&amp;#160;31, 2016, 2015 and 2014 was $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million for all periods, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current liabilities consist of the following (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,399&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:TemporaryEquityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-C2EF59575E9176F0FBB38FFB98FB9966">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock prior to automatic conversion of all shares to common stock immediately prior to the closing of the IPO consisted of the following (in thousands, except for shares):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&amp;#160;issued&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;and&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;liquidation&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;preference&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,333,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;804,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,333,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,494,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,809,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,668,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series C-1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,418,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;480,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,076,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,732,552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series E&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,490,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,916,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,799&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,460,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,096,639&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2016Q4YTD" id="Fact-E9FFB12643AA583B03A18FD95A3EDDCA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Receivables are unsecured and are carried at net realizable value including an allowance for estimated uncollectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest, although a finance charge may be applied to such receivables that are more than 30&amp;#160;days past due. The allowance for doubtful accounts is based on the Company&amp;#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical expense, credit quality, the age of the account receivable balances, and current economic conditions that may affect a customer&amp;#8217;s ability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2016Q4YTD" id="Fact-07496A43538B85CB2ECB8FC8825B6718">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>obln-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.obalon.com/20161231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:obln="http://www.obalon.com/20161231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="obln-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="obln-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="obln-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="obln-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BalanceSheetDetails" roleURI="http://www.obalon.com/role/BalanceSheetDetails">
        <link:definition>2105100 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsAdditionalInformationDetails" roleURI="http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails">
        <link:definition>2405402 - Disclosure - Balance Sheet Details - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleOfInventoryDetails" roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails">
        <link:definition>2405404 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails">
        <link:definition>2405405 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails">
        <link:definition>2405407 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>2405406 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails">
        <link:definition>2405403 - Disclosure - Balance Sheet Details - Schedule of Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://www.obalon.com/role/BalanceSheetDetailsTables">
        <link:definition>2305301 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.obalon.com/role/CommitmentsAndContingencies">
        <link:definition>2110100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>2410402 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails">
        <link:definition>2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Noncancelable Minimum Payment Obligations Under Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2310301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>1003001 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndStockholdersDeficit" roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit">
        <link:definition>2108100 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails">
        <link:definition>2408402 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>2408405 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails">
        <link:definition>2408403 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Schedule of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails">
        <link:definition>2408404 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Schedule of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndStockholdersDeficitTables" roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables">
        <link:definition>2308301 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.obalon.com/role/DocumentAndEntityInformation">
        <link:definition>0002000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.obalon.com/role/FairValueMeasurements">
        <link:definition>2103100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2403402 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2403403 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails">
        <link:definition>2403404 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Warrant Liability Using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails">
        <link:definition>2403405 - Disclosure - Fair Value Measurements - Schedule of Reconciliation for All Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.obalon.com/role/FairValueMeasurementsTables">
        <link:definition>2303301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.obalon.com/role/IncomeTaxes">
        <link:definition>2109100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2409402 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2409405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2409404 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxProvisionBenefitDetails" roleURI="http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails">
        <link:definition>2409403 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.obalon.com/role/IncomeTaxesTables">
        <link:definition>2309301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.obalon.com/role/NetLossPerShare">
        <link:definition>2104100 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>2404403 - Disclosure - Net Loss per Share - Schedule of Anti-Dilutive Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails">
        <link:definition>2404402 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.obalon.com/role/NetLossPerShareTables">
        <link:definition>2304301 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndBasisOfPresentation" roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>2401401 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.obalon.com/role/RelatedPartyTransactions">
        <link:definition>2111100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2411401 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2112100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails">
        <link:definition>2412402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2312301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.obalon.com/role/StockBasedCompensation">
        <link:definition>2107100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2407402 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails">
        <link:definition>2407403 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Stock Options for Employees was Estimated using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails">
        <link:definition>2407404 - Disclosure - Stock-Based Compensation - Summary of Non-cash Compensation to Employees and Nonemployees in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfStockOptionTransactionsDetails" roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails">
        <link:definition>2407405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.obalon.com/role/StockBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.obalon.com/role/SubsequentEvents">
        <link:definition>2113100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>2413401 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoan" roleURI="http://www.obalon.com/role/TermLoan">
        <link:definition>2106100 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoanAdditionalInformationDetails" roleURI="http://www.obalon.com/role/TermLoanAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Term Loan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" roleURI="http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails">
        <link:definition>2406404 - Disclosure - Term Loan - Schedule of Future Principal Payments Due (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" roleURI="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails">
        <link:definition>2406403 - Disclosure - Term Loan - Summary of Total Long-term Loan and Unamortized Debt Discount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetailsCalc2" roleURI="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetailsCalc2">
        <link:definition>2406403 - Disclosure - Term Loan - Summary of Total Long-term Loan and Unamortized Debt Discount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoanTables" roleURI="http://www.obalon.com/role/TermLoanTables">
        <link:definition>2306301 - Disclosure - Term Loan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="obln_AccruedClinicalExpensesCurrent" name="AccruedClinicalExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="obln_AccruedLegalCurrent" name="AccruedLegalCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember" name="AvailableForSaleSecuritiesMaturityInOneYearOrLessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_BaderSultanAndBrosCoWLLMember" name="BaderSultanAndBrosCoWLLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_BasisOfPresentationAndOrganizationLineItems" name="BasisOfPresentationAndOrganizationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_BasisOfPresentationAndOrganizationTable" name="BasisOfPresentationAndOrganizationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock" name="ClassOfWarrantsOrRightsIssuedForPurchaseOfStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="obln_ClinicalTrialExpensesPolicyPolicyTextBlock" name="ClinicalTrialExpensesPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock" name="ConversionOfCustomerDepositFromRelatedPartyToPreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="obln_ConversionOfTemporaryEquityToCommonStockPercentage" name="ConversionOfTemporaryEquityToCommonStockPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_CustomerTwoMember" name="CustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_DecemberTwoThousandSixteenLoanAgreementMember" name="DecemberTwoThousandSixteenLoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_DistributionAgreementMember" name="DistributionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_EquityIncentivePlanMember" name="EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember" name="FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_FirstTrancheMember" name="FirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_IncreaseDecreaseInAccruedClinicalExpenses" name="IncreaseDecreaseInAccruedClinicalExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments" name="LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock" name="MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility" name="MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="obln_NonvestedStockOptionsEarlyExercised" name="NonvestedStockOptionsEarlyExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="obln_NumberOfTranches" name="NumberOfTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="obln_NumberOfWarrantsExercise" name="NumberOfWarrantsExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="obln_ObalonMexicoDERLCVMember" name="ObalonMexicoDERLCVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_OwnershipPercentageHeldByShellCompany" name="OwnershipPercentageHeldByShellCompany" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="obln_PacificWesternBankMember" name="PacificWesternBankMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_PercentageChangeInPresentValueOfFutureCashFlows" name="PercentageChangeInPresentValueOfFutureCashFlows" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_PercentageOfBorrowingsForIssuanceOfWarrant" name="PercentageOfBorrowingsForIssuanceOfWarrant" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty" name="ProceedsfromIssuanceofPreferredStocktoRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="obln_PurchasePricePerShare" name="PurchasePricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="obln_ReclassificationsofWarrantLiabilitytoPermanentEquity" name="ReclassificationsofWarrantLiabilitytoPermanentEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares" name="ReclassificationsofWarrantLiabilitytoPermanentEquityShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue" name="RevenueFromRelatedPartiesAsPercentageOfNetRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_ScientificEquipmentMember" name="ScientificEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SecondTrancheMember" name="SecondTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeptemberTwoThousandSixteenLoanAgreementMember" name="SeptemberTwoThousandSixteenLoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeriesCOneConvertiblePreferredStockMember" name="SeriesCOneConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeriesCOnePreferredStockMember" name="SeriesCOnePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_SeriesEConvertiblePreferredStockMember" name="SeriesEConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants" name="SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_StockOptionsEarlyExercised" name="StockOptionsEarlyExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_StockOptionsEarlyExercisedLiability" name="StockOptionsEarlyExercisedLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="obln_StockOptionsIssuedAndOutstandingMember" name="StockOptionsIssuedAndOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_TemporaryEquityDividendRatePerShareAmount" name="TemporaryEquityDividendRatePerShareAmount" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_TermLoanAMember" name="TermLoanAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_TermLoanBMember" name="TermLoanBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_TwoThousandAndEightPlanMember" name="TwoThousandAndEightPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" name="TwoThousandAndSixteenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_TwoThousandFourteenLoanAgreementMember" name="TwoThousandFourteenLoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_TwoThousandSixteenEquityIncentivePlanMember" name="TwoThousandSixteenEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_TwoThousandThirteenLoanAgreementMember" name="TwoThousandThirteenLoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="obln_WarrantLiabilityMember" name="WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock" name="WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>obln-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsTables" xlink:href="obln-20161231.xsd#BalanceSheetDetailsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingencies" xlink:href="obln-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesTables" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheets" xlink:href="obln-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="obln-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/DocumentAndEntityInformation" xlink:href="obln-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurements" xlink:href="obln-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsTables" xlink:href="obln-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxes" xlink:href="obln-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="obln-20161231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="obln-20161231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="obln-20161231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:href="obln-20161231.xsd#IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesTables" xlink:href="obln-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShare" xlink:href="obln-20161231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="obln-20161231.xsd#NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:href="obln-20161231.xsd#NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareTables" xlink:href="obln-20161231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentation" xlink:href="obln-20161231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:href="obln-20161231.xsd#OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/RelatedPartyTransactions" xlink:href="obln-20161231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensation" xlink:href="obln-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationTables" xlink:href="obln-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SubsequentEvents" xlink:href="obln-20161231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#SubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoan" xlink:href="obln-20161231.xsd#TermLoan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanAdditionalInformationDetails" xlink:href="obln-20161231.xsd#TermLoanAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:href="obln-20161231.xsd#TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:href="obln-20161231.xsd#TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetailsCalc2" xlink:href="obln-20161231.xsd#TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanTables" xlink:href="obln-20161231.xsd#TermLoanTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4cde1efa-07a8-ded0-f592-2cecba3dedaf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4cde1efa-07a8-ded0-f592-2cecba3dedaf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_d336a89a-bb4d-935b-6897-1b0949a32913" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:to="loc_us-gaap_InterestReceivableCurrent_d336a89a-bb4d-935b-6897-1b0949a32913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_17d2cd44-6483-9e36-8c5d-71299fd686cf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_17d2cd44-6483-9e36-8c5d-71299fd686cf" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_AccruedLegalCurrent" xlink:label="loc_obln_AccruedLegalCurrent_4c00dc3f-f35f-b04c-a309-8f86d56c2f26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:to="loc_obln_AccruedLegalCurrent_4c00dc3f-f35f-b04c-a309-8f86d56c2f26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:to="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84c4a6c6-0ef3-3da8-6f9e-7c79d920503a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84c4a6c6-0ef3-3da8-6f9e-7c79d920503a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e53108a7-1cbc-ad68-00fa-93ab35ee9629" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e53108a7-1cbc-ad68-00fa-93ab35ee9629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38a4602-a509-ea84-d4a7-84b6783fb543" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38a4602-a509-ea84-d4a7-84b6783fb543" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1261866d-0058-b147-bcc2-b0839e573baf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1261866d-0058-b147-bcc2-b0839e573baf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_AccruedClinicalExpensesCurrent" xlink:label="loc_obln_AccruedClinicalExpensesCurrent_69a71c2b-0612-f5c3-0428-8f86d572e938" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_obln_AccruedClinicalExpensesCurrent_69a71c2b-0612-f5c3-0428-8f86d572e938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_89e55382-2a87-0545-0ec9-fdc5c31487cd" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_RelatedPartyDepositLiabilities_89e55382-2a87-0545-0ec9-fdc5c31487cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_abb88b5c-ef84-43b7-a075-78b44bb32132" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_abb88b5c-ef84-43b7-a075-78b44bb32132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5edda81e-c711-ca69-2826-8af23da46bd2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5edda81e-c711-ca69-2826-8af23da46bd2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_cba84dc8-4958-54c2-1b6f-e02bffbabe75" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_ShortTermInvestments_cba84dc8-4958-54c2-1b6f-e02bffbabe75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_488b886d-2c52-f9c8-7a8b-d28cd7c2737e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_488b886d-2c52-f9c8-7a8b-d28cd7c2737e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_35d7e9b2-6ffb-6e68-f590-8605f30d5f8a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DepreciationAndAmortization_35d7e9b2-6ffb-6e68-f590-8605f30d5f8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_77913d2a-d84a-6285-386d-fcf9262888b2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_77913d2a-d84a-6285-386d-fcf9262888b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_721e1a2c-7f31-841f-8094-3b154fa61fcf" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_721e1a2c-7f31-841f-8094-3b154fa61fcf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_ec473442-534a-f3e2-60d2-3a01c798e3a0" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_ec473442-534a-f3e2-60d2-3a01c798e3a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_71d33c1e-c7fc-97d1-1bc4-a959482e606f" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_71d33c1e-c7fc-97d1-1bc4-a959482e606f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_04170815-b2b6-fb8f-5ca6-e1c62554f777" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_04170815-b2b6-fb8f-5ca6-e1c62554f777" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_IncreaseDecreaseInAccruedClinicalExpenses" xlink:label="loc_obln_IncreaseDecreaseInAccruedClinicalExpenses_5fae3d77-16fe-a703-b7d1-8f86d57281bf" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_obln_IncreaseDecreaseInAccruedClinicalExpenses_5fae3d77-16fe-a703-b7d1-8f86d57281bf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_071e32b9-2ae1-0fdb-f801-d54af8ad45c0" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_071e32b9-2ae1-0fdb-f801-d54af8ad45c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_f48c0937-387b-63ed-f9f7-98f267b0cd30" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_f48c0937-387b-63ed-f9f7-98f267b0cd30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7eefdb79-b488-fe99-9b8e-a51ddf6de5ad" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7eefdb79-b488-fe99-9b8e-a51ddf6de5ad" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_39ec8106-b5d8-c4fd-2af7-167ed8b78e3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_39ec8106-b5d8-c4fd-2af7-167ed8b78e3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_e1d5c175-5fec-c1e5-c00f-3705673f3dcd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_e1d5c175-5fec-c1e5-c00f-3705673f3dcd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da5d3613-0426-0efc-e877-f02868c1f6ef" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da5d3613-0426-0efc-e877-f02868c1f6ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24372e3a-d7cf-aeb5-3e3e-92a986bb9251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24372e3a-d7cf-aeb5-3e3e-92a986bb9251" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty" xlink:label="loc_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_8B843D3762580B88D15538F32EFCA644" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_8B843D3762580B88D15538F32EFCA644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_118aefa3-1f18-dd7c-3c82-2d1b60f590a6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_118aefa3-1f18-dd7c-3c82-2d1b60f590a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_36ecd7ee-1316-61f2-d294-4d3eda953ee8" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_36ecd7ee-1316-61f2-d294-4d3eda953ee8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_a3cfa2ef-65ce-536b-4778-0ecfaa8afbb9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_SalesRevenueServicesNet_a3cfa2ef-65ce-536b-4778-0ecfaa8afbb9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_35da5251-9b8d-923d-c0c1-ee0302d8c84c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_RevenueFromRelatedParties_35da5251-9b8d-923d-c0c1-ee0302d8c84c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_5a47dae5-ba55-9292-41d8-64f380f46a8c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_CostOfRevenue_5a47dae5-ba55-9292-41d8-64f380f46a8c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c3f75946-8339-c884-022f-1e599b08f0f5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c3f75946-8339-c884-022f-1e599b08f0f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_d85959de-72ec-7fd7-3385-928760bc556d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_d85959de-72ec-7fd7-3385-928760bc556d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_aaa13f1e-b61e-5e3a-0a94-85891bf5c2c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_aaa13f1e-b61e-5e3a-0a94-85891bf5c2c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bdc6598b-bd97-4cc7-9f4f-5d5ac82ed0ed" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bdc6598b-bd97-4cc7-9f4f-5d5ac82ed0ed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b6c76c51-9163-a2c4-e48f-4450dcc2ac29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b6c76c51-9163-a2c4-e48f-4450dcc2ac29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_01db0ee8-dc9d-9a44-534f-a2200747ef03" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_01db0ee8-dc9d-9a44-534f-a2200747ef03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7988daaa-e3da-5096-4bce-cb601f0ef813" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7988daaa-e3da-5096-4bce-cb601f0ef813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bad8f4f3-f415-9ec4-1169-fc6c9b538394" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bad8f4f3-f415-9ec4-1169-fc6c9b538394" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f316d4eb-12c7-f1d0-fd3d-ba8b892345ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f316d4eb-12c7-f1d0-fd3d-ba8b892345ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_88730b7a-f2f4-51cb-d8a1-7a903025ce13" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_88730b7a-f2f4-51cb-d8a1-7a903025ce13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_79489ccf-36b3-815d-b6db-f2a6ac50099c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_79489ccf-36b3-815d-b6db-f2a6ac50099c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b8476f99-9bab-21a6-d61d-02a9c0661176" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b8476f99-9bab-21a6-d61d-02a9c0661176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ab57836-244f-310a-5a92-cb6b846a6a17" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ab57836-244f-310a-5a92-cb6b846a6a17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4ecf0d1c-66f0-0be9-cfb9-ecdef8184a9e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4ecf0d1c-66f0-0be9-cfb9-ecdef8184a9e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/OrganizationAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/TermLoan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/TermLoanAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6baa2d31-3357-b671-25ea-61502c236830" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6baa2d31-3357-b671-25ea-61502c236830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fff555d3-22e2-1be9-15a7-f79f0064a4bb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fff555d3-22e2-1be9-15a7-f79f0064a4bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c5420c55-b70f-9186-5b0e-88de7d1b3712" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c5420c55-b70f-9186-5b0e-88de7d1b3712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7b82936a-3efa-d722-acea-fbe08d94cdb3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7b82936a-3efa-d722-acea-fbe08d94cdb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6231296c-2b9b-a710-fe01-a01a31f4eeb8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6231296c-2b9b-a710-fe01-a01a31f4eeb8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8d6cb6ad-eca9-d2ff-28a4-685ac01d9f21" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8d6cb6ad-eca9-d2ff-28a4-685ac01d9f21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_4bf1b58e-d91b-9b24-5683-900eae6fad07" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_4bf1b58e-d91b-9b24-5683-900eae6fad07" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_51F5922E9F469EBC04E238DB955279F3_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_51F5922E9F469EBC04E238DB955279F3_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_51F5922E9F469EBC04E238DB955279F3_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtCurrent_51F5922E9F469EBC04E238DB955279F3_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_51F5922E9F469EBC04E238DB955279F3_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_51F5922E9F469EBC04E238DB955279F3_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_51F5922E9F469EBC04E238DB955279F3_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.obalon.com/role/TermLoanTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>obln-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsTables" xlink:href="obln-20161231.xsd#BalanceSheetDetailsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingencies" xlink:href="obln-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesTables" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheets" xlink:href="obln-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="obln-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/DocumentAndEntityInformation" xlink:href="obln-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurements" xlink:href="obln-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsTables" xlink:href="obln-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxes" xlink:href="obln-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="obln-20161231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="obln-20161231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="obln-20161231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:href="obln-20161231.xsd#IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesTables" xlink:href="obln-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShare" xlink:href="obln-20161231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="obln-20161231.xsd#NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:href="obln-20161231.xsd#NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareTables" xlink:href="obln-20161231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentation" xlink:href="obln-20161231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:href="obln-20161231.xsd#OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/RelatedPartyTransactions" xlink:href="obln-20161231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensation" xlink:href="obln-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationTables" xlink:href="obln-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SubsequentEvents" xlink:href="obln-20161231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#SubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoan" xlink:href="obln-20161231.xsd#TermLoan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanAdditionalInformationDetails" xlink:href="obln-20161231.xsd#TermLoanAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:href="obln-20161231.xsd#TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:href="obln-20161231.xsd#TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanTables" xlink:href="obln-20161231.xsd#TermLoanTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ScientificEquipmentMember" xlink:label="loc_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:to="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4B5FB923DE1E18AF29344DBFB2F72EF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4B5FB923DE1E18AF29344DBFB2F72EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember" xlink:label="loc_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:to="loc_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8012C27F61F07C3E9BDB4D38987E8A82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:to="loc_us-gaap_StatementTable_8012C27F61F07C3E9BDB4D38987E8A82" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11BB9410AEC2C9E8E4344D38987E8468" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8012C27F61F07C3E9BDB4D38987E8A82" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11BB9410AEC2C9E8E4344D38987E8468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11BB9410AEC2C9E8E4344D38987E8468" xlink:to="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11BB9410AEC2C9E8E4344D38987E8468" xlink:to="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_47D98A3F97BE530B65EF4D38987FE9C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_47D98A3F97BE530B65EF4D38987FE9C0" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_B6ADBACAA1A9DF5DCBF64D38987FDF08" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_B6ADBACAA1A9DF5DCBF64D38987FDF08" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_801E41B65F3BBE5D58D84D38987FB568" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_801E41B65F3BBE5D58D84D38987FB568" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_8701DAEF42FD21929FC44D38987FEA49" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_8701DAEF42FD21929FC44D38987FEA49" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_B33B3B1FAB6E800CB6734D38987FAF90" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_B33B3B1FAB6E800CB6734D38987FAF90" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_141AB9173A8F3F19D0914D38987F6D85" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_141AB9173A8F3F19D0914D38987F6D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:to="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:to="loc_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_AccruedClinicalExpensesCurrent" xlink:label="loc_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_0CCEED259476A0961A224D389880F1F5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_RelatedPartyDepositLiabilities_0CCEED259476A0961A224D389880F1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6B344B4309B2793A0D5B4D389880B566" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6B344B4309B2793A0D5B4D389880B566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7D96CAAE6BA07813005CF555F84C34A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_StatementTable_7D96CAAE6BA07813005CF555F84C34A1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76C588869A1D1B3D25D6F555F84D1333" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7D96CAAE6BA07813005CF555F84C34A1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76C588869A1D1B3D25D6F555F84D1333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76C588869A1D1B3D25D6F555F84D1333" xlink:to="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76C588869A1D1B3D25D6F555F84D1333" xlink:to="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_029EBCF52973FB874D89F555F84D3AEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_029EBCF52973FB874D89F555F84D3AEE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_92AF3A413B6348F63661F555F84DBCE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_92AF3A413B6348F63661F555F84DBCE5" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_F3DF34347E4CE77F7D93F555F84DBE23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_F3DF34347E4CE77F7D93F555F84DBE23" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_BAB3F3456433FDA604D1F555F84DA84A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_BAB3F3456433FDA604D1F555F84DA84A" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_8F527CCC516154526744F555F84D9635" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_8F527CCC516154526744F555F84D9635" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_AAC861D08194FF84CB64F5725827D517" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_AAC861D08194FF84CB64F5725827D517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4258BD6645F4D90D1D97F555F84D77F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4258BD6645F4D90D1D97F555F84D77F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_7C7B21D7DE43F16902A3F555F84D189E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_7C7B21D7DE43F16902A3F555F84D189E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4B5EFB3D16055667B590F555F84D6710" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4B5EFB3D16055667B590F555F84D6710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:to="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:to="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:to="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9DD237FE23871AF8CB6C671815423496" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9DD237FE23871AF8CB6C671815423496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9DD237FE23871AF8CB6C671815423496" xlink:to="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9DD237FE23871AF8CB6C671815423496" xlink:to="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ReclassificationsofWarrantLiabilitytoPermanentEquity" xlink:label="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares" xlink:label="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4097BD1D875B1A14CEAD4DBFB3D2219E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:to="loc_us-gaap_StatementTable_4097BD1D875B1A14CEAD4DBFB3D2219E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A779B0ED383FAB8938834DBFB3D2EE44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4097BD1D875B1A14CEAD4DBFB3D2219E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A779B0ED383FAB8938834DBFB3D2EE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A779B0ED383FAB8938834DBFB3D2EE44" xlink:to="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A779B0ED383FAB8938834DBFB3D2EE44" xlink:to="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_55DE614964B7D8BD40464DBFB3D2FF85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_55DE614964B7D8BD40464DBFB3D2FF85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A048ED5B63AD280FF65D4DF8A214ADC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A048ED5B63AD280FF65D4DF8A214ADC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A048ED5B63AD280FF65D4DF8A214ADC6" xlink:to="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A048ED5B63AD280FF65D4DF8A214ADC6" xlink:to="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_BaderSultanAndBrosCoWLLMember" xlink:label="loc_obln_BaderSultanAndBrosCoWLLMember_9E92AD125CBA6F7A587B4E0042B8DADB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7" xlink:to="loc_obln_BaderSultanAndBrosCoWLLMember_9E92AD125CBA6F7A587B4E0042B8DADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C3A762A169A0A1D62EC84DBFB21B29E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="loc_us-gaap_RangeAxis_C3A762A169A0A1D62EC84DBFB21B29E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_C3A762A169A0A1D62EC84DBFB21B29E1" xlink:to="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_C3A762A169A0A1D62EC84DBFB21B29E1" xlink:to="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_252922C383B92B04538D4DBFB2205B2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F" xlink:to="loc_us-gaap_MinimumMember_252922C383B92B04538D4DBFB2205B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6CF6D0C062B658A408604DBFB2203D36" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6CF6D0C062B658A408604DBFB2203D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6CF6D0C062B658A408604DBFB2203D36" xlink:to="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6CF6D0C062B658A408604DBFB2203D36" xlink:to="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_949AAADE319FA687A0624E087EC4C7FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_949AAADE319FA687A0624E087EC4C7FC" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_2A23CC332AE46F6AF2984E0880D150FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_2A23CC332AE46F6AF2984E0880D150FA" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_FC387B052CB3C654425A4E0882D49C78" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_FC387B052CB3C654425A4E0882D49C78" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_25E0C6F0F21068FC21B24E0884C85ABE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_25E0C6F0F21068FC21B24E0884C85ABE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_C45C8AEA447358ECFB654E08860FE7FC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_C45C8AEA447358ECFB654E08860FE7FC" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_32E6200D974A16C3D7814DBFB221CB4F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_32E6200D974A16C3D7814DBFB221CB4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_D7CE002DFAD7414181B24DBFB221A811" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_D7CE002DFAD7414181B24DBFB221A811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_45D5CC26142183E46C694DBFB221A37F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_45D5CC26142183E46C694DBFB221A37F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromJointVentures" xlink:label="loc_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TemporaryEquityDividendRatePerShareAmount" xlink:label="loc_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ConversionOfTemporaryEquityToCommonStockPercentage" xlink:label="loc_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_800E2D75316DA80854944DBFB2227849" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_SharePrice_800E2D75316DA80854944DBFB2227849" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock" xlink:label="loc_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_FE7802967C22001363374E087CF357E1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_FE7802967C22001363374E087CF357E1" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantOrRightExercised" xlink:label="loc_obln_ClassOfWarrantOrRightExercised_780A831754F5A7AC9D234DBFB221AFAD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_ClassOfWarrantOrRightExercised_780A831754F5A7AC9D234DBFB221AFAD" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants" xlink:label="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_4BD23FD6399C55478DAD4DBFB221C89F" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_4BD23FD6399C55478DAD4DBFB221C89F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2B55311CF5E2579659A34DBFB1CF82D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2B55311CF5E2579659A34DBFB1CF82D5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B8F58973F39E819B26D44DBFB1CE7887" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:to="loc_us-gaap_AwardTypeAxis_B8F58973F39E819B26D44DBFB1CE7887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B8F58973F39E819B26D44DBFB1CE7887" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B8F58973F39E819B26D44DBFB1CE7887" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsIssuedAndOutstandingMember" xlink:label="loc_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C" xlink:to="loc_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1A280F453DD83D48D1CE4E4ABA13D03E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:to="loc_us-gaap_PlanNameAxis_1A280F453DD83D48D1CE4E4ABA13D03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1A280F453DD83D48D1CE4E4ABA13D03E" xlink:to="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1A280F453DD83D48D1CE4E4ABA13D03E" xlink:to="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA" xlink:to="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A4CD261D10C27158BD4F4DBFB1CEC2DC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A4CD261D10C27158BD4F4DBFB1CEC2DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A4CD261D10C27158BD4F4DBFB1CEC2DC" xlink:to="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A4CD261D10C27158BD4F4DBFB1CEC2DC" xlink:to="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB" xlink:to="loc_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2B55311CF5E2579659A34DBFB1CF82D5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_290CEB1C1B4C4195A1C78F87082B6CDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:to="loc_us-gaap_StatementClassOfStockAxis_290CEB1C1B4C4195A1C78F87082B6CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_290CEB1C1B4C4195A1C78F87082B6CDA" xlink:to="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_290CEB1C1B4C4195A1C78F87082B6CDA" xlink:to="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_C6DA9ED8BB803CDB61608F87082B192D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_C6DA9ED8BB803CDB61608F87082B192D" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_F2D972C16C6DA33C0C988F87082BF6D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_F2D972C16C6DA33C0C988F87082BF6D7" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_A9700D9B18903D23F9CF8F87082C7380" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_A9700D9B18903D23F9CF8F87082C7380" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_CC6AE33D7DD9D7C5D4858F87082C88E2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_CC6AE33D7DD9D7C5D4858F87082C88E2" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_7D283EADA73058B554918F87082C3E2F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_7D283EADA73058B554918F87082C3E2F" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_655C0181933F3AB700368F87082C49D3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_655C0181933F3AB700368F87082C49D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3381F3C1CB99E0096CEBF555F679AAAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3381F3C1CB99E0096CEBF555F679AAAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3381F3C1CB99E0096CEBF555F679AAAE" xlink:to="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3381F3C1CB99E0096CEBF555F679AAAE" xlink:to="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_BFFF49D38722F30BDB91F555F679826C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_BFFF49D38722F30BDB91F555F679826C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember" xlink:label="loc_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:to="loc_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E474ACAA16F414C63243623C819E9AFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E474ACAA16F414C63243623C819E9AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E474ACAA16F414C63243623C819E9AFF" xlink:to="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E474ACAA16F414C63243623C819E9AFF" xlink:to="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_003A91C40DCFD3725650623C819E83CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2" xlink:to="loc_us-gaap_CommonStockMember_003A91C40DCFD3725650623C819E83CD" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantOrRightExercised" xlink:label="loc_obln_ClassOfWarrantOrRightExercised_E4F6F9D14F486D5FDF8D62683BBA7D80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:to="loc_obln_ClassOfWarrantOrRightExercised_E4F6F9D14F486D5FDF8D62683BBA7D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B77CBE10B751FB39B49762683C5495A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B77CBE10B751FB39B49762683C5495A2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="obln-20161231.xsd#obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:type="locator" />
    <link:loc xlink:href="obln-20161231.xsd#obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:to="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_WarrantLiabilityMember" xlink:label="loc_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:to="loc_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:to="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:to="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:to="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:to="loc_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:to="loc_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:to="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:to="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOnePreferredStockMember" xlink:label="loc_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:to="loc_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:to="loc_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:to="loc_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:to="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:to="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:to="loc_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/OrganizationAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="obln-20161231.xsd#obln_BasisOfPresentationAndOrganizationLineItems" xlink:label="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:type="locator" />
    <link:loc xlink:href="obln-20161231.xsd#obln_BasisOfPresentationAndOrganizationTable" xlink:label="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8213AA4A79A2714FA3EE6718151F6405" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8213AA4A79A2714FA3EE6718151F6405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8213AA4A79A2714FA3EE6718151F6405" xlink:to="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8213AA4A79A2714FA3EE6718151F6405" xlink:to="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_91EA88ED2DF4B956062F6718151FB13B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_91EA88ED2DF4B956062F6718151FB13B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_51F83D97C2CD603C14106718151F83BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_51F83D97C2CD603C14106718151F83BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:to="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:to="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandAndEightPlanMember" xlink:label="loc_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:to="loc_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PacificWesternBankMember" xlink:label="loc_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:to="loc_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:to="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:to="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ObalonMexicoDERLCVMember" xlink:label="loc_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:to="loc_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:to="loc_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7B583B655A25D19F2A5A6718151FADB3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7B583B655A25D19F2A5A6718151FADB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7B583B655A25D19F2A5A6718151FADB3" xlink:to="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7B583B655A25D19F2A5A6718151FADB3" xlink:to="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D6DD822D2F1FE64D997C6718151F8AAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB" xlink:to="loc_us-gaap_CommonStockMember_D6DD822D2F1FE64D997C6718151F8AAB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_OwnershipPercentageHeldByShellCompany" xlink:label="loc_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_CBD7DFD057E006A9E7086718151F2732" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_SharePrice_CBD7DFD057E006A9E7086718151F2732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantOrRightExercised" xlink:label="loc_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants" xlink:label="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock" xlink:label="loc_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:to="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:to="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_BaderSultanAndBrosCoWLLMember" xlink:label="loc_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:to="loc_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A1A76B05D9B4222CB1AD6A19FD303FDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A1A76B05D9B4222CB1AD6A19FD303FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A1A76B05D9B4222CB1AD6A19FD303FDF" xlink:to="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A1A76B05D9B4222CB1AD6A19FD303FDF" xlink:to="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_EDCA4D037A3E04D2528D6A19FD30904C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_EDCA4D037A3E04D2528D6A19FD30904C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_A26125261528B9C530166A19FD30B8CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_A26125261528B9C530166A19FD30B8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_DistributionAgreementMember" xlink:label="loc_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:to="loc_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B6C6B7A5D9ABC13588DA6A19FD41F619" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B6C6B7A5D9ABC13588DA6A19FD41F619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue" xlink:label="loc_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DB473001C404FAF258E66D4914DA07D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DB473001C404FAF258E66D4914DA07D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_3DECD104907BF7ACECC866D4914D375E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DB473001C404FAF258E66D4914DA07D" xlink:to="loc_us-gaap_PlanNameAxis_3DECD104907BF7ACECC866D4914D375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3DECD104907BF7ACECC866D4914D375E" xlink:to="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3DECD104907BF7ACECC866D4914D375E" xlink:to="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_EquityIncentivePlanMember" xlink:label="loc_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:to="loc_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_11D27BFA213B6AA85D7D66D4914F741B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:to="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_11D27BFA213B6AA85D7D66D4914F741B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:to="loc_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5AA04D494AEE6E4B823966D49150F7FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5AA04D494AEE6E4B823966D49150F7FF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents" xlink:label="loc_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsEarlyExercised" xlink:label="loc_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_NonvestedStockOptionsEarlyExercised" xlink:label="loc_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsEarlyExercisedLiability" xlink:label="loc_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_31D4E03F20443D3AF02BF555F6F1FEE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:to="loc_us-gaap_RangeAxis_31D4E03F20443D3AF02BF555F6F1FEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_31D4E03F20443D3AF02BF555F6F1FEE0" xlink:to="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_31D4E03F20443D3AF02BF555F6F1FEE0" xlink:to="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_41D8DAB197C8B49136E0F555F6F1868F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:to="loc_us-gaap_MinimumMember_41D8DAB197C8B49136E0F555F6F1868F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8C13126CED2F902961AFF555F6F21D95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:to="loc_us-gaap_MaximumMember_8C13126CED2F902961AFF555F6F21D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:to="loc_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:to="loc_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:to="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:to="loc_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:to="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A096C0628DF37B691D774DBFB0FD6865" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A096C0628DF37B691D774DBFB0FD6865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:to="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_CustomerOneMember" xlink:label="loc_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:to="loc_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_CustomerTwoMember" xlink:label="loc_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:to="loc_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:to="loc_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:to="loc_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7936F64A99092BBC997BFBFAC1312A46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_477C4F07733155561880FBFAC12EA4E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7936F64A99092BBC997BFBFAC1312A46" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_477C4F07733155561880FBFAC12EA4E8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8789D32A5AE6119CB8FBFBFAC12F32F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_477C4F07733155561880FBFAC12EA4E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8789D32A5AE6119CB8FBFBFAC12F32F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8789D32A5AE6119CB8FBFBFAC12F32F0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8789D32A5AE6119CB8FBFBFAC12F32F0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_AC60AA38D2DB20416000FBFAC12F8004" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_ComputerEquipmentMember_AC60AA38D2DB20416000FBFAC12F8004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_E6B8F571F3A8D4C85FE3FBFAC1315CF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_E6B8F571F3A8D4C85FE3FBFAC1315CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7936F64A99092BBC997BFBFAC1312A46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/TermLoan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/TermLoanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_394602A26A6EB09E56156A0F2900CE4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_394602A26A6EB09E56156A0F2900CE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_394602A26A6EB09E56156A0F2900CE4E" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_394602A26A6EB09E56156A0F2900CE4E" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PacificWesternBankMember" xlink:label="loc_obln_PacificWesternBankMember_C8694D7F7EDC2CECBFFF6A0F29001508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A" xlink:to="loc_obln_PacificWesternBankMember_C8694D7F7EDC2CECBFFF6A0F29001508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandThirteenLoanAgreementMember" xlink:label="loc_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandFourteenLoanAgreementMember" xlink:label="loc_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeptemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_DecemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TermLoanAMember" xlink:label="loc_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TermLoanBMember" xlink:label="loc_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_FirstTrancheMember" xlink:label="loc_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SecondTrancheMember" xlink:label="loc_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4A372E40237EDB0F2A7E6A0F2900A0A9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4A372E40237EDB0F2A7E6A0F2900A0A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4A372E40237EDB0F2A7E6A0F2900A0A9" xlink:to="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4A372E40237EDB0F2A7E6A0F2900A0A9" xlink:to="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_94DDCC4D2E6D695652A66A0F29002A2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_94DDCC4D2E6D695652A66A0F29002A2F" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_62EC08A201E0E35498CB6A0F29002129" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_62EC08A201E0E35498CB6A0F29002129" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_FB2DF4E323B565971B576A0F2900D894" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_FB2DF4E323B565971B576A0F2900D894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:to="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:to="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:to="loc_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock" xlink:label="loc_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_NumberOfWarrantsExercise" xlink:label="loc_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_NumberOfTranches" xlink:label="loc_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility" xlink:label="loc_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PercentageChangeInPresentValueOfFutureCashFlows" xlink:label="loc_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments" xlink:label="loc_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PurchasePricePerShare" xlink:label="loc_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PercentageOfBorrowingsForIssuanceOfWarrant" xlink:label="loc_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52DE0D643424631386596A0F239EA1D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3447427E2AFAFF52A65B6A0F239E14FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52DE0D643424631386596A0F239EA1D6" xlink:to="loc_us-gaap_DebtInstrumentTable_3447427E2AFAFF52A65B6A0F239E14FD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A4168688DEB196769B926A0F239E44FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3447427E2AFAFF52A65B6A0F239E14FD" xlink:to="loc_us-gaap_DebtInstrumentAxis_A4168688DEB196769B926A0F239E44FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_A4168688DEB196769B926A0F239E44FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_A4168688DEB196769B926A0F239E44FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_DecemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_0550EAFFA26439550A526A242C066A8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946" xlink:to="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_0550EAFFA26439550A526A242C066A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52DE0D643424631386596A0F239EA1D6" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5CB8F232828F4992B1BF6A0F239ECB20" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebt_5CB8F232828F4992B1BF6A0F239ECB20" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.obalon.com/role/TermLoanTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>obln-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_E887A79CC8E80A0DDCC493E15E804614_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_E887A79CC8E80A0DDCC493E15E804614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_E887A79CC8E80A0DDCC493E15E804614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_E887A79CC8E80A0DDCC493E15E804614" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_E887A79CC8E80A0DDCC493E15E804614" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627B19BDE560AE10FB5893E15EC783E8_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627B19BDE560AE10FB5893E15EC783E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627B19BDE560AE10FB5893E15EC783E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627B19BDE560AE10FB5893E15EC783E8" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627B19BDE560AE10FB5893E15EC783E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:to="lab_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:to="lab_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3BD03AE988FA37E9DD454DBFB3274411_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_3BD03AE988FA37E9DD454DBFB3274411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3BD03AE988FA37E9DD454DBFB3274411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3BD03AE988FA37E9DD454DBFB3274411" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_3BD03AE988FA37E9DD454DBFB3274411" xlink:type="arc" />
    <link:label id="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA_terseLabel_en-US" xlink:label="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA_label_en-US" xlink:label="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA_documentation_en-US" xlink:label="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value assets and liabilities measured on recurring basis.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:type="arc" />
    <link:label id="lab_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D_terseLabel_en-US" xlink:label="lab_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D_label_en-US" xlink:label="lab_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D_documentation_en-US" xlink:label="lab_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_WarrantLiabilityMember" xlink:label="loc_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:to="lab_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:to="lab_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury Bonds</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:type="arc" />
    <link:label id="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759_terseLabel_en-US" xlink:label="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759_label_en-US" xlink:label="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759_documentation_en-US" xlink:label="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value assets and liabilities measured on recurring basis.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:to="lab_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:to="lab_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F_label_en-US" xlink:label="lab_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:to="lab_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F_label_en-US" xlink:label="lab_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:to="lab_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449_label_en-US" xlink:label="lab_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:to="lab_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261_label_en-US" xlink:label="lab_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:to="lab_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:to="lab_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:to="lab_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61_label_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:type="arc" />
    <link:label id="lab_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3_terseLabel_en-US" xlink:label="lab_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Preferred Stock</link:label>
    <link:label id="lab_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3_label_en-US" xlink:label="lab_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C One Preferred Stock [Member]</link:label>
    <link:label id="lab_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3_documentation_en-US" xlink:label="lab_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C one preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOnePreferredStockMember" xlink:label="loc_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:to="lab_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed volatility</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6_label_en-US" xlink:label="lab_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:to="lab_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_6991A4059D26D5223A0293E15EEB4D8F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_6991A4059D26D5223A0293E15EEB4D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6991A4059D26D5223A0293E15EEB4D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6991A4059D26D5223A0293E15EEB4D8F" xlink:to="lab_us-gaap_DebtDisclosureAbstract_6991A4059D26D5223A0293E15EEB4D8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_57941DAE9786A6635F5C4DBFB1A55796_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_57941DAE9786A6635F5C4DBFB1A55796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_57941DAE9786A6635F5C4DBFB1A55796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57941DAE9786A6635F5C4DBFB1A55796" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_57941DAE9786A6635F5C4DBFB1A55796" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:to="lab_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2_label_en-US" xlink:label="lab_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:to="lab_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:to="lab_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:to="lab_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:type="arc" />
    <link:label id="lab_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932_terseLabel_en-US" xlink:label="lab_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932_label_en-US" xlink:label="lab_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:to="lab_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforward valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward valuation allowance</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:to="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:to="lab_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of California NOL adjustment</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_688624F0F918851F21DA671815418F01_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_688624F0F918851F21DA671815418F01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_688624F0F918851F21DA671815418F01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_688624F0F918851F21DA671815418F01" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_688624F0F918851F21DA671815418F01" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087_label_en-US" xlink:label="lab_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:to="lab_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="lab_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:to="lab_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:to="lab_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:type="arc" />
    <link:label id="lab_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65_terseLabel_en-US" xlink:label="lab_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65_label_en-US" xlink:label="lab_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65_documentation_en-US" xlink:label="lab_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A convertible preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:to="lab_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:type="arc" />
    <link:label id="lab_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E_terseLabel_en-US" xlink:label="lab_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E_label_en-US" xlink:label="lab_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E_documentation_en-US" xlink:label="lab_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B convertible preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:to="lab_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:type="arc" />
    <link:label id="lab_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F_terseLabel_en-US" xlink:label="lab_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F_label_en-US" xlink:label="lab_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F_documentation_en-US" xlink:label="lab_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C convertible preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:to="lab_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:type="arc" />
    <link:label id="lab_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361_terseLabel_en-US" xlink:label="lab_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Convertible Preferred Stock</link:label>
    <link:label id="lab_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361_label_en-US" xlink:label="lab_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C One Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361_documentation_en-US" xlink:label="lab_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C one convertible preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:to="lab_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:type="arc" />
    <link:label id="lab_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE_terseLabel_en-US" xlink:label="lab_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE_label_en-US" xlink:label="lab_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE_documentation_en-US" xlink:label="lab_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D convertible preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:to="lab_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:type="arc" />
    <link:label id="lab_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49_terseLabel_en-US" xlink:label="lab_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:label id="lab_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49_label_en-US" xlink:label="lab_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49_documentation_en-US" xlink:label="lab_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E convertible preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:to="lab_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:to="lab_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants in connection with preferred stock financing</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_AF8C582AE5BF727936E167181543155C_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_AF8C582AE5BF727936E167181543155C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_AF8C582AE5BF727936E167181543155C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_AF8C582AE5BF727936E167181543155C" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_AF8C582AE5BF727936E167181543155C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock in connection with Initial Public Offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock in connection with Initial Public Offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in Initial Public Offering, net of underwriting discount, commissions and issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in Initial Public Offering, net of underwriting discount, commissions and issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:type="arc" />
    <link:label id="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E_terseLabel_en-US" xlink:label="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net exercise of common stock warrants</link:label>
    <link:label id="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E_label_en-US" xlink:label="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Warrant Liability to Permanent Equity</link:label>
    <link:label id="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E_documentation_en-US" xlink:label="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassifications of Warrant Liability to Permanent Equity</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ReclassificationsofWarrantLiabilitytoPermanentEquity" xlink:label="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:to="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:type="arc" />
    <link:label id="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A_terseLabel_en-US" xlink:label="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A_label_en-US" xlink:label="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Warrant Liability to Permanent Equity, Shares</link:label>
    <link:label id="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A_documentation_en-US" xlink:label="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassifications of Warrant Liability to Permanent Equity, Shares</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares" xlink:label="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:to="lab_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability as equity</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment and other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:to="lab_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A1CB3D7D998CA860D82D67181544271F_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A1CB3D7D998CA860D82D67181544271F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A1CB3D7D998CA860D82D67181544271F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A1CB3D7D998CA860D82D67181544271F" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A1CB3D7D998CA860D82D67181544271F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_19AB06973B407F5AA79167181544DF4F_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_19AB06973B407F5AA79167181544DF4F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19AB06973B407F5AA79167181544DF4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_19AB06973B407F5AA79167181544DF4F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_19AB06973B407F5AA79167181544DF4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_FC540D22ABDF22377CA3F555F7848E7C_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_FC540D22ABDF22377CA3F555F7848E7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_FC540D22ABDF22377CA3F555F7848E7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_FC540D22ABDF22377CA3F555F7848E7C" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_FC540D22ABDF22377CA3F555F7848E7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE" xlink:to="lab_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected option life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future payments due under building lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Warrant Liability Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D" xlink:to="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation for All Liabilities Measured at Fair Value Using Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future principal payments due under the December 2016 Loan Agreement</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA" xlink:to="lab_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of long-term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7" xlink:to="lab_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loan, excluding current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8AAB47D179155182A6876718151FDA54_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_8AAB47D179155182A6876718151FDA54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8AAB47D179155182A6876718151FDA54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8AAB47D179155182A6876718151FDA54" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_8AAB47D179155182A6876718151FDA54" xlink:type="arc" />
    <link:label id="lab_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79_terseLabel_en-US" xlink:label="lab_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Organization [Table]</link:label>
    <link:label id="lab_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79_label_en-US" xlink:label="lab_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Organization [Table]</link:label>
    <link:label id="lab_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79_documentation_en-US" xlink:label="lab_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Organization [Table]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_BasisOfPresentationAndOrganizationTable" xlink:label="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="lab_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:to="lab_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:to="lab_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:type="arc" />
    <link:label id="lab_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530_terseLabel_en-US" xlink:label="lab_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2008 Plan</link:label>
    <link:label id="lab_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530_label_en-US" xlink:label="lab_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Eight Plan [Member]</link:label>
    <link:label id="lab_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530_documentation_en-US" xlink:label="lab_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and eight plan.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandAndEightPlanMember" xlink:label="loc_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:to="lab_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:type="arc" />
    <link:label id="lab_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB_terseLabel_en-US" xlink:label="lab_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pacific Western Bank</link:label>
    <link:label id="lab_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB_label_en-US" xlink:label="lab_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pacific Western Bank [Member]</link:label>
    <link:label id="lab_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB_documentation_en-US" xlink:label="lab_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pacific western bank.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_PacificWesternBankMember" xlink:label="loc_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:to="lab_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356_label_en-US" xlink:label="lab_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:to="lab_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D_label_en-US" xlink:label="lab_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:to="lab_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:type="arc" />
    <link:label id="lab_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338_terseLabel_en-US" xlink:label="lab_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obalon Mexico DE RL CV</link:label>
    <link:label id="lab_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338_label_en-US" xlink:label="lab_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obalon Mexico D E R L C V [Member]</link:label>
    <link:label id="lab_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338_documentation_en-US" xlink:label="lab_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Obalon Mexico DE RL CV.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ObalonMexicoDERLCVMember" xlink:label="loc_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:to="lab_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7_label_en-US" xlink:label="lab_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:to="lab_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:type="arc" />
    <link:label id="lab_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98_terseLabel_en-US" xlink:label="lab_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Organization [Line Items]</link:label>
    <link:label id="lab_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98_label_en-US" xlink:label="lab_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Organization [Line Items]</link:label>
    <link:label id="lab_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98_documentation_en-US" xlink:label="lab_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Organization [Line Items]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_BasisOfPresentationAndOrganizationLineItems" xlink:label="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="lab_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:type="arc" />
    <link:label id="lab_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3_terseLabel_en-US" xlink:label="lab_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage in subsidiary</link:label>
    <link:label id="lab_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3_label_en-US" xlink:label="lab_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage Held By Shell Company</link:label>
    <link:label id="lab_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3_documentation_en-US" xlink:label="lab_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership percentage held by shell company.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_OwnershipPercentageHeldByShellCompany" xlink:label="loc_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:to="lab_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:to="lab_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9_label_en-US" xlink:label="lab_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:to="lab_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance for common stock for cash (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of convertible preferred stock converted into common stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:type="arc" />
    <link:label id="lab_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0_terseLabel_en-US" xlink:label="lab_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:label id="lab_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0_label_en-US" xlink:label="lab_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label id="lab_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0_documentation_en-US" xlink:label="lab_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrant or right exercised.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantOrRightExercised" xlink:label="loc_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:to="lab_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:type="arc" />
    <link:label id="lab_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE_terseLabel_en-US" xlink:label="lab_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of warrants</link:label>
    <link:label id="lab_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE_label_en-US" xlink:label="lab_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Of Stock Issued During Period Upon Exercise Of Warrants</link:label>
    <link:label id="lab_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE_documentation_en-US" xlink:label="lab_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued upon exercise of warrants.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants" xlink:label="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:to="lab_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:type="arc" />
    <link:label id="lab_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4_terseLabel_en-US" xlink:label="lab_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase convertible preferred stock converted into warrants to purchase common stock</link:label>
    <link:label id="lab_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4_label_en-US" xlink:label="lab_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants To Purchase Convertible Preferred Stocks Converted Into Warrants To Purchase Common Stock</link:label>
    <link:label id="lab_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4_documentation_en-US" xlink:label="lab_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants to purchase convertible preferred stocks converted into warrants to purchase common stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock" xlink:label="loc_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:to="lab_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stocks issuable upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_DE74EC079DF27E1863C28F870685C52D_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_DE74EC079DF27E1863C28F870685C52D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DE74EC079DF27E1863C28F870685C52D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_DE74EC079DF27E1863C28F870685C52D" xlink:to="lab_us-gaap_EquityAbstract_DE74EC079DF27E1863C28F870685C52D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock and Stockholders' Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9D3C1F69FF09C3D3B7678F86FA1F10E6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_9D3C1F69FF09C3D3B7678F86FA1F10E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9D3C1F69FF09C3D3B7678F86FA1F10E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9D3C1F69FF09C3D3B7678F86FA1F10E6" xlink:to="lab_us-gaap_EarningsPerShareAbstract_9D3C1F69FF09C3D3B7678F86FA1F10E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:to="lab_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:to="lab_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Security Category</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:type="arc" />
    <link:label id="lab_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61_terseLabel_en-US" xlink:label="lab_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity in 1 Year or Less</link:label>
    <link:label id="lab_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61_label_en-US" xlink:label="lab_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Maturity In One Year Or Less [Member]</link:label>
    <link:label id="lab_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61_documentation_en-US" xlink:label="lab_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity in one year or less.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember" xlink:label="loc_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:to="lab_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_414C9BE72B876E809BDA8F870C3A7769_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_414C9BE72B876E809BDA8F870C3A7769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_414C9BE72B876E809BDA8F870C3A7769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_414C9BE72B876E809BDA8F870C3A7769" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_414C9BE72B876E809BDA8F870C3A7769" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Noncancelable Minimum Payment Obligations Under Operating Lease</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:to="lab_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:type="arc" />
    <link:label id="lab_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED_terseLabel_en-US" xlink:label="lab_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED_label_en-US" xlink:label="lab_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scientific Equipment [Member]</link:label>
    <link:label id="lab_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED_documentation_en-US" xlink:label="lab_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scientific equipment.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ScientificEquipmentMember" xlink:label="loc_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:to="lab_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction In Progress, or CIP</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:to="lab_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Anti-Dilutive Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB" xlink:type="arc" />
    <link:label id="lab_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE_label_en-US" xlink:label="lab_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE_documentation_en-US" xlink:label="lab_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_DocumentAndEntityInformationAbstract" xlink:label="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="lab_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97_label_en-US" xlink:label="lab_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97" xlink:to="lab_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD_label_en-US" xlink:label="lab_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD" xlink:to="lab_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0" xlink:to="lab_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC" xlink:to="lab_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374" xlink:to="lab_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053_label_en-US" xlink:label="lab_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053" xlink:to="lab_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141_label_en-US" xlink:label="lab_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141" xlink:to="lab_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547" xlink:to="lab_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0" xlink:to="lab_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871_label_en-US" xlink:label="lab_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871" xlink:to="lab_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC" xlink:to="lab_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0" xlink:to="lab_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF_label_en-US" xlink:label="lab_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF" xlink:to="lab_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26" xlink:type="arc" />
    <link:label id="lab_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC_terseLabel_en-US" xlink:label="lab_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC_label_en-US" xlink:label="lab_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label id="lab_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC_documentation_en-US" xlink:label="lab_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of common stock reserved for future issuance.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="loc_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:to="lab_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_3386D7DC81830FC339634DBFB0FD0FDA_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_3386D7DC81830FC339634DBFB0FD0FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3386D7DC81830FC339634DBFB0FD0FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3386D7DC81830FC339634DBFB0FD0FDA" xlink:to="lab_us-gaap_SubsequentEventsAbstract_3386D7DC81830FC339634DBFB0FD0FDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:to="lab_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:to="lab_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:to="lab_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:to="lab_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares, Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:to="lab_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:type="arc" />
    <link:label id="lab_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD_terseLabel_en-US" xlink:label="lab_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bader</link:label>
    <link:label id="lab_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD_label_en-US" xlink:label="lab_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bader Sultan And Bros Co W L L [Member]</link:label>
    <link:label id="lab_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD_documentation_en-US" xlink:label="lab_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bader Sultan and Bros. Co W.L.L.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_BaderSultanAndBrosCoWLLMember" xlink:label="loc_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:to="lab_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:to="lab_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:type="arc" />
    <link:label id="lab_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3_terseLabel_en-US" xlink:label="lab_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Agreement</link:label>
    <link:label id="lab_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3_label_en-US" xlink:label="lab_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Agreement [Member]</link:label>
    <link:label id="lab_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3_documentation_en-US" xlink:label="lab_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distribution agreement.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_DistributionAgreementMember" xlink:label="loc_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:to="lab_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:type="arc" />
    <link:label id="lab_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E_terseLabel_en-US" xlink:label="lab_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from related parties as percentage of total revenue</link:label>
    <link:label id="lab_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E_label_en-US" xlink:label="lab_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Related Parties As Percentage Of Net Revenue</link:label>
    <link:label id="lab_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E_documentation_en-US" xlink:label="lab_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from related parties as percentage of net revenue.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue" xlink:label="loc_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:to="lab_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer deposit from related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Deposit Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:to="lab_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_734E55B74F12FE0C7AEF4D61A1C61951_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_734E55B74F12FE0C7AEF4D61A1C61951" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_734E55B74F12FE0C7AEF4D61A1C61951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_734E55B74F12FE0C7AEF4D61A1C61951" xlink:to="lab_us-gaap_Revenues_734E55B74F12FE0C7AEF4D61A1C61951" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61_label_en-US" xlink:label="lab_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61" xlink:to="lab_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8" xlink:to="lab_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_6DA7013FB0A31611B9088F87082A3C1A_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract_6DA7013FB0A31611B9088F87082A3C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_6DA7013FB0A31611B9088F87082A3C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_6DA7013FB0A31611B9088F87082A3C1A" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract_6DA7013FB0A31611B9088F87082A3C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="lab_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:type="arc" />
    <link:label id="lab_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91_terseLabel_en-US" xlink:label="lab_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Feb 24, 2012 Warrant Issuance</link:label>
    <link:label id="lab_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91_label_en-US" xlink:label="lab_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February Twenty Four Two Thousand Twelve Warrant Issuance [Member]</link:label>
    <link:label id="lab_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91_documentation_en-US" xlink:label="lab_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">February twenty four two thousand twelve warrant issuance.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember" xlink:label="loc_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:to="lab_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value of Stock Options for Employees was Estimated using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Non-cash Compensation to Employees and Nonemployees in Condensed Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:to="lab_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C_label_en-US" xlink:label="lab_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Services, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C" xlink:to="lab_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B" xlink:to="lab_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_CB4066D89F4F2800CDF1697CE494227B_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_CB4066D89F4F2800CDF1697CE494227B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_CB4066D89F4F2800CDF1697CE494227B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_CB4066D89F4F2800CDF1697CE494227B" xlink:to="lab_us-gaap_Revenues_CB4066D89F4F2800CDF1697CE494227B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C" xlink:to="lab_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_DDE8DB3C81FECC629F49697CE4940382_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_DDE8DB3C81FECC629F49697CE4940382" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_DDE8DB3C81FECC629F49697CE4940382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_DDE8DB3C81FECC629F49697CE4940382" xlink:to="lab_us-gaap_GrossProfit_DDE8DB3C81FECC629F49697CE4940382" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:to="lab_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01" xlink:to="lab_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5102272879D9027E939F697CE494DC4E_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_5102272879D9027E939F697CE494DC4E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5102272879D9027E939F697CE494DC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_5102272879D9027E939F697CE494DC4E" xlink:to="lab_us-gaap_OperatingIncomeLoss_5102272879D9027E939F697CE494DC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Loss) gain from change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3F9877C0BB7B56C8704B697CE494A003_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3F9877C0BB7B56C8704B697CE494A003" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3F9877C0BB7B56C8704B697CE494A003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_3F9877C0BB7B56C8704B697CE494A003" xlink:to="lab_us-gaap_NetIncomeLoss_3F9877C0BB7B56C8704B697CE494A003" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B76AC482334F7324C52C697CE4940349_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B76AC482334F7324C52C697CE4940349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B76AC482334F7324C52C697CE4940349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B76AC482334F7324C52C697CE4940349" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B76AC482334F7324C52C697CE4940349" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_604EC0EF69AE98AF071F697CE495E7CC_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_604EC0EF69AE98AF071F697CE495E7CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_604EC0EF69AE98AF071F697CE495E7CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_604EC0EF69AE98AF071F697CE495E7CC" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_604EC0EF69AE98AF071F697CE495E7CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24" xlink:to="lab_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522" xlink:to="lab_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_CC3F087FBB32B29F47EF4D38983BF52C_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_CC3F087FBB32B29F47EF4D38983BF52C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives of Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_CC3F087FBB32B29F47EF4D38983BF52C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_CC3F087FBB32B29F47EF4D38983BF52C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_CC3F087FBB32B29F47EF4D38983BF52C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_11C3FBB815D12332C905F555F84C75C2_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_11C3FBB815D12332C905F555F84C75C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_11C3FBB815D12332C905F555F84C75C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_11C3FBB815D12332C905F555F84C75C2" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_11C3FBB815D12332C905F555F84C75C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, liquidation preference, value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:to="lab_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_1FC9F3D7C043EE1D933E38DB959072C2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_1FC9F3D7C043EE1D933E38DB959072C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1FC9F3D7C043EE1D933E38DB959072C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_1FC9F3D7C043EE1D933E38DB959072C2" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_1FC9F3D7C043EE1D933E38DB959072C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87" xlink:to="lab_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87" xlink:type="arc" />
    <link:label id="lab_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2_terseLabel_en-US" xlink:label="lab_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal</link:label>
    <link:label id="lab_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2_label_en-US" xlink:label="lab_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Legal Current</link:label>
    <link:label id="lab_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2_documentation_en-US" xlink:label="lab_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued legal current.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_AccruedLegalCurrent" xlink:label="loc_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:to="lab_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585" xlink:to="lab_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants for the purchase of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants exercised</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrants to stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C6BFFAAE91EFCAA298754DBFB31F6180_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C6BFFAAE91EFCAA298754DBFB31F6180" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C6BFFAAE91EFCAA298754DBFB31F6180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C6BFFAAE91EFCAA298754DBFB31F6180" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C6BFFAAE91EFCAA298754DBFB31F6180" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="lab_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5_label_en-US" xlink:label="lab_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Joint Ventures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromJointVentures" xlink:label="loc_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:to="lab_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:type="arc" />
    <link:label id="lab_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79_terseLabel_en-US" xlink:label="lab_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate per annum (in dollars per share)</link:label>
    <link:label id="lab_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79_label_en-US" xlink:label="lab_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Dividend Rate Per Share Amount</link:label>
    <link:label id="lab_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79_documentation_en-US" xlink:label="lab_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary equity dividend rate per share amount.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TemporaryEquityDividendRatePerShareAmount" xlink:label="loc_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:to="lab_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidation preference per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:type="arc" />
    <link:label id="lab_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F_terseLabel_en-US" xlink:label="lab_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock percentage</link:label>
    <link:label id="lab_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F_label_en-US" xlink:label="lab_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Temporary Equity To Common Stock Percentage</link:label>
    <link:label id="lab_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F_documentation_en-US" xlink:label="lab_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of temporary equity to common stock percentage.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ConversionOfTemporaryEquityToCommonStockPercentage" xlink:label="loc_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:to="lab_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:type="arc" />
    <link:label id="lab_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A_terseLabel_en-US" xlink:label="lab_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum percentage of voting required for conversion of preferred stock to common stock</link:label>
    <link:label id="lab_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A_label_en-US" xlink:label="lab_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Percentage Of Voting Required For Conversion Of Temporary Equity To Common Stock</link:label>
    <link:label id="lab_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A_documentation_en-US" xlink:label="lab_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum percentage of voting required for conversion of temporary equity to common stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock" xlink:label="loc_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:to="lab_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued upon conversion of convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Provision (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77" xlink:type="arc" />
    <link:label id="lab_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6_terseLabel_en-US" xlink:label="lab_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options issued and outstanding</link:label>
    <link:label id="lab_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6_label_en-US" xlink:label="lab_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Issued And Outstanding [Member]</link:label>
    <link:label id="lab_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6_documentation_en-US" xlink:label="lab_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options issued and outstanding.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsIssuedAndOutstandingMember" xlink:label="loc_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:to="lab_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:type="arc" />
    <link:label id="lab_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E_terseLabel_en-US" xlink:label="lab_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Equity Incentive Plan</link:label>
    <link:label id="lab_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E_label_en-US" xlink:label="lab_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E_documentation_en-US" xlink:label="lab_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:to="lab_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815_label_en-US" xlink:label="lab_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:to="lab_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Total Long-term Loan and Unamortized Debt Discount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Principal Payments Due</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:to="lab_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="lab_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:to="lab_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, related party</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911_label_en-US" xlink:label="lab_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:to="lab_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:to="lab_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:to="lab_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_561E7F06C217D9D019994D38988039BD_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_561E7F06C217D9D019994D38988039BD_label_en-US" xlink:label="lab_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:to="lab_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:type="arc" />
    <link:label id="lab_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68_terseLabel_en-US" xlink:label="lab_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label id="lab_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68_label_en-US" xlink:label="lab_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Expenses Current</link:label>
    <link:label id="lab_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68_documentation_en-US" xlink:label="lab_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Expenses Current</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_AccruedClinicalExpensesCurrent" xlink:label="loc_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:to="lab_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term loan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:to="lab_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:to="lab_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5_label_en-US" xlink:label="lab_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:to="lab_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (See Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:to="lab_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:to="lab_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="lab_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 300,000,000 and 35,000,000 shares authorized at December 31, 2016 and December 31, 2015, respectively; 16,773,205 and 575,126 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:to="lab_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:to="lab_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28" xlink:to="lab_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB" xlink:type="arc" />
    <link:label id="lab_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77_terseLabel_en-US" xlink:label="lab_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Expenses</link:label>
    <link:label id="lab_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77_label_en-US" xlink:label="lab_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Expenses, Policy [Policy Text Block]</link:label>
    <link:label id="lab_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77_documentation_en-US" xlink:label="lab_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ClinicalTrialExpensesPolicyPolicyTextBlock" xlink:label="loc_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:to="lab_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Warranty</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_B749D0E41C6D99828F976718152FF9C8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_B749D0E41C6D99828F976718152FF9C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_B749D0E41C6D99828F976718152FF9C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_B749D0E41C6D99828F976718152FF9C8" xlink:to="lab_us-gaap_DepreciationAndAmortization_B749D0E41C6D99828F976718152FF9C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of investment premium, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369" xlink:type="arc" />
    <link:label id="lab_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69_terseLabel_en-US" xlink:label="lab_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label id="lab_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69_label_en-US" xlink:label="lab_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accrued Clinical Expenses</link:label>
    <link:label id="lab_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69_documentation_en-US" xlink:label="lab_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in accrued clinical expenses.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_IncreaseDecreaseInAccruedClinicalExpenses" xlink:label="loc_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:to="lab_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer deposit from related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock for cash, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3" xlink:type="arc" />
    <link:label id="lab_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD_terseLabel_en-US" xlink:label="lab_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock to related party for cash</link:label>
    <link:label id="lab_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD_label_en-US" xlink:label="lab_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock to Related Party</link:label>
    <link:label id="lab_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD_documentation_en-US" xlink:label="lab_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock to Related Party</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty" xlink:label="loc_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:to="lab_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term loan, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fees paid in connection with loan amendment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D" xlink:to="lab_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term loans</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41B23FF159CC642FC4356718152F99D5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41B23FF159CC642FC4356718152F99D5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41B23FF159CC642FC4356718152F99D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41B23FF159CC642FC4356718152F99D5" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41B23FF159CC642FC4356718152F99D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5CAA9743C3365D8DAFEF6718152FC6AC_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5CAA9743C3365D8DAFEF6718152FC6AC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5CAA9743C3365D8DAFEF6718152FC6AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5CAA9743C3365D8DAFEF6718152FC6AC" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5CAA9743C3365D8DAFEF6718152FC6AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA_label_en-US" xlink:label="lab_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA" xlink:to="lab_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E" xlink:to="lab_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net exercises of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B_label_en-US" xlink:label="lab_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B" xlink:to="lab_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B" xlink:type="arc" />
    <link:label id="lab_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E_terseLabel_en-US" xlink:label="lab_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of customer deposit from related party to preferred stock</link:label>
    <link:label id="lab_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E_label_en-US" xlink:label="lab_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Customer Deposit From Related Party To Preferred Stock</link:label>
    <link:label id="lab_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E_documentation_en-US" xlink:label="lab_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of customer deposit from related party to preferred stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock" xlink:label="loc_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:to="lab_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="lab_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:to="lab_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:type="arc" />
    <link:label id="lab_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF_terseLabel_en-US" xlink:label="lab_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 Loan Agreement</link:label>
    <link:label id="lab_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF_label_en-US" xlink:label="lab_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Thirteen Loan Agreement [Member]</link:label>
    <link:label id="lab_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF_documentation_en-US" xlink:label="lab_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand thirteen loan agreement.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandThirteenLoanAgreementMember" xlink:label="loc_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:to="lab_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:type="arc" />
    <link:label id="lab_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF_terseLabel_en-US" xlink:label="lab_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Loan Agreement</link:label>
    <link:label id="lab_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF_label_en-US" xlink:label="lab_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Loan Agreement [Member]</link:label>
    <link:label id="lab_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF_documentation_en-US" xlink:label="lab_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand fourteen loan agreement.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandFourteenLoanAgreementMember" xlink:label="loc_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:to="lab_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:type="arc" />
    <link:label id="lab_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9_terseLabel_en-US" xlink:label="lab_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Loan Agreement</link:label>
    <link:label id="lab_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9_label_en-US" xlink:label="lab_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September Two Thousand Sixteen Loan Agreement [Member]</link:label>
    <link:label id="lab_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9_documentation_en-US" xlink:label="lab_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September Two Thousand Sixteen Loan Agreement.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SeptemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:to="lab_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:type="arc" />
    <link:label id="lab_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC_terseLabel_en-US" xlink:label="lab_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2016 Loan Agreement</link:label>
    <link:label id="lab_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC_label_en-US" xlink:label="lab_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December Two Thousand Sixteen Loan Agreement [Member]</link:label>
    <link:label id="lab_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC_documentation_en-US" xlink:label="lab_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December Two Thousand Sixteen Loan Agreement [Member]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_DecemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:to="lab_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:type="arc" />
    <link:label id="lab_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E_terseLabel_en-US" xlink:label="lab_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E_label_en-US" xlink:label="lab_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E_documentation_en-US" xlink:label="lab_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loan a.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TermLoanAMember" xlink:label="loc_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:to="lab_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:type="arc" />
    <link:label id="lab_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740_terseLabel_en-US" xlink:label="lab_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740_label_en-US" xlink:label="lab_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan B [Member]</link:label>
    <link:label id="lab_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740_documentation_en-US" xlink:label="lab_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loan b</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TermLoanBMember" xlink:label="loc_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:to="lab_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:type="arc" />
    <link:label id="lab_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76_terseLabel_en-US" xlink:label="lab_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Tranche</link:label>
    <link:label id="lab_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76_label_en-US" xlink:label="lab_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76_documentation_en-US" xlink:label="lab_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First tranche.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_FirstTrancheMember" xlink:label="loc_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:to="lab_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:type="arc" />
    <link:label id="lab_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02_terseLabel_en-US" xlink:label="lab_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Tranche</link:label>
    <link:label id="lab_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02_label_en-US" xlink:label="lab_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Tranche [Member]</link:label>
    <link:label id="lab_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02_documentation_en-US" xlink:label="lab_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second tranche.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_SecondTrancheMember" xlink:label="loc_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:to="lab_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:to="lab_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:to="lab_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:to="lab_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="lab_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, maximum borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:type="arc" />
    <link:label id="lab_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756_terseLabel_en-US" xlink:label="lab_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued for purchase of stock</link:label>
    <link:label id="lab_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756_label_en-US" xlink:label="lab_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Issued For Purchase Of Stock</link:label>
    <link:label id="lab_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756_documentation_en-US" xlink:label="lab_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights issued for purchase of stock.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock" xlink:label="loc_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:to="lab_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:type="arc" />
    <link:label id="lab_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF_terseLabel_en-US" xlink:label="lab_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercise</link:label>
    <link:label id="lab_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF_label_en-US" xlink:label="lab_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Exercise</link:label>
    <link:label id="lab_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF_documentation_en-US" xlink:label="lab_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercise.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_NumberOfWarrantsExercise" xlink:label="loc_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:to="lab_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:type="arc" />
    <link:label id="lab_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399_terseLabel_en-US" xlink:label="lab_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399_label_en-US" xlink:label="lab_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399_documentation_en-US" xlink:label="lab_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of tranches.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_NumberOfTranches" xlink:label="loc_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:to="lab_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, outstanding debt</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3_label_en-US" xlink:label="lab_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:to="lab_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional debt issuance under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:type="arc" />
    <link:label id="lab_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813_terseLabel_en-US" xlink:label="lab_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum proceeds form issuance and sale of the equity securities</link:label>
    <link:label id="lab_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813_label_en-US" xlink:label="lab_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Proceeds Form Issuance And Sale Of Equity Securities Required For Credit Facility</link:label>
    <link:label id="lab_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813_documentation_en-US" xlink:label="lab_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum proceeds form issuance and sale of the equity securities required for credit facility.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility" xlink:label="loc_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:to="lab_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued price per share for term loan (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares owned</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding in shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:type="arc" />
    <link:label id="lab_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2_terseLabel_en-US" xlink:label="lab_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage change in present value of the future cash flows used to classify amendment</link:label>
    <link:label id="lab_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2_label_en-US" xlink:label="lab_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Change In Present Value Of Future Cash Flows</link:label>
    <link:label id="lab_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2_documentation_en-US" xlink:label="lab_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in present value of future cash flows expressed in percentage.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_PercentageChangeInPresentValueOfFutureCashFlows" xlink:label="loc_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:to="lab_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional term loan available for draw down</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, variable interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, fixed interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:type="arc" />
    <link:label id="lab_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42_terseLabel_en-US" xlink:label="lab_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42_label_en-US" xlink:label="lab_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Number of Installment Payments</link:label>
    <link:label id="lab_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42_documentation_en-US" xlink:label="lab_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Number of Installment Payments</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments" xlink:label="loc_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:to="lab_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:type="arc" />
    <link:label id="lab_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB_terseLabel_en-US" xlink:label="lab_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB_label_en-US" xlink:label="lab_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Price Per Share</link:label>
    <link:label id="lab_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB_documentation_en-US" xlink:label="lab_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase price per share.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_PurchasePricePerShare" xlink:label="loc_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:to="lab_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:type="arc" />
    <link:label id="lab_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15_terseLabel_en-US" xlink:label="lab_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of borrowings for issuance of warrant</link:label>
    <link:label id="lab_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15_label_en-US" xlink:label="lab_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Borrowings For Issuance Of Warrant</link:label>
    <link:label id="lab_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15_documentation_en-US" xlink:label="lab_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of borrowings for issuance of warrant.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_PercentageOfBorrowingsForIssuanceOfWarrant" xlink:label="loc_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:to="lab_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AE1155346620F28D65D74D38974F58DE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AE1155346620F28D65D74D38974F58DE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AE1155346620F28D65D74D38974F58DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AE1155346620F28D65D74D38974F58DE" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AE1155346620F28D65D74D38974F58DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2017</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6FDD58CFA7D48DEFA99623C814DE9E5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6FDD58CFA7D48DEFA99623C814DE9E5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of shares, Options exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6FDD58CFA7D48DEFA99623C814DE9E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6FDD58CFA7D48DEFA99623C814DE9E5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6FDD58CFA7D48DEFA99623C814DE9E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of shares, Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CD1ED06878D8CAA1E728623C814D9332_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CD1ED06878D8CAA1E728623C814D9332" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares Outstanding, Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CD1ED06878D8CAA1E728623C814D9332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CD1ED06878D8CAA1E728623C814D9332" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CD1ED06878D8CAA1E728623C814D9332" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price Outstanding, Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CF1FB407D7C9A8450431623C814DFD84_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CF1FB407D7C9A8450431623C814DFD84" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price Outstanding, Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CF1FB407D7C9A8450431623C814DFD84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CF1FB407D7C9A8450431623C814DFD84" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CF1FB407D7C9A8450431623C814DFD84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares, Vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares, Vested and exercisable at period end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual life Outstanding, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual life, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual life, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic Value Outstanding, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F0C6873FA980C036056FF56727B57AD6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F0C6873FA980C036056FF56727B57AD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F0C6873FA980C036056FF56727B57AD6_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F0C6873FA980C036056FF56727B57AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_F0C6873FA980C036056FF56727B57AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_F0C6873FA980C036056FF56727B57AD6" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F0C6873FA980C036056FF56727B57AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8F73B11A6E4218D62ABDF56727B5AEB2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8F73B11A6E4218D62ABDF56727B5AEB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8F73B11A6E4218D62ABDF56727B5AEB2_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8F73B11A6E4218D62ABDF56727B5AEB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8F73B11A6E4218D62ABDF56727B5AEB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8F73B11A6E4218D62ABDF56727B5AEB2" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8F73B11A6E4218D62ABDF56727B5AEB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4639CC36452CE0532CBCF56727B5335B_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4639CC36452CE0532CBCF56727B5335B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4639CC36452CE0532CBCF56727B5335B_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4639CC36452CE0532CBCF56727B5335B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4639CC36452CE0532CBCF56727B5335B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4639CC36452CE0532CBCF56727B5335B" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4639CC36452CE0532CBCF56727B5335B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_76C708110948BD8983A2F56727B5DEFD_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_76C708110948BD8983A2F56727B5DEFD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_76C708110948BD8983A2F56727B5DEFD_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_76C708110948BD8983A2F56727B5DEFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_76C708110948BD8983A2F56727B5DEFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_76C708110948BD8983A2F56727B5DEFD" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_76C708110948BD8983A2F56727B5DEFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="lab_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:to="lab_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:type="arc" />
    <link:label id="lab_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693_terseLabel_en-US" xlink:label="lab_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Single Largest Customer</link:label>
    <link:label id="lab_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693_label_en-US" xlink:label="lab_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693_documentation_en-US" xlink:label="lab_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_CustomerOneMember" xlink:label="loc_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:to="lab_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:type="arc" />
    <link:label id="lab_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B_terseLabel_en-US" xlink:label="lab_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Largest Customer</link:label>
    <link:label id="lab_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B_label_en-US" xlink:label="lab_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B_documentation_en-US" xlink:label="lab_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_CustomerTwoMember" xlink:label="loc_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:to="lab_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:to="lab_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:to="lab_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_2E222D457C3E61EB77718F86FD7766D1_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_2E222D457C3E61EB77718F86FD7766D1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2E222D457C3E61EB77718F86FD7766D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_2E222D457C3E61EB77718F86FD7766D1" xlink:to="lab_us-gaap_InventoryNet_2E222D457C3E61EB77718F86FD7766D1" xlink:type="arc" />
    <link:label id="lab_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB_terseLabel_en-US" xlink:label="lab_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:label id="lab_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB_label_en-US" xlink:label="lab_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB_documentation_en-US" xlink:label="lab_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity incentive plan.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_EquityIncentivePlanMember" xlink:label="loc_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:to="lab_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:type="arc" />
    <link:label id="lab_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5_terseLabel_en-US" xlink:label="lab_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5_label_en-US" xlink:label="lab_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5_documentation_en-US" xlink:label="lab_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and sixteen employee stock purchase plan.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:to="lab_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:type="arc" />
    <link:label id="lab_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E_terseLabel_en-US" xlink:label="lab_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for issuance, increase percentage of common stock outstanding and common stock equivalents</link:label>
    <link:label id="lab_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E_label_en-US" xlink:label="lab_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Shares Reserved For Issuance Increase Percentage Of Common Stock Outstanding And Common Stock Equivalents</link:label>
    <link:label id="lab_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E_documentation_en-US" xlink:label="lab_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share based payment award shares reserved for issuance, increase percentage of common stock outstanding and common stock equivalents.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents" xlink:label="loc_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:to="lab_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average compensation cost recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:type="arc" />
    <link:label id="lab_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE_terseLabel_en-US" xlink:label="lab_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options early exercised</link:label>
    <link:label id="lab_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE_label_en-US" xlink:label="lab_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Early Exercised</link:label>
    <link:label id="lab_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE_documentation_en-US" xlink:label="lab_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options early exercised.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsEarlyExercised" xlink:label="loc_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:to="lab_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:type="arc" />
    <link:label id="lab_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB_terseLabel_en-US" xlink:label="lab_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options remaining, unvested</link:label>
    <link:label id="lab_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB_label_en-US" xlink:label="lab_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Stock Options Early Exercised</link:label>
    <link:label id="lab_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB_documentation_en-US" xlink:label="lab_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nonvested Stock Options Early Exercised</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_NonvestedStockOptionsEarlyExercised" xlink:label="loc_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:to="lab_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:type="arc" />
    <link:label id="lab_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B_terseLabel_en-US" xlink:label="lab_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options early exercised liability</link:label>
    <link:label id="lab_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B_label_en-US" xlink:label="lab_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Early Exercised Liability</link:label>
    <link:label id="lab_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B_documentation_en-US" xlink:label="lab_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options early exercised liability.</link:label>
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsEarlyExercisedLiability" xlink:label="loc_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:to="lab_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>obln-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:href="obln-20161231.xsd#BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/BalanceSheetDetailsTables" xlink:href="obln-20161231.xsd#BalanceSheetDetailsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingencies" xlink:href="obln-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/CommitmentsAndContingenciesTables" xlink:href="obln-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheets" xlink:href="obln-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="obln-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="obln-20161231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:href="obln-20161231.xsd#ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/DocumentAndEntityInformation" xlink:href="obln-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurements" xlink:href="obln-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:href="obln-20161231.xsd#FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/FairValueMeasurementsTables" xlink:href="obln-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxes" xlink:href="obln-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="obln-20161231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="obln-20161231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="obln-20161231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:href="obln-20161231.xsd#IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/IncomeTaxesTables" xlink:href="obln-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShare" xlink:href="obln-20161231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="obln-20161231.xsd#NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:href="obln-20161231.xsd#NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/NetLossPerShareTables" xlink:href="obln-20161231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentation" xlink:href="obln-20161231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:href="obln-20161231.xsd#OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/RelatedPartyTransactions" xlink:href="obln-20161231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="obln-20161231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensation" xlink:href="obln-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:href="obln-20161231.xsd#StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/StockBasedCompensationTables" xlink:href="obln-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SubsequentEvents" xlink:href="obln-20161231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails" xlink:href="obln-20161231.xsd#SubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="obln-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoan" xlink:href="obln-20161231.xsd#TermLoan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanAdditionalInformationDetails" xlink:href="obln-20161231.xsd#TermLoanAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:href="obln-20161231.xsd#TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:href="obln-20161231.xsd#TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.obalon.com/role/TermLoanTables" xlink:href="obln-20161231.xsd#TermLoanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_30486AA41F2AD1CAD08E8F86FAFD38CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_30486AA41F2AD1CAD08E8F86FAFD38CF" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D7D974D9EBBB936302028F86FAFD6C98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_FC540D22ABDF22377CA3F555F7848E7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_FC540D22ABDF22377CA3F555F7848E7C" xlink:to="loc_us-gaap_DepreciationAndAmortization_698F6984F5E18BB38AEBF555F7841DEE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_E7CA159CA250D00B30D88F86FD77DDD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_E7CA159CA250D00B30D88F86FD77DDD4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_003EF950E9DDEEBCB62B8F86FD77EB1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_E7CA159CA250D00B30D88F86FD77DDD4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_AEDD1CDF99086BB2E3798F86FD775EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_E7CA159CA250D00B30D88F86FD77DDD4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_20F0D36A87087EE32D338F86FD771CB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2E222D457C3E61EB77718F86FD7766D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_E7CA159CA250D00B30D88F86FD77DDD4" xlink:to="loc_us-gaap_InventoryNet_2E222D457C3E61EB77718F86FD7766D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8480F1FAEEE1CDD9FDB6D255CF95994D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8480F1FAEEE1CDD9FDB6D255CF95994D" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4A4551C82DD912962C38D255CF955F84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8480F1FAEEE1CDD9FDB6D255CF95994D" xlink:to="loc_us-gaap_InterestReceivableCurrent_FB848E33E19442CA8F0DD255CF95FE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8480F1FAEEE1CDD9FDB6D255CF95994D" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_FF339E0FB859A34F6866D255CF95CCD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8480F1FAEEE1CDD9FDB6D255CF95994D" xlink:to="loc_us-gaap_OtherAssetsCurrent_15B4799DC7BE56F00876D255CF95C522" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_179294D1218C88E4760A8F870042DE7A" xlink:type="locator" />
    <link:loc xlink:href="obln-20161231.xsd#obln_AccruedLegalCurrent" xlink:label="loc_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_179294D1218C88E4760A8F870042DE7A" xlink:to="loc_obln_AccruedLegalCurrent_4EE419562E3A4F606F9B8F870043C9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_179294D1218C88E4760A8F870042DE7A" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0567B79BE811FF6218858F870042571E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_179294D1218C88E4760A8F870042DE7A" xlink:to="loc_us-gaap_InterestPayableCurrent_067EC39FDFC10B594FEB8F8700435585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_179294D1218C88E4760A8F870042DE7A" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_622BECEF9691317ADA568F8700432D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_179294D1218C88E4760A8F870042DE7A" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_A81D0B101EF2CD2A692D8F8700430B7C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6C15E0F072486C6498A3D255CF90A2C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6C15E0F072486C6498A3D255CF90A2C2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7EC0A7E3EC025ACCB537D255CF90EE6E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_ComputerEquipmentMember_F9AECB347B4080E2E4D5D255CF91B64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0AF85FAC0C49AA0372DBD255CF910039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_BAB45E9627E7E3324A9DD255CF91829B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ScientificEquipmentMember" xlink:label="loc_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_obln_ScientificEquipmentMember_F2AC7B82E7E6239CB790D255CF911DED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D767F9ECE0CA22F11DA8D255CF9025D9" xlink:to="loc_us-gaap_ConstructionInProgressMember_64C06FD3183C949E3FF4D255CF913D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7B25F0433AE488A1E957D255CF900428" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2317407B63657BEC969AD255CF9153B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D01F480697B98C65D2F1D255CF911B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC560DCD236BF614D33DD255CF917407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_21E47A870DDAE33EA435D255CF91BAB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ED261A91D0FE2CEAD6C24DBFB2F75D50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ED261A91D0FE2CEAD6C24DBFB2F75D50" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:to="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_A46B08FB641A32E7B3BA4DBFB2F7F337" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4B5FB923DE1E18AF29344DBFB2F72EF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_08D38543443D5351BD954DBFB2F7636D" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4B5FB923DE1E18AF29344DBFB2F72EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_80327DD5860A5EF760404DBFB2F7889A" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember" xlink:label="loc_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_704CF91151CAE7FD55624DBFB2F8822E" xlink:to="loc_obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember_6E5C6A26808C1D8D2E9F4DBFB2F8CE61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E5FB553D3A0622B2324DBFB2F7EFBE" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799D804DC4F6CF8AA4514DBFB2F8380C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57BB565F3B299225114C4DBFB2F8F1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BC4BBA133D442C81B2B54DBFB2F8CB19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_314F8681AAEA3CDB475C4DBFB2F8393A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3736B2307CEDA4F7FF414DBFB2F8911F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_897F8451F11AE02B408C8F86FBF64781" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_897F8451F11AE02B408C8F86FBF64781" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_64F4F3E762C060E84ADA8F86FBF64D3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_897F8451F11AE02B408C8F86FBF64781" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9AB34DEDB4AC8636F2398F86FBF6484D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_897F8451F11AE02B408C8F86FBF64781" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_9174D48B743F3B17CBC28F86FC091A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_897F8451F11AE02B408C8F86FBF64781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C28AAF7D423D869A82F18F86FC097369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_897F8451F11AE02B408C8F86FBF64781" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_FC636469FA8141661B358F86FC09176E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CCB8B324DF115DB9840B8F870BE0C853" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CCB8B324DF115DB9840B8F870BE0C853" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67CB1CAD691338453E7B8F870BE13E2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_544B5BE7802377A91B38F5B053C3A28C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_544B5BE7802377A91B38F5B053C3A28C" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_6EF064DAF81DBAC71768F5B053C4B478" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_D2378B3F55292B4B54784D3897473832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_478456AF39885EAA85714D389747CFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E5B22AE710629936F9B54D5F46B388E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8B09BF797A9AC071E08F4D38974719A9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2C0E0C69C3DB8C921B124D3897472D98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_414C9BE72B876E809BDA8F870C3A7769" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_414C9BE72B876E809BDA8F870C3A7769" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_B9F2831EDB0351F64D9C8F870C3AAED0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_67917FCD7DB0C922A0F44D38987E1FA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8012C27F61F07C3E9BDB4D38987E8A82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_67917FCD7DB0C922A0F44D38987E1FA2" xlink:to="loc_us-gaap_StatementTable_8012C27F61F07C3E9BDB4D38987E8A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11BB9410AEC2C9E8E4344D38987E8468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8012C27F61F07C3E9BDB4D38987E8A82" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11BB9410AEC2C9E8E4344D38987E8468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11BB9410AEC2C9E8E4344D38987E8468" xlink:to="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_47D98A3F97BE530B65EF4D38987FE9C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_47D98A3F97BE530B65EF4D38987FE9C0" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_B6ADBACAA1A9DF5DCBF64D38987FDF08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_B6ADBACAA1A9DF5DCBF64D38987FDF08" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_801E41B65F3BBE5D58D84D38987FB568" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_801E41B65F3BBE5D58D84D38987FB568" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_8701DAEF42FD21929FC44D38987FEA49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_8701DAEF42FD21929FC44D38987FEA49" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_B33B3B1FAB6E800CB6734D38987FAF90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_B33B3B1FAB6E800CB6734D38987FAF90" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_141AB9173A8F3F19D0914D38987F6D85" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D0220B52FD6256BB43A94D38987F1356" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_141AB9173A8F3F19D0914D38987F6D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8012C27F61F07C3E9BDB4D38987E8A82" xlink:to="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:to="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66C6E8BA7C704F634A6D4D38987F17E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_ShortTermInvestments_344A0130E6846C446F354D38987F9E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_B0DA1260675BF919320A4D38987F3A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_InventoryNet_38F85E5BFAE98D530BEF4D38987F0911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_OtherAssetsCurrent_4B2EFA2BA4CA63AFD0D44D38987F75DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E7A3E10A6A9D6617F5F54D38987FC373" xlink:to="loc_us-gaap_AssetsCurrent_2D0042C9DB0D4EDEDBB14D38987F526C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_201CEDCBDE067A397F974D38987FACB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_08241875A9621C4D1DAF4D38987FA6AA" xlink:to="loc_us-gaap_Assets_561E7F06C217D9D019994D38988039BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94FD3C9BBA9A6FAE7A6B4D38987FADFD" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_C6936196E4CF9C3056D14D389880F1D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2A6A3DC3A81D1B32244E4D389880AEEF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_AccruedClinicalExpensesCurrent" xlink:label="loc_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_obln_AccruedClinicalExpensesCurrent_99B6CE5DE9D97204F9534D389880DA68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_E0EB3632FDC82551B6E74D3898802221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_0CCEED259476A0961A224D389880F1F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_RelatedPartyDepositLiabilities_0CCEED259476A0961A224D389880F1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_LongTermDebtCurrent_47D8FE0EB5C15BB55C184D3898809CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_A1677CFD7B974D3A046E4D3898804625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE5B812B4595C06029894D3898804672" xlink:to="loc_us-gaap_LiabilitiesCurrent_595F19C5578DC31126144D3898809B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6B344B4309B2793A0D5B4D389880B566" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6B344B4309B2793A0D5B4D389880B566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_Liabilities_6CB8FC7CA271E2BBF0B84D38988078C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_A3B09BC70434EB68A9654D3898800A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_2A7EB08CC75738B8C4734D3898802679" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4C27E667A58CBD7EFB164D389880645F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_CommonStockValue_4B2B1B4E11FEBF662E824D389881DC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_C8E21DC7772B34E22ECE4D3898816D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6A409B9112B47F651F24D3898814EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34369FB2469B42C38CAA4D389881A81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DEAFBB9A99C96FEC456C4D3898818A42" xlink:to="loc_us-gaap_StockholdersEquity_CDDF6F88D43D29F67A604D38988109E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FF6470C5A74915C0500A4D389880FCD5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DD4AA36565F204FA3494D389881A8BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_11C3FBB815D12332C905F555F84C75C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7D96CAAE6BA07813005CF555F84C34A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_11C3FBB815D12332C905F555F84C75C2" xlink:to="loc_us-gaap_StatementTable_7D96CAAE6BA07813005CF555F84C34A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76C588869A1D1B3D25D6F555F84D1333" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7D96CAAE6BA07813005CF555F84C34A1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76C588869A1D1B3D25D6F555F84D1333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76C588869A1D1B3D25D6F555F84D1333" xlink:to="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_029EBCF52973FB874D89F555F84D3AEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_029EBCF52973FB874D89F555F84D3AEE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_92AF3A413B6348F63661F555F84DBCE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_92AF3A413B6348F63661F555F84DBCE5" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_F3DF34347E4CE77F7D93F555F84DBE23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_F3DF34347E4CE77F7D93F555F84DBE23" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_BAB3F3456433FDA604D1F555F84DA84A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_BAB3F3456433FDA604D1F555F84DA84A" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_8F527CCC516154526744F555F84D9635" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_8F527CCC516154526744F555F84D9635" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_AAC861D08194FF84CB64F5725827D517" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_FE5904F3766AA373F8B0F555F84D377A" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_AAC861D08194FF84CB64F5725827D517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7D96CAAE6BA07813005CF555F84C34A1" xlink:to="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4258BD6645F4D90D1D97F555F84D77F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4258BD6645F4D90D1D97F555F84D77F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_ACE68ECA9200D66CFC7FF555F84D97D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_7C7B21D7DE43F16902A3F555F84D189E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_7C7B21D7DE43F16902A3F555F84D189E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_A986BA0AC1F01944C76BF555F84DCEB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_5BAE18F0E88983B94BFBF555F84D81D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_FA46A9AB7E43A11172A6F555F84D9BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4B5EFB3D16055667B590F555F84D6710" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4B5EFB3D16055667B590F555F84D6710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockSharesIssued_BCC72752E9D1A2BBAA6EF555F84D7BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69A50691929202DA5BD6F555F84D6CF1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_FCAB4337FA0B21B603D9F555F84DAA6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_916A6DD8D263173EE2056718152FA283" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:to="loc_us-gaap_NetIncomeLoss_916A6DD8D263173EE2056718152FA283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_B749D0E41C6D99828F976718152FF9C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:to="loc_us-gaap_DepreciationAndAmortization_B749D0E41C6D99828F976718152FF9C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_419E6D656FFDA818B92C6718152F2A85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:to="loc_us-gaap_ShareBasedCompensation_419E6D656FFDA818B92C6718152F2A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_195B5EF110BB0887A4376718152F6D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_46458B01AE0E3B605AF76718152FE163" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_46458B01AE0E3B605AF76718152FE163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_BB9848689BD0D00C42C16718152FACCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEF6522C20886056A93C6718152FAD36" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_BDE0EFA77F6664E91A736718152FF849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4A79BD9D67F8AB5E985A6718152FCF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_A032356E903EC9E32BD26718152F2732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_A68ED6A8100A4794F6FA6718152F3471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7FE83D0B37C59312ED9C6718152FA7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6DC7D4E1BE3F4EADADC66718152FA28B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0B3553C523DC9E570A626718152F7369" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_IncreaseDecreaseInAccruedClinicalExpenses" xlink:label="loc_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_obln_IncreaseDecreaseInAccruedClinicalExpenses_481FC8AA735043E0459E6718152F3E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_E6E2C3DDA90724D7F74A6718152FB6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59862365A27FA8D18AB16718152F164E" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_721C9FD9ED2BD0BE57136718152FEA51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_117172E69E7DB5C7678A6718152FFBFE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0F265D6884CED1DA4C4F6718152FC60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_369C71D6EEA0A0BBF81C6718152FB442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_50B07FF6FA3401B94C996718152F99DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_F5439E7769A8886832C46718152F55DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3AD77729C06CADA958696718152F76F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_FABDF6D13C219D0941D16718152F8AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0AA550B08467842B962A6718152FA5C1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F875FD827641C94C67046718152F5687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4F20E603F33C6D958D006718152F5AC3" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty" xlink:label="loc_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty_CB069B89010A19E83A5B6718152F9ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9189F3A93A082E1B9EB2671F12B06626" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9189F3A93A082E1B9EB2671F12B06626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7C630D3712F631A813D46718152FEEFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_0A0E10DCE7361E43F16E6718152F7C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_43D8E67B2B271863045E6718152F7C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_57FC39FFD0334B843A376718152F6244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_494C34B8354FFAC5BA736718152F111F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_A694968C43931B8789C76718152F6DED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_964C67E1A1BC56C841E16718152FDA35" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6BC58031D5B98D61B2CA6718152F613D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41B23FF159CC642FC4356718152F99D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41B23FF159CC642FC4356718152F99D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5CAA9743C3365D8DAFEF6718152FC6AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5CAA9743C3365D8DAFEF6718152FC6AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55AB0D84298F9D6875426718152F08CC" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:to="loc_us-gaap_InterestPaid_5687AD77E003EA8F683D6718152F35CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:to="loc_us-gaap_IncomeTaxesPaid_37194D1BB3ADE7F08DAF6718152F097E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_7CA151AE80568F8235116718152F7649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:to="loc_us-gaap_StockIssued1_4EDCC379F80554ADC9DB6718152FFE3B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock" xlink:label="loc_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:to="loc_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock_DED18089D9D77A8A33876718152F4E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_902E320BB8AA238902706718152F44B5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CEC13B3F74240DC2C00F6718152F78B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_688624F0F918851F21DA671815418F01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_688624F0F918851F21DA671815418F01" xlink:to="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20BA98F1E2FAF31A2B3967181541CB79" xlink:to="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_CommonStockMember_DE130B9F065F5DC1EE10671815424005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_96E5D0C4E3307935ADFE671815421CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02130A0F8812D1A783766718154277B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40EDB62E81F1039E74FC671815424C5D" xlink:to="loc_us-gaap_RetainedEarningsMember_981A38545C8CE46ED310671815425F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9DD237FE23871AF8CB6C671815423496" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9DD237FE23871AF8CB6C671815423496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9DD237FE23871AF8CB6C671815423496" xlink:to="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_3BB8C1A5C345837C2E7E671815425A65" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_F11D1EA510AA0DF2C2B567181542362E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_6D501DDA395EFD299D8967181542632F" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_8DD0AF88DCB2134AC6E5671815420361" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_565F67F6B153DB8A6A13671815429FFE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1C97092272F238AED10D6718154237C6" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_A8C611C89343BEE1ECEF67181543DD49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29FE6B507C6DBA8E1BF067181541D087" xlink:to="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_E468A05D6C6C73BE7E1767181543DECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_576CD60702E3D7F9192F67181543515C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_AF8C582AE5BF727936E167181543155C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_41A6C42A8F0AD28C89A367181543C241" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_AF8C582AE5BF727936E167181543155C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB5BE9CE6DC3FF519CA9671815438E7D" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FCD661535A55C79D77D5671815430B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_C45F874AAC383E37985F67181543F682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D3A1C71B6FD51C2009836718154314B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3FB45C5EABB5BDEF525B67181543B62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95523BABC01332E093B9671815438882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56F279F8FB91AAF0BA08671815431F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63098F1EF1F36868D56367181543CA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4D9878B619869B25514567181544E1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9DAF1937EB9C54D26D7867181544823C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ReclassificationsofWarrantLiabilitytoPermanentEquity" xlink:label="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity_5092BC7A8CDD17BEB8E867181544507E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares" xlink:label="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares_9FCDC5273FE9A1E0DC2B67181544805A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8CD26FC8373C484E508F6718154461F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_F7059ACA9AB84139B86F6718154413FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_NetIncomeLoss_A18E2B2A86762918461B671815443475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A1CB3D7D998CA860D82D67181544271F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A1CB3D7D998CA860D82D67181544271F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19AB06973B407F5AA79167181544DF4F" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5D514D58CE6ED1B549FC671815430E91" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19AB06973B407F5AA79167181544DF4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_82739009152232FA924C4DBFB3D26D44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4097BD1D875B1A14CEAD4DBFB3D2219E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_82739009152232FA924C4DBFB3D26D44" xlink:to="loc_us-gaap_StatementTable_4097BD1D875B1A14CEAD4DBFB3D2219E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A779B0ED383FAB8938834DBFB3D2EE44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4097BD1D875B1A14CEAD4DBFB3D2219E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A779B0ED383FAB8938834DBFB3D2EE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A779B0ED383FAB8938834DBFB3D2EE44" xlink:to="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_55DE614964B7D8BD40464DBFB3D2FF85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D0FDFE73DA839F06ECF34DBFB3D28DEE" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_55DE614964B7D8BD40464DBFB3D2FF85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4097BD1D875B1A14CEAD4DBFB3D2219E" xlink:to="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_99828E9C78A308F0B7DB4DBFB3D397E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219720F4B1BA0B24CCF44DBFB3D2754E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7E81AD567870429CC54A4DBFB3D3B750" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:to="loc_us-gaap_SalesRevenueServicesNet_ADA363CC68D52D49F931697CE493996C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:to="loc_us-gaap_RevenueFromRelatedParties_546A4D1894D9DCFFC8FE697CE494147B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_CB4066D89F4F2800CDF1697CE494227B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_EE78373F71BC70E5A4A4697CE4928B8B" xlink:to="loc_us-gaap_Revenues_CB4066D89F4F2800CDF1697CE494227B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_CostOfRevenue_F0844DFC0E7BB7EB6F74697CE494E71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_DDE8DB3C81FECC629F49697CE4940382" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_GrossProfit_DDE8DB3C81FECC629F49697CE4940382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8D339453C4A68AB15ED0697CE49479DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A6FD63CF3E29F3F1EE6697CE4941FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10387A03ECF47CE8F5E5697CE4946D64" xlink:to="loc_us-gaap_OperatingExpenses_B409684BC6A9E63DBA86697CE494CC01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5102272879D9027E939F697CE494DC4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_OperatingIncomeLoss_5102272879D9027E939F697CE494DC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1A2796091A093FE099C9697CE49492B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_C22A8A205436D95E755D697CE4944FFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_D6588E6F351059235827697CE494AB5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3F9877C0BB7B56C8704B697CE494A003" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_NetIncomeLoss_3F9877C0BB7B56C8704B697CE494A003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B76AC482334F7324C52C697CE4940349" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B76AC482334F7324C52C697CE4940349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_CA9F41CCEA8187ED6B03697CE495A25B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9976648D88EA6A877E79697CE495D58D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9976648D88EA6A877E79697CE495D58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_604EC0EF69AE98AF071F697CE495E7CC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9449D475E970C430E3E7697CE48F5145" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_604EC0EF69AE98AF071F697CE495E7CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DE74EC079DF27E1863C28F870685C52D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DE74EC079DF27E1863C28F870685C52D" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22EBCEABE78C0D158B748F8706851662" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0E4AAA479CCE963A59E04DBFB21A2AD2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0E4AAA479CCE963A59E04DBFB21A2AD2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A048ED5B63AD280FF65D4DF8A214ADC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A048ED5B63AD280FF65D4DF8A214ADC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A048ED5B63AD280FF65D4DF8A214ADC6" xlink:to="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_BaderSultanAndBrosCoWLLMember" xlink:label="loc_obln_BaderSultanAndBrosCoWLLMember_9E92AD125CBA6F7A587B4E0042B8DADB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_C11750293047982EC32F4DF8A2149AC7" xlink:to="loc_obln_BaderSultanAndBrosCoWLLMember_9E92AD125CBA6F7A587B4E0042B8DADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C3A762A169A0A1D62EC84DBFB21B29E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="loc_us-gaap_RangeAxis_C3A762A169A0A1D62EC84DBFB21B29E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_C3A762A169A0A1D62EC84DBFB21B29E1" xlink:to="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_252922C383B92B04538D4DBFB2205B2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_80A0ECC462052F46B8194DBFB220253F" xlink:to="loc_us-gaap_MinimumMember_252922C383B92B04538D4DBFB2205B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6CF6D0C062B658A408604DBFB2203D36" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6CF6D0C062B658A408604DBFB2203D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6CF6D0C062B658A408604DBFB2203D36" xlink:to="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_949AAADE319FA687A0624E087EC4C7FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_949AAADE319FA687A0624E087EC4C7FC" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_2A23CC332AE46F6AF2984E0880D150FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_2A23CC332AE46F6AF2984E0880D150FA" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_FC387B052CB3C654425A4E0882D49C78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_FC387B052CB3C654425A4E0882D49C78" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_25E0C6F0F21068FC21B24E0884C85ABE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_25E0C6F0F21068FC21B24E0884C85ABE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_C45C8AEA447358ECFB654E08860FE7FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_C45C8AEA447358ECFB654E08860FE7FC" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_32E6200D974A16C3D7814DBFB221CB4F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_17881B83DAEA88C8231F4DBFB220B02B" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_32E6200D974A16C3D7814DBFB221CB4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9DDA9851FB1F9A8763154DBFB21ADB61" xlink:to="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_D7CE002DFAD7414181B24DBFB221A811" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_D7CE002DFAD7414181B24DBFB221A811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_A8BB07B4AF0C6AAFD4884DBFB221B178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_45D5CC26142183E46C694DBFB221A37F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_45D5CC26142183E46C694DBFB221A37F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_37BE5BB5E6DB2068B1204DBFB221CAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromJointVentures" xlink:label="loc_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_DueFromJointVentures_CAF35AA6F11CAC89D8534E0109F4FAF5" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TemporaryEquityDividendRatePerShareAmount" xlink:label="loc_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_TemporaryEquityDividendRatePerShareAmount_783CC01CFB448688CB3B4DBFB2215D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_2B2BA67FCACA44647B414DBFB221D7C2" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ConversionOfTemporaryEquityToCommonStockPercentage" xlink:label="loc_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_ConversionOfTemporaryEquityToCommonStockPercentage_B60CF14769B4AA5F993B4DBFB222A39F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_800E2D75316DA80854944DBFB2227849" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_SharePrice_800E2D75316DA80854944DBFB2227849" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock" xlink:label="loc_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock_CDF4565C35D2DD7A86BA4DBFB2228D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_D32FA857E7133C99D4014DBFB22138F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_FE7802967C22001363374E087CF357E1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_FE7802967C22001363374E087CF357E1" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantOrRightExercised" xlink:label="loc_obln_ClassOfWarrantOrRightExercised_780A831754F5A7AC9D234DBFB221AFAD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_ClassOfWarrantOrRightExercised_780A831754F5A7AC9D234DBFB221AFAD" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants" xlink:label="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_4BD23FD6399C55478DAD4DBFB221C89F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9C9053E1D86BB8B7ECC84DBFB221742B" xlink:to="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_4BD23FD6399C55478DAD4DBFB221C89F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_62C35995F3AB8208EAC24DBFB1CEEC30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_62C35995F3AB8208EAC24DBFB1CEEC30" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B8F58973F39E819B26D44DBFB1CE7887" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:to="loc_us-gaap_AwardTypeAxis_B8F58973F39E819B26D44DBFB1CE7887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B8F58973F39E819B26D44DBFB1CE7887" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsIssuedAndOutstandingMember" xlink:label="loc_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_265AB270435C28B3744A4DBFB1CE9F1C" xlink:to="loc_obln_StockOptionsIssuedAndOutstandingMember_3A9BA028FF5DC21B85D74DBFB1CEA8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1A280F453DD83D48D1CE4E4ABA13D03E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:to="loc_us-gaap_PlanNameAxis_1A280F453DD83D48D1CE4E4ABA13D03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1A280F453DD83D48D1CE4E4ABA13D03E" xlink:to="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3D655ED949816CC9E1A54E4ABA13F6DA" xlink:to="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_E1B6A4432705187EA0CF4E4ABA32BA8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A4CD261D10C27158BD4F4DBFB1CEC2DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A4CD261D10C27158BD4F4DBFB1CEC2DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A4CD261D10C27158BD4F4DBFB1CEC2DC" xlink:to="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_156F9297E179AF4953004DBFB1CE37DB" xlink:to="loc_us-gaap_WarrantMember_6E2544224EFB21EABB634DBFB1CE0815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2B55311CF5E2579659A34DBFB1CF82D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_39E95BDE7B1AA15FA6C04DBFB1CE9BD9" xlink:to="loc_us-gaap_ClassOfStockLineItems_2B55311CF5E2579659A34DBFB1CF82D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2B55311CF5E2579659A34DBFB1CF82D5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AC59F3646529CEA53E194DBFB1CFB0A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_6DA7013FB0A31611B9088F87082A3C1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_6DA7013FB0A31611B9088F87082A3C1A" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_290CEB1C1B4C4195A1C78F87082B6CDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:to="loc_us-gaap_StatementClassOfStockAxis_290CEB1C1B4C4195A1C78F87082B6CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_290CEB1C1B4C4195A1C78F87082B6CDA" xlink:to="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesAConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesAConvertiblePreferredStockMember_C6DA9ED8BB803CDB61608F87082B192D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesAConvertiblePreferredStockMember_C6DA9ED8BB803CDB61608F87082B192D" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesBConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesBConvertiblePreferredStockMember_F2D972C16C6DA33C0C988F87082BF6D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesBConvertiblePreferredStockMember_F2D972C16C6DA33C0C988F87082BF6D7" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_A9700D9B18903D23F9CF8F87082C7380" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_A9700D9B18903D23F9CF8F87082C7380" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_CC6AE33D7DD9D7C5D4858F87082C88E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_CC6AE33D7DD9D7C5D4858F87082C88E2" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_7D283EADA73058B554918F87082C3E2F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_7D283EADA73058B554918F87082C3E2F" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_655C0181933F3AB700368F87082C49D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05565A12DFA691B5260A8F87082BE6B5" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_655C0181933F3AB700368F87082C49D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_F0A827391F017C953E788F87082BC502" xlink:to="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_5825421DA17BF46DD8088F87082DF741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_B10FEC59BD4AF1C7EB188F87082D9063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3786C221BBBC9FD404708F87082DBE10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_FF9B1173B80CEAEBADA98F87082E0035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_98FCD88822E2E35312358F87082D6ED5" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_E76A30975851BBED7D7F8F87082E70F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_CD438C7CF598945439C6F555F678955B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_CD438C7CF598945439C6F555F678955B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3381F3C1CB99E0096CEBF555F679AAAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3381F3C1CB99E0096CEBF555F679AAAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3381F3C1CB99E0096CEBF555F679AAAE" xlink:to="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_BFFF49D38722F30BDB91F555F679826C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_480867C75492F25E7241F555F6794395" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_BFFF49D38722F30BDB91F555F679826C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_F92D817E11D01D221245F555F67970EE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember" xlink:label="loc_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_04132BA9E9C76E06D49DF555F679E9CE" xlink:to="loc_obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember_C4E9EBFCB2A4E4A47948F555F6790C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D67AD468A3C63E10D65CF555F6784611" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ADDE727261CEE761CEC2F555F67ECE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_54F09EE5A5E51967343EF555F6799953" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38FDB4245C705AF8D18CF555F67FE623" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_F28687776B55DA4623838F87071DB014" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_F28687776B55DA4623838F87071DB014" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_D4272B2E78057E68103E8F87071E220B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_F28687776B55DA4623838F87071DB014" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1D2FC7073589A4A964E08F87071E2D26" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="loc_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_F28687776B55DA4623838F87071DB014" xlink:to="loc_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_CE4E0E7A77D5AE81F1A88F87071E4CAC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="obln-20161231.xsd#obln_DocumentAndEntityInformationAbstract" xlink:label="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_DocumentType_FFDB57F6AC88F88F13284DBFB4063B97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_AmendmentFlag_6A9181A9B8F1472957D84DBFB407D8CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_DocumentPeriodEndDate_CC3A55E975F54B26BB764DBFB4077AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_DocumentFiscalYearFocus_56EFBECC2D3C2F3CDE174DBFB40729AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9289E24BA486D16D91FC4DBFB4074374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_TradingSymbol_4822AC3894E5CD51747D4DBFB407E053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityRegistrantName_89546B7D1B173E9C6DC44DBFB4075141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityCentralIndexKey_64128D830A9F54E04D6F4DBFB407B547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_CurrentFiscalYearEndDate_D2E0D732F8EB59621C4F4DBFB4070DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityFilerCategory_29DE88601C572689F9D04DBFB4076871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_44D452721FBB62DCD4C74DBFB407FAA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9394346B0BD07DDAC5B44DBFB407B073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityVoluntaryFilers_6DED7417EE8A2BD262DA4DBFB407B9BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityCurrentReportingStatus_71CAF801B3E1DC22BE924DBFB4070FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_DocumentAndEntityInformationAbstract_7631942625D2A84E3A124DBFB406A1DE" xlink:to="loc_dei_EntityPublicFloat_25918280E44CB0544D6E4E6448CF9FFF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F8E7379180D339DC721E93E15F1A7DB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F8E7379180D339DC721E93E15F1A7DB9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3297953761A4E77EF35293E15F1A0C9D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_819D9CCB4EC0A2691F8D623C819E57CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_819D9CCB4EC0A2691F8D623C819E57CA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E474ACAA16F414C63243623C819E9AFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E474ACAA16F414C63243623C819E9AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E474ACAA16F414C63243623C819E9AFF" xlink:to="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_003A91C40DCFD3725650623C819E83CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8E705A167AB5D612AEBB623C819E6FD2" xlink:to="loc_us-gaap_CommonStockMember_003A91C40DCFD3725650623C819E83CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5BE613F5496977E5213E623C819EAD06" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantOrRightExercised" xlink:label="loc_obln_ClassOfWarrantOrRightExercised_E4F6F9D14F486D5FDF8D62683BBA7D80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:to="loc_obln_ClassOfWarrantOrRightExercised_E4F6F9D14F486D5FDF8D62683BBA7D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B77CBE10B751FB39B49762683C5495A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_330B8256A2E5A55BB8E0623C819EE139" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B77CBE10B751FB39B49762683C5495A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3BD03AE988FA37E9DD454DBFB3274411" xlink:type="locator" />
    <link:loc xlink:href="obln-20161231.xsd#obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3BD03AE988FA37E9DD454DBFB3274411" xlink:to="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_DB1A53C11236ED10A8224DBFB3285671" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_WarrantLiabilityMember" xlink:label="loc_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14048FC8130E1DDA57514DBFB3289C21" xlink:to="loc_obln_WarrantLiabilityMember_80F13DA186D5D7878A694DBFB328360D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_957CC928D3E8FC918A4F4DBFB3286F9C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_22931073A8FD9D659F3A4DBFB328DD96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ECAD75263ADE689BECE4DBFB328152D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17C031DD0FC1E80B4A724DBFB3287439" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DCA260CBE617F8604E3A4DBFB328C20D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_37E354C4596A680199B04DBFB3283A6E" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7BC1BEF1C6A1A55F67B54DBFB3288662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4448BA63C0AF0BBC99C34DBFB328D279" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0803171464A5A3377BF44DBFB328B361" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_8131D20D8F8DA812F1FD4DBFB327DCAA" xlink:to="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_961794A59215D68E20FC4DBFB3284809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_EC41E087FF8DCD8890CD4DBFB3289759" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_812A4A3BEB74544724894DBFB329041D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2B9C94290987C1A9FCE3699DA1064598" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2B9C94290987C1A9FCE3699DA1064598" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:to="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9899DBA540EDE3528232699DA1074E1F" xlink:to="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:to="loc_us-gaap_MinimumMember_4AFFBF6C8E316986DFA2699DA1078449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_ABAE1B573AAEEFDB22AA699DA1072F6F" xlink:to="loc_us-gaap_MaximumMember_557368A90D6AC9324C7C699DA1076261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E12F02B1F0ABF7F26B00699DA1082B81" xlink:to="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_BAE63CD3839B5E541043699DA1083C61" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOnePreferredStockMember" xlink:label="loc_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:to="loc_obln_SeriesCOnePreferredStockMember_5F91C8A798847437BD43699DA1089AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_578CC20566440244E408699DA108C07A" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_C32C174B0F1B9F38083E699DA108E8AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8D0D8C06A91BE5A2F0C2699DA1069F26" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BAF1840BCEE1E9B3FC75699DA10881EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6BF9574EC55BCD757153699DA108D970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_EDA012DAD134F7F4B38A699DA108FB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C4DBE7F91EBE8D3C8316699DA1091220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8F6711CB4BD1B6A79497699DA1085E43" xlink:to="loc_us-gaap_SharePrice_DBE3012C9B42AE4789AE699DA10940E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4E48BFAAAB12964A49524DBFB31FE1C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4E48BFAAAB12964A49524DBFB31FE1C6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BBE85FC220397228BE034DBFB31FB1F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_CB3D7A65DB8FAC7963C64DBFB31F589E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95A6AC9FCB738C7F3D784DBFB31F0EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0CFDDD50D533395342A94E1F3C6570DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_10C9A6930F7776B68F314DBFB31FCAC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C6BFFAAE91EFCAA298754DBFB31F6180" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18FE50C40AD0A42362344DBFB31FBA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C6BFFAAE91EFCAA298754DBFB31F6180" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_72A733881C49C2D15AB293E15F183F50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72A733881C49C2D15AB293E15F183F50" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2271EF81CCF3395E293B93E15F1845F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72A733881C49C2D15AB293E15F183F50" xlink:to="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_11BB7E6F3ABC2B7CDA9893E15F183C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72A733881C49C2D15AB293E15F183F50" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23A0A670BF6327512EB293E15F189AEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_320AB5C5F4EAE43E219293E15E8F1052" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_320AB5C5F4EAE43E219293E15E8F1052" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_DEE1903BE69EB1855F9893E15E8F0414" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_57941DAE9786A6635F5C4DBFB1A55796" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57941DAE9786A6635F5C4DBFB1A55796" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_61D5B873F9C2B206E53C4DBFB1A576DD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:to="loc_us-gaap_DomesticCountryMember_FB388314A61420C4BFD64DBFB1A5B09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_983FD6168ED02CEE122A4DBFB1A5214E" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3ECADC792123CF1FE8F44DBFB1A55198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5B8EB351F0C7AE3EEF6C4DBFB1A5F893" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_FBFB547A034F28FAA72C4DBFB1A589B8" xlink:to="loc_us-gaap_ResearchMember_EB200F03392551BF8FC04DBFB1A510F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE29255D3B09D478DA0D4DBFB1A5D02F" xlink:to="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A2DD713D909B9F53516A4DBFB1A5783F" xlink:to="loc_stpr_CA_ACCF30403BCD6FE7EBD24DBFB1A62932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_E22EE02D5410A592D7004DBFB1A59199" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_5BBD6E910A9DFB5F2DB74DBFB1AB7C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_A7464AF8B9E1944AEFDA4DBFB1AB6852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1FD638075ACEE7F8B0F34DBFB1ABD51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_06D5A83171DA177051514DBFB1AB0EF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_80675C5335FF750A09DE4DBFB1ABD96F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B7FAC967B5329AC91D194DBFB1ABB7B4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_EB8C771F5F914F5B15434DE86F0E30F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5DC14ECB16D2ECFD9F3B4D38974E5EF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DC14ECB16D2ECFD9F3B4D38974E5EF3" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_39CA7B0FB34274CC5BD74D38974E1B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_A7D49E3E249E0113ED384D38974FC09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_C7849AA274ED8361E06E4D38974FE18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4FCEE73B8B3A7EF390AC4D38974F2EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AE1155346620F28D65D74D38974F58DE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AE1155346620F28D65D74D38974F58DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73A82013B7D3D4F3CADE4D38974EB9A2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1F2A6BBB8EC52D4143BE4D38974F9270" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_DF5D75A6886581B4F3D294A4186F4B46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DF5D75A6886581B4F3D294A4186F4B46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85B911ECF6B1C87A697B94A64DE5A434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_BBF3FE5C37A3F48D27E094A7F003AE57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_A2CB84CBD59A35D21F6494A87A2BA2A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4D8026490761D18891D694A92862054E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_E5D6D4A2C46F4BF82CC094AB6C6CFD2C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3A60DB4B3E298ABA7D2D94A99CBB27DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C3AE3B4359FD0688E86AF555F635BB2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C3AE3B4359FD0688E86AF555F635BB2D" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_A0366B939017FC85C90FF555F63A8091" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_A0366B939017FC85C90FF555F63A8091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_83AD4EB398F52ED23EB6F555F63A22B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_83AD4EB398F52ED23EB6F555F63A22B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_236D0E233DC7A1CA5670F555F63B526D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_236D0E233DC7A1CA5670F555F63B526D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_A6E66CA7F09633DC9C23F555F63BF98C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_07F78DB590586F457304F56727B2B7A4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_A6E66CA7F09633DC9C23F555F63BF98C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C3AE3B4359FD0688E86AF555F635BB2D" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0E603937A452EF7CDF33F555F63BD4ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_268BA4ECB6A2F262F90DF555F63B5C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1A8CBE800FA0A478FB7BF555F63B2554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E8227E2B550668B9AA17F555F63BF218" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C63AEA3E028E2035FAD3F555F63B2809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F04C5F50AABD7AAEB5EEF555F63B1D3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C3AE3B4359FD0688E86AF555F635BB2D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_F04C5F50AABD7AAEB5EEF555F63B1D3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_33684E5CA8F6F9379786948608813C3B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33684E5CA8F6F9379786948608813C3B" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0A43B62DED0D944C63FA9486801A3926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33684E5CA8F6F9379786948608813C3B" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4038D9A7C09F2841E9FA94880335842B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33684E5CA8F6F9379786948608813C3B" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8D24716E922C1531DEE94888DBF6A76" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6871D7EED90C664BF7118F86F7D8D629" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6871D7EED90C664BF7118F86F7D8D629" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2705316FE0062493A2498F86F7D8C900" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9D3C1F69FF09C3D3B7678F86FA1F10E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9D3C1F69FF09C3D3B7678F86FA1F10E6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_06EC1526EA52E917D9F18F86FA25ABE5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_93FB352027B11E656CE58F86FA258BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9FB78450ECAB0A024B328F86FA25EBD6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5146BD91B9D2ED58C7088F86FA261125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9E3CD10D345A083439388F86FA20D705" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31B65DA3613F8887ECF18F86FA261304" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C49C45BEC7236DB0DD158F86FA26CED0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A31283882A5E4602FB7F8F86F97C5B86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_71B2EB4E04FBA78697828F86F97C3E3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A31283882A5E4602FB7F8F86F97C5B86" xlink:to="loc_us-gaap_NetIncomeLoss_71B2EB4E04FBA78697828F86F97C3E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A31283882A5E4602FB7F8F86F97C5B86" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2D032DF39459E13370648F86F97C2126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A31283882A5E4602FB7F8F86F97C5B86" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B2F8E5CE56C6C81E5928F86F97CBB77" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6DC5317AD4451F966B628F86F8A8D1D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6DC5317AD4451F966B628F86F8A8D1D8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F803C553F65C9213A77C8F86F8A92434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6DC5317AD4451F966B628F86F8A8D1D8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61745D7EFE3FA37AAB408F86F8A973BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/OrganizationAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_79FA5472C0A60EAB204EBDE91E6179C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79FA5472C0A60EAB204EBDE91E6179C4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BD43688D51D6DB680DE9BDE91E612CE2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8AAB47D179155182A6876718151FDA54" xlink:type="locator" />
    <link:loc xlink:href="obln-20161231.xsd#obln_BasisOfPresentationAndOrganizationTable" xlink:label="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8AAB47D179155182A6876718151FDA54" xlink:to="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8213AA4A79A2714FA3EE6718151F6405" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8213AA4A79A2714FA3EE6718151F6405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8213AA4A79A2714FA3EE6718151F6405" xlink:to="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCConvertiblePreferredStockMember_91EA88ED2DF4B956062F6718151FB13B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:to="loc_obln_SeriesCConvertiblePreferredStockMember_91EA88ED2DF4B956062F6718151FB13B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_51F83D97C2CD603C14106718151F83BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_339CCE3A4272E61430D36718151F1808" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_51F83D97C2CD603C14106718151F83BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_172E721A2EAB4BCCF56B6718151FE6D7" xlink:to="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandAndEightPlanMember" xlink:label="loc_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_26FE4D655ACBFE3371576718151FA870" xlink:to="loc_obln_TwoThousandAndEightPlanMember_1FBD84C3D3F064B3D8B26718151F2530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8FD369ED7DD6F4D009106718151F2154" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PacificWesternBankMember" xlink:label="loc_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_E712E687B4DF95F294926718151FFA79" xlink:to="loc_obln_PacificWesternBankMember_E1FFC7DC9790768BA2BD6718151F96BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_C1B58DB02F6B02A803EE6718151F1356" xlink:to="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ObalonMexicoDERLCVMember" xlink:label="loc_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_DBCB10E200D45C8A12E46718151F557D" xlink:to="loc_obln_ObalonMexicoDERLCVMember_4727A76444152BB3B7506718151FF338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C9798B009D2431D6B0A16718151FF64C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8AC514A5DCBC971CCD366718151F486C" xlink:to="loc_us-gaap_IPOMember_294B335CBD2B42536D3C6718151F96E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7B583B655A25D19F2A5A6718151FADB3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7B583B655A25D19F2A5A6718151FADB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7B583B655A25D19F2A5A6718151FADB3" xlink:to="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D6DD822D2F1FE64D997C6718151F8AAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_34CB2CD5EDB533DEC2F16718151FD0CB" xlink:to="loc_us-gaap_CommonStockMember_D6DD822D2F1FE64D997C6718151F8AAB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_BasisOfPresentationAndOrganizationLineItems" xlink:label="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationTable_2336B2350A30375CAD986718151F1E79" xlink:to="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_OwnershipPercentageHeldByShellCompany" xlink:label="loc_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_OwnershipPercentageHeldByShellCompany_0C2791C8A31888062C2A6718151F08E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4611C6B51ECF3587D47B6718151F55FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_391371972D0FD362FEB46718151FF9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_Revenues_3A8EA0837F4963297E9E6718151F44F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9D62C6904A2E16C29EB76718151F0AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_CBD7DFD057E006A9E7086718151F2732" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_SharePrice_CBD7DFD057E006A9E7086718151F2732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_96B46520241F3264A7336718151F4CC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C9137FA9B6E0AFDBC7546718151FD83C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantOrRightExercised" xlink:label="loc_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_ClassOfWarrantOrRightExercised_D903AD6842D0DB0072FA6718151F4FC0" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants" xlink:label="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants_3E3EC67BACBE888CD6456718151F04AE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock" xlink:label="loc_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock_1F4C4392AE96D6EA6B426718151FFAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DD5FDE89A48841C248586718151F99CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8D684D756D29D39BAC1E6718151F2245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_C7BCE22A29E68366D2246718151F006A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1951481758FE81A6004C6718151FF185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_791AC281505845F4D2916718151F3D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_obln_BasisOfPresentationAndOrganizationLineItems_A6358D1E6BCAD61A0AF06718151F2C98" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8B5C01CD42CC7569637B6718151FD53F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_E887A79CC8E80A0DDCC493E15E804614" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_E887A79CC8E80A0DDCC493E15E804614" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51FF6AEAAC6DEBBC1DB193E15E80F303" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_94509089AA7F0374E59C6A19FD30390A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_94509089AA7F0374E59C6A19FD30390A" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_F7DB1BE79E06F36DED876A19FD30B5AA" xlink:to="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_BaderSultanAndBrosCoWLLMember" xlink:label="loc_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_A29278E9B3EED3D6F1D26A19FD30F13E" xlink:to="loc_obln_BaderSultanAndBrosCoWLLMember_427261F5D6D0E3DEE7096A19FD3097DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A1A76B05D9B4222CB1AD6A19FD303FDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A1A76B05D9B4222CB1AD6A19FD303FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A1A76B05D9B4222CB1AD6A19FD303FDF" xlink:to="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_EDCA4D037A3E04D2528D6A19FD30904C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_EDCA4D037A3E04D2528D6A19FD30904C" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_A26125261528B9C530166A19FD30B8CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4A2001237DC9137802EA6A19FD30D8BE" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_A26125261528B9C530166A19FD30B8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B6752031041DC117A7ED6A19FD3089B7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_DistributionAgreementMember" xlink:label="loc_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B780C46B299DEEC317AB6A19FD302CF9" xlink:to="loc_obln_DistributionAgreementMember_EEEA0199BE34966A5F1A6A19FD415BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4E9967021FD5D51BC4636A19FD302AC6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B6C6B7A5D9ABC13588DA6A19FD41F619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B6C6B7A5D9ABC13588DA6A19FD41F619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7BFD2177768EA085800B6A19FD41AFFB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue" xlink:label="loc_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue_E3D818FE051C647194246A19FD412E1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_21C960F0B23C93B2A8546A19FD41B4F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDepositLiabilities" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_RelatedPartyDepositLiabilities_9ACC60866C707E45E8E96A19FD41E29C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_5E738AC9B6AD1ADD08606A19FD41017D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3B201EA576C3292E77586A19FD41A9BD" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_24255778240F9CBE9C256A19FD41F415" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ACA733AF6281C1719F43946697A282B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ACA733AF6281C1719F43946697A282B6" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C410B6E84E1E3A8C368894675429DAF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_734E55B74F12FE0C7AEF4D61A1C61951" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:to="loc_us-gaap_Revenues_734E55B74F12FE0C7AEF4D61A1C61951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:to="loc_us-gaap_GrossProfit_A93400FF2256F1D21BD94D38972BEF61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:to="loc_us-gaap_OperatingIncomeLoss_58F8277376C5E883B97E4D38972E37D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F1B270AB03DC3C506A124D38972E7507" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:to="loc_us-gaap_NetIncomeLoss_F1B270AB03DC3C506A124D38972E7507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_64EF7920E99C8C377CC34D38972EFBC6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_039B7A5AA495528AF4E14D3897282AD3" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_64EF7920E99C8C377CC34D38972EFBC6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B280C968A4640565DDB294669863199A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B280C968A4640565DDB294669863199A" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_C77B8693ABAAA13A365B946943E77D77" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B9ECED6677CC7D765E593E15ED24289" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B9ECED6677CC7D765E593E15ED24289" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E24647ACB4933DDE2B3C93E15ED284E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0B4AF827CC4BE7859ABC66D4914D1D5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DB473001C404FAF258E66D4914DA07D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0B4AF827CC4BE7859ABC66D4914D1D5B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DB473001C404FAF258E66D4914DA07D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_3DECD104907BF7ACECC866D4914D375E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DB473001C404FAF258E66D4914DA07D" xlink:to="loc_us-gaap_PlanNameAxis_3DECD104907BF7ACECC866D4914D375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3DECD104907BF7ACECC866D4914D375E" xlink:to="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_EquityIncentivePlanMember" xlink:label="loc_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:to="loc_obln_EquityIncentivePlanMember_BE4F01C31E22D8AEE98466D4914F65DB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_11D27BFA213B6AA85D7D66D4914F741B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:to="loc_obln_TwoThousandSixteenEquityIncentivePlanMember_11D27BFA213B6AA85D7D66D4914F741B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_788C4579EB486CE3FF7066D4914ECAA3" xlink:to="loc_obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_A65947EF4BF37910D6C866D4914F87D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DB473001C404FAF258E66D4914DA07D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5AA04D494AEE6E4B823966D49150F7FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5AA04D494AEE6E4B823966D49150F7FF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents" xlink:label="loc_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents_5723C96A68835F455D6466D49150CA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4407FDC99E6348F622EB66D491503732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_08B65523A2D437F5144266D49151DB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23581B7F327D1B48F0B366D491518572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E24FF2C033FB35FDB8F366D49151C6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3AE1C5FA630A2363E2E666D49151E73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_BA9AB520A38E49EBF42966D49152435B" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsEarlyExercised" xlink:label="loc_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_StockOptionsEarlyExercised_3B9BA68C3F21790763B166D491524FFE" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_NonvestedStockOptionsEarlyExercised" xlink:label="loc_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_NonvestedStockOptionsEarlyExercised_3EE8DFB88515CB51ADD166D4915245AB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_StockOptionsEarlyExercisedLiability" xlink:label="loc_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_167216575276B4B17B4866D491506875" xlink:to="loc_obln_StockOptionsEarlyExercisedLiability_FC58033736795EBE088366D49152DD6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ED1F9B711787BCA6BECF555F6F1D293" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ED1F9B711787BCA6BECF555F6F1D293" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_31D4E03F20443D3AF02BF555F6F1FEE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:to="loc_us-gaap_RangeAxis_31D4E03F20443D3AF02BF555F6F1FEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_31D4E03F20443D3AF02BF555F6F1FEE0" xlink:to="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_41D8DAB197C8B49136E0F555F6F1868F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:to="loc_us-gaap_MinimumMember_41D8DAB197C8B49136E0F555F6F1868F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8C13126CED2F902961AFF555F6F21D95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_62845575A18679FB0AB5F555F6F1A365" xlink:to="loc_us-gaap_MaximumMember_8C13126CED2F902961AFF555F6F21D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02C682C8AB837A369FAEF555F6F18B53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B892ED80565855EE1037F555F6F71DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0A3692131C7236993ECAF555F6F7137D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89600D6A707272C4F96EF555F6F70A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_827D4164D4D2E7EF9044F555F6F728B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332AE101530BF6D71D4BF555F6F7B2A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627B19BDE560AE10FB5893E15EC783E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627B19BDE560AE10FB5893E15EC783E8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4F542A754A9A63DA470793E15EC87DA0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:to="loc_us-gaap_CostOfSalesMember_1C493FEBE2178FFA661C93E15EC8C412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73F965E766CC603E6DF993E15EC88F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C286D24CE21472393BC793E15EC86501" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2322A08EF8EEA4D16F593E15EC808EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97E5E231AE8BB49D42E293E15EC7ED45" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_EBA25EEA49E3EFA544BF93E15EC8F5E2" xlink:to="loc_us-gaap_ShareBasedCompensation_881F23942B4A6EDF982493E15EC8FF49" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3B7941D161ABE9F65EF4623C814D5A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04D82A89F49B4CF8B76A623C814D9C12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04D82A89F49B4CF8B76A623C814D9C12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6FDD58CFA7D48DEFA99623C814DE9E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6FDD58CFA7D48DEFA99623C814DE9E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2A36D5B6569489C622A9623C814D42BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CD1ED06878D8CAA1E728623C814D9332" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DCAB38B594237355337A623C814D0C25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CD1ED06878D8CAA1E728623C814D9332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9DF4588E5486D5BEACEE623C814DED4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1D2FF773E2192D66E19A623C814DCA9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D8DF6D700B7A9B4110CE623C814D2D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_48EF6818FD447045F49A623C814DCEB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CF1FB407D7C9A8450431623C814DFD84" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96AFB0C27BDEA25A4473623C814D6A91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CF1FB407D7C9A8450431623C814DFD84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13AB621A7AB71CB60BF6623C814D9230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_CC0B8DADDEB887060B4D623C814D3F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4EE638970E8FA5CBD579623C814DF6BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4CB81821C5BB6BDDD9BF623C814D6093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6D3256DD2415C81CC93F623C814E7E47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0104DA81CEDACD0CEB65623C814EE0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_22D6793A2C25E778D16E623C814E4D20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_D52A3F13164B1A169508623C814E7630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_11ABA5FCBE688A345DBC623C814E9B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_9B7E916789DDA66901DE623C814E443D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5B2247E489C8C1C7E875623C814ED67D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A543BB411468EDDF502A623C814D726C" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5B2247E489C8C1C7E875623C814ED67D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A2A3F97D3787182D83593E15ED0F72A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A2A3F97D3787182D83593E15ED0F72A" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ACDBED63B59C8A8F24993E15ED0D639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A2A3F97D3787182D83593E15ED0F72A" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B1529E441277DF556F8A93E15ED120D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A2A3F97D3787182D83593E15ED0F72A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_E2BD7B08ECE3E3F8E92793E15ED1D280" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_C647858622B25836AFC54DB3FEE74DE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_C647858622B25836AFC54DB3FEE74DE2" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_256F9C6451550B288B1C4DB3FEE774A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3386D7DC81830FC339634DBFB0FD0FDA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3386D7DC81830FC339634DBFB0FD0FDA" xlink:to="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3B3064CE2CBB62D3213B4DBFB0FD1E40" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_67A14174CD6C1E9B98744DBFB0FD3664" xlink:to="loc_us-gaap_SubsequentEventMember_DA3AE472D822DA3B80084DBFB0FD65A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:to="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2148EB1C175BBE9FE4544DBFB0FD70BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A096C0628DF37B691D774DBFB0FD6865" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF253B1D40DCFF815E14DBFB0FDC0C8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A096C0628DF37B691D774DBFB0FD6865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_39DBD738886388661BDE4DBFB0FD0FD1" xlink:to="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_877E90695F2F8A75391D4DBFB1036313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8930993F29022AB977004DBFB103B9A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BB43934A054D67A683828F86F3789326" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BB43934A054D67A683828F86F3789326" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AEF570DE9AAAB3FA015D8F86F3788261" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2C9360708D82BF5F6B9138DB95900D70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2C9360708D82BF5F6B9138DB95900D70" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0B875620204E14A8395A38DB95901DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1FC9F3D7C043EE1D933E38DB959072C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2C9360708D82BF5F6B9138DB95900D70" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1FC9F3D7C043EE1D933E38DB959072C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2C9360708D82BF5F6B9138DB95900D70" xlink:to="loc_us-gaap_AdvertisingExpense_BD7ECF0E9FB74A12598838DB95901D87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0A805FB617FCA01B497ED25062C90A80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0A805FB617FCA01B497ED25062C90A80" xlink:to="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2BDF78CEEBA385DAD3E4D259B4852416" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_C6FF351A8FB987165A11D25A4C7B93A4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0D79A1C7EAD5D800529DD25ACBAE03B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_0550B31031FB7A2CD9FCD252D26BBD99" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_CustomerOneMember" xlink:label="loc_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:to="loc_obln_CustomerOneMember_C11AF9351B5F71DB3640D2545E125693" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_CustomerTwoMember" xlink:label="loc_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_1B29FFAA13DA468E3B76D254E54974A3" xlink:to="loc_obln_CustomerTwoMember_E0BAF7DC6CC130EDCC4CD25F7D9A424B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23BE47F13275221C45C5D25262C8F83C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:to="loc_us-gaap_SalesRevenueNetMember_91A3B0A619C706F8F0AAD2559D5C98DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F636720F7B4F211D2E17D256D96A8764" xlink:to="loc_us-gaap_AccountsReceivableMember_768A8E91A0B921D49441D258A2AFD45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_AA2D7248F91ECFA98B0BD25062CB1613" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_33B6D4F430B4271B37AFD25062CB557B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_CFA9D8C45D06264C6330D25B6084C5B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BD0F5DBAD1BBA8CE2D45FBFAC12B04A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_477C4F07733155561880FBFAC12EA4E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BD0F5DBAD1BBA8CE2D45FBFAC12B04A8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_477C4F07733155561880FBFAC12EA4E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8789D32A5AE6119CB8FBFBFAC12F32F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_477C4F07733155561880FBFAC12EA4E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8789D32A5AE6119CB8FBFBFAC12F32F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8789D32A5AE6119CB8FBFBFAC12F32F0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_AC60AA38D2DB20416000FBFAC12F8004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_ComputerEquipmentMember_AC60AA38D2DB20416000FBFAC12F8004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_06EB9785F7DDFBA36BE7FBFAC130BA7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_E6B8F571F3A8D4C85FE3FBFAC1315CF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_E6B8F571F3A8D4C85FE3FBFAC1315CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_309E1324BA2D500C5811FBFAC12FE92F" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_A6F6195E03EFB3B2BC1EFBFAC3DB5E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7936F64A99092BBC997BFBFAC1312A46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_477C4F07733155561880FBFAC12EA4E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7936F64A99092BBC997BFBFAC1312A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7936F64A99092BBC997BFBFAC1312A46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_712A3495845D6E12BB34FBFAC131E31D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_UseOfEstimates_08113144622FAD77EE8C4DBFB33EFD28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DDD76EDAA378B4F074264DBFB33E3A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_8269BE2DA2AF952024524DBFB33ECE43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_970D4A9D9970C1F3553E4DBFB33ED943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F2DA96EA2B1A48D74CD84DBFB33EBB7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_245CD3003A45E27417D04DBFB33E2A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_20A136FDF9BFC7C2782B4DBFB33F4E0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4637FC6AFB5D4C481B864DBFB33F37AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C7CCEE14EFCBB60C79C54DBFB33F15CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FF956FB32F8571C0F27C4DBFB33F7FBB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClinicalTrialExpensesPolicyPolicyTextBlock" xlink:label="loc_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_obln_ClinicalTrialExpensesPolicyPolicyTextBlock_55D6CEB236F3F2A1DF664DBFB33FBA77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0558BE70C802411943C84DBFB33F125B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8CF032795230E23361104DBFB33F8990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1B27287E12D745A020254DBFB33F5D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_D984D5E132DA00B151F24DBFB33F183F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_29CA681C2A147ACD2F9F4DBFB33FE5C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_CDD98CAF5FEED4B5D5C64DBFB33F396B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_EDBEA3DCA78C1B8C3AE74DBFB33F8531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95DC3F4CE1D8278DEBC54DBFB33E6845" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_F169CB907EA20CBCE20A4DBFB33F7AF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_626AC60F68801E2B7AB14D38983B6682" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_626AC60F68801E2B7AB14D38983B6682" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_35B97C8078F8BC07B51B4D38983BE35A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_CC3F087FBB32B29F47EF4D38983BF52C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_626AC60F68801E2B7AB14D38983B6682" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_CC3F087FBB32B29F47EF4D38983BF52C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/TermLoan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6991A4059D26D5223A0293E15EEB4D8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6991A4059D26D5223A0293E15EEB4D8F" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_E032A69A4311AC33331293E15EEBBEE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/TermLoanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D3A48FFA44205422BE426A0F2900F7A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D3A48FFA44205422BE426A0F2900F7A3" xlink:to="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_394602A26A6EB09E56156A0F2900CE4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_394602A26A6EB09E56156A0F2900CE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_394602A26A6EB09E56156A0F2900CE4E" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PacificWesternBankMember" xlink:label="loc_obln_PacificWesternBankMember_C8694D7F7EDC2CECBFFF6A0F29001508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_4B50FD09B6BF3FB5AFE06A0F2900DD4A" xlink:to="loc_obln_PacificWesternBankMember_C8694D7F7EDC2CECBFFF6A0F29001508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F01C39CFD6238D7044F46A0F29006512" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandThirteenLoanAgreementMember" xlink:label="loc_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_TwoThousandThirteenLoanAgreementMember_8AF8DF94E44E5C81EAB26A0F2900EAFF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TwoThousandFourteenLoanAgreementMember" xlink:label="loc_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_TwoThousandFourteenLoanAgreementMember_221AEB7D504AB59C178E6A0F2900E4AF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeptemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_SeptemberTwoThousandSixteenLoanAgreementMember_4CC25F042ECC585709906A0F29005EF9" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_DecemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35B982776358D37D347E6A0F29007B29" xlink:to="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_419D63C5CFD70D0CBF736A1B93705FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ECEA6257EC863493DB936A0F290013C4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TermLoanAMember" xlink:label="loc_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_TermLoanAMember_3E722DCB3C67B5C744086A0F29002A6E" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_TermLoanBMember" xlink:label="loc_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_TermLoanBMember_A30682A0D6AD0864BF956A0F2900D740" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_FirstTrancheMember" xlink:label="loc_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_FirstTrancheMember_D1847071BA21DDFCF2736A0F29004A76" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SecondTrancheMember" xlink:label="loc_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_AB52FF498697C1F81A016A0F29006CDA" xlink:to="loc_obln_SecondTrancheMember_2AF65D8D368C762CE3CE6A0F29005F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4A372E40237EDB0F2A7E6A0F2900A0A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4A372E40237EDB0F2A7E6A0F2900A0A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4A372E40237EDB0F2A7E6A0F2900A0A9" xlink:to="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesCOneConvertiblePreferredStockMember_94DDCC4D2E6D695652A66A0F29002A2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:to="loc_obln_SeriesCOneConvertiblePreferredStockMember_94DDCC4D2E6D695652A66A0F29002A2F" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesDConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesDConvertiblePreferredStockMember_62EC08A201E0E35498CB6A0F29002129" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:to="loc_obln_SeriesDConvertiblePreferredStockMember_62EC08A201E0E35498CB6A0F29002129" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_SeriesEConvertiblePreferredStockMember" xlink:label="loc_obln_SeriesEConvertiblePreferredStockMember_FB2DF4E323B565971B576A0F2900D894" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_964AED5F7E578A97603F6A0F29005998" xlink:to="loc_obln_SeriesEConvertiblePreferredStockMember_FB2DF4E323B565971B576A0F2900D894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_D7996C4343A822361F066A0F290030AF" xlink:to="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_E61705B02BB951BE4D946A0F29004B33" xlink:to="loc_us-gaap_PrimeRateMember_75E887CD576D8D589A046A0F2900A9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EDBEAD134B57B8C628AA6A0F2900F2C0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_49604B286593325C2E1F6A0F2900F086" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock" xlink:label="loc_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock_79532F5739652443800C6A0F29006756" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_NumberOfWarrantsExercise" xlink:label="loc_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_NumberOfWarrantsExercise_274FAEFD773D159BF0D16A0F29005DFF" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_NumberOfTranches" xlink:label="loc_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_NumberOfTranches_D96A6F03EC1649CC3E936A0F2900B399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCredit_FA1DEEBF8902CA38FDEA6A0F29009DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_39A58B229A3C536410E36A0F2900CD59" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility" xlink:label="loc_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility_D804163CA67DEDE9E6356A0F29001813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C2F7BFD51162C129358A6A0F29000E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_F154AA4C917DF1B195F76A0F2900F395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_A60B70AFD420306719EE6A0F29000B26" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PercentageChangeInPresentValueOfFutureCashFlows" xlink:label="loc_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_PercentageChangeInPresentValueOfFutureCashFlows_C93C0CD96B31AEF1B4026A0F29003CC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_F8A36E2AEA8B662EDB626A0F290052A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18D06B8AA2F32D2F4E0A6A0F2900DE7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11AA475443689C27FC736A0F29004FAC" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments" xlink:label="loc_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments_BD33D18C192E12F0B0A96A0F29005E42" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PurchasePricePerShare" xlink:label="loc_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_PurchasePricePerShare_7FBD793192D02ECE655D6A0F29000EAB" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_PercentageOfBorrowingsForIssuanceOfWarrant" xlink:label="loc_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02F71A72D231FD274E9F6A0F290065D6" xlink:to="loc_obln_PercentageOfBorrowingsForIssuanceOfWarrant_206DEBDD99B6D0F129E56A0F2900FA15" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D25268A73CEDA45CFF816A0F239E37BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3447427E2AFAFF52A65B6A0F239E14FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D25268A73CEDA45CFF816A0F239E37BE" xlink:to="loc_us-gaap_DebtInstrumentTable_3447427E2AFAFF52A65B6A0F239E14FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A4168688DEB196769B926A0F239E44FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3447427E2AFAFF52A65B6A0F239E14FD" xlink:to="loc_us-gaap_DebtInstrumentAxis_A4168688DEB196769B926A0F239E44FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_A4168688DEB196769B926A0F239E44FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946" xlink:type="arc" />
    <link:loc xlink:href="obln-20161231.xsd#obln_DecemberTwoThousandSixteenLoanAgreementMember" xlink:label="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_0550EAFFA26439550A526A242C066A8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3EE03014C9109A4CD3B26A0F239E9946" xlink:to="loc_obln_DecemberTwoThousandSixteenLoanAgreementMember_0550EAFFA26439550A526A242C066A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52DE0D643424631386596A0F239EA1D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3447427E2AFAFF52A65B6A0F239E14FD" xlink:to="loc_us-gaap_DebtInstrumentLineItems_52DE0D643424631386596A0F239EA1D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52DE0D643424631386596A0F239EA1D6" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BAB5444EADA2ABB0778D6A0F239E8293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64321F3FCA1F47752AC46A0F239ED3E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8A2DF8D269140E36C2DA6A0F239E2B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F553351283414680A9526A0F239EF568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_CDA19C780D44E7784D4C6A0F239E6069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5CB8F232828F4992B1BF6A0F239ECB20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F0E22D095D991F712AAA6A0F239EA209" xlink:to="loc_us-gaap_LongTermDebt_5CB8F232828F4992B1BF6A0F239ECB20" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_80E328168347033C4C6B38DB9552AE5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80E328168347033C4C6B38DB9552AE5F" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_026172D45A6CCC5B204338DB95527F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80E328168347033C4C6B38DB9552AE5F" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ECA7494070D843CE2E0538DB95526505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80E328168347033C4C6B38DB9552AE5F" xlink:to="loc_us-gaap_LongTermDebt_D6FC5791173290D9C8B638DB95524FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80E328168347033C4C6B38DB9552AE5F" xlink:to="loc_us-gaap_LongTermDebtCurrent_90602AD7AA5557D6437238DB9552E1D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80E328168347033C4C6B38DB9552AE5F" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_64310052381351A8A9FD38DB95529F35" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.obalon.com/role/TermLoanTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_15CDE9CB03D31457BBFE93E15EE93699" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_15CDE9CB03D31457BBFE93E15EE93699" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B94A00AC0C45F6B198793E15EE9B1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_15CDE9CB03D31457BBFE93E15EE93699" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_38A9BED10F439440FEE693E15EE9D3BC" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>obln10kproformaimage1.jpg
<TEXT>
begin 644 obln10kproformaimage1.jpg
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M 1$  A$! Q$!_\0 'P !  (" @,! 0            8'" D$!0$" PH+_\0
M4!   00! P,"! ('! 8'!P$) @$#! 4&  <1"!(A$S$)%")!46$5%B,R<8'P
M0I&AP0HDL='A\1<8)3-#4F(V5%B4EM/6-((9)B=%4W*2H__$ !P! 0 #  ,!
M 0             ! @,$!@<%"/_$ $<1  $# @,%!@0$!0(% @4%  $  A$#
M(00Q004246%Q!B*!D:'P$['!T0<R0N$4(U)B\3-R%21#4Y(ELA8T1%239'."
MTO+_V@ , P$  A$#$0 _ /W\:(M7OQ5_B%6WP]-F=KLGPW L<S_<[?C?+#=@
M=MHN>Y7^HNV&.9'F$6VG+E^Y66JTXM7B=)%J'"G"T]!<-)"2G;&!70;"8P5F
M-WB;P "3J8' <5WFU75IO;LSM]*OOBE5_35TZ3;G=;"ML-I<_P!G]R,DRW:K
M=BUSZIFSZ2M@-9/5,95BEPS+J["&:Y(+-;8MM_.Q)+,9M3=(0#^7>-KR!/H2
MLN8/4AL39;[9%TR0=T<3D[^8C@4?<_)=K&YZ_K32X!*F5L!C*)T4FQ8:KBDW
M-0!_ZPK[+=I7R'F6X\MAUPJP8G3*>:Q>R[XLGPX\%VNP;>?*NKS:.JVVW,G9
M/7;>Y#^DK.:[F;^%W!4&6/8Y15U7+R.UK<?ND2LM+>)4.5,28;++DU"?9[RM
MN.)(W3(SMEU^G%8P=?\ \2^5MYL1T'[\]%FXFV&YF ]4'7KL1T]W&9L1F\RQ
M^UVVSAK<-K-(5.;$Z"=-E$*UQ)BLD'+%+*AF1K"!,KV)HN R5F,DN#I$-)X'
M3B.:F72=UVY]N)UK?%OVDWOR/;W%=C.AJ^Z?RP7(Y<>)B;>-8IG. [A9/GEO
MG^66=I^CY$&$YB<2>EG,2MC5449JNFK!#Z,:QR'U^RAS0 R,W"?\+(O8GXGG
M0#U-91DN$[$]5.U>XV78E2W&27&-U%G.B7)X_C[)R;RZI(%Q75LC**NIC LF
MPG8P%Q&BQE"0\X++C9E*@L<+EI'@I@77]T9!LUM9U"N=1>V[6RN]F=QML=J]
MQ7K5]G'LTSZ5:9!3-XM5.NQ0D#9A9XKD422$R/%:A%433F.L--^HI1NDDB#(
MN1J%),\ZT.E3:[,-R\!W&WYVYPC+-F]N*S=S=.JR:]:ITP3;N[MJ^AI<ER*?
M-!JL@Q[FZMZFKJ81S5M+*=:5L>%!?<G14=(&DQ -S YE4SMO\2;I$ZG=O-\K
MGI'ZA=M]X<QV@VWRO-+&@JG;)FTK$JJ:QD5EM-QN]AT5U.QP[:/&AOVL&.Y6
M*\^S$*P:?EQT,I+7-B01/%81?"Y^-!T_]2O3WTKT'4OU+;'4O6UO?'RN/:;7
M5#Z8X;]VUNMG&*812) 1R?3X[DF2XW3X[)I\9M;N)>9$_9PI=/6OMW-:T\4O
M8070#N@YQ]5<_2;UU;@[D=;GQ;=G]ZLAV_QG8[H<NNGYS \AD18N*CC>*YSM
M]N!E.?6^?9796?R$B!!/$XMA^DYB5T:HAA.)YSY=45DH+;,C-T_.  LJNFWX
MA_1+U?Y5D>#]-?4EMMNUF6*07;6ZQ?'K*7'O0IF);,"1>UU9<PJN7>X_'FR8
MD63?435E3QWYL!MZ:!3HB/$+7-B01/%4A\3#XB4SH8H]CL(VPVDE=0'5+U6;
MCIM3TZ;-,WK.+UU[>M'4,W>2Y3D3[$@*O%L8>R+'6K!1%DI$FZA#)L:2H;ML
M@J"-;,R8 $D_0<R5\-A^J3K+VWI=W,I^*7M+TV],FUNWN(T69UG4'MKO5^EM
MK7EM+K]!3L(R>KS%QO)*/)Z^7*I4K[ 7GJG)IEO'IJ)N59^FT\2 8W223I$'
MT)5U[ _$=Z&^J2IW%N]@^I7;C<>#M)02\KW'"KF6-?98GBL%F3(F9/8TE]75
M5T6.QVXCZ.WD2ODU8NB+'S7KNLMF4%I&8(ZB%&L)^*C\.S<C<[;_ &:P;J^V
M7R;<S=*!2S\#Q6LR57)5^N1Q6YM!5!,.,W5P,GNHST<ZO$+6=!RJ<4J&U&IW
M'9D8'2G==!.Z8&=LE*K?XB_0]1=1D#I)M.IC;&/U%V-]6XI&VO"UDRK@<LN
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M1-$31%&<BS+%\39];(;J#6\BIML..>I->%/NQ!81V8^G/A2:8(154[E3G12
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M)78]GCQK#$'O/:9P6R;CIPJJ1%#^2D&J^9'&BN'D9W'/W?H9')11<HW/VO5
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M9>((:]]7#.=$?&I[S23HVI1-49G]6X+<K==QO8S;6&:Y[&4<6QN\3_#UN^
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MP U@(;OO<XAK07.:UMR23W03 .$+@U$)PY-YD<'O7ZO3K56</'(_LA>Y  4
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M2)<EIQU(K&W^5*\33?9R^;;-43SS;:)P<@P7M(A E3E$7DNH8R TX7$ Q/\
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M;:E(%YD;D)LW27D&AB8ZY4LOJZT@J+1\(XBHV:]PR/2VI[)V72 ^(:U4"_\
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M_5# [JQ:=1J=*:2JK3[NTAF6 FVKP$JIP<2*DF:*^4YC)RG'.A\N?!68TN<
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MD9$JD1K(Y555>Y>5U\VML;95>?B[.PA)S<*+&.)XEU,-<9ZSZK[F&[4]I,'
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MU,67KNV@533Q-@KC@M.3Y$<'%!L2,T!54012+A$5=(G)) S*C^/[I[8Y9/\
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MVY_.T3$SI?W[NIGM-C;^.8=&^>:5FVOIDO)+=LA[#;EVI 3$=P%\B["K&J^
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M<^/?S]U\^?LO]VIN8@D"WC<SQOZ&"3:$7<FC++1F2@#0"KAD9((B(HJD9DO
MBB(BJJJO I[^VKVS@GE?7D8X^"*K8<4MR,C:=%LOU(QZ8CSSY(J-Y%;Q2$F(
MC0KX=KXSB(Y,[A5IT!2*8'\TY\L @0%7\W0>1_8>757OJ59-$31$T1-$31$T
M14'U$_M</HX(^3L,QJ8PC]U0H=HJK_\ [( _Q)-%I3S/2W60OSU_%9Q,ZK=#
M'+3L[67I^;TZEV>&VXUK!MJQ%/CZ2<CW3[H"B$ABPZO"\#SY?^(5$MK[+Q(%
MGT\30<8F/ANIU&7XGXCRT?VNZ+VS\)\3.%VQA";LJ87$@$YBK3JTGD#,P:+
MX_W-6M?&>\Q,%5? *+S@EY(&?J1'"7E%%%4$!41?/<G:*=BZ\_@#@Z8O<^>1
MTZ:ZKU=SKY7L0!-YM\E)'(SKCB?3W*CQ(9>ERA"?LI<*B]R]Q$2)W<$"\]Y
MK8V N!$WCSXY^68O>5!(:.$#(F8.9'O+*1FN):JC2KW\H*"@ A=O>RJIQ]?"
M\@B]WT>3'RB(*H("YJ 0.7R$Z];QG:,\SEO B/,SGTXG*?GG$&D2"CFO;R(\
MJGV'N(O9 'N4DY\(G!+[^%XX76[8(CK;D?7U_:]-Y:9S.9.>6<\0#TZ:*(9"
MZ4R(\V:C]2*JBO\ :55)>/'")ROA5_\ +PO'*?4W =/+W'HOIT<0>[E CKE%
MYS_?F8L+9/KBZB>G\(U#BMK!RS!X$@^<*S*&Y95S*.(G>-/.8=B7=(V/:ALP
M*ZT9J0><D27:Q]]]PR^QLSM'M/9#!2HU6UL,TG_EL0UU2FT$B13<"RM3;8PR
MG4%($EQ822NM;>["]G>TCWXG$X:IA,>]HG'X&H*-9Q$P:])S'X;$$R Y]2B:
MY:UC!6:QH V TGQA,D],0L.FB/*>[DY=A[KK 9[2X1%]%_;ZQ<%?95_;%Q[+
M]2:[&SM^\#O[(#C.;,>6VZ'!NC741JN@U/P7HS-/M,YC8'=J;)%0S,D;S=I4
MA?7N>2[Z\^+QFT^F6!@G3W5TN62%=%NSRK/Y&2X_7@(BK;ZU=1CF+V%H1]Q*
MC1VU2#*MH:N2D)6D5NWE9U*,-LH,K']5;%&M2;;/=IT:#GG4#?8!Q*G"_@WA
M:=??QW:)];"-B:6$V>,-7J7R%2KB<6RE BXHU208W6D G67OKN+O%U&V[-EO
MGN/;Y/&C2$E5V(Q74K,+I7514!:G%*_Y>ICNM-$C:VDF-)N93 )\]92R#UEZ
M?C]H[0VH_?Q^*?4;,LHMFG0IF\;E%N[3$#-Q:7D ;[G9GU386P]B=G:7P]C[
M.I4'%NZ_%/ JXNL ;BKB:F_4<)$_"#VT6D]RFT*GF:*IAIZ<&(RRVRB?M! ?
M9"Y55[?P02Y5.Y%^R*FN!+&V;I^J>=_D;^B^V7/>9<XF<FW%O/(GIJN^K) L
M.-MM.<N$*H;;:HJM\IPG?V^$543A!5>Y57E4\<:NU\P)DWD: Z$^67/2RJ6D
M7BVA.N67S\,S"DLBP6.WZI#]7@D4S3GA![E1$3WX7PJ^>%3SX5$UJP@/!.E_
MGS]E9_F):V1I$<Q ROP UOU5X[3U3EW5ID4Z9.6HDR%@QF(TER.VVZRC8N%)
M5OL=5'25 ;17/3%!7Z",A77*_A65V%YN#( &ARDY&)MY C085<:65OX9K6BH
MQN]WF@DWRO.69@3<7%UE!28(Q&FP[#'K9ZOF+PK+4N0;T&0^GU?+O..(X]'6
M3Y 'VB)MDU0G8[PFJA\JKLMK*GQ&.@APC>@@3SN0(B#!W3-C)45-HAM%_P#$
M4!5IAI^(&C=J 2.^RX!+-6F"]M@YI%]\_P /?<67F>VF14LMUQU<5N(J--NH
MJ' 2W;F?,UBHO@%8G5DJ0X">$DRWU]R77JW8K&.Q& KT'3&&JMW02"6"H' T
M[90^FYQ']3W<E^<_Q-V?2PFU\+BJ0:!C<.27-RJ_!+-RMSWZ55C0;2QC5G_]
MOY?A_DG/^>NYKS5/Z_%/]_V_)/XZ(G^"\?Q_YZ(O.B)HB:(O4S!L#<<) !L2
M,R)>$$!12(E7[(B(JJOX)HBH;I^ Y6.Y+D#@JAY#E]I-%5]R91N.J*OYI(>E
M"OYIHKOS TA7WHJ)HBH&X_[)Z@L7E+]#.28G,KC-?"+)B_I%_MY^_*18("GG
MZS'\ET5Q^0\C/R'W5_:*BUY=:V%R[6TPBU?PP<NQN9,"KOIRV'RLG#V@:E^C
M>PHQ0GAGBI25CSXH6%8^,,C?B?I"0"0G=:9L1[]V6;Q>?<_1:L=WL?Q+!I%7
M:U!G*QU[U&+G]&E)L9]1)5U49??B-?,OL1'$%6U]1DN7!<5%!&G.=1^\1(X#
M/K\K+-5977L&QM0KZN+.FLNHAM3V0:-A6E150W!=*,X/'"B;8MN.-DG"CSSI
MQY#*>/3J)GIT*U(=+=L$$B$CP."B</1'39?3\>U45MU/?V1/Q\?;4#G[OKQ'
M)%]K'<?=#;NM^8Q;*\FQB2LA7C=K)TN X^2^222ZR;3DELB\DV^XXV:\J0*N
MD R8F+W'2?GEIQXI(R,+)'I^^(GNO%%FDW-K:W/HHDHM7#;84>0""_2 RI4%
MDZZ2#7"*IG3E,=53)Z4:J.J&F.8/#/Z>.>H5P\C.ZI;K<RJYZH;>BNK!*Z!A
M^#G\MC>/QIA.E$G74R$#]S,ESHU582K.?)B5L3N@5XQJUEEAE#_:29DN6MW;
M<<]+9\_O\E#CO%3SX;U77X'F&Y-Q?9!#@V$BKHL>QVFGW[3?Z0"PF2IMM)AU
M[TM/7>9<K*9@'&67";^:=:%6_6,78J&T7F3/ ?7K/!&1F8C[K:ENIC6VF\&V
M^6[=[N8^UDVWF1UGIY312IEC!8L:^OD,6J-NS*B97SVFVY,!A\OEY;/=Z7IN
MJ3). 66MO!6MF+$#D1QZ\M,P%KYMI6-7\5R%6O'CT/\ U1BN2H^4%RJK:\V
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M,Q,D'WX^]%V#;<2-VN2W%[W#!4 U3O05%/WO4 2YYY5Q40$$_5]E[!TW"1X
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MI@MC;-V>&_PV&8'C_K5/YM8G4[[YW9$R*88W. %Y5M;M/MS;1<,;CZIHN_\
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M<LU!(%CY<9\U]V0RK)> -7L.I37@T;=:>RN:TJ)R/K,&[!Q\"0E C8<GV0&
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ARI.*1*OE55?.BJ23F2>J[;10FB)HB:(FB)HB:(FB+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>obln10kproformaimage2.jpg
<TEXT>
begin 644 obln10kproformaimage2.jpg
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MIC4V.$535V:%AJ+"QC1&1V-S@Y*5HZ3#Q-+4UO_$ !T! 0 " P$! 0$
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MSDF5[^&GH3.PZR 2J4K)1 'OH(4A= RT*#4,08_IX..$OU8K!H__ $&LO_\
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MI,S$RE.F8$FA$A&1<.+0GY_TD'$9!331HNTQZ#+UQ))V)JW)=H*!U"E'D/\
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MI^)+GH.D5M8>E3XIG9MU&N,2@([B!:G*@ ;]^PFLIC=-_$1'S'?KK'9IXUL
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M=>[KX]?=_CKTU@*G/P:MV#=(QU9LZ!U,7]4$-F)C-P('+U'W??X^7W?/6#D
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MIKTXF%3+(;<W3OW#N\>X>GQ_'<(PIPOS\_+UTN<,NH^OBWJ@C<QZ*\O+BC)
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MO* B'N\OT^.H\UW((I;AP;H.Z+_!ED BXM7U;TT)[*SP\F[6.<=]Q'?J(A\
M[]NG?W]WSUMD(W4AL[=8@;1F[RF!^$-2STZ?/RBLE@9<H 7;ZJ90'NZ#R_K^
MP=31XM4UJW1M7!R$4$W/@ /7?Y5RA4/FNQA#;</#IY^&WZ-;S[HKX48\*>>5
MWM$$@E1;YBVOA;@8Q@M.G4-A\._Q\_'I\/=OJ*LY?3UX]+&)<D:U'TU]=&CH
MKM@#IMUV\N_K^-]MN_SU'4Q/C]?+IR^&8'%6S]/X$/FQY]) J[-RD\:*&2<(
M'!1(Y>\#!X&#J4Y1+N4Y# )3E$Q3 )3" QY@"DJ2H.E0:_CJ"#5\B U3$S#3
M)DF:B:A13,EG>2H:BX+T4DNRDD,0=T@AW;*96=BBC2*2"?,B!6\NR#<_J:JG
M0BA2CN)XUV(&% PB8R"@';J&!0B2J]4HJ0L2U$[U52EVWP "RF 9:?S#,'>3
MF$]K),K&8?\ $2T@)#(Q<B_8K5^=(+GL)I?LR22@[TM9+)4M-V:K&CSF51*8
MS)41 H]XH&'J!#&\2#_R:G\H.@^T [[T3M\,JBP78YD7Y^%- PBNQ.#[ A2!
MO25L4G^4_P IR;0TT.4+HZ(H*\PEWVW*<ANXZ1O9.4?D(@(#OL'4.[KDU#=Q
MXBH]?:-<L;J@ILR%)U20QT_2,/,QI5V&Y0YE&"@ !O$[)?VD#"/B*8CR&\A+
MKPA9"F?XAPOGW\GZ7DS9.])<5,DL[7E+;<)U:J3QZQ!W,>(&;K@7ZP\AA#^2
M8IN@@/?OT#OULWKI?BUBUNK]T:DR3^[6,W3344%6IZ=LMXO^CY"!>.&](B
M)<"VU<@>0.<DXD.H!=^X 4 >GO#4S  ]N%?^"4FV2Y;,W^GGE%1[1$?X>I#-
M_P <A8 T7)Q!5_ZJTUC])7761\L@TA'GD_TA$O-PKW,/^;\5C]F6D1U68_\
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MCYCW:-JQ)>CV;6H\PW&/)43R:SO$D;P@J&(F4@F.<Q2$( =3&,.P% ._?<0
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MX=.NP_JU)0.#BV6G1S<<CD+U4\G>UOY$CR:W!SDF9U$>8W0?$?P/C^@/LUN
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MO9NTL!B'HC&2T+%@J5.WI4P94*5D?7.^V[L>5M[V>VO@%,58C S3*4P]S$R
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M<YZT5101'F$5.8=]]?7Y<SM<'@YSN5X9 ?\ \LF37JA\M(_(^UL.,)M[;.%
M9*-H3IB$Y;F*0C%BCV_?\@S:Q4"81ZCTZ=?#Q\>GXV^>J_$BYIIGS%<J#+E4
MQ(P9JG3/I\FZ\X6\BB&YNG\X/AU$?AUZ]/OUSV*%"=.M2/7#A'58.C:4OZX>
MA6(B[1[]OGT[_?Y^[[_CS^(%3WOU!;I\XOTV!#U\[D')B&XCBT>Q/A,_BK-_
MU@<?V+ Z_1.!_P NGI_8B/R'M+_-S.:O[UQ9S4R($*7.G\5%P_W6/_MF-UJG
M_P )?+YB-^&_CR^9_M,?G@YN2WXB\\CMWYKRF/N_]O4]^GQ]_CJ,GX17)-PY
MR\-!F"8EK^-7]1OSC,5Q+H3IWB'=W_Y#Y>_6Q.;OIP^Y#,3G&E?2_6@^\6'J
M2'4@[>)?#?NVV_7Y>[6SK3F.Y[5S\LHTJMS(%C\F/*+.51MT1#;OV\//;R_'
MOU@W]9>N'(6@#3H">KOP;USLC5FP")1V\2@ ^7=^P/$-@^W61X-RN;\:/_-\
MH\'/6W>;>&@<DD18>MMNA-@[]OU=_?T^/[->C86S:S5M5@.XC4@B/(#D#UQA
M]5YI_!]/+\=/$.OGOOT]WJPXG( .Q=G%N=@[\7RHN3ZX/X0]:XQ >0>7R  V
M_'COO^ U@._"YK5\GR\&;5@8\NW6G?2GVK#LB&.Q2!MW@ ]WB/X#I]FO0>YS
MRT]>;QX)R(I3,ASSH.??E#"8L>A?9V_'?\OQ[O7K[5\8UDOP%_7++)N,5JXS
MKJ%+Q*C -E0)(VA^4%2%-RG*S22.! ';J &$3#L(=0, _#E=O8I*I^'P22ZO
M>F+ T#;KV-R^G&XCZG[ ;-4C#X_:ZTD(0A,F42]5+))TJ$IT8O&DQ<I_62MR
M#^^'&ZBIQZ"3FW$A3#_.-\NFW>&H\B4 12ODWJWAKT&+GDA2B:!P'S-S>[/P
MO:,=&5ERZ< F@8W:%<\Z^XB8%C 83'$1$VWMF'<!Z /F(;;6"I*IJ0$E@"'X
MY"K:]^=GBE..3()41O*(8'2F3'2]>EHM?CV.0A^0TG#)O8\R9TW2!VW:&*(H
MB5)1 Y]U45"* 4PJMC\QR@8!YO9U/DA:#[P)2UV%&H_)O(96Y_$S4S65)]U8
M(-RR@:DES5J,'>]#2&%.(,)9JHW2=HGAW1#M#,G2*;Y%!)P0.5!R1<57#J/4
MW%-5)4R:Z(&$I!*( 77J8E*@S#@H A23:X8VRSMQCW@\4N61[Q+T4E1WD+ N
MDI/N\:!^-HJ-G.S3K2&:52??KR[$CHA8&4>KJ.95@9,PF- 2KQ8QE99N*9#.
MH&:4$70M"FBIL2O4XUW,T>U%K_"K"G4*C?/Q"Q9=:@BJ5,WY5,IM[N?9K"R/
M\1ES\.!+WBDS9(H@.?BE"Z15EH-BRDDI*@BRG 'D9O6;#?:0Y$>SM\7!2K$H
MB/9G<QC$&S],0WV$#MC\Q@$-Q%$P_P CI28'%&0F;*MVTN2M#4]Z6%/E7W02
MSW )CMO:#9@Q^&PD^A_"3L2E8(=T3E )-7+A6ZVH40#4Q!<SUHM<N=GB$R"1
M!M*.#M0$-@]3=[.VG+W!L#==, VZ=/AKL):Q-DRUC\R1Y<&<TIE'PG%R#AL3
MB)!#&5-4&(:CN*M_*>)T,55L*/LF\>_[_=]O3X_+6OUWYYMWU:V:6:CI]*B_
M<]&?-Z_V5'85>@_ROQ\M^[KUU'7D=#G:)TLT]/"#GT_:4Z#\_=O[OC\QU%6*
MW%R&S9R1;Q^=XM)!<>N8?O,;8?1DAMC#(@>60O\ [N0VI>$^%?%7_:!%1MHO
M/E?^2/[U1H']..3FXYDAVW_\#./P^'^L;5W[:M)7\.[%RUJ\&-XYY8_><@/7
MKYQJUBDOJ!MW>[Y?/KO\_AH!FWBWZ95-.I#8]>OI#2AT-^0 #R_Q$ \?B/R\
MM;1333NIGY9.;FL:E&O75_T^_*&U"-MQ)T\O+\=  ?=MY^(^O7,C7@'CS&UL
MV)WE;X,<,6!< *YO=_O%P!$$BB=&-(C&UN*.MOOS$=EA'3A+F+L":H  #OOJ
M@Q4X'&*2/R2TIX7*CUKQU<QW&Q,.?\,+CXYO:/7,$#A9*3;.CPI:=99>BS$7
M*QRYD5F;H5FAP]DG:)FYG4<L4-@%%RD83)D$>42J&3'H!M:5RD3DD$._<.?@
M#PKSE(Q"\),%6#TKGF!K<$1<UA!PC^ZXXS+54DF\++6ZNN;$P*  2NV="49.
M'"B@![)&;M0 >HGV*D8X"8.4'*299.%G+.'GX.8YFRY*Q*4369*"54<FJD/N
MG,I(.L4^UL#*1C\'M60 ,-B,7(_$I2&3)G&8DE9R$N<REC\HF)6EV($:]IZK
MS$A:Y%F][;UWU]9$2&YA.545C<Q  P[EV4$XB'38PF'OYM39:P):2+,->\_;
MF>-9B94Q>*FI5\6^0QYG)_6;7C+S>'YF-CRNR+L7JR: N%V+1\U<2#9N @ K
MN6"*IG2*("(!VRB0)['*8#"4Q1$C$(6I@" [;Q!"26L%-NJMD:1YG[,FRY84
M%(60G>4@3$KF)3F5(22I(U) RR8Q</&,:+_ANKBIR#VL/.6:',)B]>4'YI1/
MO'<=BR?(7OZ$VV#;I#GTQ"B&8I2KG0>;97YQTNR%%6R9:5?D7-173M%*Y#XL
MJ9Q6"VLP3<[B&P%.(?;T'OZ>(B/P^&I*+=;=T5N+("Z6^N9A'3K,.T/L'C\O
M=U_1X?9K<"U<B+T>^E:N/F:Q6K<V<^JOS_1W,+YTTZ&W#SZ;?CIW>/3O\M:5
MVZ^N7ZQNE"O=6]7TH_.(N^;<H;[;_=X_I#N[Q^/349=_KPSK2U.\9Q8HMU]#
MAKE&'(D F^/?W_$>G=]@_#6M>;^'H7SMTC<APU*&G=]!^MX^CI]-M@#W^?S_
M  .H\34AF IZN3' =,-_OW#](]_CK4LNW4<B.YWI$Z2"_#EGZ\Z%XZBJ("(=
M W'N]_P]_P OTZA3"&/$^ON_.\6$NHN[>'B*>72._$)$0>I&5$"MUP,T=B;J
M -7)>R5.(=>8R(&!<G0=EDB&[P#5;B%."!\0(4FH^)+L ;A[,,C%[LV8)4^7
MO-V:WE33EV<SW%N_\K[XR"D U:)!$Q1Y1G:Z2X+S+.6#URP)T$Q96((LX0*0
M?$RR9'#8 #OYRAW:U*6$F3B$D !20JX]Q1J>0WGJ]VO'68%'XF1M'94RJE2I
MJI0I2?(<I(?->Z4T^<)O'K47DX[A#B0/IJ+D8HB2G_+O5TA",3(&P[J!* S4
M#<>Y(1WWZ#/Q+!*5 5"@7&0NH]SBCWBAV'[T^=(*@.UD39;*IO+/\-(O[PF!
M"A_2IZAHVL^A!:BWXRK 80V$,#VQJ/O]5R5BXA1$?'V=A#X^[5ELA3XD\99/
M)U2S]1WVCE?;>6$;*PU+8I$LW;]W*Q0%]0>YH_0HUW$?$(-(1Y^/3\AOPSVP
M/^;L7_=E9,=5F/\ -"?[R8L\"?W:N*V_](CQY5I/ZF_N[OU_YZKTA@'O7YCU
MTX1(4HGDPSY'[=_&+"5=/^#_ /1]_=UZ>73[-24V#@..#$7\VX1H4>^K-2C^
M+M;/NBRM21Z)CMY!\.[[@W[_ /'7H1Y)<-RY9]W :=(LY4T0'LO@7P_5OUZ]
M/N[@'6Y-F\CIZMWN7CR?I]/7?%E:FAN9+IW;>&_=]WGT]_PUZ'KT*1AZ]<QY
M'ZUKHSVEI+<!,CT_FC]O7N\>G^>M<S+K'I%B>!.73B+_ *L\77L]F:8\X-,I
M/552(R-N1>14:!C 11P60480BX)]QC=DDF].(% 1#8P[=##JF]H,8C!; VHM
M2@E<W#+D2@2Q49Y$@A(=R0)F\PJR2;".V]@-DSMI>U&Q5I0I4G"XPXJ>H D)
M["4J;+WLAO+0&)HY;,1YW(N6,UMK:3W$3-)=H]W\?WL]2<=-M^OYOX^_?IKX
MKA9_9S)2["7,EK_VJ2>=QE3Y_H[;<G>$Q)_,E2>)<$6]9ZO%N(UDBQE+##-P
M5 [2RO , ?P!F[ [IFP.78=C*"#N0$# &P)F*(=#=>DE("9LZ4EW3BIHR"2F
M6I24,!P42YR9J&/GF,.\F6LLQD @Y@K92G_VI'/E6<33DC S)R<2$3%@F13G
M$"@)MB$,._=S;@!_COW=!U;S"$A))INA[Z)'A?ASB+A$[X*14[U-*.Q'#*L,
M&FE3=))G*<!*8X;#T'H;82CW]P[AN/A]NK[9C*EIJ]@U*TKWL(J=IDH40Q#/
MSH.??3C#N29&:*G:N2"FNW,*2J9PV,0Q!Y! >OA]GCXAJ]W2@E*@04N"]""]
M0V@S_6.94L+ 4DNE501F#ZZ]\=>08%43-R^/AW_CKW^8#YZR0X]7]>/?&MR#
M0U'D>=-?.$+<H\$2K<Y=BCS" [=  -_\/GK0M-2#Z)%QYB),I7O G)NKLX;G
M7IPBIMV*"Q7"K!3LGR2*J)E2EYA.04Q32-OS%W%,#BDH8H[]D5( $1 I=5\U
M+>\+YD-D&UTN1PCI\ MFWJBE/$\B20W)]8I9EA9*)HLHT4()YCU^,GXE8AQ'
MZ/DXN0:K$ "CMS%7:(N$5NH"H4Y0,(]EN;GMJLF0IQ[RE((;5*JYY@D4R9WC
MZ9[.K,R>@ LA*5 @_G24FE!DIE-]:0+'38K:^QRS<@@5XLT?(CT*4$W!VYTT
MB=X[E]8,4YOYR8]W=KY]CD[DX* M,20:V)!%.\4$?9]F*W\,$JR2M!'$ BMW
M<#J%:$1NKR8F+O%6#) P;J!7[=#F';J!(^S*2*91'KW?3HB >&_37TO9:M_8
M^#-?=$U%3_J*_P#OOY1^9/;64)/M?M, -VDK!3>^3V)/_P"'PS:*D3*.W-TZ
M>UY=_P"KK]_CK7B?A[K\SYL_&(.$NW*I-+-Z-X6LBCU, ;=X#]_Z]O'7/XKX
M3R^1\KMI'58.XYCE;+NOS$1!ZCU'H'4!WV^?^ _KWZ:YV<>ZK5\*T;PZ7Z%'
MPG6^;?H_E'K_ .$SIBLP?_*!S_8L%K]$8'_+IZ?V(C\@[2_S<SFK^]<6<U,B
M!"ESI_%1</\ =8_^V8W6J?\ PE\OF(WX;^/+YG^TQ^>?FL@#Q$YW'O\ _#1E
M'[[S.;?LZZC('NIRM7/X7TTMIXQ+7\:OZE>9C-UQ/^"Z>0[=WR'Y?H]VMJ<[
MFK.3U%Z-=M?"-"\K9_J?6L6,J*/1(?@/7Y]_X^\=>Q=J'*C<J/SX!W.3'2HE
M@SYF[-GRZ:19^IH_P73N -OD'<'3X;>/W:Q<\XR:9V;*P9G&?6O*\63JB <J
M8[>0]P=WZ/AX]^O5:U:H%SD+$B[YV%'>->0ZGP:W/.OF(L16D/X$-@\/MZ?9
M\O\ '62SAWRKPOUXFC<8)+.= 3Y>O3P_(!)--,5E#IHHHIG67654(DB@BB03
MJK++*&(1%%),IE%%%# FF0HG.)0 1TF*1+25S%!"$@J*E,$@"Y+T?H'=AG'N
M3)G8B:B1(EKG3IB@B7+EI*EK42P"4AR3^IH(6%JXS:+3531M+A)#(,BAS$4?
M(+!#5LBI!Y3%2D7#=PZD  V_MM60-C@',DY4()3#S\[;A=0P<A4VO\682B60
M*#=#%2AF[))$?0<![ NA$W;&T$8)1 )PN&0,3B$O5IB]X29:FH0"LAC0FD9/
M%GI!(V9M$16;O0B5L)9P#%O+1TT=\U!\L<"-$%D731$Z15C"5(%0.H':F* D
M*4XF)YD;;GE<N7/E(2I9W04DE!5^5+EE(*G "E;P=M:6.)]@-E+D35X'&XHJ
M0D+_ 'R99.Z ZED) "P*DA)2IG8N&.TNH62N6.&7GHM\D\8L"KB^12$/6FSA
MJ4PJLET $3D<<Q>0"AN4X""B9C$$##:IVGAER<1,2K][AMX3I!/[V7,3^12;
MFHHI-% @@D$1PV*]E=IX+:.%P6(E-+Q9EJP^*#G#SI"U ":A;!@78I+*200H
M @QI\XJ<IJY$D55P35,FPG3HH(;&!-!LD4Y V 0WY2$3]L0#8-A'?8-?-DXJ
M=B=M";.<=HH@#("C)%<@,N[3]('8V%V7[(##87=)E"4J8M/YU $*4>JF&5!T
MK76JJYE&CVQKD3%F>3!@F8%DNU(L5 SA A6XG]8[,6I2B*_9]B)O8Y^<.4>Y
MPTD[H5FHOEQW78FR0_S-8^1[1Q#3.R!<2QND#^:ZLFHHD5Z9PS*I32"_(KR;
M@/4_383" ^QX=VW>'3ZH!MUU92D EC?PT\Z_2T<WB)V\27+ 9GP\NEXL]'PJ
M2+0B1B;[E#<!\Q#J'V_'R[MM30D -%.N<HJ<$_IR]5A=6^NJ-C"\:F*FD.QS
M\H>WS%Z@8!Z[;   < V P#N("/4-4R72E*^O"),F85$7?.X>ASY:<+/2HF=8
MQ2VP3LK;D;N6;57E7#E$[)ZW0678N2<_,8Z8/D8YR  (=6 I+"!.45Z;'2@I
M"I98A:2GK6W,L7R9PQ CNO9[$KD8B7,!4"%"CW]X OS#C1E:$Q".':]IM+=B
MNZE7(S0<2,?&2S83<HE:RX.&;@=Q#VR-UG*[<VX@)>P0-[8&#EXA2TR5R2HM
MNST N:JE3M\;S5?="B". HS1]DE[V(P^)E!)5VV%F+EJ#%*9\G<(0:W*I:%)
MHY=8<;L; N+*$*WL<#-)I[$GJNT44,!?KNHY=9DJ(B'03=B#;?QVY?,-NWP/
M^50DUW:9Y'NSU?P;X-[12PG:<Y2:":E*WM5FXFW/71]?%@3]E78 Z;]?M^?B
M'W^_6Y0=NH[Q?BU\HID&HZL+-GEU[KVBOUG3#<^_O^?3]0_=WZCKMU^OG$^6
M>M*Y=?FU'#17ZQ$ .T\^OWCT_'QU'6'T#M;BW=QY "+&22/]O'IY]\;6/1FA
MMC+(GOR" _;7(;4C"_ K^KY"*O:]9TH_^%_WJC0?Z< G-QRH]>_#E _M&U:L
MI;]GU-:4L/&M<GBA7\9.; >OG&KR(3W$OCW?C]ON\M>TWIW<NMNK.1=H\9$L
MURV>?'3NAK0J.XD^77S_ !X?X[ZV<LO7=3PH\:?T]>N%H<,$AU*.W7IU_P ?
M\/?W=-/*WKUT@;??QS;NIG8QO!RK=(FMU/AZQ).$22K3#%5-CG[D2CO#2SN/
M:N"2ANH "/KKU7Z0$>H(+J*_63 !Y2<E4S$8B:@NH*40&^)(-4\"PTK:H+Q]
M0P!E87 X65-8)F!*2NHW% !*5'+=WJ%BP=WHJ*IY3H#ZJN'K)9$PIK;+LU4@
MYBBJF('15;G* @H55,W,0Q!$%"B %$0'6W"S1,8UY:7'2M^1Y1#VMAU2PLY9
M$%W(J#?,4TUR$=GA_P L!"OGE3L)A<5F?*#&4;F'F[ 1,/(_;[@/(JR4'UM(
MQ=C% %  0]D0F392DE,V7\<LNDC72E@JQN"'-VBEP6,1,3-P6)&](Q"2A:;D
M U=-:*01OH-&4(>&4L(25ED7$W6GC=">.)5WR9C&11F"K$*JG,1S@H&**K\A
MP<KMMP-ZPL?U;G3'LF^Z7\(6E)7*4YW0'5*4"=^64@EPD@@$/:J6J8F)*535
M2)TU$C&2&29DP[DK%2V!EST+/NH7,E[JE)44@DNDDDI1 J?AZ_4A\2TOXQ8_
MJKE BZCENJNS5;/#>KND'7;I 19!TDJ+9=(P"51)90H^(!F9-0L=G5)(=F90
M(L1W#+RC;@L'/DJ&)WD30"$E:%)F((-%!2@X((+$&Z3G%H(N$:P&*7, FDFD
M*DU)3 )$*!2E%Z1(! @>!2E13*'4>X=15>]-<UH$]USYQT$A*9.&,I( !4I;
M"E5&O.O**6VB&,L^,GR[@0QE!$0$0V*!A >OF;8-N_KW=P:F(MZT;@_IXI<0
MC>4!I4VZ4;CPZF$;8HH2B?V=MMP[NOC[O 1^W?7OURRKW^-[B*\I(+-X,/H/
ME"LD&7+S=.H?/?PW\/MUJF9"C7KZ^65XVRA7K4,:>J</&(9(-OK!L&_^'AW^
M'=]VHIOG2E<M+/3.G01/2*"W2W.U_1B-G1 IO(?A\/QWCY^.M2S1N/KS$29:
M6-G-]-+WL1]+QQ&)YAOY#^/T:CJ+"AJ]>[U6)B$N:BC=+B.J;;?8?> >.W7;
MOV^'76A9IQ)^[Q/DI8$F[MW?J8X#%#F  \!_5^W;46;\)Z^1B=*#L^0?QI]>
M,9-%,HEZAW (^7EX_/J(^6JJ:74!Q;6U+=7:+;#I8=/3]"U:YPP:T@=MDNC.
M3$$"2R]>=&WZE<E<&3:/C#T#<%G2;PIP ! #<Q>HAK2:X:<FCH,Q#Z!W3W#=
M8USCK=FJ(VO@)G_SY<E:N)*-R82?]2TK*J5<0CXML$#D<JR7U8>VB8G?MR,)
M<1+MOON'*B ?8.X:GS5[\A.]7]V"1Q*1KF7U'&*W R^RVPH)HF5C5AS_ "IG
ME(R>PU^VV7T-#)-KQH7,B0 ":.)+FDF(>*9LA8K.4-_'SW_QU9;#+XDOGAW'
M_P"UEVZ>$<Y^T.6)>RT ?EVJ$\@<+B%-WOWQ[]]=]'P&#2$>?OT^H;\-5K#_
M )NQA_WJ$U68_P D)_O(BQP9:6H_^)_V1X^*R7^#Z[A]GB'[//4$<35O $U;
MK&\\!X^K<HL/62["F/O#]GW_ *-;4T#UT;C3OB.6IW>9UT]9Q9:HEW!,?+E_
M^SO^/P&R_J^?Z1@DTI2W'G]?M%H:DGU(&W=RCMW]/V_XCK:+$'FU26+TYTC!
M-1J]LLOJ"^0?E%E:DG]3SZ?KWW^/=]G?KW]HU@MG7U?4FVC,[D1:JD)=4NG@
M7I\O'X^'=L.M2_BZ?6-Z/A.5 +V<YG37A'<XX;&:-H>/**BIV:<;5VTJZ0*8
M0WD9T!E5S*  \HG23<)$()@YB&,H&_4P:^/?M#VB5XS"X%*O<PR I8&<R<RE
M/D60);9I]Z[Q^G?V.;)3(V/B=I+3^\QDY026KV4ET("3<.OM%'(LF[1IO2$4
MGQCFZ#V@FZ^7/O\ >'PV[]<?AUONCDV63?JVA#7CN-L2JJ-LZL2'=N]\HNG#
M3S5P[BI@QB@G.5V%?*"/0QY!FV-!2YS>0K3,3(.0 =C<BQ!$1WYS=MAUI4N7
M.-ITB2OB9B$=A//(S9,Q7(@MK\PVC(4RD"\N=-06_E)[66.DM:4T.4<.3)@B
M]>3604 ID':1=P';<JBIO9#KW") Z!OU'?QU)Q<PS))"14,S78*'R[QE#9DD
MRRZA=-M#>G?ZH8>6#F!YJ'(X3<D6!+\RJ!3\P)JD NZ:GD< $NY>_J ]VNEV
M/+6)22IPI@X-W+'YYY/TY?;^(2B:H -?AF0=&S?EQBP:C5PT-^<,)AZ )AW$
M3;=.\1'PV#KUVZ:O [C4YGE?7Y&.;20H<W;04R>M\NL==PX $Q\-@'?\;^'X
M[];7UT?NOZ\HP4D=;-"7NQC/FBX%W]DA^0H=YC  B #Y@(@'3N_3KPKWJYWZ
M&U2?G=VI&Z4-TI%B*O?CKJ2 YU,44NR\U'J^T)&HJ"9,3"0O* '$-]QYA 2B
M  '> [[" @.PZKY[I!UH00-:'U3YQTF"*3ND.0..>0KS?3A%:;Y4WTRR7<.%
M.V$R8F+S&*5  ,83 8  >T6.;8I W$1,'L%-L.^N7VE+5.<*(S(>P(!?B:']
M8^D^S\Y,I2"GD:$Z!G9@-=*DZ1#*DV,QM]1YAYA0=>H\PAR\Q6QBJE'DWV /
MWR  &_< !OL4 #C-K)"9B=&9VK0VIWYYQ]EV$KM),VX) +9^\"#_ &G/H\;H
MK^B!L+8>Z!^9E\DM0$-]^5,::8-^X/Y1A'IWB/GKO]BO_@^'_P#.G WRER!<
M<:\X_.WM^!_\6SZU5L_!%\_X^.&EZ4TY6J'-(_6Z=W,'WC^!W[^NO.(=B!ES
MXDWX/HU!%1A*E/0N!G1O*V<+222ZF';KS"'=U';H.V_=T'YZYW$LQ'DV@^?W
MCK,+^4\>M].ZEWY1$7J/UNG4/'Q\_P#(/U[:Y[$&YU<<O5HZ*6*)H^O7O(''
MN.<>NSA-_BL/_P!87/\ 8T%K]$X'_+IZ?V(C\?;2_P W,YJ_O7%F]3(@0I<Z
M?Q47#_=8_P#MF-UJG_PE\OF(WX;^/+YG^TQ^>SFDN_$/G7;_ ..?*&X__3B<
M_9J,F@03H"!T#>)/J\M?Q*_J/F8SE<(&Z6WN_1W_ +=;$NU>+#33UI&A=^GS
M,61J*8;)?^CU^0?K_1MK:,Z \] SUX!AUX1I5<!R'&5KM;CSRS>+050GU/AT
M'PW'I\OV:\_:U^G/SC)L7.I9M&/A;B\65JJ?LI=/YH?;T]KIKV'I;/1^2>[.
MC,UHUG)]+ZN7KY^J6+K*6XI]-^A>[PZ]WP_'AI^:S7IWE]*L//* ^%7%AZ\8
M5&=KV]EI F*H%T="-9D17NKMN<2F?O3@19" ,H00_>4:3D5DD=]EY(P-U2_Z
MO+VG+X_$''XE4A!_X7#J*%,V[.G)^(G5$M3I S4ZJAF^L>SFS)>P]F2]HSD#
M_%-HRQ,E%0&]@\$L'LP@_EG8E/[Q:KIE%" Q*W1,DUCX9D*2)" )"]1Y0WZ!
MWC\1WZ>7RUK6E*$T LU*4\6#/75HL9:ID^8ZB2YU+W.K\>;%LX2,DX]<=MBI
M<I% ?(G(J4 W()5 .4P;]!Y3% ?=YAMJBQT_=EJ6FZ'(-ZIJ*#CS^G<[%P(F
M8B6A;[JQNJ#[I*26)?E2+(6KB0O<02+@ZE/NF!&:1%9-RU-V/TF^513(HLX1
M0[(I2IID*@W!("@@BF5),H)% NN9PR\9/Q4[%+G+,R;,*U%/NA1+ .A# !*0
M$I:@2 !Q[C:\K9.'PLO"HP<E?9RDR4F8D3%2Y:7.ZA:P2'6I4U;_ !S%%2O>
M(==N,@2<N5RI(J JX>$3453*X5,4J@"INN0BIU#%$Y2*E.)3@0PB8!)L;E'?
M.G3I6*DSE %E)8[UR&<EW9LZBIME%5A),C%;/QF&22D&4L!#!K'= T)RID\,
M:LS %5009CVI5DF@AL7E."?8$ #&*4Q@*80$!$H&.!=Q+SFZ&'Z=AIF]+ED$
M%Y:%#D4CCIYZUCX+M"5NSYP4"&G307+>\%D<M2;D\+Q:JG$Y5&P*DW,?LSB(
M%#8-AVV[Q^/B(>6K&4H<Z]-6;E][-',XI+ D$AP6&8ITLQ#TU$/=0[,R* ()
MG34*D +\YRF*=7F/N=/8A!(3DY  HB<P& P\^Q@ M@Z2D9$ OQXY<-3T>*B(
M'9!*9!9$^PD.0>@^ ["'3?S+O_GK2NU1P'@?DT3,,FHZ.VA/Z \(UPYV=V6/
M558PR2A6<DHFP5=MRBJML\,"?8F)N!44^?E[14X;%+U Y=NM)C=[=(0*D,#G
M7-^&OE>.XV+NNDG)C6U';T>+PG(" 7K40SB@(H1XQVD6XB51)3=L\4(8"D.!
M1#91JF]2'8!%)18>X"@7B]IX9@E+ +$H+WF-0DJ2I[5 2E0.F]E'US86-W@Y
M+H[4H8B@W@E0/_5O*2?^D5-MNV=%3V7"^(;H?VQ?)NFPFVW$#.HN/>K)".W\
MATBX  \! P]_377[,"E8)$U0;M!O6SW!O"P_/Y1\C]L4(E;55)3_ ,O?0^J=
M]1ED-2LMHUSV$G14/>/P[_VC^K;4LT?A6G#1^[EG'*H:^F>=B[O_ $D=3%?+
M0'4P_']?[=1C8\C$U!!#D:#K1_G%>;$'13S QOT;:T320[</+T(L)2K=W2C1
MM4]&?_%GD7_S@A_V<AM2,,/=7_6? "*W:Q>;)_\ *;N6J-"WINB\W'&D/C^X
MW0>O_P X6KIJP1\ >H>V;O7PI?.*1?Q'IY1K,J\<XDW["-9IBJ[D';=DT2#<
M15<.UB-T2!MN.YU5"E#8!'XZ]I+!2C0 .3P%3X._1@&CR$J64H352U)0.*E$
M)MURC8U:(K#.*$@HQZO'VB4B$4T+#8G;QTB_?2Q *1^>/416 &38C@%BM$2$
M$ 13*903G,.J;ML9/49LN<92'(0D)!2PJ'>Y(N<\H[9.!V1@I"9&(PJ,0LI'
M:S5$IFN1=*@70SNR6 8 @WC&'H48=LPL-->'?P3Y1N59BN8JDE#G<*)I]DL8
MFQ73<BJI4@7* ' 1()R[&$X3L/BU$]EB$A,W\I3\,P@5;^53#X2] :Y10[2V
M,B4G\7@%JFX7>3ORUUFR=Y0 <A@M&\H +HI)8D$$JB[6>W1+9D=:'2.44H6
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M4CWVZ^@Q^?H-(1Y_?3Y!OPUVO_R=C#_O53#]>JS'T_V(_O,6.$#RE?\ F?\
M:!\^EX\?=:+L*?D)@^/41_9]FVJ]!=R;V]<^4;E6)]<+\8L160WY-^[V?O$
M_;_GK<C/2GF&^<1E%O'P!^;19:G@'*F/^T'X_1[];P*IY \W4WS^4>-XLW#Y
M"NNIZQ:.HAU(/P^SN_3K:,Z:^9]=8\G*I>A\!7UI%F:D7HF/P'X=VWZNGNUF
M,1;?'#$TA(QS!+^$?/&;-/;K^<=+$0)]ACAM[]:5?$>GD(DH-@+$CG>WRBO'
M&I:T9[*%C:-C_O..7.P:I@/1-%J(-D2 &^VQ4B%+T\ VV[M?F_VGQGXS;>,F
M@NG\0O==OA"F3K0) #><?N#V+V?_ (9[,;*PY2R_P<DK/^I2 M1KGO$Y=<AK
MLEP!NN(ATZB/WAM]O7](^[5AB^[EG5V/-N\Z](][0E[V]UJV8'SHWS819[&Z
MM#E<3II3]P/7[E'791*&34C'#]DI6I",*M( Z5;*%60[&4:(*,P AR H]>"<
M [85$^[V;+P4_9P3/QJ<+BI>*(D;TM:DF5,EI,Q*BGX0)B723[N\M8/Q/'S;
M:B,5+V@\K"]MA)F&>:I*TB8F>E8"-U"A[P,HJWV+^XAJ".]<F-;;U]L9G*2E
MU8)/E'C]&.BG,4J==(&8LVC)<ZKSM577(Y 1 H*I\HF(F8P%$>NV1LO"*F/V
MQVA*#E792U)2YW0P(*P;7%15@&CG-HX]<I(  PBJ-VBT[Q "B24@I8 ;KN*T
M#ZL_A'EK"=O:YRU01:-$RLNV5B89V84.P0;-O5C+%(N;M>15-- 3BH/:**@8
MZH <1WZ:5LW%3YTR;+PR9$E6[N(*D;J D!- "5,0D$N ;DYQP6VMI85&Y+.(
M,Z8D**E)"G)5[V;!P;5M04 BV-@OU,;%$%9]F)@WZ-N9V/3N P-05Y!W_DG,
M7OZ[!UU:2]ASIGQSY$MZ#=WIBNYDY9.2]JB.>1MA*2=S#SIC?S[LI/\ N454
MXM3I"BG<MUEHD=-H5Z[4, ["L9O'HB40[RG,9TH.X=P"D4WN#;;5@CV:E,-^
M?/F:]G+3*%,W7VF=.KZDZINWYEQ+PTK3?F*FJ>N2#+%^+<X2=@RP\634!E%E
M(4X#RG)&S<K^;V^MV[9N#;QYN82@G_.Y0WU92O9S!@,9,Q>O:3E #F9>Z'U+
M =T0C[0XEQNST /02Y**\A,"B6S8DTU,(FP2SV7(92232=@4YC%;'"+24Z#[
M/0YD%0W'VA^MT "B(CW;5[ P207PDA0K1:A,+-HM3./"T3\-MS%$@?BL0FHJ
ME*I?!_=0.=[/I"*NUA7,U%,C"23(D02BDA+$03$ *)=@3;O13-U,'*7LN7<-
MMM@V&CQNSY"4D2\)*0U )<N2FE0SO5W-&CM=D[1G*4DKQ4Y0=)]]4U57T4*<
M@:Y0OZ"\&3MS=.28)I1@E:J,ESJ =S'/BAR'4!4A2[ H8H"LF8OYPH .VP@)
M?G>WMC2<<E25R42R4?NIJ0G?ES&H72WNN!O(-P6+4;[-[,;?G[/6A<J<N8 K
M]_(4M79SI>]5.Z:!6[\"A8UK4'<A>=SX3P^(ARBI-Y)6$N^XAO\ D800$=@
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M.T(<18K ;J9%5 _L[ ;J'.W.B._CL8 '<!#5K@=H,C"RE&TG=56ZD+* ">"
ME5+[[<N3V[LPC$XY:$DA4[MI=+IFI$PD4:LPK2/Z8OA7S)MR-EE!  6(04S=
M_)OW%[M^H#OOW].G0.O6X>8%)!!?,MH0&]6CYOC9:G*=TC=US]&SUZQ.G#X"
M$ 2'V,4._?W>?</7W=_OU-[3=S>U+TRO:*Q,HK+;IU]<6%_K$!L$KNF<3&W$
M=P[QZ]/QW?=K3,Q' !GS]5^_"+"1AFUU>]>=/0K%2+Z]22<..94Q"J$4*/*
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MI)POZMLGVAB+((JG.J0B79%*<RJ7T/9/LAL>4E$P2D.X(WD=N<LYRIB4GB@
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MV40+EN @0P FHM^8 Q##L)"E ?:)S;EY-;DXB0H%3XCD$.!;@WE9XRG!SD*
MW9+58E8RS^(FC-2D+64OC BOK2;.>*Z%/F,D\;(-A3,9,2=B<CA\B(&+U*8$
MS*)@;VN_F#4*?B\.@N.V=JN$I8]5I)KF 1GSO\'@L2L;H$H#W30J4]0000E7
MRSI$3<W$7+-7UV+?))N-SD.H9#D$OYLAA(9N<X<H"._,4^Q@WW+U$1I<1C4,
MK>E+96I#&SU256U)\1'78'9ZTE&[-2Z0/=8W-;%B_ "G*AF>+F2:DA909K%=
M-T212I%$Q';<KMGO]<"G$Q1< @H)@V$Q3@ B7VQYG&[LP3$HM3K:OBQHSZ/7
MZ#LO>E]BJ8 "Y''\]VHWNDCH8W"9#(*6(L*MQ#J9*^O?>)7<O%-2F^(C'FW
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MHW9 (91G Q;+'6#A4>A-V5=U.SCGD.Y?R:BCM<PE   O:+B8P)D .5(G0B9
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MZ9SI(B&P@8"B E&*OVO]JTE05M+'N"Q/XR<QR<'>%-"^4>D>QOLNH)6G!8$
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M=^[8B@<C=6D"GN*9::44!4M&ZVF1;DS=HX43*8TA%LEGB"I0,10K]F@Z515
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MQ2B/Y@"CT*40_/FP\?L]*MO8C'R3B)\_#SSL\N4B5C)^( ,XU#E,L+4 7!4
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MJ[$:&EW-@*U^41<1-*IA3_\ +!0S-44+\LWS%>&Q;@GQOC%EQ&XLJT_,$O\
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M%(Z::J28F,8I3(G$B*HE*( 8R9TS''<11,.H\R6IMY.1R-2"*:.*Y$1<X7$
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M=W=(EIS4062$;PI5%'?N7C5PNL<5G  8QA'=0B"1")(@7I["92%*4O)L!2D
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M(=^O1F=XNYA*>A*T[Y7R:?K:R*Z*+A4  "B<J1DB&..X)%YDQ*8X?5*<QAW
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M(D!)$%>0K< +VB[QPU;-2\VY4Z3%I!!<^[ND\-[N<!NI.6<==@B4*D[@91F
M%(J=VE@Y!=(KH$DF[Q-L>12LK+,D3%!1054RFY.8Q1$FP")=P 1 =BA[S'$0
M[]<9BUW#W(&MM2SV\N3_ %+ )"98R%3QKD>@YFS1M5NIDJ1ABMU5'\T^M3M)
MPY*7H;Z%KP"HH50.GYM[8'I!3'H4YH4W\P=M<ECOK_*A*9"#_02N;E7>GK4D
MY$2PYCF]MSNTQ,G#@_"E6+FC(3<1NRY'^W"RPH@V,\Q4MX?FYO> _/O\O=N
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MS^CPYF4DD0@%,;N#[?QW#W?;K:XUBK*2"<^0^E/5(@V0KZS@H9XOVY2B5$X
M(F#ZVP]VX]X?6[A  ZCX!K"U!"23I\VC;(PZIJTH2+FP'GY<8UVIN8^65F,O
MV!=!YZF]6AJ5$F736YWJH+(*2#MN8%.CLQ'"+=(X& \*PLP. 8NW]8?..?,L
M;3Q@E$[\F6K?Q !H$)+A"C8&<H=F _\ #3-4-U008^B?BC[+;&F8H (QN*E&
M1@"72HSYB6,Z7F4X*6HSBH  8A>$3[Z#."8/DPBLMC^$EC'46<(KRK114YA.
MH==H]++*G,<0$QCG).=1,(F$P[B/7?5-[52O^+"@*+P\LCAN*6DY_P HRN*B
M\7?[-<3O;+W"K>5)Q^(0235ITN3.27(S45WJ[BK5Q\4_6;6&,E4EA10LT:@V
M<<I@ JQ5BHODDU.OM%.[-'B4!#8JC<I^AN7;\@;1E?@]IXV34!&*GRFR9$Y0
M#ZTW?#*I_9N&W<9LG!36"S^'E34EG92I(!4-"$F:.(60Y>MC05;J B*BI0[4
M$"AS"!1,N9(QMMN_<03$>7?KR&W#SDRM[<#.7'>!P?CSKHT<IBT[I-PQ4"S$
M>N3=(F]?F8LSUDQ*IS**B4@+#R]F=4XE("91^N&QOJ[!R^US=>\96Z3ND?\
M4"]"1K9JO3F[F.>Q3@+)H'H :D<F:K:ODX ,/Z%030<D,!=@$"DZ>'3?KY&Z
M&'?8!'KWZ]H&?KU:_P!XH,0O?00Y-%/E?UT<<1# (OV([@(@/7?PVW#H;?\
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M3'KO,=R(II&4(6!IRA@#?82H7\W:;].H%[=(3 &^P&W'IK9@Q_\ I*0[5ES
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M>L7BX?;U W"#7K][;M)!]&-^:/>*I":359I)\QDUUBE%5P1%,! BH"HLD!
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M@9>OT]%=/61Q.8HD'?KX>[R\??\ #IK(6%7L=/7IC3*'9*3^4CUH<Q"RG!!
MQR^(>'S^'X]VLE)47X FWF/7E#?W1Y5TJ:<;0O7COZW7N\/M\._P_ =_@AC]
M_*W6-G:E09_%_EZN8BSIP8PB(CW[B.P]1V\?AK8@T[_7/OB.I;4N=8P;EYL
M^UY[>8?/]?@'=OK:$/\ /E7[TYNV?J6OY/Z^];M'L/\ 0/<+UA9UAEEVTQZS
M0+VTITS%H.4C$4;4:I1;;Z->*E.4HI_E?8#@*#90!%Q"QK*4;F.W<CM9;)PA
M1,F35!BM9(!%I:5J4DZ^^I6>0"@[QS/MWM].+DX#9DA85+P4A/:E)]U6+FR)
M4M2'L?PTI&ZX9IDR:@U33U2:Z2/ET&D(IMQI8J3R1C-R8R7.FW9OHJ2$I.T,
M@RE.Q,SDA( ;G")EF[1<"AT*5=14^Q$S&+K4M4F9)Q"0YDK"B/YDD@$=0XX.
M3$K#$*[222PFI9)I10L?5V CS:6;'3^N+O8Y\Q,@[CU%&RQ!V$2B3_E"= YT
M5";*)*E]E1(Q3D$2B!A["5,ESI:)DLA2%@%)&FG BQ&1H8KIBE2UJ2HD+26(
M.9?YWX@W,(:=;<@')R@(!TY.[I_*$!#<=M@ZCJ1NI6&(R8W:_'TU\HUB>4'6
M[7J]NMX5,D*I.B F3,',<.41 H<N_> =0\1W#K^C6I6'!^$]'NWD<GORB6C&
M,'4QLU1]GX:Q$W2SU9,04W4 ^Y-N4JZ8@/@9(Y3!MN'7V V$1V'?6!AQ8@5-
MPU._OR[XR<8:[JJ7:H/@,Z9_.(X>+C%5$S&9N4%TR))G.V.4X")/X0W9J=F4
MI1 -@!03#T+[0;=,&2D-[K,P#9\@:^?&,?C)ERH*%2R@QT9TTU9KL6&LH80C
M(SLIT>U,DF4W*HN82'4,<V_:\@)D, @'\GJ4@]QC@&XS\/A]TA9#,*:DFG/B
M26%FRB#-GJ()-SD"6'4F@%>8R$,R#8%3'G(41$5P.(B&X ;91, +U]H3 ?F'
M8H<OCN)M]2BY-J7)H-#33P\(KYBB7XI.K:N-,JF_&\.NM@HB[9<A"G,55,W*
M</9$"[B(F_VB@43D'J/-ML ]PQP5=HLD,P##(N206[\J-$9;=G7-S9[AB!Y<
M8V!</N.'F4[/&P+-HH<#+MP7W,9,AU%N?E2.H4#&21Y$UG+E8H<R+)LX.78X
M$'4':FTE8'#)3*8XF>I29(-0FCKFD%W2A)%"X*E#></'O9N &+GJ,TE.&PX"
MYS$@K?X)23D5FY%6! J08W]XTP]3L9Q3-I$QK1>411(1>95:I Y,?EV.1B40
M,$<TWW C=L)1,4"F<J.%N98W&[I*E3%J5,FK+KF+)4M2LRY<CD^FD=0J82D(
M0!+E)#(E(&ZA*18,*$MF8:IB@8!*8 ,4P"4Q3  @8!#80$!Z" AT$!Z"&O4:
MXIAQ1<*-+R[29L\;%)QDXDT<NBA%)E;'64*F8YW<>1("E:S"6PK)BB4J,IL=
MD_17]8*JEF3-G8.9^(PIW5#^)+J)<Y&:%I%#P-"#4,IB-GN3TB1B!O(+[BS5
M<I2J!25&H S%B+TCR)YJ@9BCO;E1[A/OB/H.15CVK!NZ[0\D I)K1;TY5RK.
MOHN3;.&;Q$JAT@*@L!C]FJ !KI9^*DXK"">)DQ,N:C>$H*<[WYDJ<.66X(H*
M."*1[P$A<G$A'9I*T%M_=8 9J27 WBD4(]ZK&('$"3Z.8H)E'L6Q$BG5 0$J
MI"E353*4X!L?G*8@G*780#??O#>JG+")*4&X37JQ/0\K1W>S997-*S4DT#9"
MA)LU!?4TM2Y[>IW&IXR@&SML\:HVMM'6IZW,"@ G S7LU9\Y* CV9)<4'ZC,
M5RE%5%$%DQ,FLD8U%CU*3)?(^\7>@J$OFS@M<QV.QTR9V+4S'LUF6[?FE_Q4
M\T^Z"UG:C&-@G#TQ2QUCRPY 6(1-:NP:CN.,H&W:6"4$L372% ?KBD]<F?*$
M#KV22BFW*01#CP\_&RT"J9#XB9;XF:4#R<J(SIF(Z?;D[\'L>: 6F[06,%*K
M42@!,Q2PW^E*98.1)!+&*\.) RBISG.)CG,)CF,81,8QAYC&$P[B(F-WCWB/
M7OZZL)J]<KMX</0CC\&AB*5OZHU&Y-=XZPN@$ '?<0ZC\0  ]_G^.FJZ<N^7
MWJ!\WO?C'6X)+[O!AW>JWUK'244 Y@ .H<VWZQVZ^X0U1XI88G]?0H?5.IP*
M'4[4 I;AUMG'::I\Z@CX]"AX]_41#\;?9KD<<L%^MZ-D!3CZ,=SLR4P!_1^.
M=\Z:0Z,95->QS[!)-NHLV:N$'#KLTS'$_*H'J[4I2@(G5>+ 5$B9-SF 53%
M>S'6KV>V5-VQMC#IW2<-A9B,3BU$>Z$H4%2Y3M54]:1+ ^+=[18^ F(WM_[2
MR/9;V5QTSM$C:.T9$[ ;,E.TPSIZ"B=B@*D)P4I:IQ6?=[3L91(,U,>A#%U4
M/2Z+ 0+@H%?(M3.I( V':0?JG>.DA,'0_JQUO5"G#H9-N0?'7Z(E)W):4YLY
MYFOVC\*3IG:35*R=AR%!WWZPP-;(U1AK%#(6*!F8%R/*C+QCV..?;<4O6FYT
M2K%#^>B<Q52>1R%'7E2=Y)2<P1WQZ0HH4E0ND@]V76//OE?',S5,P*NW[50A
M7SDC%YS%,)6DM&)D:*MQ-R]4G*")'C-41 KE)184=R);ZYDX0R<9,6U)RTJ(
M;X5@!*]**8*?/>5D(^D8;:HQFQ\/AE'][@I:Y:7NN0I9F2U"U4;QE*8>ZE*"
M7*HLPP2!M!F5$-N5OS#OY%(7_#P_1J\18"C #A8FOGF;5N8Y.8HE9K<DTS>@
M&?T%-(U;9'G$9G,S!9^]490M0]?M$TY1,4JK6)JJ#NRRKMOV@@4SQ-I%N 8I
M;[KR ,T YNU @\KM9"\7B)&$EJ*53IR$;PNE+[RUAK;LL*5S%GCZO[*S9&Q]
MF8[:^)EA<O X.;/W%-NS5[O9RI-1_P Z:I,O1E&SQ2NV9FN&7[<\LUJE'2Y5
M5S)P\,+M=:+K<00PE80<.W54$C9BP;\B!1*0JKHY%'CPZ[QRX74ZJ1(EX65+
MP\E.Y+DH"$"[!.I9RHEW5<J)+Q\<Q^-Q.TL7B,;BYBID_$SES9JG(!4LNP%
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M39MR'*(=P@8J8& 0\P'1AH.Z,%2C=1/,F,AK,8@TA!I"#2$&D(-(1P+M6SD
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MA26#D%J9Y>,>Y<PH6E3DL034VS\(Q^+K=^5%;1;ON9O9J]R0EHC5]B.VDHQ
M6QUE4A'F!)]V)G"*@<R8F%9 IS';J@7$I6\FM%)]U0T(IXW$>IR-Q9(JA?O(
M(L4FO@['[PK,JT+BAL$W/$Q5G;'%-IMFC$(T8NY85>72QTE;U &,A+4^>B<C
MT]A(K/#\TBE'W&!FT&;\YP*Y6CQ2CT+[ 8K8DF7*..V7C,1B9"ROM,-M).&D
MXD;^\B7B)4S!XA: D>X5X>;+*DY!8*S\V]I=B_M&QV,QH]FO;/8&RMD[0PZ,
M/^&VM[(S=K8_9"^P$F=BMEXW#;?V7)Q"YJM[$)D;5P6+ERIY($Q<@ID(8."<
M/US &'\?8:J;E^]@,>UQI ,I"4.F:1DE$C*.7\F][$B:";B2D7#M\JBW3(W;
MF<"@W(5%,A0B;4VA.VKM#%[1GI2F;BYRIJD(?<0"P2A+DDI0@)2"226<U,7G
ML9[*X#V(]EMA^R>S)D^=@MA8"5@I,_$E)Q&(4DJF3L1.W E F8B?,FSE(EI3
M+05[DL!"4B,#'*M\D93/-MR)O:ECI@_AV3LY"K,Y.T2Y2IRAFHF 4EV[)B4B
M)S@!@!8C=9,QTG"1PJ1^\F[UT2P4@W!4;MR%/UCL#^ZD[MES2%$9A L^?O&K
M4STAS_0\3_1<=_4FW]UK<PT'<(CN=3WF#Z'B?Z+COZDV_NM&&@[A!SJ>\P?0
M\3_1<=_4FW]UHPT'<(.=3WF#Z'B?Z+COZDV_NM&&@[A!SJ>\P?0\3_1<=_4F
MW]UHPT'<(.=3WF#Z'B?Z+COZDV_NM&&@[A!SJ>\QV$&3-J(BV:-FXB&PB@@D
MD(AY"*9"B(= ^S1AH.Z#DW)CLZS&(-(0:0@TA!I"#2$&D(-(0:0@TA!I"(/=
M:'$W5LT%RLZBYF*5%S!V&,4["4B770>9%4H@*B"ABE[=L<P$4 H&(9)8J:Q/
M"Y86SN"*I4*$>M(V2YBI9+,4JHI"JI4.(\CE$+2=YQKA0:+P]8R&W2]E"2:2
M1:Q++D#H!Y!!X48XBX]X@T*8FW>H<PB.O ,]-"$S.(.X>H(;NC8V'74*7*.A
M3OIZ,Q[X%5LX68!:$C:UCEFKN5Q(*R!;/-))CT$8])J!(T5=A'87'9B&P&36
M3. ;X_?JHR9?%]X]&IZO!L.BKKFG(-N)_P"HFO=$XI=%AZ0R<(L#.7TC(K>M
M34[(JBXE9AX(F$5WC@VYN4ICG%% H]FESG,/.LJLLKL0@(!9R34J-5$\3&N9
M,,P@E@ &2D?"D: >9SB::]QK@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@T
MA!I"#2$&D(-(0:0@TA'7=M&K]JX9/6Z+IF[14;N6SA,JJ"Z"Q!(JDJF<!*=-
M0AA*8I@$! =M"'H:@T(.<9!(((+$6,)5.C7RAJ*!C6:CY*N&4.J2F6XSHZ4=
MSF$ZB<),("+A)(QC"*;9T)$$QYE%E'2QS&'1N3)?\-04G^167])^5!&\S)<W
M^,DI7_\ ,EM7^I)IU$=L;'FUP'JZ&.*Y'+B E"0?VY!XP*;N[0S1B0CT2>/(
M4_/MTWWUG>G92T@ZE;CN#'QAN8>_:K(T$MCWDM'8@\;R3R::6O(\VG:)U@;M
M(>+:(&;5BOJB(#VK!D< .\=D$I13?.R$5 2IF.FHN@@NF3+)5O3%;Q'P@42G
MD-7SC"IJ0DHE)W$GXE$NM0T)R' 0W];HT0:0@TA!I"#2$&D(-(0:0@TA!I"#
M2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA"OMF.!E98ELJDRO4;FDD5$\HV1*X8R
M[<G+RLYV..()/4]B%(1<P"JD4J8G(X!NW32U+EN=])W5C.X/!0]=8W(F[J=Q
M:=^7_*:%)>Z2*@\+&,.6=SA&AZL\HM6LBA/9"1AK,6(;J[= 5,UEB&7*(A[1
MRE @;[\A2AL&L;T\70A7$*;P/>8];N&-1,6C@4;S<'!RCJN*YE:]%%G;)6*I
M%:6W(\B*JJJ]GI% W11HZF%P%NT14*/(<[(#@J3G26;'(;?6-V:NBB$)S":J
M/ G*FG=&=^1*K+2J8O)2Z)2=0D7ZM#<@X**K<4SA81DDPC6*?9MVZ6X@&XB8
MZBAS"91994XF4675,=590QCJ',8PCK<E(2 E(8#*-"E*6HJ47)N8RVLQY@TA
M!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(
M-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!
MI"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-
M(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"-;/&PYX@JQD[A:'%
M7%%D'%-;SKQ#UO!-EJ,'CW =GC(B)=8CS5D)[:8&2R%B>VV-.R.Y3'L(Q.G(
MS,A I1ZKX&T,BZ63<I(])9E.D%@]=[4!J$:PJZ]Q>YAPQGOB:IF1:K=LQ88H
M/%=P?\/JF9WMCQU NZ._XAL$\(M-@#,<?0L;%.[*62SCE4UQR3]&Q]7B:RPR
M$5_3&L^W825:KJ#.S:$]S_(,/3L:A>DYQ9D/B298&@8B$>,)C-V6>'>*FXW*
M5,F,CM,CX7:WO\L)FX8-8"I<*?B9W/8TM]2K.0WD@[6E9LM;=OJQ#UFVP=@<
M(;I9^ /0LS'6KMIGE$]XC>-2SX1R'D2@4[AWM.8CXDX=(KBAR%-Q-[IU09QV
M.'%AR;!RD-",["<TA/Y"[+&4I(5> 3090$\4[IK,6ZI+-6!ID_U\_I& .+7'
ME]8CUR](G1*CFC"V-1BJ3)5W.<SBF!ILBEG''C?+[M3-$"27H]J0X>5#GO)\
M=B^<-(&<LKU_&2\:Z,[E&E5E*ZS&861G=H3IW=\*W#'&5G;)-'PY9\OTM/$4
MA<?2#YHX9XY/&%CJ5LB[?7\7Y/XK:"6OV]M;JM,/X:,AD,+Q$=8I^IR,/8;A
M98XMGK;JH5F6=U($8(NU: ][?6,=COTO^(,E-[?-UNJQDW5FF#<[9[H2]3RS
M1[C;Y:K8(9)2CZ+RK18,%I3"$]D"%<)S^/6LXZL2+J+;R3*TKU2ULBU=RC.Z
M?$#OTU]95C@R]Z1[,];P[FR<K/#.6F9;H>(,&9^HM<R'D.MV""L.(\W7F?I;
M&4L+FF+"G"W>M/ZG*MK'2&LI(QZ(RD&_AKI/H_23=DANU =[BFHYCE%VL]<2
M$IP[\/"6;;YCHB$RB]H,/8ZN2YM"5"B2%XM$+5G<]>\HC!J,*[C.C*S S5XR
M$I6W+6%KL>]E!B5BI@D*, .6YGN&6L5GS-Z3FFX%H]XME[QE+2[^K8)P1G6L
MP^,[E7\BLLLP^8\DS^,IF,Q=88=NDRM/[F[^(C+).2K=N1O(TZUUV;;-VO;O
M&K-&6\R*T9FOI?OB97OC_KT#"9/LM3@,=/*ECS,D5AIAD/+/$'CS!&,;K-.,
M0U'*\L[KMQMZ#\SP6"EO0HS"/CHB56DK7"6;UM:&B(5S):0W;<0]GS;[^A%.
M,M<<5_R%4;5F3#-LM-(HUX]'KPB\1N/J^]2@SRE5GLQ<1-AAY=V\,@G*,E)Q
M6G>HUF4%J_D(DY6(K1RB@&(\41Y-*1<N8X]!BKO**)85L3WA^KO$W4N$&QYT
M+;ZZ@[99HN5SJV+8]=AC)1$9>1QM'9>NE>QA.6]6>CYII85)*28TV3JD<-A<
M(RW>SM6P^U86J/I8\+,9"H1MRI]JIZTEAWB5R7D-=V\CGC+%%JX9)S)L+:L4
MV-TF5 KFT6 N .(^3KKA,K1%U'85L;CU8Q' &9HSNGR;6H?YA^8O#IQ+QH.\
MFY]# 4MBYKC2T1N/*-=+)"WK)D#%9&]8N6,Z]D-XXH6-%XA&1R7CBG2=@_<P
MMF2H"712B<F0T[!.:TDRC5)0R,$,'=P?5=#F!I'4XG>.RM\,&4,?46UP='>1
M%UL&**X=1WG7'-;RNX7RYDV/Q9%RM!P7)JJ7'(4#59J682=SD47< =K!DE7%
M;:VAY#/F!$ ''?EH'+GUTB^VD8@TA!I"#2$&D(-(0:0@TA!I"-;/&HOQ!UG*
MG"L3%?%'D+%5:SSQ#P>"K+48/'N K/&P\0IA;.62G=G@)/(.)K;8T[(]E\;0
M;%4DE,R4$E&N) K6'0=*HN4$>@0Q=(.=2=0,B/6<*NL\7V8<.9\XG*5D:J77
M,&&:+Q?<(G#J3,[VQX[@G5'D>(?A[X.*G7$F./X:-BGED3D\[995M^1SQ["L
M159:9)3?4YO8&K"3KE:0(HEKE)/<5?(>%88N/?2=8KR1Q(1^!Z_$0CR/G,U9
M=X?(:;C<I4R9R,UR)A-K?1N$S<\'1YE+?2\4/YG&-QK%4R$^D':LM+EK#F0K
M4)7[C S;E#=(#\'MK:N=WC"\0/%AFG!'%CF]O6\6V?->),8<#N+,^6RK1%QI
ME01J"4=E#B70OL] DL(#(VF_VBITV%:UJK)BPK\H6GN49>U5-R>.--H  M5G
M)&?!O7A$[N'I$*'4<XX9Q8K&4B0KV<)W%U=J$HWSCCU/+SA7,-;^GJ7;$^'<
MZAKR;'1GBC>!F+*^?QDPP>F<2;6J2-<;?3*R,-1_E3D^OIXJ7CSC;N>.W..L
MFYJOEHG<8U?AV],IES)D2PCXU])V$G"YQT8.HF+2QS%)!B+R=JN.9ZP4JJ,2
M/&2#WZ;!*2557,F]01ZW7%+N@#_J!?Q:+13OI!97&/Y>US._#M:L>96@:AAF
MX8]QS7+[3LAAE,,^Y?8X QW48VU-PKL/7;LWS%-UFI75E,IC6:^WLT588>VV
MF'))+QZ,;KV-*\* .2VC:.:6=GXIKT@EDJ:]@H=KX;+(CGZNYFPOAY;%5;R3
M3YN"E_\ A!5ZQ3F,KW Y)E6U8CUJDLO5+'$6DDS P5A@'E<G5&<).-TX12?1
MAK:%R.E_7C%@\1<4D/?,)Y+R]?:G(8J<81LF8JEF&L.I5G;4ZO+X0D)9O;G4
M+8(=!LA:(!Y%QA+# 2*<=%OW<;(-D)"'BY5-W'MT"*M=V;*_IH5"/&5D1G@<
M<\7K E8P_79YMCN;H+K,'$OB>B5-Y6,D,GLA'.,BW-\1=#'UG@TDHEI.U>+B
M;Z1>6L\&PJDW:"HV-S7D&JSO>SFVG/+Q:(!5?2-2N6(/AX/@7AWE\KW'B$QI
MQ*9%CH1#+./H&IU=#A8RKCO#^0D7F0SFE8JR0L[;[\W9X^LM3CI="QE^A9!Y
M'PE?EY*=K:,E)#OD0.\$_*)'B?TBM/S9DK =*I%)"(A\\8)QWGB#E,G7N!QY
M:Y*%R$TMB[BM8THSUG)?NMVC%JM5[',\?7+(R/1T9ZO/6@6)M(@9- I(!-V)
M%':G'CEUM&#M/'DUN& J)9Z;5[#4;%Q"\*'%5FNBRJDE&.EZ ]P55(%PFD_*
M#8R4B_>/[?'NX]9!,&R!HQ4KI%4JQ0! I9^#>,*H?2K4+&BF.L<VMM$VZSUS
M&7"](9GE)#*-)J^17,_GJN5I\V7QAB-^4;+EQW7XR;87B_DB3UQ%C!2R+:H#
M<;*WD*VP0W;WS9@]O31:SB>S;)8;SCPLKO[2\KV+G[/B:LV6FJ"";AM)UK&.
M#)>\MW#Q(&ZSPX03B.5E6Z3$Z2JJR0)F!4I@3%&,N+CQ>$\?TE;>EUUS:<[<
M/UXQ1&6+ADN/%?AYBQMM0OMAR-C^CR6.8B:I4K'1BT5'TC,)9#,6*VR%57F9
MZI+'MIQ3R"<L%,BU1G=>Q>K>9^1[H9>3N+S)F%\5M;UEW"F,<46)Y;GE?:Q&
M4.+C$=#H;^/0K3>QLG,5DN=8(&D+)*J'D:\TJ(4Y%4DS S#QS+(5,L9:)-&&
M&1)IIQ]%_G"5I?'KD_,.2F0T?%[:*X<+SZ/G&O&16\@+V6(:Y:JZ.4H"^S<4
MNYJS]A/UF0=M5X.(K"==43=M6,L@\LKV5FH1TG")HR0 +UWB.%,P8XTO2/O:
MYB-QD",Q#?,P4; W#)A//G%1E!_::!5K15Z_D3&"63I):!I<7#1<1D._0&/6
MKG)%Z@H!KCFJ-V$E'1M*7D95V%8C4&JV9+"G%M=>9^;/GN/MU"Y>N=,1P/9Y
M'%&.>)[!7"E<\V(W>HI,T<A<1U/P=/XU>UZAG,:RSD&VG,_T&NW9XY5AOH-"
M69S<%^5I"3\?7$-V@K<$MP#OY>L]BND>8-(0:0@TA&H]EQF9+H/I&,WXMR_:
MZ^SX3]H_'N/Y!]#Q,.;&V7ZWPU4;B7>MYJUI(H.Y6*R1CQ?-DV/TVZ7+!.,3
M1[*)(4LZX*5'IJ!A6YY.WFPZPIN'OC7X@[RE>K#F"P3M;8V3C2X2H/$M1J]2
MH41-4W"'%%7:7>Z+C+( V:M33E\X"G6^$)DR42!A?64^YGFE6GJZ5M'HLD&T
M;X7-\BQ(^646G7](#,(8.S!Q0EX=+:\X>:#7L@SU"N3"^TQ:UY3+CO(/[GJ[
M9*@+&;/:F6[NF\K8<=NGDK+)2-<C.TN1:),2$9#.D-VK.'ZL*<LL_!XX;GQW
MY0IB5Y8N.$NP2EOP7A5EQ!<2=4C,OT157&>/K#-Y/0IL'4)E1FG$Y2RE8*IB
M6V6]S4FB]9K$(B2/B'.0%W\I&F>(P #FV0?Q?0"&QC_BXD<R96L=5PSB&6OF
M*<?2="KF1\Q*7.MU@(6SY&Q)3<W0C&LT::*G)VR-A\>9*QQ+6V25EZ^[CG%M
M2CH.(LSZ)ET&B#4!UJ.3D>8I\HI+D;TK%E/BOBL<8CQUB.?S)P_XCJV7HR.@
M>(6A9IHA:_9+C/TV1C+[+XU50"MY#ICVO++S] 1?/&3QO)1RL#=Y,@/1;(R$
MU#N >AL]!GZM$CRWQN9XP#Q <05BN&%)^TXGP]P$<-O$AERE5[)5)&.PHT'*
MW&LVR_8J](24?&RF2KI-4C'5:<Q5?8,(F%EX[&L@BXGJW+K0S.T(-[J=2HCP
M2W<Y[X:5S])UBJI\2DGP_H1,)+EJV;,2\/5N?%RC36&3D\D9D:T)Q7Y"E8*<
M"I<[QC6KJ9/I;;(=[0>1'Y.<]J?QL%88FD6209H;I9^9X,'SUI;E"LJOI,;S
M4,*RF1>)'%V-Z!8;)QH9SX3</(FS-!5:A34OC'*G$!".#Y$O5H8F8T*-HM#P
M=+FL%O*WFSW^?: >G4N/>6.%JQ$-VM*L 334"W4MESAK47TBRV6I+ARKF),#
M35\LN>6W$L]E#,\E4EK2\?1?"CEC%F*<EV@MY)Z['Y IL^\R<PF<7S],9/5+
MBS5KQ7T96T)N6?55 I9ZV;Q!(\J_H[4XE.)1? >6*RD:/R=<8QEPC<9'$ \Q
MACV%J4P-Z5X>Y[AF;HL&Z#V#7NZUW.GEAQ'4MC7;-#UMT23L!K9$S3U"KN89
M& '[P.]X8V*>(MIDCAWD.(#U*BOXIC 6ZQHDQ3E>#S!3IN/JK1Z\,,!D&'B8
M1H\67!DJP?-7L'&O8681>1[QJ<&Q7"Z#5;I6G?%*I;TIJ%<HV"9^ZX;KF*K?
MQ)TZUY>Q14<R\1N+\<1#C"-3K^+I8;5:[Z^0?P,!?K)*Y7K\!5L5L49^2<J(
M24O.3M?AXF<=Q",[M2-*4&?TI>_".U>/2GQT'6'.1*3PX9+ON-:QP>X!XX,D
MV%6RTNG3U)PWG6=RU$(P:=/G7QG]@RE6FF(Y^9/5V;QM7I5JTEFI[I$R#2";
M6E#=U(%2D7N&\*_:&*X](!*0*61*I=^'BV5G.M5R=@S%]0P\VOM*L 7J5XD&
MB[W&#M2^L54JU6D8YM$6]QDTJQ99*IMZ3/.*T[OR3BOC-HPUJTKX7^UG>,C4
MN/\ B%,@Q.+LM8OD\0VQGF:\\/\ DEZ_N$)8J31,EU_A\A.*:CE;6YLTC$K#
M4<I82D96PUZQ.HZMO8N<KSZIS< UEU42:1EM*T<=[=[_ %BO$YZ9+%<$SJTB
M^Q\G#INL1XESI<ZS;LK4BH90C\?9O?3#FA,L:8RER!8\NY$1HL4A?[=1XX*V
M:#CYN&K47,V2ZN5*\@AN^;6.5R3D/I81*,Y<:>59G(5&K6(L<66$Q3 \?^%N
M&"[9P);:<7Z?F4;7 )90JX8\?IGGR4%=62=X_-;6CT\\XMT<]20K#.L=C;U$
M !5_Y2>6GUY-&VS2/,&D(-(0:0A6Y)Q!3\JRN)IBUDDS/,+Y299?I?T>^]32
M+<(^FW:B-SRI.Q5]?C @K_/@=B!D.9X+)QVP V%-1&79^(8]X/F(7-EX3<36
ML^6%)9.QB;,V=L#<1-S]7F@1 V1.'%?!CC'!HL/4S^H09%.'G'GTY%CVXRA2
MS8 Y;?291;(/Y$=[_6/C'_"U5\6Y%G+O1,AY=@*O8KQ>\FR>$T+7&+8=4R%D
MUS,2M\M*,,ZKJ]L;'LMHL$U=GU=0N9*82ZR;NS-*TVDU3+:0)>_)\Z6X6I:T
M(C./ B7B$XDK[DRYY(OM3Q;>.%RC\.\Y5\6Y!FJ=.76+99!S%9<AUJ\-$X5U
M%*4ZS5Z_5^+C9^"E([(D.NA9&U>FZJTDWR\ZS?EX/]8/1F%R:C@WKI$T?< 6
M$G.33Y(83&3*ZR6RIB7-[K&%<MS>+Q:\ROA.HTG'M!N#F )#*2RHQ]"QY4*H
MO6/RA"D*M89K-)5EO;$R6$B#^1'?Z/?$BKG!7BFL/VJ[.=R,\A8?B5LW%=4Z
MA)V=H[K%)RM=I+*%@NHUAN$*E)MZS:[7F*^6N4@9*5DR(S,H@2)<QD0Q:Q::
M#^3<_31C*IP/8YIU&O>)(G(6:%,(W3'^0L91N%7UTC'6/\=5')2;Q"=CZ"'Y
M,IVQLG&M9!XPJ#>T6FU,*=&+_15<91T8D@T20?D[N_JGA&;OO!;A3(\;>(RR
M)6OL;]P^4SAKEUXVQJQSQE0,?SUEL]2D(5T@V!1A;HB?M+Z32FQ%=%5=K'%6
MCU$$%4G"#GQ)[[PU9[$\A.8SA\>)Y?R]!RL,E$ GE6#FZNWR7(NXH.55_,KO
M*>_I$JI,E,J68CWE'4@E^V$S6(9J-V9VR,=.GJL5\C_1X<,D:]X77J=9G' \
M)$)DN QHU?6%T\CYN.RW'I-KPED=@LD9K="/Y=%&WL&KQ-NP@[:BC*PS-BFD
MDT(CUO&M;L_1_K&#J?HW\#X[Q?@K%^-;'F#'R?#O-Y%FL>7RNWTJV21-EL9L
MF2&5ALUAAIU.:2M#.=7CS2:L:E9(%HQB?R4G8%U&MW((P2Y>GR[HS+'T>?#O
M'4".QJT;W8E8B^'O$O#*S34M2CA^3&&%KB[O%)24?N&2JZ\^2<>+?2TTN*BL
MDTY43HIG RQD8)<DZUC+NN!;#CS)[S(2LWDX*_)YCA.(B5PFG=#EPI)9XKBD
M0^A,INJJ,<,R6;86& @[H$"VL[>B.;[$L[R]J3FU$/+*(R].C/5V]4Y4B 7?
MT7_"=D&3RQ*V.O6U5SF;-E"SO<2-;<]:H)VFA-;,S" @TR(C]$42YHW_ "D&
M0*JB8[6T&RSDD5UD/RF7!)&=XTK8$#K\[,> TA^S/#)4;+GBG9\M%QR59);&
M\U+6K&M"EK%&J8WQ_<9_&TKB2=M5:BV\"VLA'LM1)^Q1;F'E+7)U%)Y/RD\S
MK;6?51DT$8>C=#QJ]>L0'*_ QB3+^29[)4]9LJP:UR>X4EK_ %"HW-*%IE_F
M^'BXA>,12UG9*0[V:%2K30%!6+A9Z&KT^U(B6R0TNY;-72*#T;GT>[1<[2,0
M:0@TA!I"#2$&D(-(0:0@TA"NR/B"GY3F,1SEJ+)F?84RBVR_2?H]]ZFB6X-:
M->\>)&E4^Q5]?C KV1;$!F(&0YGPL7/;;-1250A;V+A-Q+:%<J*RB=C$^8N(
M# G$M<?5YH$0-DOAP/@53&YXP/5#^HP)!X<<<!.Q7YX90"SNSIJ,H46J,N:<
M 1T+OYF/G'G"U5\59#F[G0\AY=@:K8+O?<ER&$D;7&+X=_= R>\F9F^V=M#.
MJZM;&HV2U6&<NSRN(W,M,1N<H\LC&M-9%3M00)?R?-A:(;GK@;Q9Q"7BRWVT
M7/,]3E+UB&*P%D*.QMDA[3X&^X;CYR\S[VB66+08NRF;SKK(,^V?V2)5BKM&
M1JGJ-3L];1D)X)A $AK4+V>L8Y[P!X3<90/DIA,Y,KS1;+&+<Z.,85VVMXO%
MKK+6':;3<=4BY.(!.%/+JBRH- J=67K V'\B5&\0WFD*RVM9"V J#T TIXOZ
M[H[RG -PY/88M:G*_.6.M'QEQ;8AD("9GW"D?+T7C6RI5LP9QC7YV*3%\#E[
M;*A$DK$DQ>,GM;BQ<MVJRKHZ+Y!#>/D>J0P,88/1]89E:]D.)R);LT9?L.1*
MUCJGN,E9(R,N^R14:]A^XFR/BEK0K%7(RLH5>0HF1^PR#'V1M&K6F=M[&,F;
MI-V=:+CBMD'/*]N-^_2W")'6^"'$\,Z1GIRQ9-R'?E,QT#.,[DV^VEE)76T7
M'%L"[K% 82RD3!P=<8T^LPCYXUCZG5ZY78@KE[)S"B"DY,S4E(H.?DWGWPXZ
ME@C'5/K>5*@TC'$M6\S77(U[O\3/N0D6DM*94,8;BP*0$D.QA'Z2BC9*/W.*
M+94Z?;GYN;2#FG"T5M9>CYQVQI%+I)<S<2STF*;=1;?A2QS646<_8,+N<<U2
MZT.KQM&).5:1KKMD2DY#MM7FGUZKUSLMGC7T>K9;!*R5;J[^%0?@*WXY\[C)
MO$PL)3T;<<SR+P\*8XRYEO&F-,*8DXSJJXL%4RG--,W25WXK<WX-RZ\=+V&3
MK\[$6JLK#3\H(SBEN%U,Q<O*T>>@4U[3#MK97D9WJ&@<E.6@(^8X4TI#[:\#
M>'8]; \7&2^18[%_#<3&R^*L'-[0V5Q=#3V(89S!8\M2R+V'=W=>>@63D%%^
MRN[>'L4@@C)VF(FWXN'"Z,/?4W-K\J>$0BK>C=P+5)#UAM9<S2L+&4'-V+*)
M2YW)#F1I>+L=<0*S9SD*IT&"&-2(S:*.&C4824G5K!8HADSCX1*94K\7%Q+)
M#>)?C>@JWK*&#'<&%"K%SB[KCS(69<8.BU;%]/NL)1KC&,Z]E2'P[&%@J*I>
MV,Q6IMRE,L:^0E>DK#1WU+G9^!090\W(/F$7%(,4')OZ>_?#=R5@G'66[+1+
M->XQQ,KX^9Y$CHJ*4<@6#DHW*5,>4*XQT_'BD?Z39OZV^=-4T>U0[)145!$X
M>QI&']<HK/">CAX?FM:L=0N<OEO+T!+X-FN&FMM<IY&D)YUC'!=A7@W4O0L<
MR\6T@IF).]>U.EO7-YF)">R8Y=T>G+NKJN>OL!31ZWCRJ]-=?'T\9M_P+U.8
M3HLC.9UXG)N^X]F;D_K^5I/*+!;(",#D&K0%-N5&2<IU-&M1%6G(*L0G:+5F
MLP5L93;9Q;(NT,;9*2\X_1A^ '#+/Z\H[U7X$L-TC]R=&GS>2J[&8GX98KA&
M0A6-K;*Q5ZPG6ZZ]K]2A,@HOX5XM*RU2-)2$Y"3T*XKTA]./5U9,\E'"6-(@
M23U+]?E$2G?1NX!G(]*NISF6X&CS&*,882RMCVNWX\;3<\XVQ#"GK=,@<ML/
MHI=\_.%:6<5BQR=/DJ9*7&K+_DM:GDO76[*+:H.?%^L.27X2\23:F15'J5B
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M63HG%\P^;4VEN(Y*2R33\:-<QT56_P!I+(U1X1)S,EJ-;MCV">L=(PUJW<]
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M0%X&2ME%XL\L/,U9HH<\_".=.$:_,W]V$C$O*\>!M4"R;(Q<=9$V*S])X@_
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MHIJ9 5"WXOJUKGU6"-LFY-.A'G:["2$E)L*.JC+ ;UZ)'0[R=.!^47W@>,J
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*A!I"#2$&D(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>obln10kproformaimage3.jpg
<TEXT>
begin 644 obln10kproformaimage3.jpg
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MSX<;QGZW[/\ H[))ZD5^$%B5U23DSY2./D;Z1,%L^YA(B9<B=>.0/E#JCH-
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M_P!1W8#]>WWA_'S_ "X3 !H3WY>8@,^9_=8<'YY9->.Z3VPW.(;6_P"2O?\
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MF, &33.90.XB70#KA<R6CVUI3P)OX9QVE50M\"4J;,L<OEXF+#9BYS>9S %
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MA^X%+H-]^_KK0]]0B4%  ,ULN(YEW?@">^,*N<N6LJ+D@DW?+(:#UKN1UM)
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MLF:HK"9:72A^T52@Y$J:+J5*'X<UB4LIGU-Y>PY:<26^4I]M8&:OV2AA16*
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M_KNL(S]?@"/WY%7::YXACTNI95!NLJ9%F38B!@;D55*+@Q003,4AAZC@8 T
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MRCV]MQY+JB4RRE?DR$<%BGQR !1E(-108UZ)0*"YDB.B$*FN4.)4B:N<D%0
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MYIW'QH#TB)?EV //Y!K^[\^$#Z#O[@Y?=KW^/3NS'UZ'QB<L(K]43%[?ZO\
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M9FJE2;*0E(XDHU!#&]A&H3.!EVS])]'RG4FY*"$G%J*M?M"/>@F14>LK1PX
MJ)R*%VFL=)=NH($42Z%4CFO*=*2,)NV2AD0#FY&NA%CI'-6M;E8MH4*L1;,L
M]LNS\B(0U<@74S,-P2 QS&6*)C=QT.]]Q^?[?VAQ(F*"$'P_4"^6?#RAF2DS
M" +N;B]@P<7N6[HV9UJ./+59" 35*+YDV [-8_Q]+LJ>NE3J PF16$ 16 V]
MIG/L!XS\U9QXRY#ZYX3F'UTMO;2-,F2$!(2&["4]G)VON&8)TXQ7*03>.9,9
M55HJ5=":)"V%H)#E.W?,'2+605<)B AI6$;2,8[3, "*WOYC"'C$$TP,P +#
M"2ESF",P;YD@I^,, **L;?U8%X;W0;EAI@203D;FP(?;)4&<.;%E4<1901!_
MC>7Q]--"@0I")P45&-G:14RF,!32(2XR)P$>H5Q ^^M,!XKG2)KNQ,S&5'>5
M:]QURMRAJ9+F=9-E+[2$39,Z4= '+#DDRVL]GC5LXC *LL4A!Z"*'(41  $0
M*80 >_F/;N/EQ=E9P@NUL[]WH%S#29)"F9@+-N9]WK*/<WR'!K!D,'R9UH/R
MI\ '%W1_RSS'^41F=H?SAR/^=4:-.9=OXN5"FUO_ )-Q&^V_^>?_ +?W\02-
M?'-[>LFO%AQU9O37A:133?2&@]/R[!_OV/E^WOSG=P^0^9T=L@V>O X:D.JP
M[AQ!\F#O#,BF7ZOP]QUZ_D'8/7SUPMK6OIK;?PMR)R@S.K9VWCZ.1XVAD13'
ML70=QUO?R^0^HZ^?"VRRY"WT]/S6&-&,-%*&OEL=>?;R_P!H?GVXY]HG-A8C
MB\#X;M<Y?H/@<N9B?1T?OIT7Y  ^FM?/MK7^[SWKN.38[U'P'Z>9._.)U'1@
MCT@4OXF$.X^6Q_#^'XCV3X;H,N).?U.X0W*;4FSLSB4EE 9P$,E[[+O#B!2@
MB0!,5JB8V@%R[,7PTPW\ "936B<1ZF?+II,R=,5AERT.3J=P&8.+(:OK$S9]
M%4;0K)%'3H5-GU$Q,M"$@D!RV(M_2G,DZ!N= ^9[-Y[W8G<3&G%K6H%$R)&Z
M!^E%)JW 2-6B>A .M7I #&_7$/$4[F#?'GTF5-Z1;3>9:G27( +(E G"A)LR
MIF1.YR;N(^FZ>32] >C."44JKYJ!B60,4VJ4FZB+O+DW89. &S;7#.V!5X[5
M.0"I(%V5-/L4A"%'0=@^'8ZV81[CW$3#QZ+34,FD0)4B3+E)2+!" DEAF38D
M[U$Y]\>1U^TZRNG*G553-GK4Y/6+4H!\PE)+) >P2 &9M#"#3<&6DY!PLH4I
M 5$J*)>Q=&$QCJ=@ P@ F A!\A #:'BUI2M<]3J)2!A2!DXL?F1?P>*RKPB2
MHLZF#'>_&^65W MD,F#5U&9W7NIWR:2[DGC 4X%^$J8](]S  %%81!,!$0[;
M$ \]:2D6$J:P?Y:#G8<#W1B:U*B2L(<I*A9R#8!QGK=LVR.YYM*JX=Q)':9
M8N4>H059.#,7"J:90\-10454S@8_Q")1$Y3 4#G+TF .+U<J5,1VD##A!R +
M&[%FX<7R:*?[R92B4K(+.&OQL'X@V-WW/$!:VVU1S]RD+I"139J^%_IZ3-0
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MBKDKQ/A((8@6.2SD>+<(4$E['3G%@Q\6.?XEM)0[D)"724:K' !'L);)6()
MIA\]>\"7?]/AH3I+$$J%S9C;X\O'F7135 +C H78X[<._D_RA>3OLZ.=RKIB
M=YA*5DD2"( K7;+2K&90I?Z16D/9'CX -_1*HU(<?4H#V QH8$*YN"&[_6G<
MG5U(<%%Q[JP?)W.EARA(6/&F5\5O6K/)F/;I0EWHJ R+;*Y+P9'X(B *C'KR
M#5!"0(F)@ZU&:BY"]0")NX<= !1LQ>W[_,1P9LR6.V%)YN'TU'=KX1-:Z)U4
MR@8.H!T'J/<-CZ:[^7R'YZ[\-S)8L</#?P'C=M^<2I54X?%=K#OYVX[@\3]E
M&]2@&Z1T(@'GZ".M#W_#U'L&AUQ%5*7< /D;C+SM;AYQ(%3B/M :9M?D#:S-
MOB8-8W10$"AW^H#K_:/\?H <,F2D,XRUO<#O_7?#HJ$G@S7WY."6LX8MN&L0
MC(D>(-XH>G0^*Z]//X$-^OIZ?CZ^C9E^Z,NX^8O<97YQ(2L'(Y^FNWEQA8D9
M:UL/W?7Z_7OY\=A!N]G  NY#=['PW/'49!%B!P ?D/IV[_L#\QWH?SXY4D L
MPM<&X/Q;>\.I+W?<#EW<>.[SCME8AZEW\A[#Z>7_ !]/IP@+'>V3\F<,7?G'
M7<[^-[M=K>FCD%B :T&M^?X]O0 _(/0>&U@YC7-NYN/QA8N?R^22MIJ;S'3M
MZZ2D:]*.YNF+)D?K"T4GXU9C)IJJQZ+ETRCVBS1"0.LFD9--1=P3X#N@$:#;
M$G N74D>VG L !G3<$W%R,R+G#K%E0S%=H=EDA(4Y&(R\04,(+!2@H%*03_4
M-P$:OLDX\A&EAL;BQ6J89/5'SE9,WW-D3(3/2KT 9O)S<U&.W;A80\50YV)2
M]8F,;H+V+.IYI,I EH0<( 8+#IX$)269["VX:QW42SUI5,44!9)+I)/=VF6<
MC96%W[\;C>+:)N%_<"K+I$5-X;E9 $53E#N7K3*=8"&UH3%*J<"B/8Y_UA)Y
M4PQEK9 V?RW[A8;H>H@"MDC<Q4 %-RNUQ>^?"\7WPW5'DB]9) 02F=NFZ1E#
MAI-(AU"%.JH<>Q$TRFZE##V  \]ZXH:R;A20 YN6Y\-3N;>T:1 Q8=P9]!ED
M38;]6R>QA;\P-8D(?+EO& 1ASU6W7^PSD)_I10?.5'+U8WB':BD HM(\AEE5
MC$.<7I3%+U@)_P#1W:28%R$!>+K42PE>>%(!+,1F38 EL*FT$1\*Y>$,C"I0
M.$J[15AN2&LD .6OR,6EPNE(?=2NC*B8K66GU' ( <PD!JO,D9K'$I@+I15C
M[NFJ&@$2IE*;NF'$*HQ)GE(-@$EM 6#][O\ H,IJ@A<I2\(QX5I%@2S**;[F
M;5@YUSJ9>ZF[K5ML<&\0\!>.EGJ(I"7IT3QSG1Z?F4R1B&*(=C (" ]]\7<N
M9BEI)N"!Y6._416##F+XF4[EG4'YLY\H]G_(F'3A")#Y-JX'Y5&!#C2T?\L\
MQ_E&ZT8W:'\_N/\ G5&DCF*1Z\F@;_YOQ0?DJ^'_ &>GE^(\03\_0X;[;BXW
MV.;;A<FWU'ZY:Q!(=IV*80[=A\OR_8/;]@<( _!K#2P(?+><R(Y!L3J2<_#7
MA=[6OG#/B6G<G;OV_P"/U]/+OH/V<+^PT[O&VD=0S(=E^KV^6NW;\A_?^&^$
M5H!KGO8<>7E"C?NY_*&3%LM](].P\@#RV/;OKZ_PX7(<HX?^KN2.>[GXM#%C
M& :+V^7;OW_9KO\ Y\N#7+O@]D;R=./#EZTAI5JN.I5XV8-$NM9PH!0[:*4
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M^$!0S4.]B0X?=PSX&SB<I))-4UV#AR*BY0$"E20%$IM!L $J8&*(&'0  !W
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MW[LLX2-[RDF+4Z"ZPO8.P9DNMEHI5)GTU+URF7/2D=8B:J64$JP*'X:C9V(
M)T"2OM!Z=T\W8]1-VLE5%M':0I4)5+I)A5]WJ*674)F(EH"Y0PU4L +PE258
MTI*645*2[<P/,A;;'EZ8?P4G,W&X$CIN1<_<V$B26 ]:DIS1V,N=-O%L @:Q
M)/#.EB)1YU&JK=)=1T;P0U$FDV)L^7(I%2IB52Z94](EJJS-5)$V3))2JG4,
M:^MJ): E/:.(*;"YCQ[:&WNG/2*HK-J(JZ>:)^TTT<Q=2C8Z)$NI525=6A"D
M5R"F5*-)LZHFF8L"23*4G$5D(.>7=7Z"4G:;.0U:/:H.^&J4A%EIE#E#ISC#
M[3BWC!)5C"N&C]8LBV4;I.6BS@%Q$/=G"B2P">WDT.S9TREJ9$VL33SMGKJ$
MK&T=IRSU9F2%)5>I"TIPJ<I+9#$ 4@QA-H=(^DM)1[3V?5TFPYVT*/I'3[+F
MR%]&>C%4]4B1M"6N4#+V8J7.5UTO F<A2R0_5S,*UA3"8TW(]7LM-F;;CBKQ
ML8&386I.'XUZN-74=8&UJEX99DLC"JH/&#PLC4+4V8KN&R39VXKLI[H=T1DO
MIJL30SJ#:$NEVEM!:QLVHJ$RS6U*T3)*J9$Q*VJ.L2I.&?)*@%%24S4 LXB5
ML*IZ0T/2#H_4;5Z,='Y-.KI3L_9<R>G8NRZ:;(K$[4FTTR7AV>J1,DSDSZ"O
M1)6N6)<Q='.ZLS!*+;%LBL@,A'!K>EG(CH!WL"(Z\_\ /IQ\U+L5:.,LQ\V(
MMDU^\#]0*>Y07LSMEY7<>)(WWA,G9"4V^D1 1\^_F&_S[ &_7Y^O%<O,BSBQ
MW9;],RWU81?2LNX?/?Y:1S)1IQ_H:#?F/?0:WY#Y?/\ R''.INY:X Y6UY6W
MZWA[XQWBQWZOJ.O3Z?\ 1Z1^?^_A6=VS.=@X?1W?RRTO"L3E'V+(0\BAL.WE
M\OGVWOU_SV0@>\>6=]=WUSAT!0%@E\N[NWQ)(:@6BQ+((1$'(/E%SE32!!JJ
M?K.<0 H%T78[V&NGJ^G#"YLI%BL/DUG\ 3#J94P]HI2D"Y4HA( &O:R'&\7I
MQ;RE6/'+%SE/([QK7!B8F0<0<:Y621<K2BK,Z38%BJ"4Q/!%8%/##].8_204
MRAU"&?K]I&HGB@D(*@05U$W26A(=()#@+6KV4W-B3I%G3IDBG54DF8N9-13T
M\M*2TTJ(,U:=5(EH!"E!@,3:QK]R=29[,EEDERJ-S-6B@E5EEU-=90'PR@(F
M\_U-EW_1\^$DX:9%G4278Y\#W\N(B\7+$U*$%*4)2 Q X D 96UOGSB[MPY9
M(&U<IF.;L$ZW3EJV1BHL_<(IJ( JP<&CG0* JDLF<H  ;!4IB"!.XZXAKK)B
M*K"6P+.!K^TP(;<-^6FD;%&SI$_89PA2I]++15%20"DRPOJUA@7!2+N+PD,=
M86?1P(!!62O.SI@!FZK>P0J2I3"76CI.WJ7ZY3"11%4@E.4PIJ$,!A 2>O$E
M06@85)N<\[<Q=MV;B* +3*8E*PQ_V:F8;V!WMD7Y1.(GE=:0\L:>2I=/C7:S
MDD@Y=M'C1=-=Z@8QTW)&"$HX9-3%4.98J;=H=$51ZRHDT&HBYDQ2 @S9F !@
MDER$_P"(I?+4%VL\.2JJE"E*1+!6;OU:TIQ&]P2'+Z$,.(S>,O'<O=T:!&9B
MBEXN991S=BUM-,11CIY$6J((( ]:&(G#R35NFFB0@*M4W)DDRIE=I@!=-RJB
M;)!ZD (#DI-P;OKD<[N2Y\6)E%5J49LF:)AF**E(G=I*26UNM-WL"!PM&[SD
MV;LFF,'#6-<*NHYM(,&\>Z63*DLY9(UZ(3:N%4B'4(FJL@5-11,ASE(<PE*<
MP  CZ'0'%(269P@MN="2W='GVT@14$*L1B!#O<+4#?6^L:*N9:]9$K.0RMZI
M%U1Y'EK\:N8TS"(OW:KE19[XJ9G*FS B0J:?AI@)0*(F'OU=LKM/[]U_^C3U
M2D=6FR3_ %.7+-D;#SCUKHBGH\K9Q&U=FR:N>JIG?B3'Q"6$R\";*!9)Q7 U
MYPJJ+S+U!Q*HUO,52)2G[I8$&MIJQ5 C2G/V*J^B72BB1T^O^<%JHB<"]R!Z
M<4ZMN;1V<0JKEFJDN<;)2F:E(S*,+!1=B0=+"[1L%_9[T:Z1RE?P69_"ZT)>
M6@S%S*:8MO86E=Y;_P!)?#?*SB[#>NJM&S678NVLY7I I3QM@BC^\1SHAP 2
ME,8 $[9P!1 3MUP(H4=Z Y0ZN-10[1HMIR4S:2<E8(&)+@+03HI.8(L2XLVX
MQXWMWHWM?HW63*/:M*N0M#X9F$F5-!/94A;,<68(-Q<6,3F'2_5+Y[Z1[_AH
M/W!]0'Z<6*4 XFOA#"_'YL/5XH%.XTT[F^;"\6 H=83?)K34PK]G5J*#Q9*1
M5_1@<" )@9M>K0*.E@V4 +V2*(*J"   &B5E5)HI"YTZ8$I2";YE5V2 6OH-
M.X&+#9NS:O:M7)I*24N;-FK"0$@ZD.2=PU.F69 BCW-KS*$MLF6D598&<)')
MF;="!_T#./;CTG,(@.C*&  ^(P[574* F#K$>/-%3:KI#M,)90DXNP,\,L?U
MEK"WLY.6)ME]2;%V/0= >C\VIG836+0#.6/:7-4 $R4$'V7S8Y O87U86F?5
MG'_@-]D8-Q\)$._Q@F(AU"/D;8;-U#OJ$PG'N/'L&RMG)II$J4A(2$H2!_A
M%]]\R]^,>&;>VRNLJJBKGS'F35*4-6<V;0) LD: /"\7='7.**0 *0GT@B!=
M^*<FR@JH;6^@!V(%V #VT CWXTLN4$@ "^3%P^6G,MP\CA:BH*E%9/$W!PBP
MS?/,=_*&54JRY<NVWP^-(.A(F@@4-=!1\REUOI(0FS*'$-%(!C&'S'B:A#6
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MTTO:*98:^$:ZJ _3NWZMS@D3II [)G36&C!2@._U:%!<HR2207(D50 ,0P*
M&P*8O8X%.'D8 , " #L , #V$.%0A)4"6[/B#FX8WUOOTALJ[.6;@,1N'AGE
M%3[FSBF\7$N&+Z5<6A:2F&\Y#JQY2L&;)$(\\(\CY!)8YW:C\5Y!)VU402.U
M.Q2.0ZI'103FC"SC,ON"6YOFY-F#-F26$,E>-0*4]6 "E042I2U%6,% 38)
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MD)*'!-TGT"FD\4(HD=4K990BAD2@8GZ-15$X)G -*D JB8F(8HC63ZH*2L(
M.%KWNV=\[9'5ASC0TU%@ZI2L3NY2X+%FSS</H]AQ(AXT":M-I2/!(1:1&;A6
M/<I. 9)%<%210737<&>*%%T5N'CCX+<%2H/'(%/X9Q(4Y:\U4PXFEN,*< *6
MQ,DXBY8%G&[X$VDND1UDL!>:UE?;=A;" !P+G@7U C:9R_TE1BPAUDF J2*J
MB,=7VJA.I8BS@XI%4 @AOKZC>*H8="/P@(AKOCMLURJ2E[(QU-1,,FEENZC,
MF'"" /=S)=K).Z/3NC>S94V<N?.:5L_9\DU=;-5[/5RDE8239S,9@#?,D:1L
MXR 9M2ZU5L9,52F5BVR<K8U"_P#QB8>)@II02B F%+K.;1M_SA?EVKZB2BAH
MZ;9Z?;EI$VH5[T^8,2MVI.]M>&/I:Q>V]L;3V_-#)JYQD4$LC^50TZL$O"-
ML@/P2#"9>SB;9'IZMF /+T\@WKO_ +M?/?%*99*E%M2?$W8V=_#Q:-I(K$2D
M)!.@MJ>6Y^>FD+UE+"_GN@1WI%4WF(]P41#^ ^?%]L%&"M9F_ F7.9[2-.[?
MEH(QO3BK-1LH)OA%9*-[NTJ>,^_=Y1NSX]*CPJ#@@BD/,RHHE?:H=(PD.%;5
MT8O80V\DP'O]0$0'Z;X*=(57R$D @RYS@W%I4U7D0#W1&VI,7*V+6KEJ*%B9
M2LI)8AZF2#<;P2(1"AWSIPS;-UE!5711 A06\,!4/U=Q.8Y2%[ &S&,';BXP
M21UBE(0P5JA)8,G1LHR2YU5,53(ESI@7-D2RPF%(*U8B225,.9T:*F\_45*E
MY(N;)8SLA3M<!Y'=] /1.L*05%R\*L0$Q-TE%%=(Q#'$G6;J2*(J$.4)5 J1
M]_HQ@!"JB6@'J@V+'A(+@;B,C:]PT4_2.37C8&VU?>#BE;+J9[BH6I>#[OUN
M( $D# H,5805$BY##P90$<-B<T.$7F&L42:=!&*S$PNN2,C0?6%PU&0DE4DU
MUR,6151<.CIHK*%;I'\-,YM%'TB61*^_S4R2M4H(4$2PDK64R,6! + J61A2
M"0,1%QG'R_7(FUDKH]2S*Q-.*J9.D*J:F9,%/3B=M&9*,^>4A:^JEA6*84H4
MH(22E)+"'!)X/>Q+'(TB6PQCUOCRL5.P.!0:O07DG=B?T2/E*Z**I2_9LW2G
M-[CV=N:.C&4BI5N:,,0RJOBI+)VE+4:-)E+0NLGU$I(4M#2Q(14J1-Q!PN74
M"G5U"D_S$JQBP8P*OHG4RD;<GBOD3I>Q-G[/KE]5+G8YTRMG;,E3Z(H4 9%5
MLQ6TY:-H(FEY$]'4*[:P4[\?^Q^FS=[;.9=!PH=)'[D8,6.JF4#] )!DXXF,
M)A*1-,!*'B*&'1"B(Z,;139SI,M294I6?^F5; [U"G&E\W+<-!'K'V72TSJR
MJEK4I*?X%L994@ D!"*U1)<@ 6 )4^$78LT>F4(QLS&,=-%E%DU7A$Q.J11$
M3"(@HF9-$Z)/@%/I$5 65 PFT&@#8X[K%+$U"DA*@A5@01[(U!.1)T$>S&E3
M)71S)4Q2TKJ$)*EH*">WB20@H PE*7*@M0)L&8OY.^9'&..[;SA\P4W?&-R*
MG)9TG:RUEXA\R2KI7$12Z!-MH^4!5@4&"CY-_)1Q5'EAB',U*2U995I)?W*S
MO([T_9VT:VEV91(HETKHV<F>J5-EK5.(7.JI;R\*G7A4E"V1*FB7*E3U3E(*
MI"5_)72CHUL/:O2G;U1MN3M1**CI&K9\NJI9\E%&@R:'8]1U=1BE-)ZR5/GR
M4KG5=,JHJ:BAET:9@D[07)K.W@Z9#9;?4QN^@'M!89ZBZZ#V5L:[&KN*N65=
M-%%).V1HR+MA"_9G6$A.,#2#IBS*L^;F=JHD,ILJ2IJ9U-(J%B<FK5L6HF%*
M)(5.Z\JE%/5R5X J85]I$M00E9(2<+L/"MJ['V91;1K]F2YM'-V,GI[LFF$V
MHK9DJA5L\(VBF9]XKY/6S)-,)1*9U5*ZV9*EA<Q!F*2"7@YFL2NI^EL:73:_
M6)Q+-5,9-/L>P2MD>'K\,@V^UI5_(K66SPGNMLFIR-5B8^)E)((?[M/V:D@Y
M.91V]6:G: HMH+JJF;/E'8M<I?62D20)TQ*^J0E DR9F.1*EK$Q4Q".LZQ)"
M1D.::9T95M[H]3[(V50T%:CIUL"5(^[5E17SYE!3*DBJJ9U0JNKZ3J:^KJ:=
M5-(IZB=]V-)/E&=,.):]H%\(/NT8.NPJ.=]O/X4>P^7UUW[Z^O'S:I@"-[AQ
MQW_&WZ1^J4I))3Q:S=^?UWPN$F_6(#K\?3S^?U[^?;L'KQ&-R ':[GY/O'E8
MM%S*8)<YC+3?I^]HRS=F/^0[^7D !Y_[_/TX5N_GPAP8E:D#Z^#Q:7 =;B8-
M*7RO86*+Y&K.$(^K1SPA#M'EL<)"X3?.D3@(.6\$T '@-Q#I.^<QQE041*JF
M>MVE.PI1(2>U,&)8UZMRD \%$7.X-JXE4\A2U84$A2G=89T( [2D_P!XXL*3
MI=3N #@\K9;F991^^DGRJ[AR*ICF%39C&4ZNH1,/?U'7D <5\N2I9  *GS'+
MAEW6.5R8NY<J122@$ ##E8 O:[FY)-W?F[7H1.W)\]=F01.)2BIKI*/?S]3?
MK&^HB/R[:#BT31!KY]^GI]=XB)-K%*4^>0N0V6F?JT7?Y:& EAWLLZ^(R:)S
MAU!OL!.WF'GY_GQ2ULO#,PZ@L]_W\=-^L^2I2J?"'[2M&[(.]]-&\MT/RE=#
MNY4S4IS 5!<Y2>'H!-U#T '<HAW'0!V\^P:X83(<.L.&=BXNSB_>-?TLY4P2
M@$H9V <>'+7=IQBQW,)9"XKY>,4539DG-@C&3IRGU?I!!0OV@\,?L4?B6\,A
MA\Q X@(:[\4DJ1]XKTJ_I1+F3@#IB694MV/N@G+2VZ/1*^<G9G1Z;)%IL^=2
M4"O_ "9*:JJW%NN4$J<,,3;B:7TK($<JN@4QM%*8!4V( '<_5H1'N/?OO0=N
M)ZY)2<G#CQXG>,L]^EXQR)J5L1[37'QU!TL<HN+2YZ%E'$<!E$SE.Y3*)=@(
M 8P=)=]M!W'0;[]] 'GQ$J+RP/ZG! M>^@[SP> RE@3%IN#+5>S@M\V(\VTB
MTV6:JV?4-I*I(E!6*+_HYB% #%2*8QE$P#0!T*$,)M=@ZB%$?B =QYJ24*)
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MMZ /[?3AO%@*A@%B2&'Y<O/(CG$I"U(]E36 /DUN+:WTRC$ P7<Z 5E!2)U
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M+4HV;6Y9RWE&TWEMJK2*CY/+UA0 L'54#H5ILJ %"0F3EZ4SIE,&ATH) *8
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M;*%W'WJ7N_V<Z-]''HD>-P<$$4?YG/\ R[JW_JVIO]KZ2#CJF_UA(_W<Y_\
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M(8=CY>?4 >0B&N_KY<([!CN+;C?CRMPR=Q!$X^\C(6I$# 8'"A 3'X?U1,
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M?QZJ*EH'?JP<&^O\\V#_ #_=Q/V.&KE?[A0\T:[N')S%5TG_ -5#_P"*E_\
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M ]YNX\XS#V<?.DR@NZ.).RA@.?H3 Q@V&P "% 0W\?PAO]7N&PXK:F;@26+
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M\A]#I$B;,5]^FA/L&12JL6 49"!H-PN=PYQKLL\(BDJL)B@ F$PE[!ZF[=@
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M"D9/SV(*[#RXJE$!_P"KEF=$@'>26'$N':.ZJ?U4LE/\PG!+ T4K)O\ #[1
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M%#M(EH20<W  /SSW12]8%+6L9*42#P#W^D6,R<]-C#EKDW*!Q;SF5)-"IL#
M/0L2N,0._G%DQ_6Z7()H,U.GLHUDB ;MQ'I*<3JB2%!TI>I7;262F4G<,2\2
MB-R0SQ4U,\S*@@%TTZ0^1_&FLS9>P@\64#:-I7)7_P#!,'_TB*__ ,:AN/0:
M/^6>8_RB,/M'^?W*_P ZHK2TE6\?2YLRC<5WL$5X_2;F$2@)UP1:B93N/Z-
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M/W,0=#V Q1\OD''! &1+:Z[]UN'?#F(-< MENOG;URB+FEBI*&3=I&24*/Q
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M4R8@591NB/NS<3!\/O+Q04VC83?T/'63Z@ 1#?HT3@+J(OQOX9Z;N^'<)6"
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M*CQ/P&0[H_)^KUZTLSL;!#L95N<HE '2!3*H]0:$[9R7I<M50W\*S95)4O\
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ML_'@S?..6^G%M/"S/?/+*)4R8E#IT0 \O\]_\CY?/A02SFX>P'[VXOXQUO\
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M!:8?]Y-.+5\6=S&5OJ44,3(LG"+AM*/$TS>\- !84FBJY2K'6:ZT"8M^LPF
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ME&V7"E16IN/(6.=H^[R#WQ9B00$O09%>0Z#(MSDULBK9@FS;+$']59)0 T
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M & &@/62>[_M/7?:.O,&9W<E AX!9<A?U05L-;$Q?P$9@ #]GY\<_P 6H?\
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M@DJDW.0""BJ@Y:(J&]W'J$ * D, CTB8P\ V7/(4B;(,PXW1.$R4"$M[)!F
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M(]U/Y1](,:_>5^8_6,JSC8^.(*<>P9,$S:$Q&;5!J0VO+94"$*.O38<* !D
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M,2)"0Y@_5'?FO63<NI+\5AO%H.KDBYG@C<):L1X 'YQ\L<>V.TRC*?RI)L)
MD<L#J(I<*14M;8.2[\-U('<?II=VF Z JX&13-XA 56;*F0X!+4HA4T@M[*$
M^R.)>Y/EW6@,U* 4R4E+V,Q1[9&H#62#PO#JX>B/!P00<$$'!!!P00<$$'!!
M!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!
M!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!
M!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!
M!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!
M!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!!P00<$$'!!
M!P00<$$'!!!P00<$$'!!!P01!LCQ^2I.HR3+$5LHU(OJJC 8BR9'Q[/Y3J+%
M%-^W4DR25)K.3L.S,JH[C"NVC!5KD"'+'/UV\BX1E&[56+>$$:?J3SJ\WS/
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M5D/',ICS!=6Y<;C,%IF+[(ODK&%'N=EO-/45C)NK+5^H72MR]WO*47.0<.K
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MQ!"7JSY PE+2S&XS*SJVPU:QK=9IO9ZRQL6))I. ?1<%DF2L""L.0A2DC=8
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MM\LT>VSER+UCD6EW;5A%*+P=/K#;,;9O>8XBQ?#7LCHN8Y,RS%S_ -ZR##L
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M2YZ.M9(F7GX>:=*9 R'<G\/8H2:EX&9K#R#>5^6E8,\?(N2!0;#Q2_\ S$?
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M)^#(RZ2^4J#4UFUI<W4LM6V6-<CG;3%DI-=IEH/1+,G3[18#,T?>2!BS\'/
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MSS#D9A58H,;X4L-JHT?DJ(JN299]9&4\UFB4>:KUCGE:Q6K1!5",LL ZN$U
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M8KO8^8?.^&<:4S#&)Q83;ESAEDTFI>O2Z]HR8[KJCF'@U'+IUDF;L% J,Z=
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&!!P01__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>obln10kproformaimage4.jpg
<TEXT>
begin 644 obln10kproformaimage4.jpg
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MM"8T-4-SH0HE)SERM_ V155B97B%L\7_Q  < 0$  04! 0
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M/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93
M\!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A
M[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6X
MY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^
M[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>
M93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R
M"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$G
MP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9
M$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9
M/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93
M\!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A
M[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6X
MY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^
M[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>
M93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R
M"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$G
MP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9
M$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9
M/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93 \!R"=A[$GP6XY^9$9^[*9/B>93
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MFT:E.+W&3-+OD%CLS:IE#GC'&[IE6*OTPDC,,229O>$S:O2R9=B4YJQR_/K
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M:T-:QQ;TZQ(@<%2!(H6HDKB784X)DBHTJ\],G7%%V%K"23+"U1=EEA]M]MH
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M\XTRXAV[3O*^Y="(7>E1(;HA%[D3:Y6/+<CN8&H4J!X*  *=42<4@DI7(L
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M:UGN:;EC>HHB:UGN:;EC>HHB:UGN:;EC>HHBH"JX0<(M.%NL.$(&F#<%O?$
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M"2K.%:2E1(R+$UZES=W1880VLS.WDJ7-X=%21M;4JE8I))ORZ&AJ[E5P4-#
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MK0=A_81U$>S9(5D).I3JR2U*0\E4G.M"\E0G-L.)-L'N7EFEW7%WVCWKK;A
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MT)<1AL&2,U^SZ+W/]VK*K1^I=NI[DUUPMA<=S8[A2Q"L@;G_ )Q13!H(+IL
MD?19LAL3RJ!MM/*:WKM!<POURID>K;A'5P;$#BA3WJM0_P#>(KE1(]H;3+@$
M!K,H=)+173"D%0ZDK]F;;<HI+?7@GN;3538W3?UZ<S1GN>5AUVCEWH835&G;
M5T&W%QMTL=?0$#O=44QD;#_4J!#(.]@6]>&KW<CG5_FM;Y:)3AK.^G3\ZO\
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M)Q)^]W\D3T*(G$G[W?R1'0HB@D'7 -MRJZZVX!"ZT22! 0$-0@(#9J$!#M"
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MK(S3U],3C;+3N.3&<C5GB,E/)D:DKEG"M$MNE$2B)1$HB4100 0$! ! 0$!
M0U@(#VA 0'M" AW0H0""",@["#M!!W@A <;1L(V@CN6,Y+BJ-R)24K+*+9#K
M;3 4WM"% FN777C:-IBRZT@+CS"M5P%W7C<-H&7AK[=<E==#;3=)63-8VWR
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MG "_UE$=6]V2MHV-SK5UNS=[?@;Y'&F8VO@8=_YU"&MW%_>=Z!IA:*_K,R2
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M/AA3^)@W]EH]HQ%C_JMT_P#M=349^.>.5^;L71TZVX%CA,7&ZZT0X2^<RTX
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M76WW:$S4%3'4-8[4E8W6;- _:#'44\C63T\H(.8YHV.V9QC:LG^W/ F\IO\
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MCPVC@N$^6?4\,]YBQYA.!3G2-ALI5XPQ"^8%D,[>\9OU\JEL0R-',*EY+R&
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MQJ5WIB;E<C5NSJ=];?9]]GM+HQ2"KKF1U-WJHQV\A;K,@8X ^SPAPR& _J)
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MKT$8;_)#BK]&\&_=AKJP=Y\S\U?&X>0^2R14*4HB41*(L:9E_)1D3_=!]_Y
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M].7$8V>WL&<[0$]F5#8[^)F'&&=L&7%ZK#W*=8O>7R'EGA_I+0GV,+Y_#2R
MU776JG!Y;[!*#C#+2=?!"?P76U./N:Z6&_9VMBH+K#!6%O=F@NHMU:7'8-6.
M&0Y. 3O4_BFE@_PI;[Q:,;'25EOEFI0>_P#NVW^VTH;X.?*S9M("SCC_ #3B
M'*Z<%.,\GP*>6#9QEY<4E;(^*DX:M=UJM$WK3UB(VP/](2K().+[AEEHUHKA
M9+Q:7:MSM=PH#G -723P,=X%CY&-8\'N<QS@>XE;>BNMLN3=:@N%'6#&2*:I
MBE<W^LQCR]A'>'-!'>%DVM6L]*(E$2B)1$HB41*(O-?60L=>@C#?Y(<5?HW@
MW[L-=6#O/F?FKXW#R'R62*A2E$7%72NP_D',^+,EPJ,I\*S5ODN,7UC8,69X
MQPWS''*_*@JB'" SJ7K'(B2)E3!!GM*W2$8K=!'4QT<6A(8G=FI3Q*I,4@X(
M.W8>[^7^]=?>D-ZG1E*7XZT<L"X<9<4(L3:,V/EF(,;/$YR#) DS(M<HWA<J
M.:4R!C08L=$3;FW#CQ!)\AB34CD-RE_+G:Y_+R!#S7-S9BRJ#AM)SD[2 !@[
M]F_<?+9C<5VD9X;G19C67*$,@5M"5#&'\UQ;TZ%J5%/9(H[;K4RD]>C4JD=E
MEA1Q8&-QJ4X04WW7&#<62-DMWC9WA6W;CY%9<X@_?#N23=34*?C\NBO$G;V;
MR:?J:*,<3Z=%.(/WP[DDW4T4J\2=O9O)I^IHHQQ/IT4X@_?#N23=313\?[/K
MBKQ)V]F\FGZFBC'$^G13B#]\.Y)-U-%/Q_L^N*O$G;V;R:?J:*,<3Z=%.(/W
MP[DDW4T4_'^SZXJ\2=O9O)I^IHHQQ/IT4X@_?#N23=313\?[/KBKQ)V]F\FG
MZFBC'$^G13B#]\.Y)-U-%/Q_L^N*O$G;V;R:?J:*,<3Z=%.(/WP[DDW4T4_'
M^SZXJ\2=O9O)I^IHHQQ/IT4X@_?#N33=31/B?3HKQ)V]F\FGZFB8XGTZ*<0?
MOAW)INIHGQ/IT5XD[>S>33]31,<3Z=%.(/WP[DTW4T3XGTZ*\2?OAO)I^IHF
M.)].BG$'[X=R:;J:*?C\NBO$G[X;R:?J:*,<3Z=%.(/WP[DTW4T4_'Y=%>)/
MWPWDT_4T48XGTZ*<0?OAW)INIHI^/RZ*\2?OAO)I^IHHQQ/IT4X@_?#N33=3
M13\?ET5XD_?#>33]311CB?3HIQ!^^'<FFZFBGX_+HKQ)^^&\FGZFBC'$^G13
MB#]\.Y--U-%/Q^717B3]\-Y-/U-%&.)].BG$'[X=R:;J:*?C\NBO$G[X;R:?
MJ:*,<3Z=%.(/WP[DTW4T4_%7B3]\-Y-/U-%&.)].BG$'[X</[--]A-$QQ/IT
M5XD_?#>33]31,<3Z=%.(/WPX?V:;[":)CB?3HKQ)^^&\FGZFB8XGTZ*<2?OA
MP_LTWV$A1,<3Z=%>)/WPT/V:;[2:)\2>7\@IQ)^^'#^S3?82%$QQ/IT5XD_?
M#0_9IOM)HGQ)Y?R"G$G[X</[--]A(43'$^G17B3]\-#]FF^TFB?$GE_(*<2?
MOAP_LTWV$A1,<3Z=%>)/WPT/V:;[2:)\2>7\@IQ)^^'#^S3?82%$QQ/IT5XD
M_?#0_9IOM)HGQ)Y?R"G$G[X</[--]A(43'$^G17B3]\-#]FF^TFB?$^G13B3
M]\.']FF^PD*)\3Z=%>)/WPT/V:;[2:)CB?3HIQ)^^'#^S3?82%$^)].BP=D'
M1@P)E-0*Z>XI@L@=Q,XVR1F1=G0RL@W6(@:DEC6D121&:%P\,#$CH3>!@6WA
M=P[;;@WMNTGTBM+1';[S<::$#'LPJ9)*1PW8?1RF2E>,;"'Q.!&S&-BU%;H_
M9;B=>MME'/)O$Y@C94-.<Y;4Q-9.TYVY;(-NW>L;EZ)CG$Q$W#NDEI"8T KM
M(6%UF"/,4)2%]OVM;'LQ-<S<"4G> EKD35<6 B)1I=XA?;M/Q;'5>[>M&]';
MIG]=1%1.LU<X_P!(U-EEH8W/\734TV=F00,+ _#;Z;;:KY>K?C 9#)5-NE(T
M;!J]A=65;PW P!'/'C;C!VK2K[M.7'R54L+.P3I"M+:G.4;(F2RK!F0'0LDJ
MXSB$MEI>6H>N<S.#P"2@MCR8\S5: DC> !4QN@MR>QA-_P!&Y97-;KN-'?K=
M"7'&LXG[IK61C>XYJ'-&?U84/.EU$USA]S7R*-CG!H%59ZV3 )PT 7.E?(=@
M&R!I/<,[,">I[:9><]*M_P O-.5L;-\+0P4]O]:G=B9GMI3(URM8M3*H<_62
M%2X7*Y"C)3V*[SD@MUY192@%C6GX])70?:+H38M$Z>SRVFZS5LE>V3MH:B:F
MF<]C&,<VMIS31Q!E.\NU U_:AQ+3'*[5>M-H5I3=M(YKE'<:".E91EG9RP13
M1!KGN<TTLXG?)K3-#=;+>S( <'QC+5V?\2?OAH?LTWVDUY8O0,<3Z=%.)/WP
MX?V:;["0HGQ/IT7Z HX!M$51MP ("-HED %P /;M$0* 0 >X(@(#X! :)CB?
M3HM112E$7FOK(6.O01AO\D.*OT;P;]V&NK!WGS/S5\;AY#Y+)%0I2B+9N0)]
M',8Q)UF\M%^MC[+L.WW1F'R^>/0>N#BD:TPI(K!&*22ESM!6M(VFYL9E8(4O
M'N"X4[>E5*B2+$!&EQ@!9%\'3)LFKB^1W213I%N%ED<@.1Y(IFK8M2-Z\EYL
M:F*(N+NPL):%U;EJU^E"!D9FY(L(4N"Y*3>%]%.#M'AO^"R-F7\E&1/]T'W_
M ) ZI&\>8^:I.X^1^2R74*4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+S7UD+'7H(PW^2'%7
MZ-X-^[#75@[SYGYJ^-P\A\EDBH4I1%@C-V!FO-$:FK0$XR3 'R98PE>)OPGA
M4ZE2 IACLT),2/;NU08QY,QN?-R$AZ@M@G#O$7*3QPR\N]J<B"B@3W$SU6",
MT:"<5S(S0"&*)NJB./L5R."..+X]',>XR_"#%$=@;;"D2.-8ER*X1A7-\>J'
M$V&A:ME+0[7O]C,^NL?2J"$!#,+64YW\=^TC._?@CQ^7'/,"6P>.SA*6ADA+
MHJ16$JT]Z-!))(PI59"ZTFQ22XIV!V;"G,F^TBRVTMQL56$VW' 3:6"@\#)!
MQ_N"I(!W_P U\/L31'>9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<I>F5,GAR'
M1,#CS/5.Q-$=YG7TJY2],J9/#D.B8''F>J=B:([S.OI5REZ94R>'(=$P./,]
M4[$T1WF=?2KE+TRID\.0Z)@<>9ZIV)HCO,Z^E7*7IE3)X<AT3 X\SU3L31'>
M9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<I>F5,GAR'1,#CS/5.Q-$=YG7TJY2
M],J9/#D.B8''F>J=B:([S.OI5REZ94R>'(=$P./,]4[$T1WF=?2KE+TRID\.
M0Z)@<>9ZIV)HCO,Z^E7*7IE3)X<AT3 X\SU3L31'>9U]*N4O3*F3PY#HF!QY
MGJG8FB.\SKZ5<I>F5,GAR'1,#CS/5.Q-$=YG7TJY2],J9/#D.B8''F>J=B:(
M[S.OI5REZ94R>'(=$P./,]4[$T1WF=?2KE+TRID\.0Z)@<>9ZIV)HCO,Z^E7
M*7IE3)X<AT3 X\SU3L31'>9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<I>F5,G
MAR'1,#CS/5.Q-$=YG7TJY2],J9/#D.B8''F>J=B:([S.OI5REZ94R>'(=$P.
M/,]4[$T1WF=?2KE+TRID\.0Z)@<>9ZIV)HCO,Z^E7*7IE3)X<AT3 X\SU3L3
M1'>9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<I>F5,GAR'1,#CS/5.Q-$=YG7T
MJY2],J9/#D.B8''F>J=B:([S.OI5REZ94R>'(=$P./,]4[$T1WF=?2KE+TRI
MD\.0Z)@<>9ZIV)HCO,Z^E7*7IE3)X<AT3 X\SU3L31'>9U]*N4O3*F3PY#HF
M!QYGJG8FB.\SKZ5<I>F5,GAR'1,#CS/5.Q-$=YG7TJY2],J9/#D.B8''F>J=
MB:([S.OI5REZ94R>'(=$P./,]4[$T1WF=?2KE+TRID\.0Z)@<>9ZIV)HCO,Z
M^E7*7IE3)X<AT3 X\SU3L31'>9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<I>F
M5,GAR'1,#CS/5.Q-$=YG7TJY2],J9/#D.B8''F>J=B:([S.OI5REZ94R>'(=
M$P./,]4[$T1WF=?2KE+TRID\.0Z)@<>9ZIV)HCO,Z^E7*7IE3)X<AT3 X\SU
M3L31'>9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<I>F5,GAR'1,#CS/5.Q-$=Y
MG7TJY2],J9/#D.B8''F>J=B:([S.OI5REZ94R>'(=$P./,]4[$T1WF=?2KE+
MTRID\.0Z)@<>9ZIV)HCO,Z^E7*7IE3)X<AT3 X\SU3L31'>9U]*N4O3*F3PY
M#HF!QYGJG8FB.\SKZ5<I>F5,GAR'1,#CS/5.Q-$=YG7TJY2],J9/#D.B8''F
M>J=B:([S.OI5REZ94R>'(=$P./,]4[$T1WF=?2KE+TRID\.0Z)@<>9ZIV)HC
MO,Z^E7*7IE3)X<AT3 X\SU3L31'>9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<
MI>F5,GAR'1,#CS/5.Q-$=YG7TJY2],J9/#D.B8''F>J=B:([S.OI5REZ94R>
M'(=$P./,]4[$T1WF=?2KE+TRID\.0Z)@<>9ZIV)HCO,Z^E7*7IE3)X<AT3 X
M\SU3L31'>9U]*N4O3*F3PY#HF!QYGJG8FB.\SKZ5<I>F5,GAR'1,#CS/5.Q-
M$=YG7TJY2],J9/#D.B8''F>JU:'&<7;EJ5>F43*Y0B4%*2+5>2<C.*432;P,
ML!0@<)4J0K"1NM#C$RQ,>F.MUEG%&6776BSY<AT3'GS/5;_J%*41>:^LA8Z]
M!&&_R0XJ_1O!OW8:ZL'>?,_-7QN'D/DLD5"E*(E$2B)1$HB41*(NE/$&E?G>
M6^J62C";CE4QV8$&4M)"$S#1G"-0 DK$F%<;8KPK)L(9ZO<$,73Y92&Y4F4O
M>&^Q_ELS=8%+BY2+)$F%"OA"D\HJB-F<;,#;XGO'ALY[.*[K**E*(E$2B)1$
MHBZC\W:360(1ZJ)HGX*B6;S'2"9*_"QERQ@1I<,'2IR92[,-9(E\5DCICE+"
MDFD;"F*^01Z/O"[-RG(SGC NXU#C^^%$+WP]\3E4!D$XW=^[O&1X'?NW]^>X
M]N%%2E$2B)1$HB41=,^G9ID9;P1IJ:,N+FMZ?F+$DD9()(%L9A3UBYFR!G>9
MR_2*@V)U\!BS;DW$^35N1T,#C#ZGEDY@&+7;%4]+A,A>IE9DAGMC#:6:^N[:
MJ@ 0?'X[!CX?S\EW,45*41*(E$2B)1%TU^K!:1>DOHY0S&LCT=LF,L-<E\?S
M/>WPE"[X,MR=E_,[4TPN_ \$C,)S2V.SEDN!.T@72%HR9$,+)2<SK#GN$?@F
MXMR6YV4 530#OX>.P=Y\,^&=B[C$=ZDQ(E,6$V)U9B<B]4G+,XVPA3<5;<>3
M8:':,L*-&ZRTP/ZX6A=WZ*E:BB)1$HB41*(NJ_23TK3<0>J Z/.&7C2JQ[C?
M'.2]&W23DLNQ@[EXS(D$?E4+"$*L;9)5KY#<MF"FYW3K,A61:.IBVN/OP8_E
M 7(9,<V.'K.50&6G9DY&W^SX>ODM3ZE#I#2723PKE:?/.DBVZ2L6OSU,2,-2
M9P.PV3EMBPJ#+&+(<@SC'L'QV&Q*'3E_=2)1,VJ)N</CLR8H)(XFWS-N0R4A
MS:FPCA@XQCN._&1X9^'#.[9A=H]%2E$2B)1$HBZU--;29<,!Z2?J><8+TB(%
MC**YJTB'['.2\6R0<>I':?0I;@W,3RT2$'N6'&R)G:&;+3!BV*(U$3(9]NE4
MU9(ZY/:P^0-+&J*H#(=LW#/J/Y9/PSW%; ]3+TCLCYBEFDOC[)^;K](B18P<
MX*[=DB"RO L[T?V]).W3)FP0#'LAPQAG$[RRSF+-<7;QR;C[*+ED651@I?#E
MY4IXN0*BSR.&,;,;..?/:=Q[B,#?X+MJHJ4HB41*(E$76QZI;I*.VC!"M'2:
MMFD'!L%(GS2_T8(9-TDRMQ^4.0<32W.>/8UF-J)=9^:81'V&-XM>9;*IA(F!
MOM?(ZS-H/]DCC#>U+UB@JF@'(([CCS )'K@+BUH/Z9.<<R^J.Z4>%YGE6Z88
MGBA>D:,#AJ%!B@XB,EXKSY#,>QN]\9(I&FG+^&E26/.[@A8AS1(ILATF&]0J
MRYC,Z'QJ/^L"TI<  #Y9W]XSXG/PQC<=I7>914)1$HB41*(NN3U4_/U^CCHD
MR.=M6D"]:.T\<Y"VPS$LE8TV&Q,E^6Y(T2 F 0%Z=\]1:68RB<*<7Q.3(LAR
M]]3-/X/0*+R1<3(F8;+U-#]?1V*6C)W9[SY=ZP_H^:6LG?M.Z"X F.EUA#+J
M"9: N.<J%P7&:K&=K2MS,==$7)^E</=6Q2LFTG13V&*GW*4;06K$C$7BYU8W
MIMC6QH3I.Z%./=S@[\?#_>%V]T5*41*(E$2B+B'IX9EBVC_HIY8RQ,<S2_ C
M+%6YF,'(^/FC'KY.TKBODC0VM$;A[=E>+S+'0O\ .'-6EAJ)PE\=6,3)Z^7O
M;@I:$S<:\MY2!DX74?B?3DTRUV9/4KH/.)M=-H-DLED@N?LK8<QA'<BX6TF\
MFS+1ZTAII(;XMFF%1IV@#.AP+,\80!,^WXL?8\4]O"W+CJ[MC=CV I@5E.!A
MW=C:!WCW@!Z$\@>]>BRBI2B)1$HB41>:^LA8Z]!&&_R0XJ_1O!OW8:ZL'>?,
M_-7QN'D/DLD5"E*(E$2B)1$HB41*(OSP;0N&\+;>$(!:-VH.$-MHB-H"/=$+
M1NN$ $=0#<.KNC1%^J(E$2B)1$HB41?G@V\+A\&WA\'@\+4'"X.O7P>%W>#K
M[>K7JU]NB+]41*(E$2B)1$HB_(VVB-MPVVB-@B-HB "-HB VB-HCVP$;1$!$
M-6L!$.X-$7ZHB41*(E$2B)1%^1MMN&T;K;;AL'A6B( (VW:AMX5HCW!X-PAK
M#4.H1#N"-$7ZHB41*(E$2B)1$HB41?(:9 PO_KGZQ/;0]>LCNLC[SZTN2-R]
M:'YNXH7!D<]C..V!W0 >2*QM5<4L2\<5QY-G&6:R+Z]$2B)1$HB41?FVVVW7
MP;;;==PW#P0 -=UPZ[KAU=VZX>V(CVQ'MC1%^J(E$2B)1$HB41?D+;0&ZX+;
M0NOU<*X  !NX(:@X0]T=0=H-?<#M!1%^J(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(O-?60L=>@C#?Y(<5?HW@W[L-=6#O/F?FKXW#R'R62*A2E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1%\&51IGFD8D<.D*4%S!+&%XC3XBNN&T%C.^MZAK<THW6_C6@H1*C
MRAN#M@%^L.W1%X3X5F++$06Z+<RD,ED!+!_Z/=*H]AO2<,+*6<4X-^8M,V;Z
M+TD"TJVR\UT+9]%C',:DMIB:Q000D=C0LOV0#^&5_ P?])DMQP&MC:!_%L\>
MY<CX1I=:96&8/A6+XLEK3A64Z:^%-)[U4)RG$Q<=&V/ML^RSG+/+@OQGC=_D
MFE3+XI#D6/H3B%7CMPG+)CA89E,YH>$:^/G-3(TJ#RBC#23G'ND-_BQ@#!QJ
M@G).2"=GFN6N5?5(]/Y?I3/>,H9(,-8S<\50#05E96-WK(&BJP8?S:ISO%X[
M,LX+E>1<R9%:,F2J*(E;G(L;XL>M&X]S2$2&.(5,B6/)D@0IS2I ;J@^>=^=
MG<, C=M.M\"-I6C]3YTD<HQCU2W2-T9%\@2XDP5DCU0WU1G(#5)54?9WX[25
MS%%0Q:B-T?&Q]="3NQP? (>H[+RU2B*]?9ZFXMC:%S<F:':UPI;W_P!8_7UX
MH1[N>\!OPSG;Q\.')>I:JE;2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B+S7UD+'7H(PW^2'%7Z-X-^[#75@[SY
MGYJ^-P\A\EDBH4I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(ME&XVQT>1+4IT!A1R:?'6J)TF-BS&81-
M#[;.+M/EI-Z 2Y&=:7^):8\6K+PL_%"[@]JB+2R?%&+9NTL;!,\:P"7,49O3
M&1MED\.CK^TQXQ&06F27L;:ZMRM&TWI4Q12=-<@)3B006644-I=EMH$7[?<5
MXPE+U'9))L<0.1R*'\4$2?WV(1YW>HN!)@'$A'71P;E"YDXHT -*];#TW%F
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51-<\/7JNL+\.7;=V[D5/G=5JA?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>obln10kproformaimage5.jpg
<TEXT>
begin 644 obln10kproformaimage5.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X63&:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S4X:C,X/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,38M,#DM,#A4,3 Z,C<Z-#<M,#<Z,# \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#$V+3 Y+3 X5#$P.C(W.C0W+3 W.C P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,38M,#DM,#A4,3 Z,C<Z-#8M,#<Z
M,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R
M5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H
M/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z:&5I9VAT/C$W-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @
M(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!
M0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!
M04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL
M04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$
M06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'
M>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C
M>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%S045!07=%4B8C>$$[04%)4D%1
M35)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K
M2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O
M3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I
M8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY
M63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+
M0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C
M>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1
M645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-
M2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G
M2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2
M;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A
M86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y4E<Y=D%927E9,7)X
M6#EK94=+<B8C>$$[+W$Y=B]V<% K0D=+=2MR,B]W1'9P4#A!9U)I<G9Q.78O
M=G!0*T)'2W-E,4AZ>#5(,#5T5%<Y=EEO6#!C>$QQ2T=*>7E'96YP.%%%2B8C
M>$$[:W)Y2#)+,#<P>%9'>BM9=DM&=DTP3GAQ96YW>DI*-D12>51W2W=L+S,R
M45="-6(O04=E=4MQ32]M>GE81'!D,7%P,4MZ;# K>3E0-B8C>$$[,6-7-W!C
M3$@V<D)9*U%H-6MC:7=P:7$R.#@R*U9B3S5T-V5D;C4S5'E25S=2,FQX3$<W
M=S$Y54-33TIK*T1G>&(T=&=#96=X5G)2=B8C>$$[3U!K+U=:-$E.3W5&;&UU
M5F0T63)G;&E:;&I33U)M<$MI54A#-&I:82]A0G%+-'%O=C4Y.&A)<&%454E%
M079J<&)C;S-7;#).:6A"5"8C>$$[6E(O=G<O0B]L67%Q=C4Q.&E*3D)',G)7
M05,U:FQK:'505FDY0FA!5D5I*W18,"M1.5%(:E=T2VYT:7%T6F5A=DIL-V-3
M5S%R<59L2B8C>$$[4$9/='$P9DY!>E1/=DY544=N4&MV5&I51VA(54=I<7!"
M-6DX;UA!9TU'<#9F2TQQ47=7,T-E0G96;$9#630V3CA49D=U=S,S1TMU:B8C
M>$$[.'@K5'!)67!O.54P-31:-5!1:&Q794%Q.'1!9E169S%'96A(=VIF1E5D
M6GDV6&4R,&0Q6E!"8S)S;W)&4$-5:VI95G!65U=O3RM+<"8C>$$[279N:GE/
M>G%I,W-2:V954#!1<V9P4'E.-E1X.5!J=W)3=C=F,E!F1E528RMA+TID=&)X
M,TUM<%=2:&UN1G)#,&-K8W!E67-Q1TY22"8C>$$[>4Q-<&M8;%0W23-.0FEQ
M03 O.$%-5'E"9C-F,5,S=C105T9O3"M5=6AJ:FIG6E5C3DI)-FE.5'AK1E%7
M<4\K2W!S;75E5U@Q4T13;R8C>$$[-W$S;#%#-6A.>D1B>#A867=Q1E!Q2&I5
M2T-(0E=V,G4Q84A&5790;C,X=FA9<F5T<3%K<T1,12]%<V]L5EIY;VI:-%-0
M5E%(,490>"8C>$$[2TM$8S!'2W!H3G(S;%-$,5!8,4=W:3E+65<P=D]A1F5-
M-T%S<U163WIK2U-&-C1Q:% X04=F:VHY1D16=C!H86I4:F1F569R2C)56"8C
M>$$[2%!H=V)B-&9'<#(T+T98:G9I<4PO5&YL<')/-W9)3&E#-V=S0U9V4'%9
M*W101W<V<3!C06ME;S=I;4MO5%0O3U!K;2]T9G)-1V]7<28C>$$[4E9J0D9X
M4S)C975!,$Y9-7A'-$5Q:T9$5#1H=4LT<7)195HO2C%X<4YT<#%T<49N8UAL
M,S9V,65+1C!L-4=!07ER>51K;UI1,65*3B8C>$$[979G8U95-"].=FLU-6)L
M1&514DQA4R]6-7 U,$U-2')C:79P<%!+<5)334="0D--4TU68G1V3FYK<31T
M-6)I4%4W15)15$<R;DUK:R8C>$$[8U)364]Y0DA75&E63$Y',T=O*TEB:6]X
M5F5N;6)Y9DIR365I>&%H6GDV<DM:5E=Z:F1(8TYB+S-Q349R=UIF-5=O9&HT
M1VEQ8B]6-R8C>$$[9B]F4V8X0TU69#E8="\X06939CA#359D.5AT+SDY2B]W
M27A66F-7.$%G:TEJ5W9&=C)2-%EQ=G0O=T1E94PO55@Y5TMQ;4MU>%8R2R8C
M>$$[<TTQ>CAP+TLK<S,Y,698:C-);G9';F5B,#-13%=E,U,R-D9$+V1R1GI3
M=&%-4V9B1E5&92]K=#5E=7 Y46Q85DY7=&PQ3C-E-FAG=28C>$$[5E=-<DEZ
M=3!61$<S-W9N2WIC4U1U9#A.<6TK;&9L>F]/;5=&>EEW4$\X1C-A5S%L3C9H
M:EDK;F%'46]W*T%!3V963E0X=4Y$9W17-R8C>$$[6#AU=$)T;5%X4UA)4TLW
M=7(R2TEY2U52<GDS83)E2D)X*T=*56(T1DA1.3A645=G+VQ4;W5H5#)%*VY8
M.3E%*VYY4U-)2S)W5U)::R8C>$$[:&ID2D970E9O>3)Q5EI11TIQ4WA*<FEQ
M;&1F:S4U575,;5,U370S2%!)>E-E<$A)9TMY3F5'.3E287AK8RM2.4]V.$%*
M=#$S=S)Q;B8C>$$[82]K>C5B:'9R92MM=CE3=F)Q,VQM;3E7-FY35G!';FA3
M1G9567AH:E)9>'@S+T1B1S%63&8X;F9,9'9.<#AK9#5F:$Y.;6=U24EF5B8C
M>$$[:D--.$-12BLX<$='65-F531M658V<CA02$)A<C1V>6PP1TIR5#!B+T%&
M0TM+,&MT6E1"2$Y'<V-R5U551558<DM)+VE(*VE)>"]Y<28C>$$[;G=O,G$S
M+VQ4+VQO4DQ';'IE>&=1:3)C<3A1-7=F5EEB4C!A<U9"-FE7<4UZ3%)U5F%%
M1&)$87 U;TAK-U1D13 K=W-R931V2FPP.28C>$$[-7!)<%IB;55.23EW-6MK
M339X1T]+8C1M,C5O869/<'=+:R\O04-Q4'EO9%-854,Q>5HQ;#EE;G%,>#E4
M-C9B-VQ12C$U9G4V.694,B8C>$$[-B]&:F%Q35@U3RM7;S0W9$9U-S<Y=S9-
M5TUK5EI)-'9Q+W!X3U!3<'A8-FQ&=6]$1VTW1W5',61.*U18;&5724EB<2M6
M;&=J=#!K4R8C>$$[5D5D4D1&87A2=7!%66\V:7AJ8G=Q5S)P44)T57<P3#AT
M=$(P6%=B9E9B4V$U86$R=%9T231P2%)O>49H:70O54Y%1&-Z2&))1#A82"8C
M>$$[=T%W2VPV9FLS-5E3,&IT;S=M.50P9U!4;41X8W=65S!65W%9<4AI9%!J
M64%I;%,R,C1O8E9U9CAN=DQ--#%&6DQQ*TLV;$\Q>DM$2R8C>$$[:D)'84\U
M:DMX8V]Z>%=T.4LY3B]I;V9%15=Q4&DO3&92;V)+93!I=DPY5FQV;#%'0FIC
M1GAB5$I0.5E545)30C1655-62G%H2G)U5"8C>$$[=&EQ+U%0>38P4%)0<D@Q
M864W;"MS5S1S-E-Z9D-L=6=92D=%:D5A3G<U='AA4E=C5E!X63)Q0G9F>6LX
M=%AE:4QP16QX94I#:VM%9R8C>$$[;FIL4DIJ.5AS:W-!:%E*>$MV0D@X47 Q
M3%5O1%1&551O9C5B-E9P1W!W-FQ$<48O8UAC37,X=D\U;&IL-6DU:6EH84YV
M,UE00E9T,"8C>$$[-%5O4E1R5&)&5DLY+TMZ4F)U,VMT2'8W-4Q&<'!P-&).
M2&@Y2T4S4WER8TI&>6E:9W-O=4AR56MI=G=K63)Q:&,O:SDU6&Y59WHS:R8C
M>$$[6DEK47-J>%9+5%-85'E+87A..6]8.&E6-CAE3D-#2S1B5DYR1'E*<$9H
M<4YP9C)S<SAC,7!09EA#<GE1<2\V4EE03D<Y57)W57%V0R8C>$$[:$)&3GED
M.$-S:GA6,DMU>%94=5 Y-35F.5)V,5EQ>$QZ>C4X9GEJ<#EH2VQG3#DW<%-%
M:F%B,$ML1$=O4D1W;#5/9E8U53(K1E=08B8C>$$[1E4U.' K6C=,>DQO,&5P
M,FE017!D-'!O2E)2-#59>GAD0T]U>#A11#=9<3=Z1#5L9S!71S%M:W1:-VA,
M;31J=&DP4V)2*W%A0C-,8R8C>$$[44)88DQS3TAX0U)D54QA<W589W)A-TY*
M=#9Q*T1F.$%!="]42U<Q,W%R-$XO=T%#,SE-5F0V:2M$9CA!070O5$9897%V
M9S,O04%,9B8C>$$[,'A6,W%,-$XO=T%#,SE-5F0V<2M$9CA!070O5$9897%V
M9S,O04%,9C!X5C-Q3#1.+W=!0S,Y359D-G$K1&8X04%T+U1&6&5Q=F<S+R8C
M>$$[04%,9C!X5C-Q3#1.+W=!0S,Y35996C4T.'8V.7$K<F%B3'!K<G=24E)3
M4G9C3$I*03!$3F,R,')/0VYX:WE7.$US6'<O=T$Q1%%%-"8C>$$[5E%L:C52
M.#EW,E9Z8C-V;5 Y23)4>%A555=K5%%T4FQK3"MH-FUO1EAU5'A6;$QF0V8U
M9#A64VDT+TMU+W5T2E9,:3 P.&%N8C9%=28C>$$[:U%01S@T16QY07-*=5IP
M:&)Q-45C35-'3D]*,TQ,,"M,1E=8959D3#%A>#%F53=M*VE%559X8C9F17%X
M<S!I4%!B=W-K.'%K<7)54"8C>$$[2D5Q>7%4=W)3;4MS;CE29D)V.$%G5R]P
M9U8S<4PT3B]W3&8P>%8S<4PT3B]W3&90=WA6,W%,-$XO=T%#,WHX359D-FDK
M1&8X0S,Y328C>$$[5F0V:2M$9CA#,SE-5F0V:2M$9CA#,SE-5F0V:2M$9CA#
M,SE-5F0V<2M$9CA#,SE-5F0V<2M$9CA#,SE-5F0V:2M$9CA#,SE-5F0V:28C
M>$$[*T1F.$,S:E1W>%8S<7(T3B]W04,S.4U65U1S1W1P0TLO66)Q0T\S=FER
M9'8O=E!&+W%,*W)&5E1&54QQ=6Y186QP='I95#=26%5B4B8C>$$[35(Q2$E5
M1$0S53=J2C0U;4UG4C!9>FE*06<Y54PU6C%'92LP94HW<6=V<F-T8EAY:G10
M07AJ:U!Y67)Y2'-2:W,X0D=7,TQM4&-73R8C>$$[2U)-9"MA85I5,D]X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5E%G9V=-15I-86ML45-30C19
M<7=R>B]W1&U2<"]K-U9T3B8C>$$[<THY2TXT;6]7,3-/<S!B2W!74S-#3$1$
M=TMM<'5*6E9I0G%+35(R-DMP4$@K9#)G>3)&:W<P=C Y4W5R8E1R,7)6<%E(
M:E=+*W5,4R8C>$$[1GAY:EIP9UEX9D%Q6DE51#!02&]A2W))+W=!*U!,8W1Z
M84Q&;TXR;')08GE833AT=SEJ8G1%;VAT<FE&:4IB9U)C2EER,41Y859E3R8C
M>$$[,C,R=4MQ:%DO=T1/46YK*S0K=E1(4V)P-T\R96)H3&)R8E-K43)K5G4Q
M>DI,*SE#9D)*8VM$,&YK-4MT4C%&5EA89B]!1&M4-4AA>28C>$$[=EI.23 R
M-#%/.'1,85<X4S-5,G%),79%4#<U-4),2C9A,3(T379Q:G(V9$U65$Q8+W=!
M,7IP=FUJ5CE"<R],:F%I,FU1<DET>$9)5"8C>$$[-FHQ='966# T-%IN-'=P
M94)N.4U024%.-#9&4U956$XK6DUA,F9K-B]44E%M;F5A630U3&DX=4=K4T]Y
M.59O1FI2;6ET-3%:-51C2"8C>$$[,"MB4G$S2#=1<FER=$(O3DQ2-S(R=FTQ
M9E1F,$QE-EAP.7AQ96\V9$MW;&YJ:'1:6&IK2TMI04]&15EQ469T2&IU43%&
M55!9+VTQ6B8C>$$[-FYR63!Z5'9,;'=F<3ER95AE<4<U93)I:W1X85)24TMI
M;VIZ2DLP;C%M26)3041N-TU!<6LY;"]Z:THU8U<Q1GIR;6=83VQ1>4,R1B8C
M>$$[=DU(=%HT,VMU<DM+.5--=GIJ-$9L;2M&;4A';$,U43%65EAP2&Q86&1'
M.'IA1&)A,W!S6"MI6%)K5D$T:DQ";UI7:&M(2TYP23)O."8C>$$[6DA*1TMN
M<4-2:7%::4].3&AE0VAA;S%A041U=4MR<FHO9658+U5B.5=+<U@X,2ME;V9,
M549L1V)5,TTY>$<U4EA:;TEY571P6EDP5R8C>$$[6FMA3FUD-$](2&Q695%.
M3GA65DY02V9M97DX>39.2'%D;VIX2UAE2V%#555E3U=-.%A1:G)S9D5!*S)+
M<'0V<2M$9CA#,SE-5E-#3R8C>$$[4F1..#)34C=I,3%U3#%K1D<R=3=:47-L
M0E0O9&M(12\W035K2#%9+T]0,T@Y=C-T23E-+TM8,VHY;C-*+W=#<79G,R]!
M04QF,'I(8B8C>$$[;F5O=F<S+T%T+U1&6&5Q=F<S+T%T+U1&6&5O=F<S+T%T
M+U1&6&5Q=F<S+T%T+U1&6&5Q=F<S+T%T+U1&6&5O=F<S+T%T+U1&6&5Q=B8C
M>$$[9S,O070O5$9897%V9S,O070O5$9896]V9S,O070O5$9896]V9S,O070X
M+T1&6&5O=F<S+T%!3&90=WA6,W%,-$XO=TQF,'A6,W%R-"8C>$$[3B]W3&8P
M>%9)=DY8;2]44$M8;&<V-7%C8S!L;D-923-3,E%34S%N9%EL;W!:83!,,4\Y
M9D-U2W-C9CA!33,X<DY5;'5,;E5&4GIP9"8C>$$[-4Q9>%A6>&%F5TMM,DU.
M>$I00S!A>DUT=6HK:S5L8FEO259V-51I<3),6"]!36QO<GDR5F)'>70W>31K
M4W=H-3962D1)<'0R=%1#:R8C>$$[;DLS57A2<3 Y<5EI.48S47%D:&ER96\S
M,S5A1%=R>GDS3C589W5D47-$0DAB,FHR5FUS9'=:8E%"1G18=41(13-'1TI)
M1%9L02M"3R8C>$$[;$U66359+VU0*U558VUN5U,K5"]!2VI(<C%S3&E"1%HV
M64)*8C,X:E%K=$9&3SAJ3$MB565O1E)Q2T9,,$%X5FM5:W8U3VY39$=V3"8C
M>$$[=E%,0TY03D5A-FA95V(V6D9,2DMZ=W))>GEI2T]61EI5;4%D,V)I2R]A
M<&ER96PK6G9Y:S@P-E)Q975Y-F9A4SAD3VAV=DU8,7%W.28C>$$[4U=/,T59
M=453-4II8C%39VDU2V],5C1H;'%+2$96;S@U+VMT3F-.<6=I=%@Q0WAM:D-Y
M2%,U:F5R3U9A1E!343(O<G,V<EIS:#1!;"8C>$$[4DA1,$,T<7-K+TY0.'!)
M-T]85DQ"5C%!4DY$<&MR5V1I-6LY1SAU2&I65C52>"MP05I58VYG5U5K8E99
M9T965SAN960O=T%P<FE04R8C>$$[0F]&<D1P.3%Q0W9B,E9H1G W=U1X97-K
M3GI.1WEX4F-9,%!Q>$UZ.'948C131T]X>%9,4$Y0;3<X;E!,8TTK;5-E5VMV
M5V=M;&$U,"8C>$$[>7HP;$)X361V3#9T>%-D24EM5#!,959F559J5E998F=.
M4E9K5FPK65@U8V%862]5-T]68D,S<V])2G8P9$):5'AM2DQT-%9J4EE);R8C
M>$$[=G0X-WE,;$=G-4QZ6&M"6$975VU25$Q%.412:UEG1E-$=58V:6Q2.4]+
M='IS1W1P0TLO66)Q0T\S=FER9'8X03=Z>&8V:2]Q>%95>"8C>$$[5C)+<% U
M<7-R:30P:WHR:3@W+U0U179B3E(Q85-$8W@O=T104D]59BMY>3="24-62&MD
M:BM0=&%S,%-9,D]9,R](,TIJ65AT=F975B8C>$$[=F4R>F,W935J5U=*=D98
M05EF9V-R;D5X2D(U:&Y'46M,2$EQ*U):3WA6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+<&)Q3VEA5B8C>$$[<E=L=S)7<5<T=6)53D)0-E1&;$AQ5S=R
M3$=4>$MN6C!"<#!043=9<7AM-R]!0U,O2S8W=$QE>G5.0VIK=#=6,6QG47I8
M031S:T56=28C>$$[4&E%9UEG>%<X65E%,&%L5%4Q3TMO:7<O2TPX=DQ#2F]B
M5%-F5&IE4G!N0G5,;#9Y3DYB6$1-4S!J9%IB0T)V.6HT33%657IU9DQV;"8C
M>$$[2'I$3F(V<$Q$1'%-;'!D>%A&=&1*2WII3S5S2&M23TI2=4E-56I307(P
M-59Q2S1Q:V1N-4(O2W958FDQ5WAI:'4S,%-#0S%I9V=V<"8C>$$[-45I:'1:
M-7915V%*2FEJ;4]D6F5,4W%4>41B,5A:5DU&+TQ(>5=U;C9D<'AS-7!,1%-:
M4%8P*S)L=DQY4T].:'@T,58U;35Q;G!R=R8C>$$[5G%H9C)1359D<%@U6"M2
M=$MS3"MW<TY.34YP<6QP*VHY46HK<UA,*W1B0E=127I027I65DA+<3%E45A9
M1V='2W),<CAQ=DED,5!C6"8C>$$[175M:UA&,4E:-6)I3S1U67!F56%A861M
M4U-/5E=1;#=U5W9!:EIU4#)A1$963T@X;W9Y-FAT2G)32%)K:70U:$='4T]7
M9$M#1S1E-R8C>$$[:CE-<DE$2'AM;%IH=W T9EI!1TMU='9Y-B],<4A5-V%'
M0S%56"MM9E9,>4<P1C-C16],84I,5S!M:V=-<$1"17,Q5D=D5'5P4#)U4B8C
M>$$[>%9E9GEN+TPT-FIF-FDR:VAR>E4S:VMV<%=M=4<Y4G!O6G)E4W%M5&E!
M,%8S2W1!2V(K=V]Q=710>7,X:#)M<$YQ8T=L.&119$Q72B8C>$$[-VQP-V@S
M6F)'5T=E,S5&<$1Y2WE7<U1&:G4S2#1Q-S1Q>61V.39%+S%(+U=U2W5U4#DU
M-68Y4G8Q67%X5'I8-3=8>31B0S%J=$9V3"8C>$$[;35T-7!6:&55,C5)9V=E
M54-.,VIA2U-P:C1U02]*3U-M:#5$1E4S.' K6C=,>DQO,&5P,FE017!D-'!O
M2E)2-#59>GAD0T]U>#A11"8C>$$[-UEQ;3-Q<C1.+W=,9C!X5C-Q<C1.+W=,
M9C!X5FIV;'4V9W-.4C%(>39Z+T9A=6)U=VEP.%@Q4S5*96=(5VMC=DY0;'AZ
M2GI!>6E*.28C>$$[*W@Y-"]9,%EI0DEW-W0O9U=296]V9S,O04%,9C!Z1V(S
M97%V9S,O070O5$9896]V9S,O070O5$9897%V9S,O070O5$9897%V9S,O028C
M>$$[="]41EAE;W9G,R]!="]41EAE<79G,R]!="]41EAE<79G,R]!="]41EAE
M;W9G,R]!="]41EAE;W9G,R]!=#@O1$9896]V9S,O04%,9B8C>$$[4'=X5C-Q
M3#1.+W=,9C!X5C-Q<C1.+W=,9C!X5E-G;FA%15E-:6=H44-#4EAP:7$O-GAB
M+T%/+U4O=T-#1TMU*W-7+RLO52\T25EQ."8C>$$[9'5V>49%;6TV=EI7+VU7
M0S-/<5A0<BMP.5%I:T-J,6)M6&MY>51.>75".6,T3$]V1FQ61C1G159X5F90
M*U%T=DQA,VM(*TI!4')K=B8C>$$[<717,E5O4#-T*SEE4')#<G K:S9X4%@T
M2&I$,% R47%R6#,U13)&-DY45V98+U9&+U!.8V]:65$W0U-30RMJ:6QM4')$
M,5HT6DY25B8C>$$[;&LK2#19:U-G*S%I<5IE92]W07!94$Y->'4P,7E/>G9X
M83).;6QX3&%X6%E-9&TY>3AQ>7AY=45K4V1R;$=+:V).1W)B.6Q5;#!B+R8C
M>$$[04IX*S S5$IT2W56.'=M4SDP-F,S170V649%.#<O6&\W<%=:+U9*1$-*
M2DEE5R\Y-'@X5DMR5VYF.#0O5U9L3VLT.'A+-T=/4DQM228C>$$[,GDK:$]Y
M,C,Q93!K:VE->D%T13=35'EB+W9:2$I02$97569L-2M84RM58F\S33)T2G%-
M:'-H6F-5=#0W4D9(,3(U=DMP2$<W26DO-B8C>$$[6'=61D%694\R>&]&5V1F
M5TQF.$$S-FXO04%1>%8S,6DS+S,V;B]"1$96=G%X=$]H5F<Q1F%V2#1U<%AW
M>%9U9&<Q=$E26#=$9%%2,B8C>$$[.3A68G0O.$%E94PO049&+U9I<7!I<G-6
M9&ER2&9-;6MR0F1295IR0S-$-G1P-"]F2V\K3S1T3B]6:#DR0VYK;BM504\K
M6D](2EDX328C>$$[;C!N-T0S=$=71DAJ03E1*S!D>64R9#-B,VQR1&0R>FE7
M,W5%5U-'4F5J231Q0U!O>DAL17A.2&TS4FM#3$A*5G=*9&ER<U9D:7)S5B8C
M>$$[9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U95-VHO9658+U5B.5=+<U,X-BMF-"]+;6XR:"8C>$$[4WI..61Z
M.$9I=&DP:T%F:W)%96Y.-E5K4EEC4&E5<T]),S=Q0W%N4&Q0>E!:95ID1VHQ
M3S!2-&Q,=D9.0DM+4$A,1V5,;U(Q,E!I028C>$$[9F)&53(Y5F9"=CA!9U<O
M<&ER=E98=V(O04E&=C99<3<Q5CA'+W=#0F(K;4MS9#!Y4F1%,7 Y25E&9$XQ
M079C855A1VE3+V%N=&=+9"8C>$$[4#DR2C=C:"MZ;510,7<T=C1H<V8P2#E$
M4D@P4S1E:#5F<$@V5U)E<79G,R]!04QF,'I'8C-E;W9G,R]!="]41EAE<79G
M,R]!="]41B8C>$$[6&5Q=F<S+T%T+U1&6&5O=F<S+T%T+U1&6&5Q=F<S+T%T
M+U1&6&5Q=F<S+T%T+U1&6&5O=F<S+T%T+U1&6&5O=F<S+T%T."]$1EAE;R8C
M>$$[=F<S+T%!3&90=WA6,W%,-$XO=TQF,'A6,W%R-$XO=TQF,'A6,W%,-$XO
M=TQF,'A6,W%,-$XO=TQF,'A6,W%,-$XO=TQF4'=X5C-Q3"8C>$$[-$XO=TQF
M4'=X5C-Q3#1.+W=,9C!X5C-Q3#1.+W=,9C!X5C-Q3#1.+W=,9C!X5C-Q3#1.
M+W=,9C!X5C-Q<C1.+W=,9C!X5C-Q<C1.+R8C>$$[=TQF,'A6,W%,-$XO=TQF
M,'A6,W%,-$XO=TQE3E!$1EAE<79G,R]!="]41E9K-T)R85%I=C)'-F=J=#<T
M<3-B+T%/.#A8*V]V-G-65B8C>$$[359D:7)S5F1I<5@V-W!),514,F=6+U)U
M63)787IU4G59<#1Z5TYX.&IS4C-&4C-Y>D9K-$I8,#8K-6AK:'A#:T@U43@Q
M5W9M3%1N;B8C>$$[4D=G=3=743(Y+V)/0W!J;E5$;4)89FI8;V8T-5IQ34)X
M>7)O95AU83A'8UI"9E5B2#-P-6U/,W5X5C)+=7A6,DMU>%8R2W5X5C)+=28C
M>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5E1U4#DU
M-68Y4G8Q67%X1'HQ*UEL=C50,'5Z:RMP4U@Y-6-V1D9$8B8C>$$[,6%"1#9I
M=G8V-TDP9%%9-D92=4MG:U5/2W S-50X>C)8;5A2;SE4=$5E2E,W>%114VEJ
M>'EX;FDV161D:C1G2#)X5DYV5EAW8B]G5R8C>$$[+W!I<G966'=B+V=7+W!I
M<G966'=B+V=7+W!I<G956'=B+V=7+W!I<50V=F]I,TTV-FAP.')73W-X3'=I
M=7=J1EA3=&93;E1B,4EY9B8C>$$[<$A515ID:GDP3T=7.&9X>6%P-#=.:F%8
M-#5T-E(U:49Z3610,4-%,D]S4DQY:W1$5FQD2S Y5T)Q1&Y'9G9(4F=-8VU+
M:'A$95 T-28C>$$[<D1*6F\W4R](2DXO5EAW8B]G5R]P;$QA-S%6.$<O-$9V
M-EEQ-S%&.$<O-$9V-EEQ-S%6.$<O-$9V-EEQ-S%6.$<O-$9V-EEQ-S%&."8C
M>$$[1R\T1G8V67$W,48X1R\T1G9N-%EQ-S%&.$<O-$9V;C19<3<Q1CA'+S1&
M=C99<3<Q5CA'+S1&=C99<3<Q1CA'+S1&=C99<3<Q1CA'+R8C>$$[-$9V-EEQ
M-S%&.$<O-$9V;C19<3<Q1CA'+W=#0F(U*T=+=3E29D)V*T)B*VU+=3E29D)V
M*T)B*VU+=3E29D)V*T)B*VU+=3E29D)V*R8C>$$[0F(K;4MU.59F0G8K0F(K
M;4MU.59F0G8K0F(K;4MU.5)F0G8K0F(K;4MU.5)F0G8K0F)X<#19<3<Q5CA'
M+W=#0F(K;4MR2C)$5S!H1B8C>$$[9G-.,4)(8C-X5G4S+W="-31V.$%56#E7
M2W%M2W5X5C)+=7A6,DMU>%9+9DTS;#9,6$Y.83(Y6G)3-U%H-U!526@K*W0U
M069T>'15128C>$$[5D=X;U)56F1G>F5(2RM9-FIV87,R3&IJ6$DY+V-G;W11
M,3-1;S%I,6A',4Q4,$%5871B251+:6=F87590GE0>F5/=G5Q-4UW:&LK;B8C
M>$$[,&YU4#9$*W1I2E-H.5<T-R]W0EDO56YT;F4R;#=B4C-6<$UL>&)Y:7-C
M<V)";$DY:4UO;$5X3DAM,U)K0TQ#=&M5=7A6,DMU>%8R2R8C>$$[=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W%D>"]V4$PO04MJ
M9G%X5FDS;2]Z,48U67,W44,P83=U6C%P2"8C>$$[1WAK:&I.24I:1E9::$9,
M1UA:;V501W9W,41.455Q<6UV;%!Z4%IE6F1':C%/,%(T;$QV1DY"2TM02$Q'
M94QO4C$R4&E!9F)&53(Y5B8C>$$[9D)V*T)B*VU+=3E69D)V*T)B*VU+=3E6
M9D)V*T)B*VU+=3E29D)V*T)B*VU+=3E69D)V*T)B*VU+=3E29D)V*T)B*VU+
M=3E69D)V*R8C>$$[0F(K;4MS5C$O=T%R4VDX:3%R44I:3$LO=#5"8UA&:D9Y
M:F=V=4DS4U92.%!.;$I54%1V=C=:94Q50W5'93106'%(1WE91%EL13!2,"8C
M>$$[-D@S<"]P5W-797 R360U8F-V5&M"1$EY<T=2,5!&-#-&3FU29U9).&-X
M.&U-=TY&=FA-4T9H1BMQ=F<S+T%T+U1)36YE<79G,R]!="8C>$$[+U1&6&5O
M=F<S+T%T+U1&6&5O=F<S+T%T."]$1EAE;W9G,R]!=#@O1$9896]V9S,O04%,
M9C!X5C-Q<C1.+W=!0S,Y359D-FDK1&8X028C>$$[070O5$9896]V9S,O04%,
M9C!X5C-Q3#1.+W=!0S-Z.$U69#9I*T1F.$,S>CA-5F0V:2M$9CA#,SE-5F0V
M:2M$9CA#,SE-5F0V:2M$9B8C>$$[.$,S.4U69#9I*T1F.$,S.4U69#9Q*T1F
M.$,S.4U69#9Q*T1F.$,S.4U69#9I*T1F.$,S.4U69#9I*T1F.$,S:E1W>%8S
M<7(T3B]W3"8C>$$[9C!X5EI/=V$R:TER.6AU;TDW92M+=#(O*S@X6"MO=C9S
M5E9-5F1I<G-69&ER<U9D:7)S5F1I<G-6635Q:5-A0G%-;75106Y3<FMJ.28C
M>$$[3E<V:79!9V-294M0.&M!0U=N5F9I+UIZ2F=F16IW2#9H.5 V=C%.12]1
M94EC=78V+W="8DEK9$A26%)G>4U!5EE';TE/-$E)>D=B,B8C>$$[.%9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U95-VHO
M9658+U5B.5=+<U8X-BMF669+96U7:W8Q3B8C>$$[-W4T;F%/2T].=E9I:4Q0
M1DLV3#8T:6Q4;7I18V50559"86DW-'%M,VQ0>E!:95ID1VHQ3S!2-&Q,=D9.
M0DM+4$A,1V5,;U(Q,E!I028C>$$[9F)&53(Y5U!X+UAI<G96:C8Q+U@X.%9C
M6E5(9D9897%N:FER=E9J.&8X*VU+=3E74'AX5C-Q>"M0-CA69#9S9FHK=C4T
M<3!Z>$UP5B8C>$$[<4930T=5:6])-S1Q=RMW;'9V2VPY8W<V:$U*4$MK<FHY
M1WI+<"\P1W!0-W%9;C1H1E4X5F%P03(K>FUB4&AZ04=0.$%E9&8V6'4X,R8C
M>$$[1FIE36TO;S9E6#='64Q.17EH;&%Q;F]2,#-Z0V-P=C%9+TA&6&5R2#0O
M-3EC5F0V<V9J+T%*.6-69#9Q95 X06U-5F0V<650*V941B8C>$$[6&5Q;FII
M<G965'AX5C-Q>"M0.$%N,7A6,W%X*U K9EA&6&5R2#0T<3<Q53AF."MM2W4Y
M5E!(1EAE<6YJ:7)V5FHV,2]8.#A69#9S9B8C>$$[:BMV1EAE<D@T-'$W,54X
M9C@V,'A6,W%P-#1Q=&Y93F)3161/1&9Q>%8Q=B]!3'IX9C9I+W%X5E5X5C)+
M=7A6,DMU>%8R2W5X5C)+=28C>$$[>%8R2W1/:4]J239H:UE%37!&45%D:4-$
M:7)';G1B>GEU1VUS164V.'9I<E0V95!I;'12,4PR,69T4FIV1C(O62]L>DM%
M:&PR3S K+R8C>$$[=CDO;C4O3G@V3U!L=DAU-W9D*W(U9'EC-DYR5VUA,7 X
M96]A6D],:3!K3$)*04-U-FUH0D1!16)J=FQ/5$9+175'46]T=5!*1UEU2B8C
M>$$[<TDS2S)B<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<6YC9C=Z>2]W0V\S-G-667@U;C@U6$=G<EIW5W5N+R8C>$$[04M1;FQT
M-7 S:DQY44%*0F)Y5%9747=Y4DY5=SA'*TU&4WEB9D5-5E10>6XU;G-V375J
M4C9N84DX4VPS:6UG;$9(:FQJ4$8P238W2"8C>$$[>$%0=&EQ8F5R2#0O<GA6
M,W%X.6$O<BME2W5-<41V:7)V5E1X>%8S<7@K4"MF5$9897)(-#1Q-S%9+T@Y
M94MU.5=0>"]8.#A69#9Q928C>$$[3TMU.5902$9897%N:B]N,'A624QR>2\Y
M5VYA+SAU>4IP.31X0FYT:7 K<5A(+T=73F9S=G1T26TO:GE',EI%8S%I<#=J
M-U(K3S5P;"8C>$$[:6\S2%DO669X,V]J5%!.3FQC>6UZ=E9/;39O9TAQ5TTU
M1E1Y3D$P3"]:;%%K,$1,.&E!9'-J4$-13$AQ:C,O<C=K=WEG-TA9.7EB*R8C
M>$$[<D@T+S4Y8W!B6&5Q;FHO;4U69#9Q95 K9E1&6&5Q;FII<G965'AX5C-Q
M>"M0*V981E5$<5AM1%)D3$U!,4,Y:7148W8V8TAQ='@U3B8C>$$[4W4Q9C$Y
M37-H:6Q/*T585$-E4TUA<S%A2VAV8E-D3V-%>5-P+TUH1$0W>&M$16IM>4)T
M53E74'!8+U!P9U-P>EAT<$%V2V5:26PO;28C>$$[8VA2.35W:4I02D))0U=1
M96102U4O<65N<D9O9E1D;S,U5$EV>$QS9G1%5DAU3G-T3VUY1"M%+TIR1V5"
M-5-$8R]N3'EN0D$X.'5R,B8C>$$[9VIJ0EIQ5$EX;T)86E9*66XR07A';GE%
M,7=N-4MC.$%,2D-J+VIB44I"+V],>F%K,U5#>6AL;E@O:UEQ*VM0<%E:3#AT
M36,O5#=Z4R8C>$$[4$AI95<O=5$P,G9E8TIR>3)&:&]+4E=B1B]R1#,Y>6M4
M:%%V=S=19E=/3E0W3CAH,7E1>#1G1&-T+TEF<G!I8VU1:V--9'9-+W%T1R8C
M>$$[9E@O3C,O5G,P-R]U250K3E K5TQ)8T],*V1,+T%%;R\T<%!&;"]M>"]W
M0DUF*TID<$XY-6YL,5,V5%9,3S%T=%!73TTR<VQV33@W3B8C>$$[25-E64IA
M3TDP+S)!*VYS36MC66E/16MN,U5N1V-H2C1G05!),RMG2G9/=V$R:TDV8T<O
M5FQ,8S8S+S-N:2\Q1B]6:7%P:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<58K669,3VHK64Q23%A5-&954TIX3$,V<U5D2$@W4W-U-'DS
M1&YL:DYX87-U1T]15DI"9B8C>$$[5U!-5VEB6&%0<E=M3#!U;U9(,3)-9CA!
M1G-+,%=99C559$<O>50Q>7EO5#5E;5@R9G,K4'I9,T](4#%$-V8R+T0U2GAP
M,G R1W!7<28C>$$[,U9J3VQX07A)-6]A,%ED5EED5EED=V0X;VY!>$Y%53)X
M:TI#=VAT43AY84)P-VU/.'8T27!U;F]C=UI39F%.875F;T=4:&AN3&M#:28C
M>$$[5U=-95I3=3$X-G9F>C-51VUA2G%&>6):=V=M:VI3,FEB:V]93GEU1VIB
M;V5N1W91,#-Y,E=M-%%$2U529G@K-7%J<4]):T--='9H.28C>$$[-DEF+T%"
M=&5)>7(Y4C!H6$)#=BLX=G!6.2M.3&%/=C!S4&YK4C1592M8,F9R6DAX1#-2
M*S,Y4VI9954Y4DYN1$AR5W4S,2]-:6=30R8C>$$[2U%7:UHY=CE(16-P*V)/
M835+96]J9F]I0CEV,W-965164VM4.6XS275,>6(U56E)66%68E!)1T0K<DQ'
M<W-H661#6DI/5&XV5&M$<28C>$$[8V@O:4Q0=TED=UA4*U502W,W8W!.27-Y
M+W=$=G=14G$K+SA!;$M!,S0T0G%-9R]I4'I5-$E(96=G:BM8;FQC-F=,,S!*
M95%I35AO+R8C>$$[5TIV4V]71%8T."](=%=N=%A,4'IM5&AQ+W-$2#AT1&EV
M.4I2<TAK+WER05$P96M766-F-W--16)0="]L<T,S-#579%)K4#A!169M>28C
M>$$[1T-!,V])=412=$ET,4MW5TYV17)-6%I5:5)15U!5;6<V-4$U2DAM4WI%
M04]16%1A5'!C,%1X4S)C16M59TMU:E)O5DE0545%66I*228C>$$[8F=L5$%(
M66A%;VE2;W%);U)%0596555!03)!04=12EI.-'$W1EA9<7 S2"LX.'8K;S,V
M<U998C4V+TUI1'EF8F%F1TQ#4R]U-W-$,"8C>$$[-#9V0D9X-&M#:S5J9$=C
M=49(06)G2&MA1'%Q;C-L4'I06F5:9$=J,4\P4C1L3'9&3D)+2U!(3$=E3&]2
M,3)0:4%F8D95,CEA3')Z6"8C>$$[-WAI<G97:2]N6#=X:7)V5FE(5C$K.%EQ
M-S%9=C4Q*SA9<3<Q678U,2LX9DQ&6&5R1B]/=C-J1EAE=$8Q-7(Y-'A6,W)2
M9GIR.30K928C>$$[2W4Y5TPK9&9V1TMU.5=,*V1F=D=+=3E73"MD9G9'2W4Y
M5TPK9&9V1TMU.5=,*V1F=DAZ>%8S<7AF>G(Y-"ME2W-F,4QY5C57,4A7228C
M>$$[.5=U678Y2U)':FM%8FU.2E%A9C-O46IM5B\R-C=::U$Q531X-%%D;6E7
M;FA+6$5E86$R1VYA3'!Y8TQ#,G0W4D1S4D%I4C$K9D5#=28C>$$[5E1Y4VQZ
M2DQB1T59.&A33#E73"MD9G9'45I/.5=,*V1F=D=+=3E73"MD9G9(>GA6,W%X
M9GIR.30K94MU.5=,*V1F=D=+=3E73"MD9B8C>$$[1'%0;&ER=E9I+VY8-WAI
M<G96:2]N6#=X:7)V5VDO;E@W>&ER=E=I-C@Q*SA9<3<Q66@Q9&9V1TMU.5=,
M*V1F=DAJ5$9897)&+T]V,R8C>$$[:D96:S=+,71)5DE)2TYU3BLR2W0R+SA!
M=E!&+W%,*W)&5E1&56DX,2MA4#!"*VE0.48K<VY69%)G,#9N4# K2'(X=FI(
M=W1Y230O6B8C>$$[,G(T:D95.7A62E@X>7AP-7EI.'1E;6I03' W-F@V;VMB
M,48T5$Q%1F%0:'@T=GE*5FA*6#130V\R2E94<D95;3AS*UI)9&1456YI:B8C
M>$$[168V3S%#-3 U,'$U4$LR8FIY8FMK64)B-U9&3$%!:F5T4496+VUZ6#$X
M=F58<C-75V@K<TQ:<7)M271W0C5/1G%70W510GEQ84M4-"8C>$$[031Q:F1,
M=F9R*VU7;#DV5%%F5V]9-2]29C=396]G8FDS=71A2$97365B9GI#5'DY-6<P
M-U-$87=Z1R]22%=34S970GAZ=45G-')'528C>$$[97 O96-X>5I147)B-UEQ
M>D1&5T8V4BM:14=O965,,WEQ8F5'1U<P:VQJ5U581%-03#93:&E6:E-);W1/
M5D=$>4-H,D930T%Q>4QZ2B8C>$$[<D$P6%%.43%C>&EB-FA"2F-E:7HK;4@Y
M3E,S2&U1,4LY0G-C5E-Z>5@U-7-V3DPV<W1T14EX<&PR,7-(5U%3<DMG,E=5
M14%!8VU6<28C>$$[3'9T43EX:7$O=T$Q*V)L,$,V,#)!>%%Z3G%"=4%"3&-R
M8G-O=#142U=(3E-R3'1X66QH>'%/=E1&57DX=F%V2')/9S9D<7E)23%V-R8C
M>$$[84LT.4E.>C1'5D%X5&M!2VQ394HR>%9J1W5F;61"<%!M=%!,-S)A5'1*
M9#)&;4IO-7A61&8X=#59>6YW1D%V24%-95%)3S)+<S-X5B8C>$$[:"]K6'HW
M4#5Q=7(K35=-14YR6D)E3C5B,U@Q<$I'85=334M0,U5.3F]E9BMQ>6YV:7%B
M*V-F36%E5R],5CER8E)P2TQ*031H:VMA228C>$$[3U-W54E(5DII1V)L4F9H
M<%AQ44YW<6\K4V9.;BM*.4IL,40V;S%N-F,W=V5K>F-Y94MQ,6$X56]2>C1S
M=%!H645B,'A60V5C4%!C2"8C>$$[;'4Y=$Q74T]#43-.=F0S2F%79#1J1W1P
M15IA<W%1>F9#-4A!2#=823=+,CE&52LP8E50,&QO.6IQ4'!'2#8W8GA82&]K
M.&EN<6](-"8C>$$[:S!&86-Q67%X4V(X,$Q33'IV.$$T5F$S475B:4\R5SA7
M5U9K-5-2.'I'47-"06Q',W<X=4Y/<F=G:D-R3EIP0D9#.&I&5E9&3$9N4"8C
M>$$[1E%!2S%:=7<Y.$-S32],<CAY5C@U>C9N171H.5185'91-'I,2S!Q4VEC
M3V%R>6EH2VHT2VEO<5%E9WA632]04&Y+,CAP-E9B,S P828C>$$[>6TU=6]B
M3TI:2D1&1W)3:VMV2DE%;$MQ:4MZ13A4:7%9*UA.62]45V<R1W)E:TEF<C!#
M5"MI<FE53'I&86-W0E=N>4AY1TMS93@R+R8C>$$[;5AP+VPS6%ET2&QH5C5P
M8F%/-4UK:VI2<4),9'@R>7%!<V-R36%/-VYI2S!8<'952W-Y>%9G2&PW.#)R
M9EA03T0K6')F5'EK4WHS9"8C>$$[=70V6G%L=G%Q:'59:3E-8E O<F)B94]'
M;%HS8V8W>GDO=T-O,S9S0W5T+SDU-'8Y4F8Q67%Q67$W1EA9<3=&6%EQ-T98
M67$W1EA9<28C>$$[-T9867$W1EA9<3=&5T$K85!Z6&HP1'I%*VAV<&)4,T(O
M=T(U-4),>%8K8TMV1'DO9'1W.5=9=$5/=E-U+U1$4W%'="]N:C56,'E4528C
M>$$[3%I)3&DU=DQ%5%5J0FA62&%",FDK,39J3T%:5C0O64Q!9DAX-&9&:E-P
M:&%F;69:6&UU*UAT371B2FU46#=D<G!*,VUH5F\T=W-P528C>$$[*VM#>DYY
M.4@R;T1V.%$T-$9:<FER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ
M;F-F-WIY+S9J9G%X5EI"4$%)27=:1D)#9R8C>$$[145J=WA69CE9="\Y*W O
M=U%X5C,Q:3,O04XK<"]W045-5F0Y670O.2MP+W=1>%8S,6DS+T%.*W O=T%%
M359D.5ET+SDK<"]W47A6,R8C>$$[,6DS+T%.*W O=T%%359D.5ET+SDK<"]W
M47A6,S%I,R]!3BMP+W=!14U69#E9="\Y*W O=U%X5C,Q:3,O04XK<"]W045-
M5F0Y670O.28C>$$[*W O=U%X5C,Q:3,O04XK<"]W045-5F0Y670O.2MP+W=1
M>%8S,6DS+T%.*W O=T%%35919'AP,F=83C!T,V,R,7!09$HV9D=E4DDS:R8C
M>$$[2'!-6&IO-T%N-$A02F9!-VI&54QC95=V2FQZ3$Q.8S96<# X<WI'4V%3
M4S-G9&YC:6A::7EK:VM(<6-64E5';2M8<F573V%#,71)6B8C>$$[;U%W:&MJ
M:FE6:T1L;6)I44MJ:S!J13 X5#0T<6I0<D9V+W8Q4"M#1TMU*W-7+SA!=C%0
M*T-'2W4K<U<O*R]5+S1)67$W-GAB+W=#+R8C>$$[52\T25EQ-S9X8B\W.50O
M9VAI<G9R1G8O04PY5"]G:&ER=G)&=B]V,5 K0T=+=2MS5R\X078Q4"M#1TMU
M*W-7+RLO52\T25EQ-S9X8B8C>$$[+W=#+U4O-$E9<3<V>&(O-SE4+V=H:7)V
M<D9V+T%,.50O9VAI<G9R1G8O=C%0*T-'2W)*-31$0DE"27!*56=!165'2W8O
M.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA
M:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @
M('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HY,T4P-4(X
M0T4Y-S5%-C$Q0C1".48U-3E!0C V-D%&,#PO>&UP34TZ26YS=&%N8V5)1#X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HY,T4P-4(X0T4Y
M-S5%-C$Q0C1".48U-3E!0C V-D%&,#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT
M/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HY,D4P-4(X0T4Y-S5%-C$Q0C1"
M.48U-3E!0C V-D%&,#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HY,D4P-4(X0T4Y-S5%-C$Q0C1"
M.48U-3E!0C V-D%&,#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1"
M,3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S
M=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.D,X,S!!0S W-S4W-$4V,3%!1C@W1C%$0T,R
M-4%$-3!!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#$V+3 Y+3 V5#$U.C4Q.C0V+3 W.C P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#HY,T4P-4(X0T4Y-S5%-C$Q0C1".48U-3E!0C V-D%&,#PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q
M-BTP.2TP.%0Q,#HR-SHT-RTP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B
M92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R
M;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!4
M4&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @
M(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \
M>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(
M87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E
M<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53
M:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM
M.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N
M:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A0
M86=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @
M/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA
M;64^0V%L:6)R:4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y#86QI8G)I/"]S=$9N=#IF;VYT1F%M
M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO
M<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N
M4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A
M;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1FEL94YA;64^0T%,24)224)/3$0N4$9".R!#04Q)0E))0D],1"Y0
M1DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z
M1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @
M(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A
M=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@
M;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z17AT96YS:7-&;VYT4V5N<V4](FAT=' Z+R]W
M=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E;G-E+R(^"B @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(" @(" @(" @(" \<F1F.D)A9SX*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT
M2VEN9#Y0;W-T4V-R:7!T/"]%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*
M(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y#
M86QI8G)I/"]%>'1E;G-I<T9O;G1396YS93I&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^-# P
M,S,\+T5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93X*(" @(" @
M(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^36EC<F]S
M;V9T/"]%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/@H@(" @(" @(" @(" @
M(" @(" \17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CXU+C P,CPO17AT96YS
M:7-&;VYT4V5N<V4Z5F5R<VEO;CX*(" @(" @(" @(" @(" @(" @/$5X=&5N
M<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G13
M96YS93I+97)N:6YG0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E
M;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C4P-3$Y-C,Y
M.#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3X*
M(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M
M/C4P-3$Y-C,Y.#PO17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M
M93Y#86QI8G)I4F5G=6QA<CPO17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP
M=$YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/E!O<W138W)I
M<'0\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/@H@(" @(" @(" @(" @
M(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/D-A;&EB<FD\+T5X=&5N
M<VES1F]N=%-E;G-E.D9A;6EL>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N
M<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93XT,S@Q,CPO17AT96YS:7-&
M;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-:6-R;W-O9G0\+T5X=&5N<VES
M1F]N=%-E;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I
M<T9O;G1396YS93I697)S:6]N/C P,2XP,#$\+T5X=&5N<VES1F]N=%-E;G-E
M.E9E<G-I;VX^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS
M93I+97)N:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN
M9T-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N
M<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3XX-C(T-3@T,S4\+T5X=&5N<VES
M1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @(" @(" @(" @
M(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XX-C(T-3@T,S4\
M+T5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/@H@(" @(" @(" @(" @(" @
M(" \17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^0V%L:6)R:4)O
M;&0\+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @
M(" @(" \+T5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $;
M 9P# 1$  A$! Q$!_\0 '@ !  (#  ,! 0            <(!08) @,$ 0K_
MQ !'$   !00" 0("!0L# P$( @," P0%!@$'$1( $P@A(@D4%B,S5I85%R0V
M05%VI;74U24Q5#(T0T(8&71UD[.VTBAQ66'6_\0 &P$! 0$  P$!
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MR+D-;_:F[,YO/&I21=FX I4NF-T%"!5<P$LD1[\:ZR]AN">V(Q3!DD"E<D?
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M%^[I\X@07[WZG-'_ )M-DJRN,H043[X5TSJY=AAV-=D-0$@T44$>(+]W3YQ
M@OWOU.:/_-ILE65QE""B??"NF=7+L,.QKLAJ D&BB@CQ!?NZ?.($%^]^IS1_
MYM-DJRN,H043[X5TSJY=AAV-=D-0$@T44$>(+]W3YQ @OWOU/:*?;=>R597&
M4(*)]\+*9U<NPP[77=#4!(-#Z"/J%^[*<<>WJ!!?O?H>T?\ FZ]DJRN,H043
M[X64SJY=AAVN-T-0$@T/H(^H7[N^'GL5PG'BW$[@WB<KNR@MI>OI-8F1^/$]
M@CPT$NL)N! '-]02YA)D[:LJ8<>JC,C%)P):DG@3*6.7NZ%2G$HHG5%VOGF+
M]V4\]B7V2WC+&)#)I9&HU"6.32]!'VN2OK<PB2.C^W0ME5-L)1/*Q.H+.7)8
MR-Q<R&PDT50(FE8:D1T(-&8<.9S=AGT%^[*>>%Q'EX?&&RWD"J9EM[;.6>NN
MLC)#HFC2F?P=')CV1.YID9AY" US$>-*4J=T9*A< BH GI24Y=* 4EU45J+3
M'DM,W9]!?NRGGA<;M'[51:(R5ZF,5AT!8)6_1^/Q1UD3;'*)'APC,-:C4D+8
M%J\@\"@UGCJI4MH@;J&!2ID!_2G**4[**P7[LIYX7%8Y9\/CQ[7PJ\,7MM;*
MV5CGV]L!E=L9I<:U<"8X_.E4)FQ;>9*V:CM1.:$94@5(QEN-3R3@_+C3GDEA
M<$A2GEKLVW4];KA?N[X>>Q<5E8U4;96N.L)+$VLK"UIF5C;B4BVB=O:VMG3(
M&=$6'YVM>E&>GH 5*5R)N"40"H% 1'BF<W"_=WP\]CX#)>W@$:"LP@H!@$H#
M0!CD100!T1  0$T/Y6I78MSH:-12FM1(J@(!UJ B/%:+@N>1*[VTX[O/"X\1
M3%L]^DR@=/M^O9S3UQE$"B;?#M3.KEV&'ZZ[HJ@)+ZSPB/$HN"YY"N]O7=Y[
M 4Q;/?I,H'3[?KV<T]<91 HFWP[4SJY=AA^NNZ*H"2^L\(CQ*+@N>0KO;UW>
M>P%,6SWZ3*!T^WZ]G-/7&40*)M\.U,ZN788?KKNBJ DOK/"(\2BX+GD*[V^O
MM=ZX[=P%,6SWZ3*!T^WZ]G-/7&40*)M\.U,ZN788?KKNBJ DOK/"(\2BX+GD
M*[V^OM=ZX[=P%,6SWZ3*!T^WZ]G-/7&40*)M\.U,ZN788?KKNBJ DOK/"(\2
MBX+GD*[V^OM=ZX[=P%,6SWZ3*!T^WZ]G-/7&40*)M\.U,ZN788?KKNBJ DOK
M/"(\2BX+GD*[V^OM=ZX[=P%,6SWZ3*!T^WZ]G-/7&40*)M\.U,ZN788?KKNB
MJ DOK/"(\2BX+GD*[V^OM=ZX[=P%,6SWZ3*!T^WZ]G-/7&4)=$V^':FVKEVF
M'ZZ[H:EDE]9]!'B47!<\A7>WKT[[P*8MOOTF4#I]OU[.:>N,HBZ)M\.U-M7'
MM,/UUW15+)+ZSZ"/JHN"YY"N]O7=YXW<+PIBV^_290.GV_7LYIZXRB+HFWP[
M4VU<>TP_77=%4LDOK/H(^JBX+GD*[VYV>MU_$"F+;[])E Z?;]>SFGKC*(%$
MN^':FVKCVF'ZZ[HJ@)+T/H(\2BX+GD*[VY3CCV IBV^_290.G_<=>SFGKC*(
MNB7?#M3;5Q[3%&NNZ*I9)?6?01XE%P7/+#/H*[V[K]WGL!3%M]^DR@=/^XZ]
MG-/7&41=$N^':FVKCVF*-==T52R2^L^@CQ*+@N>6&?05WMW7[O/8"F+;[])E
M Z?;]>SFGKC*(NB7?#M3;5Q[3#]==T52R2^L\(CQ*+@N>6&?05WMW7[O/8"F
M+;]9K,H'3_N.K9S3UQE$71+V8=J;:N':8HUUW15+)+ZSZ"/%:+_E=GD*[V]=
MWGL!3%M^LUF4#I_W'5LYIZXRB+HE[,.U-M7#M,4:Z[HJEDE]9]!'B47_ "NS
MR%=[>N[SV IBV8,UF4#I7](ZMG-/6E,HRZ)>S#M3;5P[3%&NNZ.I9)?6>$1X
MI1<%SR%=[<IQQ[ 4Q;/K-9E Z5_2.K9S3UQE&71+V8=J;:N':8HUU[$=2RB^
ML\(CA*+@N>0KO;E../8"F+9]9K,H'2OZ1U;.:>N,HRZ)>S#M3;5P[3%&NO8C
MJ647UGA$<)1<%SR%=[<IQQ[&=3*7->GHK;G!@6)3Z*:I%28"A2G,I1*$I/6A
MQ"X19M"W,"BJFI8J;):!(!U* #.%./,M_I3*>>QF$]%5 C^:$0(>_LJG 8 -
M"^L&:#H8896H^WMKFE:!ZZ@IKM00A"E*O)/]>6K^$T/]8?>:LV<_PAD_;R_*
MEKX#^HL,_A2/?TA)S-=J\5]S1-B<$]C;>0HX X!2#X@%NY%*K#&W&M\1V79\
M<)0Q^0EM*@ (1JMUMR::XR".B"3^D*DDHAHY S&-8*U+<EAZ HXHZA8 <[Y]
M.K2EI32%+,M%U+'TGE)C1RU*JE&0K3:D*6F?W?M:^5G4EXR15HL-C8BM5M54
MZ-]0K-F9NP%M*SFUM?1N:@:0V6J5UGQK.58DQ+K3]SV34FLQ!="2Z*]8:.1U
M$0M':VXL=N[;>"W0B1_S$;G\58Y8SC$((C2T;XWD+P)55 5K0M:B$<)&N(K@
M:=80>08$)A8@TZG:UFS-C6G:%E3C=6:LZ<F)..E%1%?+Q70U>RNV&_5UX;MC
MF.:Y%5%13M5E6C+6Q9LA:DH[6EK0E($W!6J51D>&V(C'TV1&:RLB-VM>US5H
MJ*;YSYY^\< < < < < < < < < < < < < < < < < < < < < < TN#)DPX
MFR"$G($*J45:B$4745:]YWK6M0UK6O\ _?!Q9_*G/W4VSY1+_P 9/_\ 1+__
M %X.15 'F?XQC\N3_!H4S"1Y*$P,BXX80HB4D(0*XVH2&N1=$,O-90Q)8\U:
M4ZMX_()#T-VJU('%:!((IN753BT6FMZ5IS]_P?/8/S;\5O)ESONV6>N"WO\
M3QMG)EN[MNKG'WJ*QYDDA2UY;:_DR12AK:&:2LQB^/O"5/(8\M<F14-%4Q,N
M-3J$AQX*BI2OK>A+IMVH:3=1NM2)ADPE#I:U;=I/<$N*J!VC"PHI.SQ8+(?<
MBE/H\5,UZI[2NC9&*GU7KF E8\$Y2IZU$(>N?7RL;:]-#UL]N!#8XCG]RF>S
M\05JE9!Z9ZN8_'*T[7#B3T):HM.[''H591U%HDR="80(*\]-6H:""E>5YLLJ
MG,.BC--'0S5_7P2)NTR>HA$DA$DG)[4TMBATZ6F)-PC'AQ<W0I/\LQH"D]#7
M9>>E1I*C-4%TJ!Z8;<"&3.+0>4$@%&Q3]@C;^T1::(28O-T(I1'R)*A8'Z*.
M0RW5HE21M/%^58\H*JX-RA*M).+RE-%0%NN]C;2E\</=%;&0L93GM G(6+F<
MI0A,=$2156M$RI6W@'56G3J*TK0@\XD!1M:5H6(6. 0;%?(^TDU\A)OXUQL2
METGD!M/!KQO3JD1M2N&GQ6?RZ=PEH2MCZC<E!JI]1/MNY 4\MYC>G)0E51:+
M%"@Q2G2"TNKZ*JITIY0K4A^*AX,*9-,8^NN"]QMJA\?OE)P7&EEI;E1NTTW:
M/&=?^2K_ !MK[DNL13Q6Y*BU3I2K?)$</<'94>J#4#$4\!]W!=5V'JB>E:K>
MEVV\G'QD\OK#>6I<[)M0*8(9!;)7%T\[@]S[63FT<^C:2=L-)1 GU=#KBQV.
MOOT<G,;V>HH^DI#6YW1DJJ$G44HU9!(BHJ;?=%[I<0_'_B8^)$C2WE>40KO)
M(;8ANN0X3JY+QXV7Q:+7*3K43RELIBQ0JXZ^WQ$.N#*T\ZH?'&N*0QX>I"^.
M*%S):FY55L7_ "XNJJ4V7TI>E;[TNK5.9+EM_,3Q]NVZVIC\!<7EZDMVZW>$
MU1<<)?6N1Q!-864NEO[M+KF,SLWH5UOT,/N8UBMD>HD)24#K.5J!G8?RJ XQ
M42)14V[N]Z=KRS"YQC38L;&]R7,;>O>CC$S.A7*D"18[*"@T&:0V)CQEG+SB
M@"",PI* T8 BH(0:4K2O!"MEJ_+"U-Y;[^0-A8-'I>M<_&E>SL%R[AJV-C26
MP+F3LP,,G.A#(^5?C'QQD;&R21J6/G=&43*FJ-2F3/*Q6B5$%"JE$15];T3=
M54KV-72>>/BP]/WC@U1.8I)FT>4C[>N.VVG,>2H*PI$XV B\DE5Q_IBZ/"QH
M6Q].@31-Z;D1WY,6T5N:<N@@D-QQ;C4*+?NI7F6Y4ND71C:2UCBPI3'\X*=B
M I5MY WI0,KO 0TA-,")Q.&1]<$I'0X8BOK*!J#UX(9;Y1+_ ,9/_P#1+_\
MUX ^42_\9/\ _1+_ /UX!K,'I2D>!2E*4I1XE%*4I3%*4I*'FE*4I3TI2E/]
MJ<J[>2>R$39S7W4V[D*4C\D_UY:OX30_UA]YJS9S_"&3]O+\J6O@/ZBPS^%(
M]_2$G,UVKQ7W-$V)P3V-MY"C@#@'B, 3 B ,(1@&&H!@'2@@C"*E:""(-:5H
M((J5K2M*TK2M*UI6F.$545%1:*EZ*ERHJ;%10J(J*BI5%N5%O147:BH<Y_"$
M0[+7!\A_"MQ&(A!:.8#NE9 DZM0@4V%O"M6/[>UME!UJ8I(@,U'(8TXJJT+
M%0J1IRBZ%@#6OIFGB);EG:-Z<PDUHELR263;SF_X-(;%8R6BQ8M+F.M&126F
MH3+U5K'N5:JIYOH,JV):.D>A,1=6'9$XMJV&CE_GL"V7OF(<*%7]SVV?.K,2
ML5]R(Y[&HE$2O1KGF9Z0. . . . . . . . . . . . . . . . . . . .
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MV?-)8=ON2YJV%;$1D-D>,NW[=G6BL"8:V[]T5U:[#HM5U-P*M&=V'2E#:AJ
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MA MIKE=3[88JH"LZY7 & >B>E%-0KN7U[<[Z^E )U-IO_H[N+7NQJ4B]_4A
MLIIE=3[88JH"=M<K@# /1/JH$%=RY2N.5 G4VF_^CNXM>[&I2+W]2$"RFF5U
M/MABJ@)VURN , ]$^J@05W+E*XY4"=3:;_Z.[BU[L:E(O?U(0+*:974^V&*J
M G;7*X P#T3ZJ!!7<N<YO G4VF_^CNXM>[&I2+W]2$"RFF5U/MACJ@)SKE<
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MS$^(@=* )VMSM\2[W-<UK)%8\^*$0NK\[KJ^R];L*YV\/Q!+TVB\EK4>,-?
M^Y\VEM[6>6/5L))%[V^/R2+2Y#;&,0:07>5(ARJ;1UZ:$D 4SI$TA^E[1&'*
M5C2'+8VUK2!T 6"(E*ZU-U%W^#0+0?& @ET;LI+9K?'^Z<0:Y6\>6C!;&?'2
M6U\D:9B[>&JU\375(>HU'Y>IG-ODBHMB/%%WB51LAE>5BI$VDN(52HCL%5E/
M5-B*J7^O*B]2_7C;Y(Q'R-\8+3^5"1$? 83=.UK-=>B*7N+82=$H^ZM'Y944
MD+J4?1I) THZ&FN"^B@"(HDDQ0,PLH(JA'%R:JJF!!JGXB_CX\J++N]K)O;^
MYMM+G3RXD*DEPD=P$$>+A0;=64?;XN+HSQAV:ZOERA*8FU(W(#=%04'2,NI4
MO2J5[230)X46_=NWTV[,T++6K\A['7P4K$EG[I0VY!S=#K?3]?\ 0]W(>RD,
M/NLV+WJW+XK4H^Q.F3S!H:USHRDG&@5J6\BJRJ<"<PHP8*BIM2EZIS3;T*IG
M_%M^&<F(=%)WF]X[@*9T3,XKJ4N"U#.HC?1C B,2)@"$H<A)^LT;T2VE*SXX
M24<?(2FLDHPP(NJY;J*31*_./P_@USX;9B6>1]HV.Y]P"8H?$8BKF+75>[ES
MVM0P/"@DXUN0F3H0=822Y+$9TN$(L,> Y5,+H(357;1:<,-O3UP]317GXE?@
MBS2&?PPSR@M(OG5L6"ZTAF4&;)6WJY6U)[)&/9-T&XQJ[2ZT?XD../)KFP#-
M+=2D"(UY^5_(F''@47!>G3K6[$J6W_'%\+US[XWO*Z:QN&6'\B+#7*N^GO!<
M.7(HTL@\JM\_VM9Q6>?H4D;WLM=,S4MQECD^B:I8>7'"HHY&_+NK7\V[-HY:
MCOW7*JM5$HB*NVM_"[N=%&KRP\;7Z[3-8IAO3 7Z[4ACC;+6>%,;X0\N*V/O
M4:531D7@4MM%3875[AJ)7+V5(>N*7.\63F2)N3*6>GSO!QHM*^F?*&#E?FIX
MH0:\-+ 2^_EMX]>/!8!P)S?BD[R0L/BXINE9U0A JA22%=#@TE+;&U2PE_<F
M U.ZH&U0B5)SC0HM*T6AS6\9?CP>+-]I3;Z,R\V.VU-OM?*[5HK#5;+@$3I<
MYMUL%ZIJ;9+>)O-C$._-2YW-6E-OYOXRR*KFD.)4ECU5LA0B4JOE1R5BI6E]
M&HJK2FU*YK38MQT)1?$ \*7$ZZ)"'R;M"I%99J<7ZYIA4M0B31=A9I*7#'M^
M-69HD<V)BF!Q,5?GEE.<FQDD9Q+(ZJDCF<6F$.-%NNVYSU)XM'=^V%^K?,-U
M[-3B/7(MO*#'DN.36*+@.<>?*Q]^=(N\&-;@72A*PA$_,KHVB4D5&G-.1F#3
MFFDU+-&)L/?#G(TIB,!1J=#J$O<RI09):2H#_EWQU5A$34:PL50J1F51)MPE
MU$L+,";0HB@3Q5>/HWV.*+N7:[W5?CB;TG/$>$8A)ST^H]*!44+"(=.L ]P=
M9IM*@I4=2\UJ&O86.FNM B%#D4J\D_UY:OX30_UA]YJS9S_"&3]O+\J6O@/Z
MBPS^%(]_2$G,UVKQ7W-$V)P3V-LJ$-:YK2E:TI4-*UI3- BQ45,_[X%4(<T_
MVKK3/^U.0I^\ < < CJ[MLH[>>UT_M1+"NV/7!B;W%',5 !,-2E.Z$Y*4XI*
M#K2@5[6H&2Y-YN0B(7)4YP!!&6$5/IV-:LS8=K6=:\FM)FS9R!.0D5:->L&(
MUZPGTK_#BM1T*(E%K#>Y%144^;;%F2]M65:%DS:5E[1E(\I%6B*K$C0W,2(R
MMWW(3E;$AK_A>QJI>A6[P&N;(9WX_MT/N ;F[=@9$^^/]UB1F",.'*K8G@9T
M;R(PW!JHN3QC\@R&CA4%"5JEQ5B(&: NHZ]G^H=E2UGZ11)VSD_W/I%+2^D=
MD.1$1J2EJM6.^!1+F+*S?ZB6^U76AMA,1R(JT.M?3^U)B?T>AR=H+_O?1^8C
MZ/6LU557+-V6Y(+(]5HYZ34K^GF/N4I$=$>K55$J76YT4[N. . . . . . .
M . . . . . . . . . . . . . . :E!/U18_P#X07_WSN#BS^5.?NIPH=?@
MEN4@N5:^<.=ZFQ$TMOESY(7COM&6=@7EH[Z>/UW/*&-^6L"L5(ZJ%0J5+AET
MX'$U+FI%JB7I5\G GIUJBR#QMKW4I_A1$XHE%7FBKOV&FO7P2;D$(+>JF>ZT
M!F2YMA?F!:*Y<&E\F\F;8V^F5LO)[RDFGD8C )R\<KO6NF3P8S)9:;#)O I@
MN>[?W 0]:A2D;5C.SKB@U]W^6ER+>UJ)L5%2_P!%VIS4FYZ^%SY OWE79NZK
MKY&,[E8^PU_+17AM=;-2[7VZ83$+;V/':$=GXO;A1=%PLDB1%+UCS*D%UGF'
M2*\KH!V''WB:%M='0+X..LFK2EZI15N_S(M=E=U*T]22/"OX9DH\5)+X3OSC
M<6)2$'BSX=WG\9I(0QQYP:C)F^W3NS ;EI94VF'GBHD;&_Z*.A*Y&OH<L4N+
MH%8693916I+D1, JW.3%R+__ %Y[&8\IOAR2#R0N/<6[(9#;F*21O=+.CLBQ
MMC$[-#.Z-T4F<*E][G"^S_&@LTJD<JOM$V1^\=?RLV*UU;=6,>9"UL=7.MRK
MALCD(BTSTZ+?Q-IMSX%7!B-POAJSV4WF)GCCX.6/\@+6SAR>D3XI?+F.]Z8G
M:^/H'1H<7-U=%B-MBYD"4D!#(%[J[+6HULH>M-6E*CA@J[=ZU]_)1^R_P5;@
M6\O@BN4X7(\?(LACMU/+:Y8)U:2S4ACGD7>%N\F!7! V6OOK<]3,BVV26S@=
M)NC6D1^L;=1J3HLSHVY2T:5<0CFY]<;T:E*W)2EZ8+<O52]GA)XJ>35@/$ [
MQ&OC,?&BYD7@UE&>S5G%<7MM<=&B<FM+&)#'G>M\VF27!7$3%M=0J(\!2V0V
ML(HH;@2-(8<4-P;SV\<7.17:R5O6JW^WGL54L[\+?R2M@981Z'?F!K0^.%^+
MOW<LS9]P/O!/+6VFB<Q\4)38.&VAA<JN7+)/=!1!FR;O@9VX-3L[_D]@8E:^
M*P]$E+3D*E8NNE%2FU$1:>JHZM=GJEW<L%\+?X<TF^&^P7>M^&YD<N5 [IN5
MNKE_,%0]+%Y6SWC+M^TQ&\E &MI1;:9:U]=H\T/-K(B4 @5MVLYQC98G @P"
MX0CG:U+J42G+TZ%;K>?!QE4+M1:FW:NZ%OW!;;OX=?F9X5+',F(.):=REOE)
M,&V2M<_3DF'"-)9XZG*=TCT@-$)S<C'10).<$M4IH(MZ*F)=;T_\Z.Y)6XP2
M[X/%[!HIG:A!?BUE+"W_ /\ V"'KR!5.=O)2LO0TR'P@B-I(P%MLW(RI4FCR
M1CN.*S<?4D.$M;%3A _RU(*MB!W$<2'@NLF"U361-E/W*JWU1=E5)DC?PIY$
MU2>USVMN=%:)X7YG?$+\FWXUMC*XMT=HWYL06\$*9HTC.-4!!^7H61<5E->5
MRP8D#J1'_EDH2P!2:":USDIM:U/_ &T]Z&F6O^%1>QH@MC8I="[%G7U78?X>
MODKX$QQ9$X5+$25S:+KM=MHU )ZY$2!Y=C"G9KC\(<@S=*A,3)EISW\DS%%H
MP*#% *[:M-KD=MPUKMF\W[Q[^&U>BQGD;XWW48[M0.'0RTMAK4VAO4FMN&[3
M;(?*D%K/&YELK&V^[T/>IPOL\L!$)>@43>$7(;X<CN$V1A&PV\/J).C4OR@1
M7514V[52OI556[UXWTOV7(IX7O\ AQ^1]Z/-J&>0+WY*(G&S%NO)VQ/D3 K9
MO+M>4(X:UVLAI$5D5LV2WC/<!!84XR2.QSU-";LO=O7BY9:AU%$PNB%@HI-6
M CJ(J4VHJ*N.'+<BHFQ=J'S6U^&;>:SK#X '0>[=LE\R\-[_ /F#<"1BE,3E
M9L:FUN?,*<77>),VL@6=];G=IFT-B]Q4Z5A4+#CF1=(4)BI?0#<$*50*KD57
M7;43JB(G2XJ-'O@03MF\=KP>.BRYMM'WYSQYNAX^6/O:^R3RIDT]88[<.Z$/
MG=0/MM9C>Z36(@34<VQ5.EF#9:6 M0Y1)$;)(4JN/E)G5L>!=>KD6E$1R.HE
M/3@B5W5K3>?TK(D21N1I&] E3(D*%,0C1HT9!29(D2IB@DITR5,2$!*=.04
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M"H.HE4Q05=VH.VSFWAU[-LK4U->E*%<;MDWTZD0P+#,_]"405 L%"H.H53%
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M,:]63$5SXCFHG3/GEIZ>. . . . . . . . . . . . . . . . . . . .
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MFFA9=%!&N.A<(:TK52,1E6=F<W;!3>O7EV^5O F8D6^5KO3?OSJ[KPZ]Z("
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M?LZ:8L"T+-FFU1\K/2KOWP8C7-<U'7PXFJY8;WHBTGSG73L X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MQ6LBPUN>QJW$@\^<?0' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M@+ Z9<*9[S!U0$;:Y6EC";U)J!4B<Q7<O;"N/+B!.AP=\,KN+3OQJ!O]_2B
ML#IEPIGO,'5 1MKE:6,)O4FH%2)S%=R]L*X\N($Z'!WPRNXM._&H&_W]*("P
M.F7"F>\P=4!&VN5I8PF]2:@5(G,5W+VPKCRX@3H<'?#*[BT[\:@;_?TH@+ Z
M9<*9[S!U0$;:Y6EC";U)J!4B<\YO^17<N>?("=#P[X97<6G?C4#?]9TH0+ Z
M;. ?^X,'5 1MKE<6,)O4FH%2(*[ESSY 3H>'?#*[BT[\:@;_ *SI0@6!TV<
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M:;G'6D&!0/!(J#JIGM[BJ8I_3:!/+.'?9U;0]?=OLN2TT^72 7G[Y-]O0A,
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M2F. >80A#F@0A#2M<UH&E*9KBE,UQ^W%*4__ *I2G[. 4E\D_P!>6K^$T/\
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M:16:W37GEAZ>. . . . . . . . . . . . . . . . . . . . . . . .
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M(L)[(D*(UKX<2&Y'LB,>B.:]CVJK7-<U45KFJJ*BHJ*J'U\X',< < < < <
M< < < < < < < < < < < < < < T2=72MG:]!^5;DW#A%OVW01E%TTE3'&$
MHPASGJ.>ER(!M<TK2@2ZC$(7M#2HJTISZ$A9-J6K$^U9=FS]HQ:HBPY&4F)M
MZ*NRK8$.(J;?6A^"?M6S++A_=M.T9&SX5%5(D[-P)5BHFVCH\1B+A=6^[:43
MN/\ $^L(ACLO#8!-./)NX+&S.JEMC=H[=S^31ZKJE1FG)/R_-$$;,84#($P
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M0V2<1;"JR;@_?UUGK/ALE64:Y6SSXTS#9*Q$:]KE;%<E?W-2KX;V-\Y9]6-
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MM7BON:)L3@GL;;R%' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M*QW^\2+.^0XVU\D[:Z12YD;P9"KSVZ<S8?=>&*RJ#^7.9Y:W!HI4I2*F&UHS
MO13HS5[CAT0 /'0\/:M'=,;:T;2+ E(L*;LN:NGK#M*$D[9$\Q::S8\G$74:
M]R(G\: L*/\ M:GW%:FJO5](-$+&TC6%,34*+*6I+7R-M6;%=)6M)/1%U5@S
M<*CG,;K._@QTBP?W*OVT<NLE:_SR^4WA_A%Y+QY9Y(6)1>PCR4M-&ZEW%AS8
M7[0J;TVD;ZFB6HTA6QKC,H*)2F3(4M53D@5.:SIIVC^Q-$M,_P")HM,LT8T@
M?>[1>V9JMFSL5?\ #8=LQ4:C(CUHV'(V@C7/B/U(41D)FL=9_MK2O0[]FD\L
M_26P67-TFLB6I:,E";L=;=D0];78QM5B3L@KFM8S6BPW17T+Y6TNE;J\<1;I
MW:V9Q^=1%U#E&^1UP)7I>T(0"-1JP@K10W.27<(%K6XDI7%";6I*Q*0=2H*>
M?6I9-IV).1;/M:1F;/G(*_O@3,-T-]+Z/8J_MBPGTK#BPW/A1&_N8]S;SOUF
M6K9ULR<*?LJ=EY^3C)^R/+1$B,K1%5CT3]T.*VJ(^%$:R+#7]KV-6XS4IF40
M@S68]S651N'LI.>UWE+XUQ]K*UIL+L7NRI(D!@/K78VF*>M?3F$I(SL_%2!(
MRDU.QUV0927BS,5:W)2'!8]ZU6ZY#>:G9.0A+'GIN6DX";8TU'A2\)*8Q(SV
M,3FI3&0_$G\34#F='8--)!?67%?9Q/Q_@LLNTYJJYJ$-$SC&&L^+B[!TT+[)
M"50RM<@K4%!"#W>6^F&F$2$V9M"1EM'Y)=LYI':$G8T)GK^^%-16S:42]:2S
MJ>M%HATJ9^I>B,.*Z6D)V8MZ<39*:/2$W:\5_I^R+*PG2BU6Y*S*5]*I>5"2
M>;7Q$[@^3JRW5K_#0^*6Q=8[5=%E/D#&)G!%3.G+;0*:RF=39B7/T>154N9:
ME 3$6E$M<JU-1-G>%R+6*J=S?H)]-;-T59:5JZ;MG+5@S/VYMNCLW(V@R,Y8
MJL_26?(1X<O,Q$;"5L1TY&B0X5T2+JK"5C#IS-./J/:&E#[.LO0MTI9<:7UY
M1VD,K.R#H+4A([]5/ST")'EV*Z(CX;9."Q\6]D+6^XCWEHOS+_$%N/[[D^6]
MN;,-QWM61?QNL^4[*#"1?[E)K@W;7.CR@.!3%/FT<?*,,'[PA(!DH75/[<^G
M%F767H;:=N1&WLF])[:6"U')ZNLVQX<*!$1?\CYER(EU7+^Y.U_V+]0[2OM/
M2ZS;%ANN?*Z-6.D9RM7T;:-KQ(L>&Y/\[)=%5;TU4N/<G^&K8)\.)77LD]\_
M)=R), > ^^MY)C(FPI0&M!93Q>/K(O%@)@BSU(3690E*#BE"Q"#0?.+OJAI%
M+M=#L*5L#1:$Y%:K; L22EHJM6[]TW,,FIM7JG\T1([7N6M]%H&_3+1^.Y(E
MN35O:3Q$5'(MO6U.3,)KDV:LK+OE95&HM=5CH+FM3T]2;;'>''C5XW2"6RFR
MMJF2$/TU,+J^."58]N9@4Y1AIP6UE ^.;F3&VBIYYIPVJ/EMK>:+I"8G&4C1
M%IO@V]IKI1I/+2<I;EKQY^7D47[$)[($)%>J(W[L=8$*$Z:C:J(U(TRL6(U-
M:CD5\17?<L+0S1G1J8G)NQ+)@2,Q/*GWXC7QXJHU%5R0X"1XL5):#K.5RP9=
M(4-5U45M&,1MFN=6.T#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%(_)/]>6
MK^$T/]8?>:LV<_PAD_;R_*EKX#^HL,_A2/?TA)S-=J\5]S1-B<$]C;>0HX X
M X X X X X X X X X X X X X X X X X X X X X X!QU\L?A2(;SWM@5W
M+$S]%XXB(=DCE<XB$MSFQKG9U0N(UB:>17Z.KV] WST*52L0F+C$Z+N-JG<S
MUQBJBL"SVK0_ZNQ+#L*T;&T@LZ)I-K07PK*=/Q84Q#@PHD)&.LZ<_50XL2)9
MVNQD1(:.B:J:T)L-&:BL\:TM^DT.V[<L^V+!M"'HVK8K(EIMD8<6!$BQH<17
MMM"466B0X<.T-1[X:Q%;#JNK%6(K]='VABWPWO$-B="Y%)K:J+QRZF*J9;?>
M4R6[[NN&&M!;JDDU<W./;5'3<7RS&G",5:U$&N*4IU2;^IVF4Q"66E;4;8DE
M_AD]'Y25L6##391CY&%"F:4N36F'438=IE/IKH?+Q4F9JS'6S.?XIRWIN9MB
M-$6M:O9.Q8DM6MZZL!J*NU"YL>C$;B+82RQ2/,<89DU,)VF/-*!E;$],4#@E
M VITR4JFM*4]A0?2E*?[4ISI$S-34Y%='G)F8FH[OYHTS&B1XKO_ %1(KG/7
MFIW67E9:3A-@2DO E8#/Y8,O"AP(3?\ TPX36L3DB&<Y^<W' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' *1^2?Z\M7\)H?ZP^\U9LY_A#)^WE^5)
M^(13A?:Z"DP)ZC#*YA98L:Y5E+ ]O:9T80L@*.+*V*6"611;%WMP$).!OEX_
MI,F8*@-4F0]^&(LDO-=J\5-$V)P3V.05LO!+RNC=LFDIQD3H@N/'WN6N1(:7
M#2"8GR,.MB;>P"3Q5U;&A04<4]7$FC=**I'V,S"%G.;-WW-N \M=ZUK8^((4
M[6V_!*2X'"2YP@C[5-01&-@F#7$Z'!BS;*0LR(,@01H*DTY12/HW:BM.S44'
M&G4;BTU#33#-A5 S1I;U4PVI"MK 549_0$UO5F& +JB"%+0T8',H)@RW'8\\
M0 %4.15"E+"0?2JRK.;B7^E,IY['A4M^]VJQHI]KIEM6"QE" !&V'4.VCGN>
M;C7L0U D!U* U6B9S<+]V4XX]A4M^]VJQHI]KIEM6"QE" !&V'4.VCGN>;C7
ML0U D!U* U6B"_=E../8"+?O=JL:*?:Z;-JP6,H0 (VPZAVT<]SS<:]B&H$@
M.I0&JT07[NF[CCV BW[WZK&BGVNFS:LKC*$ "-\.H=M'/L/-QKV(:@2 ZE :
MK1!?NSSQ_KZJ$6_>_58T4^UTV;5E<90@ 1OAU#MHY]AYN->Q#4"0'4H#5:(+
M]V>>/]?50BW[WZK&BGVVFS:L%C*$ "-\.H=M'+<\[&O8AJ!(#J4!JM$%^[IN
MXX]@(M^]^JQHI]MILVK!8RA  C?#J';1RW/.QKV(:@2 ZE :K1,YNPSZ"_=T
M^<0(M^]^JQHI]MILVK!8RA  C?#J';1RW/.QKV(:@2 ZE :K1+LK\8>=POW=
M/G$"+?O?JL:*?;:;-JP6,H0 (WPZAVT<MSSL:]B&H$@.I0&JT2[*_&'G<+\4
MZ?($6_>[58T4^VTV;5@L90@ GVPZAVT<J&'G8U[$(@) =2@(EHV<W89]!?NZ
M?($6_>_58T4^VTV;5E<90@ GWPZASHY4,/.QKV(1 2 J4H"):-=E?@7[NGS^
M.@$6_>_58T4^VZ]FU97&4( )]\.H=M'*AAYVNO:AJ!(#I/"):-=E?@7[NGSB
M!%OWOU6-%/MNO9M65QE" "??#J';1RH8>=KKVH:@2 Z3PB6C797X%^[I\X@1
M;][]5C13[;KV;5E<90@ GWPZAVT<J&'G:Z]J&H$@.D\(EHV<W"_=T^<0(M^]
M^JQHI]MU[-JRN,H0 3[X=0[:.5##SM=>U#4"0'2>$2T;.;A?NZ?..?4"+?O?
MJL:*?;=>S:LKC*$ $^^'4.VCE0P\[77M0U D!TGA$M&%^[I\XY]0(M^]^JQH
MI]MU[-JRN,H0 3[X=0[:.5##SM=>U#4"0'2>$2T87[NGSCGU BW[WZ+&BGVW
M7LVK!8RA %/OAU#MHY4,/.UU[4(@) 5)/"):,+]W3YQSZ@1;][]%C13[;KV;
M5@L90@"GWPZAVT<J&'G:Z]J$0$@*DGA$M&%^[I\XY]0(M^]^BQHI]MU[-JP6
M,H0!3[X=0[:.5##SM=>U"("0%23PB6C"_=T^<<^H$6_>_18T4^VZ]FU8+&4(
M I]\.H=M'*AAYVNO:A$!("I)X1+1KLK\8>=POW=.GJ!%OWOT6-%/MNO9M6"Q
ME" *??#J';1RH8>=KKVH1 2 J2>$2T:[*_&'G<+]W3IZ@1;][]%C13[;KV;5
M@L90@"GWPZAVT<J&'G:Z]J$0$@*DGA$M&SF[#/H+]WKZ=/7J!%OWOT6-%/M^
MO9M6"QE" *;?#J';1RH8>?KKVH1 2%U)/ ):-=E?@7[J<.GJ!%OWOT6-%/M^
MO9M6"QE" *;?#J';1RH8>?KKVH1 2%U)/ ):-=E?@7[J<.GJ!%OWOT6-%/M^
MO9M6"QE$ *;?#J';K<J&'GZZ]J(0$I?2> 2P:[*_ OW=/G/<"+?O?HL:*?;]
M>S:L%C*( 4V^'4.W6Y4,//UU[40@)2^D\ E@V<W"_=T^<[-X$6_>_18T4^WZ
M]FU8+&40 IM\.H=NMRH8>?KKVHA 2E])X!+!LYN%^[I\YV;P(M^]^BQHI]OU
M[-JP6,H@!3;X=0[=;E0P\_77M1" E+Z3P"6#9S<+]W3YSLW@1;][]%C13[?K
MV;5@L91 "FWPZAVZW*AAY^NO:B$!*7TG@$L&SFX7[NGSG9O BW[WZ+&BGV_7
MLVK!8RB %-OAU#MUN5##S]=>U$("4OI/ )8,+]W3YSLW@1;][]%C13/?U[-J
MP6N40 IM\.H=NMQH8>?KIW(A 2EU)/ )8,+]W3YSLW@1;][]%C13/?U[-JP6
MN40 IM\.H=NMQH8>?KIW(A 2EU)/ )8,+]W3YSLW@1;][]%C13/?U[-JP6N4
M0 IM\.H=NMQH8>?KIW(A 2EU)/ )8,+]W3IZ@1;][]%C13/?U[-JP6N40 IM
M\.H=NMQH8>?K4':B$!*7TGA$L&NROQAYW"_%.GR!%OWOT6-%,]_7LVK!:Y1
M"FWPZAVZW&AAY^M0=J(0$I?2>$2P;.;L,^@OW=.GKG<!%OWOT6-%,]_7LVK!
M:Y1%A2[X=0[=;C0T\_6H.Y$(M*7T'@$L&NROP+\4Z?($6_>_18T4SW]>S:L%
MKE$6%+OAU#MUN-#3S]:@[D0BTI?0> 2P:[*_ OW=.GKG<!%OWOT6-%,]_7LV
MK!:Y1%A2[X=0[=;C0T\_6H.Y$(M*7T'@$L&NROP+]W3IZYW 1;][]%C13/S'
M5LW+!:Y1%A2[X=0[];C0T]1KIW(A%I2^@\ E@UV5^!?NZ?..?4"+?OK-%C13
M/S'5LVK!:Y1%A2]F'4._6XT-.4:U!W(A%I2^@\ E8UV5^!?NZ?..?4"+?OK-
M%C13/S'5LVK!:Y1%A2]F'4._6XT-.4:U!W(A%I2^@\ E8V<W"_=T^<<^H$6_
M?6:+&BF?F.K9M6"URB+"E[,.H=^MQH:<HUJ#N1"+2E]!X!*QLYN%^[I\XY]0
M(M^^LU6-%,_,=6S<LKKE$6%+V4HZAWZW"AIRC6H.Y$(M,7T'@$K&SFX7[NGS
MCGU BW[ZS18T4K7YCJV;5@M<HRPI>RE'4._6X4-/4:U!W(Q%I2^@\ E8POW=
M-W''L!%OWUFBQHI6OS'5LVK!:Y1EA2]E*.H=^MPH:>HUJ#N1B+2E]!X!*QA?
MNZ;N./8R">BJ@1_-&$&#WR"J<DPD-"^L%*T&$P\^HA]M#1;4$$/6( --@"&,
M7CGNI2KR3_7EJ_A-#_6'WFK-G/\ "&3]O+\J6O@/ZBPS^%(]_2$G,UVKQ7W-
M$V)P3V-MY"C@#@%5H_Y2-3_Y&O\ 8$J&NR=.SN,LC"2>#<V\Q$YS6#P.S]RI
M(R?D  *.*)L*BUZ8Y^37\U08%>\M$C;S6Y"F(9W%[ M3P!P"N?C[Y!$7U47=
M;1Q0^(/-GKECMR]H#GDEW"M/,B47F"1S3[(&=S2EB1R@IN4@6-):$QS;7 3"
M[R%H"F=U##?_ $!8S@$57ONRRV,M1-KL/[>YO#;#&FB^K.S%!-='A>K6)6MG
M:$(1^P*AT=UZ%  XS):?YBIY@1 +$&H'V6AN.@NU;J-W ;PMQ13Z6Y%*4K6X
M+W-*VNK*\.# ^- U3JQQEV"N9GEK7M3HB=H\R.K:Z(UC:Y-B-:D/( !)/ *G
M^6_E8S>)4*:9U((:]2IF5'20]W4MZPAK1,K-$8D\S)X&-Q5)E*=1)'-N95#?
M"XR9\G]*7TP#=^5FL 3%027W MA3U]?W\ < HY<CS,60"+^0LC*LO(WE1X\7
M:8+9/$<%,(BWOLT32:#PV:1UZA!!2AT)=WJ8"G<:CT&@5#PR=_?7EJ;W I@6
M'KTC8IW!>(-=@A%4-0UK2E:A%C8.:9U%K45,T_VKBM:9_P!JUIZ\ ^5P4GHT
M"U6F0*G52E2*5*=K0F(2ESD>02,TI C-<UC<VEJEA@0ITYC@X(4(#C "5K$J
M>AAX *26^\UDLZDMA&95;-UAK1?2,JG9#)I.^]+2V2<A?.T +=-KBB8%D>DL
MT'2"*G$;.&1,ZHQI7D+FPAT"0<7P"\W (:O_ '>_,1:F3W3'$7>:I(J6A4N+
M.S.#.V*2F]0O3(U;F<J>EB4KY5O+/[S2413@Y*!4+)2H#=S#"0(QM9Y7L=T?
M(N\WCRBBB]J=+/$".5ORIW1G =_EU+,D4U+:Z)B-2#37M.:B4,KG) I"234T
MP##WM0ULSB!;/@%?;PWR76FFUE(J7 '"8I+Q3LN EK6:0LR9[97$]N7NWY12
M11;JND+,SM34YO4N<2%3>FC3$C,<33%@ZA2< V"P]W WOMR3/_HHZ0@_Z:W7
M@SA%GI>U.CFU.]I;KS6T[R!4O8U*UG4"4NT)6K2ZMJU<D 2I+*)6K @^9-?'
M>\$Q< I3=;S,;+.W%N7!97;YP,1PFV#)<!@D;9*XZH(E+Q*I8Q0*$P)V0G"3
M5@3[/IB\K&V&*Y$LJW.39$9M(W UH9HZ>I.9SP!9&S]QFZ\-I[979:4AC>V7
M,@$/GR%M.4D+3VQ-+H^WOQ;8I5)L)U"IN"O^25&DT"6)0094(0T]M )%X!S]
M%YM2KY=<<58)8H&T^2S-XS+2TUS8ZK*=95(10,*1;"EJ)G4H9=]&QRY^27*0
MIU"$B!.5MYVC6.S@%C6J$P'0+@&F7#E2J$0B32Y$T4?5,>:E#F!J$L4("U84
M^HC:'*T;6]K2""2MU!XD+,[+ZDDC"B;%RH1*4T"F%CO/V,WQEMK8^T6X?F=H
MN:VLJ$N1*I$P.-&.XKQ9UROK6%J6MN$:<I0(K?M*P:J2T4IC4\BZH\LCZ-8%
M:-$IGG0'0+@%<_)SR#3^-4!;KB.,4.E#(9+&".O(2'DED,:DCXKHD_*0%*I
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M)D]2.7Y)3*&0,IQWW;+Z9WW V7QH\VKCS[S5N)8N61M='FR<%PJX[$W3I_*
MGMRVE^(WCE/)!9NWYS2V*4$TGZ>;7*<I/*41R]J1M\81OTD;S7*A@$20J7)F
MMZ_A/8'MM-Y:7[N%\1B;V(-<*@LO&Y=?=*4VBM=/&S5CM=;WQ^:6X )H[6Q0
M-"D!]RIU*W$3B"8C1'&U&E_*!C'(+2DRU2[I^?'<'7KD X X X X X X X X
M X X X X X X X X X X X X X!2/R3_ %Y:OX30_P!8?>:LV<_PAD_;R_*E
MKX#^HL,_A2/?TA)S-=J\5]S1-B<$]C;>0HX X X X X X X X X X X X X
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M$A,6L/\ RFJ;&U2X=IPOG3V]$<I[#$A BP-@X X X X X X X X X X X X
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M (GC4;AW7R-=V/9/ _/C='[T?R6._P")XU&X=U\C7=CV3P/SXW1^]'\ECO\
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D)JE*./4 *ZT*=,2+4Y2>/<1=3*[ZU'4(0!#41$V$557:?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>performancecharta01.jpg
<TEXT>
begin 644 performancecharta01.jpg
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M+!$@R,^2$\EA((   @@@@  """"   ((($"0SWL  0000  !!!!   $$$$
M@2P1(,C/DA/)82"   ((((   @@@@  """! D,][  $$$$   0000  !!!!
M ($L$2#(SY(3R6$@@  """"   ((((   @@@0)#/>P !!!!   $$$$   000
M0 "!+!$@R,^2$\EA((   @@@@  """"   ((($"0SWL  0000  !!!!   $$
M$$  @2P1(,C/DA/)82"   ((((   @@@@  """! D,][  $$$$   0000  !
M!!!  ($L$2#(SY(3R6$@@  """"   ((((   @@@0)#/>P !!!!   $$$$
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MN.$&MSPO+Z_X"U_X0G&=.G7<M+:U?__^0_(GFQ&UG*CYDVV7^0@@@  """"
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M8P+XI-'SE;9MV^9GE7KV\YLT:5)J?N)$U'*BYD_<'M,(((   @@@@  """"
M  +51^#S*+/Z[%.5[HD"_G'CQME%%UUDNLJ]8,&"P]Z?Y<N7NY8!Z]:MLS%C
MQK@R=;N^^*3^_DJZ)5]8\O/+:DH2M9RH^</VC7D(((   @@@@  """"   +5
M0R!G@_RGGGK*W09/(^6'I<&#![O9:]:L"5N<]CR-WC]HT"#38 [WW'./_?*7
MOPR]I9X/MC=NW!A:]OOOO^_F=^W:-72YGQFUG*CY_79X1@ !!!!   $$$$
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M?OW;;[_==*_Y\\X[SQ8M6N1G6]1RHN:/;:B"7JC%0@Z_+2M(E6(10  !!!!
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MCS_^N T;-LSZ]>MG5UUUE3WRR".F;2=+4?-GJIQ,;3?9_C ? 0000  !!!!
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MUXF5!,GR)9N?R?4UQLU##Y7<>E!'ISN3Z-:#M]UV&U?SDY]NEB"   ((9+%
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M7^U."3M4"0)J': K_[$6 DDJ!K;N,-NS+[T=TJT#6P2!OBH!RKJ[@+H5D!!
M  $$$$   01JO@!!?LT_AUEW! 3Y67=*.: ,"^S\+*XR($5W ;4.2/?N.+YU
M0+)6 ;[%@%H'Y-7)\ %1' ((((   @@@@$#&! CR,T9)09D2(,C/E"3EY+K
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M@*\LT!@#M [(X FE* 000  !!+)4@" _2T]L33XL@OR:?/;8=P00D,"^H'6
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M*P%4(:"* #_=^/.?)ZF*81D"""" 0!4*$.2GB3]TZ% ;/WZ\S9HURS6S]U?
MM7I^?K[-GS_?E:21]I7T7+]^?==\_XHKKK ! P:X^?JC_O4:I$_IO//.<\^-
M&S>V*Z^\TJ9.G>INTZ?^_3[-F3/'-FW:9-___O=+-?W7[>\^^. #5SG@*Q6B
MEA,UO]\GGA%   $$$$"@^@BT#(;LT2-9TJT#W_\X?(! M0S0> 'J%J \>B1+
MM8,;X!QS5-P@@0<'#%0E@+]KP!'A8P@G*Y+Y"""   (9%JA5'*0,EYFUQ6G
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M>H29*@Q("*0K0)"?KE1"ON+@/_:55UZQKEV[6MVZP?T\2!D3(,C/&"4%(8
M @@@@  ""%21@)K\NY8 <:T /@Q>^VX!6K8]J @H*ZG)?[N6A[8"\%T%]-RX
M45FEL#R7! CRRW&VBX*JN]=??]U./?546[9LF?7NW;L<I;!*,@&"_&0RS$<
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MTRPO+\^..^XX6[-FC5M'VWO@@0>L3IWTANB,6D[4_*5V.L,3!/D9!J4X!!!
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M5-.FV&FGG58==NFP]R%YM'C816=7 6J.GRHM7;JTU.)WWGG'78W_ZE>_>DB
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MF]5\I=6K5[OG]NW;N^>M6\,[G?CYOO+ 90[Y$[6<J/E#-LDL!!!   $$$$
M 0000*!:"C0*&DH?&UQ/[7VRV7W3[[$&&X.6U\$5_90I6*Y\TZ8&@_+5P$20
MG^9)T]7ZT:-'V[)ERT+7\*/HKUFSQBWW0;Z_ I^XDF^2[@?:\\&V[\N?F/_]
M]]]WL[IV[9JXJ-1TU'*BYB^U,2800  !!!!   $$$$  @1HBH-OC:5"]!ALG
M) _T78!?LP??(\A/\PWYUEMON<'V%BY<&+K&\N7+W?S.G3N[YW[]^EE>7IZK
M%"C2?202DOKE*RF?4L^>/4TC^&N@OMV[=[MY_H_65[]_50RH+W^J%+6<J/E3
M;9ME"""   ((((   @@@@$!U%D@9Z&=!@"][@OPTWX%#APYU.6?-FF7KUZ\O
MM59^?K[-GS_?S=-(^TH*]M5O7P/PJ3E_?-)M\.Z__WZK7[^^#1@PP"UJW+BQ
M77GEE;9SYTYWF[[X_!J\3Z/R:WF7+EUBBW3[.]W^X=UWWXW-BUI.U/RQ#?$"
M 0000  !!!!   $$$*B! J&!?I8$^#H=M8+[MA?7P/-2);NLYOJZ=9X&JQL[
M=JP;:&_,F#$V=^Y<V[%CAPT;-LSFS9L7VS<UW5<0_\$'']@YYYQCYYY[KAM8
M;\:,&?;))Y^X$?HOO/#"6'XUU>_>O;NI__UEEUWFUE40KXH%;7/5JE7N:K]?
M0;>?T\C]YYUWGBU:M,C/MJCE1,T?VU %O5"+!=Z6%81+L0@@@  """"   ((
M(. $%&M==_T$V]/N5FNP>;)KRJ\*@!J?%.23TA?X\8]_7!S<RUX5([%'O7KU
MBB=.G%B\;]^^0PH*KN07!T%X<=VZ=5W^(( M#@+YXN#J_"%Y-6/MVK7%O7OW
M+E8^OXV@'WYQ,!; (?F#6\RY/"H_,44I1^M&S9^XO4Q.Z[A)"""   ((((
M @@@@$!%"P2!?O%7SAI8K.=L25S)+T<U37#R;<6*%18$XZ8^^D.&#'%-[U,5
MM7?O7G<EOF/'CM:Z=>M46=VR@H("-_*^KN!WZM3)]<<O<Z60#%'+B9H_9).'
M/8LK^8=-2 $(((   @@@@  """"0HP($^>4\\86%A19<P3?UKU?@3LJ< $%^
MYBPI"0$$$$   0000  !!')+@('WRGF^-7+^XL6+K4V;-N4L@=400  !!!!
M  $$$$   000R*P 5_(SZTEI&1#@2GX&$"D" 0000  !!!!   $$<E* *_DY
M>=HY: 000  !!!!   $$$$  @6P4(,C/QK/*,2&   ((((   @@@@  "".2D
M $%^3IYV#AH!!!!   $$$$   0000" ;!0CRL_&L<DP(((   @@@@  """"
M  (Y*4"0GY.GG8-&  $$$$   0000  !!!#(1@&"_&P\JQP3 @@@@  """"
M  ((((! 3@H0Y.?D:>>@$4   0000  !!!!   $$LE& (#\;SRK'A  """"
M  ((((   @@@D),"!/DY>=HY: 000  !!!!   $$$$  @6P4(,C/QK/*,2&
M  ((((   @@@@  "".2D $%^3IYV#AH!!!!   $$$$   0000" ;!0CRL_&L
M<DP(((   @@@@  """"   (Y*4"0GY.GG8-&  $$$$   0000  !!!#(1@&"
M_&P\JQP3 @@@@  """"   ((((! 3@H0Y.?D:>>@$4   0000  !!!!   $$
MLE& (#\;SRK'A  """"   ((((   @@@D),"!/DY>=HY: 000  !!!!   $$
M$$  @6P4(,C/QK/*,2&   ((((   @@@@  "".2D $%^3IYV#AH!!!!   $$
M$$   0000" ;!0CRRWE6BXN+[>677[;"PL)REL!J"""   ((((   @@@@  "
M"&16@""_')Y%147VVFNO68\>/6SERI7E*(%5$$   0000  !!!!   $$$,B\
M $%^!%-=O9\R98JU;-G23CWU5+=FGSY]K'___O;00P^E5=*R9<OLJU_]JOWJ
M5[]*FO_QQQ^W8<.&6;]^_>RJJZZR1QYYQ+3MJ"EJ.5'S1]T?\B.   ((((
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M__K7O]SC6]_Z5JD@7[?)"TOOO_^^F]VU:]>PQ;%Y/FA/MYRH^6,;X@4""""
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M#V5A)@((((   @@@@  """"   (U3X @O^:=,_88 0000  !!!!   $$$$
M@5 !@OQ0%F8B@  """"   ((((   @@@4/,$"/)KWCECCQ%   $$$$   000
M0  !!! (%2#(#V5A)@((((   @@@@  """"   (U3X @O^:=,_88 0000  !
M!!!   $$$$  @5 !@OQ0%F8B@  """"   ((((   @@@4/,$"/)KWCECCQ%
M  $$$$   0000  !!! (%2#(#V5A)@((((   @@@@  """"   (U3X @O^:=
M,_88 0000  !!!!   $$$$  @5 !@OQ0%F8B@  """"   ((((   @@@4/,$
M"/)KWCECCQ%   $$$$   0000  !!! (%2#(#V5A)@((((   @@@@  """"
M  (U3X @O^:=,_88 0000  !!!!   $$$$  @5 !@OQ0%F8B@  """"   ((
M((   @@@4/,$"/)KWCECCQ%   $$$$   0000  !!! (%2#(#V5A)@((((
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M?B\^M6_?WDUNW;HU?G;LM9_?K%FSV+RP%U'+B9H_;)O,0P !!!!   $$$$
M 000J!X"!/EIGH>GGGK*1H\>;<N6+0M=8_#@P6[^FC5K2BW7:/SJL[]]^W;7
M!_^7O_QEZ"WU?+"]<>/&4NO[B????]^][-JUJY\5^ARUG*CY0S?*3 000  !
M!!!   $$$$  @6HAP,![:9X&-;?78'O-FS=WS>X35]/5>J7.G3N[9_U9NG2I
MG7ONN5945&1__.,?[=O?_G9L6>*+GCU[FD;P?_KIIVWW[MVF%@(^:7WU^]>
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M"""   ((U#P!@OR:=\[88P000  !!!!   $$$$   01"!0CR0UF8B0 """"
M  ((((   @@@@$#-$R#(KWGGC#U&  $$$$   0000  !!!! (%2 (#^4A9D(
M((   @@@@  """"   ((U#P!@OR:=\[88P000  !!!!   $$$$   01"!0CR
M0UF8B0 """"   ((((   @@@@$#-$R#(KWGGC#U&  $$$$   0000  !!!!
M(%2 (#^4A9D(((   @@@@  """"   ((U#P!@OR:=\[88P000  !!!!   $$
M$$   01"!0CR0UF8B0 """"   ((((   @@@@$#-$R#(KWGGC#U&  $$$$
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M@ OB55&@,E:M6N6N]OL5]&;4;>C..^\\6[1HD9]M4<N)FC^V(5X@@  """"
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MS..//SZH#(T2:@8'@0 $( "!OA/X_///PV:;;>:64GTO9=3GY%TRZIES1 A
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M BCY'0+/82$  0A   (0@  $(  !"$   G430,FOFRCE00 "$(  !"   0A
M  (0@  $.D0 );]#X#DL!"   0A   (0@  $(  !"$"@;@(H^743I3P(0  "
M$(  !"   0A   (0@$"'"*#D=P@\AX4 !"   0A   (0@  $(  !"-1- "6_
M;J*4!P$(0  "$(  !"   0A   (0Z! !E/P.@>>P$(  !"   0A   (0@  $
M( "!N@F@Y-=-E/(@  $(0  "$(  !"   0A   (=(H"2WR'P'!8"$(  !"
M 0A   (0@  $(% W 93\NHE2'@0@  $(0  "$(  !"   0A H$,$4/([!)[#
M0@ "$(  !"   0A   (0@  $ZB: DE\W4<J#  0@  $(0  "$(  !"   0AT
MB !*?H? <U@(0  "$(  !"   0A   (0@$#=!%#RZR9*>1"   0@  $(0  "
M$(  !"  @0X10,GO$'@."P$(0  "$(  !"   0A   (0J)L 2G[=1"D/ A"
M  0@  $(0  "$(  !"#0(0(H^1T"SV$A  $(0  "$(  !"   0A   )U$T#)
MKYLHY4$  A"   0@  $(0  "$(  !#I$ "6_0^ Y+ 0@  $(0  "$(  !"
M 0A H&X"*/EU$Z4\"$   A"   0@  $(0  "$(! APB@Y'<(/(>%  0@  $(
M0  "$(  !"   0C430 EOVZBE <!"$   A"   0@  $(0  "$.@0 93\#H'G
ML!"   0@  $(0  "$(  !"  @;H)H.37393R(  !"$   A"   0@  $(0  "
M'2* DM\A\!P6 A"   0@  $(0  "$(  !"!0-P&4_+J)4AX$(  !"$   A"
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MB_I$9D$4U3?)B[GN>5UL$-(WY]M-;>AK>Y@_!M\AT"T$9":'0  "$&A)0%'
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MUY[*0P "$(  !"   0A   (0@  $() 10,G/4/ % A"   0@  $(0  "$(
M!"#0W010\KO[^E%["$   A"   0@  $(0  "$(! 1@ E/T/!%PA   (0@  $
M(  !"$   A" 0'<30,GO[NM'[2$  0A   (0@  $(  !"$   AD!E/P,!5\@
M  $(0  "$(  !"   0A   +=30 EO[NO'[6'  0@  $(0  "$(  !"   0AD
M!%#R,Q1\@0 $(  !"$   A"   0@  $(=#<!E/SNOG[4'@(0@  $(  !"$
M A"   0@D!% R<]0\ 4"$(  !"   0A   (0@  $(-#=!%#RN_OZ47L(0  "
M$(  !"   0A   (0@$!& "4_0\$7"$   A"   0@  $(0  "$(! =Q- R>_N
MZT?M(0 !"$   A"   0@  $(0  "&0&4_ P%7R   0A   (0@  $(  !"$
M MU- "6_NZ\?M8< !"   0A   (0@  $(  !"&0$4/(S%'R!  0@  $(0  "
M$(  !"   0AT-P&4_.Z^?M0> A"   0@  $(0  "$(  !""0$4#)SU#P!0(0
M@  $(  !"$   A"   0@T-T$4/*[^_I1>PA   (0@  $(  !"$   A" 0$8
M)3]#P1<(0  "$(  !"   0A   (0@$!W$T#)[^[K1^TA  $(0  "$(  !"
M 0A   (9 93\# 5?(  !"$   A"   0@  $(0  "W4T );^[KQ^UAP $(  !
M"$   A"   0@  $(9 10\C,4?($ !"   0A   (0@  $(  !"'0W 93\[KY^
MU!X"$(  !"   0A   (0@  $() 10,G/4/ % A"   0@  $(0  "$(  !"#0
MW010\KO[^E%["$   A"   0@  $(0  "$(! 1@ E/T/!%PA   (0@  $(  !
?"$   A" 0'<3^#\[0(Z^7,D%E     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829042576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 17, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OBLN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OBALON THERAPEUTICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001427570 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,773,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829896896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,975<span></span>
</td>
<td class="nump">$ 3,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">9,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Accounts receivable, related party</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,244<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">78,061<span></span>
</td>
<td class="nump">13,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">78,778<span></span>
</td>
<td class="nump">14,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_AccruedClinicalExpensesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyDepositLiabilities', window );">Customer deposit from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term loan, excluding current portion</a></td>
<td class="nump">9,881<span></span>
</td>
<td class="nump">9,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,473<span></span>
</td>
<td class="nump">14,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000,000 and 35,000,000 shares authorized at December 31, 2016 and December 31, 2015, respectively; 16,773,205 and 575,126 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">140,898<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(76,609)<span></span>
</td>
<td class="num">(56,142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">64,305<span></span>
</td>
<td class="num">(55,139)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">78,778<span></span>
</td>
<td class="nump">14,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Expenses Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyDepositLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deposits held by the entity for a related party (entity, shareholder, employee).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyDepositLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829814288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,773,205<span></span>
</td>
<td class="nump">575,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,773,205<span></span>
</td>
<td class="nump">575,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">2,333,332<span></span>
</td>
<td class="nump">2,333,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">4,333,332<span></span>
</td>
<td class="nump">4,333,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,809,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,783,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,546,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815576656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue, related party</a></td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">3,823<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
<td class="nump">3,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,912<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,872<span></span>
</td>
<td class="nump">12,978<span></span>
</td>
<td class="nump">5,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">10,217<span></span>
</td>
<td class="nump">3,491<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,089<span></span>
</td>
<td class="nump">16,469<span></span>
</td>
<td class="nump">10,467<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,505)<span></span>
</td>
<td class="num">(14,933)<span></span>
</td>
<td class="num">(9,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(477)<span></span>
</td>
<td class="num">(549)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">(Loss) gain from change in fair value of warrant liability</a></td>
<td class="num">(466)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,467)<span></span>
</td>
<td class="num">(15,557)<span></span>
</td>
<td class="num">(9,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (20,468)<span></span>
</td>
<td class="num">$ (15,552)<span></span>
</td>
<td class="num">$ (9,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (4.85)<span></span>
</td>
<td class="num">$ (27.14)<span></span>
</td>
<td class="num">$ (18.61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">4,221,893<span></span>
</td>
<td class="nump">573,181<span></span>
</td>
<td class="nump">531,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Related Parties<br> -URI http://asc.fasb.org/extlink&amp;oid=16382449<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831564320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Convertible Preferred Stock</div></th>
<th class="th"><div>Series C-1 Convertible Preferred Stock</div></th>
<th class="th"><div>Series D Convertible Preferred Stock</div></th>
<th class="th"><div>Series E Convertible Preferred Stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive (loss) income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,773<span></span>
</td>
<td class="nump">$ 6,454<span></span>
</td>
<td class="nump">$ 16,393<span></span>
</td>
<td class="nump">$ 4,984<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of warrants in connection with preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,773<span></span>
</td>
<td class="nump">$ 6,454<span></span>
</td>
<td class="nump">$ 16,393<span></span>
</td>
<td class="nump">$ 4,984<span></span>
</td>
<td class="nump">$ 20,222<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2013</a></td>
<td class="num">$ (30,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (30,695)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">529,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in Initial Public Offering, net of underwriting discount, commissions and issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign currency translation adjustment and other comprehensive loss</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,890)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2014</a></td>
<td class="num">(39,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">733<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(40,585)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">533,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of warrants in connection with preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,773<span></span>
</td>
<td class="nump">$ 6,454<span></span>
</td>
<td class="nump">$ 16,393<span></span>
</td>
<td class="nump">$ 4,984<span></span>
</td>
<td class="nump">$ 20,095<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign currency translation adjustment and other comprehensive loss</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,557)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="num">$ (55,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(56,142)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2015</a></td>
<td class="nump">575,126<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">575,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of warrants in connection with preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options (in shares)</a></td>
<td class="nump">808,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">$ 820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock in connection with Initial Public Offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(804,595)<span></span>
</td>
<td class="num">(1,494,248)<span></span>
</td>
<td class="num">(2,668,533)<span></span>
</td>
<td class="num">(480,286)<span></span>
</td>
<td class="num">(2,732,552)<span></span>
</td>
<td class="num">(1,916,425)<span></span>
</td>
<td class="nump">10,360,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock in connection with Initial Public Offering</a></td>
<td class="nump">70,498<span></span>
</td>
<td class="num">$ (6,773)<span></span>
</td>
<td class="num">$ (6,454)<span></span>
</td>
<td class="num">$ (16,393)<span></span>
</td>
<td class="num">$ (4,984)<span></span>
</td>
<td class="num">$ (20,095)<span></span>
</td>
<td class="num">$ (15,799)<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">70,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in Initial Public Offering, net of underwriting discount, commissions and issuance costs</a></td>
<td class="nump">67,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">67,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in Initial Public Offering, net of underwriting discount, commissions and issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity', window );">Net exercise of common stock warrants</a></td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrant liability as equity</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign currency translation adjustment and other comprehensive loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,467)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 64,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 140,898<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (76,609)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">16,773,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,773,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ReclassificationsofWarrantLiabilitytoPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications of Warrant Liability to Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ReclassificationsofWarrantLiabilitytoPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications of Warrant Liability to Permanent Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ReclassificationsofWarrantLiabilitytoPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831616960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - Series D Convertible Preferred Stock - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in dollars per share)</a></td>
<td class="nump">$ 8.2932<span></span>
</td>
<td class="nump">$ 7.5351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816380848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,467)<span></span>
</td>
<td class="num">$ (15,557)<span></span>
</td>
<td class="num">$ (9,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of investment premium, net</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="nump">121<span></span>
</td>
<td class="num">(481)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(464)<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(985)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_IncreaseDecreaseInAccruedClinicalExpenses', window );">Accrued clinical expenses</a></td>
<td class="num">(812)<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Customer deposit from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,368)<span></span>
</td>
<td class="num">(11,392)<span></span>
</td>
<td class="num">(9,907)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(18,897)<span></span>
</td>
<td class="num">(18,590)<span></span>
</td>
<td class="num">(12,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">25,450<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Sales of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">6,201<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
<td class="num">(7,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Issuance of preferred stock for cash, net of offering costs</a></td>
<td class="nump">14,517<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty', window );">Issuance of preferred stock to related party for cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">67,233<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term loan, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Fees paid in connection with loan amendment</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Sale of common stock upon exercise of stock options</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">82,786<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
<td class="nump">22,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">69,619<span></span>
</td>
<td class="num">(3,546)<span></span>
</td>
<td class="nump">4,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">3,356<span></span>
</td>
<td class="nump">6,902<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">72,975<span></span>
</td>
<td class="nump">3,356<span></span>
</td>
<td class="nump">6,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">70,498<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Net exercises of warrants</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock', window );">Conversion of customer deposit from related party to preferred stock</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accounts payable</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of customer deposit from related party to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ConversionOfCustomerDepositFromRelatedPartyToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_IncreaseDecreaseInAccruedClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_IncreaseDecreaseInAccruedClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Preferred Stock to Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ProceedsfromIssuanceofPreferredStocktoRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819688736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Basis of Presentation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obalon Therapeutics, Inc., or the&#160;Company, was incorporated in the state of Delaware on January&#160;2, 2008. The Company is a vertically-integrated medical device company focused on developing and commercializing innovative medical devices to treat obese and overweight people. Using its patented technology, the Company has developed the Obalon balloon system, the first and only FDA approved swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Obalon Therapeutics, Inc., and its wholly owned subsidiaries, Obalon Italy SRL and Obalon Therapeutics, LLC. Obalon Therapeutics, LLC is a shell Company, which owns </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;"> of Obalon Mexico DE RL CV.  Obalon Italy SRL was dissolved during 2015 and Obalon Mexico DE RL CV was dissolved during 2016.   All intercompany balances and transactions have been eliminated in consolidation.  </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles, or GAAP. The Company&#8217;s principal operations are located in Carlsbad, California and it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016, the Company has devoted a substantial portion of its efforts to product development, raising capital, and building infrastructure. The Company has incurred operating losses and has experienced negative cash flows from operations since its inception. In July&#160;2012, the Company realized initial revenue from its planned principal operations. The Company recognized revenue, including revenue from related parties, of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, 2016, 2015 and 2014, respectively. However, the Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and has funded its activities to date almost exclusively from debt and equity financings. On September&#160;8, 2016, the Company received premarket approval from the U.S. Food and Drug Administration, or FDA, to market the Obalon balloon system for temporary use to facilitate weight loss in obese adults with a body mass index, or BMI of 30 to 40 who have failed to lose weight through diet and exercise. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. For all periods presented, all sales are to customers outside of the United States.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 5, 2016, the Company&#8217;s Registration Statement on Form S-1 (File No. 333-213551) relating to the initial public offering, or IPO, of its common stock was declared effective by the Securities and Exchange Commission, or SEC. Pursuant to such Registration Statement, the Company sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share for aggregate cash proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$67.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts, commissions, and offering costs. The IPO closed on October 12, 2016. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2016, immediately prior to the closing of the IPO, the following events occurred:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate of </font><font style="font-family:inherit;font-size:10pt;">10,360,419</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, excluding any warrant conversions, were issued to the holders of the Company&#8217;s Series A, Series B, Series C, Series C-1, Series D and Series E convertible preferred stockholders upon the automatic conversion of all shares of convertible preferred stock to common stock. As a result, no Series A, Series B, Series C, Series C-1, Series D or Series E convertible preferred stock remain outstanding at December 31, 2016.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiated on October 11, 2016, Series C-1 and D warrants for </font><font style="font-family:inherit;font-size:10pt;">36,562</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's preferred stock were exercised by Pacific Western Bank (as successor in interest to Square 1 Bank) via cashless exercise resulting in the subsequent issuance of </font><font style="font-family:inherit;font-size:10pt;">16,558</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock on October 12, 2016.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D warrants for </font><font style="font-family:inherit;font-size:10pt;">24,550</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s preferred stock were automatically net exercised resulting in the issuance of </font><font style="font-family:inherit;font-size:10pt;">12,217</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The remaining outstanding Series C preferred stock warrants exercisable for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">24,224</font><font style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock automatically converted into warrants exercisable for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">24,224</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Plan, and the 2016 ESPP, as described in Note 7, were adopted.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate of </font><font style="font-family:inherit;font-size:10pt;">223,371</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock reserved but not issued under the 2008 Plan became available for grant under the 2016 Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company filed its amended and restated certificate of incorporation on October 12, 2016, authorizing </font><font style="font-family:inherit;font-size:10pt;">300,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">10,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">February 2014 Reverse Stock Split </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the board of directors of the Company approved a 3-for-1 reverse stock split of the Company&#8217;s common and preferred stock. All share and per share information included in the accompanying consolidated financial statements and notes to consolidated financial statements give retroactive effect to this reverse stock split for the Company&#8217;s common and preferred stock. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September 2016 Reverse Stock Split</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, the Company&#8217;s board of directors approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock and convertible preferred stock at a 2.9-to-1 ratio, which was effected on September&#160;23, 2016. All share and per share information included in the accompanying consolidated financial statements and notes to the consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for the Company&#8217;s common and preferred stock for all periods presented.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As reflected in the accompanying consolidated financial statements, the Company has a limited operating history and the sales and income potential of the Company&#8217;s business are unproven. The Company has not been profitable since inception, and as of December 31, 2016, its accumulated deficit was </font><font style="font-family:inherit;font-size:10pt;">$76.6 million</font><font style="font-family:inherit;font-size:10pt;">. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its IPO and, to a lesser extent, debt financing arrangements. The Company expects to continue to incur net losses for the foreseeable future as it builds its sales and marketing organization, supports commercialization of its product in the United States and continues research and development efforts. The Company may need additional funding to pay expenses relating to its operating activities, including selling, general and administrative expenses and research and development expenses. Adequate funding, if needed, may not be available to the Company on acceptable terms, or at all. The failure to obtain sufficient funds on acceptable terms could have a material adverse effect on the Company&#8217;s business, results of operations or financial condition. The Company believes that its existing cash and cash equivalents and short-term investments and expected revenue will be sufficient to meet its capital requirements and fund its operations through the next two years.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813152320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses, if any, reported as a component of other comprehensive loss within the consolidated statements of operations and comprehensive loss. All of the Company&#8217;s short-term investments are U.S.&#160;Treasury notes with maturities of less than one&#160;year. For the years ended December&#160;31, 2016, 2015 and 2014, unrealized losses were immaterial amounts, respectively. Realized gains and losses would be calculated on the specific-identification method and recorded as interest income. There have been no material realized gains and losses for the years ended December&#160;31, 2016, 2015 and 2014. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable from related party, accounts payable, and accrued expenses approximate their fair values due to the short maturity of these instruments. The carrying value of the term loan approximates its fair value as the interest rate and other terms are that which is currently available to the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels in accordance with authoritative accounting guidance: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2 inputs: Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables are unsecured and are carried at net realizable value including an allowance for estimated uncollectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest, although a finance charge may be applied to such receivables that are more than 30&#160;days past due. The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical expense, credit quality, the age of the account receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. The Company&#8217;s allowance for doubtful accounts was </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> at both December 31, 2016 and 2015, respectively. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company&#8217;s customers consist of distributors. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div><div style="line-height:100%;padding-top:1px;text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes certain financial data for the customers who accounted for 10.0% or more of sales and accounts receivable. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Single largest customer:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, related party   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, related party   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second largest customer:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or net realizable value, computed on a standard cost basis. Inventory that is obsolete or is in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The useful lives of the property and equipment are as follows: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter&#160;of&#160;3&#160;years&#160;or&#160;length&#160;of&#160;software license</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of the assets to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the difference between the carrying amount and the fair value of the impaired asset. The Company did not recognize any material impairment losses for the respective years ended December&#160;31, 2016, 2015 and 2014. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All research and development costs are charged to expense as incurred. Research and development expenses primarily include (i)&#160;payroll and related costs associated with research and development performed, (ii)&#160;costs related to clinical and preclinical testing of our technologies under development and (iii)&#160;other research and development expenses. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into contracts with third party hospitals and doctors to perform clinical trial activities. The Company accrues expenses for clinical trial activities performed by third parties based on estimates of work performed by each third party as of the balance sheet date. The Company&#8217;s clinical trial expense is primarily driven by patient visits to the third party hospitals and doctors. As such, the Company uses the estimated patient visits based on third-party reporting and the contractually agreed upon cost for each visit to calculate its clinical accrual. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based awards issued to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). Because non-cash stock compensation expense is based on awards ultimately expected to vest, it is reduced by an estimate for future forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for interest and penalties related to income tax matters, if any, as a component of income tax expense or benefit. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to sales of components of the Obalon balloon system, which includes the balloon and accessory kit, EzFill inflation system, pre-filled can of gas and placebo capsule. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when (i)&#160;persuasive evidence of an arrangement exists, (ii)&#160;delivery has occurred, (iii)&#160;the selling price is fixed or determinable and (iv)&#160;collectability is reasonably assured. Determination of criteria (iii)&#160;and (iv)&#160;are based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company does not provide for rights of return to customers on product sales, with the exception of products that fail to conform to the Company&#8217;s specifications. As these non-conforming returns have historically been immaterial, the Company does not record a provision for returns. The Company does not have any post shipment obligations or acceptance provisions within its customer contracts. The Company occasionally offers discounts off its standard prices to non-distributor customers, which are agreed upon and known at the time of sale. In these cases, revenue is recognized net of these discounts. Shipping charges billed to customers are included in product revenue and the related shipping costs are included in cost of revenue. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Warranty </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company warranties its products to be of good quality and free from defects in design, materials, or workmanship for approximately one&#160;year from the date of purchase. The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based on historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is possible that the Company&#8217;s underlying assumptions will not reflect the actual experience and in that case, future adjustments will be made to the recorded warranty obligation. The warranty expense as of December&#160;31, 2016, 2015 and 2014 was immaterial for each year. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Costs </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs are expensed as incurred and included in selling, general and administrative expense. Advertising costs for the years ended December&#160;31, 2016, 2015 and 2014 were approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for 2016, 2015 and 2014, respectively. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock Warrants </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of preferred stock warrants issued in conjunction with debt issuances was initially recorded as a warrant liability and debt discount. The debt discount associated with the initial warrant fair value is being amortized to interest expense using the effective-interest method in the Company&#8217;s consolidated statements of operations and comprehensive loss over the term of the debt. The fair value of preferred stock warrants issued in conjunction with preferred stock issuances was initially recorded as a warrant liability and reduction of the proceeds received. The fair value of the warrants was estimated using the Black-Scholes option pricing model based on the estimated fair value of the preferred stock at the valuation date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying preferred stock. Prior to the automatic conversion of the warrants in conjunction with the IPO on October 12, 2016, the warrant liability was remeasured each reporting period with changes in fair value being recognized in the consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As noted above in Note 1, in connection with the completion of the Company&#8217;s IPO, all the remaining outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As such, the Company reclassified the remaining warrant liability to stockholders&#8217; equity as the converted warrants met the definition of an equity instrument under derivative accounting guidance. The Company performed the final remeasurement of the warrant liability as of the IPO closing date. See Note 3 for the amounts associated with the fair value remeasurements and Note 8 for further description of the remaining warrants.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per common share, since the effects of potentially dilutive securities are anti-dilutive. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive common stock equivalents are comprised of convertible preferred stock, warrants and unexercised stock options outstanding under the Company&#8217;s equity plan. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.</font><font style="font-family:inherit;font-size:10pt;"> ASU 2014-15 requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable that when, considered in the aggregate, raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued, for both annual and interim periods. ASU 2014-15 also requires certain disclosures around management&#8217;s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that will alleviate the substantial doubt. ASU 2014-15 is effective for annual reporting periods, and interim periods within those periods, beginning after December&#160;15, 2016. The adoption of ASU 2014-15 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July&#160;2015, FASB&#160;issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. This update applies to companies that measure inventory on a first in, first out, or FIFO, or average cost basis. Under this update, companies are to measure their inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion. The amendments in this update are effective for annual reporting periods, and interim periods within those periods, beginning after December&#160;15, 2016 with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. Under this new guidance, at the commencement date, lessees will be required to recognize (i)&#160;a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii)&#160;a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09, which was issued in March 2014 and has been codified with the Accounting Standards Codification as Topic 606, is now effective for public companies for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. ASC 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In addition, ASC 606 provides guidance on accounting for certain revenue-related costs including, but not limited to, when to capitalize costs associated with obtaining and fulfilling a contract. ASC 606 provides companies with two implementation methods: (a) full retrospective adoption, meaning the standard is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance.&#160;Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within ASC 606 to clarify various elements of the guidance. While the Company is continuing to assess all potential impacts of the standard, they do not believe that their current revenue streams will be materially affected. As the Company begins commercialization in the U.S. during 2017 and enters into sales agreements with customers as part of this commercialization, the Company will continue to assess the potential impacts of the standard, including the impact to the pattern with which they recognize revenue based on the terms entered into and finalizing the determination of transition approach.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which involves several aspects of the accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This new guidance will require all income&#160;tax effects of awards to be recognized as income tax expense or benefit in the income statement when the awards vest or are settled, as opposed to additional paid-in-capital where it is currently recorded. It&#160;also will allow an employer to repurchase more of an employee&#8217;s shares than it can today for tax withholding purposes without triggering liability accounting. All tax-related cash flows resulting from stock-based payments are to be reported as operating activities on&#160;the statement of cash flows. The guidance also allows a Company to make a policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. This new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2016, with early adoption permitted. The Company does not recognize any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance on its deferred tax assets. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, which addresses the following eight specific cash flow issues: Debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies); distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2017, with early adoption permitted.&#160;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The Company does not anticipate that the adoption of ASU 2016-15 will have a material impact on its consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819717760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Instruments Recorded at Fair Value on a Recurring Basis </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2016 and 2015 are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices<br clear="none"/>in&#160;active<br clear="none"/>markets&#160;for<br clear="none"/>identical&#160;assets<br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>other<br clear="none"/>observable<br clear="none"/>inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>unobservable<br clear="none"/>inputs<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury bonds(2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;active <br clear="none"/>markets for <br clear="none"/>identical&#160;assets <br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>other <br clear="none"/>observable <br clear="none"/>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>unobservable <br clear="none"/>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds(1)   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury bonds(2)   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Classified as cash and cash equivalents on the consolidated balance sheets. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Classified as short-term investments on the consolidated balance sheets. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s investments in Level 1 assets are valued based on publicly available quoted market prices for identical securities as of December&#160;31, 2016 and 2015. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 2 above, </font><font style="font-family:inherit;font-size:10pt;">61,112</font><font style="font-family:inherit;font-size:10pt;"> warrants were exercised to common stock and all of the remaining outstanding </font><font style="font-family:inherit;font-size:10pt;">24,224</font><font style="font-family:inherit;font-size:10pt;"> warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock in connection with the IPO and are equity classified at December 31, 2016. Prior to the exercise and the conversion, the Company estimated the fair value of convertible preferred stock warrants at the time of issuance and subsequent remeasurements using the Black-Scholes option-pricing model at each reporting date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following assumptions were used in the Black-Scholes option-pricing model to determine the fair value of the convertible preferred stock warrants at the exercise and conversion date, and December 31, 2015:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">October 12,</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed risk-free interest rate   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.90% - 1.64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.28%&#160;-&#160;2.06%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed volatility   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.42% - 62.36%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.76%&#160;-&#160;70.66%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.40 yrs - 7.96 yrs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.15&#160;-&#160;8.75 yrs</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock fair value:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.41</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C-1   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.72</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions were determined as follows: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed risk-free interest rate &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Based on the average yield of U.S. Treasury bills as of the valuation date for the expected term of the award. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed volatility &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Based on the historical volatility of a number of publicly traded companies comparable in size, business model, industry and business description. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected life &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Based on the remaining contractual term of warrant as of the valuation date. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected dividend yield &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Based upon the Company&#8217;s historic dividends and dividend expectations for the foreseeable future. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred stock fair value &#8212;</font><font style="font-family:inherit;font-size:10pt;"> On October 12, 2016, the conversion date, the Company used the closing price of its common stock. Given the absence of a public trading market on December 31, 2015, the Company considered numerous objective and subjective factors to determine the fair value of preferred stock at each valuation date. These factors included, but were not limited to, (i)&#160;contemporaneous valuations of preferred stock performed by unrelated third-party specialists; (ii)&#160;the prices for preferred stock sold to outside investors; (iii)&#160;the rights, preferences and privileges of preferred stock relative to common stock; (iv)&#160;developments in the business; and (v)&#160;the likelihood of achieving a liquidity event, such as an IPO or a merger or acquisition of the Company, given prevailing market conditions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2015, reasonable changes in the unobservable inputs would not be expected to have a significant impact on the consolidated financial statements. The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no significant transfers into or out of Level&#160;1, 2, or 3 for the years ended December&#160;31, 2016 and 2015. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides reconciliation for all liabilities measured at fair value using significant unobservable inputs (Level&#160;3) for the years ended December&#160;31, 2016 and 2015 (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value <br clear="none"/>measurements <br clear="none"/>at reporting <br clear="none"/>date using <br clear="none"/>significant <br clear="none"/>unobservable <br clear="none"/>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2014  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of warrants for the purchase of convertible preferred stock   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants exercised</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of warrants to stockholders' equity (deficit) </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2016   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Instruments Not Recorded at Fair Value on a Recurring Basis </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of long-term loan is determined by Level&#160;2 inputs and is based primarily on quoted market prices for the same or similar issues. The recorded value of long-term loan approximates the current fair value due to the proximity of when the long-term loan was negotiated.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813155152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss per Share </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except shares and per share data): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,890</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,221,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the outstanding potentially dilutive securities determined using the treasury stock and if-converted methods that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:13px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock, on an as-converted basis   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,443,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,654,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,443,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,714,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813167216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Balance Sheet Details </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity <br clear="none"/>(in&#160;years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated <br clear="none"/>fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury   </font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;year&#160;or&#160;</font></div><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,501</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity <br clear="none"/>(in&#160;years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>gains</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated <br clear="none"/>fair value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2015:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;year&#160;or&#160;</font></div><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid assets   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest receivable   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress, or CIP   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense for the years ended December&#160;31, 2016, 2015 and 2014 was $</font><font style="font-family:inherit;font-size:10pt;">0.2</font><font style="font-family:inherit;font-size:10pt;"> million for all periods, respectively. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,399</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813156832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Term Loan </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2013, the Company entered into a loan and security agreement, or 2013 Loan Agreement, with Pacific Western Bank (as successor in interest to Square&#160;1 Bank) allowing for borrowings up to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">. In addition to the interest payments, Pacific Western Bank received warrants for the purchase of up to </font><font style="font-family:inherit;font-size:10pt;">8,693</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s Series&#160;C-1 convertible preferred stock. On October 11, 2016, all the warrants were net exercised into </font><font style="font-family:inherit;font-size:10pt;">2,689</font><font style="font-family:inherit;font-size:10pt;"> shares which were subsequently issued as common stock on October 12, 2016 in conjunction with the IPO closing. In October&#160;2014, the Company amended the 2013 Loan Agreement and executed a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> credit facility with Pacific Western Bank, or 2014 Loan Agreement. The 2014 Loan Agreement was separated into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> tranches, Term Loan A and Term Loan B. Term Loan A was </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">, which included the existing </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> of outstanding debt and the additional </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> that was funded upon closing of the 2014 Loan Agreement. Term Loan B was </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> and was available upon receipt of at least </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> in proceeds from the issuance and sale of the Company&#8217;s equity securities to investors. Term Loan B was funded after the close of the Company&#8217;s Series&#160;D financing in January&#160;2015. As part of the 2014 Loan Agreement, the Company issued Pacific Western&#160;Bank additional warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">27,869</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of its Series&#160;D convertible preferred stock at </font><font style="font-family:inherit;font-size:10pt;">$7.5351</font><font style="font-family:inherit;font-size:10pt;"> per share. On October 11, 2016, all the warrants were net exercised into </font><font style="font-family:inherit;font-size:10pt;">13,869</font><font style="font-family:inherit;font-size:10pt;"> shares which were subsequently issued as common stock on October 12, 2016 in conjunction with the IPO closing. As of December 31, 2016, Pacific Western Bank held </font><font style="font-family:inherit;font-size:10pt;">16,558</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock associated with its warrant exercises and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> warrants outstanding.  </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The present value of the future cash flows under the 2014 Loan Agreement terms did not exceed the present value of the future cash flows under the 2013 Loan Agreement terms by more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">. As such, the Company treated this amendment as a modification and recorded the associated immaterial facility fee and the associated immaterial fair value of the warrants as a discount to the 2014 Loan Agreement. This discount and the remaining balance of debt issuance costs and debt discount of the 2013 Loan Agreement were amortized to interest expense over the remaining term of the 2014 Loan Agreement using the effective-interest method.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September&#160;7, 2016, the Company entered into the September 2016 Loan Agreement, with Pacific Western Bank, which amended the existing outstanding debt agreement described above. The September 2016 Loan Agreement allows for total borrowings up to </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> tranches as follows: a first tranche consisting of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> funded on September&#160;7, 2016, of which the full </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> must be used to settle the existing debt with Pacific Western Bank on a net settlement basis (pursuant to its original terms); and a second tranche consisting of an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> which may be drawn at any time prior to March&#160;7, 2017. The first tranche and the second tranche are collectively referred to as the &#8220;Term Loans.&#8221; The Term Loans bear interest at the greater of prime rate plus </font><font style="font-family:inherit;font-size:10pt;">1.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum, or </font><font style="font-family:inherit;font-size:10pt;">5.00%</font><font style="font-family:inherit;font-size:10pt;">. The Term Loans mature on September&#160;7, 2020 and have an interest-only period through March 2018 followed by </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> equal monthly installments of principal and interest. The Term Loans may be prepaid in full at any time with no additional cost.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the September 2016 Loan Agreement, the Company issued to Pacific Western Bank a warrant to purchase a number of the Company&#8217;s Series&#160;E Preferred Stock, at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;"> per share, equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the total amount of up to </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> of debt drawn over </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> divided by the purchase price, which automatically converted into a warrant to purchase the same number of shares of common stock immediately prior to the closing of the Company&#8217;s IPO, and will only be exercisable in the event that the Company borrows all or part of the second tranche. As the Company had not drawn down on the second tranche, </font><font style="font-family:inherit;font-size:10pt;">none</font><font style="font-family:inherit;font-size:10pt;"> of these warrants were exercisable.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 21, 2016, the Company entered into the December 2016 Loan Agreement with Pacific Western Bank, which further amended the existing outstanding debt agreements described above. The December 2016 Loan Agreement kept total borrowings consistent of up to </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> tranches as follows: a first tranche consisting of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> funded on December 21, 2016, of which the full </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> must be used to settle the existing debt with Pacific Western Bank on a net settlement basis (pursuant to its original terms); and a second tranche consisting of an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> which may be drawn at any time prior to December 21, 2017. The Term Loans bear interest at the greater of prime rate plus </font><font style="font-family:inherit;font-size:10pt;">1.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum, or </font><font style="font-family:inherit;font-size:10pt;">5.00%</font><font style="font-family:inherit;font-size:10pt;">. The Term Loans mature   on December 21, 2020 and have an interest-only period through June 21, 2018 followed by </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> equal monthly installments of principal and interest. The Term Loans may be prepaid in full at any time with no additional cost. The Series E warrant issued with the 2016 Loan Agreement was canceled without exercise in conjunction with the amendment.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The present value of the future cash flows under the 2016 Loan Agreement and the December 2016 Loan Amendment did not exceed the present value of the future cash flows under the predecessor terms by more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">. As such, the Company treated the amendments as modifications and recorded the associated immaterial facility fees as a discount to the amended debt. This discount and the remaining balance of debt issuance costs and debt discount are amortized to interest expense over the remaining term of the December 2016 Loan Agreement using the effective-interest method.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2016 Loan Agreement also requires that the Company's accounts maintained with the bank contain an aggregate balance in an amount equal to or greater than the total amount of outstanding debt under the December 2016 Loan Agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan and unamortized debt discount balances are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Face value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion of long-term loan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan, excluding current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016, future principal payments due under the December 2016 Loan Agreement are as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="padding-top:1px;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future principal payments due under the December 2016</font></div><div style="padding-top:1px;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Loan Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819717760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted an Equity Incentive Plan, or the&#160;2008 Plan, in 2008, under which </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> further shares of common stock are reserved for issuance to employees, nonemployee directors, and consultants of the Company. The Plan provides for the grant of incentive stock options, nonstatutory stock options, rights to purchase restricted stock, stock appreciation rights, dividend equivalents, stock payments, and restricted stock units to eligible recipients. On October 4, 2016, the 2016 Equity Incentive Plan, or the&#160;2016 Plan, became effective. The 2016 Plan serves as a successor to the 2008 Plan. The 2016 Plan permits the award of stock options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards, cash awards and stock bonuses. The Company reserved </font><font style="font-family:inherit;font-size:10pt;">2,200,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance under the 2016 Plan, plus the </font><font style="font-family:inherit;font-size:10pt;">223,371</font><font style="font-family:inherit;font-size:10pt;"> reserved and unissued shares under the 2008 plan on the effective date of the 2016 Plan. The number of shares reserved for issuance under the 2016 Plan will increase automatically on January 1 of each calendar year continuing through the tenth calendar year during the term of the 2016 Plan by the number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding shares of the Company's common stock and common stock equivalents as of the immediately preceding December&#160;31.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recipients of incentive stock options shall be eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Plan is ten&#160;years. The options generally vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">. At December&#160;31, 2016, </font><font style="font-family:inherit;font-size:10pt;">1,386,549</font><font style="font-family:inherit;font-size:10pt;"> options remained available for future grant under the 2016 Plan. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed risk-free interest rate &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Based on the average yield of U.S. Treasury bills as of the valuation date for the expected term of the award. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumed volatility &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Due to limited historical data, the expected volatility is estimated based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group consisted of other publicly-traded companies in the same industry and in a similar stage of development. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected life &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Based based on the simplified method, which is an average of the contractual term of the options and its ordinary vesting period.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected dividend yield &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Based upon the Company&#8217;s historic dividends and dividend expectations for the foreseeable future. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common stock fair value &#8212;</font><font style="font-family:inherit;font-size:10pt;"> Upon the effective date of the IPO, the Company began using the closing price of its common stock for the price of new stock option awards. Prior to the effectiveness of the Company&#8217;s IPO, given the absence of a public trading market, the Board of Directors considered numerous objective and subjective factors to determine the fair value of common stock at each grant date. These factors included, but were not limited to, (i)&#160;contemporaneous valuations of common stock performed by unrelated third-party specialists; (ii)&#160;the prices for preferred stock sold to outside investors; (iii)&#160;the rights, preferences and privileges of preferred stock relative to common stock; (iv)&#160;the lack of marketability of common stock; (v)&#160;developments in the business; and (vi) the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of the Company, given prevailing market conditions. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed risk-free interest rate   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">1.40% -1.53%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.57%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.82%&#160;-&#160;2.09%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed volatility   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">52.91% - 53.49%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.53%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71.09%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected option life   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized stock-based compensation straight-line over the vesting term of the options. The Company recorded non-cash compensation, including non-cash compensation to employees and nonemployees in the consolidated statements of operations and comprehensive loss as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized compensation expense at December&#160;31, 2016 was approximately </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average term of&#160;</font><font style="font-family:inherit;font-size:10pt;">3.4</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity instruments issued to nonemployees are initially recorded at their grant-date fair value and are periodically revalued using the Black-Scholes option pricing model as the equity instruments vest and are recognized as expense over the related service period. Stock-based compensation expense to nonemployees was immaterial for the years ended December&#160;31, 2016, 2015 and 2014. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option transactions for the Plan for the years ended December&#160;31, 2016, 2015 and 2014 (in thousands, except shares and per share data): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of <br clear="none"/>shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br clear="none"/>average <br clear="none"/>exercise <br clear="none"/>price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br clear="none"/>average <br clear="none"/>remaining <br clear="none"/>contractual <br clear="none"/>life</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate <br clear="none"/>intrinsic value <br clear="none"/>(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,787,517</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(808,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,816</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,225,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,929,465</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and exercisable at December&#160;31, 2016   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average fair value of options granted during the years ended December&#160;31, 2016 was </font><font style="font-family:inherit;font-size:10pt;">$2.99</font><font style="font-family:inherit;font-size:10pt;">. The intrinsic value of options exercised for the years ended December&#160;31, 2016 was </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> and immaterial for the years ended December 31, 2015 and 2014. </font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All options outstanding under the 2008 Plan are exercisable under the early exercise provisions of the Plan. Options granted under the Plan that are exercised prior to vesting are subject to repurchase by the Company at the original issue price and will vest according to the respective option agreement. For the year ended December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">252,453</font><font style="font-family:inherit;font-size:10pt;"> options were early exercised and </font><font style="font-family:inherit;font-size:10pt;">238,638</font><font style="font-family:inherit;font-size:10pt;"> remain unvested with a related liability of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> recorded under other current liabilities on the Company&#8217;s consolidated balance sheet as of December 31, 2016. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> options were early exercised for the years ended December 31, 2015 and 2014.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 5, 2016, the 2016 Employee Stock Purchase Plan, or ESPP, became effective.&#160;The 2016 ESPP was adopted in order to enable eligible employees to purchase shares of the Company&#8217;s common stock at a discount. Purchases will be accomplished through participation in discrete offering periods.&#160;&#160;The Company initially reserved </font><font style="font-family:inherit;font-size:10pt;">180,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance under the 2016 ESPP. The number of shares reserved for issuance under the 2016 ESPP will increase automatically on January 1 of each calendar year beginning after the first offering date and continuing through the first ten calendar years by the number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding shares of our common stock and common stock equivalents as of the immediately preceding December&#160;31. Stock compensation expense related to the ESPP was immaterial for the year ended December 31, 2016 and is included in total stock compensation expense disclosed above.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813156832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders' Deficit</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Preferred Stock and Stockholders&#8217; Deficit </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Preferred Stock </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock prior to automatic conversion of all shares to common stock immediately prior to the closing of the IPO consisted of the following (in thousands, except for shares):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares&#160;issued</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">carrying</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">liquidation</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">preference</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,333,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">804,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,333,332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494,248</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,809,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,668,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,418,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,286</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,984</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,076,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,732,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series E</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,490,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916,425</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,893</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,460,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,096,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series E Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2016, the Company completed its Series E financing.&#160;The Company sold </font><font style="font-family:inherit;font-size:10pt;">1,916,425</font><font style="font-family:inherit;font-size:10pt;"> shares of Series E stock at </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;"> per share for proceeds of </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;">, net of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> in issuance costs, which includes a non-cash amount of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> issued to a related party as further described in Note 11.&#160;The holders of Series E stock are entitled to receive dividends, if declared, at a rate of </font><font style="font-family:inherit;font-size:10pt;">$0.6635</font><font style="font-family:inherit;font-size:10pt;"> per annum.&#160;In the event of liquidation, the holders of Series E shares are entitled to receive liquidation preferences at the rate of </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;Each share of Series E stock is convertible to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of common stock immediately upon (i)&#160;the Company&#8217;s sale of its common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, in which per share price is at least </font><font style="font-family:inherit;font-size:10pt;">$12.44</font><font style="font-family:inherit;font-size:10pt;"> (as adjusted)&#160;or (ii)&#160;the affirmative vote of more than </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;"> of the holders of the then-outstanding preferred stock voting together as a single class.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2015, the convertible preferred stock was classified as temporary equity in the accompanying balance sheet as the shares included provisions that allowed the holder to cause redemption of the shares upon certain changes in control events that are outside of the Company&#8217;s control. An aggregate of </font><font style="font-family:inherit;font-size:10pt;">10,360,419</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, excluding any warrant conversions, were issued to the holders of the Company&#8217;s Series A, Series B, Series C, Series C-1, Series D and Series E convertible preferred stockholders upon the automatic conversion of all shares of convertible preferred stock to common stock immediately prior to the closing of the IPO. As a result, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> Series A, Series B, Series C, Series C-1, Series D or Series E convertible preferred stock remain outstanding at December 31, 2016.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Warrants </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following warrants were outstanding as of December 31, 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br clear="none"/>average <br clear="none"/>exercise <br clear="none"/>price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issuance date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration date</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feb&#160;24, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feb&#160;24, 2019</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Prior to conversion upon IPO, the remaining warrants were for the purchase of Series C preferred stock.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter 2016, warrants for </font><font style="font-family:inherit;font-size:10pt;">61,112</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of </font><font style="font-family:inherit;font-size:10pt;">28,775</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Reserved for Future Issuance </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock reserved for future issuance consists of the following at December&#160;31, 2016: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,225,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized for future option grants   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,386,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,636,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819726640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax provision (benefit) consists of the following (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign   </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current provision   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred provision   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax provision (benefit)   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The difference between income tax benefits and income taxes computed using the U.S. federal income tax rate as of December&#160;31, 2016, 2015 and 2014 are as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal provision (benefit)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At statutory rates   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,959</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes, net of federal   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign operations   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax provision (benefit)   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Internal Revenue Code, or IRC, Sections&#160;382 and 383, annual use of the Company&#8217;s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an IRC Section&#160;382 and 383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Until this analysis has been completed, the Company has removed deferred tax assets for Federal and California net operating losses of approximately $</font><font style="font-family:inherit;font-size:10pt;">20.8 million</font><font style="font-family:inherit;font-size:10pt;"> and research and experimental credits of approximately $</font><font style="font-family:inherit;font-size:10pt;">2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#160;generated through 2016 from its deferred tax schedule, and has recorded a corresponding decrease to its valuation allowance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets as are shown below: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign net operating losses   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total gross deferred tax assets   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less valuation allowance   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A valuation allowance of $</font><font style="font-family:inherit;font-size:10pt;">5.5 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and $</font><font style="font-family:inherit;font-size:10pt;">7.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of December&#160;31, 2016 and 2015, respectively, has been established to offset the deferred tax assets as realization of such assets are uncertain. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016, the Company had federal and state net operating loss carryforwards of approximately $</font><font style="font-family:inherit;font-size:10pt;">58.7 million</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">14.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Each of the federal and state tax loss carryforwards will begin expiring in 2028, unless previously utilized. The Company also has federal and California research and development tax credit carryforwards totaling $</font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">1.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The federal research and development tax credit carryforward will begin to expire in 2028 unless previously utilized. The California research tax credits do not expire. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commencing with the 2013&#160;year, the Company computed its California net operating losses, or California NOLs, under the Multistate Tax Compact apportionment rules as provided for in the California Court of Appeal&#8217;s decision in Gillette v. FTB. That decision was overturned by the California Supreme Court on December&#160;31, 2015. As such, it is the Company&#8217;s intent to compute its California apportionment factor, and resulting California NOLs, under California&#8217;s Single Sales Factor Market rules. In 2015, the Company adjusted its California NOLs and deferred tax assets to the Single Sales Factor state rate. The impact to the California NOLs was approximately $</font><font style="font-family:inherit;font-size:10pt;">(13.5) million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not provided U.S.&#160;income taxes and foreign withholding taxes on the undistributed earnings of foreign subsidiaries as of December&#160;31, 2015 and 2014, because it intends to permanently reinvest such earnings outside the United States. If these foreign earnings on these were to be repatriated in the future, the related U.S.&#160;tax liability may be reduced by any foreign income taxes previously paid on these earnings. Due to historical losses, as of December 31, 2015 and 2014, the foreign subsidiaries do not have cumulative earnings. As of December&#160;31, 2016, all of these entities have been dissolved. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon an audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. As of December&#160;31, 2016, 2015 and 2014, the Company continued to have no unrecognized tax benefits. There are no unrecognized tax benefits included on the consolidated balance sheet sheets that would, if recognized, impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819800880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Commitments and Contingencies </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases facilities under a noncancelable operating lease that expires on March&#160;31, 2019. Under the terms of the facilities lease, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturing organizations and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table below. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Future noncancelable minimum payment obligations under the operating lease were as follows as of December 31, 2016 (in thousands):</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future payments due under building lease   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense totaled </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December&#160;31, 2016 and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2015 and 2014.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819663680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2013, the Company and Bader Sultan&#160;&amp; Bros. Co W.L.L., or Bader, a healthcare products distributor based in Sufat, Kuwait, entered into a distribution agreement, whereby the Company appointed Bader as a distributor of its products. Sales to Bader began in November&#160;2013. The Company&#8217;s agreement with Bader restricts Bader&#8217;s ability to sell competing products and requires Bader to purchase a certain number of products from the Company monthly based on annual forecasts that the Company provides to Bader. If Bader does not resell the minimum purchase quantity specified in the contract by the applicable date, then the Company has the right, in its sole discretion, to sell to other distributors in the Middle East or terminate its agreement with Bader. The initial term of the agreement expires in December 2019. The agreement can be terminated by the Company immediately upon certain breaches by Bader, or by either Bader or the Company for uncured material breach of the agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the 2014 Series&#160;D convertible preferred stock financing, Bader purchased </font><font style="font-family:inherit;font-size:10pt;">875,903</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s Series&#160;D convertible preferred stock. All terms of the purchase of preferred stock were the same for Bader as the other investors. Sales to Bader for the years ended December&#160;31, 2016, 2015 and 2014 totaled </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which represents </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">94.7%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">52.4%</font><font style="font-family:inherit;font-size:10pt;"> of total revenue for the respective years. As of December&#160;31, 2016, the Company had accounts receivable from Bader of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January&#160;2015, the Company and Bader amended the distribution agreement. In accordance with the amendment, Bader provided the Company with a deposit of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, and committed to minimum product purchases for calendar year 2015. Under the terms of the amendment, the Company reserved the right to keep the deposit as liquidated damages if Bader did not meet the minimum product purchases. The Company classified the deposit as a current liability at December&#160;31, 2015 on the consolidated balance sheets as the minimum product purchase levels were met. In April&#160;2016, the Company and Bader entered into a Payment Direction Letter, resulting in the exchange of the distribution agreement deposit for </font><font style="font-family:inherit;font-size:10pt;">154,585</font><font style="font-family:inherit;font-size:10pt;"> shares Series&#160;E convertible preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$8.2932</font><font style="font-family:inherit;font-size:10pt;"> per share. All of Bader's outstanding convertible preferred stock converted to common stock in connection with the Company's IPO.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819701248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the quarterly results of the Company for the years ended December&#160;31, 2016 and 2015&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(unaudited, in thousands, except for per share data)</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue         </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,131</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,495</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="16" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue         </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,020</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,370</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,674</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820453024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Extension</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 15, 2017, the Company extended its facility lease agreement under a noncancelable operating lease that expires on March&#160;31, 2019. All commitment tables previously presented reflect incorporation of the amendment. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Grants</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to December 31, 2016, stock options for </font><font style="font-family:inherit;font-size:10pt;">0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s common stock were granted to new Company employees, including the Company's new Board of Director member.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829858096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses, if any, reported as a component of other comprehensive loss within the consolidated statements of operations and comprehensive loss. All of the Company&#8217;s short-term investments are U.S.&#160;Treasury notes with maturities of less than one&#160;year. For the years ended December&#160;31, 2016, 2015 and 2014, unrealized losses were immaterial amounts, respectively. Realized gains and losses would be calculated on the specific-identification method and recorded as interest income. There have been no material realized gains and losses for the years ended December&#160;31, 2016, 2015 and 2014. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable from related party, accounts payable, and accrued expenses approximate their fair values due to the short maturity of these instruments. The carrying value of the term loan approximates its fair value as the interest rate and other terms are that which is currently available to the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels in accordance with authoritative accounting guidance: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2 inputs: Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables are unsecured and are carried at net realizable value including an allowance for estimated uncollectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest, although a finance charge may be applied to such receivables that are more than 30&#160;days past due. The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical expense, credit quality, the age of the account receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company&#8217;s customers consist of distributors. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or net realizable value, computed on a standard cost basis. Inventory that is obsolete or is in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The useful lives of the property and equipment are as follows: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter&#160;of&#160;3&#160;years&#160;or&#160;length&#160;of&#160;software license</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of the assets to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the difference between the carrying amount and the fair value of the impaired asset. The Company did not recognize any material impairment losses for the respective years ended December&#160;31, 2016, 2015 and 2014. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All research and development costs are charged to expense as incurred. Research and development expenses primarily include (i)&#160;payroll and related costs associated with research and development performed, (ii)&#160;costs related to clinical and preclinical testing of our technologies under development and (iii)&#160;other research and development expenses. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClinicalTrialExpensesPolicyPolicyTextBlock', window );">Clinical Trial Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into contracts with third party hospitals and doctors to perform clinical trial activities. The Company accrues expenses for clinical trial activities performed by third parties based on estimates of work performed by each third party as of the balance sheet date. The Company&#8217;s clinical trial expense is primarily driven by patient visits to the third party hospitals and doctors. As such, the Company uses the estimated patient visits based on third-party reporting and the contractually agreed upon cost for each visit to calculate its clinical accrual. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based awards issued to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). Because non-cash stock compensation expense is based on awards ultimately expected to vest, it is reduced by an estimate for future forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for interest and penalties related to income tax matters, if any, as a component of income tax expense or benefit. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to sales of components of the Obalon balloon system, which includes the balloon and accessory kit, EzFill inflation system, pre-filled can of gas and placebo capsule. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when (i)&#160;persuasive evidence of an arrangement exists, (ii)&#160;delivery has occurred, (iii)&#160;the selling price is fixed or determinable and (iv)&#160;collectability is reasonably assured. Determination of criteria (iii)&#160;and (iv)&#160;are based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company does not provide for rights of return to customers on product sales, with the exception of products that fail to conform to the Company&#8217;s specifications. As these non-conforming returns have historically been immaterial, the Company does not record a provision for returns. The Company does not have any post shipment obligations or acceptance provisions within its customer contracts. The Company occasionally offers discounts off its standard prices to non-distributor customers, which are agreed upon and known at the time of sale. In these cases, revenue is recognized net of these discounts. Shipping charges billed to customers are included in product revenue and the related shipping costs are included in cost of revenue. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Product Warranty</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Warranty </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company warranties its products to be of good quality and free from defects in design, materials, or workmanship for approximately one&#160;year from the date of purchase. The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based on historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is possible that the Company&#8217;s underlying assumptions will not reflect the actual experience and in that case, future adjustments will be made to the recorded warranty obligation. The warranty expense as of December&#160;31, 2016, 2015 and 2014 was immaterial for each year. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Costs </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs are expensed as incurred and included in selling, general and administrative expense.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock Warrants </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of preferred stock warrants issued in conjunction with debt issuances was initially recorded as a warrant liability and debt discount. The debt discount associated with the initial warrant fair value is being amortized to interest expense using the effective-interest method in the Company&#8217;s consolidated statements of operations and comprehensive loss over the term of the debt. The fair value of preferred stock warrants issued in conjunction with preferred stock issuances was initially recorded as a warrant liability and reduction of the proceeds received. The fair value of the warrants was estimated using the Black-Scholes option pricing model based on the estimated fair value of the preferred stock at the valuation date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying preferred stock. Prior to the automatic conversion of the warrants in conjunction with the IPO on October 12, 2016, the warrant liability was remeasured each reporting period with changes in fair value being recognized in the consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As noted above in Note 1, in connection with the completion of the Company&#8217;s IPO, all the remaining outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As such, the Company reclassified the remaining warrant liability to stockholders&#8217; equity as the converted warrants met the definition of an equity instrument under derivative accounting guidance. The Company performed the final remeasurement of the warrant liability as of the IPO closing date. See Note 3 for the amounts associated with the fair value remeasurements and Note 8 for further description of the remaining warrants.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per common share, since the effects of potentially dilutive securities are anti-dilutive. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive common stock equivalents are comprised of convertible preferred stock, warrants and unexercised stock options outstanding under the Company&#8217;s equity plan. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.</font><font style="font-family:inherit;font-size:10pt;"> ASU 2014-15 requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable that when, considered in the aggregate, raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued, for both annual and interim periods. ASU 2014-15 also requires certain disclosures around management&#8217;s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that will alleviate the substantial doubt. ASU 2014-15 is effective for annual reporting periods, and interim periods within those periods, beginning after December&#160;15, 2016. The adoption of ASU 2014-15 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July&#160;2015, FASB&#160;issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. This update applies to companies that measure inventory on a first in, first out, or FIFO, or average cost basis. Under this update, companies are to measure their inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion. The amendments in this update are effective for annual reporting periods, and interim periods within those periods, beginning after December&#160;15, 2016 with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. Under this new guidance, at the commencement date, lessees will be required to recognize (i)&#160;a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii)&#160;a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09, which was issued in March 2014 and has been codified with the Accounting Standards Codification as Topic 606, is now effective for public companies for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. ASC 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In addition, ASC 606 provides guidance on accounting for certain revenue-related costs including, but not limited to, when to capitalize costs associated with obtaining and fulfilling a contract. ASC 606 provides companies with two implementation methods: (a) full retrospective adoption, meaning the standard is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance.&#160;Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within ASC 606 to clarify various elements of the guidance. While the Company is continuing to assess all potential impacts of the standard, they do not believe that their current revenue streams will be materially affected. As the Company begins commercialization in the U.S. during 2017 and enters into sales agreements with customers as part of this commercialization, the Company will continue to assess the potential impacts of the standard, including the impact to the pattern with which they recognize revenue based on the terms entered into and finalizing the determination of transition approach.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which involves several aspects of the accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This new guidance will require all income&#160;tax effects of awards to be recognized as income tax expense or benefit in the income statement when the awards vest or are settled, as opposed to additional paid-in-capital where it is currently recorded. It&#160;also will allow an employer to repurchase more of an employee&#8217;s shares than it can today for tax withholding purposes without triggering liability accounting. All tax-related cash flows resulting from stock-based payments are to be reported as operating activities on&#160;the statement of cash flows. The guidance also allows a Company to make a policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. This new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2016, with early adoption permitted. The Company does not recognize any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance on its deferred tax assets. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, which addresses the following eight specific cash flow issues: Debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies); distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2017, with early adoption permitted.&#160;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The Company does not anticipate that the adoption of ASU 2016-15 will have a material impact on its consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ClinicalTrialExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Expenses, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ClinicalTrialExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054294&amp;loc=d3e8384-108330<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68072981&amp;loc=d3e8275-108329<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6403650&amp;loc=d3e20905-112640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6626378864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk by Risk Factor</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes certain financial data for the customers who accounted for 10.0% or more of sales and accounts receivable. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Single largest customer:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, related party   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, related party   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second largest customer:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Estimated Useful Lives of Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The useful lives of the property and equipment are as follows: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter&#160;of&#160;3&#160;years&#160;or&#160;length&#160;of&#160;software license</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress, or CIP   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6651351744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis at December&#160;31, 2016 and 2015 are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices<br clear="none"/>in&#160;active<br clear="none"/>markets&#160;for<br clear="none"/>identical&#160;assets<br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>other<br clear="none"/>observable<br clear="none"/>inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>unobservable<br clear="none"/>inputs<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury bonds(2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;value&#160;measurements&#160;at&#160;reporting&#160;date&#160;using</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;active <br clear="none"/>markets for <br clear="none"/>identical&#160;assets <br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>other <br clear="none"/>observable <br clear="none"/>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>unobservable <br clear="none"/>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds(1)   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury bonds(2)   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Classified as cash and cash equivalents on the consolidated balance sheets. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Classified as short-term investments on the consolidated balance sheets. </font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock', window );">Schedule of Fair Value of Warrant Liability Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">October 12,</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed risk-free interest rate   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.90% - 1.64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.28%&#160;-&#160;2.06%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed volatility   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.42% - 62.36%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.76%&#160;-&#160;70.66%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.40 yrs - 7.96 yrs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.15&#160;-&#160;8.75 yrs</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock fair value:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.41</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C-1   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.72</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation for All Liabilities Measured at Fair Value Using Significant Unobservable Inputs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides reconciliation for all liabilities measured at fair value using significant unobservable inputs (Level&#160;3) for the years ended December&#160;31, 2016 and 2015 (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value <br clear="none"/>measurements <br clear="none"/>at reporting <br clear="none"/>date using <br clear="none"/>significant <br clear="none"/>unobservable <br clear="none"/>inputs</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2014  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of warrants for the purchase of convertible preferred stock   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from change in fair value of warrant liability   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants exercised</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of warrants to stockholders' equity (deficit) </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2016   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6658403632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share of Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except shares and per share data): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,890</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,221,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the outstanding potentially dilutive securities determined using the treasury stock and if-converted methods that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:13px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock, on an as-converted basis   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,443,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,654,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,443,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,714,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819622864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Short-term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity <br clear="none"/>(in&#160;years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated <br clear="none"/>fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury   </font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;year&#160;or&#160;</font></div><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,501</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity <br clear="none"/>(in&#160;years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>gains</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>unrealized <br clear="none"/>losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated <br clear="none"/>fair value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2015:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;year&#160;or&#160;</font></div><div style="padding-bottom:1px;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid assets   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest receivable   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The useful lives of the property and equipment are as follows: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter&#160;of&#160;3&#160;years&#160;or&#160;length&#160;of&#160;software license</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress, or CIP   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,399</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813150560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Total Long-term Loan and Unamortized Debt Discount</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan and unamortized debt discount balances are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Face value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion of long-term loan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term loan, excluding current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments Due</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016, future principal payments due under the December 2016 Loan Agreement are as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="padding-top:1px;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future principal payments due under the December 2016</font></div><div style="padding-top:1px;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Loan Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819796384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Stock Options for Employees was Estimated using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed risk-free interest rate   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">1.40% -1.53%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.57%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.82%&#160;-&#160;2.09%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed volatility   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">52.91% - 53.49%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.53%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71.09%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected option life   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Non-cash Compensation to Employees and Nonemployees in Condensed Consolidated Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded non-cash compensation, including non-cash compensation to employees and nonemployees in the consolidated statements of operations and comprehensive loss as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:8px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option transactions for the Plan for the years ended December&#160;31, 2016, 2015 and 2014 (in thousands, except shares and per share data): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of <br clear="none"/>shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br clear="none"/>average <br clear="none"/>exercise <br clear="none"/>price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br clear="none"/>average <br clear="none"/>remaining <br clear="none"/>contractual <br clear="none"/>life</font></div><div style="padding-bottom:1px;text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate <br clear="none"/>intrinsic value <br clear="none"/>(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,787,517</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(808,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,816</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,225,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,929,465</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and exercisable at December&#160;31, 2016   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813117008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock prior to automatic conversion of all shares to common stock immediately prior to the closing of the IPO consisted of the following (in thousands, except for shares):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares&#160;issued</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">carrying</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">liquidation</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">preference</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,333,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">804,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,333,332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494,248</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,809,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,668,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,418,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,286</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,984</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,076,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,732,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series E</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,490,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916,425</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,893</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,460,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,096,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following warrants were outstanding as of December 31, 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted- <br clear="none"/>average <br clear="none"/>exercise <br clear="none"/>price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issuance date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration date</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feb&#160;24, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feb&#160;24, 2019</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock reserved for future issuance consists of the following at December&#160;31, 2016: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,225,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized for future option grants   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,386,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding   </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,636,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813192704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Provision (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax provision (benefit) consists of the following (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign   </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current provision   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred provision   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax provision (benefit)   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The difference between income tax benefits and income taxes computed using the U.S. federal income tax rate as of December&#160;31, 2016, 2015 and 2014 are as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal provision (benefit)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At statutory rates   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,959</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes, net of federal   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign operations   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax provision (benefit)   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets as are shown below: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign net operating losses   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total gross deferred tax assets   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less valuation allowance   </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6812995200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Noncancelable Minimum Payment Obligations Under Operating Lease</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Future noncancelable minimum payment obligations under the operating lease were as follows as of December 31, 2016 (in thousands):</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future payments due under building lease   </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6658540448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the quarterly results of the Company for the years ended December&#160;31, 2016 and 2015&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(unaudited, in thousands, except for per share data)</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue         </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,131</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,495</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="16" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue         </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,020</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,370</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,674</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832774032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 12, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 05, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 1,093<span></span>
</td>
<td class="nump">$ 1,052<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 3,393<span></span>
</td>
<td class="nump">$ 4,039<span></span>
</td>
<td class="nump">$ 3,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,233<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of convertible preferred stock converted into common stock</a></td>
<td class="nump">10,360,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="nump">61,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants', window );">Common stock issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3448<span></span>
</td>
<td class="nump">0.333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,609<span></span>
</td>
<td class="nump">$ 56,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance for common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stocks issuable upon exercise of warrants</a></td>
<td class="nump">24,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance for common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=obln_ObalonMexicoDERLCVMember', window );">Obalon Mexico DE RL CV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_OwnershipPercentageHeldByShellCompany', window );">Ownership percentage in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants', window );">Common stock issued upon exercise of warrants</a></td>
<td class="nump">16,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=obln_TwoThousandAndEightPlanMember', window );">2008 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">223,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock', window );">Warrants to purchase convertible preferred stock converted into warrants to purchase common stock</a></td>
<td class="nump">24,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_BasisOfPresentationAndOrganizationLineItems', window );"><strong>Basis Of Presentation And Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance for common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="nump">24,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants', window );">Common stock issued upon exercise of warrants</a></td>
<td class="nump">12,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_BasisOfPresentationAndOrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis Of Presentation And Organization [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_BasisOfPresentationAndOrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_OwnershipPercentageHeldByShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage held by shell company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_OwnershipPercentageHeldByShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase convertible preferred stocks converted into warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_WarrantsToPurchaseConvertiblePreferredStocksConvertedIntoWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=obln_ObalonMexicoDERLCVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=obln_ObalonMexicoDERLCVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=obln_TwoThousandAndEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=obln_TwoThousandAndEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815647456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831637568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration Risk (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Single Largest Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">94.70%<span></span>
</td>
<td class="nump">52.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Single Largest Customer | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Second Largest Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Second Largest Customer | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=obln_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=obln_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=obln_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=obln_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829341152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813132176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="nump">61,112<span></span>
</td>
<td class="nump">61,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stocks issuable upon exercise of warrants</a></td>
<td class="nump">24,224<span></span>
</td>
<td class="nump">24,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832918880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 12,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">9,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">12,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">9,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | U.S. Treasury Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | U.S. Treasury Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=obln_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=obln_WarrantLiabilityMember', window );">Warrant Liability | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=obln_WarrantLiabilityMember', window );">Warrant Liability | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=obln_WarrantLiabilityMember', window );">Warrant Liability | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets and liabilities measured on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=obln_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=obln_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817202208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Warrant Liability Using Black-Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 13.92<span></span>
</td>
<td class="nump">$ 8.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOnePreferredStockMember', window );">Series C-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock, price per share (in dollars per share)</a></td>
<td class="nump">13.92<span></span>
</td>
<td class="nump">2.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 13.92<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Assumed risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Assumed volatility</a></td>
<td class="nump">53.42%<span></span>
</td>
<td class="nump">66.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Assumed risk-free interest rate</a></td>
<td class="nump">1.64%<span></span>
</td>
<td class="nump">2.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Assumed volatility</a></td>
<td class="nump">62.36%<span></span>
</td>
<td class="nump">70.66%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
<td class="text">7 years 11 months 16 days<span></span>
</td>
<td class="text">8 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813326704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Reconciliation for All Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance balance</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of warrants for the purchase of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss from change in fair value of warrant liability</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Fair value of warrants exercised</a></td>
<td class="num">(591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Reclassification of warrants to stockholders' equity (deficit)</a></td>
<td class="num">(207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815842384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,495)<span></span>
</td>
<td class="num">$ (5,260)<span></span>
</td>
<td class="num">$ (4,131)<span></span>
</td>
<td class="num">$ (3,581)<span></span>
</td>
<td class="num">$ (4,838)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="num">$ (5,024)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="num">$ (20,467)<span></span>
</td>
<td class="num">$ (15,557)<span></span>
</td>
<td class="num">$ (9,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,221,893<span></span>
</td>
<td class="nump">573,181<span></span>
</td>
<td class="nump">531,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (5.46)<span></span>
</td>
<td class="num">$ (7.15)<span></span>
</td>
<td class="num">$ (6.22)<span></span>
</td>
<td class="num">$ (8.42)<span></span>
</td>
<td class="num">$ (6.21)<span></span>
</td>
<td class="num">$ (8.75)<span></span>
</td>
<td class="num">$ (3.74)<span></span>
</td>
<td class="num">$ (4.85)<span></span>
</td>
<td class="num">$ (27.14)<span></span>
</td>
<td class="num">$ (18.61)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817656800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Anti-Dilutive Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">830,145<span></span>
</td>
<td class="nump">8,443,994<span></span>
</td>
<td class="nump">6,714,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,443,994<span></span>
</td>
<td class="nump">6,654,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">830,145<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819833616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815272960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Short-term Investments (Details) - U.S. Treasury Bonds - Maturity in 1 Year or Less - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,501<span></span>
</td>
<td class="nump">$ 9,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 9,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=obln_AvailableForSaleSecuritiesMaturityInOneYearOrLessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6658693040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6658292720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other assets</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817585200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,801<span></span>
</td>
<td class="nump">$ 1,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,084)<span></span>
</td>
<td class="num">(894)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=obln_ScientificEquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress, or CIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=obln_ScientificEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=obln_ScientificEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6658312784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_AccruedLegalCurrent', window );">Accrued legal</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,399<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_AccruedLegalCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued legal current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_AccruedLegalCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829558912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>installment</div>
</th>
<th class="th">
<div>Sep. 07, 2016 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>installment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=obln_TwoThousandFourteenLoanAgreementMember', window );">2014 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_PercentageChangeInPresentValueOfFutureCashFlows', window );">Percentage change in present value of the future cash flows used to classify amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=obln_SeptemberTwoThousandSixteenLoanAgreementMember', window );">2016 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_PercentageChangeInPresentValueOfFutureCashFlows', window );">Percentage change in present value of the future cash flows used to classify amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2013 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2013 Loan Agreement | Series C-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock', window );">Warrants issued for purchase of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_NumberOfWarrantsExercise', window );">Number of warrants exercise | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2014 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2014 Loan Agreement | Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock', window );">Warrants issued for purchase of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_NumberOfWarrantsExercise', window );">Number of warrants exercise | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Shares issued price per share for term loan (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding in shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2014 Loan Agreement | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Term loan, outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Additional debt issuance under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2014 Loan Agreement | Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility', window );">Minimum proceeds form issuance and sale of the equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2016 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_NumberOfWarrantsExercise', window );">Number of warrants exercise | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_PercentageOfBorrowingsForIssuanceOfWarrant', window );">Percentage of borrowings for issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2016 Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Term loan, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2016 Loan Agreement | Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_PurchasePricePerShare', window );">Purchase price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2016 Loan Agreement | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | 2016 Loan Agreement | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Additional term loan available for draw down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | December 2016 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, fixed interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments', window );">Number of installments | installment</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | December 2016 Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Term loan, variable interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | December 2016 Loan Agreement | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowings</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember', window );">Pacific Western Bank | December 2016 Loan Agreement | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Additional term loan available for draw down</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights issued for purchase of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ClassOfWarrantsOrRightsIssuedForPurchaseOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Periodic Payment, Number of Installment Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_LineofCreditFacilityPeriodicPaymentNumberofInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum proceeds form issuance and sale of the equity securities required for credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_MinimumProceedsFormIssuanceAndSaleOfEquitySecuritiesRequiredForCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of tranches.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_NumberOfWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_NumberOfWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_PercentageChangeInPresentValueOfFutureCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in present value of future cash flows expressed in percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_PercentageChangeInPresentValueOfFutureCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_PercentageOfBorrowingsForIssuanceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of borrowings for issuance of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_PercentageOfBorrowingsForIssuanceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=obln_TwoThousandFourteenLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=obln_TwoThousandFourteenLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=obln_SeptemberTwoThousandSixteenLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=obln_SeptemberTwoThousandSixteenLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=obln_PacificWesternBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=obln_TwoThousandThirteenLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=obln_TwoThousandThirteenLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=obln_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=obln_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=obln_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=obln_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=obln_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=obln_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=obln_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=obln_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=obln_DecemberTwoThousandSixteenLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=obln_DecemberTwoThousandSixteenLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6705733216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Summary of Total Long-term Loan and Unamortized Debt Discount (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: debt issuance costs</a></td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total future principal payments due under the December 2016 Loan Agreement</a></td>
<td class="nump">9,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term loan, excluding current portion</a></td>
<td class="nump">$ 9,881<span></span>
</td>
<td class="nump">$ 9,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817509344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Schedule of Future Principal Payments Due (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total future principal payments due under the December 2016 Loan Agreement</a></td>
<td class="nump">$ 9,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=obln_DecemberTwoThousandSixteenLoanAgreementMember', window );">December 2016 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">December 31, 2017</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">December 31, 2018</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">December 31, 2019</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">December 31, 2020</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total future principal payments due under the December 2016 Loan Agreement</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=obln_DecemberTwoThousandSixteenLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=obln_DecemberTwoThousandSixteenLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817987040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average compensation cost recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_StockOptionsEarlyExercised', window );">Stock options early exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_NonvestedStockOptionsEarlyExercised', window );">Stock options remaining, unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,638<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_StockOptionsEarlyExercisedLiability', window );">Stock options early exercised liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=obln_EquityIncentivePlanMember', window );">Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">223,371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=obln_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">1,386,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents', window );">Shares reserved for issuance, increase percentage of common stock outstanding and common stock equivalents</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents', window );">Shares reserved for issuance, increase percentage of common stock outstanding and common stock equivalents</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_NonvestedStockOptionsEarlyExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonvested Stock Options Early Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_NonvestedStockOptionsEarlyExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share based payment award shares reserved for issuance, increase percentage of common stock outstanding and common stock equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceIncreasePercentageOfCommonStockOutstandingAndCommonStockEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_StockOptionsEarlyExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options early exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_StockOptionsEarlyExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_StockOptionsEarlyExercisedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options early exercised liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_StockOptionsEarlyExercisedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=obln_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=obln_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=obln_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=obln_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=obln_TwoThousandAndSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815838016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Fair Value of Stock Options for Employees was Estimated using Black-Scholes Option Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Assumed risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Assumed volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.53%<span></span>
</td>
<td class="nump">71.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Assumed risk-free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.82%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Assumed volatility</a></td>
<td class="nump">52.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Assumed risk-free interest rate</a></td>
<td class="nump">1.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Assumed volatility</a></td>
<td class="nump">53.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817963488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Non-cash Compensation to Employees and Nonemployees in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815835424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Transactions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">1,298,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted (in shares)</a></td>
<td class="nump">1,787,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised (in shares)</a></td>
<td class="num">(808,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Options canceled (in shares)</a></td>
<td class="num">(51,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares Outstanding, Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Outstanding, Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">5.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">1.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">3.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Outstanding, Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Vested and expected to vest at end of period</a></td>
<td class="nump">1,929,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of shares, Vested and exercisable at period end</a></td>
<td class="nump">485,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life Outstanding, Ending balance</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual life, Vested and expected to vest</a></td>
<td class="text">8 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual life, Vested and exercisable</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic Value Outstanding, Ending balance | $</a></td>
<td class="nump">$ 8,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest | $</a></td>
<td class="nump">7,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and exercisable | $</a></td>
<td class="nump">$ 3,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">3,636,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6830868096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2016</div></th>
<th class="th"><div>May 04, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Oct. 11, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,096,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock, shares issued upon conversion of convertible preferred stock</a></td>
<td class="nump">10,360,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,096,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="nump">61,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants', window );">Common stock issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="nump">24,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants', window );">Common stock issued upon exercise of warrants</a></td>
<td class="nump">12,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock issued price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Cash proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_TemporaryEquityDividendRatePerShareAmount', window );">Dividend rate per annum (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_ConversionOfTemporaryEquityToCommonStockPercentage', window );">Conversion of preferred stock to common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock', window );">Minimum percentage of voting required for conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember', window );">Bader | Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Cash proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromJointVentures', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_ConversionOfTemporaryEquityToCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of temporary equity to common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_ConversionOfTemporaryEquityToCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of voting required for conversion of temporary equity to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_SharesOfStockIssuedDuringPeriodUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_TemporaryEquityDividendRatePerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity dividend rate per share amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_TemporaryEquityDividendRatePerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from an entity in which the reporting entity shares joint control with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816228416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit - Schedule of Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Oct. 11, 2016</div></th>
<th class="th"><div>May 04, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,460,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,096,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,096,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 70,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">2,333,332<span></span>
</td>
<td class="nump">2,333,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">4,333,332<span></span>
</td>
<td class="nump">4,333,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,333,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,809,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,809,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,418,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,783,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,076,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,546,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,490,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819789040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit - Schedule of Outstanding Warrants (Details) - Series C Convertible Preferred Stock - Feb 24, 2012 Warrant Issuance<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares | shares</a></td>
<td class="nump">24,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.1918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=obln_FebruaryTwentyFourTwoThousandTwelveWarrantIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817814448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Oct. 04, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock</a></td>
<td class="nump">3,636,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock</a></td>
<td class="nump">24,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=obln_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock</a></td>
<td class="nump">1,386,549<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=obln_StockOptionsIssuedAndOutstandingMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock</a></td>
<td class="nump">2,225,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=obln_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=obln_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=obln_StockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=obln_StockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815833072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating loss carryforward valuation allowance</a></td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">5,538,000<span></span>
</td>
<td class="nump">$ 7,919,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Impact of California NOL adjustment</a></td>
<td class="num">(13,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforward valuation allowance</a></td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">58,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">14,400,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64814285&amp;loc=d3e30536-109315<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Valuation Allowance<br> -URI http://asc.fasb.org/extlink&amp;oid=6528051<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813280736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816092816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Federal provision (benefit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">At statutory rates</a></td>
<td class="num">$ (6,959)<span></span>
</td>
<td class="num">$ (5,290)<span></span>
</td>
<td class="num">$ (3,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">6,961<span></span>
</td>
<td class="nump">5,291<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813027840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">5,279<span></span>
</td>
<td class="nump">7,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">7,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(5,538)<span></span>
</td>
<td class="num">(7,919)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819802944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease rent expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813114352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Noncancelable Minimum Payment Obligations Under Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">December 31, 2017</a></td>
<td class="nump">$ 248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">December 31, 2018</a></td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">December 31, 2019</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future payments due under building lease</a></td>
<td class="nump">$ 745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829235744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 04, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Oct. 11, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyDepositLiabilities', window );">Customer deposit from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,096,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance for common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue', window );">Revenue from related parties as percentage of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">94.70%<span></span>
</td>
<td class="nump">52.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance for common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">1,916,425<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember', window );">Bader</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyDepositLiabilities', window );">Customer deposit from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember', window );">Bader | Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance for common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember', window );">Bader | Series E Convertible Preferred Stock | Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from related parties as percentage of net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">obln_RevenueFromRelatedPartiesAsPercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>obln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyDepositLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deposits held by the entity for a related party (entity, shareholder, employee).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyDepositLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=obln_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=obln_BaderSultanAndBrosCoWLLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=obln_DistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=obln_DistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832905472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 1,093<span></span>
</td>
<td class="nump">$ 1,052<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 3,393<span></span>
</td>
<td class="nump">$ 4,039<span></span>
</td>
<td class="nump">$ 3,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="num">(99)<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,534)<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="num">(4,075)<span></span>
</td>
<td class="num">(3,444)<span></span>
</td>
<td class="num">(4,674)<span></span>
</td>
<td class="num">(3,370)<span></span>
</td>
<td class="num">(4,869)<span></span>
</td>
<td class="num">(2,020)<span></span>
</td>
<td class="num">(19,505)<span></span>
</td>
<td class="num">(14,933)<span></span>
</td>
<td class="num">(9,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,495)<span></span>
</td>
<td class="num">$ (5,260)<span></span>
</td>
<td class="num">$ (4,131)<span></span>
</td>
<td class="num">$ (3,581)<span></span>
</td>
<td class="num">$ (4,838)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="num">$ (5,024)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="num">$ (20,467)<span></span>
</td>
<td class="num">$ (15,557)<span></span>
</td>
<td class="num">$ (9,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (5.46)<span></span>
</td>
<td class="num">$ (7.15)<span></span>
</td>
<td class="num">$ (6.22)<span></span>
</td>
<td class="num">$ (8.42)<span></span>
</td>
<td class="num">$ (6.21)<span></span>
</td>
<td class="num">$ (8.75)<span></span>
</td>
<td class="num">$ (3.74)<span></span>
</td>
<td class="num">$ (4.85)<span></span>
</td>
<td class="num">$ (27.14)<span></span>
</td>
<td class="num">$ (18.61)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813051232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,787,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=AZ;7;F'QM?!$4'O_Z%^ )02P,$%     @ >4=72IE<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M5.)W@R'* $5),O-P,JE$):YD<HQ/#O!I)Y.'\0DDWH7AF)^<\E,YPLT=Q2"
MGAU-HPE%,RB;^\'DXX!\=C1YF'Q DF9QGHO<X0:CCX/JT0XEIT4A<4,E7*DL
M$8ZRAF.,<H!14KG3@I"XH1*_&PQ1#B!JA])H?*$$$J82[O*"X<D!/$DJP_ $
M$O_*8'AR"D_E*( Y!AX'P".IS!]+94@VW\]AZ@E /3N5(DP](.%IUO^K=)03
M E-/@*K13J4(5XU (K.89XZO2F" B@>VT\*WGS9FJ,1KQK'Q!O2T,VDTODP"
M2>(L805&IP#HM",IPN@$$N^Z8'(*2DZ5.GK M!. =G8BC29X4R,DF_O!Q!.
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M!\1N)HQ%T""--(C*K^8"HVDWNNN!PF@$'=+@-,0447.%(24U[T3"2 0!TER
MF")JT.N5<X[,S**?"T,2-$$#35 )C0F<"9Q3)J.5W']*T4 V(GJ38@XHNB4
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M%\FT(%!*/=VI.;?M9!>2=>--@:;K*OL+4$L#!!0    ( 'E'5TI&AW_@!@8
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M0$6. NL+QKAC@#NY3YFS!E5"62+W3X!,UZT$JHNZ7;K&U&.P*HH#JR(.',@
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MR\;^-X@.O)3=E1^ASG^PQ9#0N'"\\6<SC=ED..SG'\26;US^ 5!+ P04
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M..[]V8QC-AH.N^D'L?D;%^]02P,$%     @ >4=72M)L-E:U 0  T@,  !D
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M<CCN0WP,>! PNM69A$K.QCP%XTM=T%T0!!(J'Q@X;A>X RD#$<IXGCGIDC(
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M<BVE 6LENK%>6MO%ZX)#;=STUL[5_);GA9'#TJ9D_5<4OP%02P,$%     @
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MXB40T+BP/?B]F=[R%#C=SV-*EO^*\B]02P,$%     @ >4=72K14SKSO 0
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M5L,C3/5L,9J*_P%7X [N,W$:A>(F?%'1&ZO$Q.)2$>QM7%L9UF$\V=$I+!Y
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M]JF8 @Z%<=N]W:MA8(; R'9\"\CT(*4?4$L#!!0    ( 'E'5TIQ@XJ%U $
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MSL#EF.$8OSN>V[HQSD'RM&<U? /SO;\H:Y&%I6P%=+J5'5)09?@Q/IT3A_>
MEQ9&O=HC5\E5RE=G?"XS'+F$@$-A' .SRPV>@'-'9-/X.7/B1=(%KO?O[!]]
M[;:6*]/P)/F/MC1-A@\8E5"Q@9MG.7Z"N9X=1G/Q7^ &W,)=)E:CD%S[+RH&
M;:2866PJ@KU-:]OY=9Q.=OLY+!Q YP"Z!!R\#IF$?.8?F&%YJN2(U-3[GKE?
M')^H[4WAG+X5_LPFKZWWEM-#DI*;(YHQYPE#5YAX01#+ODC0D,29_A-.P^&;
M8(8;'[Y9JQ__0[ -$FP]P?:O$O=W)88PA[#(+BBR"Q <[T0"F&,4%DF"(DF
M(+X3"6'NVT56MT. JOU<:%3(H?,SN?(NH_=(_>WZ Y_F]BM3==MI=)7&WE%_
MDRHI#=A4H@=;<&.?BL7@4!FWW=N]F@9F,HSLY[> + ]2_AM02P,$%     @
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MYO J"%OT5(.MXS0Y4IB^C9.\\,X#>\_CF_R#C]/^3=A:MHY<C,>7C?VOC/&
MJ20W.$(-?K#94%#Y<+S#LQW';#2\Z:8?Q.9OG/\%4$L#!!0    ( 'E'5TK9
MA@CCQ@0  &\9   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;)59VW+B
M.!#]%8H/B"VU)4,*J%J2R662#&2V=O?9"2)08V/6=L+LWZ]M;():W<3D(6!S
M^J;6.6K#:)=FO_*5,47O=Q)O\G%_513;2\_+7U<FB?*+=&LVY2?+-$NBHKS,
MWKQ\FYEH41LEL2=]7WM)M-[T)Z/ZWCR;C-+W(EYOS#SKY>])$F7_34V<[L9]
MT6]O_%R_K8KJAC<9;:,W\Z<I_MK.L_+*.WA9K!.SR=?III>9Y;C_A[A\#OS*
MH$;\O3:[_.A]KRKE)4U_51?WBW'?KS(RL7DM*A=1^?)AKDP<5Y[*//YMG/8/
M,2O#X_>M]YNZ^+*8ER@W5VG\SWI1K,;]0;^W,,OH/2Y^IKL[TQ2D^KVF^D?S
M8>(27F52QGA-X[S^WWM]SXLT:;R4J231[_WK>E._[AK_K1EM(!L#>3"0IPV@
M,8"N!D%C$!P,(#QIH!H#=3 0P4D#W1CHK@9A8Q!^UG ZI4%C,/@T$"<-AHW!
ML*N!\-O.^9U-#LT67>L0;;N%[!RE;;B SB9MRT70V:1MNOCL.IQNHFC;+G3G
M\MO&"]QY;\^KFJC741%-1EFZZV5[K=E&E:2)R]*J=%[=K:E??UB2-2_O?DSD
M<#CR/BI/#6:ZQ\@C#/B^C;FB,,+&7%,8:6.^41BP,3<4)K QMQ1&V9@["J-M
MS#V%"6W,=PHSL#$/% :M\R.!$6B=GR@,6N<?% :M\XS"H'6>=\CYF?+SV0NO
MW'R''2CI'2AK#V!Y4+0'H#U [2&P/* ^SO8856,V-4;0,0(Z1D#$0/O@=H_1
M1S'"$*W['85!ZWY/8="Z?W<QPM<(].""A@,4[)%R-$2@)PJD4&D_B&AX:\Y<
M# ".-G=!@0]XXQ&>U!'(ZJFB>ZJ(GB+>SI031H<2<,8N"O'V^13"RE73N6HB
M5ZS3VMWC/F@_$,RRA'2HT TE43G3T FEA< B<_L5RLIF0&<S(+)!N^IVX,21
M@S!D1&1(QQD2<7 ]0R<.:-"!0D(P^QIG951-2N39[#LY83V9-A@KEM_\X2.Q
M,_2!@BH*.>ON=-[%J;TNW,PBB%X!7AA!L.%D-.9\$I*(AL:-;PVH*O&3X!<0
M!$A/;EJ@L(%'BF(GQ1QY@CCSI,(-!_<@T1H?X0\$3&D1.!-#)V_S+[W9]3''
MK7#/6^%S/AAY%ZK[9"$8V16$[DH\6PA7>$_O:T9X!:&\^$"Z;D#H1&)#,:HJ
M*%D-,84(70TDWONWW6"S+V%VXHQ,"TJG![0/R>BJ]+MO#,EHD*0T"&V,:^EJ
MT,F-(;D1F9*@(0XFW2&-*XI1%4FH"G"Y,LR5P1F+RS!7$I,9X$.?!&'1^@)D
M9\-H@"0T@--KR5!;AF>L"L-927$6/X=+EV6@E>9*9E@F*9:A!DRE.^8(K11#
M1F#(".Z0 \"( C!D!''&,R3#,: XAJ>M!F1I6/DT$#+/DL ]L+H\TURZ#,W@
M#)H!0S.@R*%PR>H<V0:&0^!R2#/3,# 4@C,H! R%@*(04NUG( ZJL)RN%$,B
M8$@$%(GP@Q2X))*!4HSH!@R) H)$#E\#=_X64@K<!N_HN\/JIXBG*'M;;_+>
M2UH4:5)_5[A,T\*4+OV+TMG*1(O#16R61?4V+-]G^Y\ ]A=%NFU^WO .O[%,
M_@=02P,$%     @ >4=72GWY7;4@ @  # 8  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL?57;CILP$/T5Q'O7W.)D(T#:)*I:J96BK;9]=L@DH#68
MVD[8_GU](2PQ*"^Q/9QSYLR )VG'^+LH :3W4=-&9'XI9;M&2!0EU$0\L18:
M]>3$>$VD.O(S$BT'<C2DFJ(H"#"J2=7X>6IB>YZG[")IU<">>^)2UX3_VP!E
M7>:'_BWP6IU+J0,H3UMRAE\@W]H]5R<TJ!RK&AI1L<;C<,K\EW"]PQIO +\K
MZ,1H[^E*#HR]Z\/W8^8'VA!0**16(&JYPA8HU4+*QM]>TQ]2:N)X?U/_:FI7
MM1R(@"VC?ZJC+#-_Y7M'.)$+E:^L^P9]/0O?ZXO_ 5>@"JZ=J!P%H\+\>L5%
M2%;W*LI*33[L6C5F[7K]&VV>$/6$:""$^"$A[@GQ)R%Y2$AZ0N(0D"W%]&9'
M),E3SCJ/V[?;$OT1A>M$=;_00=-L\TRU1ZCH-8]CG**K%NHQ&XN)1IAP0""E
M/J2(YE)LH@D]ND^PG2)B![*;0E;!O(EXML[8\.-Q#?AY7B"9%4B,0'+7J*73
M*(O!!M,83.!4^@AQ9V(Q:V(Q,1'&B6/"8A:C% EVWNAVBG%E=HN)TR\A7LZ;
MQ;-F\4S'5HY9/,GR'+@]FV)B%[-[C+%FT>A.U,#/9MX(KV"71NI/:Q0=1MI+
MI.^4$]^H46<GTZ>,G9,_"3]7C? .3*H;:^[5B3$)RF+PI#I:JM$\'"B<I-XN
MU9[; 64/DK7][$7#'T#^'U!+ P04    " !Y1U=*O3N(4$P"   E"   &0
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MYS*=L8*</6CTV0P^[,*'3A[$T:<4#$NQ81_"&1Z>HA6F(3Q[4V&* S(4D 5
M^@:0X8 9"I@A%<S>G1'FD^-)<C1)C@#F.&". N:WRUR@@,4-,C&?*S*7:)(E
M EC@ )K@-S:Y72B]<NGI#5)1I^65/.C-7U/V$9$G5Q#X[:?I?ZC%[S_-;E&+
M.;U72RZZB@1]#/W41)4ZM:&97UBGGKUFH2O]<Q\:_G>NCTUKHIVRKK>%#G10
MRH*K);ES'U/MWIAI(>!@_73NYGIHM,/"JFY\1,CTDI5_ 5!+ P04    " !Y
M1U=*OH6<!M<!  #D!   &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R-
M5-%NFS 4_17D#ZC!$#I%@-2FJCIIDZ).VYX=N 2K-F:V$[J_GVT(30AK^X+M
MRSG'YUR,LUZJ%]T F.!5\%;GJ#&F6V.LRP8$U3>R@]:^J:42U-BEVF/=*:"5
M)PF.21BF6%#6HB+SM:TJ,GDPG+6P58$^"$'5WWO@LL]1A$Z%9[9OC"O@(NOH
M'GZ ^=EME5WA2:5B EK-9!LHJ'-T%ZTWJ<-[P"\&O3Z;!R[)3LH7M_A:Y2AT
MAH!#:9P"M<,1-L"Y$[(V_HR::-K2$<_G)_5'G]UFV5$-&\E_L\HT.?J"@@IJ
M>N#F6?9/,.99H6 ,_PV.P"W<.;%[E))K_PS*@S92C"K6BJ"OP\A:/_:C_HFV
M3" C@4R$*'F7$(^$>$; @S,?]8$:6F1*]H$:/E9'W9F(UK%M9NF*OG?^G4VK
M;?58Q&F4X:,3&C'W X9<8,@E9G.->4-@ZV"R019M$$^/+[:(EP7B18'8"R3G
M B2<Y1@P*X]I/2:-HFB>Y"/4A9EDT4QR928*_R.P6A18?;X=Z:) NM".VUD[
MTJN@)"$DF;7C(]1@!I^=-_?_?Z=JSUH=[*2Q1]<?L%I* U8QO+%BC;URI@6'
MVKCIK9VKX<<;%D9VXYV"IXNM^ =02P,$%     @ >4=72L]/^Q]X P  2!0
M !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULE9CM;ILP%(9O!7$! W\!
MJ9)(:Z9IDS:IZK3M-TV<!!5P!D[3W?W,1[,DO*;F3\'D/:_/.?&3&L]/JGJN
M]U)J[[7(RWKA[[4^W 5!O=[+(JT_J(,LS2=;516I-L-J%]2'2J:;-JC( QJ&
M45"D6>DOY^VSAVHY5T>=9Z5\J+SZ6!1I]?=>YNJT\(G_]N QV^UU\R!8S@_I
M3OZ0^N?AH3*CX.RRR0I9UIDJO4IN%_Y'<K<2M EH%;\R>:HO[KVFE">EGIO!
MU\W"#YN,9"[7NK%(S>5%KF2>-TXFCS^]J7^>LPF\O']S_]P6;XIY2FNY4OGO
M;*/W"S_QO8W<IL=</ZK3%]D7)'ROK_Z;?)&YD3>9F#G6*J_;O][Z6&M5]"XF
ME2)][:Y9V5Y/O?];& Z@?0 ]!Q ^&L#Z '83$'29M:5^2G6ZG%?JY%7=MW5(
MFT5![IAIYKIYV/:N_<Q46YNG+TL6\7GPTACUFOM.0R\T]%JQ&BK8?TE@$CAG
M06$6M(UG5UD(;,"@ 6L-^)5!=%-&IXE:3=F5(<+PII*AB- X2G N'.;"02[Q
MS32=1EQ,PVP=$W 2 2:Q9!E!@\B]Y3$TB-]O^2H>EBEF#,^2P%D2,,L,&\R@
MP<R]3A)B1$*'Q=6+Q/CJ JH9B6WI6(@EPW3BT&*!<2,3>",8..)"7"]ZKRE#
MU0AS!$-'7*@C0^QLC</4$8!=3"P6F#LR 3R"R2,NZ)$I[!$,'P'TQ9:?*8+Q
M(Q/XHY@_ZL(?=>(/J.S\4<P?1?Q9^DHM_^XF\$<Q?]2%/SHD:]"1,<EU(A@\
MZ@(>=0:/8O H H];+#!X= )X%(-'7<"C0_!LM6+J**+.EBBFCDZ@CF'JF MU
M;,C38$,U)KE.!//&$&^1Q0+SQJ;L+RT;3*<=YON\C4JN$\&\,1?>V(3])</$
M,41<;+' Q+$)Q#%,'',ACCD3QS!Q#!%GV7\P3!R;0!S'Q'$7XGI1-++$N#-Q
M'!/'$7&633?'Q/$)Q'%,'$?$#=ZCACA9%SJWO*X!H!);PS K7$RH%K/"(Y=J
M(^=O%N/$ 4Z)9?_*,2L\F5 K9H7/7&J=N=8J,$X"X)38WK$Q"(*XURHP"((Z
MU-J+HM%5'%P<Z31G;-_3:I>5M?>DM%9%>X:S54I+8QA^,&W;RW1S'N1RJYO;
MV-Q7W=E6-]#JT)_;!>?#P^4_4$L#!!0    ( 'E'5TIA7C 1L0(  *4+   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)56[6[:,!1]E2@/0&+G@Z0"
MI)5IVJ1-0IW6_39@(&H29XZ![NUG.RD%]Z1+_Q#;.??XW(N/<V=G(9_: ^?*
M>Z[*NIW[!Z6:NR!H-P=>L78B&E[K-SLA*Z;T5.Z#MI&<;6U0508T#-.@8D7M
M+V9V;247,W%495'SE?3:8U4Q^?>>E^(\]XG_LO!0[ _*+ 2+6</V_"=7OYJ5
MU+/@PK(M*EZWA:@]R7=S_Q.Y6]+(!%C$8\'/[=78,ZFLA7@RDV_;N1\:1;SD
M&V4HF'Z<^)*7I6'2.O[TI/YE3Q-X/7YA_V*3U\FL6<N7HOQ=;-5A[F>^M^4[
M=BS5@SA_Y7U"B>_UV7_G)UYJN%&B]]B(LK6_WN;8*E'U+%I*Q9Z[9U';Y[GG
M?PG# ;0/H)< FKX;$/4!T6M ;)/OE-E4/S/%%C,ISI[L_JV&F4-![B)=S(U9
MM+6S[W2VK5X]+:(LF@4G0]1C[CL,O<:D]!:S!)A72* E7'10J(/:^.A&1XP)
M(D@068+XAB!Q$D&8%&\2PTUB0#!U-D&8S*G6^Y@;(0D4D@""'!.DD" =7^\I
M))B^59"'3BDZ3&8QM<60:)*[1^<M*IO$!&O)H)8,:!D@R"%!/KX:),0^"D?4
MHP<1^I^*(!R=T"%% \XF0-& )PDV)?F *PFV)0&>>UN7:-1!0;#)="@E[& "
MK)=' Q38>R3Y0%6P^T@*5,1N51 H<6N"0 -W&L%.)LC*[JT&0>ZU!D$#UQ+!
M5B; R^X]O@2@. P']L&.)SF@&+@S*+8\#<>? XH]2I%'W7, 0''H>@."!LXU
M'?@$TQ'G (#B,';%(% R( ;?&W3,]QR XC!UQ2#0U!$37/5+IH']P>2^J%MO
M+91NO6R#M!-"<4T83K3_#[IGODQ*OE-F.-5CV36.W42)IF^*@TMGOO@'4$L#
M!!0    ( 'E'5TK7QI''. (  *$&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;'U578^;,!#\*XCWGL%\)$0$Z9*J:J56BJZZ]MDAFX#.QM1VPO7?
MUS:$X\#7E]A>9F=F'7N==UR\R I >:^,-G+K5TJU&X1D60$C\H&WT.@O9RX8
M47HI+DBV LC))C&*<!"DB)&Z\8O<Q@ZBR/E5T;J!@_#DE3$B_NZ \F[KA_X]
M\%1?*F4"J,A;<H&?H)[;@] K-+*<:@:-K'GC"3AO_<=PL\\,W@)^U=#)R=PS
ME1PY?S&+;Z>M'QA#0*%4AH'HX09[H-00:1M_!DY_E#2)T_F=_8NM7==R)!+V
MG/ZN3ZK:^FO?.\&97*EZXMU7&.I)?&\H_CO<@&JX<:(U2DZE_?7*JU2<#2S:
M"B.O_5@W=NP&_GN:.P$/"7A,"-/_)D1#0O26$-OB>V>VU,]$D2(7O/-$_V>U
MQ)R)<!/IS2Q-T.Z=_::KE3IZ*^)@G:.;(1HPNQZ#)YAP1"#-/DI@E\0.+]+Q
M>X']$A%AMT+D+"*R^=&[(C(W0>PDB"U!/"4(@]DN])C48IK>9#0O9(E)4K>/
MQ.DC<?@(9QH])IEHX/B#W4J=(JE#9%;(+EV(Q&DZ,[+$1+';Q\KI8^7P$<U\
MK!8:GY+L@].W=JJL'2KQ3&6]5,'!RJV2.54RATHR4\D6AV-VQ/9+1+2X"&AR
MLQF(BVV"TBOYM5'F#DVB8Y]]Q*8SS.([W7_[=OE&TS?O'T1<ZD9Z1ZYTW['=
MX<RY FTQ>-"[5.GW8EQ0."LS7>FYZ+MFOU"\'1X$-+Y*Q3]02P,$%     @
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M]>K+]ZR\*I8-P<_5+=BNK^*3_U!+ P04    " !Y1U=*4Y,?/4@"  !2!P
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M9:%)I6PI=*)EG<>AROS'S>X8:[P!O+0PBMG>TY6<&7O5QK<R\P.=$! HI%;
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M"@LV3#X"RF%"#!Y^H,CJF%A>@,<?V#M:@L<6L-R.6C*.)/22T+5D#,HG_D$
MCRV,<\M2,D&!)P[2=W0$SQQD<SJ2C<TFP] @H"R;\H/G%[  9Q,4>/)@,;\E
M%(\>)3-:TH'Z>P@CPQT3 =&AEJBWB;M3U7>N#D6M@R=I['G []I[*8VP?.3&
M-O=H#W+702GVQMUF]EZUIYEV8&33G=2BZW%Q_1=02P,$%     @ >4=72@S*
M\BP* @  \04  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL?93OKIL@
M&,9OQ7@!!__;-M9D=5FV9$N:L^SL,ZVOU1P4![2>W?T K;/(.5\4\'D??@\@
MV4#9*Z\!A//6DH[OW5J(?H<0/]?08OY$>^CDEXJR%@O991?$>P:XU$4M08'G
M):C%3>?FF1X[LCRC5T&:#H[,X=>VQ>SO 0@=]J[OW@>>FTLMU #*LQY?X">(
M7_V1R1Z:7<JFA8XWM',85'OWD[\K4J77@I<&!KYH.RK)B=)7U?E6[EU/ 0&!
MLU .6+YN4  ARDAB_)D\W7E*5;ALW]V_Z.PRRPES*"CYW92BWKL;URFAPE<B
MGNGP%:8\L>M,X;_##8B4*Q(YQYD2KI_.^<H%;2<7B=+BM_'==/H]3/[W,GM!
M,!4$<X$??5@03@6A48!&,AWU,Q8XSQ@='#9N5H_5F?!WH5S,LQK4:Z>_R;1<
MCM[R*-IDZ*:,)LUAU 0+3?"H*-:*\+\$28"9(K!2!+H^7-3[&\]N$%H-0FT0
M/<38&C%&3:(UG=;$H9%C+?&3=X)$5HYHS1%[!L>HB9<<B:$IUAI_&]M!8BM(
M; 'Q#9!X-4D4&1P?2AXP$BM&8L$P#L\A6<V11N8!6VNV[^Q+:N5(5QR^9RY'
MNM[\<&L<HF(MBK:A08(6/Y^Z#']@=FDZ[IRHD/^Q_MLJ2@5(/^])9JKE_3MW
M"%1"-5/99N,M-'8$[:<+%LVW?/X/4$L#!!0    ( 'E'5TJY+**MP 0  ,\;
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;)69VW+B1A"&7X7B 2S-
M67(!58'U;E*55+DVE>1:AL%0*R$BR6;S]M')+,S\K96X,$C^NWMZIK]I'1:7
MO/A6'JRM9M^S]%0NYX>J.C\&0;D]V"PI'_*S/=7_V>=%EE3U8?$:E.?")KO6
M*$L#'H8ZR)+C:;Y:M.>>B]4B?ZO2X\D^%[/R+<N2XK^U3?/+<L[F'R>^'E\/
M57,B6"W.R:O]TU9_G9^+^BBX>MD=,WLJC_EI5MC]<OX+>_QB6H-6\??17LJ;
MW[,FE9<\_]8<_+9;SL-F1#:UVZIQD=1?[W9CT[3Q5(_CW][I_!JS,;S]_>']
M<YM\G<Q+4MI-GOYSW%6'Y3R:SW9VG[REU=?\\JOM$U+S69_][_;=IK6\&4D=
M8YNG9?MWMGTKJSSKO=1#R9+OW??QU'Y?>O\?9MB ]P;\:B#B00/1&XBK@1PV
MD+V!_&$@!PU4;Z"N!GPX!]T;Z+$&IC<P/PQ,NX#=[+;+]2FIDM6BR"^SHJNX
M<](4-GLT=4%LFY/M^K?_JU>LK,^^KZ02B^"]<=1KUIV&WVGDO6:#-.I>\PEI
M]+WF"6G,O>:SKQ$AN]=\07ZBJR:HY^0Z,1Q.#&\=R#L',78@H /1.A"W#G2(
M'4CH0/HCT$Z:3[Y&2&*4"@91( C'#C1TH,>G:: #,R)-7T.F&<$@D>] ".P@
MA@[B\6FR$),6@D2%6_Z=2+6B4RMB6E&5RPBF&8@D"1>X^AF?D"^N?R; *)2+
M:2?2-_F*L/T0L3 J#+&B"1<8!*8F9(Q18!J,PK@9:V^%(QT3M<@P,@PQ$[F[
MI/$"<1T1U#",#?.YD9IR@<%A$\CAF!R.R'&;2R^ZK206#I42Q_!P (\)W6#,
MGULB"M%=0'LQC'"!^>(3&@S'V'"$C7%SE7ZN)J*J@&.Z..HS;L7VHKO-3]"1
M,(0<0&BXFU,GBF\BF0<E%+4"&$,.,#3NCLY]#*E%P@QRP* A=G..&>03&!28
M03&&0>$SJ(80%!A!@1#T8OD(#G8.@4$4"$3MQN(^ H.QB"M"T!&-(5Q@8H6<
ML)(818%0]&;71W%X)3&, L$8N;&T5S5\<.<6&$>!<*0NV3%K(IHPO9@U$?]\
M>C>]Z*Y9#<ZOQ%1*1*4SOT_2OZ:DHF >Y8B6N)&C6Z+$)$I 8N1%02)BUY:8
M0@DHC+@;1X#=A0A#W+V!WAH)-PP2$7N[Q#A+@'.D"!>84CGA'DYB]B1@+])N
MMDA$['\2 RI!,XR(NR.) 943FJ'"V"F W<V5=9=M+[J]QH@>>"P^]K;Z0Q2N
MPA@J@&%,#1PSIB;<UBF,CQIQ6[=1_FW=\,6XPA IP$=,S1KQ@&/"?9W"?"C0
MQ6)WQU!^%QO<T14&20%&J+M#A1E1$YJ8PHRH$4ULK:8V,8UITH FM[VLM=_$
MJ,=4F!X-Z'';RQJ*B'K3&#&-.A1WX_@7E%1[T1A##3",B<ZA,5QZPK6DQG!I
MU'RTFRP2$=N^)AXR(@*))J<Q6-I,R!:#I='3$)>*7C1^Z],800T0C(E'6@:#
M9<+Q*1M,C4$]QZWF7O3SK2^X>2O1O.KZ(RE>CZ=R]I)759ZUKR'V>5[9VFGX
M4%?-P2:[ZT%J]U7ST]2_B^X54W=0Y>?^]5EP?8>W^A]02P,$%     @ >4=7
M2B0X.+[Z 0  BP4  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL?51;
MKYHP'/\JA/>=<D<-D.RX+%NR)>8L9WNN^%?(:2EKJYQ]^_6"#*&9#]*6W[7:
M%@/C;Z(!D-X[)9TH_4;*?H>0J!N@6#RQ'CKUYLPXQ5)-^06)G@,^&1(E* J"
M#%'<=GY5F+4#KPIVE:3MX, ]<:44\S_/0-A0^J%_7WAI+XW4"Z@J>GR!'R!?
M^P-7,S2IG%H*G6A9YW$XE_['<+?/-=X ?K8PB-G8TTV.C+WIR==3Z0<Z$!"H
MI5; ZG&#/1"BA52,WZ.F/UEJXGQ\5_]LNJLN1RQ@S\BO]B2;TM_XW@G.^$KD
M"QN^P-@G];VQ_#>X 5%PG41YU(P(\^W55R$9'554%(K?[;/MS',8]>\T-R$:
M"=%$")/_$N*1$"\(R"8S53]AB:N"L\'C]L?JL?Y/A+M8;6:M%\W>F7>JK5"K
MMRK9Y@6Z::$1\VPQT0P3/2+V:T3\#X)4@"E%Y$P1&7X\XX>;V"T0.P5B(Y \
MU-@L:EA,9C"=-0G4QVV3.&T2A\UV86,QZ<SF0QANW2ZITR5=N:2SF-8E7;EL
M-YO0[9(Y73*'2[APR58NBQS[;+6I>9*[8^3.&/DZQC)%OO)XZ&J#.$#!-EDD
M0;-CH:^I[YA?VDYX1R;5"3/GX,R8!"48/*G:C;H9IPF!L]3#7(VYO1_L1+)^
MO/K0=/]6?P%02P,$%     @ >4=72O+Q#J<( @  0P8  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3 N>&ULE97;CILP$(9?!?$ :T,X1@2IV:IJI5:*MNKV
MVH$AH#68VD[8OGUMPR)"'"F]B4___-^,L9UL8/Q-U #2>6]I)W9N+66_14@4
M-;1$/+$>.K52,=X2J8;\A$3/@90FJ*7(QSA"+6DZ-\_,W('G&3M+VG1PX(XX
MMRWA?_= V;!S/?=CXJ4YU5)/H#SKR0E^@OS5'[@:H=FE;%KH1,,ZAT.U<S]Y
MV[UG HSBM8%!+/J.+N7(V)L>?"MW+M89 85":@NBF@L\ Z7:2>7Q9S)U9Z8.
M7/8_W+^8XE4Q1R+@F='?32GKG9NX3@D5.5/YPH:O,!44NLY4_7>X %5RG8EB
M%(P*\^L49R%9.[FH5%KR/K9-9]IA7(G3*<P>X$\!_AS@C[6,()/Y9R))GG$V
M.'S<_)[H;^QM?;4WA9XT6V'65/)"S5[R$/L9NFBC2;,?-?Z59C-KD/*?(;X5
MXAN#S95!8#?86 TVQB"X,L"K+$=-9#2=T:1)XMDI@9426"BAW2"T&H2/UQE9
M#2)+!M&JSE$3+NK$=D1L1<061+Q"Q#<(=<WO4!(K);%0DA4EN:$$=RFIE9):
M*.F*DOX'Q</V.X)O.=[Z^$VB![Z+=^<F>@\<\DFT/.4>OJT'+:Z_?EY_$'YJ
M.N$<F50OB;GO%6,2E"5^4BG7ZD6?!Q0JJ;NQZO/Q61L'DO73DXWF_XW\'U!+
M P04    " !Y1U=*,'/K_NL"   N#   &0   'AL+W=O<FMS:&5E=',O<VAE
M970U,2YX;6R55V%OFS 0_2N('Q X&P.IDDAKTFF3-JGJU.VSFS@)*F &3M+]
M^]E 4;"/*LV'@)UW]^Z.NX>SN,CZM3D*H;RW(B^;I7]4JKH+@F9[% 5O9K(2
MI?YE+^N"*[VL#T%3U8+O6J,B#T@8QD'!L])?+=J]QWJUD">59Z5XK+WF5!2\
M_G<O<GE9^N"_;SQEAZ,R&\%J4?&#^"74<_58ZU4P>-EEA2B;3)9>+?9+_PO<
M/1!J#%K$[TQ<FJM[SZ3R(N6K67S?+?W01"1RL57&!=>7LUB+/#>>=!Q_>Z?^
MP&D,K^_?O7]MD]?)O/!&K&7^)]NIX])/?6\G]OR4JR=Y^2;ZA)CO]=G_$&>1
M:[B)1'-L9=ZTW][VU"A9]%YT* 5_ZZY9V5XOO?]W,]R ] 9D,(#H0P/:&]#!
M@+ /#:+>(+J5@?4&S#((NMS;8FZXXJM%+2]>W?5#Q4W;P1W3CVMK-MNGT_ZF
MZ]GHW?.* 2R"LW'48^X[#!EAR!BS=C$68N,BJ 5Y<"%I.$ "G<>0#$&3(:T]
M'05*<0<4=4!;!]$H1CO3#L-:3-EA8AI'+,&)(I0H<H@81!91AP%ZQ<1F@+,P
ME(4A+,QBP3 Q3A*C)#'B(+%(.DQZE0F9S><X2X*R) A+:K$D;L%@1G"6%&5)
M$9:YQ9(ZSY\P$K&)/INC/'.7AX06S]SEH6E,K:0W+LQR]/ 18A0KA+A$A$BT
M8,]_Z!8_G"H^3&@1($13+G %@$]( . : #>(P#VX*D (I8E3%A<W57Q<* !1
M"C*5$*X"P#Y1$WS&P1URI"8Q4I/0?.RBN$#0K<VB"44 7!( T002V4%A(#;!
M@XL"(*I 8IL' TV\$@ 7!<!4(;5Y7!!E$WI-\'DFV#Q/E)[@DTK@]I8B$^]J
M<D-+]:!1IZ2CCAI3X1--W(EV&P4#49LGN#I6F9/T3UX?LK+Q7J32)[3V'+67
M4@GM,)SIJ(_Z\#XL<K%7YC;1]W5W@NT62E;]Z3P8_B*L_@-02P,$%     @
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M=G%X\WEKHD\1>@Y5]3-M-,4V[U1YA+*>DPBCV#MKHA:3-IB@A_E >(J]"Q%
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MC7G7!+N)9$W?X,'P+R/[!U!+ P04    " !Y1U=*@*W]Y1,#   J#   &0
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M'XWF,N)S67\$P94! Y6!^=D]&LVSF[%0)F"X,&"@,# _M_&R,.1YZ"./X=J
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M7 TYW-L+Y7A@.*Z&_('7A1S7% XUA26VIAA(C>:/*7?LV+GCA2&F(ZY7CKA
M\ =64QQ_]#GVZ!.[3B34&#;E=JF@E+7Q_8I19.K*&Q<1CH@('*08"V0_S^'5
M"_SN,]+O6?5V.-:3U[)IRJ)_8[\KRT:W'J-IV]U[G6TO%[G>-=UIW)Y7P^>;
MX:(I3^;35'CY/K;X%U!+ P04    " !Y1U=*?S/"ZB0%  #K'@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U-BYX;6R5F>]NHT84Q5_%\@,L\Q^('$M-XJJ5
M6BG::MO/))[$UH)Q@<3;MR]@XO7,/3 D'V+ OWOGC!G.O<#J5%;?ZYVUS>)'
MD1_JV^6N:8XW450_[VR1U5_*HSVTW[R459$U[6[U&M7'RF;;/JC((\&8B8IL
M?UBN5_VQQVJ]*M^:?'^PC]6B?BN*K/KOSN;EZ7;)EQ\'ONY?=TUW(%JOCMFK
M_<LVWXZ/5;L77;)L]X4]U/ORL*CLR^WR%WZS46D7T!-_[^VIOMI>=%-Y*LOO
MW<[OV]LEZQ39W#XW78JL_7BW]S;/NTRMCG^'I,O+F%W@]?9']E_[R;>3><IJ
M>U_F_^RWS>YVF2P76_N2O>7-U_+TFQTFI)>+8?9_V'>;MWBGI!WCN<SK_O_B
M^:UNRF+(TDHILA_GS_VA_SP-^3_"<( 8 L0E@*O) #D$R+D!:@A0/P/D9( >
M K0W0G2>>_]C/F1-MEY5Y6E1G=?#,>N6';_1[>EZ[@[V9Z?_KOT]Z_;H^UJG
M?!6]=XD&YN[,B"M&N,0])70<N\P#8HS+;"@C?PX5M1.YS$; V8@^7CJS&4D@
M80+9)U!. NE-]LSHGCF<12IE6*Q3/)*"(RDPDO)&4F0DSEAJC!P92<.1-!A)
M>Z=8DY&8IX42TUH,U&* %F\1W)T9,Z&%$C%3:>(M)DII9=(1N3&4&P.YWKJ^
MCZD8KIG!PR1PF(0,8R2.3V%\.G_9<X9M@(47_MT 7:\!(;L_8@<SP<T,T%4_
M8F(\?#'=#=#4&@=(PA2Y6C9ASE6-S8J+&1?F $VJI@A6'>1<U=@A.;)(_Q(>
MH*EK&" FCJ6O.4"YBK'3<F2UL:]8A153)&:,^8H#E*L8.S:GEFW42 ;LL]Q\
MPA*P]W%D?L028K*F%+:$F>!F!NBJQY;*J:<"2TC"%Q=%N$J54'ZUF0&ZNK&5
M\W2.*:1AW109T1T&W<8+%Q"!"HAO"P,T=9$!Q"CMG;A-B'(5XZ(A4-'P;6&
M)A53Q&AB"R'*53S2W=*"84;,6V#S%G*^+0CLI@*YJ6\+@G:NY&>C2)RPE#'_
MGF $3,<:3X$]5: VV#<$$>Z# 2*,2;3T2]<,T-6-G5R@EMDWA &:U$V1$=UA
MT-6-RX= Y8,8 FV>B6Z*\/:F@Z@.8:YF7#0$*AK$$I*P9HIPHP71',)<S;A@
M"%HPS,C-A\36+=DG[IJQETKDI;XIR' ##A"N>-NE^ET" $6<M%W"2 V0V%$E
M:L%]4Y#A%AP@*F$B\;TLS+FJ1QY2H!;<MP1)'U,0U13!JH.<JQH7#HD*AV\(
M,MR& Z2]]_<[A!#E*L8E0Z*2X=O! $TJIHBF-PXARE6,BX6DQ<+$(QFP;<OX
M$V: 750B%R5F$&Z] 9*PV"A)UB=HO;E6AO$1*Y782B7JO8D;A'MO@(A8"JV)
MBX5!]TDB-G"%>F_?#Q1]U.+K!@C6/0-T=>.JH5#5\!U!A3MP@ C&R/./(.9J
MQA5#H8KA>\( 36JFB& Z]4T!8(JW!7%$,ZX7BM8+,W)WIT8>5JOYKJ"PF2ID
MIKXKJ'#_#1#.5,H,Y_YO-Y7,E8S=5*'6V_<#%6Z] <)3;I3P5NC#7' S.:@[
M-6SS"G7GQ#+HHQ@R-8J,*)[*Y2K&546AJD+,(MR; X3K^.JUP*!W*I.K%Q<3
MA8H),8HTK)<B7"?D_F<RTUEO=/5.L'L-_&=6O>X/]>*I;)JRZ%\"OI1E8]MT
M[$M[HG8VVUYV<OO2=)MQNUV=7[^>=YKR.+Q:CB[OM]?_ U!+ P04    " !Y
M1U=*R:'@G[,!  #$ P  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6QM
M4^V.FS 0?!7+#Q"#0](D J3F3J=6:J7HJEY_.[ $Z_Q!;2=<W[ZV(8B+^(.]
MZ]F9V37.>VW>;0O@T(<4RA:X=:X[$&*K%B2S*]V!\B>--I(Y'YH+L9T!5L<B
M*0A-DBV1C"M<YC%W,F6NKTYP!2>#[%5*9OX=0>B^P"F^)U[YI74A0<J\8Q?X
M!>YW=S(^(A-+S24HR[5"!IH"?TT/QRS@(^"-0V]G>Q0Z.6O]'H+O=8&38 @$
M5"XP,+_<X F$"$3>QM^1$T^2H7"^O[._Q-Y]+V=FX4F+/[QV;8%W&-70L*MP
MK[K_!F,_&XS&YG_ #82'!R=>H]+"QB^JKM9I.;)X*Y)]#"M7<>U'_GO9<@$=
M"^A4L(X%9!"*SI^98V5N=(_,,/N.A2M.#]3/I@K).(IXYLU;G[V5F_TN)[=
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M-J>..QN.0F@PT.C)X$IS78P=#D=MFPO3EOV9V7>T:(?[ (V74O$74$L#!!0
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MD6T.UCUCDJIZ_">U^$?5:_6#BNZEODW4/;<-AQU(UG;-E-=W=,5_4$L#!!0
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MO<+AWOL0GBG$UM/,O7& G:[P%4FJ2Y:N&<(WYNE+>W^4YX,L J.#0#H(A@Y
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MU14T%Z5F3(+*,=BH:6K56S,9!&JIMY_4GMN)LX9D@WM,T/2BY?\ 4$L#!!0
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MFMQI!J>)TUT8D@8A:0"RO8-X3;:")!^V84@6A&0!R.X.DCU -E$4AN1!2/X
MR=/L#I(_;-=VI?$0LCI%]I)^I_+<#PJ=A#8'TAV;5@@-QB]Z,O5VYK^P! Q:
M;:=;,Y?^=OA BW&^^&3Y^U3_ %!+ P04    " !Y1U=*)7ET\W<#  #?#P
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MO6ROG.U BKV^3GN7._WL'U!+ P04    " !Y1U=*(X7,],P#  !E$   &0
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M<!-#N^EZ#@]'1]=I&GW,MVG4ZQY77D4YXG6Y2>;IO_T.!(4R+1[2W_TQJG<
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M/L%3,AC'HW'?+(O9O-^7M<'1QBM#)RO/%=POP&JCG^'Z3HLU:+CK7Z(CX"O
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MUEXXN/UT41ET?1M1A6XO_R;./#]$-[J5H)]A K3:04A5E3=]:))S E$.<TL
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MPP3FHIW-.75&IENZ*;D1.G1+U[U3=JIYZ-HN&RJ\:T-MS*Q_->6>LSUAD7L
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M*W#PI3._;T'$OV,@!./H<(3%V&/0BK]L?9$D#W9/ D4#_3EE_\;"%C;CE1Y
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MCO'I23S0-]#QC<@!;WR4B8LA#)<"QKLK&$UGF62K\ODWG*QZPG4:*4W9-^/
M,([\=8U8$?N?/G[CL3?(W.X*DW%>$-_7+I8(.5J:PF#Y; M8""]GR4%H[/44
M6=+*$6]80V0L7HP44P!&-HWZ^X'BUHS%T4?(+/*50!"Y"H?_78PZD^_CF@$G
M$I-B@U446<-OPXQJ5:2;$1?W//;.>(;:2]NV(3E>FG/]V>0>FN?)3OD9"8GD
M"ZZ):U</S3IE*BZY!<EZ?JXMZ4<>B<KDX(1 KWC?:*=L&SV"9]"XN!426CX=
MLQZ V\1@?BCA S'B!A+8G46/:83>"U0,03Q3Q#0'S%1]O06(3F52]BX0?*?#
M?Z@NP$OFW510RB$R5? ?D-_@8=F5\$ )=]-%,RYAQ%9C.8$FG_2MY JW1-1&
M_QD Z5D$\  -G&;]6D"#J\"VKRNHMC<YC/6H?QR]BOKQJ-LU_Y* W']C/GW)
MMYZN#GGAMUV!464%/)2AG?^10!$>-WT[.';K\\%B+1,2_E$/EV$0CV8#\V]]
M5BTK.(M[DY'\5Q]M6;E>/YZ,I_9#O9?WGF1?:YRO43%@@(-^XXO\"_=HZ?ZY
M-W#Z9SXX+2GW0.WG#?& 0:H["'NX)F%[+5C+AS1FN)ZO6V/:,&B2!C:#2&_A
M.0V;J0,$5T&G5)11IJP0$M,&,+4<364)9%QR\3$NQ+'/(8]Q-.[%O5[?!-2&
M9>(JY?18 /#8U<T!CE(?[)\4Y]@6NRE%3%@59.')1#XV%^H+XF5=A3N#+B!A
MLZ&]S#NI*W?%_E Q$RD69A6YBG-LQW=)Y)4XP_W1SR<5#(!M-0C7I^IZE2/(
M]$#*V)4^].: 7O9=G X,\O %"7; !"VS<Y?!5BH<^G4M1+F!BY_B--&XWAR3
M'74[L^Y/T4G4ZXR'/\%_^U/\J]_ICG]R[YJH[-&@,^SC$^-^9P"/C,>=R1C_
MGG0[8_APKH8(DOS[G6$W>BI*_+TS&]/'00=&=1)-.\"Y\>_S:DAX])2ERX7R
MRY_\AZMJZ2:WX*]]V<17O4%G!IQWVAGV;)5)_;[?@>/K2A/JM[W.I,^Q 56J
M,*B5%GWJN655;O_6RET:?,(3Q+BV\'(#2;LT\0UA%+[/\W*V'@NLBP:A3M..
M-8[$)&J%(?>),3(Y!DYHD@OC-6+H)DGZC\KLUS3V"BD=C]@YU8AVW8\F,KA3
M(9;&@>[/.M"HY[8UZSQ'7=*9*]):O?5TG2KY"JXQW@N)=VPO[M390[MN*)_:
M4@YJW, R9!;B[WTY7I<P42U/W(G^1) V1"[ :#6I6OW)N,N9QP"'UVK<).S:
M1"P"T:0%>JMR@C@E_QTS=/U3@6N?89L-"2F,8E/9UR^46JJ-:D(:.U/IW%8]
MJD<$Y;06 (HUP:"[1ALO[0!U"*M%B#W1H/*0P2I99F1T.M),<R/75-NDVM)8
M=4;*=[-4!5-X8S+5.=<ZEI<%(H.PIH#LENE=LXS!EJ>'M"K7O.'\<X,HY2+*
M]%2RC>3H@;LGV(?L'O-<D3SFH$0^L$?9PWY2;&3LT$&3-2?-H&$*".$N+=@
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MJ]UTVY ,UL0Z2JFB8;(6=UM'6IQ)Q2)::_955:D.SGHLB"6J@3/&C[Z*0-7
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MW&YB&R<LW!MP-\$+8BXA9H,B%12G%ZDQ$GY3*W@HJ,3:4PA[W.!ED7K>:?&
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M,9E+MB97+P>14@"5$4Y82<.]8@&(N":CZ2D6!:K#*J8P!(X*L[X?:J<*7J=
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M\Q_)R]=4((;8A!^@_DB>/\R-PJ2% B,WB;&;,8B/CI2#PJ_!;56@_>/E"C=
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M<P1XZF^+,T&N93'P3SGK-=@*XOO[CMJ2WS7>R4/X^CCM6(.:Z'H7%#3S.AX
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M[/'R9!.!2'2'*#X?"/_VR>4PIDMO6\;!>M+\^3Y;IH%5("M5VZ/5R"6)FC=
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MMJQ<KQ]/QE/[H=Z+.1>O->K?& .0\?0;7^1?N$=+]\^]@=,_\Z&J2=D.6WU
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MW42#20EO/VWK/4NQ;![TNM7#C8;<ML:6(V20>A[)UOG!UB.KJZW!J @0M;:
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M5SD"32K>U_-GDLL"PFWY32@R:1(!7B#3K-G;<H5YULSV$ W1#YU06>*9%?S
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MC#/WN>X)>V+\ 7L]"UIP/LC+\6TZOKD>#J:CH;@8W QN+T<B_3X:35,"& +
M<&> 8F^B"&0$(*,OA$RG?O-C=.L!QU=B/!G])) Q@(QW!ND/W1%("2#E+B$3
M ID R&1WD(/T.X$\!)"'O)!C^Z!*\[<[T(6@"^6,$]5<3*QVFD > <@C7LBT
M*0IE7UNJU#R4QE^F?,0<9%G5^(A)((\!Y#$OY)4R5MRIO-'BAU:NL;J]P-$
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MK-MVS/8=H)C(0I)[+(0P)1T+260AN:-BS@*36D@B"\E=UG0DM9"$BP*X5P5
M3&HAB2PDV<L\")-:2"(+R5W.PTDZ%I+(0O(KY^$^^Y)B(@M)9@NM87[\]7U;
MO=#PGB +)<P66L,<S>>Z6QWW!DPQD8429@NM80Z7;V?;GP-'BRH)LE#"O2H-
M3L/N4TQDH81[71K"3*B%$F2AA-E"VRO/W7=/,9&%$F8+P4GM9&5M&ER<QET-
M6B\_KP9/BHDLE'06ZG<GN_/3F9Z;4L]N_2V<WY^I/)M8T6X6*WEBV=;<YTV>
M7_I]X]+GY>W^KHWEHMSS_P!02P,$%     @ >4=72A>M++HY @  7B@  !H
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MNL!>"=HLX>NM0&_EZZU ;^7KK4!OY>NM0&_EZZU ;^7KK4!OY>MM0&_CZVU
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( 'E'5TJ*"+P][P   "L"   1
M          "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( 'E'
M5TJ97)PC$ 8  )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ >4=72I650YRF @    H  !@
M ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( 'E'
M5TH\S'PIIP0  * 8   8              "  =0+  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !Y1U=*7LQM@I($   )&P  &
M        @ &Q$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ >4=72I6[A,C  P  4A   !@              ( !>14  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( 'E'5TIMP"5,9P8  '8E   8
M              "  6\9  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !Y1U=*R4'@?_ !  "Z!   &               @ $,(   >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ >4=72D:'?^ &!@
MUR$  !@              ( !,B(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( 'E'5TI7ML=]M@$  -(#   8              "  6XH
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !Y1U=* ,47
M];0!  #2 P  &               @ %:*@  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ >4=72K![I3.T 0  T@,  !D
M ( !1"P  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !Y
M1U=*4_F/SK,!  #2 P  &0              @ $O+@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( 'E'5TJK>E2OM0$  -(#   9
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M970Q-BYX;6Q02P$"% ,4    " !Y1U=*S=%A>;4!  #2 P  &0
M    @ &R.0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M 'E'5THXD/R1M0$  -(#   9              "  9X[  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ >4=72MJZH,"S 0  T@,  !D
M             ( !BCT  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !Y1U=*FPC5.[4!  #2 P  &0              @ %T/P  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( 'E'5TJ8':ZLL@(
M !,+   9              "  6!!  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ >4=72GT>J)S& 0  -P0  !D              ( !
M240  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !Y1U=*
M]ZAI(M !  "<!   &0              @ %&1@  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( 'E'5THDO\2OP0$  #<$   9
M      "  4U(  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ >4=72K14SKSO 0  9@4  !D              ( !14H  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !Y1U=*G(E7V,8!   W!
M&0              @ %K3   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( 'E'5TKV>CY3S@$  )P$   9              "  6A.  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ >4=72G&#BH74
M 0  G 0  !D              ( !;5   'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !Y1U=*L+MZ(=0!  "<!   &0
M@ %X4@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( 'E'
M5TJR.L<#LP$  -(#   9              "  8-4  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ >4=72NA:K@^X 0  T@,  !D
M         ( !;58  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !Y1U=*V88(X\8$  !O&0  &0              @ %<6   >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( 'E'5TI]^5VU( (   P&
M   9              "  5E=  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ >4=72KT[B%!, @  )0@  !D              ( !L%\
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !Y1U=*A9XD
M\!<"  #5!@  &0              @ $S8@  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( 'E'5TJ^A9P&UP$  .0$   9
M  "  8%D  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M>4=72L]/^Q]X P  2!0  !D              ( !CV8  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !Y1U=*85XP$;$"  "E"P  &0
M            @ $^:@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( 'E'5TK7QI''. (  *$&   9              "  29M  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ >4=72FVBIN(0 P
ME@L  !D              ( !E6\  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !Y1U=*4Y,?/4@"  !2!P  &0              @ '<
M<@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( 'E'5TKM
M<M.0Z@$  -H$   9              "  5MU  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ >4=72NN_U^[Q 0  :04  !D
M     ( !?'<  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'E'5TJY+**MP 0  ,\;   9              "
M 0J#  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ >4=7
M2B0X.+[Z 0  BP4  !D              ( ! 8@  'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " !Y1U=*\O$.IP@"  !#!@  &0
M        @ $RB@  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( 'E'5THP<^O^ZP(  "X,   9              "  7&,  !X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ >4=72OHG$B*# @  : D
M !D              ( !DX\  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " !Y1U=*""=M0F\"  !Q"   &0              @ %-D@
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( 'E'5TJ K?WE
M$P,  "H,   9              "  ?.4  !X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ >4=72HU'O>J_!   *QL  !D
M ( !/9@  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !Y
M1U=*?S/"ZB0%  #K'@  &0              @ $SG0  >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( 'E'5TK)H>"?LP$  ,0#   9
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M970V,2YX;6Q02P$"% ,4    " !Y1U=*!H-;[AD"  !_!@  &0
M    @ $"KP  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M 'E'5TKP/\KBZ@$  -T$   9              "  5*Q  !X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ >4=72@5$[>_1 0  B00  !D
M             ( !<[,  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " !Y1U=*)7ET\W<#  #?#P  &0              @ %[M0  >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( 'E'5THCA<STS ,
M &40   9              "  2FY  !X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ >4=72C^FV9[X 0  .04  !D              ( !
M++T  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " !Y1U=*
M:L-WWSR#   ?# ( %               @ %;OP  >&PO<VAA<F5D4W1R:6YG
M<RYX;6Q02P$"% ,4    " !Y1U=*^9 B>VX"  !(#@  #0
M@ ')0@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( 'E'5TK@[;-*S00   ,L
M   /              "  6)% 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !Y1U=*%ZTLNCD"  !>*   &@              @ %<2@$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !Y1U=*<"V0'/P!  "A)P
M$P              @ '-3 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..3 !, ,84  #Z3@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>224</ContextCount>
  <ElementCount>313</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/TermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/NetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/BalanceSheetDetails</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Term Loan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/TermLoanTables</Role>
      <ShortName>Term Loan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/TermLoan</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficit</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Warrant Liability Using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/FairValueMeasurementsScheduleOfFairValueOfWarrantLiabilityUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Warrant Liability Using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Fair Value Measurements - Schedule of Reconciliation for All Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/FairValueMeasurementsScheduleOfReconciliationForAllLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Reconciliation for All Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/NetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Net Loss per Share - Schedule of Anti-Dilutive Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/NetLossPerShareScheduleOfAntiDilutiveCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Anti-Dilutive Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Balance Sheet Details - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetailsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Details - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Balance Sheet Details - Schedule of Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetailsScheduleOfShortTermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetailsScheduleOfInventoryDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2405406 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2405407 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/BalanceSheetDetailsScheduleOfOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Term Loan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/TermLoanAdditionalInformationDetails</Role>
      <ShortName>Term Loan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Term Loan - Summary of Total Long-term Loan and Unamortized Debt Discount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/TermLoanSummaryOfTotalLongTermLoanAndUnamortizedDebtDiscountDetails</Role>
      <ShortName>Term Loan - Summary of Total Long-term Loan and Unamortized Debt Discount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Term Loan - Schedule of Future Principal Payments Due (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/TermLoanScheduleOfFuturePrincipalPaymentsDueDetails</Role>
      <ShortName>Term Loan - Schedule of Future Principal Payments Due (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Stock Options for Employees was Estimated using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/StockBasedCompensationSummaryOfFairValueOfStockOptionsForEmployeesWasEstimatedUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Fair Value of Stock Options for Employees was Estimated using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Stock-Based Compensation - Summary of Non-cash Compensation to Employees and Nonemployees in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/StockBasedCompensationSummaryOfNonCashCompensationToEmployeesAndNonemployeesInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Non-cash Compensation to Employees and Nonemployees in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/StockBasedCompensationSummaryOfStockOptionTransactionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Schedule of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit - Schedule of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Schedule of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfOutstandingWarrantsDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit - Schedule of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/ConvertiblePreferredStockAndStockholdersDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Noncancelable Minimum Payment Obligations Under Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/CommitmentsAndContingenciesScheduleOfFutureNoncancelableMinimumPaymentObligationsUnderOperatingLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Noncancelable Minimum Payment Obligations Under Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.obalon.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="obln-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.obalon.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>obln-20161231.xml</File>
    <File>obln-20161231.xsd</File>
    <File>obln-20161231_cal.xml</File>
    <File>obln-20161231_def.xml</File>
    <File>obln-20161231_lab.xml</File>
    <File>obln-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001628280-17-001603-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-17-001603-xbrl.zip
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M:N>:6,?QDU3#XM28_DXN_O#HM?#B#X_)'](K)*XH.E-%O.C-N211NY;3XRT
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MK9OA(+VZU>Y^/2WYGD-PPLVU,#SEB.:F.9B9.=AI=']KW&>5&<58I]/DO;3
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M15+>V^FE!7T?DV3FBZN^:@F8!A(3<*,J,D&YBTH2JQD3%@7!:"AOL$EWZ"M
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M#558<#R!G!):&ELITVV#17G9%(&*"MALE_P_'GK=Z:]N<4,B4A)TNN.DE">
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M 7(NF'-"NO*L45$%^!)HG@-W#<4=4VE<J'+I#B,&TX>=&<%M&"3X)5FYPO1
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M9?"F6[T%?O.;$@93P2Q0GQ>;]:@2.F7ZT6FB."IW[<_G&IO MCN<ZJX2*F1
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MNA&FPJ7#G+J)ZL>$:HTLI^7>.D!PGB:1:>1D)&-9%C2J\FJ)@V"YQ/2;R6*
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M1>V5[!6SS[WY[VT>;"FN#"*(.P@*G16.IC%,@")6J;19$SK4 [0##.I.W4F
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M(>OU$'^R%-%KR4F"EM-@L*HXL.)\8=[EZD&PSQU;ZSU-X\=,H(@J01VQSD[
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M62JF$\ H$,XZKE+(S>*%W2R> $C7L=XO5<GWO^U#/(G=XZ;]4F@R]5]67WE
MR/=OJ\FO\^&L/X+%\I/Q-(S__N<_;_2IVPOF>"S,E.7@J8M96!T4Q&T1](D
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M?AUL7+)@(RB'Z+^Y!H"*U;P\5':>4OQ2?>P/L&D@.$.S"8 P[P_Q\6P/N*(
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M"Y/>L)I.,8>.274\;<(WW\\G-W?]:86G+>^JW@TB6#T@^*:W!'?SI<4.JU^
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ML4S:*491*#@K\;VUTK-9B;'[0YN:E\V\<VG>.A$V-CL"\LS(*RV?;T#G=RV
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M^U(WS;T*Y >M9O]'"1J02S'I-.F1Z6 .L2&G0@38K13FOL1_*X!SG]'_ZAV
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M5X))_(=(@_?$\]<^%<U[7)W4P\D]L^Z&BY_)T=7,K3 <"PT+S0Y"\P"OL2=
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MH*\C3D9N5?.G2BVV;X4S+&*#LAA, ; L,P;EZ,4T8D E#4V9R2>#HTHQ\'3
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MI9,M(E1039?NH-[/OT1-/F-K=NJ=7,>6Y=^Z<6<"V^DB)<M+@AR[8B%>8$#
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M2Z+WM:F)-3"3<IC)6Z_>L%!J: MJ30Z'ZP9V@ ^F)Y*% BPB/><9=]IJB P
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M?J-LXRH/Y$:,:76*PQCU$2__1)F2EOIFJ6*0;H#S2/M#+L@Y*!PXTPH$"AO
M**"6UND3PX#TQDL0Z\O49BD AP 35M3O(0"(KK3ULU,\CP]/]F=EMX'4BC]#
ML'[P\D#I*%04%,!B;(,L^NJWD0A><)>B^VT7I-N&G9745E4Y&4U,PDD"8 (L
M\1WV8/INS?!<K*8K;#]EWBK!-*7^>47Q9AIVMD#SMK28"1-%$A!?XB.%"P*E
M[T*@D52K6'WEH8(-6@9JX.9WHHA&>@T4:!(B"AHO4QN-X*F'17S%# P4TW_-
MT Y?G7ZRWA7 ND+X!.4?[# GLK 5_B&JKG1,+LP*=],4Q"4SL65FYW$71J_J
M<.MM4B&Y,LN()K2BXR7HC1\H4TB-0UBQ!Z*R".2S)YHRR?>T$%@O7&W+:AM$
M0%^U\WU+SV'%2S*KNED5>/(%S,A/RI3K]\>O51Y??.L-$9165\]9J25^]"XB
MD)*NB:/6-4O8%%^DBZ;_*QP_T;VJ1'K=^-_EHP+-+XF_N@:/$EB=!GZ3P%LU
MY"&E+&\R,_7TEQ@OFF0UE,R,2U+!I-2>#UA,6F80B3FPK4,"$=D;6$X[81BP
MDN%J27H'/(E, 3.I [W PT@R%ZON^Y&*\ :U-B@""QM\5@G ^OJ>_[J[$C!L
MW-W<7K5O!LU;^'70N;]K#@?W-W?-?O?Z=CB\.T,E0-.R*AI -%P )MI$$_3R
MP+A&AK0\8.X+A2(I9P\PKA5@7PCZ'8$#]F-?8F!:3?\%MCUNH;;\B"R,'DE]
MF(6[&!Y.@D46^R_I"3 $=XS.87HHW8N.KVB0$81Z(U#Q14"281,\BN\(2I$G
MPS+))Q9*$^$.]&J8?X"F+99+UP7N061I'N.5 Z.M7PU*RG VUR@_PBEIM64L
M@&G'Z>'A:\0EOD1A)^ M[ !CY4>4)-V^;L!!#0DB:#707?N2FG.L(=G1L_<0
M_-5"O2CXDC;9W27_JMWM-7O7@]N[[FWWNC7HW7::(/F#3J=_>]_JWIZ=Y#^
M51Y</@I_9B1TK8@AD-[<+ <X'HQ65#O(O$[F@IO5LVD[*":7P**7TG2$]GJC
M_T5F3Z>#E(Q-3-"NE61I.SUCFM>4VP8M8UV+Y@D4+ZUF:J]9M&7Z GWO"%1+
M>Z='B?WXE2] 59&HQY.^GC*L,_Z!V&X@Z-!*OJ=?O/R<NG$5.\]6'AQ(8H(
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M.\/<W!P,$@P2#!*G!Q*M1JW3RRVF_SQ0@F/4WD?HK\*'$<YFGJM:_!13<?J
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M&E$NHKN4L0BW6V8(L@*", 9UQ3->O- 9X]$H'AI?Q@._((9.V=UX(OZ,GK-
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M01-+5H$*/.;6DX-Y=?M6PD?@V]+QZM4,C @JR+".6;$X G,G<^<QN//O/M9
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MEK'U*N_5(97K?=.T]"'5JR0Y;PBK$5I53AL@(+IP(.J8C:8V(X. B("(@(B
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M53+21DOND#KXD4B$282KP8DDPA4189VDZUH7(K U4;LKIET?(P#+G#!PCQ.
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MJ9926/;K"4NQB>+:1L+Q(?CCC0\&Y!6P?(AEOE0K:>Q&@!=,0Y?Y8A#X\*<
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M)$IW'7E=CN%OJ"-Y+!Y6(=^E^>'$@S NDA,WB[&?+@ONA+!Q&9A(%4X]!UG
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M;(D("';Q./$-.^41F"C,0LX-&\?>AE. KKE\9K]I]7Z"M>"<<8YMA-/VLHJ
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M!<1EA<2B+38@3BQO]3TI91[*+5[O9LW+-U^)&X2X%D:0M<1>-S6\;],@%-*
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MT?H1__PC7OA.71_/9W!]JKB\PT?_N/+LG__RMQ_Q.=X'_._/_S]02P,$%
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MS8&.3*_]53,[?CU;,[I&3& 9247"?<U@R=#\IJ5B\;8)NO]C0>>]C'A-DX2
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M>A5W3LS&$A0UYAUAV-0'4[\$7;W(933ONES0%6(]M*8<"_5&A-A36S3^.O;
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M]A+MR?S.?=QI<#<97T0O8$=2C8Q7#A&P$U#,UZK&1JX\94HD_W,(Q4$K^M@
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M((4Q)&@3P1 6>4]A25 222,MK?>&)*)D-ZVY_XS':9=L'4]I'21AS:$4P8K
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M-N6C<GFXW).-="XK!W.< Q9[NB'BTUPNGX-48!(<CA&.>&\",I;S_'A< NZ
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M@SYL=-A);4N*G%!BR/#1Z;R6#LQXGKS2!8%)9ZA4E)GE;+T^]-.LB1\='9-
MJ+4D$"AGD)%.N"(>5P)#V)"-",Z+&+7D[S$QZ0C,8"4:CY99Z]W^_N'$ H2
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MLJ1(MQA0>1N%V9$!ZLKL(:X70-0!PSSP" (FO"G,TQU%Q BJ=/M4PD&O%^C
M\N@833NIT!3WV068".&8"F=\4&UVM##@79?#>]#K!=KS.S) '9G=\_4"&#F&
M +"2$P69P98+6"8;&$W:^] &O5Z@/;,C S24&?:\G_.N KJV?OC$J,1RXP!
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M#@;] FGH@=*>!^U" U#JPTB+(?G\^C6P6# /W$B@]84,E MC$*",$0(0(8X
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M(!D1\/HS2,HD58#I"4@D!>%]>/?58OY'NMZD^4K/5C6F^K'G$Q>69;@UDDO
MF= *:5NN5S(]04],/!9D\0%JUQCD,ET4'SDI?BB831Y]V^%7R=OT>K9TJ\UQ
M1>"%IQ(#-156 ^19^#\EP"/?(\2T?2;?^?6YXY_]W0'JA[7[Y1S=GI\_DEAM
M- 0. 6 )-4(%42?EFBGE=IH'=B?TLZA0O XV3NHT'85[D0[*BUW2R6_IM\4\
ML^[#6_/WTP?EL><3PA%7G!%"($5:8\UII3%XC <-3)T^*-M#G<4'8BC5]^/V
M\WIQN9CE]Q]G1797HUR$8V.2XK07.FB%%A$,;1!Q!2L:&6E_V^GYG0S&/SIC
MPS682#RLLG C75Q]RF>K]6S74KR^E5[MX$0H0R%1U!H= (#&!).BI)H(9J9Y
M%$?DYG/YZ NR/XO 3.K0G[2<C",?;]Y?U-8[5,\DP>[4&%.C+=($4<PL-@^&
MHVL?"^VO6V-$QCR_W*4E+(-]^F4&3]'%87-?Y(9GJZ*50]-TQI?&)3SHR%@7
M(0M$+90>*:JJD(750[:FF9 :$1&RP2J?GBZU]C!X\?D$$Z.1L=1933&VSB!?
M;9@6&#UQA2$.WYZ7/D5$ZL>2AFEJ Q,2@G&8_Z@2J$%%[+-G$\NL%0A95-Q?
MQ(B5DE>GGU!J@N[VCKSYKO"U&R+M_4!?5VF^OEG<O0_'8'&N7:?_,UU>ZON/
M-^ER69 W6]T?=0HU&9P @[B$1B@,A1" (8,JZ0?"M3_MH_-VF(J8/E ;ZBM_
MMRV0N[BJ6O4=.IF?T@6/CDD(@] P3:$S/@#)+>'ZP0'GVQM^T3-@>Y>,V& -
MECF79_,TO5P7-;!OUNMMT>?W(M];3/LM\E0V7>W@!$N(.90<65"$II%WNO+1
M>FG;NY>C-UD>3$2BHS:4K'Q(OZ2K[<D6J.4C"5;"%:V5N">2822YDU4<A9 I
M-5$>C.\ML1G.51"4ET(>TTN[S</.%8ZW17:Y*]9>OTN_[OYTVF?09()$VG 6
M,@F(0@XR@Z335;YC@+)]/63T;LJ#248OR TF-\4JW^>+D_WX'QY*C+;<!F6:
M<@< 4])Q4/E7$.]PVTOTOL;#\;\M.F-J"6\*!LR6[[>?EXOYQ=556@CNF<K"
MBW,DDH73KN@21*#'B!'%<5631(R!K26$OUH)Z0N\X;P+1TK%]GO<?N_[/9CB
M^P<?NW%/=^1J.EMB"I7**ZF9"Z!;;3BM5"HK<'M;1;Q:H>H?QM9NC4.EXA^S
M/)^M-A?YAZ+"P7T+!O=B731I>=F?<7I48B7  2!!@EIM-0 <^<HD)]ZT+Q61
MKTX$XL/5OE9W)VR'^-SW2E A?^6:JK4>[5C3:K($.^P,XUH9[800QC)"*\6*
M*-=:,"!XG9(Q!(RM!:9\WZ?L_3:?W\S6Z=&-;'WX2WKY9K7)7AI8N6V/250_
M;TN*PYA@B923S#*GPJG]*)G;M"]@@J_4JSH)G =3AU[:>4O7X4.#.C-;+M-+
M?5^2>'CPE!'><>;$6NJM$U(1(0@TB A:V1]2F@Y;X>OUZ0Z+Z0@!/S.[6VQF
MR_VN7]PTGG])+WV6^^UFFZ>EO=$L(-ALKD04BH7EE%DD+9;AS("5#PPATJ$K
MUNMU#/>-X@B2M2?@</72OU[4W!N,2@S7QB&DD'1,8!;(19754;A)VDO+ZW4G
MQ\-K."_2]T9F(]$X/3"!DD(B(*?".P$5 X!4H78/18>]Y/6ZE*-"-F@(XB9;
M!O#7^TC8NVRS[Q[]\6ZYV#SX(3X4,,$3(G/N5 F74!D4  !4$.I)V%&KS ]L
M.]P=#%^Q7[I?$(>+6VX"G.EEV=99S>?;V^+NLF#5!H[-%Z=Z=M</3H2F!D!C
M"3(FG,62X8?(OJ6X?2,P^'H=UM%A>Q"67MII?TAW:WL_RS?WC]+#^VM0?>R%
M)WI#CW>3WI'%5F)R\OLY/33!.KS4*<J9P4@BQ\.AQ!24WA*HI&Y4,MK3<53U
M5#_&+'W_Y"^-+[@[8[Z$."D9!ZCX*(I+M@UA>(\/!DB9(2^N.7F/73Q&'[V?
MKC_89E/N1]V,[)J*CN:3))Y;#;7CT@'F,;/."EY"IZGJ8&V=+7$M+XGK15"^
M.^%Z G0XM>AAF;6Y_M\_G 3K$G'AI,;.66R9AQ:55'F(W;3+/OI@WPD)Z839
MCR(1XTA"3>G'- 4A4JQ,SP)^'X- S797D>39VF1_O'U[NE?$R4%)T2F804\M
ML\!AZQP'LERYY';0%A_-2CVZP)_UA,O@!:!1[K)04'&F ;52$X20T3 8A0<:
ML;=#MKR>L&80"[^!HY&M[S8@"@$0]IVBFQC$7 #D5$F5%7KBBD $;M5?<M .
MHA]% "9Y[D^"[[%RJ(:X[\!9HX@%F"OL +&((E'!(D&'YD%#7F[1F"$M[CLX
M#Z".S':=F%TW.BDN5 P$,!B(T-)0')91J;K"O([++3HP.S) 0^WDG\+;+JY4
MD8!RO=O<:E2]%Y]/-.,4 0P!@=9 R!5WE2 +J=NW>.FIN_8X:EX,[(:2BT>K
M7 ?;Y5VVFCW\YC% M;7_9\Z4Z/#9!40UDC+81 8'1'2%KO$3[\3=D<?/KZ$=
M!+M_R]0D]<UIBU(DW<0NUIM\\7F[P_4Z3W?+.:V0G!B2..<4@%)JAXD,QROU
M4)4A(ZKMA%I/],Z7K!?(?K3B8LT,TUP%TTUI S$5PE;4>P8'W1G.=T[&#9OV
M@=B/TI:":V\1Y)RS72D^%0#H"E3OV_<KZLV\Z4U.HJ/5^O X-$@H%O*(VF",
MJ?5#JYV+JW?IYO#DL2/E[(D2AZV PCM H6&$0TD0*2E$#K;W8$7/1N]-'@9!
M;C#==#[/MN$(_I#.T\67PLQ[2H[9!GM^=2KOK^$,"8)&,N"!1MC(@+D2M*)?
M$S_D;11C[R3]0#9*\#N]R]:+S=O%['-Q#\NBIN?-J8&)5,8P(!@S''!'J!-.
MEM0Z)(?LN3ZV@$1%:C"76GI[E^6S_'Y_&#ZNC3_E6#L^*J&.8Z&,#&>HA<K:
M0#(HZ02PPR49T3/->Y>(>#"-) X!DJ L%:&DR[_/EMLTG)([(IJ+QK$9$D00
MI9P+1("71CMI$*TT<P+;E[5$SRH?6DPB0=9S2OG'=)G.PQ+_]S;@D>;+>[]8
M!>5Z,5O:V6;V^VJVO5QL'C:1Z!GF#=]_.K=\L&7L?/$]KJ*PAO5LG5X6#3K3
M()J;1Z&$@5XWR=S^W9?S_5(?O%;Z_N&1][/[G>ORZRR_?-L@^[_[Y ED'$%&
M.46<::(AUR2H")9(2 $3O-$VV'=]0"V9ZV-T-J\9Z/B.A%M-. 8 &@*(5QY1
MX?8X$JO H%=SG:PC&%)DCE8:# OVI*L/'E\W?LKI]OA6\J)SMH6 2,"UY\HX
M8T1)/N9TR(2@E@'DP03@R+WL+6 <S#?[Y/[R!B)QR,;@0AA"N73%UV@<]IZ#
M S7.*(6G'0ENQY@CW.V$R&OG\R2CLV.P-Y+;?&\3O5D5WMG%E[18Q.F(Z]$!
MB7;$ART+0X>0%<HY*<AAQ9Y1.\%K'-I"GO6 1VL.?OJ:?;K)MNO9ZO+C(FC^
MZ>ILGIXQ10*A14&P%8)8,Z4$M=R65'$")QC\BL'E_A"*P7?UL*K;NV5VG^[;
M+)0MS<X2@,9S)8I12;CS1'O,)02651N=%]RV=S'U%O:*+ E]035"JZ41FGA1
MI0 )$)"P,S)'M$!8EG:6Y[Y#XXN^Q&=$X[)O>-OGD[?%Y+OU/W2FGN=I\?D\
M"AD_(O]BNUEOPL>W6%V'[^_1'XH-^<ML>>0^FNDN-J&\"&4RQ83 U!-*+2,E
MIXQB[>W=WD[4$3Z$'X9_@R7-%21_KL?J\W.L=O_W]W1=W#^T[T'Y $Z=LS;V
M^Q)" /?62.D8)L(SA)PNL<5=[GOH3<<8TP,Y 18,*MYM8'Y,ZSZI\60GN(BO
M28 HKH%$6"%+,/<4$H(.2$*K<?NVS;UE^XPMS.,@/Y0,5U9#.)46\_1EBM\5
MI63K3;JG:_TI"[K?X[^;;+UYEVW^;Y%4-\^N5S7=,'M[9X(P%5!SCQ&W,##9
M XU+C$4X(Z>7JC2B=$^%#:]>U/=?>-#H#K\JGCNUH0^[D,0AXCTR &.O@W)H
MM? 5-PS3[6\-Z2U;ZT?\*&+P9O**S<7=KC3H;[OV\6]6>YK_2 MU+H#U)<V#
M,K?[HYUM4C];Y+OLISYTGW8K2;!RT%"O& 8*888=<JSDA^,=+EGJ+67M-:I'
M@S#GM7PLY3TT%1"[[>3-:I,O5NO%O.\OI,GK$ZVDTA0!A84CTFE/4.G(0P33
M]@&7Z'>/_0"?10\<:>]:W7F@#NN:Y<O[VBO,CH](L)9:,6&P1Y!+P!G6L%JS
M]^V=C-&O+QO=R1@+Q-:,KU2<\R6@P= $.R>LUT)02(VF17;\ Q54=8C31[^P
M;&Q9B ]G#[M!607S4E5KTZ&)-U0$39ACQB5UV@$A2F486<LZ",6/%([K"<Z^
M:PE>S"?_N+V]G>7W%U>5DG?H?W0@+9A+I4&V_F.V=NO-XK8HFOA]O5A=Z^5L
M_H^/\YLP_7K_?'$#<?C#;]EENOQW5OIIL1.(6P(9L<0BQYV7@!!/*?7,<R2:
MM4CZ=U9ZF@!DF$!&*"V*OFE,>N4..$*AZ9#)@GUGI3<6F=ZRTL\#>])9Z1\*
MDNM:WI?/)!A:XD#0^0+DV&+E =(EX=ZY]CZ\5Y./WICUSTMV6V(X6-5VL;[:
M!E./GDH8$H0&?4%!$4YVKT$P!$LZ C!TVFGH+?CQ$D<[8?%Z>3O)U/-A63H.
M*W\+D-YN;VN9^>2YA$ KK-)0<B-T4+PQ<Z#:M)B88'YA*TYD\3 8C)^S;\WX
M^?BY1!B((6+&612T'R19T3UH3PN"5K;_//OKNA2#GQTPF+P7OK(\U7J]O=V;
MG1\6ZW_X/$W?!/4P3]>;#\'F[,,::_KN1 N)G!6 ,BHH=0Z"(H-DKWE#Z^#T
M]I$QS8V)L>-5?@+NV]VNZ<'?LV68IO G#?D1O/SV!!1Z/PK;C^$H_"2Q,ZK"
M'7>H )]REO(D/H,H#)E\VO$IRC^E^6UMEF8O+TV$9 !8ICC@B"-#O&2EZ<N!
M$A/L[3>VV$^!#Z]ZV[>++XO+='4YQJ;_^-T)QDB%\Q52#+1G-AROI+0HN4:J
M?4;GE/.5)[7E=V#'N#&E=]G*S-8WC__V*:O"2?O>UFGYGV]6)EL%,G>3K=;9
M<G$YV\5<#W?LK"^N+N[2?#?+>E^'<Y>G-X6'Y$OZ-ENOQXXW-4I<5,O=%Q)^
M*FZ8>)J:6"0MKIL$GR*_*7%:H:!$*R(==EY1$D0J:!*0.B,\=8T^\;XC47%H
M;AZ5BOB^1'(74,10.:$UD98@AP[X<F?)D#[%DQ&JT>3J:+AJ/"Y,.G3U9A6V
MX+3:&M\>R*\)9IT8E833C2#%*5%2,6P5"2I6R2INU2L(;XTB*EE?" ^ENQY9
M<6W#GI/C$H,$LX@8AR )=JG$VE2T,@K@M -D4;C83#(ZX?5CR\@D VW3$XUQ
M1*+8*R^NBAL>ZJ]F^N[9!!HBL7<ZT,2%]XHQ:$J:#('M3<K>G.F1>/1=/X]N
MR P614_7:7C73;"Z;/HE769W!0B%>1JLM?KH>OWHA&,O&76<L:)_.W;,>EG2
M+3QO?UU@;W[E?B0B/E:#.<'299CS^F_I*MCHR[!^=7D;V+'>%!;[E_1 0OUN
M<=8\25#2$%) ."\*.\-"YFF)1?AM^VJQWARS_<A-GZB-ZT8]V_>9" %]@(X@
M311SX>,0B%16IR<3O,!K,G9W#$#'=3D^REU_?%5>[QWJ7UQ5WPWIMY_7Z3^W
MQ0'QY7'#J]Y?-,TF]$\7V<2/>FQ((CAW$C!)/?(BJ/180DNL]AH"S#!LE%(^
M")6U_LP7'D^PM-IR+(1@X?^"BJFMVU$'O W_&]+R.ITPWYD]S_>W[FA,VBWX
MG+ZPXAJ7X)$1"=88L$(-,5HS9''1Q;0$!3HR77=@)P[7B$L[< 93G[Y?;:V'
MYNB8A'$%">3$6&:@DUH*3DH:,6-DVAZ\SIRKEX1../V8,C%)C]UT1&$2(E!O
M?[_T?&(55BY8I%8@%'[6 @!1TL9HAR20_M)?N_/I-.=;(3,4U_=E6_7G_Y/G
M$@2)<!H:R*G63GI':(4,![I]L<3Y7KCQ3OTND$PFX^QH*=\#=:O+QK=S]/&Z
M1'F/*-9!<P?6>"\@=;!$U@ CIJUAM)22<]/%A@/VWZ(;#^%)*D*O6&+'D=0G
MUSGL78JUVM/1,8D"DAG D+ ><\TDM)Q7>H(8MJXT4AIMKZP^UA6R(["3V>;.
MZLSWMSQ;]]*-Y/C;$B$QD!)[) %"2DO. 2B=;%H.>P=7*Y4_@K]P=%C[#J94
M89/%]6IQM9B']:KY/-NN=GVSL^5BON@U@-'D]2>B#2.OS&2[BY_V.>E%G>+8
M,9#O%M0D"G)\4(*Q9I9X@H$FB$.-N?(6T;#;&DTI;]0/;"!*ZR(A+P](E$*6
M(R*\A,YX)84&NJ00LF:1GB%B(3&8]%WV401$)AT/^8Y"?=_ )W)B5(*T]5P8
MY[3"@EIEL2,!'*F)H(A -J"XG.4AZ<KK.M%I#=%P"8O/ 6CB"S\Q*C',>TRA
M$K[P($)&57'E'U7$<"VQFGB$) H':S>4KFC]N-(Q21?!U(1B)&'8KC?9;9I_
MM_+Z3.?3(Q-@N530<*<LM0( BJ0MZ#5:N4+[GYY)%85[SR4B*DK#M2OZ?UE>
M+GU=HT)\_W "* 4:!R,/>LT5,E9Z$ZA"%C&MK6S/^YYC*Y$UA\[(#,7OPF=U
M<?5DN;4'PM$Q"=1(>J\4+.I"F'!8<Q9H)(X2R<G4+Z[OPK2L7XA^3'&8I'8P
M"2DXE_M'^JB7;[U8':]?>?G!Q$"HO P'GZ9%KRF-&0'%"JF#B#(Y0;]H!+2S
MB)!T9MJGKUDSIE4/)@YHY;DUS!B(@;/&D$)0PZ^D(HA,\+[ZGIC6%I+1+#%]
MK]/5_.9VEO_C?+_-DZ$)PMH1[B%&G"($#:&&%KM5T%F$%QVNECJ_6&ABSILN
M.(TG&>6BSS?4GPU-/,.,(^"Y)AX55HR#/%#,K&1*\*EGN\9C:*VD1,'MSR Q
MD]3@IBLH(P7IB\KK#^F7=+5-WZ4-<F-?>CZ14&$-%(/2<,"\\$"I0!N5EAHI
M;/N>F,-Y=5JSZWG / ) @Z7([L.Y8;GS=/&E.%%K^7]L2,*94,(%.H&6"%HB
M"2E<84(AY2VA0R;.CBT"D3 :[8QXN//^5*_14\.20AFS(FR>-NABC!B&<6$.
M:08$,51/T$(<(KK<'J%)),$\NODJO=HNWRZ^I*-W''R?9\&,V-P7.78;M;IT
M_]PN=@TCWC9(^Z@?G'")F6=$20DDTMI(R;777NWZSP?;<[STCX>V7T?):-[J
M[_04">'<$ \XQQA22AD4 NQ10$X1-V2V[\D4D9@,/=J0+RI6DTX>.4IIHR22
M!J,3P86T&"FJ'(-!.=+"'[B!/$9^ND6VT:4AZQN\H=2)XX T22AH,#K!0+I@
MGQ&MD*4 &"H@+.EV$OEINRJB<K:IU'1&[\\C/9-T6TQ=:,:R7&[OMILTKU;<
MH!'?BR,295BPR+&PR&H$"&0 E-NT%P ,ZLMJ9J]$Y=IWADL,E 9S8657FZ^S
MO*BT*7]\U#ANUQ>JWJW5=(X$,*<E%T60R'JM,-..'_1'H!5O?P]&;WZ./B6E
M+]R&DAV_S0,CMCL"_.);\5.]L!P?E#@6=EW*H<=*6&("N0Z7U@4UOGV*4V_-
M^/J4CFA #9?A-K\)EF)^_QB(!M?S'1V5J&!L0DD=P,YKK)$VT.WHQ%93Q]L+
M1&]7A_0I$/&0&ET?+7U@5Z<<+ U&)QPBA8FD@E#+'$1:8U)^"0[#"<9.>O2R
MQ =L$I[3B901]MR,L;B@ZFTV6_7^@DDV7[3IY\V;U7J3;YNZGX^,2 #R'"J.
M+,+06\2)DYXI4-3+ A9D?CR?\],5U[F77W@Z<58[92$FFG(M#$-"J9(VC\R0
M#K^3GN3.O,EB8S%I3W$!T,65R=/P8?K9?'<Y8XU[^-B0!$O" %*(J6 R!$6#
M,DA+6(PC[2VLGGW"G5B<]0+.4%K22\M]6VR\]1GB=4.3 %W1KDIJIGTP$:CR
M#I046TO4M+V]W1G90#(BX/5GD)1)>G:G)R#G"L:15/7WX=U!$?TC76_2?*5G
MJ^/%@R>?3XQ@DECNN;,&&6>T]]61"RD8M-54,P,I'@NR^  -]:4_/0YKE('O
M'TX\@ 9+XRU#6%A>W#Y*'C2M#C?D]%PM&%,-Z S+.,QNU);NV) $4RT%XIQA
M*BSF%A/N2@JY1G+:!WX7EIWD?F>$?D19F.21/@41B'2(?_J:?;K)MNO9ZO+3
MS2+?I.EJYX"YSM/TI&_\C-&)4%Y8+XDCQ%$CH%,:E;0XY0>-R#<[X+NS)>L;
MIA@L]]FV \M/C$X0@LII;BD@2E-I(!<53HZH"6:+]\;R>#"U9OG']&ZS>^&C
M97U<?#N3]>?-DA!C$/6 (&<,%90#*2L=F+HIADKCBD"O<+46!9O.NTO"69,D
M!$K+L*&F:+MK03!?.&8*:HDYH-ZWKTGM+40:5Q#Z1&LPMTZVN@Y6Z6V!3(/4
MX)<>3YQQBB'*BWO^,)'8!IHJ,Q:;]CE8/=<F1_7[=@=F+);7^^]>')"$@PT5
M5^@))KF!7D 5WE>JQL9.W;_;B6$UW.^$T(\F!Y,T]:; _EAZ?QE<KU'PGSZ6
M8,<1LD9CP[BFAA,"1+DZI-B0T;JFWMF.,&?1T.C,*]V,5[I,L<* ":2 9<J&
M=157HE8A!<L[7&G7F]75!Z_:H=&:5WZ1KS?%1:SSFYI&2]\_F5@H" <<:H6@
MM=YXQ*NMA"C>OMEN;T923(YU!J2#13S/5I>-N/;"HPE2GE$;3  F#&?(.&PJ
M.R 8<>UC%[V9-#'9UAV1P4H'RCO(S7*V7A^N3JZ[+_38F(0HS)$C &$>]/]
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M68EYO]\4=]GG];=71,T/8P]2S.(P"G 0(#_UF]K7XK6O,);M-&-,V.LX#2K
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MW-N]!BT3 U-WH7M^SJVGV:!X 4ML5MQ2NQ>MRYO<)LB?>R[,7_+[#QEOC!S
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MB?G)F*WK6Z=)04' +,5"(D/,'P:UQ-&.EZ^ZBW+MP+G!#!K00*#N$\E)EEE
M2!12S?RAT<M Q^%1L\;>'QUXL\>,34Q:C)W+5W;I7T :L^Q@,5E35DAZW;<_
M%Q]XZ_VRKK*S,ZLJZ59*WN\/Q6N_*')!_:,KL=+EH=C%+ YHP'! O)/ZJXE4
M ?DY\5E.FQTX<"C ?0M/99'JS]=_7W7E:M86()&+OX/@JR7K/NZ?"] A P/+
M817HW0+"+W#F W7@%4H-S!IXA8S_'30 O2&!J@!4R@HP=NA@A_IS8XN9 [V
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M%Z0LON;U/.N'Z\:9\^.+V2.E*);+"I*:M+*;FVQSR+^*RB&]R/*I30:>0KT
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MY%9.Z*:C54W@>ER@ 3:[K@T2-:!G9@A>AHX9\J6PT01U%_/JCOFEV''JJ@;
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MYOOL_2&[JU91&++8"6(_==,(ASZ*8?-D.710@*#4<S:CC4R^"2B@@1K;N)U
M!1ZU)K-V*!P[GY5A;XHY;<^._+16G="%Z-YH-X8GM[J\&!O/GE/*JWOQ@]7?
MZKMD[_<?LC(OMG\KBXHCC9$3QRAU8\=U,8G#T'$ZI"3&:M(U S[;1Q_[0\W-
MF?(+T&(%MP+LF//FLT33T"!WYD J:J^ ^NY:8 6G_H 3A\#U(SC]N=:I9F#<
M!_T"-)X!'O/&-_$WW+N%C9C5PS-FP&RQ,2PD;\S)@.IPV7HTU*M ?,QVZX-
M4QX>/W/[U7I38R&/3_ZE/F#CL3@.0L>%*?6I#TGB!2C ,$XI<ER<:%: ,(G
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M?ED F"8D# .,,9%)0WXD+#9F,0M\"X-)Q]Q8(ZH\8;(P = B=, ,P!63EJ8
MMPJDCJ=59VAT!<N$YQFKEI$[*M)ESI.A?I%\MWL2UM"#O*>'#G7-+[E[\ZF\
MRZN[>9QG. @@P*E/&&(8490U.)@@-!XD:!;L.U<X64UAV>"LT[8'*9P-RHTD
M;V2NAVI@"]>K\=YXYXB]0^G5F"<5QK<I55=*B\TS2^FTZ5^_EEIGTGAK6ORQ
MJC)+[JHK((7@;<%@@N3C!7$:"VUG%%+(6]/0Y^D@/34SZ5Q"T9<ON^)+?BB\
MS0E@<R]&(ARX<VU$L^$NMFM^A\KF&4+O[FV"Q]G<?H4TG8WN(9S/4@L'NO36
M!OAPOI1?="[O#]^%I*+MJOV2%M^*3?DHJRF1<G]H:WG["<,93&,.*>48@00S
MR#%')  ^1E#K$3U[5AT?U\D'N8\'>:^O@:GY%K,]=M74;AIB]22O!58].M#]
MY0RF5^%\NS:WFS>651GLT3_[K3 /$73@U^7[R8Z84Y7#W_/EU_6VV#T) %*,
M'\^J9J.$RVL9S >,8X!#3 )66004QPQJO=,RQ(YCR?NX7 LLZ_OUTBM:9'JJ
M-XA$-9T;BS\]9>M05=+6X9I(R7HXZM$N&\S.0ZVL>%+:[W?:-:@?B]WAZ4[T
MM,.YU;_OB_OCYOWZOEC ($0@RN(TBFG"@A!C$#5:&# 0:%64L6'/L4*Q_6']
M4!4".%:8Q)KT7G-B9H55-:D:FU ]R6K1W7@5ON?"=>/5&+WW?02[*N']%FL]
M(F:3\WF(F56/7E;QMLR6\JVUW9=\N_YWM=0EY79?;IIUKT AEK[[MJ#O[7UW
M1;PJ^5 ]0'7*S?]4_#A@P=:_%IA&($E3&@<TH3A)?<HR+/X+6!*$A&GER(\.
MSK%LGOM3/ZR;[]=5NO>Y-YHWZ$9O0#71G77;Z2GTN2LWWC-GJE8\=T<VYJG\
MQLFC9_>7I%->Y=7($U+;C=(3 "9K_WE$B^G<O[RW.&T[J,:AYNK#/ZO7# ^W
MNP_K+U\/]1T(FD!$HR1%@"2 !3Y-8L+C..8)3*,DT"JA,,",ZWW.]F95@\V[
MW7D5.K-+5D/X5!/XD:C4D^KN_E3+8JG*HA.]O<Y1CW):('8>&FC#D=)ZI[.@
M2]73U3P+:1I %@34#V@8!F$4-_8RZ#.MTQAS*Z.HTBOCR8(:J;$X0(RL$VA-
MBR9XP?XJ0[I*I,7JC(5(SP\5'3)@9I ,U0^"+_PH "%&&<L(3)B?T"BCK47Q
MO>%"I&CG)Y8B528'B)$#$JW)T20OR_>PI"M)FMS.6)1T/5&1)2-VE)X!Y,7G
MW3'?/7WZ+A:+3USTO$_?RT]?R^,^WZ[$-S??B@9*^S1A<U!#(I8QS D.4<0B
M%,$L2ELL/LF4EG1N$3@6,X';"Z,;3XR-L!N0+42-!^?<M4"_U,V'?#T1;"%[
M-69/@A9?EUX+VZMQOV@3DW?JW36.QJ. LV@DL[<!N\8ZU(UU+QOK(!KKT#;6
MH6ZL[TUCM4_A#GT;T)2S5^+6.&TP@Y<"W?M8CMFK+4S/WW=5%.*(^QEC,8I9
M'&0)!!%@K=$LB\'@&;JZJ>EV,=^;5ED92NZ 2;L;7JW-VU4H'6_N_EZA (LE
MEF<\@S=P1F42;\K1( 4[OTN)*&4PA&$2$,:@_#\)&[.,L'CX+H..,=<)F-5-
M4@LJI47@ )URQ9TEI;J9[AKV6W3I:I4)TS-6*R-W5/3*G*=!BL5^%+OE>E_<
M[=;+HOOAOOGI/EB E%,<A5%,H!\CGM(@;4^).$M"S4(M;C#HC%"CNX3_+"22
M8O5;+OZY?%J]:"![CQ*SE2>U'#7/ )$<M5VL*6>+VJM@G_W.OONED=]*-2)7
M5V>M-=:,Q=>>CRJ*;)E1Y>N-RZ_%ZK@1%JM9%<[W\B78)[D;A+[GNU55[/3V
ML7H[0#XC5N<FB47[0_V]ZG#_E'V4($(QHPG <492E/(PRC+ @IA17WQ7ZPK0
MR-!<3UJ/#P]RLTPF(.;K7?-$7U=*N/'#NQ>JP1X>-^534>R][_G>.T_FE\4B
M\"9?_NLW08X LF_^7:4^\H>_EZMBHWD%<^0>H!8B9MSX>K&C=:1J:NG*;Y^E
M+U[CC%=Y<_.\%]QXG4O>F4]-DI0W67ZJW4;IB3D3M?X\@M%4SE_>-)VR#?3#
M5RN:'XO=-Q%!3YCE#?5BNZ_A;:K&K?)I/Q3+\LM6%J2\*W;K<E7=G3W+HPWB
M,&-1%(00RH/8A*>HP1N$/O7-(MG8*,<+:G^4V]^6^?ZK=^Z)+&)TBF;R2$C\
M6M%]0ZQC2+E=B=\6@GC*?A9_.<O,%Y]]VSU?5'V&M+ KOHI_MOY6>/*I%].(
M-WJGT0U^<^XOYG&P]<IKW'H6&,\]N_%.OLE_>/+.J]UK*R',)C!:;C"E&#E5
M)YE;N)R,AZN1<]J6&;(&/ =X'NG1\K#^MCX\741W%F(*L9\RP@ #/&59"%M@
M-$P-HZ4S...%Q?-YO?=)+.GW^=+@(;XQFLA\839AZ]A9C#V/.1=KL=:+&449
M4^HUEUR.VG5N<<.]PPI+*Z=<JT8"EN^VZ^V7O0@^%;*3O1#Z,0@2SGP_$2LW
M@,3_4IXF'-*49+Z6P)M;<:S;L@YN]6BJ/%6IH.FI] #ZU,1W'.;T-+7%)&?D
M-6D3WJ"^2E"/\@TG=1Z"9L&/TG9WTYR(MJO^V_OZ&5>T73U;[#??;5^:S*(H
MHQ&,609]$@%?2"%,,DB83!H,(M4JTK;-.IR_M$CE!.;Y-DCS;O%4CZ]J<M@W
M$7'4&O,8I,Z\NYQB.&51=4!_*+X5VV.Q[\PP!E,  8<!)M!G,8I05)O)PA2G
M6&<:H?WACF</#9[_U)LSZ%.D)FI.V=%3K1;*9.)TR46/^AC3-@]Y,8=?6NH^
MFA$_WQ3[QE:S2;87L_ %H@@D@) DI7%(HXQG8K916P-9EA"M_21#&^/(A>8^
MD"E?BC.A$:C2G/%(1%X#Z:8],-C?> +6R#.<U[GIF\D,9',>DC+8B\N9B156
M-&<@7+CUH=C(L\6[?'=8%S)1/T$1#=(LHADEG).4L\9>%$309"IB8&4<D;GQ
M=C4L[U'@>C*:H9A0J#55<<R>T9S%D^/!:U!Y#:Q))B\OV7E[%C. T7EHCP4_
M7I_7#&9&=P6T(#CRDX2F&8]XF/H^H;R5MR@,I=R4AWRCM_)Y\T.UU*6SKSQ(
M/LE_(J2E?R+C=$JO,)579FE6?5X#]I6INZ;?RA<[ROU!'E171A;<3Z.(<N(S
MB#%D..&P719$# 9:$W6]3W8<.248N<OV5N^VP9%:F'1'CUYH;)EY:P'CYG;#
M.0D]@]^,K'DH@"'VRUL& QA0U8*_[<K]_FY7WJ\/"TI92C$@:<"9F,6'0G6R
MUH(/TE GP.E\KN,85T'Q'BLLXW;U,Q)Z.KH)5?/HYD;(R^$=1;,">YU[NOW"
M?LCS^;,=L4!\*$0^8(1'PDK*8Q:W]A*:1%JEU(VM. Z#'3"O:)!I[F\/X$\M
M+(Y#G5Z(/+'6@IIL[_LJ/3V:,IS2>2B,!3\NRW5;8D9]^;@OQ.]^1=O5V3-?
MC?%%2@'(HAB0""4IPM5=BM8FS"C2V\(:8LGY-E8-KDK_7YW@Z6YD#2)3=3-K
M+!YU-[3.*#Q_2["!-O;RO8>EWC6]#7;GH4Z6?'FQ^K?'D/(I7K$1/_WRMV(K
MU'$C+*/5PWJ[ELIX6'\K6N,)2CA- .& B<D9X %C2;?#QKG>H9X=DXYUJT%Y
MXWVI<5:#+W^&5//\SQ+3BL>!XY.L>3K8\ONW,WZ?@YQ&W]28ZSL[M$O]/!3/
MME.7)XLN.#->)RYPY&=)&F&2H(PE@&*4=G8(\0.=#1']3Q]EZ[]\L3H<N#A\
MFS3#1:%5OH8N!B=> >JL_)1YFX?"#,#_UDI/DPEMW:@3,N7U@T4<^&$(PU3,
MR#(_A"P#&6\M41(Q(^70^'S'VE%=L:@.ULON8O=$0^)$BLJ@,*!P9L/"Q(-K
M \.8#=6A\6XKIMS%_E ;:L;A'^6VBSHR;2A (<P2/PN0GP'._"PCW:YO%F*M
MBTE6##I>4K08VXA[XVU[,N$<\JH6B$>G5"\V=VPVUR=^:1#^>N.=@YP@W5"%
MN![-LLK[/$3,KDNEPWZJ)W.R'%A5#0RM_O=Q?Z@O;;3UWQ8D#%&*0C^.0$*S
MF,$XIJW-B'.ZV!9?9!J3FL(-LZ4T#K-Z')[#4AZ.O\AH\JOW)5]OZPG"\JOX
M<2$+Q=S+HFG?VJ)I[9,"FW7^>;U9ZZ8T#J1<3?I&X-KLD8U3^;D3LO/*E>,*
M72]-/0IGA]YY2)LE7TH7'5!S.7/X6NS.=?.9H"YH$J<I2S@0,\8X"T&<AK U
MBG"L=6(UT)3K@W.)SONEF:7]*B1,@C.8K0UE5''#9#PR-7=/*A[/D;V8JXV\
M=NQEJF\9:8?B>2B6+6<N%Y<V.5+5+#&U.UO+ IZE$!(?8XCCA*30CW!G0S"E
ML_FB]\F.MUUD=8M-7[$\)\/E&04]H\.,JGD,!D/LI8W.8A">7[D'+DT*^[?W
MG_(?"PP31*(T!"#B$(01B4-R2J2+M(HX6S$X2JA>/BNG\,NF6HG447N" /,&
M96^%&5N,SV-\V77IM9!CER_UJQ0OK'86"<IX%!#"4!JDD-$$^Z"Q&*,PUKHO
M-,3.2$&I.KE_/@1[8Y5]/M7FR6-1J3=)?K443+V94FU=RM6]0'CCH<-AM_Y\
M/%2%[ ZEO-'8ET;GZ K'50I[9,T&\?-0,RN>O+CL88L=5>UJ'ZE!]1LU?QSE
M^XU-0;NSUX5POE\O92[:>G,4O[U(_(@1G_$D0RQ+$?=AT)X4Q0P2K1PP1Q <
MSS9>O.XC&NNAW-:O^.R]\@3\QOLLH==)KS7XZNV?^C='7O::D=TSH!VWWCS&
MNFLGRU%'A)Y"W.V*QWR]:M;NY+B3H681H2B. Y*&E&9!F"4A 2D-XYCP+(YY
MJG5KQLR"X_'=@/+R_;[HV4NW29G:U,4]6WJ3EI8HUAYD-Y#&U;576>F1K6$L
MSD.5!OI0VNQ79BDA'XIEL?XF9[&M/8[3*&4 L""+HI"@E/NTM<=9J*4KYE;&
M2O[8=<C,4C\,^-/+]W!+G6&2QPG41&)SE1V%3 YS1N<A.A;\N)*S,909K<U3
M5(7UW]?[9;$1O:PHC_O.*@<@8[XP'F<(1#Q)DZ2U2@@-M?=-!]@:9<O49(HS
MF$2-\\R1^#,YT*RAW7C/P$VD2F]P]=9>LP66YZ%0UKQY;8?9&DL&:M4:"F(<
MP2RC!&(6)]SW4W@R%(=:)3H,/M[Q5G)U)<58C)0YTM8?%_0,D9RI-49+5G3)
MFYV2:#MP73S,N-!]!6I_>T^DE]O#KGV4:KW_%WZ2_^?Y4M!Z>@8 Q#B#)/5A
MRE-,?(CC $<4I%D*, -ZZ5PN[#N>!760ZW+\9Z"K^E@"L/?YJ?ZS1F[VZ)/5
M%E&3KZD;0T_?WFZ'FXN&F,U;3AH$]PBFR^::AZ(Z]?#*\TSNV%3?0I>)<(>G
M.]'=#VB[8O_GN*[J.9P,$P*X"  <8Q!B6?,*,MX:YG%(%M^*W>=2?4=]L$&=
M87Z.37FTGQY$__N^N#]NO/?K;_70;]'?>!7^ZN"L\V#L;>6WB.S=8[;6"O,8
MO38=>K'[;)DK@\>*^'J;;Y?K?'-7[M?5DYY=5:A V,8X#6(:A "$)/-C'E<;
MX 3&1'4U8<66P_A[_BQ1!]!K$<[A4:*KM/5%59NLSV,@VG7I^IM#MOA2'8R?
MBH?'<I?OGN3P/SQ5!]Y[=#Q\+7?R,=T%(BQ)&4&9((TF">$$\L8JS2!-=!8J
M0VTY7I2(*8L(JX>UG-X^BL%4B$7CRMO+)R5OVB23O$,[[H!\@[J>L6B+]'D,
M0VO>E&ZZIH7!=Y9NLD!9FF#D(Q)P7Y[($)C@UBQA6"NA?+"Q&0R_LQRO&8R_
M,_)T!Z )[S,>@4;NJ Q!<YX,Q^#[M?AC5:U:[ZI.6 A6%C%&+$BYS])J[IM%
MF'>FTX & \:AF<$IQ^+FA+CYH81\4]\QGW18OLJE^M <UA2S')X#7>H?HC;X
MTKCQ\="\[WV7[VYWU91Y55W2;A_977 4)2A#&+((H" (8(B2+DAC2O6>U!AN
MS_D@K=.?ZU'YF+=5'F2F\ZK<;/)=_1YW%3NO)SV[HUMMB3XVTWHK](;DCS7)
M J 8PEX-L2D%<??FD^>N+H.\15N/\MDD?1["9]6CEY=$++-E('OUA.C=?G\4
MZQ%," QA'+*,!BC$&*&$M=8@9MQ0ZK1LC"IOS0)@74$SUC(]#K7URQE]0S2K
M!G7CO>NGSK5(G7.C)DQ&;,Y.C,R\N"Y  U@Q%IWS51@G"$< 0(Y\' 8X\0'-
M6I/"_##ET3$TA?Q,MO_0QY3.:#(A>*9#RLB5M\:5.3_*IU_YIKB]K^<2N_7R
M-('(LC1,649@BH OUD\84AQ1L7@"%&1B5J'[<K>1$==Y/P*7/.JJ1I65A8HY
MG8H'B&,PJ7EHV)#8KDDDK*E6(=?HZ3L<',KH//1HN!NO/.]M@1=5'3J5MMM_
M*M%J51TVYIN[?+UZMR7YX_J0;RHP]51#_C\7Q,C'$?<+R-( T3B!LKI.F!$2
M1ZB%A&&L53O8*1#'>M:"\982C9YRN6T -76;#?=Z"G@&6];B. 'W)')9]+3!
M?E.+9+/VJ== 57N1WO9R(I5#N.Z1TU&:<!Z2.XZKY01#1']]MJXAH>V*E%M9
M[Z_8+M?%GJ[WRTVY/^Z*4Q97 @D."*))%@"01C%@$*=<(,(L "S4?&G:JND1
MUG -VBJE\1E>_4TDFYRK[RU-1+?^EM-5IKT35N_/R1+'];A\8U'MH%'FH;&N
MG'MEX>V,0^6E^/K+=GV_7LK\U^6R/%8@[LK-6L(X&4>,Q]"G+$,(8<"1'\14
M&$\X@&D:)EJ'_Y9,NEZF'Q\>\MU3M<@\ ?9.B+T6LN9BW1+ABDOW\;G67,CW
M<SNA5JI1U[?(M\O]/+31ME.7&P N.%/>#MALRN]RXLK+'2V/GP_WQTV#8G\J
M$['P<0KC)/1#/V)!A%*0Q0BD%&=QY@<4:\TE+9ETK(4=2N^^W'FK!J>7-T U
MU_R66%9<W8]/L.8Z_AFW+<16"_=G96=&7JHK$=>W*+?+_#SDS[93EPMM%YS9
M>4HHX"3C@$+B1X"Q@&8 L-8F#(E6?9IAEEPOF >_&O03O72CRO4\1I\E7[1>
MNM%C2/WDH<HMWI^>"%U@"AGA/LLXAA$*PCA+T].@3J'>>8+VQ[N>0IP0M8\/
MZAX5Z#.F>@#@E"S=;?T33Y,\/OZ2C=Z-=V/JYJ$H0QQXL4D^D(NWM*/\O-DN
MQ&Q@=RQ6[XLO^::KELE8%&1B0L  BGCB)SRK=X:$9)$,*85FXP]WK1LU)&\C
M,:DIACE/_7HQ"D6::M&P4\%YLS:3)996Y?(H@V1UZ6%:MIY!,>M3WK+&]1^J
M,BL=J\0S"!OIO.;J*\(YF)5I97,X_-)2[]"<;M66[G;E?;'?5X>7O"BZFEA^
MG$ ,,\S2(. \"8,TC1NC80P#IC7U&F9J)#E]/(/GW1>ZF]A#^52<F(U'I9GL
MGB/S)+2)ZN/U$]4W?[/#\$SF<I:<N9S7V>1(MU3Y7?YT7IK83\2$$F2<<A+X
M.,XBSCIUC.,T-JE3KFEB)(%:-^C,*I3KTJ:F1R,PIJ=#76WR!M'$A<F?\](C
M.P.)G(?<#'7B2CWR09SHE?=MIE_-?N;ZI&E)&&)&&,]DKD$ $45QTAH-J9[,
M##3E6&Z:4N2-Z#0;4T9%R<W)5!.?$7G4$Z&F/G"[$CU!F[18\#6B>E3)$L/S
M4"=;SKQ:4-@21UIJ]8HUE ;4QX$?,!X2&J(D"VEKS<>0:%<D-["AI4_CE24W
M84M#AQP392) ,Q$>?<49P.6,I&:(%Z]IS&!6M$^]SRS^7N0R]W)UN_U0R.W!
MYM6[_=^WY>=]L:L.X=]M'X_R\1C!D?A7U08DR3?+XZ;Z\D.YV?!R]SW?K19!
MREGLD\A'U$=1")(01'4"?, Q L#HY'PRM(XG9-+!NJC(S?F0]EHGO7+K=6YZ
ME9\WWKFG7N6J]]Q7H0@G;[T_I;]>X_#UK,*Y=A<UG9X>J#O%GU$G<9OKX:KM
M5/)%)N\W\XAN,^+C6M[*],C,(FX#5A[@_7-]^/H"X_XYR/USEUJOGZK/6F#,
MTIB3,/1!!L,PQ<P''=: P\5CL5N7JX^'?'?0C+6CXM11S4N7E 44YYLJY?1S
M_:=A"!RW_33#WFP;S3S4G;GD?1<^O1+2]A<Q3<2]%X&P\ZW^W(E"F\WV40EG
MD_2'F86P:3BX%K8F;!'7H>H*U.IZ]'Y!,* 0)3'%*4<$9@D@28LU3C.M=(-I
M$#I>!'8E"DYIU_OJ>L3A:^$]BG_T-=]7/UQ>K]$[3DP;V-!N8]IX;3QJ3.L+
M::?R%B-7MG#21@[BFIT^\7/'-4L<6(IK-EMDHKCVMWR]?5_N]^^VR\UQ5:S>
M;5F^VXI?VR^R&"6(9)Q@"%("Y4V*M,7O,S9EK!N VG'\DZ@\V=^]Y>#+2'-O
M_TE"X$A-/Z.P*#WV?I$^_^JU7LMNU?K]4T?+Z\TY7@2UT*7^DE'5!B]N(ZVU
MEILH^GXL#H=-]2'[A4\XI33V:0P R&(0A2B+6,#%K$$63$"+;?%%UFW_-%G4
MU4&KI+59K;4O'-/3W<O(NO>*'\5NN=[K5EJ?LG$GB:76&W1^P?/,Q9\Z3I[Y
M,5Y@-.D??\E(:$2$V]!GWC:N8UT'\9-0X_V]4/7;X^'V_GWQK=B 1>"3#"49
M\#F$,,%)RD'0QF6"2#!BF!L&=)P()Q!O\OV^*JS4/FS?Q;E#66^8?BTW8CSM
M_X=75 ];>;^L"O'[ZX-F,?*)&MQMZ!NAD:>)>F=!KG--OO @>TCEG0=^CHC7
MVT(.@IV='O%SQSE+'%@*<39;9-I4%I)@SA%B6< $-A1F*8Q;K$F0^DTJ"]NN
MIDQD>0NE?B)+ZY"R_+'JD9(WLUAF)53S2F10;<2?6Z@L<3!*(H->BRB7^5U^
M+5;'[G$-_$3DA/!354TNHQ1E:5SE260HA0D(:HMA@"C6K.T[P([C0Y46FG?;
M/!OCX2>O@N?]60'4S 0?1*G:='4L-O4FG1V1[?L[WF=5(MT4ZKW.4H^>VN!V
M'JIHQ9/+.KS6V%%^T$$::,R]7V^+=X?B8;_(2.;'@ 4T33!.,62$U!OP81C
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MP;^]O\#RJ90/6I?;:D-"8%C*R<"78H$3G_ @@DF&(X1BGF6=J(<(9%QY[N[
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M^LDYB'$G20UX;U6CK^]$/*_#(R9+%_,GC4(P3INK7[EFU5+&LZO;>Z_%[37
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MEARG@NUB;/"ZF"O?;H8_^L,2RV%K =-AU!/]'8([G@6?E&]!Z]S$K[H[".K
MA+D=P'[,=%N*I7+1!9_JU&[O>"7_[_>_]9_(?]2BS^]_^Q]02P,$%     @
M>4=72AASG(UAC   B0L' !4   !O8FQN+3(P,38Q,C,Q7W!R92YX;6SLO=N6
M&S>R)GP_3^&_Y]IMG ][3<\L'/O7C.S22'+W[*M<5%56B=.LS-I)4E;MIQ^
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MZRL!WM[26+;/3'V83*_>%69R-PUNU:/1[\M>.=@X,\*A(![G' 47V"'D3!V
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MKO)V,,?E*+]HEE&J-+""("F\M$QP2E#8 02DR,<+],/E)O^6+^)P/U3EMVG
M5]__/L^OWA47=WDUB55&U.5B^FV="7\8@^,[RX)]%2PLQZ3C5M/@,G*A:F2"
M97_.J6/M,*;L605];31!D(=;B/LY]_!=)B%3S%IA$<.08^<0H+4L"HESSG/N
M4O,O278RYOU=A_^_R\W3HI_+C_EE65Q.9_F3D7\NVUOZNOBY+%AYC")D$! B
M^!#!+<5FBZS%YWRTTB.;1Z"ZOB:%S8/2+Z=K,A17ZK:L%M/_7/WK'F[O:95I
M3J0%CD##K)0"A=V*;T&7)N7!@+$ON,/RYD7MW+9TU%NJ3'12]"0@$DL/Y,7\
M$ U?;Y 1*!VSC#+OK1)0:(FVB"$ESCF-?%0,;$4]?9'O[Y-I$>&Y*.QT?K>Y
M6'AQO7YU#^XAX?Z&&90T!OT@!%H'_+@B>#O5F"4IH8SFQ]=R3<8BOUF]4/-C
MTK%51?5%2S^95JO3B <H+Z[_.:FJ2;'WV<V][3+""!4:0.6 PSJ J/Q65@=9
MBE,T]O/O45&R32WU6.ZIRE=*?V117%R'.;5^="W8&A^J_':ZO)W'U]4W6.]S
ME$[J,--:"B*8D-H""X AR, MYL:DQ(F:'['_N;#VI<#>Z/U4AOS+HI9C(\,^
M)A]JF\77FYU7G'O&&'$2*HZWAK<@*8E'8S^T'Q=E6]947^P,6%5YL*AMOO[G
M(W0V]0(;1*::=Y)1*1C"C"K$O1(6"J6W<Q0&6,XX^;+'>%-G"AF.EO43K&&B
MY]-O!ZK<-&F>$<7#3B$MXSX(39T4= NN\30EWZEY7&FH_;X+AAPD8;(2AJ.?
M7>8^@/CH0;M&[S$=UU&F $:8,B<!=D8ZC+3='LDACE.NT30/-/U0E&Q1'<.1
M,QK!16#"_J=5]K;+%!/.,B5@+&#')?',;R<B)KR?TK<_%/5.1W] XW!5QW?S
MEMHJSG6<6?BB><:]$]@"C;FA$D/DK'PPN+E*B:TWCQS]4+Q+5L+P1N"'R7VT
M'N(IU/H)[&:/DYW68<:LX98XJ!WVQ"FKK&&/L@]2ZJ"._>[%H&9BBTH9CK+N
M]FY6WN?YQL(XE:B[N\G"M*44&XJP#48*Y4"QK97",3OG$- @]&Q-%2>7%GEU
MRL0)8D+;6(77?8^GHZ]2[+@.,B*@-T(ICBD@V %"I=L:)BZ)7&._PM$AN3I5
MPCBLPU,7NAU]9(XY9+"U2@*.B.6>DZV%K)E..6$<^TV0P:W$T_4P:, FG@H\
M=NN/C=,\;Y]Q!(WT5CJ+=+"6PP(/MR%\IVB*CSSV6R1#!6<2==!C*GG#V'XK
M=QLRX!&CE@E!C+/0*F*(WX9-&4A) CH^WZ+?IQGZ34+O1B$#TW)]:-[2U9L]
MG65 *4J!!H($R G2DJ$M\(HFO:<U]L3)/J_>M*>"OH@97/O-P;VZ_(_EM,H_
M?2VKQ>>\NFV6XM.H?18\+L.A9<XIH(#67L!M6$N3I-=.QW_"UR57RNZUT1L3
MJ_(RSZ_F\13HU\EB6:T@^5#E=QNAXG/HD]DLUIV,4BV:<S2MYRQJ@OMX$H )
M@%H2(V6-EY0VI93PV!?//KG;JY:&8/6GR2S?#/Z(!;91!YFG! >KBC.IXJ,5
M B-#:NDIM8UN'7>1SG-6M&P-_\%V]R!-L)D7]Q]FDV(1)E0LOW1WNS]UHGDG
M&58V/F$K#6!&626I8-LYR)E/N2$V_C/$(??YME0RW+)X$C.;]Y)YI:UG%F*#
MH+1 $FBWP1"A5+_/<I[W MF6$L;GG+?BE&<^N)G>"L09@2;8*8R#A[TB^*"]
MGA..(F;4!2\[4\C M-R\D=A.S&A/9YED$0D'%=2&,B,(=-O):E720QACSQ#O
M,V;4G@J&V+QC ;/X FU<]1^_W+"^&;2IY+GZFX;[>/,.,^(1< Q@CW&\[4Z%
M!6 [;97Y 0O M,*E/?M[9\HY.0.C'MWUH]&5ST:W>'QT]=I#W"?VE!D-F-1"
M @@4E$Y@1?4VY!!,G:$"0V^6<_TH8LAU\ET1$)K,/BR_S*:7%]=!I/W%%!OW
MD4DHI,=*8@4$<E!+I^.VY"$*X#"44D#H[42 ^EH VU#!L-OU^[*XB4&L>$/R
MZ*WY<>.,&X:!Q1PBSS!4 F*[M9Z=\RFKX-A+#@R^#2<HHN\8Y/HR[L?@?%7+
MRQC>+VY,.6]TN+BK:? -@8/ &L<Q@^LW+K;Y>-R(%.J=6BG@\UDM?>TJH"_*
M?=R>&35>YW8UR0BV(HBDD49!KC#!"'TD(4^Y<] \6'/&%&L)^$$"U]$2O;B+
M6IV[[WEU.9WOK:U^L&U&N3=8>F\!QD0+@M6C2D6(D#-.\AYH*VU##^,+"+82
M",R(C,\O:H$I\5X9JA\5RH 0]EOS?Q1QZB[8V)E"^J*E"^[/Y>+BVGV__#HI
M;O*/88^Z**),JXR-^==X_O-M,CN0Z'!,-YEBDD@F#,$20RVXD.9123>78OB-
M/0&\1VIVJ)*^R/GZ8#\$?[V\>I[GOH><QW23L8"R !A:JJ6P#&IDMB=6+#AE
M*7%I\.?"V8-.AF6G"A!6U7U :U5!\&A:/FN?D2 M]AY2:0PCR(<INBW:+J7M
MYV;_AHYW*_5\6DRJQ1L_SNL"^_/B'35*24ZPP9A1*ZSR[M%5#)62DWATRLV:
M=Z[H,1]L0-8=AWQ?K/NTO+N;K1"9S&I$WA77976[5F^#AW>:]9!)@!Q&0&NA
M%,(B_"O?'CX2HE-6O+'?Q.^$==W@WM^=U*"#?+[X,)GN"\\\_BR+:3\Q<](%
M#3@E/!/8;F]ZA^EUQKD%K2O[Q?72DW'N\19S>9M_GGS/YP=)\^3+#',HB85:
M8V4=#Y,JK+W;&29Y2EG-$:8$=$^5%'1[LZ;*XEN >E5P=IT.<QO+YJS_>I%?
M[7MCX&#;C!L%*51.@#!7O$"8PJU[Q%E28>$1GNMWS:BV\>[-=HIC7;\6NH].
MCS_+B+/&8"Y]$(4298VTVZP8[W#*T572P?S;9$X"M"=GMSUFJUG.%V$QK&R^
M>N'B6;',^\_ETPRI76EN"5UFUEDH@)!6AAU;"86QV(;XB*/]%.8_+Z.H9YWT
M%V!8E2)9%4ZZFBZ6\:GCXC(6L;G2R\5OY>+?\T/F>-,N,N,,Q!I[3A !UB #
MP-8HX$*G')HF.7MOBX@=P_Y O/Z?&5[O[=,OL_Q%UO+JGU_+6=#V/,93%O<V
MOYY>3A=/1S_,D\0O!W?<V\2[VV=,"(:(!UY"(2CT"-I-.)Q X4&C>B =R__Y
M0&GYIQ]F2'K'- 7<,*N5<%![4$MD0=*EJB2'O?,H3QM:?F'J)$#;GT6\&>1:
MZ/@075FL@J'?I_O.F?>VR\**J:3PT"&O/(8*:2QK68WF*=[6F&ETI*)W\:4%
M2'O+6G@Z5%O>3J;[7J1\]?N, !<,?^0$]!#$ @#$;TJIA%W1]/1T1?]T2=/S
M\RR#%I#M+]1S>UL6JR7WU_SV2U[M#>T\^S;8ZA #+<.DHIY: YV#8"L3 "G'
M$B-D2Z)>7P1NTM#LBR'JZFKU_.1D%JWD=\7&GC[(EKWM,LD<M< 0AS'@$E-E
MO:MEA<:<V4VS=IG3)K*]L>CR<GF[7+G]Z_JO 8LJ_YH7\^FW?!T5/\RHIGUD
M (69I( 7 B(+%1>8LQH#SG5*>;81AIA;9E='*/=W5V(1Q,^OW*0JIL7-_""M
M7F^020$5%I10(XPCS%G\L!I3CU(X-,)@<[L<:@72WOTN,YO,Y_4I2D.?ZWF;
M3%J+,/<.8<&A\L)HMH4,$YER:W6$&UO;_E8BG+U9S8^&>=#1>OEQ!HWD0"+$
MD0^"*6<AL%NI GCG93>WH-WGMG,JI"<?8'W*XZM::F<(=N=N<T3K#&LM#%34
M8$+#IFJ0XUL3CBIV9FY5BC++KL%-)(I.(LJAUIF'T,)8FQXH!:Q'!FFZQ2GL
MV^>UV;1+E);!322*22+*H=89LQ1 :Q66U'F+I+2B#F4AAE'*S;<1.D3M$J5E
M<%.)<E'D:5PYW$$FK 5A.Q;6Z.#C$668VU(?8)9277^$OD_+=&D=WT3&V"2Z
M'&J=448]XYYI2+'50C%5/YM"@CO@!\NA>0M<:1G<1**X)*(<:ITI81B$1DA,
ML'8..E/?X2#8VJ2\SQ&FM;1+E);![3VT\GY:Y._"'QO%5+8?9T93[:1QS!KL
M/872J'IGQ<+QE%."$9HM;0=33L6QQTL)SY[E^IS?WI75I+I?AR,_EK.9+ZL_
M)M6!&PN-N\D(5,P0I(0'RB(1)HRJ%U1L$$FQ;$;H6J=0X> ;:JVAW!??G@VX
MOF&X3I@/\LV65^%?/Y352K&+137]LES$J?BY_*TL+LMB$: /H[JI+_SL6\W:
M_[',$284H)899GA8Y;F#?+O&NZ0STZ.Y^_+:<S<,[H9VY<AT-= ,>'0#P*YJ
MH*UK#:RNW/Z6_['Z+T=PO%%W&>7,6 9X3.>UW$LHT=92H9"F7*(>8<QJ"/YV
MH8<_U^AF\SX>8E"!E*/:<\0E9G7M#X(A36+WT1;K\Q(!Y\/P_C4UG$W\,AWZ
M5+-X;T\9M1022T4P#8-GJBF1V[-^#)P<[$7--V@9MPETK_<QGXSYE&FUU[UO
MXP<R'S8M!BFF*LQ1'N^(6;I%3^.4%[G>D!'<$L->NQ':MXH&R'3^]#7 /K]8
M+N:+27&UOU[]OF:9(=0+3I0R6&"'N11T:T-Y)E)RQ(Y>,\^-C"T"/\"=]L>&
M]WKXQQ;7/;ZSS&(%#8>:^8"YB666Q=:Z@B3IXN@(PZ6]KHI=*F)@>J[\PI;8
MN;NO#'M-J*%.Z6!G6><IJI\T(5@S=&;%&P8F9VMZZ.^6R?]=;IZ>_5SNN."P
MFG%? IA7,4\Y+^8K'GS, YCSZ2+_E%??II?Y&H"/^65Y4ZQZ.53[K^N?SB2E
M"&NE#8 8(P<DU@^.A4BR$D9X0MX7\T>FME'8&$_J;CR<&'_*+S>OCY]J;QSL
M.*/,HU@^QFL)E?) *R"V6YZ'*20?X>G^*&R/MI4R!CND P8WZS=C&*PN^WKH
M,1-,!)_U(32I<$J]A:2G*LZ2P)WH9 S\;7)LUNQ\AE@IN- ,2L&D1C3@7T=1
MB(,F)1Y[_&,5/P0?3\5^%%M_ O&>=9!)JSR4F#LM#246,<OK78,(A%/.L(Y^
MBR(L"E_*\^9>&OPGYWP&>S>F*$ZOIY<K+<W+ZW].JFH2CT0F7Z:S(/2B#".\
MG13; AF[,D!/Z2NC0")MN!+&6LBUT\)MY:0@J;+L":]*O/D5KB]%]$JX]=QH
MDW;K'K, IC44<>R=5-#%>F]Z.\D 32J'/<)$P-&2[R1UC"DHM9%PO:PG1IF>
M])6%Z8B8-P)S;(@@C@)1GW$0!GU2Y:X1GLB/*6Z4HHB^R+FK.,?[<AZ,B<7%
M]>?)]SU\;-(\\QQ0J8R22@L"L=2";26'V">MDD>?*)V3*=@!^GWQ+@SO8:Q[
M"/;DNTQ!X9!&*A@6#$DHPL39+O"8\*0K[3_P\4\*R']F%CU-6U'0:&RYE5*8
M "&P M77LPCB2:^#PN3GG=XV30?1T%M.+()AS0=,<JP)X)XJQ66=G$JL)TE<
M//HXY;RXV"+N#PQ[&S7 /ZP4\35?! =M]E24LRL(+H(S*0&0D"*$D5<2$4.L
M]F$!0<PV>WF\8_F/+ A.@.3:0BLXU5!!8IRRM40(RJ1XV?@LJ):UO+\@^''0
MOLW"=(ISJ8&S6 3700N)A<"UC,XUFQ!OD#Y'*KAQ8;KCX'PKA>DL\-8[CJT2
M.!8B=L9OI1+6G>L:<[IV#Q>F.P[2D==ZH=8Q2"0CFENA+0&$U;)X+\Z_,%UC
M99Y2Z^4H<-]*"8^PNG($/-%0*Z##]FP\J:7BE)Q9B;JVMYU3<>R-'9-9OIDA
M'ZIU*N7*J=K'D1U-LN#5(^&DX4)A(#P(LT!O),22NW,U4$Y0\7.VM(/HF$[5
M'J5*Q/^?%)>Y*?=?YD[I-N-.0!5OJ0D.")+&4*)JI#2GX$Q7J73N]8CZ@-&6
MB[N\6A]IQZ?J'Q_;/#X$&3*2LCX%>#ZZS=\>%5-ITE,F"9&6<.HD!R;&V[#C
M3'+CB/ Q66ZXZ,K'_%M>+/-Y Z&??YHY%]\PP)Y#;3AP5 4ZKJ622&B1<D5I
M]&^D=T6 %R\#)&'>IUTSWXQU<TLDGLL>,&M>:9$IJS##QL3D962)]!+#C7Q8
M2I:23#EV3IVNZU<,G'1L^^+.9J#/'KK=?W5A9YN,$A;V1"@DL=(:[XWP;B,C
M@82GK$E)ELE;XD];Z/;,H :$B55+"&#,"NF)1P( 8WT]!PA"2?PX_LYW&:R]
MM\N/8\'L[X!Y'K;ES2#WGB@_^B[S0,0S2P,<UYH[S3ROP2".P\'JK)V1,9,"
M>%_D^7L5/)0/57D]W6>]//HJL]8)J[$1T+NPMZ(P&60M!\!)UY7'OJ+T19S3
MX>XMNW3M\18WJW?3YXW\J9UM,A@$X0I@9SP)D@5P'*UE9):EA/:2DO_.B%)M
M@=^?C3//PV]]#7#8L(#.RKO5.[SKP>\U?/:TRX3%6!**#5%,* VILZ"6E4N;
ME+ \<J*U0( 79E%[4/?FN.>KE,&_YT5 8Q9&KJYNI\4T(K$(D^TPOYIUD#'%
MO V^I\<NK-C80^?8UG$(?L096U?M$ZT3S ?;*8_9(;/@<$@FB#9,2<=P+/2_
ME<D8D'++>^S&5OL\2H6W=\HTNDCQRM<9A2"^(R+"0BL!XDYBZ6NYK$DZ53^^
MI-!YVNCIL/=%ISH_?CW0#?=_*XNREF!_Y+I)\PPJQ"4#$BH@L7= 2K/U4B32
M*0>D2>5]SHAP'>BA+P;ZR;1:E=!X. Z^J._^[EO:]K;+#$)** 0HP<Q*ZCBE
MMI:5>)_RWD7SBCQRS;DBOXEQX_-C79LJZ/7JZ^.9\63*[-M*]S;,+*-"..9Q
M6.>I1)@*Q&MIE4XJ"I!4<N>,Z-:J!L9]Y15[*3@W0&NN*3,QQT5O90D:2F#3
MT65TSM1&2P'\G.[I:\Z4B<6!,/$<(V(H,@\QY*2G%=-*Z9P1USI01(\W5)^/
MN@'S]K3*C)*>0&.<$E!P9YD&>",G58@F94H='V@]S\6M/?S[XIF;5$78TN=U
M K*>S*>7,7H\G2T7>ZOC'&B92<D9(\(&XT Q%59YQVNWAUHJDIZ^&WN\M2^^
MM:N#OCCWSWQZ\S4,3WT+!N5-_MLRWJ6YN%Y)\.AF=W,JGM9AQ@!Q!CC/I')2
M* \XK$-#P6TR27E^28\OG!%#>U%-/VGFC2[O;Z[M#Y9?WOA*_K-;V=;QB#B7
MUB/NH&#8(.&#/<X$#191H]6ZJXSYYU?)?RL7N9W.+V?E?%GEGP.Z.OSTO_;F
MRC?L(T/(Z;!%:\>% 192H3FI<8",I632C/TT^E1&'"P<TP[6XYOD#W=GWA77
M976[^CV;+R;3V7 73$Y= ( C2BG"9;!0)<.*2@=6%WL05$C91L3O: &X_)I?
M+;?WY?3]ZI+OP4H<NUMETEHE \>\AEX&LXAA2&M9K6:#O2C>_R1OK/7GD[PU
M=/M+7MIFD=]_KB;%/(@?;X?I^\?_Y4"ICN:=9 H0X2S5 52+!/">44NL%PI!
MHJQA0W&L(W.R#3Z\R&7J".PA*'>PLL?+CS,#(:< 20S"!!7(&8Q\+954)N5Y
MBQ%2J MU[V'421B?7.I#3P+LGY:SX.X$6T)7Y=R4_WS_?G^%C[V-,NED6*$A
MHD8KYKFB@FOB "!("QLFUOFRXUC5E1UAVMLZ,BEN\D,[4_U-9K#B#"D87&>@
MH&4!&+%9;C62;K!'H?L(:G2Q"YT(;*_DV+F.O/)5)H "SAC"$*!AQC MH%S+
M@0"B.*E0Y<@)<H(R7Z/#24#V18A?I\7T=GE[D!)/OLL011*A^#2OCCE)A&)A
M:UFH1F=]Y_D4E9;M@=E[6:A6:A,RXYD%!C"D&16* ,% +2.V.,6_&7WLO(-M
MIBV@>SN?3JQ:"+D04 MLE5-"&!&L95]+I4'2T\)C7V]:4/7A$H;'X7NR7[.N
MDZ>22A@>:IW)8,XK91V&TBL6KQDP%*QRP9TAAB==W!FAIY.BS)<E#%L&-Y$H
M.HDHAUIG2"%L#,9(.<(\4QY)$641\70!)+U],L*28.T2I65P$XEBDHARJ'7F
M@VW&=3#QC,:&Q:<(J%K)$DO2&"Z&,E[> E%:!C>5*!=%GL:5PQT$>]X!PSSP
M" (FO(D^XDHB8@15.N7JU@@?PFF9+JWCF\B8CNLM&T*-"# 1PC$5SOA@RJUD
M8<"[-&/E^&M^;XPK+8.;2!271)1#K3.,' N(6\F)@LQ@RP7<X 2-3GHO9NS7
M\]IE3<M(#^%!OV]0J/O5[S-I)*#802N8UD('J[V.8R+(29(?/?HR+1V$8=H
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M 8@01X"HI3* G_-UQQ94_?IUZ=/Q[6T-RZLPQ^R'6CW-*O#L:96%!9]A8['
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M"U,?L@WVM0D4$J:MA%I:Y"P5AH-R]V$0HMY"=BZ95TVA?2':Z?L:)?2:^D3
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M\E:[P*,VB'7R;R)JH?1(457Y-ZW&&5QB ^52MU$K#:#>V9VUYUT]NKV]^7S
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M[&Q?'F=[Q';WW?X<+1:CV>IF\2E=,G!_%XOQ9/EF>L$:K8*5 $> !(DVC-4
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M"5J-7Q-_C0646E_;VL&^ERB&XOM\.5F]GXR^IAIDDR.IY0XU#%(9PX!@S'#
M':%..%F.UB%YC4566F=:HY!WYKLM'K[/%Z/%S^T^_S2]RB$/[OY6@3J.A3(R
MJ@<6*FOCD$$Y3@"SJGT-]>Y+Z]1J#N^>>!4AB0IE.HZ]_==HNBZB K 91'V.
M[7M#0 11RKE !'AIM),&T<H0(C#GMM]0DX1US;>&L.\@L/US,2W&L9O_?QTQ
M*1;3GWXRB];,9#2UH]7HG[/1^G:R>ES:.H]E?]VOIX'VU=6!&J'M)[XI*)/R
MMBG/D( &1MW:$RP)8Y(K))"NI5OV@$F=JS#U7A!,7 \U<X)$2P(K83 3(B+
M*4'2*G]EU=1;X\>\ _"'LU+T??FEOP4#8)G\BTH122D2RD?1$8N%Y)$/JMZ)
M5EM&4?W,VAP31ZGFQ$/D'3!<.4_214]H6+JXWN6D?^XP',:TKRWE?5FU3P.X
M*_7S'XOY<OEQ,;\[>(WZR5-!24P \!Y%#2:%+$-MY0X([3S+(<J <C-U39/S
M$>Z**579BG>SN#<4[V-_#S#FC:<#%5X@SG%4LJ-1+["6T;S?CLMA?BT%'[IF
M3C[273'H0[&JQ9UGSP4/->) :8"MP88FDQV58^$4Y(2[#2C[4=>LR<&X*[Z4
M*2-**SJEJQBKV:V=3->K@VZW(RT#(\YSB8"3TD05FW-C<#E>K[-NZPXH[U'7
MG&H6]>&8-IO(F%_1LM%( ".94(010!FU5J.-J2L8AE(.XM+_8;,Z2:Z.9^2L
M]P7#N19,8J654A KS*B.^$B"'>>6]U;E>AC+2&WV[+WVWYXLNEA<4GA27 *+
MVU1 L)@M-V_H;15Y%-#-W=,.[5SC9KY<+3>K]M?4Y8^CG]LPU>.+2MZ+ ]?2
M&6<92]M!%!2CCFY3OEA$D*@5&=<S8OKIP.JL-IEO#@[%*<65T41B;*U#.AW%
M;S$3Y"H+@7;-MGF?$NMM=1ID6J.AKEQ $Y7,;&.(=ES0%%_*F"4R*LO0TEHA
MEFUK1X^<?";F)Q<1],]7O%5_C1:W]=,D97XC<*L)QP! 0P#QRB,J7(FC EEQ
M$%>^FM5FX%X-JUO9=19</1W-/HP>BB/7*Y\^%E+I>@L!D8!K'U=J9XPH1X(Y
MO>K;_]W3X65<]?F2Z)I31S-+/'\P<"$,H5PZ300S#GO/P6XTSBAUS;K:>5+=
M0XVSX#P[O'X;SO-NEH*O)S^*U(G#5Q[W-@C:$1\G!(8.(2N4<U*078]]-(IS
M;F)<"@%.E=V\!6#/IL*7O^9?OLW7R]'L]O,D:KW%[&1RG/"* *%%<88H!+%F
M2@EJN2U'Q0GL].).^SZE)AC2'KI-<$8]]NKA^W3^L]AF8"_+1)U$GMKO"HI1
M2;CS1'O,)0265:NM%]SFQ'H.\*BU81:U!7-GEUJ/:7'[E+CW-:Y<Y[\\0,81
M9)13Q)DF&O(DIPUJ%##!<\@Y]#0X_:O:G<NOL_1OO98#HTH!$B$@40]ACFB!
ML"PQ\=QG59$8.J<[9%1VT;#3Y'1^.K%S,7G5_\>2X^-%D7:?)S="GPS_9KU:
MKN+>-9G=Q^WKR1^2+O1C-"V.%<T=6F<#Y>F"(5-,"$P]H=0R4DK**);CD!F@
M(MS#)+H:V7>J5WT]CM77EUAM_OE7L4Q1>MN2FH_@'%.UFOY>( 1P;XV4CF$B
M/$/(Z1);S'%.S:T!F@8];DY#$-_@38ZG8]WF;SE88*[!SP0@-*,4884LP=Q3
M2 C:(0FMQCF5LP<86-KW1.A':IV%JI:.@K@;3L;%VR/^D)*6+E?%=ES++_.H
MKS[]>SKN^S!?_4?*\S&>W\^.%/=L[9L!82J@YAXC;F$4L@<:EQB+N#?W%1Y[
MW<;,4.1Y\7-FNU1$E73WJ_3<H5VEVXZD6"#OD0$8>QVU6ZN%KZ1AF,ZY7COT
MO _7.+N:$/+@U;2;[YN,D?^(#ZZ6[V;;,?]9).4T@O6C6$35=/-'.UH5?C19
M;-(?M*')G=>3@)6#AGK%,% (,^R08Z4\',<Y>7RRDE]<W3P;MF O9:*YOZ/%
M-UD6%1";I>C=;+68S):3<=NSJ\[G@U92:8J PL(1Z;0GJ'2E(H+KQ3_NF5+B
M]Y0:MC3/=XQO?("[?HT6TY]EY]ZR=(ZT"%A+K9@PV"/()> ,:UCUV?L<%['\
MS<#&!7 V:2JU['3VU&@:L'/">BT$A=1HFG*#/8Z"JJP(+?!;(W^35,W+I84E
MJ<Q*^%8NYKI-@S=41#. 8\8E==H!(4I+ %G+LMCU^VCXU"7K7+GT=B7G\_KA
M8;3X>7-7J;R[*DJ[X47#LS1MEW^.EFZYFCRDNP/_7$YF]WHZ&O_[\_A;?/UR
M^_S'Q60<__#'_+:8_K[8\_:U"N(L]%)S"+G@VBBFG?&44K_)QB)[3.AT61=[
M #),(".4%JE\&Y->N1)'H>DUA[YWQ<#6+O:<)KO.LCRGWA\KDEX^$S"TQ(&H
MFP)"L,7* Z3+,7CG>LMC>%%QAK6)\#+OV9EBZ)1*1XNA/7DJ,"0(C8J(@B*J
M#%Z#:"^7XTCI!JZ83F<(\RTZG 5D5X3X8S*;/*P?CE+BV7.!0"NLTE!R(W34
M'3%SH)H>3%QSW.=9(ITW!V9GQ!C]78\83Y\+PD ,$3/.(B\!DBQ5?]F.!4$K
MKSG(O1%B9( Y>"?_^V[N60C$+8&,6&*1XRXB1\@.-8Y$5J'8H5.P?_VG<_D-
MGO65 T,ME^N'K??BTV3Y;[\HBG>S2)!BN?H4K:,V)D7=;P<M)')6I'Q5@E+G
M($A!9EO,H76=ID&^/&==;<8V-5E:DNM%SB7W]_=--L-_S:?Q-<G'V>5L>OOK
M :0E$\7=VW 4?Y+8&57ACK.2NPQ^#[J2^=2(9 =_1^/0R+\4BX>C8>FM?#0(
MR0"P3'' $4>&>,E*]8,#):ZYV&+?\V<( KWHC<A.?DQNB]EM']O0TV\'C)&*
M.SZD&&C/;-SP2>FTXAJIG'CVH9>+['L2#4BN_1_A?IC/S&CY[>G?OLRKTULU
MNXT/%.5_OIN9^2P.=?.RV7(^G=R.-O$2\=^-W7ISMTO]'_^ZO4H9N_TM-IC\
MV&1U_WV\^_;A&D-<0ZFMHPPD^GA-Q387I^$"NUIE*-H^WJT5K:ZFF\[%GV[N
M7L:C;T"H?]3;X/>"Y(XZA*%R0FLB+4$.E?@Z2Z[YG*0K9NX]]NU/CEUI*MNJ
M%=4J^'XWDB.'P@=:A;B9$:0X)4HJAJTB437;C5-PJWZ-8^)>B#-O2T@]D_%H
MCLB#[8)!@EE$C$.01-M:8FVJL3(*KMD'V0@%ZM'J++"[2V:T7-W<?1Y-B^71
M<\=7SP9HB,3>Z3@F+KQ7C$%3CLD0F&/O7"B!3A7VJSQ#>1!W%M0291:_]2T5
MW2E^%-/Y]P1"LIVB&7$\V.5XZ\"QEXPZSE@JTHX=LUZ6XQ8^J^3)T/VY[5"K
M>= [\QD5T_C.^W\4LVB%3F/_U>W#9#9)NFS*NKD;PO'UZZ3WA*A8(*2 <%XX
MIXB%S-,2B_C;G(N<0W>(MD/ -N$?5"J!H]IKG;",AK\4G%:()B2EP\XK2HCV
M)9X^:M%7O)X.R_CH5[#]^OE/=LX'(:"/:PQ!FBCFXG8D$*E&YTFMJDT7JF'V
M1I1:[O43)=._3_S)7:8OBU'\ZWCCT/[MO'[;11CY@>.Z!B%APEGK*4"*(6P$
M))8C5DO]&=@1XNXBVY/$D)_FTZF?+](?VS@W//C!8(W26&@:IQ#FF%*,>84P
M,*@W]_4@/=:UZ=AP2H-&9#?XP_77@_VP/F9,-?VM@#67!$9%'RKMI(]VJ"<E
MIE3)3NN7?-]LH-$"6JPNX B](:ZV-W7.DO"ES)KGB83^L3A<<[Z%KP5 K$!*
MR*AU:6*\T)Q5$I8FRPT[>-ONNN9,OG0[FS5)G4ZIN(M;NUY4>5,WHUL^2XMP
M('/*^2\+BGEKJ3!><4N$C0:-E"4J3KIN"L_(+>=GQ7W287Y=UK<MODO9"B*0
M=\4DU8&HYG"+6\$;7PM(86:I9I1)(J1A"*D*UVBJJXQI43\"\?>T&(A\+V7>
M]&MX& N=33E^A!5&*>@X$M4&B[,*%9R<A7IK>+C9[UG3EWPO<,Z\2%Y:[K(I
M!5.11'+7I8NK9F>"9,KK2 2NK5.(*D(X+J7"E,P)/AI@V9W+=W^U(]<KFVW]
M3[$@K2=4"$>)2)J"4\:Y2K.VY+<;K4_.]S,]3^3$8.;DWHP)=5)X-S8OF^M%
M@!9YSSEV"$ID&7-05LNX4?+W)>7+F)6],>)B9N:K3.!]3<Z3.A*LL.EZ'P":
M*YG4+6"J=1)9V%LUZ]_S\V)(<3%3] WO4E^3],2N!"*<9P(*;R-E *&>/%DT
M75:^J:N]9GV!T[1=6@QFHEZ-Y6D\])H ;KF12A *"(8E_MZ*G#J7OY@?M?>I
MV0LC+F5&_FM;N6UV6R5<F:=?=7F(4;<+ 6*E&8***\VAT2SEKZA\WPCGW#D>
MND9[H2[7ED1[X9-KMZZDFQ=]3:Y770C& "VLLM9I(3B($HC+[DX"V,N<*V)#
MUT.O:W+EBO;")U?_*F9>QP)QCF$A.7#"*VJTI;R*BO!,YR2O&WH=Z>N:B.T(
M_,*GYY/5:5C3LV;' C$ZFN4(&JHUT]9:&565TDP!]>H<76@AZNN:GNT(?/ I
M6X]:O9^*=#,^_M[,9QO!K4?3E(43'9N3W?8F,(L19=8B FD4AC$2EW)QW)$<
MQVE6<>HKGXB#EO*ES+Z3-89] +628+GQ3@8  ;$JBL]992PP+@7][J3H@,N)
M%<BJ>OU[K@Y.^!<^A?=K%0.:PF=T,B!D&9=8(8.HXUQ8R,J38T<LRG&^9I4-
M_SV%!R?\2S%1GRQF[^* )[/E9+Q)H=W-^>/S;P9+D<(>8LB(A@HR28&H-!V6
M=;IQ>D'U'HX<+]2Z;$J@ES)ICBL&ZOY^L;DMU]FD.KM/ 4*E%?5&.R:$PH1:
M;4H920URC,C!UYF_T G7E; O?$(^V>8',R&/]RE(S9V$C MIK6), F@?-0V"
M<RQ%./2P\NN:D(T+N[LTT@\/\]GFJK\9?9^L1M/-\)<IZ>SB1W'KYPN_3I%\
M*4O :';PL.+D=P6J$2+<I0O1PD##G>"5M1R5\*P)D!7E<E6<;ULNO:4(W.3S
M_)T!\"5/HND:=7')+>:"0X&LP+L,O!9XCFJEDFAI^W^CZ.[31?9IRI&T:FXG
M]6.-IXW OT01Z]B_?Q_:TQO]4&#*6!V9CS6-,T()CX@L$8V_O>9DIEUQ<6_!
MFAX$V)DVW'1^XY-F1L/?#!I2)*,J Q'G<7.BS NUPQ@B8'-\.E>NS.9/DGYE
MV?U\>7N 3Q<%-5Y-?D2I9VT9I[T\.*0MURG)O<,.>^$DXB5J%HG?,=N=;!.M
M"JT+77?]=5G\USHV=3\22+WIMR\[4D-SW=<D&$:XH((AI!$5F"EO*+$:>^<X
ML?6J&'0SREIKQ;XV <6E4L;!4D@IT$@(#4TY3D[4-9<VS)?]R\G=$,H]S%EU
M>SM)[QA-W\WNYHN'S0O[SEC?Y'S&6##+K1%08. -QI+A* &O@8\KMNW3QGS>
MY:,53M]X/&!IXZ: A1 L_L,8U-8]&=TUU]?+E_CA67P.P)WIER^Z&C]^I&KH
MGA8!:PQ8JK1DM&;(8@2Q+L<'';GJBJ%9\CY"GO/P[9$_1PM][FT3&%>00$Z,
M908ZJ:7@I!PC9BSG5O:E<>ADL1^GT5D@]T2DXP7RWGH^6(65(SP:4PC%G[4
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MQ$0!2FPT/)G  @DO6-R[HF@0Z]%+?@C_6D=@M5X0E/.4 ^ND4DICKP"DMD1
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M/9SL18]VU-?YY9&M<90[V'*^%(N']_/1K+?MQ!9?5W:R'$_G*?2VQE;R=H/
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M;BTR,#$V,3(S,2YX<V102P$"% ,4    " !Y1U=*TE;I#KXB   =;P$ %0
M            @ &HD0$ ;V)L;BTR,#$V,3(S,5]C86PN>&UL4$L! A0#%
M  @ >4=72FC:3-IF60  B%,$ !4              ( !F;0! &]B;&XM,C Q
M-C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( 'E'5THV^8_+4M,  .<5"P 5
M          "  3(. @!O8FQN+3(P,38Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" !Y1U=*&'.<C6&,  ")"P< %0              @ &WX0( ;V)L;BTR,#$V
B,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  $MN P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
